Clustering O 0 6.51501068205107e-07
of O 0 1.514092878851514e-10
missense O 0 8.349779091076925e-05
mutations O 0 0.0007584640407003462
in O 0 4.363256422834638e-08
the O 0 1.3135623703419697e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999991655349731
telangiectasia I-Disease 1 0.9999998807907104
gene O 0 0.051643308252096176
in O 0 6.41961994674034e-09
a O 0 2.3963033779494936e-09
sporadic B-Disease 0 4.455699308891781e-05
T I-Disease 1 0.9972903728485107
- I-Disease 1 0.5496131181716919
cell I-Disease 1 0.9720858335494995
leukaemia I-Disease 1 0.9942958950996399
. O 0 1.4516203350467549e-08

Ataxia B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999940395355225
telangiectasia I-Disease 1 0.9999996423721313
( O 0 0.003882895689457655
A B-Disease 1 0.9999983310699463
- I-Disease 1 0.9999982118606567
T I-Disease 1 1.0
) O 0 1.2888090594742607e-09
is O 0 3.705889414784558e-11
a O 0 3.125748826438013e-10
recessive B-Disease 0 0.0007402790361084044
multi I-Disease 0 0.005326507613062859
- I-Disease 1 0.9999415874481201
system I-Disease 1 0.7430635690689087
disorder I-Disease 0 0.4874536395072937
caused O 0 3.2664744242794086e-09
by O 0 7.91166264446641e-12
mutations O 0 1.4409781101676344e-07
in O 0 8.111947918942874e-11
the O 0 6.198389024270057e-11
ATM O 0 2.9556733807112323e-06
gene O 0 3.4963193229486933e-07
at O 0 2.779284713483321e-08
11q22 O 0 5.841812367179955e-08
- O 0 1.5175775160969351e-06
q23 O 0 7.049096950595413e-08
( O 0 1.981177027987613e-11
ref O 0 1.0653430990714696e-06
. O 0 2.3756037068056735e-11
3 O 0 9.208993984044511e-11
) O 0 7.817539671162166e-11
. O 0 7.273268654017784e-10

The O 0 1.3921480501721817e-07
risk O 0 1.5404634723381605e-07
of O 0 2.785416619577319e-10
cancer B-Disease 0 0.005165059119462967
, O 0 5.147164916508018e-09
especially O 0 4.636525385848245e-09
lymphoid B-Disease 0 3.633577216533013e-05
neoplasias I-Disease 0 0.0004031699209008366
, O 0 1.1387896181602741e-09
is O 0 2.2098434193651428e-10
substantially O 0 1.1206905980998272e-07
elevated O 0 1.9259447071817704e-05
in O 0 3.653649969237449e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 1 0.8703363537788391
and O 0 1.1097737342424807e-06
has O 0 1.4736484672539518e-06
long O 0 3.657923741684499e-08
been O 0 3.729207165292792e-09
associated O 0 1.9096043857302902e-08
with O 0 1.2407707572492654e-07
chromosomal O 1 0.9999998807907104
instability O 1 0.9999983310699463
. O 0 4.1880988987941237e-07

By O 0 4.43261649607507e-09
analysing O 0 1.6122729675771552e-06
tumour B-Disease 1 0.9999853372573853
DNA O 0 0.00018802600970957428
from O 0 4.083669166710102e-11
patients O 0 7.332467411025334e-10
with O 0 3.581554844367396e-11
sporadic B-Disease 0 0.00010738232231233269
T I-Disease 1 0.9995998740196228
- I-Disease 1 0.8700422644615173
cell I-Disease 1 0.9053533673286438
prolymphocytic I-Disease 0 0.04782875254750252
leukaemia I-Disease 1 0.6335023045539856
( O 0 2.1755175438897822e-09
T B-Disease 0 0.01354013942182064
- I-Disease 0 7.305657345568761e-05
PLL I-Disease 0 1.5427820471813902e-05
) O 0 6.785483286364524e-11
, O 0 1.3373671961525169e-11
a O 0 6.520894241246467e-11
rare O 0 1.7155464604456938e-08
clonal B-Disease 0 5.6140484048228245e-06
malignancy I-Disease 0 0.027495410293340683
with O 0 1.2998534193453537e-10
similarities O 0 1.0394509075695169e-07
to O 0 1.0988794318933515e-09
a O 0 3.0670999073834082e-09
mature B-Disease 0 6.64254400817299e-07
T I-Disease 0 0.34235328435897827
- I-Disease 0 0.15058457851409912
cell I-Disease 1 0.8863214254379272
leukaemia I-Disease 1 0.6266211271286011
seen O 0 1.2224566035001772e-06
in O 0 3.333520126602707e-08
A B-Disease 1 0.999998927116394
- I-Disease 1 0.9999979734420776
T I-Disease 1 1.0
, O 0 4.769075871990935e-07
we O 0 2.351254968502303e-09
demonstrate O 0 6.494276145498079e-13
a O 0 2.7409672770958675e-14
high O 0 9.988349123496443e-13
frequency O 0 7.284177427901994e-11
of O 0 6.660099446768875e-13
ATM O 0 6.396086064341944e-06
mutations O 0 1.383471271765302e-06
in O 0 5.680031556209997e-09
T B-Disease 0 0.06435786932706833
- I-Disease 0 0.0006289913435466588
PLL I-Disease 0 0.00042073862277902663
. O 0 1.1236460650820845e-08

In O 0 2.0820198898263698e-09
marked O 0 7.640719168477972e-10
contrast O 0 4.926232755053661e-10
to O 0 1.1050091397457606e-11
the O 0 3.179380586929015e-12
ATM O 0 2.716514245548751e-06
mutation O 0 2.9688109748349234e-07
pattern O 0 5.019420132157393e-05
in O 0 2.0464146643917047e-07
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
, O 0 1.0802849459423669e-07
the O 0 5.035046685142319e-11
most O 0 1.271553825774041e-12
frequent O 0 1.9034052112232303e-11
nucleotide O 0 1.6507653022301838e-09
changes O 0 4.2569042735252083e-10
in O 0 2.974820945134127e-10
this O 0 4.155320254550787e-10
leukaemia B-Disease 0 6.588292308151722e-05
were O 0 4.746819048939699e-10
missense O 0 1.4502011254080571e-05
mutations O 0 1.0840165487024933e-05
. O 0 1.0266314021123435e-08

These O 0 8.195517153808396e-09
clustered O 0 2.0452634430512262e-07
in O 0 1.8770693333003408e-10
the O 0 2.0339507855737793e-11
region O 0 3.382474578206285e-10
corresponding O 0 4.5128012438055976e-11
to O 0 3.088659536465421e-11
the O 0 5.072385653864808e-12
kinase O 0 2.851969611583627e-07
domain O 0 8.935493838180264e-07
, O 0 1.6557791804316935e-09
which O 0 3.174263629723839e-10
is O 0 5.127921524905599e-12
highly O 0 1.7800351036906248e-12
conserved O 0 6.984156031286659e-10
in O 0 1.6258755453080198e-10
ATM O 0 7.398215984721901e-06
- O 0 6.796579441470385e-07
related O 0 3.571326123719132e-09
proteins O 0 5.320359974803068e-08
in O 0 1.170541108486134e-09
mouse O 0 5.931481155130314e-06
, O 0 2.6203025860205287e-10
yeast O 0 2.576573798762638e-08
and O 0 2.585965885870678e-09
Drosophila O 0 7.003582158660038e-09
. O 0 9.075759588306198e-10

The O 0 5.405274450254183e-09
resulting O 0 7.953854241904423e-10
amino O 0 4.379195228665367e-09
- O 0 3.932374852411158e-07
acid O 0 4.768327954707274e-09
substitutions O 0 1.1347604800260314e-10
are O 0 2.7196914425403618e-12
predicted O 0 1.2919051384230329e-09
to O 0 3.8125960721835384e-11
interfere O 0 1.2438411189918952e-08
with O 0 4.983472315367443e-11
ATP O 0 1.5927375329738425e-07
binding O 0 1.0698229857553088e-08
or O 0 1.3090248884850553e-09
substrate O 0 2.962875669254572e-06
recognition O 0 3.946560411804967e-08
. O 0 8.02897730523e-08

Two O 0 8.810851492846439e-10
of O 0 5.8930894018816016e-12
seventeen O 0 4.88722751157411e-09
mutated O 0 4.835431354877073e-06
T B-Disease 0 0.006121885497123003
- I-Disease 0 1.5355453797383234e-05
PLL I-Disease 0 3.5450313589535654e-05
samples O 0 5.629556767416943e-07
had O 0 2.1670704342113822e-08
a O 0 2.3864124218397897e-11
previously O 0 2.0234597997159653e-08
reported O 0 8.235838322434574e-07
A B-Disease 1 0.9999819993972778
- I-Disease 1 0.9999724626541138
T I-Disease 1 0.9999984502792358
allele O 0 2.18388104258338e-05
. O 0 2.0933494937480646e-08

In O 0 2.0958734747722474e-09
contrast O 0 6.762208126787073e-09
, O 0 7.809954072346414e-11
no O 0 7.10631137268436e-11
mutations O 0 6.281623665671532e-09
were O 0 1.1458001908382087e-10
detected O 0 8.092750647392677e-08
in O 0 2.824356547248552e-11
the O 0 4.5221586891797116e-11
p53 O 0 1.3661826114841347e-09
gene O 0 2.5067976139325765e-08
, O 0 4.022259955660523e-11
suggesting O 0 4.679720500000428e-10
that O 0 1.2839705965106418e-09
this O 0 1.6098894661809027e-08
tumour B-Disease 1 1.0
suppressor O 0 7.112105959095061e-05
is O 0 5.9011775022099755e-08
not O 0 1.1693187751404821e-08
frequently O 0 1.9375242743535637e-08
altered O 0 1.0455953088239767e-05
in O 0 1.1717769865526861e-08
this O 0 5.765059540863149e-08
leukaemia B-Disease 0 0.3259374499320984
. O 0 1.5601232306039492e-08

Occasional O 0 1.0920683962467592e-05
missense O 0 5.750833952333778e-05
mutations O 0 4.3735039071179926e-05
in O 0 1.6281719028565789e-10
ATM O 0 6.665606633760035e-06
were O 0 1.1595045812384797e-08
also O 0 1.672832894428211e-08
found O 0 1.0912520664874137e-08
in O 0 5.905746114365229e-09
tumour B-Disease 1 0.9999998807907104
DNA O 0 0.01533445157110691
from O 0 5.93957383276944e-11
patients O 0 3.138139748060098e-09
with O 0 1.6164383720429498e-10
B B-Disease 0 0.0621601864695549
- I-Disease 0 0.0008476086077280343
cell I-Disease 0 0.258795827627182
non I-Disease 0 6.716117241012398e-06
- I-Disease 1 0.998457670211792
Hodgkins I-Disease 1 0.9999666213989258
lymphomas I-Disease 1 0.9851105213165283
( O 0 2.6339836978195308e-09
B B-Disease 0 0.0002918159880209714
- I-Disease 0 2.2099777652329067e-06
NHL I-Disease 0 1.0693092633573542e-07
) O 0 1.930387273640921e-11
and O 0 7.311403565912755e-11
a O 0 4.4465009452210325e-10
B B-Disease 0 2.1155008653295226e-05
- I-Disease 0 2.849533586868347e-07
NHL I-Disease 0 1.4051618535404486e-08
cell O 0 3.872298293572385e-06
line O 0 5.079312359157484e-06
. O 0 1.946657945950392e-09

The O 0 8.246112126464311e-10
evidence O 0 1.302315200124582e-10
of O 0 1.828115837963079e-13
a O 0 7.000686922525867e-12
significant O 0 2.2081136832191595e-12
proportion O 0 4.725644320302536e-10
of O 0 1.3400942681929262e-11
loss O 0 3.7391134810604854e-06
- O 0 2.7174212391400943e-06
of O 0 2.899337714357131e-10
- O 0 0.0017875186167657375
function O 0 5.538781238101365e-07
mutations O 0 1.5487773907807423e-06
and O 0 1.574177943552968e-08
a O 0 2.1523880455731614e-09
complete O 0 9.049352911461028e-07
absence O 0 6.862054813261409e-10
of O 0 9.474869890405135e-13
the O 0 2.519108532883507e-10
normal O 0 4.923518259758453e-10
copy O 0 4.039778289666174e-09
of O 0 8.750629344397853e-13
ATM O 0 1.148741921497276e-05
in O 0 5.823094784140892e-10
the O 0 3.4643309054782634e-11
majority O 0 8.476173651850161e-10
of O 0 7.027715215324193e-11
mutated O 0 0.13067461550235748
tumours B-Disease 1 0.9999994039535522
establishes O 0 4.5125497649678437e-07
somatic O 0 1.5479971082754673e-08
inactivation O 0 1.8080447716783965e-06
of O 0 5.034964957982557e-13
this O 0 1.4257776383141962e-11
gene O 0 2.5678211557078612e-08
in O 0 8.394822337276509e-11
the O 0 4.82097972653861e-11
pathogenesis O 0 1.2912042279822344e-07
of O 0 7.833357226760818e-12
sporadic B-Disease 0 0.001509486697614193
T I-Disease 1 0.9986457228660583
- I-Disease 0 0.07596585154533386
PLL I-Disease 0 0.0001253652444574982
and O 0 1.6666765745299017e-08
suggests O 0 3.4910907498186816e-10
that O 0 8.000405025965218e-12
ATM O 0 1.1696449320197644e-07
acts O 0 2.0647026310882666e-09
as O 0 2.298474188755506e-10
a O 0 6.369336347233912e-08
tumour B-Disease 1 0.9999988079071045
suppressor O 0 0.00024107989156618714
. O 0 6.855572820541056e-08

As O 0 4.598520175758125e-10
constitutional O 0 1.3235681994849813e-10
DNA O 0 1.7867376300273463e-05
was O 0 7.15862924494104e-08
not O 0 1.6430495852759464e-10
available O 0 1.895116702455013e-11
, O 0 2.8789526318462322e-11
a O 0 4.715793866516549e-10
putative O 0 1.1542567335709464e-05
hereditary O 1 0.5387622117996216
predisposition O 0 0.003989942837506533
to O 0 1.9640839354906348e-07
T B-Disease 0 0.25816187262535095
- I-Disease 0 0.0005394294857978821
PLL I-Disease 0 7.999099761946127e-05
will O 0 5.661521806921144e-10
require O 0 2.823121727710265e-12
further O 0 3.0145436927947467e-12
investigation O 0 1.3723951142186053e-10
. O 0 2.4040297530447674e-10
. O 0 1.917468628320762e-09

Myotonic B-Disease 1 0.99998939037323
dystrophy I-Disease 1 0.9999918937683105
protein O 0 4.2775362089741975e-05
kinase O 0 1.0935274985968135e-05
is O 0 1.910804847682357e-10
involved O 0 1.4476310775113355e-11
in O 0 9.122152902843461e-13
the O 0 2.0149894665137669e-13
modulation O 0 4.83937750983543e-11
of O 0 3.2910257635396234e-13
the O 0 1.0258435073629002e-10
Ca2 O 0 1.1108029411843745e-06
+ O 0 1.956991809493047e-06
homeostasis O 0 0.0001041425930452533
in O 0 2.6098311067812574e-08
skeletal O 0 0.0525813028216362
muscle O 0 1.0333646059734747e-05
cells O 0 6.542917958540784e-07
. O 0 2.4850643765006453e-09

Myotonic B-Disease 1 0.999976396560669
dystrophy I-Disease 1 0.9999970197677612
( O 0 1.1431530765548814e-05
DM B-Disease 1 0.9999995231628418
) O 0 1.2976653351870482e-07
, O 0 2.4883023419519645e-10
the O 0 5.12652559292448e-11
most O 0 8.777086835110026e-10
prevalent O 0 0.00023830414284020662
muscular B-Disease 1 0.6510124802589417
disorder I-Disease 1 0.5386975407600403
in O 0 3.9398795337319825e-09
adults O 0 1.1942974253997818e-07
, O 0 8.357123326696581e-10
is O 0 9.907951126209014e-10
caused O 0 5.879054132407191e-09
by O 0 4.4204539334513626e-11
( O 0 2.6275632711292296e-11
CTG O 0 1.1994281123861583e-07
) O 0 8.717400065694214e-12
n O 0 7.436531035409644e-08
- O 0 4.4801590775023215e-06
repeat O 0 2.831584424711764e-07
expansion O 0 1.9469206802291694e-10
in O 0 1.222347093335352e-12
a O 0 8.848072556751074e-13
gene O 0 3.623551805831404e-11
encoding O 0 8.56022804723855e-12
a O 0 5.05495575953141e-11
protein O 0 1.6126953994444193e-08
kinase O 0 2.3133791273721727e-06
( O 0 1.1584583292645334e-09
DM B-Disease 1 0.9999982118606567
protein O 0 5.564837465499295e-06
kinase O 0 4.969620476913406e-06
; O 0 7.970408222313097e-10
DMPK O 0 7.971690365593531e-07
) O 0 9.73808447074509e-12
and O 0 5.666345431060149e-12
involves O 0 2.4814276067958163e-12
changes O 0 4.4284541311778725e-11
in O 0 2.6744041009552078e-11
cytoarchitecture O 0 2.41291581914993e-06
and O 0 7.583808248057267e-09
ion O 0 3.1753575058246497e-07
homeostasis O 0 0.0003338528040330857
. O 0 1.2945698735222777e-08

To O 0 8.109307669812438e-10
obtain O 0 1.3418750832716597e-10
clues O 0 1.7938961427432787e-09
to O 0 2.592215331276293e-11
the O 0 1.0067788616674456e-11
normal O 0 8.864623479709621e-10
biological O 0 1.875227528813639e-09
role O 0 2.4275833079845377e-11
of O 0 2.2308040831253706e-12
DMPK O 0 3.0895002964825835e-06
in O 0 1.8519377698034134e-10
cellular O 0 6.164243018247362e-07
ion O 0 2.003920656079572e-07
homeostasis O 0 1.9696673916769214e-05
, O 0 7.445352112611658e-10
we O 0 1.8936661128066135e-09
have O 0 1.164192006686271e-11
compared O 0 1.1535689070640842e-11
the O 0 2.187920331020443e-11
resting O 0 1.1822429257790645e-08
[ O 0 4.097869613084448e-11
Ca2 O 0 1.4131436021358468e-09
+ O 0 3.997743025507816e-09
] O 0 3.843523543878291e-08
i O 0 1.7270645003009122e-07
, O 0 6.445494637151439e-13
the O 0 2.437463208701529e-13
amplitude O 0 1.9779827081789492e-11
and O 0 4.176400059119345e-10
shape O 0 1.8459576089924212e-09
of O 0 1.333879079239153e-12
depolarization O 0 9.117122057311633e-10
- O 0 9.558331157677458e-07
induced O 0 5.540989036489918e-07
Ca2 O 0 5.619964049685677e-09
+ O 0 7.326879103430883e-09
transients O 0 7.8384442758761e-07
, O 0 2.606246607417262e-10
and O 0 3.7508107730843676e-11
the O 0 1.9172170361708707e-12
content O 0 4.223855293306045e-11
of O 0 7.042562063033775e-13
ATP O 0 5.0584354482907656e-08
- O 0 1.9934915940211795e-08
driven O 0 3.4482423583170885e-09
ion O 0 2.017874312087997e-09
pumps O 0 2.129357801194942e-09
in O 0 6.70811808878291e-11
cultured O 0 9.793984645511955e-08
skeletal O 0 5.59780492039863e-05
muscle O 0 3.1318329263285705e-08
cells O 0 2.3929735970540378e-09
of O 0 7.158612353071192e-13
wild O 0 2.603592008654232e-07
- O 0 3.66424756066408e-05
type O 0 0.00017167808255180717
and O 0 6.697810306377505e-08
DMPK O 0 8.805371862763423e-07
[ O 0 6.447644085305626e-10
- O 0 4.836062998947455e-07
/ O 0 5.9571859310381114e-05
- O 0 0.000194426960661076
] O 0 1.7887058447740856e-06
knockout O 0 9.4136767074815e-06
mice O 0 6.397805918822996e-06
. O 0 1.314639619387492e-09

In O 0 6.76206823868597e-08
vitro O 0 1.304784291278338e-05
- O 0 4.113156137464102e-06
differentiated O 0 5.640466724798898e-07
DMPK O 0 7.612485205754638e-06
[ O 0 2.4830045575185977e-08
- O 0 1.320044702879386e-05
/ O 0 0.00010690703493310139
- O 0 2.2398646251531318e-05
] O 0 4.6753175553249093e-08
myotubes O 0 3.815191362832593e-08
exhibit O 0 1.2970802210077181e-09
a O 0 3.815433038956151e-11
higher O 0 8.991019040394121e-11
resting O 0 6.084632353520192e-09
[ O 0 1.8816972979784907e-10
Ca2 O 0 7.853939720803282e-09
+ O 0 4.23309636232716e-08
] O 0 2.1829139029705402e-07
i O 0 9.064347068488132e-07
than O 0 1.974590282949329e-11
do O 0 2.0794519439704118e-09
wild O 0 1.8607488883048973e-08
- O 0 1.2947274399266462e-06
type O 0 9.63501634032582e-07
myotubes O 0 2.1919477148912847e-06
because O 0 9.447165272291613e-10
of O 0 8.044111980253649e-14
an O 0 9.118000625363276e-12
altered O 0 1.3427671774479677e-06
open O 0 2.2149261980075607e-08
probability O 0 4.893939073435938e-11
of O 0 1.2050455034870455e-12
voltage O 0 1.8812631878972752e-06
- O 0 5.112246526550734e-06
dependent O 0 8.18869239083142e-08
l O 0 7.562547352790716e-07
- O 0 6.25987013336271e-08
type O 0 3.625548572472326e-08
Ca2 O 0 4.248130291983898e-09
+ O 0 4.134364406382929e-09
and O 0 1.0582261733560472e-09
Na O 0 3.7909137517999625e-07
+ O 0 6.70291999682604e-09
channels O 0 6.326536095002666e-08
. O 0 2.5858573060588697e-09

The O 0 3.1033782210698746e-09
mutant O 0 3.949127957980636e-08
myotubes O 0 3.1651504173169087e-07
exhibit O 0 2.6658153462477685e-09
smaller O 0 2.869442738973049e-10
and O 0 2.639444218743847e-10
slower O 0 3.5728522362887816e-09
Ca2 O 0 2.3297388906939887e-08
+ O 0 1.8860902173400973e-08
responses O 0 3.8369782351388437e-10
upon O 0 9.61868171917013e-13
triggering O 0 1.5792429863825674e-11
by O 0 4.2629756061979274e-13
acetylcholine O 0 2.0796343846996024e-07
or O 0 2.569134238683546e-08
high O 0 6.1883568491794e-08
external O 0 1.9928421579606947e-07
K O 0 3.7544853057625005e-06
+ O 0 5.567925427385489e-07
. O 0 4.872682524137417e-08

In O 0 2.5292536953713807e-09
addition O 0 1.5520870699781142e-10
, O 0 6.549839143277225e-11
we O 0 6.025885346261362e-11
observed O 0 7.82283092470859e-12
that O 0 9.84533635173257e-13
these O 0 1.3896787366685093e-12
Ca2 O 0 5.911056888407984e-08
+ O 0 6.375486805154651e-07
transients O 0 3.515469506965019e-05
partially O 0 9.529001545161009e-06
result O 0 8.429434927847979e-10
from O 0 2.0679973304540272e-13
an O 0 1.0624528736175379e-13
influx O 0 9.583594768464154e-13
of O 0 1.9012504922201814e-14
extracellular O 0 2.63034261038797e-10
Ca2 O 0 2.2148702871760406e-09
+ O 0 4.6022408106694e-10
through O 0 1.781228116393141e-11
the O 0 1.41628314978548e-11
l O 0 2.378862973273499e-08
- O 0 1.8887144292989433e-08
type O 0 2.3397586090823097e-08
Ca2 O 0 9.04697028403234e-09
+ O 0 1.670795235497735e-08
channel O 0 5.791786747977312e-07
. O 0 4.050387136800282e-09

Neither O 0 7.549174370069522e-07
the O 0 6.616714814944302e-11
content O 0 6.071251279493595e-10
nor O 0 4.14757028721624e-09
the O 0 2.8042043513643033e-12
activity O 0 2.781889996139597e-11
of O 0 2.9853490556355777e-13
Na O 0 5.684596544597298e-07
+ O 0 2.12926032361338e-09
/ O 0 1.0043467568721098e-07
K O 0 4.1766671898813e-08
+ O 0 1.8255585931825635e-09
ATPase O 0 2.0863426186679135e-07
and O 0 3.728880315634342e-09
sarcoplasmic O 0 1.4085165389587928e-07
reticulum O 0 6.693640557386971e-07
Ca2 O 0 1.690306987711665e-07
+ O 0 1.5890142890384595e-07
- O 0 4.254374744050438e-06
ATPase O 0 5.281144694890827e-06
are O 0 1.117986259124848e-10
affected O 0 2.3201537913131176e-10
by O 0 2.276935064104979e-11
DMPK O 0 1.1670409548969474e-05
absence O 0 8.053635980331819e-09
. O 0 1.0964674723723533e-09

In O 0 1.0397696925679156e-08
conclusion O 0 9.791286670335353e-10
, O 0 4.76375952573882e-11
our O 0 4.717300335077557e-12
data O 0 5.665289071199453e-11
suggest O 0 1.076580907755087e-10
that O 0 6.762253257353024e-11
DMPK O 0 5.465652520797448e-06
is O 0 5.788961324193487e-11
involved O 0 7.026264119136538e-12
in O 0 4.8010558202638e-12
modulating O 0 4.576586221105572e-09
the O 0 9.199057487974116e-11
initial O 0 1.4665661740576041e-10
events O 0 6.202087454720839e-12
of O 0 5.945438369056588e-13
excitation O 0 2.27096941252114e-09
- O 0 1.3010924703849014e-05
contraction O 0 1.3165956147531688e-07
coupling O 0 1.1326818594170618e-07
in O 0 6.068981983631261e-10
skeletal O 0 0.00023779393814038485
muscle O 0 9.834170668909792e-07
. O 0 2.122856196384859e-10
. O 0 1.1527409027323188e-09

Constitutional O 0 1.532663191028405e-06
RB1 O 0 0.00027472589863464236
- O 0 5.251261973171495e-05
gene O 0 1.0426321750856005e-05
mutations O 0 5.239947131485678e-05
in O 0 1.225040069385841e-09
patients O 0 1.3700950596273742e-08
with O 0 2.6941834874172343e-10
isolated O 0 0.02514965645968914
unilateral B-Disease 0 0.0033567666541785
retinoblastoma I-Disease 1 0.8484682440757751
. O 0 6.354205197567353e-07

In O 0 9.878254658701735e-09
most O 0 2.452801295405038e-10
patients O 0 2.491181483321725e-09
with O 0 3.6746541920429365e-10
isolated O 0 0.008437692187726498
unilateral B-Disease 0 0.0615469254553318
retinoblastoma I-Disease 1 0.98978590965271
, O 0 1.2366542705422034e-06
tumor B-Disease 0 8.36264734971337e-05
development O 0 3.6714381534963536e-10
is O 0 7.9518449117022e-12
initiated O 0 2.9470450385593594e-11
by O 0 1.9955636806640725e-13
somatic O 0 6.069595381852366e-10
inactivation O 0 1.8163643744628644e-06
of O 0 3.1514973465075757e-13
both O 0 1.2113864078511227e-10
alleles O 0 4.652315685471642e-11
of O 0 2.7548117866732502e-12
the O 0 7.842783644740337e-10
RB1 O 0 9.631363354856148e-06
gene O 0 4.6968850142548035e-07
. O 0 1.423592266291962e-08

However O 0 1.6933758217874129e-07
, O 0 7.42820995686122e-12
some O 0 1.281993174812035e-13
of O 0 3.588963978437554e-13
these O 0 2.5236146505847046e-10
patients O 0 2.7470610231006276e-09
can O 0 1.761771173391935e-09
transmit O 0 1.728204733808525e-05
retinoblastoma B-Disease 0 0.00465404475107789
predisposition O 0 0.0006992925191298127
to O 0 1.9537560902449513e-08
their O 0 6.963555954087042e-09
offspring O 0 3.864179234369658e-07
. O 0 5.148657056253114e-09

To O 0 7.392134127037764e-10
determine O 0 1.1870750216136372e-10
the O 0 8.842015661314484e-13
frequency O 0 1.0430869501476536e-08
and O 0 2.1457393639678912e-09
nature O 0 1.319946152378293e-09
of O 0 2.113271363457514e-12
constitutional O 0 2.428049938885124e-08
RB1 O 0 3.4759224945446476e-05
- O 0 1.4709429478898528e-06
gene O 0 4.255506610206794e-06
mutations O 0 8.279045687231701e-06
in O 0 2.7758451093262693e-09
patients O 0 1.30956747668165e-08
with O 0 3.447661878208663e-10
isolated O 0 0.0017000425141304731
unilateral B-Disease 0 0.00017399812350049615
retinoblastoma I-Disease 0 0.004395482130348682
, O 0 7.0164580812104305e-09
we O 0 5.952210391235724e-10
analyzed O 0 6.364412885595527e-10
DNA O 0 4.957465762345237e-07
from O 0 6.375949247738877e-12
peripheral O 0 4.210178303765133e-05
blood O 0 4.577558684104588e-06
and O 0 7.444876359841146e-08
from O 0 6.993997825333054e-09
tumor B-Disease 0 0.00146323477383703
tissue O 0 0.00013258513354230672
. O 0 5.5609369553621946e-08

The O 0 9.1800095303185e-10
analysis O 0 9.988364579882614e-10
of O 0 4.70461780643916e-10
tumors B-Disease 1 1.0
from O 0 4.878257242602047e-10
54 O 0 3.6635025679743194e-08
( O 0 2.6014478765601368e-11
71 O 0 8.814977547899616e-08
% O 0 1.2736177563976714e-11
) O 0 4.54973775668166e-12
of O 0 2.9514821576342998e-12
76 O 0 9.109270990848017e-07
informative O 0 1.2434337804734241e-05
patients O 0 5.931323698860069e-07
showed O 0 1.1903595975581993e-07
loss O 0 1.3423679945390177e-08
of O 0 6.878139550969831e-12
constitutional O 0 5.022086924100222e-08
heterozygosity O 0 0.00018048982019536197
( O 0 2.3267903159762682e-08
LOH O 1 0.9999508857727051
) O 0 3.356326550019162e-09
at O 0 1.3027090517425677e-08
intragenic O 0 6.6195275394420605e-06
loci O 0 8.294087905369452e-08
. O 0 4.8088986126515465e-09

Three O 0 5.848308504141642e-09
of O 0 1.9277529225703027e-11
13 O 0 2.8482218805692128e-09
uninformative O 0 8.216271089622751e-05
patients O 0 1.081222421817074e-06
had O 0 8.921535510353351e-09
constitutional O 0 1.8066179663378534e-09
deletions O 0 6.55640396871604e-05
. O 0 3.11941533936988e-07

For O 0 2.635474893875056e-10
39 O 0 3.090418587703425e-09
randomly O 0 1.653652681454787e-08
selected O 0 5.20842718287895e-07
tumors B-Disease 1 1.0
, O 0 2.357560902055411e-08
SSCP O 0 0.00011826288391603157
, O 0 7.703187532293043e-10
hetero O 0 6.042779432391399e-07
- O 0 4.7989139773108036e-08
duplex O 0 1.3225573638919741e-05
analysis O 0 1.5404405528940401e-10
, O 0 4.549961210749409e-13
sequencing O 0 3.873775189511264e-10
, O 0 3.120671776546402e-11
and O 0 2.1239619785173858e-10
Southern O 0 3.296047168532823e-08
blot O 0 9.702709212433547e-05
analysis O 0 1.3903853068875094e-10
were O 0 6.740769400992441e-12
used O 0 2.789670161540414e-10
to O 0 9.506412324000735e-11
identify O 0 1.242399427781038e-08
mutations O 0 4.5434512685460504e-07
. O 0 3.854937702385541e-09

Mutations O 0 4.4965716369915754e-05
were O 0 6.372843364133018e-10
detected O 0 3.264862513674416e-08
in O 0 5.1592490696306115e-11
21 O 0 6.385691420085493e-10
( O 0 7.085452016775129e-12
91 O 0 1.8981003435669663e-08
% O 0 1.0411612544336535e-11
) O 0 2.036097332402953e-11
of O 0 4.746438797553765e-10
23 O 0 0.015976931899785995
tumors B-Disease 1 1.0
with O 0 4.916279067401774e-05
LOH O 1 0.9999959468841553
. O 0 7.966872317410889e-07

In O 0 3.714930363329927e-09
6 O 0 5.037623651560352e-10
( O 0 2.1614353102467065e-12
38 O 0 3.7447939194024116e-10
% O 0 5.392918750457554e-12
) O 0 1.2836362181523064e-11
of O 0 2.983167879389015e-10
16 O 0 0.14305076003074646
tumors B-Disease 1 1.0
without O 0 3.958369234169368e-06
LOH O 1 0.9999983310699463
, O 0 4.758551774841635e-09
one O 0 8.84690029567814e-11
mutation O 0 8.358562730848007e-09
was O 0 7.1310304328164875e-09
detected O 0 3.82534949494584e-07
, O 0 1.6561574334161833e-10
and O 0 1.4737370213069312e-09
in O 0 4.5878581489411374e-10
9 O 0 1.0172906961258832e-08
( O 0 1.1249288826842285e-11
56 O 0 5.34586908074175e-09
% O 0 6.792394337956642e-12
) O 0 1.1933125494689723e-11
of O 0 2.3901158829886526e-11
the O 0 0.0002738344483077526
tumors B-Disease 1 1.0
without O 0 5.426036295830272e-06
LOH O 1 0.9999958276748657
, O 0 2.5129287539726874e-09
both O 0 4.757043092773472e-10
mutations O 0 2.259810401028517e-07
were O 0 1.9821504437800286e-09
found O 0 3.786685809359369e-08
. O 0 9.640263698429408e-09

Thus O 0 2.7964656368340002e-08
, O 0 3.0396376388130975e-11
a O 0 2.3951892986345813e-12
total O 0 1.1248296131333158e-12
of O 0 3.781796924229308e-13
45 O 0 6.315004630330634e-10
mutations O 0 1.7319366918400192e-07
were O 0 3.040870000248219e-09
identified O 0 4.6013155952095985e-06
in O 0 1.9465794593998e-06
tumors B-Disease 1 1.0
of O 0 5.617667442336938e-10
36 O 0 7.726053809165023e-06
patients O 0 5.57188229777239e-07
. O 0 2.34679231603252e-09

Thirty O 0 2.1002729511110374e-07
- O 0 4.4009616431139875e-06
nine O 0 4.2406564371155753e-10
of O 0 6.691422589633067e-13
the O 0 6.088759357814055e-11
mutations O 0 1.770973767634132e-07
- O 0 3.15003973128114e-07
including O 0 2.407306021190436e-10
34 O 0 2.54850762715364e-09
small O 0 5.800613878115257e-10
mutations O 0 1.3200648254496627e-06
, O 0 6.433906879488305e-11
2 O 0 1.0064241107166083e-10
large O 0 4.872566239377818e-10
structural O 0 1.994538979488425e-05
alterations O 0 0.00010080162610393018
, O 0 7.619402886405169e-09
and O 0 4.346218496209531e-09
hypermethylation O 0 0.0008054194622673094
in O 0 4.798777126779896e-07
3 O 0 0.0003917055728379637
tumors O 1 1.0
- O 0 0.0007443236536346376
were O 0 8.941845663912318e-08
not O 0 3.1811020484440178e-09
detected O 0 2.4035415435719187e-08
in O 0 6.544028773730615e-12
the O 0 3.997096490598873e-12
corresponding O 0 3.5762184880105963e-10
peripheral O 0 1.96057644643588e-05
blood O 0 6.380815307238663e-07
DNA O 0 6.0382066294550896e-05
. O 0 1.1703384927841398e-08

In O 0 4.344345327922383e-09
6 O 0 1.3865883996544426e-09
( O 0 9.445516417627697e-12
17 O 0 5.061431829211926e-10
% O 0 1.6912056607573667e-12
) O 0 1.3458416239092719e-12
of O 0 2.3738167464690263e-13
the O 0 3.248258106935964e-09
36 O 0 6.010466790939972e-08
patients O 0 2.3199866472367603e-09
, O 0 2.198716686149793e-12
a O 0 1.7738505109221592e-11
mutation O 0 1.6924031953635676e-08
was O 0 2.1814813067067007e-08
detected O 0 3.467780373966889e-08
in O 0 6.625007833993557e-12
constitutional O 0 3.8784994660368e-10
DNA O 0 0.011648613028228283
, O 0 5.9584150946534464e-09
and O 0 4.077369109012352e-09
1 O 0 9.400158429428984e-11
of O 0 4.492411217332792e-12
these O 0 4.2790979648543725e-09
mutations O 0 7.24147241726314e-07
is O 0 2.560369971593701e-10
known O 0 4.637993544776009e-09
to O 0 1.2260030768374008e-09
be O 0 2.5599158903766295e-10
associated O 0 8.217160285539649e-10
with O 0 5.111881473673918e-10
reduced O 0 6.560774750141718e-07
expressivity O 0 0.00361627247184515
. O 0 7.167783877548572e-08

The O 0 2.2614212724647587e-09
presence O 0 1.2738346488738728e-10
of O 0 2.0585052759591882e-13
a O 0 2.4991935604345983e-11
constitutional O 0 6.758207327095533e-10
mutation O 0 6.240355219233606e-07
was O 0 3.053455088775081e-07
not O 0 3.0853180010836923e-09
associated O 0 5.728422181050519e-10
with O 0 3.2159271773357645e-11
an O 0 5.835210786786504e-11
early O 0 7.87333647167543e-08
age O 0 4.0487417862777875e-09
at O 0 4.650563489860815e-09
treatment O 0 4.3044185105145516e-08
. O 0 6.483357184450256e-10

In O 0 1.1787776088567625e-08
1 O 0 1.6560570692547572e-09
patient O 0 6.882994796342246e-08
, O 0 7.650015169946567e-12
somatic O 0 3.3147196099037046e-09
mosaicism O 0 4.816010914510116e-05
was O 0 3.974578532961459e-08
demonstrated O 0 3.139489709869103e-11
by O 0 4.3115955684208673e-14
molecular O 0 2.1064395019920745e-11
analysis O 0 7.388954031961603e-12
of O 0 9.831501932011655e-14
DNA O 0 0.00010080508218379691
and O 0 1.4069847509290412e-09
RNA O 0 7.957479283504654e-06
from O 0 1.9066180578786174e-10
peripheral O 0 0.0003577915776986629
blood O 0 1.335398519586306e-05
. O 0 2.1138642836149302e-08

In O 0 3.121974501141267e-08
2 O 0 2.0301051506521617e-08
patients O 0 1.5220281923689072e-08
without O 0 1.9761199621104453e-11
a O 0 1.7945488151038802e-10
detectable O 0 2.8509846288216067e-06
mutation O 0 1.1357346920704003e-06
in O 0 3.692135264188323e-09
peripheral O 0 0.3849252462387085
blood O 0 6.48268178338185e-05
, O 0 3.4861002973229915e-10
mosaicism O 0 1.6955798400886124e-06
was O 0 7.531571100116707e-08
suggested O 0 3.837895334868335e-09
because O 0 2.115088243437313e-10
1 O 0 1.4077188199845825e-11
of O 0 1.9892260581799714e-12
the O 0 1.3114896724175651e-08
patients O 0 1.9911894355573168e-07
showed O 0 1.0559166184975766e-05
multifocal O 1 0.9999967813491821
tumors B-Disease 1 1.0
and O 0 2.9158450161048677e-06
the O 0 8.123209327415282e-10
other O 0 3.0397784289704077e-10
later O 0 4.3106547309434973e-07
developed O 0 1.0241669770039152e-06
bilateral B-Disease 0 1.574686194771857e-07
retinoblastoma I-Disease 0 0.002291389973834157
. O 0 5.9542717423255453e-08

In O 0 3.369610590553407e-09
conclusion O 0 1.6850616457730894e-09
, O 0 3.2116256876157934e-10
our O 0 2.1159073104737303e-10
results O 0 4.0218609692610485e-11
emphasize O 0 1.683136685581843e-10
that O 0 7.943632557294578e-11
the O 0 4.888162357524761e-12
manifestation O 0 9.773859499517812e-10
and O 0 2.489954631368363e-10
transmissibility O 0 3.166641704410722e-08
of O 0 3.2599899342511396e-12
retinoblastoma B-Disease 0 1.8986364693773794e-06
depend O 0 3.3645499719625604e-09
on O 0 2.3845629915086874e-09
the O 0 6.370384775244986e-11
nature O 0 1.1042032843633365e-09
of O 0 8.548573632825851e-13
the O 0 1.2122994275109988e-10
first O 0 2.130702503322368e-09
mutation O 0 8.00603494610641e-09
, O 0 1.4360149354353258e-11
its O 0 1.2152991286928927e-11
time O 0 3.5195810710320075e-09
in O 0 4.852104482089281e-11
development O 0 6.891711645806708e-10
, O 0 9.657042943089778e-10
and O 0 1.5619774362818362e-09
the O 0 3.054673181068779e-11
number O 0 6.734916513373435e-10
and O 0 8.287695862918554e-09
types O 0 1.270450944446111e-08
of O 0 2.954919295361513e-11
cells O 0 4.030495404094836e-07
that O 0 1.562257545550949e-09
are O 0 4.799675240585444e-11
affected O 0 2.2619042194804706e-09
. O 0 1.5897760885508205e-10
. O 0 1.4966080597034193e-09

Hereditary B-Disease 1 0.9999642372131348
deficiency I-Disease 1 0.9997652173042297
of I-Disease 0 3.1940014522113813e-10
the I-Disease 0 1.4941067272289388e-09
fifth I-Disease 0 6.897319337895169e-08
component I-Disease 0 1.2877843236225317e-09
of I-Disease 0 2.49556235051851e-12
complement I-Disease 0 2.3534456161655726e-08
in O 0 3.898868783380749e-09
man O 0 9.576301636116114e-06
. O 0 3.1148710277761893e-09

I O 0 0.007983888499438763
. O 0 9.597281547257808e-08

Clinical O 0 0.0005167126073502004
, O 0 1.5937457575887493e-08
immunochemical O 0 6.998900789767504e-05
, O 0 1.7086529524590333e-08
and O 0 1.1377285780156399e-08
family O 0 1.619609690806101e-08
studies O 0 1.1872844929428084e-08
. O 0 1.8073487151326617e-09

The O 0 1.542832706036279e-08
first O 0 1.218294243265916e-09
recognized O 0 1.010886152563728e-09
human O 0 1.588334974655936e-08
kindred O 0 8.237650035880506e-06
with O 0 5.598142706730869e-06
hereditary B-Disease 1 0.999995231628418
deficiency I-Disease 1 0.998288094997406
of I-Disease 0 3.0675531559332114e-11
the I-Disease 0 3.2432190266717953e-09
fifth I-Disease 0 2.385128823334526e-07
component I-Disease 0 3.891350353057987e-09
of I-Disease 0 1.5878872869357075e-11
complement I-Disease 0 2.0464790395635646e-07
( O 0 3.9371431115320377e-10
C5 O 0 2.0679631234088447e-06
) O 0 7.820120245805029e-11
is O 0 4.3608558430996425e-10
described O 0 1.5327231039918843e-07
. O 0 6.761021520418353e-09

The O 0 8.46073611171505e-09
proband O 0 8.128654371830635e-07
, O 0 1.0482015949664358e-10
a O 0 2.1514005854594842e-11
20 O 0 6.914670919178079e-11
- O 0 1.7342506453132955e-07
year O 0 2.3618251798751544e-10
- O 0 2.9677057682420127e-06
old O 0 1.2018710549455136e-05
black O 0 9.604771378235455e-08
female O 0 8.423174335803196e-08
with O 0 3.125475132037536e-07
systemic B-Disease 1 0.9999986886978149
lupus I-Disease 1 0.9997419714927673
erythematosus I-Disease 1 0.9999985694885254
since O 0 6.941935862414539e-05
age O 0 9.171649821837491e-07
11 O 0 1.4542362869462977e-08
, O 0 1.3606513693531497e-09
lacked O 0 2.335925273655448e-06
serum O 0 4.182784778095083e-06
hemolytic O 0 6.341084826999577e-06
complement O 0 2.240521101981585e-09
activity O 0 8.655563377146791e-09
, O 0 1.324040321826203e-10
even O 0 1.3211752802888554e-09
during O 0 2.4980806312413506e-09
remission O 0 1.2237403268500202e-07
. O 0 6.973813193589251e-10

C5 O 0 0.0036144242621958256
was O 0 2.5454107799305348e-06
undetectable O 0 2.3570539724460104e-06
in O 0 1.64329411189712e-10
her O 0 8.208735913228793e-09
serum O 0 2.6592756441345955e-08
by O 0 1.957176174599562e-12
both O 0 2.828821898948064e-10
immunodiffusion O 0 0.00011940622061956674
and O 0 6.535447027999908e-07
hemolytic O 0 0.0004166175494901836
assays O 0 9.098851478483994e-06
. O 0 2.4132294385026398e-08

Other O 0 1.3124742959114144e-10
complement O 0 1.4436447870469493e-10
components O 0 1.8586197025882711e-09
were O 0 1.7839217603121682e-10
normal O 0 4.008432252788907e-09
during O 0 4.0780204213497484e-10
remission O 0 1.7635976234942063e-08
of O 0 9.945731738181252e-12
lupus O 0 0.001361589296720922
, O 0 1.3055638792280888e-09
but O 0 4.181968549232806e-08
C1 O 0 1.8712553355726413e-05
, O 0 6.991670437050956e-11
C4 O 0 1.9669234916364076e-06
, O 0 7.209311370104388e-09
C2 O 0 3.584901787689887e-05
, O 0 3.061610132082393e-10
and O 0 4.32658309179601e-09
C3 O 0 3.172579454258084e-05
levels O 0 5.916967893426772e-08
fell O 0 0.0002702695783227682
during O 0 7.952057501370291e-08
exacerbations O 0 0.08321122080087662
. O 0 3.780493784688588e-08

A O 0 2.2233817276173795e-07
younger O 0 1.9196175315983055e-08
half O 0 2.665642373500532e-09
- O 0 1.5036760487419087e-05
sister O 0 5.4324631491908804e-05
, O 0 6.823621223617238e-09
who O 0 9.141278383140161e-07
had O 0 2.3902321117930114e-05
no O 0 4.0100181308844185e-07
underlying O 0 0.0001508059212937951
disease O 1 0.9845901727676392
, O 0 1.3878742599615634e-09
was O 0 1.8763752223094343e-06
also O 0 1.308693953205875e-07
found O 0 4.462827263296276e-08
to O 0 1.4580906482208889e-09
lack O 0 7.069183016739089e-09
immunochemically O 0 2.74181438726373e-05
detectable O 0 9.50068988458952e-06
C5 O 0 6.113108975114301e-05
. O 0 3.4545244886885484e-08

By O 0 1.3889395411581518e-08
hemolytic O 0 0.0003391495847608894
assay O 0 5.767815309809521e-06
, O 0 4.369008710369826e-09
she O 0 3.808284532169637e-08
exhibited O 0 9.816568669052117e-10
1 O 0 3.3482220468394885e-11
- O 0 1.6190033136354032e-07
2 O 0 5.559361859752698e-10
% O 0 7.0463242445723e-13
of O 0 7.601021591654988e-14
the O 0 1.446155278861383e-10
normal O 0 8.40330827145408e-08
serum O 0 1.933486117877692e-07
C5 O 0 1.2996444809232344e-07
level O 0 6.605738178677711e-09
and O 0 5.835592564729097e-10
normal O 0 4.106086581856516e-10
concentrations O 0 2.7777307121112926e-09
of O 0 6.797133927753662e-13
other O 0 1.4439551117295668e-11
complement O 0 1.363524737563182e-09
components O 0 7.090400089282411e-08
. O 0 1.4001562576027027e-08

C5 O 0 0.0005470465985126793
levels O 0 2.9662524525519984e-07
of O 0 6.158965698555008e-12
other O 0 3.2712593051043015e-11
family O 0 4.28250851447487e-10
members O 0 1.7250411440006969e-13
were O 0 1.1497445356889457e-11
either O 0 1.0017492391156679e-10
normal O 0 2.1845656394958723e-09
or O 0 6.628955023790795e-11
approximately O 0 3.733275910633438e-10
half O 0 1.230159512033424e-07
- O 0 4.201402407488786e-05
normal O 0 5.149661888026458e-07
, O 0 1.9265225525977314e-10
consistent O 0 5.1052002625340265e-09
with O 0 7.379398758722289e-10
autosomal O 0 0.007185952737927437
codominant O 0 1.5514218830503523e-05
inheritance O 0 3.558551497917506e-08
of O 0 1.3443926527578753e-11
the O 0 1.3973354695551166e-09
gene O 0 5.052575943409465e-05
determining O 0 0.00032767016091383994
C5 B-Disease 1 0.9999995231628418
deficiency I-Disease 1 0.9999995231628418
. O 0 5.861377161409109e-08

Normal O 0 5.984562449157238e-05
hemolytic O 0 0.002844638889655471
titers O 0 6.701180973323062e-05
were O 0 1.9341863222166467e-08
restored O 0 1.247349928235053e-06
to O 0 1.1977147051922543e-09
both O 0 9.940626988225176e-09
homozygous O 0 0.004941405262798071
C5 B-Disease 1 0.9999994039535522
- I-Disease 1 0.9999982118606567
deficient I-Disease 1 1.0
( O 0 8.510867701261304e-06
C5D B-Disease 1 0.9999998807907104
) O 0 1.0183565102295233e-08
sera O 0 1.0012902151856906e-07
by O 0 4.5431101372214733e-13
addition O 0 1.0370007803850445e-12
of O 0 1.1557860788227736e-12
highly O 0 1.7103084504199728e-09
purified O 0 2.2868059090797033e-07
human O 0 1.541967797891175e-08
C5 O 0 6.006483999954071e-06
. O 0 7.885762265402718e-09

In O 0 2.4792552455465966e-09
specific O 0 1.033357510671351e-09
C5 O 0 2.4446080715279095e-06
titrations O 0 1.1671032552840188e-05
, O 0 5.087809729076298e-09
however O 0 4.728693880906576e-09
, O 0 1.8010364033482773e-10
it O 0 8.20086487607341e-09
was O 0 1.8481293295735668e-07
noted O 0 3.5133167486378625e-09
that O 0 3.8965919380018477e-10
when O 0 4.13597128767762e-10
limited O 0 3.490496433555812e-11
amounts O 0 1.045277688190016e-12
of O 0 2.8730707049562376e-12
C5 O 0 1.5981252090568887e-06
were O 0 3.483886790167645e-10
assayed O 0 4.547569076862601e-08
in O 0 4.1018109048218676e-11
the O 0 4.0334510904849186e-12
presence O 0 1.5009689671718895e-11
of O 0 1.7355226685032005e-13
low O 0 1.8873342888525713e-09
dilutions O 0 2.2024487122962455e-07
of O 0 4.9789117273491e-11
either O 0 2.2658448415313615e-06
C5D B-Disease 1 0.9999996423721313
serum O 0 4.2732557631097734e-05
, O 0 1.816997073633697e-11
curving O 0 2.3133335247393916e-08
rather O 0 6.180736478178517e-12
than O 0 2.9445529673398363e-13
linear O 0 9.345370033386757e-10
dose O 0 3.7527039253859584e-09
- O 0 4.091203322786896e-07
response O 0 5.781450318487202e-10
plots O 0 1.0746585985543788e-06
were O 0 1.3025674761024675e-08
consistently O 0 8.921638539050036e-09
obtained O 0 1.4740559467485426e-11
, O 0 3.8681509167623473e-13
suggesting O 0 1.9484453113449707e-12
some O 0 2.5053475461757346e-13
inhibitory O 0 1.8419586966800239e-09
effect O 0 4.20997725569805e-09
. O 0 1.1805411093135376e-09

Further O 0 1.360496337809991e-08
studies O 0 4.921321128392719e-10
suggested O 0 2.741427640451377e-10
that O 0 3.5861140446069584e-11
low O 0 1.2841230301319229e-08
dilutions O 0 2.79679661616683e-05
of O 0 2.8922086947602565e-09
C5D B-Disease 1 0.9999996423721313
serum O 0 0.00014863864635117352
contain O 0 5.683605253103963e-10
a O 0 4.815576062910942e-11
factor O 0 2.0347590279357064e-10
( O 0 1.4828908934116924e-11
or O 0 4.825729260637956e-10
factors O 0 1.8820632552429828e-10
) O 0 5.5521078186349104e-12
interfering O 0 1.6409521519378245e-09
at O 0 1.7374472971454225e-09
some O 0 1.312302805485388e-12
step O 0 1.388912318489588e-09
in O 0 2.5970552097742683e-11
the O 0 2.4601667925061577e-10
hemolytic O 0 2.9414420623652404e-06
assay O 0 5.4106926938857214e-08
of O 0 3.572085335856734e-11
C5 O 0 1.0844922144315206e-05
, O 0 2.0652923815589475e-10
rather O 0 3.757998686543251e-12
than O 0 1.0831832392838026e-12
a O 0 5.515527617960814e-11
true O 0 4.435102507471811e-09
C5 O 0 4.6712798962289526e-07
inhibitor O 0 5.8881244768826946e-08
or O 0 2.198744963877175e-09
inactivator O 0 0.00012182732461951673
. O 0 1.9705675313730353e-08

Of O 0 1.0165221997482377e-09
clinical O 0 5.006101559956733e-07
interest O 0 3.2129859883767153e-10
are O 0 2.4079797183995666e-11
( O 0 1.423247977805353e-11
a O 0 2.8177021826891746e-10
) O 0 3.6552330606731687e-11
the O 0 1.2906157045855515e-11
documentation O 0 7.128381440679732e-08
of O 0 1.6124392931970988e-09
membranous O 1 0.9999899864196777
glomerulonephritis B-Disease 1 1.0
, O 0 0.024046869948506355
vasculitis B-Disease 1 0.9999998807907104
, O 0 6.375584052875638e-05
and O 1 0.5347633361816406
arthritis B-Disease 1 1.0
in O 0 6.306669320110814e-08
an O 0 3.3986438108257744e-09
individual O 0 2.6420696741524807e-09
lacking O 0 1.0340386324969586e-07
C5 O 0 7.332169388973853e-06
( O 0 3.889491159703162e-11
and O 0 1.1234027597062379e-10
its O 0 3.227582697634679e-12
biologic O 0 1.1522363507765476e-07
functions O 0 1.1073458816568404e-09
) O 0 7.196349072202679e-11
, O 0 5.015093895721634e-10
and O 0 6.144390329865246e-09
( O 0 8.269970819263506e-11
b O 0 1.7195502550748643e-06
) O 0 7.498774171055267e-12
a O 0 3.720280333796566e-11
remarkable O 0 1.516226477704663e-09
propensity O 0 1.227845245921344e-06
to O 0 2.0361201677587815e-05
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 1.0129034500039324e-08
the O 0 1.1085419249212691e-09
proband O 0 6.678574663965264e-06
, O 0 1.1074974270997018e-10
even O 0 1.2320151843159266e-10
during O 0 1.2288088081791049e-11
periods O 0 3.234005424568309e-11
of O 0 1.672477667425884e-13
low O 0 3.820213922978155e-09
- O 0 3.4647126057052446e-08
dose O 0 2.5464655384332957e-10
or O 0 9.626633691584008e-12
alternate O 0 3.5924757613159386e-10
- O 0 2.687258700007078e-07
day O 0 9.4164032127253e-10
corticosteroid O 0 1.3607356663669634e-07
therapy O 0 2.0315422233352365e-08
. O 0 1.4608235454627305e-10

Other O 0 3.919004565311468e-10
observations O 0 3.1134690381406926e-09
indicate O 0 2.293102374650857e-09
that O 0 1.452527126355463e-10
the O 0 4.468691805481484e-10
C5D B-Disease 1 0.9999995231628418
state O 0 2.180852165523106e-09
is O 0 9.556133662158572e-11
compatible O 0 1.1539772470925413e-09
with O 0 1.0689529122975827e-10
normal O 0 1.5366536487704252e-08
coagulation O 0 1.7089551995752572e-09
function O 0 1.8889126707222204e-08
and O 0 2.8386388795098583e-09
the O 0 7.494474485447711e-11
capacity O 0 5.7366635747291284e-11
to O 0 7.260676001402677e-12
mount O 0 4.705023926021568e-09
a O 0 1.2525975812138768e-08
neutrophilic O 0 0.04389755427837372
leukocytosis O 0 0.019108889624476433
during O 0 9.675244427853613e-07
pyogenic B-Disease 0 0.27766627073287964
infection I-Disease 1 0.9561027884483337
. O 0 8.963011999263415e-10
. O 0 3.0606774892305566e-09

Susceptibility O 1 0.545639157295227
to O 0 7.324290345422924e-05
ankylosing B-Disease 1 0.9999998807907104
spondylitis I-Disease 1 1.0
in O 0 0.00010837626177817583
twins O 0 0.002375968499109149
: O 0 2.353380268438343e-10
the O 0 2.364107824434636e-12
role O 0 9.655595767377179e-12
of O 0 7.649398150490205e-13
genes O 0 3.3489022666088886e-09
, O 0 2.0801692313110465e-10
HLA O 0 6.381892308127135e-05
, O 0 1.7669570251399591e-09
and O 0 2.5553901217278963e-09
the O 0 3.3835201307397256e-10
environment O 0 6.599166795240308e-07
. O 0 1.0653385951187033e-09

OBJECTIVE O 0 1.7953352937638556e-07
To O 0 1.9274744300634694e-10
determine O 0 1.4406546788858776e-10
the O 0 2.6875652311270093e-12
relative O 0 9.445071114111414e-11
effects O 0 8.933042083825171e-10
of O 0 2.871805007340078e-12
genetic O 0 5.284686267259531e-06
and O 0 3.062990083790851e-09
environmental O 0 5.079613951686213e-10
factors O 0 2.964018613882402e-11
in O 0 2.6458202295742694e-10
susceptibility O 0 0.00048530567437410355
to O 0 6.638429476879537e-05
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 5.346521356841549e-05
AS B-Disease 1 0.9999926090240479
) O 0 8.578088461774769e-09
. O 0 4.109340423497088e-09

METHODS O 0 1.4732053386978805e-05
Twins O 0 2.5377332349307835e-05
with O 0 9.694580693775379e-10
AS B-Disease 1 0.9826623201370239
were O 0 2.7080679365631966e-10
identified O 0 3.782056889889418e-09
from O 0 3.3472625712849258e-12
the O 0 6.256045681496403e-10
Royal O 0 1.9313829398015514e-06
National O 0 3.256553782193805e-08
Hospital O 0 4.496292967814952e-05
for O 0 7.317354278058019e-09
Rheumatic B-Disease 1 0.9999620914459229
Diseases I-Disease 1 0.8075579404830933
database O 0 5.273922397464048e-06
. O 0 9.670949197015943e-08

Clinical O 0 4.554842962534167e-05
and O 0 2.1148029993867112e-09
radiographic O 0 6.487473001470789e-06
examinations O 0 6.583118761227524e-07
were O 0 3.317684460490966e-10
performed O 0 7.373257915332943e-08
to O 0 1.9296889086639624e-10
establish O 0 3.734398035248887e-08
diagnoses O 0 0.2525191009044647
, O 0 2.7222094445278344e-07
and O 0 0.00012500546290539205
disease O 1 0.9765268564224243
severity O 0 1.197397978103254e-05
was O 0 2.8202697066603832e-08
assessed O 0 5.876178016395173e-11
using O 0 1.583351644240949e-10
a O 0 3.661486946970882e-10
combination O 0 5.4887929756830545e-09
of O 0 8.287588497413179e-12
validated O 0 7.40228472295712e-07
scoring O 0 1.2528365012087761e-08
systems O 0 1.3615602938443772e-06
. O 0 1.4406012383005873e-08

HLA O 0 6.332894554361701e-05
typing O 0 2.638191745063523e-06
for O 0 4.291361710428987e-11
HLA O 0 5.984345534670865e-06
- O 0 8.036987537707319e-07
B27 O 0 4.5062883202717785e-08
, O 0 3.409964324796455e-11
HLA O 0 1.2527652870630845e-07
- O 0 2.5925158908535195e-08
B60 O 0 5.4054085651955575e-09
, O 0 6.1702062729984686e-12
and O 0 2.8165938331659035e-11
HLA O 0 2.957006927317707e-06
- O 0 2.2070396425988292e-06
DR1 O 0 0.012147215195000172
was O 0 5.481219034209062e-09
performed O 0 8.125156797378352e-11
by O 0 1.7325790596049023e-13
polymerase O 0 2.0829979519021435e-08
chain O 0 2.2910931818387326e-07
reaction O 0 1.670573679390941e-10
with O 0 2.8789236619641834e-12
sequence O 0 4.647326967699428e-09
- O 0 8.36178326579784e-09
specific O 0 1.2814590534537817e-11
primers O 0 2.8976111821066297e-07
, O 0 5.298022784372414e-11
and O 0 1.3052396663493226e-10
zygosity O 0 1.286160511426715e-07
was O 0 5.00706587303057e-10
assessed O 0 2.3880515620522402e-11
using O 0 2.536866827718143e-10
microsatellite O 0 2.2565320250578225e-05
markers O 0 0.0012323926202952862
. O 0 4.684654797415533e-08

Genetic O 0 0.0009230442810803652
and O 0 8.753313074372215e-10
environmental O 0 9.42453406982402e-12
variance O 0 1.9013079305407743e-11
components O 0 7.166933269076026e-09
were O 0 8.043177790462153e-10
assessed O 0 6.299269994514134e-10
with O 0 5.002080347149551e-11
the O 0 1.9363770309421824e-10
program O 0 3.413872295965348e-09
Mx O 0 3.448119798576954e-07
, O 0 3.7248275210760573e-13
using O 0 8.622278780713588e-13
data O 0 4.733050062988298e-10
from O 0 2.4251477562242663e-12
this O 0 1.9079678115208054e-10
and O 0 2.6004631781262333e-09
previous O 0 1.3514023233796024e-09
studies O 0 9.093671649029744e-11
of O 0 2.0349548868897616e-12
twins O 0 0.00023066173889674246
with O 0 1.8803142154411034e-08
AS B-Disease 1 0.9999929666519165
. O 0 9.89102204584924e-08

RESULTS O 0 9.151763151749037e-07
Six O 0 3.983781082794735e-10
of O 0 2.1266148564347276e-12
8 O 0 3.7946876751959735e-09
monozygotic O 0 4.099262696399819e-06
( O 0 2.9500570875029553e-09
MZ O 1 0.9987223744392395
) O 0 4.325793057091687e-08
twin O 0 0.0019838486332446337
pairs O 0 1.5813053323654458e-05
were O 0 6.932685892024892e-07
disease O 0 0.006876032799482346
concordant O 0 1.6764221300036297e-07
, O 0 6.0050758809993e-10
compared O 0 3.0732778544262374e-09
with O 0 2.5171825734915387e-10
4 O 0 5.175575967797386e-09
of O 0 1.37167230698787e-11
15 O 0 5.3677133848850644e-09
B27 O 0 1.173876853499678e-07
- O 0 1.390945840284985e-06
positive O 0 6.091921411766066e-10
dizygotic O 0 1.63960436339039e-08
( O 0 4.004805861934635e-11
DZ O 0 2.3365790184470825e-05
) O 0 5.769539013211755e-11
twin O 0 4.12246123460136e-07
pairs O 0 5.558092208701737e-09
( O 0 7.448639795237799e-12
27 O 0 2.1190584842400995e-09
% O 0 1.733704000674019e-12
) O 0 1.1451485593116928e-11
and O 0 7.291757198046867e-10
4 O 0 7.884043418115994e-10
of O 0 4.121337646156853e-11
32 O 0 1.2349688631729805e-06
DZ O 1 0.9633517861366272
twin O 0 0.000468609418021515
pairs O 0 2.32618670992224e-08
overall O 0 6.4790097731304286e-09
( O 0 6.667436568130736e-12
12 O 0 4.637369654947321e-11
. O 0 1.7567126572859415e-11
5 O 0 1.2405322602493385e-10
% O 0 1.6280780543165285e-11
) O 0 1.2621365064191536e-10
. O 0 2.2129742482945858e-09

Nonsignificant O 0 8.877064101397991e-05
increases O 0 2.2394798904201707e-08
in O 0 2.1509740169567415e-11
similarity O 0 1.1739776928365586e-09
with O 0 2.0343386697430077e-11
regard O 0 5.912167422295056e-10
to O 0 1.6319386730856422e-08
age O 0 9.10295128164762e-08
at O 0 2.3932593649078626e-06
disease O 0 0.05613398551940918
onset O 0 7.382125204458134e-06
and O 0 4.1623366087151226e-08
all O 0 1.0869198596719087e-10
of O 0 2.0568864320114066e-11
the O 0 1.9052863819979393e-07
disease O 0 0.08341191709041595
severity O 0 2.2217432160687167e-07
scores O 0 8.452320798824076e-08
assessed O 0 8.749728941381818e-09
were O 0 1.1614901040957193e-08
noted O 0 1.8289264289705898e-06
in O 0 2.871723381758784e-06
disease O 1 0.9614308476448059
- O 0 0.00340273673646152
concordant O 0 0.0007206275477074087
MZ O 1 0.9987230896949768
twins O 0 0.00023567384050693363
compared O 0 5.957642379428307e-09
with O 0 1.4020181682283805e-09
concordant O 0 0.0002205375931225717
DZ O 1 0.9970723390579224
twins O 0 0.014866407960653305
. O 0 5.1240991894019317e-08

HLA O 0 0.0038769482634961605
- O 0 0.0002272324200021103
B27 O 0 5.12181770773168e-07
and O 0 7.545540303688369e-10
B60 O 0 8.231109127621039e-09
were O 0 8.633148362857668e-11
associated O 0 4.095496441980373e-10
with O 0 1.156513440569995e-09
the O 0 5.396046844907687e-07
disease O 0 0.3396010994911194
in O 0 2.8634178361741647e-10
probands O 0 5.0181944970972836e-05
, O 0 3.231979794904305e-09
and O 0 4.225712668670667e-09
the O 0 2.062505305433504e-10
rate O 0 9.621823693350962e-08
of O 0 9.702492975716126e-11
disease O 0 0.0001609424944035709
concordance O 0 1.2481521594054357e-08
was O 0 1.1962632662232409e-08
significantly O 0 4.5036907536655235e-09
increased O 0 4.792350960514113e-10
among O 0 5.86056703166804e-10
DZ O 1 0.9893561005592346
twin O 0 0.07538444548845291
pairs O 0 7.863429232202179e-07
in O 0 1.5347431103762688e-09
which O 0 1.541932448390071e-08
the O 0 2.36263741903997e-09
co O 0 0.0003555163857527077
- O 0 6.539606692967936e-05
twin O 0 3.853709131362848e-05
was O 0 2.0372269204926852e-08
positive O 0 1.6360555488495465e-12
for O 0 3.366203800078682e-14
both O 0 2.4029557857407902e-11
B27 O 0 3.741263654433169e-08
and O 0 5.014178405815528e-09
DR1 O 0 0.042702291160821915
. O 0 9.33169541639245e-09

Additive O 0 1.651985712669557e-07
genetic O 0 1.411322841704532e-06
effects O 0 2.0495271257914283e-08
were O 0 2.2003706148798763e-11
estimated O 0 3.289554392771343e-11
to O 0 3.858067337825233e-11
contribute O 0 4.844204898324378e-12
97 O 0 8.438973964075558e-10
% O 0 2.096118200886621e-12
of O 0 1.62795517626331e-13
the O 0 1.1302415947600508e-10
population O 0 1.1409587857835746e-10
variance O 0 2.8756188541478878e-09
. O 0 1.0798602012584979e-08

CONCLUSION O 0 3.1117255616663897e-07
Susceptibility O 0 0.00016252006753347814
to O 0 2.93988676958179e-07
AS B-Disease 1 0.999862551689148
is O 0 5.629487431768609e-10
largely O 0 2.450523950425776e-10
genetically O 0 1.5206468972905895e-08
determined O 0 6.530001996907231e-07
, O 0 1.3791371378246708e-09
and O 0 1.8845645044507364e-09
the O 0 6.767181259803579e-11
environmental O 0 3.874302212381053e-09
trigger O 0 5.409365826380963e-07
for O 0 7.875026186709988e-10
the O 0 1.3796345683658728e-06
disease O 1 0.6811802387237549
is O 0 3.816112148502526e-10
probably O 0 7.299831850104965e-09
ubiquitous O 0 1.7950491155716009e-06
. O 0 3.164148054679572e-08

HLA O 0 0.008870583958923817
- O 0 8.52928715175949e-05
B27 O 0 2.2096355678513646e-07
accounts O 0 4.2974412917118343e-10
for O 0 1.380477221250842e-12
a O 0 1.1520450392266124e-11
minority O 0 7.40754624306561e-10
of O 0 9.517252437529766e-13
the O 0 6.732652629848346e-11
overall O 0 1.3357606576391845e-08
genetic O 0 1.384096890433284e-06
susceptibility O 0 4.982157861377345e-06
to O 0 5.129144753368564e-08
AS B-Disease 1 0.9999867677688599
. O 0 3.1141482281782373e-07

Cell O 0 0.0018647672841325402
cycle O 0 5.5952859838726e-05
- O 0 5.868687821930507e-06
dependent O 0 1.205089272815485e-08
colocalization O 0 2.3382425240470184e-07
of O 0 4.198890540818567e-11
BARD1 O 0 0.00014274455315899104
and O 0 3.659849667769777e-08
BRCA1 O 0 1.4507821788356523e-07
proteins O 0 5.841650496662965e-10
in O 0 7.970369156340418e-12
discrete O 0 2.2119793996466797e-08
nuclear O 0 2.6772495402838103e-05
domains O 0 1.6519494465683238e-06
. O 0 1.2112235658889858e-08

Germ O 1 0.5567021369934082
- O 0 0.002561390632763505
line O 0 9.70482960838126e-06
mutations O 0 2.7213106434942347e-08
of O 0 1.8184454593159205e-12
the O 0 7.50647738412269e-11
BRCA1 O 0 2.131075007127947e-06
gene O 0 4.894768039775954e-07
predispose O 0 4.2835259250750823e-07
women O 0 7.2847408105758404e-09
to O 0 1.0878781209200383e-10
early O 0 3.1102126740734093e-07
- O 1 0.9965740442276001
onset O 1 0.9998077750205994
breast B-Disease 1 0.9999994039535522
and I-Disease 1 0.9999996423721313
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
by O 0 1.6424739346376782e-09
compromising O 0 1.6838821466080844e-06
the O 0 1.217114409257647e-09
genes O 0 2.1875527522752236e-07
presumptive O 0 2.9921434929747193e-07
function O 0 1.0025130059432286e-08
as O 0 1.4320412911050795e-10
a O 0 3.5203799875205277e-09
tumor B-Disease 0 3.098663000855595e-05
suppressor O 0 1.4440158338402398e-05
. O 0 1.791049584198845e-07

Although O 0 1.9437722542647862e-08
the O 0 3.630358860751137e-11
biochemical O 0 1.386853565321644e-08
properties O 0 3.332134212996607e-08
of O 0 1.0468908379079878e-10
BRCA1 O 0 2.6205556423519738e-05
polypeptides O 0 2.3376901481242385e-06
are O 0 1.7731487389482936e-09
not O 0 1.399622195918937e-08
understood O 0 1.9508442861138064e-08
, O 0 3.0892014640793164e-11
their O 0 1.1384322304297534e-11
expression O 0 9.984439941490564e-10
pattern O 0 1.6014847687984002e-06
and O 0 6.9707715155686856e-09
subcellular O 0 3.1216729894367745e-06
localization O 0 2.5505957523819234e-07
suggest O 0 1.2041466712631177e-09
a O 0 1.5437429112807877e-11
role O 0 2.925518438612329e-10
in O 0 4.536067008120703e-11
cell O 0 1.1547775102371816e-05
- O 0 0.00015186176460701972
cycle O 0 4.415238436195068e-06
regulation O 0 1.273604368634551e-07
. O 0 9.304604864368571e-10

When O 0 7.972383173182607e-06
resting O 0 3.667264252271707e-07
cells O 0 1.0194487920500706e-08
are O 0 1.3987554170480365e-11
induced O 0 2.4727307845751056e-06
to O 0 4.801051778358101e-10
proliferate O 0 4.535685548034962e-06
, O 0 3.7119730900148085e-11
the O 0 7.193929913579256e-12
steady O 0 3.898943390368004e-09
- O 0 1.381220116059012e-08
state O 0 5.3342618516749596e-11
levels O 0 2.2058585860684765e-11
of O 0 5.0742389619534006e-14
BRCA1 O 0 5.245771372841546e-09
increase O 0 5.4301181606764004e-12
in O 0 9.60645799019666e-12
late O 0 3.25460047800874e-10
G1 O 0 4.0968370740301907e-07
and O 0 2.323018860606041e-10
reach O 0 2.125946814424129e-11
a O 0 1.386205495008952e-12
maximum O 0 5.367490306384948e-12
during O 0 2.3237588242519536e-10
S O 0 7.19258480330609e-07
phase O 0 2.607427695977549e-08
. O 0 1.98100535975243e-09

Moreover O 0 9.179603921438684e-07
, O 0 3.9602651713543935e-10
in O 0 2.6914599021710117e-11
S O 0 6.913532502039743e-07
phase O 0 2.2016545031533497e-08
cells O 0 1.3063497306120553e-07
, O 0 8.481813168481622e-11
BRCA1 O 0 5.491602550478092e-08
polypeptides O 0 2.181518965471696e-08
are O 0 4.14607931320532e-11
hyperphosphorylated O 0 2.9160648864490213e-06
and O 0 3.3855616088374063e-09
accumulate O 0 7.272495938792645e-09
into O 0 2.0697948563408453e-11
discrete O 0 2.083892951532107e-07
subnuclear O 0 0.000165130608365871
foci O 0 1.4647816897195298e-05
termed O 0 2.085575715682353e-06
" O 0 2.111776709057267e-08
BRCA1 O 0 9.585031648384756e-07
nuclear O 0 8.584538591094315e-07
dots O 0 5.770973803009838e-05
. O 0 1.854552493796291e-07

" O 0 3.0436632414421183e-07
BRCA1 O 0 9.441548172617331e-06
associates O 0 5.221076662564883e-06
in O 0 2.2201392113618823e-10
vivo O 0 1.0018172815762227e-06
with O 0 2.9623230951569823e-11
a O 0 1.91829066520377e-10
structurally O 0 1.6380155329898116e-06
related O 0 6.178541678281135e-09
protein O 0 1.281912886952341e-06
termed O 0 5.536413300433196e-05
BARD1 O 0 0.25174131989479065
. O 0 1.4200294629063137e-07

Here O 0 2.742885101270076e-07
we O 0 3.795281422469543e-09
show O 0 2.3037320662222527e-10
that O 0 3.4389171198190294e-12
the O 0 1.033113481915815e-12
steady O 0 1.8869994455883443e-09
- O 0 1.777294045268718e-08
state O 0 2.0795939970064126e-10
levels O 0 7.289097797569255e-11
of O 0 1.5184750158658833e-13
BARD1 O 0 3.055283514186158e-06
, O 0 1.2307040803127833e-11
unlike O 0 6.833252019777802e-11
those O 0 1.9385925156822914e-12
of O 0 2.0524530425919396e-12
BRCA1 O 0 1.1452416401880328e-05
, O 0 1.368396840284447e-09
remain O 0 1.3402765008940776e-10
relatively O 0 7.931758548573864e-12
constant O 0 1.0095387026343161e-10
during O 0 4.315981461111562e-10
cell O 0 6.553474122483749e-06
cycle O 0 1.3241323358670343e-05
progression O 0 6.053612378309481e-05
. O 0 7.01714109041518e-09

However O 0 7.487633411074057e-07
, O 0 9.467170380972334e-10
immunostaining O 0 3.493963504297426e-06
revealed O 0 2.004859283033511e-07
that O 0 6.767817417596689e-10
BARD1 O 0 1.4767177162866574e-05
resides O 0 1.3942697307811613e-07
within O 0 1.361751406081524e-10
BRCA1 O 0 4.707100060841185e-07
nuclear O 0 2.5239691581191437e-07
dots O 0 2.905963185639848e-07
during O 0 5.044529682862731e-09
S O 0 6.425441938517906e-07
phase O 0 1.3355765382527807e-09
of O 0 9.286152576060136e-13
the O 0 1.9039651799612756e-10
cell O 0 1.6794874682091177e-05
cycle O 0 4.509667235197412e-07
, O 0 3.089171973780225e-11
but O 0 1.1875642136338627e-10
not O 0 1.2383543843141886e-11
during O 0 2.0896075668408454e-12
the O 0 4.26514119161725e-12
G1 O 0 6.593605661464608e-08
phase O 0 5.523923984895873e-09
. O 0 1.6588864726330144e-09

Nevertheless O 0 2.096833304676693e-05
, O 0 6.849946165843335e-10
BARD1 O 0 1.0746718999143923e-06
polypeptides O 0 8.116928285062386e-08
are O 0 9.554055463434352e-11
found O 0 3.5657837793579006e-10
exclusively O 0 3.986606531003467e-11
in O 0 3.8038214938973525e-11
the O 0 4.460520928312173e-12
nuclear O 0 1.3524751318882977e-09
fractions O 0 5.7472399235536376e-12
of O 0 1.4893605283523154e-13
both O 0 6.385079964754681e-11
G1 O 0 2.94726419269864e-07
- O 0 3.629610318967025e-07
and O 0 3.091446032499334e-08
S O 0 1.922404408105649e-06
- O 0 3.15981225185169e-07
phase O 0 9.612501905564841e-09
cells O 0 2.5799078429145084e-08
. O 0 5.59147728118603e-10

Therefore O 0 1.8542199597959552e-07
, O 0 2.3256344072741797e-10
progression O 0 1.9485501923099946e-07
to O 0 1.600647253630072e-10
S O 0 2.5730480501806596e-06
phase O 0 1.5707676936926873e-08
is O 0 6.58467308456423e-11
accompanied O 0 1.197090621074537e-10
by O 0 2.753671856509099e-12
the O 0 3.2329614246123795e-12
aggregation O 0 3.146163052303308e-10
of O 0 3.7953767732801236e-12
nuclear O 0 3.080256419707439e-06
BARD1 O 0 4.149068502101727e-07
polypeptides O 0 1.1129449362101695e-08
into O 0 1.2899894485940422e-09
BRCA1 O 0 1.3407249070951366e-06
nuclear O 0 6.083729999772913e-07
dots O 0 7.911971806606743e-06
. O 0 5.770428401774552e-08

This O 0 2.7588962225877367e-09
cell O 0 2.2794863525632536e-06
cycle O 0 3.427763658692129e-06
- O 0 1.299742848459573e-06
dependent O 0 9.207194118232565e-09
colocalization O 0 4.914633677799429e-07
of O 0 1.9202556211794786e-11
BARD1 O 0 0.00020919341477565467
and O 0 3.773138956830735e-08
BRCA1 O 0 5.926302719672094e-07
indicates O 0 2.3928081738233686e-10
a O 0 5.153758496356797e-12
role O 0 1.7389914508392224e-10
for O 0 9.829899047519852e-12
BARD1 O 0 7.864623512432445e-06
in O 0 3.051467745152081e-09
BRCA1 O 0 0.00011852524767164141
- O 0 0.0003783597203437239
mediated O 0 0.00029875035397708416
tumor B-Disease 0 0.0002189870283473283
suppression O 0 7.034483360257582e-07
. O 0 1.4369431866612103e-08

Ethnic O 0 1.5753184925415553e-06
differences O 0 5.904938120693259e-07
in O 0 3.2345190414950764e-10
the O 0 4.279683274432955e-10
HFE O 0 9.309069719165564e-05
codon O 0 1.2616691265066038e-06
282 O 0 2.614739571527025e-07
( O 0 1.2871458343610698e-09
Cys O 0 0.0028686777222901583
/ O 0 1.7783877410693094e-05
Tyr O 0 8.030980325202108e-07
) O 0 1.0984764486909881e-10
polymorphism O 0 2.4814309540488466e-07
. O 0 5.850205653246121e-09

Recent O 0 7.161141724054687e-08
studies O 0 4.673870623861376e-09
have O 0 3.7438582789484087e-10
shown O 0 7.83446019170242e-09
that O 0 1.2549285202112515e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 1.85291519301245e-05
HH B-Disease 1 0.9997023940086365
) O 0 4.461387259624416e-09
is O 0 2.4010065047264106e-09
likely O 0 1.566800023056203e-08
to O 0 6.257692142241922e-10
be O 0 9.250403221194858e-10
caused O 0 6.363090054861686e-10
by O 0 6.101869877428445e-12
homozygosity O 0 7.289878567462438e-07
for O 0 6.3225674695743805e-12
a O 0 6.649168438066511e-10
Cys282Tyr O 0 3.017788549186662e-05
mutation O 0 1.1715270886725193e-07
in O 0 5.875909481201091e-11
the O 0 6.475938535421832e-11
HFE O 0 7.761871529510245e-06
gene O 0 1.153387430008479e-07
located O 0 4.516355716077669e-07
4 O 0 1.041733383999599e-07
. O 0 1.685219785940717e-08

5 O 0 8.555380048846928e-08
Mb O 0 1.1423727301007602e-05
telomeric O 0 0.0002387703862041235
to O 0 2.2049533754398e-08
HLA O 0 0.000615471217315644
- O 0 5.4889536841074005e-05
A O 0 9.906636222467569e-08
. O 0 6.050746126362583e-09

Population O 0 9.099180964255993e-09
studies O 0 6.815549513650154e-11
of O 0 5.778384904895836e-14
this O 0 6.285110236078917e-13
polymorphism O 0 1.0656606974634997e-07
are O 0 3.98852131877625e-12
facilitated O 0 1.1688683798638522e-08
by O 0 3.95595951829808e-11
the O 0 8.361360215314306e-11
fact O 0 9.003070511326428e-10
that O 0 3.9304354215730086e-10
the O 0 3.0262298222893946e-10
Cys282Tyr O 0 1.1961161362705752e-05
mutation O 0 1.9769371917277567e-08
creates O 0 3.4034422502493555e-10
a O 0 2.388599595892771e-10
Rsal O 0 3.1920490073389374e-06
restriction O 0 1.4638931844501712e-08
site O 0 3.264947281422792e-07
. O 0 8.303422838196184e-09

We O 0 7.533754455835151e-07
have O 0 9.610127277293046e-11
studied O 0 2.632425388782167e-10
the O 0 8.634577428057177e-12
codon O 0 3.0091385383457236e-08
282 O 0 9.733420291979655e-09
( O 0 4.6511090118217524e-11
Cys O 0 0.0003220742801204324
/ O 0 2.060706492557074e-06
Tyr O 0 4.535372966074647e-08
) O 0 2.830324950103824e-12
polymorphism O 0 2.602259296935472e-09
in O 0 1.6347213513401293e-11
different O 0 5.811461121357775e-12
ethnic O 0 1.4894773192608568e-09
groups O 0 2.0229997677034817e-09
. O 0 4.646671047936479e-09

In O 0 2.362308570980076e-09
agreement O 0 5.491366250609531e-10
with O 0 9.338571582695465e-12
previous O 0 1.8816685709577285e-10
observations O 0 5.518139833959879e-10
the O 0 1.9501827236423352e-11
Tyr O 0 1.8810961677218074e-08
allele O 0 1.5750211135312497e-09
appeared O 0 5.6611714427390325e-08
to O 0 8.449084487605063e-11
be O 0 1.3444088897696105e-10
rare O 0 9.045154625297869e-10
or O 0 2.813568267256983e-09
absent O 0 2.2928498211172155e-08
in O 0 9.58064849676532e-10
Asiatic O 0 1.436158981960034e-06
( O 0 2.6578403106852777e-12
Indian O 0 9.929030042599152e-09
, O 0 2.3594207143595725e-10
Chinese O 0 9.771021491911114e-11
) O 0 2.0529669977897846e-11
populations O 0 3.4772897894441712e-09
. O 0 1.2388705616928064e-09

The O 0 1.2138565153030356e-10
highest O 0 4.773653260875532e-12
allele O 0 1.1623171175534353e-11
frequency O 0 1.043773067976872e-09
( O 0 2.6846142496539382e-12
7 O 0 1.0841723352417176e-10
. O 0 1.2789586230355088e-11
5 O 0 9.778627907408577e-11
% O 0 9.464868125363957e-12
) O 0 4.86231437057949e-11
was O 0 6.407181984968702e-08
found O 0 7.088328590754145e-09
in O 0 1.8079587826846932e-09
Swedes O 0 0.0006633020821027458
. O 0 5.388382628979116e-09

Saamis O 0 2.2700651243212633e-05
( O 0 3.1317043402978584e-10
2 O 0 2.473501126143418e-10
% O 0 7.646222197066344e-12
) O 0 8.09628579456767e-12
and O 0 2.650633879053288e-10
Mordvinians O 0 1.2459470326575683e-06
( O 0 1.8684910389754616e-12
1 O 0 1.6505904282260175e-11
. O 0 1.9336154205573663e-11
8 O 0 1.5844392464714474e-10
% O 0 1.9755538351040602e-12
) O 0 6.4830046712927025e-12
had O 0 7.674403335045099e-09
significantly O 0 1.206217792315556e-09
lower O 0 1.29249111413543e-10
frequencies O 0 3.278275428897359e-10
of O 0 4.542609777918871e-12
the O 0 2.1422705276386012e-10
Tyr O 0 2.7646194666886004e-07
allele O 0 3.2189021226258774e-08
. O 0 4.786341989415632e-09

Comparisons O 0 4.2217838114311235e-08
with O 0 2.3410407293256164e-11
allele O 0 2.3177697261456132e-10
frequencies O 0 4.2713002579297665e-10
based O 0 1.6637877187086758e-10
on O 0 3.7467298708016017e-10
prevalence O 0 2.649141151778167e-06
estimates O 0 1.9886913449340682e-08
of O 0 3.900932701861315e-11
HH B-Disease 1 0.9988791346549988
showed O 0 6.776310328859836e-06
some O 0 8.766704376328427e-12
disagreements O 0 3.7504229055684846e-08
with O 0 3.612558863164139e-11
the O 0 2.289717374037714e-11
RFLP O 0 3.1388842103297065e-07
data O 0 3.6735696706813314e-09
, O 0 3.339000256841196e-11
particularly O 0 4.440117370996255e-11
in O 0 3.020808880815906e-10
Finns O 0 3.2737494620960206e-05
. O 0 3.488263677908776e-09

The O 0 1.0868691724397195e-08
newly O 0 1.0871096911557743e-08
described O 0 1.2576967911570591e-08
HFE O 0 2.2544949388247915e-05
marker O 0 1.351121682091616e-06
provides O 0 5.85818338283417e-11
a O 0 5.213823296712494e-12
new O 0 1.6817720827067006e-11
approach O 0 1.0841688657947657e-09
to O 0 2.304371537337202e-12
the O 0 2.901523964669861e-13
screening O 0 9.107505721805964e-11
of O 0 2.8621685100108096e-13
HH B-Disease 0 0.061861928552389145
as O 0 7.90841614417559e-09
well O 0 8.27706014838725e-10
as O 0 6.872791918910437e-11
studies O 0 2.286400756223994e-11
of O 0 6.570787615184023e-14
the O 0 3.7405301078763387e-11
relationship O 0 2.637356999457552e-09
between O 0 1.3546094801419883e-10
the O 0 3.623767952376511e-10
HFE O 0 3.75028103007935e-05
Tyr O 0 7.236205590288591e-08
allele O 0 1.1998920967926097e-08
and O 0 1.2923198511316514e-08
different O 0 1.2489285161620955e-08
disorders O 0 0.009324111044406891
including O 0 7.462619322495812e-08
cancer B-Disease 0 0.3663579821586609

Autosomal B-Disease 1 0.9998194575309753
dominant I-Disease 1 0.9992400407791138
neurohypophyseal I-Disease 1 0.9998749494552612
diabetes I-Disease 1 0.9999922513961792
insipidus I-Disease 1 0.9993601441383362
associated O 0 9.518810657027643e-06
with O 0 5.107982925522947e-10
a O 0 4.93962204473064e-10
missense O 0 1.57885533553781e-05
mutation O 0 1.3190563663556532e-07
encoding O 0 1.6561683580107456e-08
Gly23 O 0 0.0003494940174277872
- O 0 8.50970100145787e-05
- O 0 0.000250065146246925
> O 0 1.493397348895087e-06
Val O 0 0.0003399840206839144
in O 0 9.373684051183773e-10
neurophysin O 0 2.8666654543485492e-05
II O 0 2.848133044608403e-05
. O 0 7.447571448437884e-09

Autosomal B-Disease 1 0.9998382329940796
dominant I-Disease 1 0.9987828135490417
neurohypophyseal I-Disease 1 0.9997286200523376
diabetes I-Disease 1 0.9999897480010986
insipidus I-Disease 1 0.9995428323745728
( O 0 3.808110875525017e-07
ADNDI B-Disease 0 0.01860053651034832
) O 0 8.77028050183526e-09
is O 0 5.100283146930451e-07
an O 0 0.0011497939703986049
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 0.00016838681767694652
by O 0 8.446869870226692e-09
progressive O 0 4.392220580484718e-05
degeneration O 1 0.9777501225471497
of O 0 6.252940526474404e-11
the O 0 9.405167755716093e-10
magnocellular O 0 3.2879083846637513e-06
neurons O 0 1.0603849176504809e-07
of O 0 1.1647250872104387e-11
the O 0 3.3093547346929597e-10
hypothalamus O 0 3.506342949322061e-08
leading O 0 2.2574058178292944e-08
to O 0 4.384801133294758e-10
decreased O 0 1.9310499510538648e-07
ability O 0 7.273022628595527e-09
to O 0 1.1891961027021836e-10
produce O 0 1.592136977812686e-10
the O 0 1.8437504301083152e-10
hormone O 0 1.871631877259361e-10
arginine O 0 4.3263992388631323e-10
vasopressin O 0 7.172983734760052e-11
( O 0 1.569345868535077e-11
AVP O 0 1.2610902899723442e-07
) O 0 4.2532039001841326e-10
. O 0 1.297416729606482e-09

Affected O 0 2.1746450329374056e-06
individuals O 0 8.865295303417398e-11
are O 0 1.65556266612521e-11
not O 0 1.4161197769979594e-09
symptomatic O 0 3.777200561216887e-07
at O 0 1.380346361656848e-07
birth O 0 1.136982064053882e-06
, O 0 6.343377378925652e-09
but O 0 9.330343573310529e-07
usually O 0 4.448051186045632e-06
develop O 0 0.0005195237463340163
diabetes B-Disease 1 0.9792929887771606
insipidus I-Disease 0 0.19476936757564545
at O 0 1.3350241943044239e-06
1 O 0 1.7927550288732164e-07
- O 0 0.17637482285499573
6 O 0 1.5639494677088805e-06
yr O 0 2.8551026844070293e-05
of O 0 1.0857409415976349e-10
age O 0 4.258281194324809e-08
. O 0 1.3058379932928688e-09

The O 0 8.14429679252271e-09
genetic O 0 6.16277361586981e-07
locus O 0 3.224518962952061e-08
of O 0 3.540755189046507e-10
the O 0 2.777377858365071e-06
disease O 1 0.6200449466705322
is O 0 2.9396307610340955e-10
the O 0 2.4030624712345627e-10
AVP O 0 1.4704417480970733e-05
- O 0 0.0001629471080377698
neurophysin O 0 8.983313455246389e-05
II O 0 1.8635335436556488e-05
( O 0 4.568453254583105e-11
NPII O 0 2.2596509552386124e-07
) O 0 7.2268402200037496e-12
gene O 0 2.0124559796386166e-08
, O 0 1.0335842182129795e-09
and O 0 1.2708629704150098e-08
mutations O 0 3.431511686358135e-06
that O 0 2.2230015161994743e-08
cause O 0 7.780719357697308e-08
ADNDI B-Disease 0 0.0013716239482164383
have O 0 1.356673493546623e-07
been O 0 8.261591410985147e-09
found O 0 6.082160552978166e-09
in O 0 1.6656221540900518e-11
both O 0 1.1417005361946675e-11
the O 0 9.076783920834719e-13
signal O 0 8.550245927940736e-11
peptide O 0 1.3362631313962314e-11
of O 0 1.3034737948291325e-13
the O 0 6.067786550989496e-11
prepro O 0 2.2511558199767023e-06
- O 0 3.4127851904486306e-06
AVP O 0 2.1301727883837884e-06
- O 0 9.756375902725267e-07
NPII O 0 3.8531248947037966e-07
precursor O 0 1.6700710814276931e-09
and O 0 3.850637031455051e-10
within O 0 3.370843049133043e-10
NPII O 0 8.577831977163441e-06
itself O 0 2.4595030012619645e-08
. O 0 2.0310801929213085e-09

An O 0 6.245497008450229e-09
affected O 0 3.523021518958558e-08
girl O 0 4.917741534882225e-06
who O 0 7.049362871214271e-09
presented O 0 3.453972524658511e-11
at O 0 6.833125731908751e-10
9 O 0 7.322334960591093e-10
months O 0 2.899142731438431e-11
of O 0 2.202813452478747e-12
age O 0 4.1823113861028105e-07
and O 0 4.463091727302526e-07
her O 0 1.7457016383559676e-06
similarly O 0 1.78944461026731e-07
affected O 0 1.299669349918986e-07
younger O 0 1.0036669806368081e-07
brother O 0 2.7735557068808703e-06
and O 0 2.0846753656655892e-08
father O 0 1.4050947960697613e-08
were O 0 1.7112440631184e-10
all O 0 9.039091523888043e-12
found O 0 2.455929681843827e-09
to O 0 2.0384997856393028e-10
have O 0 1.5142574694149147e-10
a O 0 1.8317023245395525e-11
novel O 0 3.8390613354977177e-08
missense O 0 4.190418621874414e-06
mutation O 0 1.170285344187505e-07
( O 0 1.458979465018828e-11
G1758 O 0 1.8424973546871115e-08
- O 0 1.5818852716620313e-06
- O 0 2.6769607757159974e-06
> O 0 2.230714812867518e-08
T O 0 2.4210746119024407e-07
) O 0 1.3839379945854158e-13
encoding O 0 5.638099796062557e-12
the O 0 6.3918271717144926e-12
amino O 0 1.4100520751014756e-10
acid O 0 2.8114788275246383e-11
substitution O 0 1.2566973503491674e-11
Gly23 O 0 7.69476642403788e-08
- O 0 9.531914315630274e-07
- O 0 8.290912774100434e-06
> O 0 9.309174942018217e-08
Val O 0 3.209791975677945e-05
within O 0 3.144652760411759e-09
NPII O 0 1.6203197446884587e-05
. O 0 3.563079831181426e-09

The O 0 8.710498100583663e-09
mutation O 0 9.68049036487173e-08
was O 0 1.5449934664957254e-09
confirmed O 0 9.135673467719485e-11
by O 0 3.4973454254155767e-12
restriction O 0 1.8224829423374445e-09
endonuclease O 0 2.197879621235188e-05
analysis O 0 3.2624603818476317e-07
. O 0 1.5141926823503127e-08

A O 0 2.7037099670224052e-08
T1 O 0 2.558625965320971e-06
- O 0 1.6363427945975673e-08
weighted O 0 7.020885539610333e-10
magnetic O 0 4.5381026714252926e-10
resonance O 0 9.454647065254562e-10
imaging O 0 6.943172934370523e-07
of O 0 5.1577239007505327e-11
the O 0 2.577655067170781e-08
fathers O 0 4.356460067356238e-06
pituitary O 0 8.619567779533099e-07
gland O 0 1.5795561125742097e-07
demonstrates O 0 1.865098120390485e-08
an O 0 3.746451204822421e-10
attenuated O 0 0.060611139982938766
posterior O 0 0.09495050460100174
pituitary O 0 0.00020880720694549382
bright O 0 1.2085948810636182e-06
spot O 0 3.0129171136650257e-05
. O 0 1.218301903804786e-08

This O 0 1.828521511981762e-08
mutation O 0 1.2226385024405317e-06
may O 0 7.318345041085195e-09
be O 0 7.737002878649424e-12
valuable O 0 3.0621909088285326e-12
for O 0 8.450558503826644e-13
developing O 0 2.851351377231026e-10
models O 0 5.940123060099722e-09
of O 0 3.516465729713758e-10
dominantly B-Disease 1 0.8452430367469788
inherited I-Disease 1 0.9999074935913086
neurodegeneration I-Disease 1 1.0
, O 0 1.1842666935990565e-07
as O 0 1.9352583424669945e-10
the O 0 1.9737092168958803e-11
early O 0 2.9968794112988917e-09
age O 0 2.6081961590485037e-10
of O 0 5.840749975685733e-13
onset O 0 2.7966259494860424e-06
of O 0 2.166565149508415e-09
symptoms O 0 7.801804895279929e-05
suggests O 0 1.7234923488373965e-09
that O 0 2.409474009201773e-10
this O 0 8.501946369143809e-11
mutation O 0 4.4504770357889356e-07
may O 0 2.5874919984403277e-08
be O 0 1.9321970412544687e-10
particularly O 0 2.4332156081663392e-11
deleterious O 0 3.4333316190071628e-09
to O 0 3.4743841137441223e-10
the O 0 1.068196781028874e-10
magnocellular O 0 4.6563450268877205e-06
neuron O 0 1.2154758223914541e-05
. O 0 1.2470902088779212e-09
. O 0 1.1140359745809292e-09

Frequent O 0 7.417742835968966e-06
inactivation O 0 1.3738439520238899e-05
of O 0 1.0940562344963212e-10
PTEN O 0 6.0211757954675704e-05
/ O 0 0.004592799581587315
MMAC1 O 0 0.009729591198265553
in O 0 1.0885796655202284e-06
primary O 1 0.6561946868896484
prostate B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.999998927116394
. O 0 6.999538300078711e-07

Sporadic B-Disease 1 0.9992526173591614
prostate I-Disease 1 0.9999852180480957
carcinoma I-Disease 1 1.0
is O 0 6.032154487911612e-06
the O 0 2.080594585507356e-09
most O 0 1.7162165022455156e-09
common O 0 1.9856749133850826e-07
male B-Disease 0 4.8231945584120695e-06
cancer I-Disease 0 1.3047232641838491e-05
in O 0 4.317916579843484e-10
the O 0 8.218841607288141e-09
Western O 0 0.046964265406131744
world O 0 2.371426126046572e-05
, O 0 6.626796889008801e-10
yet O 0 6.419053621975479e-10
many O 0 4.155099929490508e-13
of O 0 1.2324176238993206e-13
the O 0 6.814990238801499e-11
major O 0 3.238197765487172e-10
genetic O 0 1.199886838776365e-07
events O 0 9.262280525890176e-11
involved O 0 1.8350532204891579e-10
in O 0 3.3204572424949674e-10
the O 0 3.3775493513132915e-10
progression O 0 8.000991329026874e-06
of O 0 1.82890941974323e-11
this O 0 1.3454368286147655e-07
often O 0 0.0001642513816477731
fatal O 1 0.7888151407241821
cancer B-Disease 0 0.22353903949260712
remain O 0 4.433793776570383e-08
to O 0 1.5356713678471579e-09
be O 0 8.38796410107534e-09
elucidated O 0 0.00021704076789319515
. O 0 5.74301894928908e-09

Numerous O 0 5.964670890534762e-08
cytogenetic O 0 0.00041125001735053957
and O 0 9.177076520927585e-08
allelotype O 0 1.0780720913317055e-05
studies O 0 2.5249363488910603e-08
have O 0 2.521498787544374e-09
reported O 0 1.3894297268279843e-08
frequent O 0 9.828679026213649e-08
loss O 0 1.393424327034154e-07
of O 0 3.1536518188546303e-12
heterozygosity O 0 0.00011001474194927141
on O 0 4.52604837164472e-07
chromosomal O 1 0.9985021352767944
arm O 1 0.8643659949302673
10q O 0 5.583325673796935e-06
in O 0 2.5878085807562456e-07
sporadic B-Disease 1 0.998320996761322
prostate I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999990463256836
. O 0 4.138714757573325e-07

Deletion O 0 6.426282925531268e-05
mapping O 0 1.8214490410173312e-05
studies O 0 1.5832269184556935e-07
have O 0 3.381779745126323e-09
unambiguously O 0 3.866490260406863e-06
identified O 0 2.8161664999970526e-07
a O 0 5.849589146400547e-10
region O 0 1.3562421408153114e-08
of O 0 8.672952113430998e-12
chromosome O 0 4.496485780691728e-05
10q23 O 0 8.389088179683313e-08
to O 0 2.849752933631322e-10
be O 0 7.748097302640033e-11
the O 0 5.777861696032449e-12
minimal O 0 9.19399756327266e-09
area O 0 3.6918453361067805e-07
of O 0 1.6395122759416125e-10
loss O 0 1.9911483832402155e-05
. O 0 4.097696049143451e-08

A O 0 9.465585648626984e-09
new O 0 4.846816281656174e-10
tumor B-Disease 0 8.475583967992861e-08
suppressor O 0 6.430332888385237e-08
gene O 0 3.1462207061849767e-07
, O 0 3.977661533483001e-10
PTEN O 0 1.0219551768386737e-05
/ O 0 0.003469419199973345
MMAC1 O 0 0.06632595509290695
, O 0 1.5354553184465658e-08
was O 0 5.127041617924988e-07
isolated O 0 0.0001267689367523417
recently O 0 5.9417398006189615e-06
at O 0 4.300168043869235e-08
this O 0 2.6030958638623147e-11
region O 0 7.581533179035205e-10
of O 0 3.1139750066716543e-12
chromosome O 0 3.649544669315219e-05
10q23 O 0 1.2889539391380822e-07
and O 0 5.408110403948285e-09
found O 0 3.266449555283657e-09
to O 0 3.144751820061131e-11
be O 0 7.645872650285934e-12
inactivated O 0 1.776026614663806e-08
by O 0 6.691336720821006e-12
mutation O 0 1.0692358642927502e-07
in O 0 1.304686350067641e-07
three O 0 0.007224684115499258
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999986886978149
cell O 0 0.013554304838180542
lines O 0 0.05258889123797417
. O 0 4.625680674053001e-07

We O 0 3.604676021495834e-05
screened O 0 0.0001398759486619383
80 O 0 1.0041673704108689e-05
prostate B-Disease 1 0.9996033310890198
tumors I-Disease 1 0.9999998807907104
by O 0 2.88229468070611e-10
microsatellite O 0 6.125877553131431e-05
analysis O 0 6.495728825939295e-07
and O 0 4.6592312230586685e-08
found O 0 3.408012361205692e-08
chromosome O 0 2.4917422706494108e-05
10q23 O 0 9.167559511524814e-08
to O 0 1.1814392519848838e-10
be O 0 2.542605882782656e-11
deleted O 0 1.429333735813998e-07
in O 0 2.2775585861722902e-09
23 O 0 3.187315078534425e-09
cases O 0 8.199468881642247e-10
. O 0 7.816488789558207e-09

We O 0 2.4672049221408088e-06
then O 0 3.342310428422479e-09
proceeded O 0 2.6295249311303337e-10
with O 0 1.1215961698892579e-13
sequence O 0 1.6245890743782354e-10
analysis O 0 2.84535763006577e-11
of O 0 2.939973839464344e-13
the O 0 2.3693682432712748e-11
entire O 0 9.86752013432124e-09
PTEN O 0 2.6190396056335885e-06
/ O 0 2.2521951450471533e-06
MMAC1 O 0 5.951522780378582e-06
coding O 0 0.0011372679146006703
region O 0 4.823028803002671e-07
and O 0 3.7193474966557005e-09
tested O 0 1.4517967938942888e-09
for O 0 1.6325130266711674e-14
homozygous O 0 8.111685628753307e-11
deletion O 0 2.569764845361533e-09
with O 0 2.5411273779640808e-11
new O 0 1.524456005874697e-09
intragenic O 0 4.2745177779579535e-06
markers O 0 3.759404717129655e-05
in O 0 1.547552641589789e-10
these O 0 4.456245789041802e-11
23 O 0 2.897784234789924e-10
cases O 0 3.437023582408827e-11
with O 0 2.5774410383760937e-10
10q23 O 0 1.779955709935166e-06
loss O 0 1.7927648698901066e-08
of O 0 2.1031594868436976e-11
heterozygosity O 0 0.00017897044017445296
. O 0 4.310547652153218e-08

The O 0 8.771609133484404e-11
identification O 0 7.744108132534677e-11
of O 0 9.137459669114611e-13
the O 0 1.1094785506982063e-10
second O 0 9.415079382790736e-09
mutational O 0 1.974272890947759e-06
event O 0 3.4862215336772806e-09
in O 0 8.223004221985519e-11
10 O 0 1.70354789302829e-11
( O 0 3.1954668945621822e-12
43 O 0 1.2320729325665525e-08
% O 0 1.679789307651447e-09
) O 0 5.754117751166632e-07
tumors B-Disease 1 0.9999998807907104
establishes O 0 2.0661495000240393e-05
PTEN O 0 0.00018934205581899732
/ O 0 0.00268718134611845
MMAC1 O 0 5.875929127796553e-05
as O 0 3.2312447162397007e-10
a O 0 4.996606947638149e-11
main O 0 1.0515668336097406e-08
inactivation O 0 2.2021263248461764e-06
target O 0 1.021585926963553e-08
of O 0 4.667164658217482e-12
10q O 0 2.2037042981537525e-06
loss O 0 1.0475589533598395e-06
in O 0 7.81237901037457e-08
sporadic B-Disease 1 0.9997013211250305
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 1.3299668921717966e-08
. O 0 6.041013467239509e-09

Risk O 0 2.7644821329886327e-06
reversals O 0 4.8338961278204806e-08
in O 0 1.005974557127809e-11
predictive O 0 2.016097866430755e-08
testing O 0 1.3966481446914258e-06
for O 0 6.003340757843034e-08
Huntington B-Disease 1 0.9999998807907104
disease I-Disease 1 0.9999998807907104
. O 0 1.4396293579466146e-07

The O 0 3.314743202142978e-10
first O 0 7.608485022569944e-12
predictive O 0 2.059864501191555e-09
testing O 0 9.870103667708463e-08
for O 0 1.6533878266500324e-08
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 1.3967965672989635e-10
HD B-Disease 0 0.0011548075126484036
) O 0 2.2273465294375683e-09
was O 0 2.540098797965129e-08
based O 0 4.1773383363530314e-11
on O 0 1.387873566072173e-10
analysis O 0 4.44436223934197e-11
of O 0 1.6733583106404853e-13
linked O 0 1.3651336061570873e-08
polymorphic O 0 9.334935491267515e-09
DNA O 0 5.321526259649545e-05
markers O 0 1.2110051102354191e-05
to O 0 1.9230715631035622e-10
estimate O 0 4.8324926282816705e-09
the O 0 1.8372236024188915e-11
likelihood O 0 5.985335838065708e-11
of O 0 8.491257827078491e-13
inheriting O 0 3.0744269352567244e-09
the O 0 2.2783294348349692e-11
mutation O 0 1.5240024797691376e-09
for O 0 9.391068651887213e-12
HD B-Disease 0 0.0003843197482638061
. O 0 5.0908116833170425e-08

Limits O 0 1.216249412294701e-08
to O 0 2.4206203014243144e-11
accuracy O 0 1.0825322860341657e-09
included O 0 1.3874354139534195e-12
recombination O 0 5.782627154893305e-11
between O 0 2.1873653929804782e-11
the O 0 2.5213905616161547e-11
DNA O 0 0.00010085701069328934
markers O 0 0.0010703320149332285
and O 0 5.1176137105812813e-08
the O 0 1.6181358475364505e-09
mutation O 0 2.9091734177200124e-06
, O 0 1.7948372788012534e-09
pedigree O 0 1.3294618383952184e-06
structure O 0 2.3623397282790393e-07
, O 0 1.0868680261344466e-10
and O 0 9.971108140549578e-12
whether O 0 6.714157008147481e-12
DNA O 0 6.60142006836395e-07
samples O 0 1.3199032977695424e-09
were O 0 4.396666017369988e-11
available O 0 1.7678586025637877e-11
from O 0 4.12363199142618e-12
family O 0 8.058241851571779e-10
members O 0 3.8362941295888575e-12
. O 0 3.8494912812936377e-10

With O 0 8.488291181052432e-10
direct O 0 8.056320055516153e-10
tests O 0 9.897623165500136e-09
for O 0 1.9358866181103107e-13
the O 0 6.123742572056168e-12
HD B-Disease 0 9.238822713086847e-06
mutation O 0 5.186409453017404e-07
, O 0 4.2686448820106193e-10
we O 0 2.5721922369825734e-09
have O 0 7.970795898315508e-12
assessed O 0 9.478507388693824e-12
the O 0 2.9959318446209915e-12
accuracy O 0 7.398896855193016e-07
of O 0 5.208207563139888e-12
results O 0 1.08372633089715e-09
obtained O 0 3.7472712433039845e-11
by O 0 6.860133663390278e-13
linkage O 0 6.695933052469627e-08
approaches O 0 1.4137906401145983e-09
when O 0 4.196882841256411e-10
requested O 0 5.119402124442729e-11
to O 0 5.474633524293893e-10
do O 0 1.94844096412794e-09
so O 0 2.456169599304725e-12
by O 0 1.9713068254590543e-13
the O 0 2.8594212067578617e-11
test O 0 6.837381505420126e-08
individuals O 0 6.825173239077831e-12
. O 0 5.319268359116336e-10

For O 0 1.1205912864298284e-09
six O 0 9.356513480662798e-11
such O 0 4.6924790442215425e-12
individuals O 0 6.77903740087249e-12
, O 0 8.828072300959278e-11
there O 0 2.5102686596056856e-10
was O 0 1.7068507718320802e-09
significant O 0 2.9795254805065063e-12
disparity O 0 7.681663638514635e-10
between O 0 5.233443539642835e-11
the O 0 3.5520447694281643e-10
tests O 0 9.729284045079112e-08
. O 0 5.340780595552985e-10

Three O 0 2.4085393235395713e-08
went O 0 1.4201696707516476e-08
from O 0 4.2666361437827816e-13
a O 0 1.0892464014089498e-10
decreased O 0 2.4193145691242535e-06
risk O 0 9.577806281413359e-08
to O 0 2.141330862626134e-10
an O 0 2.9412555724306344e-11
increased O 0 1.4771428524795738e-08
risk O 0 3.5594484870671295e-07
, O 0 3.7832745269916757e-10
while O 0 5.554528503814993e-10
in O 0 1.1932996257790762e-10
another O 0 6.804512509006599e-10
three O 0 3.9531863893493835e-10
the O 0 1.335263344337534e-09
risk O 0 4.617148263719173e-08
was O 0 6.068524527336194e-08
decreased O 0 6.129855023573327e-07
. O 0 4.401830899780634e-09

Knowledge O 0 9.464701022920963e-09
of O 0 9.452851695845865e-12
the O 0 2.017664334219571e-11
potential O 0 6.839468661562487e-12
reasons O 0 1.6990430330016126e-12
for O 0 2.1448962668913635e-13
these O 0 2.495253136058917e-12
changes O 0 1.0259223470754364e-09
in O 0 7.380796418487989e-09
results O 0 3.8683049297105754e-07
and O 0 5.174894734949476e-09
impact O 0 1.137200777989733e-09
of O 0 6.039229880072661e-12
these O 0 8.284088415244639e-10
risk O 0 8.237669990585061e-10
reversals O 0 4.3353227674458594e-09
on O 0 6.5270984173082525e-09
both O 0 1.800550641917198e-08
patients O 0 1.2239967261962192e-08
and O 0 3.9132530549323974e-10
the O 0 1.4471790432679654e-10
counseling O 0 3.1972398062407592e-09
team O 0 3.3171401736531436e-10
can O 0 8.655885730401991e-11
assist O 0 6.384114157459431e-12
in O 0 1.9205487894469186e-11
the O 0 9.614082967235316e-12
development O 0 1.7895370948983746e-11
of O 0 1.9091478886072016e-13
strategies O 0 4.706125489306601e-10
for O 0 2.0190020987541357e-13
the O 0 7.409040048145243e-11
prevention O 0 5.14442945132032e-07
and O 0 1.0189860510934068e-08
, O 0 4.6294978961469724e-10
where O 0 3.4406692606125944e-08
necessary O 0 3.7179146428201193e-09
, O 0 3.033741313718252e-11
management O 0 2.1641767544711144e-10
of O 0 6.271767366517952e-14
a O 0 7.70993435761369e-10
risk O 0 1.6807988334477386e-09
reversal O 0 4.716639301349801e-10
in O 0 9.299091444786578e-13
any O 0 5.703795725661709e-13
predictive O 0 4.108063222929559e-09
testing O 0 2.5632507671957683e-08
program O 0 6.902669547059759e-10
. O 0 3.604238088539269e-11
. O 0 8.150337627021997e-10

A O 0 8.249958938222335e-08
novel O 0 6.720767942169914e-08
common O 0 6.1555809338642575e-09
missense O 0 6.106928140070522e-06
mutation O 0 8.554903843105421e-07
G301C O 0 2.9275643242954175e-08
in O 0 2.4731130338073726e-11
the O 0 4.793765384647486e-11
N O 0 3.100229878327809e-05
- O 0 6.672848394373432e-05
acetylgalactosamine O 0 8.28015326987952e-05
- O 0 2.108893750119023e-05
6 O 0 8.113276095400579e-08
- O 0 7.322143119381508e-06
sulfate O 0 9.364958373225818e-07
sulfatase O 0 7.648292807971302e-07
gene O 0 5.790196055954766e-08
in O 0 1.989251874334741e-09
mucopolysaccharidosis B-Disease 0 7.920704956632107e-05
IVA I-Disease 1 0.8389987945556641
. O 0 1.8360849196596973e-07

Mucopolysaccharidosis B-Disease 0 0.24756604433059692
IVA I-Disease 1 0.9978564381599426
( O 0 7.024308433756232e-05
MPS B-Disease 1 0.9999932050704956
IVA I-Disease 1 0.9999998807907104
) O 0 8.535459983249893e-07
is O 0 1.6667853230956098e-07
an O 0 2.677118970950687e-07
autosomal B-Disease 1 0.9999974966049194
recessive I-Disease 1 0.9999978542327881
lysosomal I-Disease 1 0.9999994039535522
storage I-Disease 1 0.9999990463256836
disorder I-Disease 1 0.9999967813491821
caused O 0 2.9030566111032385e-06
by O 0 1.7446125100128995e-10
a O 0 7.635655379090167e-07
genetic B-Disease 1 0.9999998807907104
defect I-Disease 1 0.9999994039535522
in O 0 1.3237481111261218e-09
N O 0 0.0002466741425450891
- O 0 0.0008031431934796274
acetylgalactosamine O 0 0.002844319911673665
- O 0 0.0019283619476482272
6 O 0 1.691220973043528e-06
- O 0 0.002310963347554207
sulfate O 0 2.0777877580258064e-05
sulfatase O 0 1.1487047231639735e-05
( O 0 1.42302072903e-10
GALNS O 0 1.3854979670213652e-06
) O 0 2.4255342179202444e-10
. O 0 6.805991881186912e-10

In O 0 4.365343198031724e-09
previous O 0 4.432836320233946e-09
studies O 0 2.6385040818865946e-09
, O 0 3.5852473767583604e-10
we O 0 9.679286705477352e-09
have O 0 1.7433318677539944e-10
found O 0 2.5332597131111356e-10
two O 0 1.451366197363635e-11
common O 0 4.060642100345291e-10
mutations O 0 1.4685746840825686e-08
in O 0 3.970420520138518e-11
Caucasians O 0 1.847612679739541e-06
and O 0 1.1446132042181034e-08
Japanese O 0 1.369655706184858e-06
, O 0 1.5533843655823887e-10
respectively O 0 4.3228385315785545e-09
. O 0 1.9752703916964265e-09

To O 0 3.5400953279918213e-09
characterize O 0 1.3135981191680912e-07
the O 0 7.971453358512903e-11
mutational O 0 1.8678147739592532e-07
spectrum O 0 1.0523272031548458e-08
in O 0 3.191363145971238e-11
various O 0 2.4767559964750108e-12
ethnic O 0 2.3717081631957626e-09
groups O 0 1.007431027488792e-09
, O 0 1.2481746192172238e-10
mutations O 0 1.4587061336612805e-08
in O 0 1.2599350382447305e-11
the O 0 2.4799905185002302e-11
GALNS O 0 1.130404257310147e-06
gene O 0 4.0815649526848574e-08
in O 0 2.216827166279245e-09
Colombian O 0 4.946207354805665e-06
MPS B-Disease 1 0.9999805688858032
IVA I-Disease 1 0.9999998807907104
patients O 0 1.880148920463398e-05
were O 0 7.53192286317983e-10
investigated O 0 2.4499851747350476e-07
, O 0 2.975304891350561e-09
and O 0 6.927562079539484e-09
genetic O 0 6.767829177078966e-07
backgrounds O 0 2.642921437256973e-09
were O 0 6.815263631221313e-11
extensively O 0 1.6974269101410755e-08
analyzed O 0 4.7525766433409444e-08
to O 0 3.152877611767302e-11
identify O 0 9.542199669310136e-11
racial O 0 2.5475732634561155e-10
origin O 0 1.849759651006977e-10
, O 0 6.07212500766674e-12
based O 0 2.46487509222848e-12
on O 0 2.5601196509961177e-11
mitochondrial O 0 1.5405662168177514e-07
DNA O 0 4.117567641515052e-06
( O 0 4.580718616919999e-12
mtDNA O 0 2.5128423786213716e-09
) O 0 2.3389875106194502e-11
lineages O 0 2.3609359800502716e-08
. O 0 3.808043214093004e-09

Three O 0 5.408443470855673e-08
novel O 0 8.349084623660019e-08
missense O 0 0.00012924266047775745
mutations O 0 0.001873230328783393
never O 0 3.0302526283776388e-05
identified O 0 8.657021055569203e-08
previously O 0 2.456361869462853e-08
in O 0 1.138293903579779e-10
other O 0 1.784912218028012e-10
populations O 0 7.52818039018166e-07
and O 0 9.250394583659727e-08
found O 0 9.689061641893204e-08
in O 0 6.07213113124061e-10
16 O 0 1.1832772262021507e-10
out O 0 1.0419549667517458e-09
of O 0 4.1519331375750035e-12
19 O 0 3.335351550504129e-08
Colombian O 0 2.1446362552524079e-07
MPS B-Disease 1 0.999889612197876
IVA I-Disease 1 0.9999988079071045
unrelated O 0 1.1664780430464816e-07
alleles O 0 4.095201511233881e-09
account O 0 9.149296875676782e-10
for O 0 2.7441359948254807e-11
84 O 0 2.8025453957525315e-07
. O 0 6.619056414081115e-09

2 O 0 9.021398739150754e-09
% O 0 1.4669935405331458e-11
of O 0 2.3530266277105305e-13
the O 0 9.549623244953231e-12
alleles O 0 1.7202664293058945e-10
in O 0 5.5237498602922486e-11
this O 0 5.338965033963028e-11
study O 0 6.485657566557279e-10
. O 0 1.2740611898820475e-09

The O 0 8.655233862953082e-09
G301C O 0 2.2341643557410862e-07
and O 0 5.577534545331275e-10
S162F O 0 8.88158613321366e-09
mutations O 0 4.6702016476274366e-08
account O 0 1.2470918742124582e-10
for O 0 2.8138661539722776e-11
68 O 0 1.7474371816206258e-06
. O 0 1.044060216059961e-08

4 O 0 8.640706283813415e-08
% O 0 5.699171690132232e-10
and O 0 1.0268736971852377e-09
10 O 0 6.321150824994959e-10
. O 0 2.44731634957418e-09

5 O 0 5.153117488276848e-09
% O 0 7.526601737695149e-12
of O 0 6.868709702574638e-13
mutations O 0 1.1988029200438177e-06
, O 0 6.801658125610288e-10
respectively O 0 5.2261968086497745e-09
, O 0 2.9901234266382914e-10
whereas O 0 1.2031050822258749e-08
the O 0 1.3782087693314793e-09
remaining O 0 3.386525548876307e-08
F69V O 0 4.8719040933065116e-05
is O 0 1.7665449658643695e-10
limited O 0 3.5381292340375126e-10
to O 0 6.374793921903876e-12
a O 0 1.0055141615172847e-11
single O 0 2.9752027508322954e-09
allele O 0 2.4719849278653783e-08
. O 0 6.047688572152765e-09

The O 0 4.316206059229444e-09
skewed O 0 4.0757772268307235e-08
prevalence O 0 1.467997208237648e-06
of O 0 8.372511017817885e-12
G301C O 0 1.5743768244647072e-07
in O 0 9.557482583133492e-11
only O 0 6.534427859916647e-11
Colombian O 0 1.1013491230116301e-09
patients O 0 2.1533559657616053e-10
and O 0 4.398861483401184e-12
haplotype O 0 3.275853543982521e-08
analysis O 0 6.0392559009248e-11
by O 0 4.735363576952034e-13
restriction O 0 6.232855898069545e-10
fragment O 0 1.0515411474898428e-07
length O 0 4.9654524048037274e-08
polymorphisms O 0 2.9667212402273435e-06
in O 0 1.1262051291538455e-09
the O 0 3.1568445080232266e-10
GALNS O 0 5.131276793690631e-06
gene O 0 4.3542193850498734e-08
suggest O 0 5.791769841501093e-10
that O 0 3.729964601073554e-11
G301C O 0 1.6764668542279537e-09
originated O 0 3.268710024872945e-10
from O 0 4.659477556394342e-13
a O 0 3.699166320481062e-11
common O 0 2.3732410481258626e-10
ancestor O 0 4.0369918963278906e-08
. O 0 1.6115576428887834e-08

Investigation O 0 3.1682244383546276e-08
of O 0 3.971471155411743e-12
the O 0 3.59767840518721e-11
genetic O 0 3.528159098209471e-08
background O 0 3.7154406218320446e-09
by O 0 1.4162804609640922e-11
means O 0 3.2508825492660876e-11
of O 0 2.6221188306578547e-13
mtDNA O 0 1.677862293547605e-08
lineages O 0 5.4580167052620254e-09
indicate O 0 3.669332837574757e-09
that O 0 2.1270116778993042e-09
all O 0 3.0442109943962237e-10
our O 0 1.9915459503749844e-08
patients O 0 1.3504284357424012e-09
are O 0 1.006972283335017e-12
probably O 0 3.4719463415378016e-10
of O 0 4.2401401400410377e-13
native O 0 1.633402213485624e-08
American O 0 3.958087404498656e-07
descent O 0 5.731780765927397e-05

Low O 0 2.6980026746059593e-07
frequency O 0 6.054650469877743e-08
of O 0 9.170240261591189e-11
BRCA1 O 0 4.125263330934104e-06
germline O 0 3.6908036236127373e-06
mutations O 0 5.1643751248775516e-06
in O 0 1.0392913196710651e-09
45 O 0 2.468404716182704e-07
German O 1 0.9999184608459473
breast B-Disease 1 0.9999991655349731
/ I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 2.2936606001167092e-06
. O 0 3.2196453503274824e-08

In O 0 2.84771140002249e-09
this O 0 2.44491579759476e-11
study O 0 1.580882473539713e-11
we O 0 2.4892742381266153e-11
investigated O 0 1.3805556697832344e-09
45 O 0 1.49440975150128e-08
German O 1 0.999795138835907
breast B-Disease 1 0.9999991655349731
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 6.704825583625507e-09
for O 0 3.062654296837053e-11
germline O 0 6.159604254207807e-06
mutations O 0 9.265559697269055e-07
in O 0 4.1222657232165005e-11
the O 0 2.016480593614034e-10
BRCA1 O 0 7.331910637731198e-06
gene O 0 2.5108611225732602e-06
. O 0 3.1151756729741464e-08

We O 0 3.911832493486145e-07
identified O 0 3.1137068479125674e-09
four O 0 3.8977196470391107e-11
germline O 0 4.70680390662892e-07
mutations O 0 7.118474513845285e-06
in O 0 5.79778536291542e-09
three O 0 3.0141814022499602e-06
breast B-Disease 1 0.9993914365768433
cancer I-Disease 1 0.752177894115448
families O 0 4.886866733500028e-08
and O 0 2.123836111422861e-06
in O 0 1.8999170379174757e-06
one O 1 0.98467618227005
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 1.055638767866185e-05
. O 0 4.767452543852357e-10
among O 0 8.152299365085658e-13
these O 0 7.0658830349235036e-12
were O 0 1.8940445045689813e-10
one O 0 5.341279640802554e-10
frameshift O 0 2.070081973215565e-05
mutation O 0 7.795913461450255e-07
, O 0 3.8167452531823187e-10
one O 0 1.4979361084854759e-09
nonsense O 0 2.5780645955819637e-05
mutation O 0 1.0136184300790774e-06
, O 0 2.753869077221083e-10
one O 0 2.677993937716394e-10
novel O 0 4.6100293360495925e-08
splice O 0 0.0002609257644508034
site O 0 1.9484146832837723e-05
mutation O 0 4.5022002268524375e-06
, O 0 4.89391360769531e-10
and O 0 3.400210946136184e-10
one O 0 3.604865295159243e-10
missense O 0 2.6861242076847702e-05
mutation O 0 8.43996531330049e-06
. O 0 9.811968126882675e-09

The O 0 3.2327751586791464e-09
missense O 0 1.0953758646792267e-06
mutation O 0 1.1876582902914379e-05
was O 0 2.8014096642436925e-07
also O 0 8.600844481065906e-09
found O 0 1.5990644364194395e-09
in O 0 3.194020048447044e-10
2 O 0 5.588177742765765e-08
. O 0 1.8382358746293903e-08

8 O 0 1.8593828698953985e-08
% O 0 9.299698164322301e-12
of O 0 1.4602112108439563e-13
the O 0 1.6499608970765856e-11
general O 0 9.634721492846055e-11
population O 0 1.3060938441888936e-10
, O 0 4.540204323610908e-11
suggesting O 0 3.7371394867591334e-09
that O 0 1.7519495854045886e-09
it O 0 3.176919705083492e-08
is O 0 3.682291094264656e-08
not O 0 1.9444585177552653e-06
disease O 0 0.00024340894015040249
associated O 0 2.355816874910488e-08
. O 0 3.160529260526346e-08

The O 0 1.8565515347290784e-08
average O 0 1.1677435196588704e-07
age O 0 5.4655071579645664e-09
of O 0 1.6781680212130112e-10
disease O 0 0.1201275959610939
onset O 0 4.4076525227865204e-05
in O 0 5.8735731833792215e-09
those O 0 2.255093889402815e-09
families O 0 6.049196143997904e-10
harbouring O 0 2.702952315303264e-06
causative O 0 3.421946303205914e-06
mutations O 0 5.276619049254805e-06
was O 0 5.044984519031459e-08
between O 0 1.5075580783729947e-09
32 O 0 1.0369499392481885e-07
. O 0 8.112436056251227e-09

3 O 0 1.7958556952635263e-07
and O 0 1.2394338000376592e-08
37 O 0 5.755753917924267e-08
. O 0 5.191889584921228e-09

4 O 0 1.1115324838328888e-07
years O 0 1.5660104324410895e-09
, O 0 5.466679886545478e-11
whereas O 0 1.1707531610838373e-09
the O 0 1.833391355399172e-10
family O 0 3.4506504320575004e-09
harbouring O 0 2.5595579700166127e-07
the O 0 4.698947481118765e-11
missense O 0 1.2745379081025021e-06
mutation O 0 1.296521531912731e-06
had O 0 1.2739967303332378e-07
an O 0 5.498791959962501e-12
average O 0 1.6951975823076282e-08
age O 0 8.419103192380817e-10
of O 0 1.807952659110823e-12
onset O 0 6.439133812818909e-07
of O 0 4.585003904322704e-11
51 O 0 3.752290922420798e-06
. O 0 1.9376276583216168e-08

2 O 0 1.6549250858588493e-07
years O 0 1.0480027512471679e-08
. O 0 1.943897487421964e-09

These O 0 2.3346797828338595e-09
findings O 0 1.3962219158614175e-09
show O 0 1.0562585472939645e-08
that O 0 3.3130131971148558e-09
BRCA1 O 0 6.018146450514905e-06
is O 0 1.880051447855635e-09
implicated O 0 3.2814941874903525e-08
in O 0 5.539470618320941e-11
a O 0 3.121362196489841e-11
small O 0 2.737042537059864e-11
fraction O 0 1.7340637814555748e-09
of O 0 1.0828094900716678e-06
breast B-Disease 1 0.9999997615814209
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 8.55749782147086e-09
suggesting O 0 2.208462523967114e-09
the O 0 1.2818672338876791e-11
involvement O 0 2.3340018806550233e-10
of O 0 3.8922405337822596e-13
another O 0 7.202614060730639e-10
susceptibility O 0 1.2794311032848782e-06
gene O 0 1.146661475104338e-06
( O 0 4.394649977257359e-09
s O 0 0.00019491197599563748
) O 0 1.1671901489762604e-07

Paternal O 0 0.0010384130291640759
transmission O 0 0.014458767138421535
of O 0 1.4296515473688487e-06
congenital B-Disease 1 0.9999946355819702
myotonic I-Disease 1 0.9999991655349731
dystrophy I-Disease 1 0.9999985694885254
. O 0 1.1316920790704899e-05

We O 0 5.558737939281855e-06
report O 0 2.9076946406192405e-10
a O 0 2.5231787145751916e-12
rare O 0 1.7260600934654313e-11
case O 0 6.277764419415632e-10
of O 0 2.752146843754133e-10
paternally O 1 0.9485400319099426
transmitted O 1 0.999970555305481
congenital B-Disease 1 0.9999996423721313
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 0.9999998807907104
( O 0 1.3256232705316506e-05
DM B-Disease 1 0.9999992847442627
) O 0 1.4189264447850292e-06
. O 0 4.378270546112617e-08

The O 0 8.468518331028463e-09
proband O 0 1.2033664233968011e-06
is O 0 3.807835990965458e-11
a O 0 1.6981983527730726e-11
23 O 0 4.087723493029216e-10
year O 0 1.1385234768845898e-11
old O 0 2.1102176106069237e-05
, O 0 1.5370368373623933e-06
mentally B-Disease 1 0.9999998807907104
retarded I-Disease 1 0.9999996423721313
male O 0 0.00015310212620534003
who O 0 0.00016841507749632
suffers O 1 0.8607775568962097
severe O 0 0.00022186606656759977
muscular B-Disease 0 0.09470009803771973
weakness I-Disease 0 0.0031413587275892496
. O 0 3.0823493091247656e-08

He O 0 2.0178695194772445e-06
presented O 0 8.18739209762498e-09
with O 0 3.3011630762302957e-07
respiratory O 1 0.9986086487770081
and O 0 2.1085302250867244e-06
feeding O 0 2.963459337479435e-05
difficulties O 0 5.962226623523748e-07
at O 0 2.962621614699401e-08
birth O 0 1.5374517658983677e-07
. O 0 2.7011621828165744e-09

His O 0 1.007379751172266e-06
two O 0 2.9545859092650062e-08
sibs O 0 0.24930980801582336
suffer O 0 9.517874423181638e-05
from O 0 8.676386276107451e-10
childhood O 0 0.00041726246126927435
onset O 1 0.7257093787193298
DM B-Disease 1 0.9999990463256836
. O 0 1.0527334779908415e-05

Their O 0 2.570614476837818e-08
late O 0 8.606391155296933e-09
father O 0 7.047937788939862e-09
had O 0 6.641855399003305e-10
the O 0 3.0762510052316505e-13
adult O 0 6.246956424371675e-11
type O 0 5.2086154056496525e-08
of O 0 3.0006069851040706e-10
DM B-Disease 1 1.0
, O 0 2.935443603746535e-07
with O 0 8.442971655142628e-09
onset O 0 2.6784059627971146e-06
around O 0 1.6156624926821905e-09
30 O 0 3.9397424211884413e-10
years O 0 1.2742670807419643e-10
. O 0 5.300148098186241e-10

Only O 0 8.013643082449562e-09
six O 0 2.4116063312984437e-11
other O 0 3.2193486158155205e-13
cases O 0 3.7188663606912975e-12
of O 0 3.2028318799198763e-12
paternal O 0 0.0002462459960952401
transmission O 1 0.8919147253036499
of O 0 9.773121689704567e-08
congenital B-Disease 1 0.9999995231628418
DM I-Disease 1 1.0
have O 0 0.0001458115439163521
been O 0 7.680513647301268e-08
reported O 0 1.0778830272784035e-07
recently O 0 9.519904438093363e-07
. O 0 4.354682392460063e-09

We O 0 6.56207745919346e-08
review O 0 2.2222532147786467e-10
the O 0 1.5716156674672188e-12
sex O 0 1.3266517051579996e-10
related O 0 5.3527297178002087e-11
effects O 0 1.4261035019558221e-08
on O 0 2.0443266635084e-08
transmission O 0 0.012823397293686867
of O 0 9.452978133595025e-08
congenital B-Disease 1 0.999997615814209
DM I-Disease 1 0.9999997615814209
. O 0 2.293023862875998e-05

Decreased O 0 8.981874270830303e-05
fertility O 0 4.2502015276113525e-06
of O 0 1.458684562027912e-11
males O 0 2.000303672700099e-10
with O 0 3.984183816196918e-10
adult O 0 4.207706297165714e-06
onset O 0 0.046692196279764175
DM B-Disease 1 1.0
and O 0 1.050723312800983e-05
contraction O 0 3.928221303794999e-08
of O 0 7.94541244863306e-13
the O 0 1.238114194501705e-10
repeat O 0 8.886995317425317e-08
upon O 0 2.6923211923768342e-12
male O 0 3.2100702651582935e-10
transmission O 0 1.3640270708492608e-06
contribute O 0 4.766177036374941e-11
to O 0 2.0360711727729353e-10
the O 0 1.514107311750834e-10
almost O 0 2.140396970773395e-09
absent O 0 1.6073512520975441e-09
occurrence O 0 9.21040843593346e-09
of O 0 9.033473621911092e-12
paternal O 0 4.328791419538902e-06
transmission O 0 0.005212944466620684
of O 0 1.6913647016281175e-07
congenital B-Disease 1 0.9999979734420776
DM I-Disease 1 0.9999997615814209
. O 0 3.249649307690561e-05

Also O 0 2.5564090719853994e-06
the O 0 9.675567291811404e-11
fathers O 0 2.1392079774251727e-10
of O 0 8.818487389969376e-13
the O 0 3.2520935944191365e-10
reported O 0 7.511585522479436e-07
congenitally O 0 2.5513463697279803e-05
affected O 0 6.137236141512403e-08
children O 0 5.430941807382794e-10
showed O 0 1.235525104448243e-08
, O 0 2.8331226253897057e-12
on O 0 2.438597102027984e-10
average O 0 1.1421728451921354e-08
, O 0 2.4147222416059932e-11
shorter O 0 3.39292007822678e-08
CTG O 0 1.9888675524271093e-06
repeat O 0 3.4280774343642406e-06
lengths O 0 4.754426299768966e-06
and O 0 3.056624464647939e-08
hence O 0 1.3536345377929138e-08
less O 0 2.9136084656045114e-09
severe O 0 1.0844798453035764e-05
clinical O 0 6.240547372726724e-05
symptoms O 0 1.591226100572385e-05
than O 0 4.2298217012293193e-11
the O 0 4.344187676252886e-09
mothers O 0 2.7095589771874984e-08
of O 0 5.551398750414105e-12
children O 0 1.434224685681329e-07
with O 0 7.899033676039835e-07
congenital B-Disease 1 0.9999963045120239
DM I-Disease 1 0.9999996423721313
. O 0 3.1855674023972824e-05

We O 0 3.0586662091991457e-07
conclude O 0 5.6580380380921724e-09
that O 0 3.022674818775606e-11
paternal O 0 4.2329392613282835e-07
transmission O 0 0.006121136248111725
of O 0 2.8278753561039593e-08
congenital B-Disease 1 0.9999997615814209
DM I-Disease 1 1.0
is O 0 2.8427632059901953e-05
rare O 0 2.768423996712954e-07
and O 0 5.04753501218147e-08
preferentially O 0 1.1847942005260848e-07
occurs O 0 2.063694770626512e-09
with O 0 4.521158100678768e-11
onset O 0 5.567171115217207e-07
of O 0 6.480118108775912e-10
DM B-Disease 1 1.0
past O 0 0.0005487893358804286
30 O 0 1.2415656058806235e-08
years O 0 8.691022901352596e-11
in O 0 1.527027115866275e-11
the O 0 9.960696850663808e-11
father O 0 2.0511931708711018e-08
. O 0 4.663074093524955e-11
. O 0 2.5843130413427673e-10

The O 0 1.2162912454982688e-08
RB1 O 0 9.203804438584484e-06
gene O 0 1.359539680834132e-07
mutation O 0 1.9653543859021738e-07
in O 0 8.097186116051702e-11
a O 0 3.6160368033222312e-09
child O 0 5.553661594603909e-06
with O 0 4.593738367475453e-07
ectopic B-Disease 1 0.9999843835830688
intracranial I-Disease 1 0.999757707118988
retinoblastoma I-Disease 1 0.9992210865020752
. O 0 9.083471923077013e-06

The O 0 4.851418111684325e-08
RB1 O 0 7.537695182691095e-06
gene O 0 1.681996621982762e-07
mutation O 0 4.0016593061409367e-07
was O 0 6.726472268070438e-09
investigated O 0 3.1876812300879465e-08
in O 0 7.843856814071515e-11
a O 0 1.070592503538137e-08
child O 0 4.424882718012668e-06
with O 0 1.7593147561001388e-07
ectopic B-Disease 1 0.9999697208404541
intracranial I-Disease 0 0.17461808025836945
retinoblastoma I-Disease 0 7.4294953265052754e-06
using O 0 6.027788934659384e-09
DNA O 0 3.3377593354089186e-05
obtained O 0 1.89723081689408e-09
from O 0 7.325107534428277e-12
both O 0 2.720301206515785e-10
the O 0 1.237460689473835e-09
pineal B-Disease 0 4.443466241355054e-05
and I-Disease 0 1.0778047908388544e-05
retinal I-Disease 1 0.9997140765190125
tumours I-Disease 1 1.0
of O 0 1.020467599310848e-09
the O 0 1.4353645383380353e-07
patient O 0 1.8830649423762225e-05
. O 0 4.287063148922243e-09

A O 0 4.476681070286759e-08
nonsense O 0 1.3120973108016187e-06
mutation O 0 4.712031298481634e-08
in O 0 1.236890798117507e-11
exon O 0 2.0323450655723718e-07
17 O 0 1.08218802807869e-08
( O 0 1.5954069662593717e-11
codon O 0 1.6826890103516234e-08
556 O 0 1.1145419032132509e-09
) O 0 8.526317672730155e-12
of O 0 4.5046182495928067e-13
the O 0 2.2395074683601024e-10
RB1 O 0 2.3777301976224408e-06
gene O 0 1.220132617163472e-07
was O 0 8.131246431730688e-08
found O 0 1.7170088684181906e-09
to O 0 6.319146594879754e-11
be O 0 3.4910425245060495e-11
present O 0 4.637473998564401e-12
homozygously O 0 2.0038957870838203e-07
in O 0 8.706735332708604e-11
both O 0 3.178043939122688e-10
the O 0 2.7212662678799404e-10
retinal B-Disease 0 0.0006392407231032848
and I-Disease 0 9.461110153097252e-07
the I-Disease 0 2.5228044364666857e-07
pineal I-Disease 0 0.34579411149024963
tumours I-Disease 1 0.9999990463256836
. O 0 1.754138025944485e-07

The O 0 1.1561339663401782e-09
same O 0 6.004740454867985e-11
mutation O 0 1.5502543249112932e-08
was O 0 3.279659432919857e-09
present O 0 6.224236404062111e-12
heterozygously O 0 1.0814023454486232e-07
in O 0 1.1004365821354334e-11
the O 0 6.471601900204238e-12
DNA O 0 1.1645349331956822e-05
from O 0 1.803592323233738e-12
the O 0 1.8689161329632498e-11
constitutional O 0 6.224005200117233e-10
cells O 0 1.0077486400916769e-08
of O 0 1.0761487187482821e-12
the O 0 2.817682087652429e-09
patient O 0 8.025314741644252e-07
, O 0 5.6875382875576364e-11
proving O 0 5.183838069910962e-08
it O 0 4.3930072912701235e-09
to O 0 5.905661376592874e-11
be O 0 5.4830718958231994e-12
of O 0 6.38726539107376e-13
germline O 0 1.0470375855220482e-06
origin O 0 8.784828864349947e-09
. O 0 6.270707064714998e-09

The O 0 1.0956230367398234e-09
initial O 0 9.587649563158607e-10
mutation O 0 3.233572343219748e-08
was O 0 6.20530382633433e-09
shown O 0 2.869552095940975e-10
to O 0 4.2712736125771755e-11
have O 0 1.859619680466551e-09
occurred O 0 7.921931199916799e-08
in O 0 1.6905109256892814e-10
the O 0 2.8227367665500935e-10
paternally O 0 3.17412201411571e-07
derived O 0 1.3868555193141674e-09
RB1 O 0 8.9303824779563e-07
allele O 0 4.8011479236720334e-08
. O 0 6.99335789278166e-09

The O 0 5.060797114708748e-09
mutation O 0 2.808653789543314e-07
is O 0 1.9181735366746722e-10
in O 0 7.120310417663145e-12
an O 0 4.7022715582434316e-12
area O 0 3.089418143531475e-08
of O 0 9.83927349318403e-13
the O 0 5.0352194636005265e-11
gene O 0 1.2851987030160217e-08
that O 0 4.7495337524017245e-11
encodes O 0 2.0087302654570038e-10
the O 0 5.821703535913159e-11
protein O 0 1.1623344065014862e-08
- O 0 8.305769370053895e-07
binding O 0 1.2136354143876815e-08
region O 0 1.7320473943982506e-09
known O 0 9.484141250126754e-10
as O 0 6.972789567960547e-10
the O 0 9.157153368910542e-10
pocket O 0 0.014224984683096409
region O 0 6.929540177225135e-06
and O 0 1.8862164097299683e-07
has O 0 4.070856984839111e-09
been O 0 1.7444794220278226e-10
detected O 0 7.18294446144796e-09
in O 0 1.3052682849498676e-12
other O 0 7.169147545581234e-13
cases O 0 4.653174113383729e-12
of O 0 1.048728486864603e-12
retinoblastoma B-Disease 0 8.363336746697314e-06
. O 0 2.8275666252852716e-09
. O 0 5.199440877845518e-09

Low O 0 9.253318239643704e-06
levels O 0 3.312337071292859e-09
of O 0 5.598586373146974e-13
beta O 0 1.0300706815291605e-10
hexosaminidase O 0 7.489125550819153e-07
A O 0 4.373496409471045e-08
in O 0 3.823720451379131e-09
healthy O 0 3.866993392165341e-09
individuals O 0 2.732237396399495e-12
with O 0 1.629546053649733e-09
apparent O 0 2.252369449706748e-05
deficiency O 0 0.015169224701821804
of O 0 2.174386105197046e-12
this O 0 1.5939486397442693e-09
enzyme O 0 1.3304942285685684e-06
. O 0 1.1189387194576739e-08

Appreciable O 0 8.793463734946272e-07
beta O 0 1.8612954733043807e-08
hexosaminidase O 0 2.437714783809497e-06
A O 0 1.0755906387771574e-08
( O 0 3.686530247737352e-11
hex O 0 1.7322174983291916e-07
A O 0 5.03712627164532e-09
) O 0 1.0196319483180005e-11
activity O 0 5.971575456342748e-10
has O 0 1.5682464216126846e-09
been O 0 3.245153867847961e-10
detected O 0 5.035390415741858e-08
in O 0 5.723693186077128e-10
cultured O 0 1.9173005057382397e-05
skin O 1 0.8468005657196045
fibroblasts O 0 0.0018326941644772887
and O 0 0.14266051352024078
melanoma B-Disease 1 0.9999901056289673
tissue O 0 0.20785747468471527
from O 0 2.6036060418732632e-08
healthy O 0 2.78521838481538e-07
individuals O 0 9.472597185811171e-12
previously O 0 3.5347870408486415e-08
reported O 0 1.168988546851324e-06
as O 0 3.0547539608960506e-07
having O 0 0.00012732160394079983
deficiency B-Disease 0 0.0007902556681074202
of I-Disease 0 6.697040925290887e-13
hex I-Disease 0 2.8391061732691014e-06
A I-Disease 0 1.1165467661555795e-08
activity O 0 1.878331046256676e-09
indistinguishable O 0 9.744913764819785e-10
from O 0 1.4736475928422976e-12
that O 0 1.3161738192379868e-11
of O 0 1.8821548052744275e-12
patients O 0 3.2681274575452335e-08
with O 0 1.4428857184611843e-06
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9998973608016968
( O 0 2.704573509593189e-10
TSD B-Disease 0 9.660930118116084e-06
) O 0 1.0279633810839073e-09
. O 0 1.2715630770543385e-09

Identification O 0 1.2121992654101632e-07
and O 0 1.0514138448769472e-09
quantitation O 0 2.7291576998322853e-07
of O 0 4.0182015700884754e-12
hex O 0 6.168100981085445e-07
A O 0 3.802701264987718e-09
, O 0 1.5217674342871135e-11
amounting O 0 4.884203458344061e-11
to O 0 8.609715718144173e-11
3 O 0 1.3400113241246459e-09
. O 0 2.4490067751514744e-09

5 O 0 3.8850263450740385e-08
% O 0 7.018609582409852e-10
- O 0 6.962761290196795e-06
6 O 0 1.1456696569211999e-07
. O 0 4.306494272299233e-09

9 O 0 2.8917742866951812e-08
% O 0 1.3950199502510419e-11
of O 0 3.0129211300335135e-13
total O 0 2.77856522512554e-11
beta O 0 1.7458574863571386e-10
hexosaminidase O 0 2.2084946067479905e-06
activity O 0 1.9043309862354363e-07
, O 0 1.565887280952083e-10
has O 0 6.119542372839959e-11
been O 0 5.2446927009675015e-12
obtained O 0 1.3914139805615289e-11
by O 0 3.994916810551308e-12
cellulose O 0 0.0020548265893012285
acetate O 0 0.010984616354107857
gel O 0 0.00892365537583828
electrophoresis O 0 1.98552834262955e-06
, O 0 1.3284064126484196e-10
DEAE O 0 1.3642882379372168e-07
- O 0 1.791958048613651e-08
cellulose O 0 1.0447740351082757e-05
ion O 0 1.2145038752464643e-08
- O 0 6.280835691541142e-07
exchange O 0 1.8878489882467875e-09
chromatography O 0 1.2926740788898883e-09
, O 0 1.4094329002511952e-11
radial O 0 4.8300132782230776e-09
immunodiffusion O 0 3.856540047308954e-07
, O 0 2.466312154503214e-10
and O 0 7.932735024418491e-10
radioimmunoassay O 0 9.530856004857924e-06
. O 0 5.411763037699302e-09

Previous O 0 9.663381206337363e-06
family O 0 3.1659652677262784e-08
studies O 0 8.732218836904337e-10
suggested O 0 2.1599551036644016e-09
that O 0 2.1799735627769934e-10
these O 0 2.207971652734564e-11
individuals O 0 3.992342047232089e-12
may O 0 1.7015849840262831e-09
be O 0 2.2992139442346016e-11
compound O 0 5.060893482067286e-09
heterozygotes O 0 1.4124653446856428e-08
for O 0 3.886952825576939e-12
the O 0 4.371304707095902e-11
common O 0 5.35051780659046e-10
mutant O 0 1.4281994253906305e-08
TSD B-Disease 0 2.444654398914281e-07
gene O 0 4.3195933585593593e-07
and O 0 5.425591975694033e-09
a O 0 6.408178987449276e-10
rare O 0 5.1252104782406604e-09
( O 0 1.6761486296146266e-11
allelic O 0 1.83950454868409e-09
) O 0 1.648400686782292e-11
mutant O 0 9.141155388192601e-09
gene O 0 5.61689034839219e-07
. O 0 1.4673370962725585e-08

Thus O 0 5.812492176460182e-08
, O 0 5.838884931108623e-11
the O 0 3.449039664982223e-12
postulated O 0 4.460051439281187e-09
rate O 0 1.3144565436107314e-09
mutant O 0 1.2416170314111241e-09
gene O 0 3.056478803387108e-08
appears O 0 1.4155931982173797e-09
to O 0 1.7582570599125602e-12
code O 0 4.514229962060412e-11
for O 0 5.442436432079312e-12
the O 0 7.567790144547004e-11
expression O 0 5.264220725997859e-10
of O 0 9.379284458474468e-13
low O 0 3.2754956524883028e-09
amounts O 0 3.375169284683399e-12
of O 0 1.8938726455142163e-12
hex O 0 6.384333346431958e-07
A O 0 8.270707496649266e-08
. O 0 5.986883433450885e-09

Heterozygotes O 0 4.008215910289437e-06
for O 0 2.3344606803199497e-10
the O 0 3.675002663294791e-11
rare O 0 3.3525945908330357e-10
mutant O 0 1.371695788066063e-07
may O 0 1.4508009904545816e-08
be O 0 7.135795426771452e-12
indistinguishable O 0 3.728067576869165e-10
from O 0 1.6101440927090982e-12
heterozygotes O 0 9.829276059747372e-09
for O 0 3.049967613535931e-12
the O 0 6.316206585532669e-11
common O 0 2.1638022484893327e-09
TSD B-Disease 0 4.369321231934009e-06
mutant O 0 8.277034453385568e-07
. O 0 6.367949278995866e-09

However O 0 6.068397340186493e-08
, O 0 1.2033808845235416e-11
direct O 0 3.0307225479253574e-11
visualization O 0 2.1426872081065085e-06
and O 0 9.23306320288475e-09
quantitation O 0 2.982726755362819e-06
of O 0 2.012314620492006e-11
hex O 0 8.305009373543726e-07
A O 0 8.121536221317172e-10
by O 0 1.190402160525239e-12
the O 0 2.2916911424086805e-12
methods O 0 3.444950635866917e-08
described O 0 1.854272966284043e-07
may O 0 1.4345497234558025e-08
prevent O 0 2.798080656063462e-09
false O 0 2.6853248513702965e-09
- O 0 6.424696493922966e-06
positive O 0 1.5730395874768988e-09
prenatal O 0 8.71360953169642e-06
diagnosis O 0 2.053503158094827e-05
of O 0 2.9402836502351315e-12
TSD B-Disease 0 0.0001434573787264526
in O 0 1.2737027077491803e-07
fetuses O 0 3.5708148971025366e-06
having O 0 2.8232338689093694e-09
the O 0 5.967337041168363e-11
incomplete O 0 4.83207088564086e-07
hex B-Disease 0 0.00013434147695079446
A I-Disease 0 5.244701242190786e-05
deficiency I-Disease 0 0.004479160066694021
of O 0 1.289721909998598e-12
the O 0 6.1991484168189e-10
type O 0 2.7868554752785712e-05
described O 0 7.440304443662171e-07
in O 0 3.392167657878531e-09
the O 0 7.184287831307756e-09
four O 0 2.4319943392470122e-08
healthy O 0 2.3524538761421354e-08
individuals O 0 1.609777311450955e-10

The O 0 4.826535260349374e-08
tumor B-Disease 0 1.031631882142392e-06
suppressor O 0 4.168192617726163e-07
gene O 0 1.94593326341419e-06
Smad4 O 0 8.53873643791303e-05
/ O 0 4.6719240344827995e-05
Dpc4 O 0 2.6160638299188577e-05
is O 0 1.5524306840042357e-10
required O 0 7.725471304342868e-12
for O 0 4.874055260957466e-13
gastrulation O 0 1.7829969465310569e-06
and O 0 1.2028600337998796e-07
later O 0 1.4220893262972822e-07
for O 0 8.401646045541611e-11
anterior O 0 6.369280072249239e-06
development O 0 2.4457063041438687e-09
of O 0 3.5177503271421884e-12
the O 0 1.92610816185379e-09
mouse O 0 4.4736625568475574e-05
embryo O 0 5.692962190551043e-07
. O 0 6.836309740521074e-09

Mutations O 0 0.00018596190784592181
in O 0 7.663692458415028e-10
the O 0 5.866896968242941e-10
SMAD4 O 0 0.0006415389361791313
/ O 0 0.001783781684935093
DPC4 O 0 0.00042932998621836305
tumor B-Disease 0 2.927653667939012e-06
suppressor O 0 1.0821822371553935e-07
gene O 0 3.24874349644233e-07
, O 0 6.17010331716017e-11
a O 0 5.548974474356427e-12
key O 0 1.9618948132738012e-10
signal O 0 2.341561167185091e-09
transducer O 0 4.4995354109289565e-09
in O 0 1.0436371905564457e-10
most O 0 6.781963879376463e-11
TGFbeta O 0 4.873474608757533e-05
- O 0 3.4557315302663483e-06
related O 0 2.3441094398890527e-08
pathways O 0 1.329697624896653e-06
, O 0 3.3741735100401016e-11
are O 0 1.347934757518418e-13
involved O 0 1.9603667647527523e-12
in O 0 1.9608240378610198e-11
50 O 0 1.2024431450541329e-10
% O 0 7.125092182924675e-12
of O 0 4.476898851635269e-10
pancreatic B-Disease 0 0.2162976861000061
cancers I-Disease 1 0.9244032502174377
. O 0 7.990309569549936e-08

Homozygous O 0 5.994352250127122e-06
Smad4 O 0 6.905187183292583e-05
mutant O 0 6.204646979313111e-06
mice O 0 0.002818621462211013
die O 0 6.120553007349372e-05
before O 0 5.755166343490714e-10
day O 0 2.677687793717354e-10
7 O 0 4.519558949311886e-09
. O 0 2.170196466977359e-09

5 O 0 1.869528709619317e-08
of O 0 1.379828473702105e-10
embryogenesis O 0 7.789665687596425e-06
. O 0 3.961334371638259e-08

Mutant O 0 1.8785184465741622e-06
embryos O 0 9.736226758150224e-08
have O 0 1.515081726743972e-09
reduced O 0 9.015906909937144e-10
size O 0 9.617640017722806e-08
, O 0 9.748732310299602e-08
fail O 0 1.5595453533023829e-06
to O 0 5.232385358322489e-11
gastrulate O 0 6.6762950154952705e-06
or O 0 2.058238468549689e-09
express O 0 4.891310134702564e-10
a O 0 3.3551196543246675e-11
mesodermal O 0 1.1097065311105325e-07
marker O 0 0.00016283216245938092
, O 0 2.3385484659854683e-09
and O 0 8.320323097166238e-09
show O 0 6.301438588707242e-07
abnormal O 0 2.9831741699126724e-07
visceral O 0 3.838592732563484e-08
endoderm O 0 6.481198215624318e-05
development O 0 9.037849935111808e-08
. O 0 3.078076682427877e-09

Growth B-Disease 1 0.9999845027923584
retardation I-Disease 1 0.999993085861206
of O 0 1.4048977259317752e-10
the O 0 2.8481892400122888e-09
Smad4 O 0 0.059405241161584854
- O 0 0.061119455844163895
deficient O 0 0.0014901416143402457
embryos O 0 1.9317051069833724e-08
results O 0 3.20532267394924e-10
from O 0 2.0829262793731207e-12
reduced O 0 3.1835967195803505e-09
cell O 0 2.1079727957840078e-05
proliferation O 0 4.207563506497536e-07
rather O 0 3.50642258284406e-12
than O 0 9.753545627405602e-13
increased O 0 2.510910368513919e-10
apoptosis O 0 1.0702024155762047e-06
. O 0 1.2710059671405816e-08

Aggregation O 0 7.700608080085658e-07
of O 0 9.231346242977168e-11
mutant O 0 4.285842862827849e-07
Smad4 O 0 4.115682531846687e-05
ES O 0 1.9878501689163386e-07
cells O 0 2.5045704177273365e-08
with O 0 8.957368180517733e-11
wild O 0 6.181196567922598e-07
- O 0 0.00028866229695267975
type O 0 1.3652146662934683e-05
tetraploid O 0 5.1808615353365894e-06
morulae O 0 2.8971717256354168e-05
rescues O 0 4.923466804029886e-06
the O 0 5.826205629055892e-10
gastrulation B-Disease 0 1.146710474131396e-05
defect I-Disease 0 2.6053032343043014e-05
. O 0 7.650027278316429e-09

These O 0 3.019717453867088e-08
results O 0 5.033649941310614e-09
indicate O 0 1.3176721935792557e-09
that O 0 2.9202498752489703e-10
Smad4 O 0 1.4125231245998293e-05
is O 0 9.944940704276206e-11
initially O 0 3.8877723262942254e-10
required O 0 5.82165652490696e-12
for O 0 7.652167473889276e-14
the O 0 2.1150416487647483e-12
differentiation O 0 1.7880513736301396e-09
of O 0 3.0682481295257746e-12
the O 0 4.223921767909644e-10
visceral O 0 1.7612780567333175e-08
endoderm O 0 8.991939466795884e-06
and O 0 1.1483655804056525e-08
that O 0 8.517934968477192e-11
the O 0 3.5308197338101976e-11
gastrulation B-Disease 0 1.1779121678046067e-06
defect I-Disease 0 1.5796465504536172e-06
in O 0 4.773437201066599e-11
the O 0 2.415925792753626e-10
epiblast O 0 5.776115722255781e-05
is O 0 3.799887959843318e-09
secondary O 0 3.7729446233925046e-08
and O 0 1.3711041191299955e-08
non O 0 1.1984048198243613e-09
- O 0 7.5804355219588615e-06
cell O 0 2.913779826485552e-05
autonomous O 0 8.869365046848543e-07
. O 0 1.364160162609096e-08

Rescued O 0 0.0002539260603953153
embryos O 0 1.3432307923721964e-06
show O 0 4.6906650823075324e-05
severe O 0 8.419853111263365e-05
anterior O 0 0.00020065909484401345
truncations O 0 0.0002803280367515981
, O 0 8.389584138512873e-08
indicating O 0 2.852681646459132e-08
a O 0 2.2120627551913685e-09
second O 0 1.0375429404518854e-08
important O 0 8.627316742948477e-12
role O 0 8.86064693839117e-11
for O 0 1.502945684572765e-11
Smad4 O 0 3.5629229387268424e-05
in O 0 1.98250216243423e-09
anterior O 0 6.45072805127711e-06
patterning O 0 6.027334165992215e-05
during O 0 2.5729443464683754e-08
embryogenesis O 0 1.042934627548675e-06
. O 0 8.834482478903283e-09

Prevalence O 0 0.00015441578580066562
of O 0 8.915607141446458e-11
p16 O 0 6.266188989911825e-08
and O 0 6.71906086324725e-09
CDK4 O 0 6.8630947680503596e-06
germline O 0 1.9149022136843996e-06
mutations O 0 4.776823516294826e-06
in O 0 1.0938271399751898e-09
48 O 0 3.3586386507522548e-06
melanoma B-Disease 1 0.9999806880950928
- O 1 0.999945878982544
prone O 1 0.9994231462478638
families O 0 7.583405903233142e-08
in O 0 1.970052743160977e-08
France O 0 1.7344969819532707e-05
. O 0 5.212727138825812e-09

The O 0 2.2677615163502196e-07
French O 0 8.729114779271185e-05
Familial B-Disease 1 0.8533086776733398
Melanoma I-Disease 1 0.999936580657959
Study O 0 3.890469599809876e-07
Group O 0 3.4432497386660543e-07
. O 0 3.2808478156454157e-09

Germline O 0 0.00047259379061870277
mutations O 0 0.0002675080322660506
in O 0 2.0110495213554458e-10
the O 0 1.7718217518170043e-11
p16 O 0 5.270180736260954e-09
and O 0 2.6232445105023317e-09
CDK4 O 0 4.806141532753827e-06
genes O 0 8.961497854897971e-08
have O 0 7.870569973533748e-09
been O 0 5.285875737115475e-09
reported O 0 9.885454232971824e-09
in O 0 3.984354512986954e-12
a O 0 8.462853681723281e-12
subset O 0 2.192874326567562e-08
of O 0 4.045793033924383e-09
melanoma B-Disease 1 0.9999366998672485
pedigrees O 0 0.0005407860153354704
, O 0 1.3539547261132157e-08
but O 0 1.4442025353389454e-08
their O 0 3.7924063889249737e-10
prevalence O 0 9.259357284463476e-06
is O 0 1.2753352818251074e-09
not O 0 8.929073591623649e-10
well O 0 1.3810501353628268e-10
known O 0 8.739521106804204e-09
. O 0 4.755521310073618e-09

We O 0 4.523761276686855e-08
searched O 0 2.3236490509503938e-09
for O 0 2.374401131439996e-13
such O 0 3.1445521100209595e-12
germline O 0 5.581487130257301e-07
mutations O 0 2.552915475462214e-06
in O 0 1.3984899904784243e-09
48 O 0 2.683944330783561e-06
French O 0 0.002540047513321042
melanoma B-Disease 1 0.9999592304229736
- O 1 0.9746549725532532
prone O 1 0.7400559186935425
families O 0 2.9823257752248367e-10
selected O 0 2.005949573113952e-11
according O 0 2.6413602208230635e-12
to O 0 1.3773718277043656e-11
two O 0 1.5318142587705808e-11
major O 0 2.1157296747897902e-10
criteria O 0 6.628376736372843e-10
families O 0 3.483072771176543e-12
with O 0 2.9567685105869046e-11
at O 0 1.2064531595967765e-08
least O 0 1.983892043699864e-11
three O 0 1.4677547371944044e-11
affected O 0 5.1986425581018736e-11
members O 0 3.265114483582028e-14
( O 0 7.018639142097882e-13
n O 0 6.698793981740891e-07
= O 0 2.047812085947953e-05
20 O 0 2.959500977617324e-10
) O 0 2.346852746859529e-11
or O 0 1.4179873941699839e-09
families O 0 1.4262788172736407e-10
with O 0 1.8465483309082487e-10
two O 0 2.621517725120981e-10
affected O 0 7.531190671095089e-10
members O 0 9.805993365398502e-14
, O 0 2.9802527633238096e-12
one O 0 3.68785037230257e-12
of O 0 1.6468372347235027e-13
them O 0 9.243926457624951e-11
affected O 0 1.1754043571787776e-10
before O 0 6.587713013983532e-11
the O 0 4.98603675708198e-12
age O 0 3.0404882171014558e-12
of O 0 6.313736578504982e-15
50 O 0 8.920485010388557e-12
( O 0 2.9004353172684683e-12
n O 0 6.38476240055752e-06
= O 0 0.00035673414822667837
28 O 0 7.075819929980298e-09
) O 0 1.7418353218112692e-11
, O 0 4.665333397380067e-11
and O 0 1.1973053104519238e-10
one O 0 1.0031311718783353e-11
additional O 0 2.1985195781948352e-12
minor O 0 7.365899556965871e-10
criterion O 0 1.5213132655844674e-06
. O 0 4.756718574583374e-09

Sixteen O 0 4.974002365543129e-08
different O 0 5.064155206291332e-10
p16 O 0 1.7209474734158903e-08
germline O 0 2.0541870071610902e-07
mutations O 0 3.2170814847631846e-06
were O 0 1.647091796286304e-09
found O 0 1.6318195683595604e-09
in O 0 3.2477356914917266e-10
21 O 0 2.2451253300914686e-08
families O 0 2.4551885524637385e-10
, O 0 1.011682126961233e-10
while O 0 1.609562344517812e-10
one O 0 1.3031400958318784e-10
germline O 0 4.366070243122522e-07
mutation O 0 2.160735448342166e-07
, O 0 9.090481145612728e-11
Arg24His O 0 2.8009740162815433e-06
, O 0 1.9157751773857257e-10
was O 0 8.309427812491776e-09
detected O 0 4.549529819541931e-08
in O 0 1.3081649478940971e-11
the O 0 8.76426847762346e-11
CDK4 O 0 6.909222520334879e-06
gene O 0 2.5956859417419764e-07
. O 0 5.2538515760147675e-09

The O 0 1.2657429271367704e-10
frequency O 0 5.936563463038169e-10
of O 0 1.628794646900411e-12
p16 O 0 1.5096701666550416e-09
gene O 0 2.025548972994784e-08
mutation O 0 3.254759306514643e-08
in O 0 3.819313962316606e-11
our O 0 8.379753141385393e-11
sample O 0 1.4956941241095478e-10
( O 0 1.337251815357321e-12
44 O 0 1.2043872843481296e-10
% O 0 9.977572153901937e-13
) O 0 2.756104589343722e-12
is O 0 7.638817529909137e-12
among O 0 3.7189213297414425e-13
the O 0 3.320620167723831e-11
highest O 0 3.738344300785457e-09
rates O 0 5.8937875024867026e-08
yet O 0 1.4847885143609574e-09
reported O 0 1.2573969421225684e-08
and O 0 1.1878320549385535e-09
the O 0 1.0882475476314823e-10
CDK4 O 0 9.734731065691449e-06
mutation O 0 5.90597473149046e-08
is O 0 2.1125602656102416e-10
the O 0 2.0707031575528667e-11
second O 0 6.070478342223851e-09
mutation O 0 1.7514190986389622e-08
detected O 0 1.333655887947316e-07
in O 0 1.509772168395429e-11
this O 0 3.560617078957051e-11
gene O 0 4.1150602925199564e-08
worldwide O 0 9.83745351845755e-09
. O 0 1.4695498151695574e-08

In O 0 1.1721368764483486e-08
summary O 0 5.232401235844009e-06
, O 0 2.0834898251109735e-09
our O 0 6.772079008676712e-10
results O 0 5.426561977550648e-10
show O 0 1.314459097123688e-09
frequent O 0 5.311837081301007e-10
involvement O 0 2.4560034561638133e-10
of O 0 7.913817171023574e-13
the O 0 4.1120648552883665e-11
p16 O 0 8.736734113945488e-10
gene O 0 2.817436239865856e-08
in O 0 6.448066081077286e-09
familial B-Disease 0 0.15244518220424652
melanoma I-Disease 1 0.9999839067459106
and O 0 1.2689258710452123e-07
confirm O 0 2.0395207229739754e-06
the O 0 9.249852273018888e-11
role O 0 3.48546858042198e-10
of O 0 1.0151371930555708e-12
the O 0 9.118821669984456e-11
CDK4 O 0 1.2833759228669805e-06
gene O 0 1.347624412062487e-08
as O 0 2.340448113091753e-10
a O 0 1.5604653569312177e-08
melanoma B-Disease 1 0.8457995057106018
- O 0 7.438784814439714e-05
predisposing O 0 2.3340057850873563e-06
gene O 0 6.891953603371803e-07
. O 0 1.4168816120374572e-09
. O 0 2.6586353119029127e-09

Progression O 0 3.638893031165935e-05
of O 0 4.583465551544208e-11
somatic O 0 1.2796638770851132e-07
CTG O 0 2.4821372790029272e-05
repeat O 0 2.577088025645935e-06
length O 0 3.775140555717371e-08
heterogeneity O 0 6.960370342312672e-07
in O 0 2.5145157067640866e-09
the O 0 1.3458462122528658e-09
blood O 0 4.674568643281418e-08
cells O 0 3.7036483035990386e-07
of O 0 1.987409703474441e-08
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 0.9999997615814209
patients O 0 0.00033259508199989796
. O 0 3.15325365818353e-09

The O 0 4.833100586409955e-09
genetic O 0 4.2525833521267487e-08
basis O 0 5.980021478002584e-10
of O 0 9.466795347634616e-09
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 0.9999998807907104
( O 0 7.08889774614363e-06
DM B-Disease 1 1.0
) O 0 5.214410592202512e-08
is O 0 1.3680410970717816e-10
the O 0 1.0321510139632561e-11
expansion O 0 6.886402559302951e-10
of O 0 4.075823446109128e-12
an O 0 7.449557082317426e-10
unstable O 0 1.614573920960538e-05
CTG O 0 1.932444092744845e-06
repeat O 0 3.5831595823765383e-07
in O 0 1.7826963863432077e-11
the O 0 7.105562666032128e-12
34 O 0 3.754188973581485e-11
UTR O 0 2.8377902694387558e-08
of O 0 1.4440838932636146e-12
the O 0 1.8258510259272498e-09
DM B-Disease 1 0.9999983310699463
protein O 0 1.2413435968028352e-07
kinase O 0 1.5525158403306705e-07
gene O 0 8.332762035934138e-08
on O 0 6.643454675270277e-09
chromosome O 0 4.314020407036878e-05
19 O 0 2.7104530175847685e-08
. O 0 3.1123885690931274e-09

One O 0 3.806344128776118e-09
of O 0 2.3964185670577454e-12
the O 0 1.3442183997847135e-11
principal O 0 1.1578966951919512e-10
features O 0 1.4002969894733042e-09
of O 0 2.743419207085207e-11
the O 0 1.9954818242240435e-07
DM B-Disease 1 0.9999998807907104
mutation O 0 0.00037780212005600333
is O 0 4.3067138744135036e-10
an O 0 2.2909306830048992e-12
extraordinarily O 0 2.636557416835217e-09
high O 0 2.4636053197468755e-09
level O 0 4.954766597009552e-10
of O 0 5.250425203114084e-13
somatic O 0 6.786965656147004e-09
mosaicism O 0 9.508467883279081e-06
, O 0 1.3864190906431872e-09
due O 0 1.2206452515428623e-10
to O 0 3.891257455146402e-11
an O 0 2.148844687258067e-12
extremely O 0 6.645314298836524e-10
high O 0 1.560327006489004e-10
degree O 0 1.2214766698104285e-10
of O 0 1.924005009132368e-12
somatic O 0 7.688375944781001e-07
instability O 0 1.2314840205362998e-05
both O 0 4.7804116221072945e-09
within O 0 5.263821822865111e-09
and O 0 1.3226837403124136e-08
between O 0 6.668270380316699e-10
different O 0 7.846583938153628e-10
tissues O 0 3.0492460609821137e-06
. O 0 3.5747336202263114e-09

This O 0 3.434335482666029e-08
instability O 0 1.912542870741163e-07
appears O 0 2.4842963242122096e-09
to O 0 2.7235080510279452e-11
be O 0 8.668222389873748e-12
biased O 0 7.047991967823464e-09
towards O 0 7.073731357609692e-12
further O 0 2.5125847583074012e-12
expansion O 0 9.784597437834108e-11
and O 0 1.9863920230900334e-10
continuous O 0 2.0025605618201325e-09
throughout O 0 7.69785923893096e-09
the O 0 1.619614886649856e-09
life O 0 3.5137992515643646e-09
of O 0 5.535672831583072e-13
an O 0 7.181649719356642e-11
individual O 0 3.205223239599597e-11
, O 0 2.8725844619659213e-11
features O 0 1.5813498066563625e-07
that O 0 1.6062648455772432e-07
could O 0 2.7526489247975405e-06
be O 0 1.1957790313488204e-09
associated O 0 1.6100729638424127e-09
with O 0 6.855069289990467e-10
the O 0 1.8129832080049368e-09
progressive O 0 9.293899694284846e-08
nature O 0 6.419659825951385e-08
of O 0 4.5928465891575954e-11
the O 0 6.256515803215734e-07
disease O 0 0.036724165081977844
. O 0 1.0103097247693427e-09

Although O 0 5.9336686675237615e-09
increasing O 0 1.3251545694092925e-10
measured O 0 1.6525388835120225e-09
allele O 0 1.3462493342331072e-09
size O 0 1.137639493720144e-08
between O 0 4.482944504502484e-08
patients O 0 3.7527132690229337e-07
clearly O 0 2.054026726483471e-09
correlates O 0 3.620598709730416e-09
with O 0 2.3075923116788744e-11
an O 0 6.7545149161352125e-12
increased O 0 1.4832883810100839e-09
severity O 0 3.5134584322804585e-05
of O 0 3.1266089717263412e-09
symptoms O 0 0.0034596745390444994
and O 0 2.6935786934245698e-09
an O 0 1.353868128717295e-10
earlier O 0 4.821980041924689e-07
age O 0 1.0190308152857597e-08
of O 0 1.1293424528879825e-11
onset O 0 1.043014071910875e-05
, O 0 6.405795338615405e-10
this O 0 4.808800059541429e-12
correlation O 0 1.1265065325005708e-08
is O 0 3.047197216776709e-10
not O 0 1.0775197401002856e-10
precise O 0 5.568749372741877e-08
and O 0 4.018843924313842e-09
measured O 0 6.332123270169632e-09
allele O 0 3.5335043779838315e-09
length O 0 4.430844910530141e-06
cannot O 0 6.2798685576126445e-06
be O 0 3.175602003580025e-10
used O 0 1.467120980258585e-09
as O 0 5.472918646054481e-11
an O 0 2.4601828820663973e-12
accurate O 0 9.121548316670669e-08
predictor O 0 5.204206487974261e-08
of O 0 2.9385343984500434e-12
age O 0 3.5930189934418877e-09
of O 0 3.693955905048618e-11
onset O 0 5.4612286476185545e-05
. O 0 2.535872845044196e-08

In O 0 5.81810200017685e-09
order O 0 3.479782573201362e-10
to O 0 9.876204888625839e-12
further O 0 8.893286281008717e-12
characterize O 0 2.7574984073908126e-08
the O 0 4.033853112650476e-11
dynamics O 0 5.989010531948225e-08
of O 0 1.3918984853589222e-09
DM B-Disease 1 0.9999995231628418
CTG O 0 0.014234183356165886
repeat O 0 2.7042415240430273e-05
somatic O 0 3.954148439788696e-07
instability O 0 1.3897437384002842e-05
, O 0 2.69511385431187e-10
we O 0 8.781875782126747e-10
have O 0 5.65572068345066e-12
studied O 0 3.084851818435652e-10
repeat O 0 2.280070798832412e-09
length O 0 2.1027111996030357e-10
changes O 0 3.9372616278399164e-11
over O 0 3.006278559425368e-10
time O 0 2.3011554883822782e-09
in O 0 1.8629140452475212e-09
111 O 0 2.5757641196832992e-05
myotonic B-Disease 1 0.9999995231628418
dystrophy I-Disease 1 0.9999997615814209
patients O 0 8.201867558454978e-07
with O 0 5.335836807118799e-12
varying O 0 5.36688138375041e-10
clinical O 0 8.385371074837167e-06
severity O 0 3.462992754066363e-05
and O 0 8.11076539264377e-09
CTG O 0 1.705679460428655e-05
repeat O 0 6.218552357495355e-07
size O 0 3.4670163961969536e-10
over O 0 3.621454913727007e-09
time O 0 1.450180642237342e-09
intervals O 0 6.392751217276782e-09
of O 0 7.552137626203048e-13
1 O 0 2.8652111794258417e-09
- O 0 1.0568413927103393e-05
7 O 0 4.9656325273872426e-08
years O 0 1.3497640782844655e-09
. O 0 6.426355003696926e-10

We O 0 1.3486896023096051e-05
have O 0 3.6241065703990216e-10
found O 0 8.894779010559795e-12
a O 0 1.166460699732197e-12
direct O 0 8.919400634743724e-11
progression O 0 2.495754415576812e-06
of O 0 6.639539178870946e-13
the O 0 8.094205861119974e-11
size O 0 6.066227520307166e-10
heterogeneity O 0 5.2458037913538647e-08
over O 0 5.741146225091143e-09
time O 0 3.224417122194012e-10
related O 0 4.234729233942858e-11
to O 0 4.2734493027607456e-11
initial O 0 3.7909512334843853e-11
CTG O 0 6.808179620065857e-08
repeat O 0 1.109702267854118e-07
size O 0 6.466515323211297e-09
and O 0 1.4988369656521172e-08
the O 0 4.0002426371366084e-10
time O 0 8.817900187807481e-09
interval O 0 9.027854162013682e-07
and O 0 7.074035246468213e-10
always O 0 2.9387503541755677e-10
biased O 0 9.265113121159629e-10
towards O 0 4.483533769944481e-12
further O 0 8.190254030537858e-12
expansion O 0 2.5849304918779126e-09
. O 0 1.690208750737554e-09

Attempts O 0 4.207017525459378e-07
to O 0 8.713397364745745e-11
mathematically O 0 9.535072731381433e-10
model O 0 5.418621551456226e-09
the O 0 9.403440526245532e-11
dynamics O 0 5.265128038445255e-06
have O 0 6.73390877636848e-06
proved O 0 2.280367334606126e-05
only O 0 1.4547218540883478e-08
partially O 0 8.920992513594683e-06
successful O 0 3.1837483760455143e-09
suggesting O 0 1.97425342740587e-09
that O 0 1.0042879722282905e-10
individual O 0 7.822364175673335e-13
specific O 0 6.324545488017863e-12
genetic O 0 2.259625716760638e-06
and O 0 9.237189146915625e-08
/ O 0 0.007767604198306799
or O 0 4.143082037444401e-07
environmental O 0 1.328078980122882e-07
factors O 0 3.3445808345078376e-09
also O 0 5.248615764230635e-08
play O 0 2.6094278737787135e-08
a O 0 3.78205314288671e-11
role O 0 1.2853175468396927e-10
in O 0 1.8914116800550218e-11
somatic O 0 2.407251953329137e-09
mosaicism O 0 1.4543412589773652e-06
. O 0 2.901362483598291e-10
. O 0 9.857132887702846e-10

Aspartylglucosaminuria B-Disease 1 0.9996135830879211
among O 0 1.8037335181020353e-08
Palestinian O 0 5.949037813479663e-07
Arabs O 0 2.332152234885143e-06
. O 0 2.7670557400938378e-08

Aspartylglucosaminuria B-Disease 1 0.9999773502349854
( O 0 1.0443497558298986e-05
AGU B-Disease 1 0.9999909400939941
) O 0 6.515108008642301e-09
is O 0 6.035562605255507e-10
a O 0 9.636127451528864e-09
rare O 0 4.292622634238796e-06
disorder B-Disease 0 0.059317998588085175
of I-Disease 0 3.5809126497365895e-11
glycoprotein I-Disease 0 0.005044413264840841
metabolism I-Disease 1 0.6050205230712891
caused O 0 1.4888951227476355e-06
by O 0 1.1582903525209076e-09
the O 0 3.2704039654163353e-07
deficiency B-Disease 0 0.04573003202676773
of I-Disease 0 1.0621135915211966e-11
the I-Disease 0 2.6104434169837987e-08
lysosomal I-Disease 1 0.7734545469284058
enzyme I-Disease 0 1.9062303181272e-05
aspartylglucosaminidase I-Disease 0 1.7532594938529655e-05
( O 0 3.540221726883175e-10
AGA O 0 9.191561503030243e-07
) O 0 8.091323722148047e-10
. O 0 2.526331810415172e-09

AGU B-Disease 1 0.9999759197235107
is O 0 7.475863185391063e-06
inherited O 0 0.0004152371548116207
as O 0 5.669575919853287e-09
an O 0 1.0477828382704502e-08
autosomal O 1 0.9997920393943787
recessive O 1 0.9998878240585327
trait O 1 0.8807196617126465
and O 0 1.3108943676343188e-05
occurs O 0 3.708334261887103e-08
with O 0 2.4455592065319998e-11
a O 0 2.3033498719460255e-10
high O 0 4.534116193610771e-09
frequency O 0 4.964022650710831e-07
in O 0 2.2324897486214468e-08
Finland O 0 0.002265386516228318
because O 0 5.531915814316335e-09
of O 0 2.625922482929477e-13
a O 0 3.538790649404433e-10
founder O 0 1.496660928523852e-07
effect O 0 5.8992166707128035e-09
. O 0 1.2810497107551555e-09

While O 0 3.0621333735325607e-07
very O 0 1.3367845719258753e-09
few O 0 4.3930722948282153e-10
patients O 0 8.310204968609014e-09
with O 0 2.0288966062764757e-09
AGU B-Disease 1 1.0
have O 0 1.6051759530455456e-06
been O 0 2.3586000708064603e-08
reported O 0 4.101347528262522e-08
from O 0 1.4693093963735748e-11
non O 0 7.093031717531062e-10
- O 0 6.591998044314096e-06
Finnish O 0 6.803571523050778e-06
origin O 0 2.3572193086351945e-08
, O 0 3.8381315903279756e-08
we O 0 1.269895847144653e-06
diagnosed O 0 5.53045947526698e-06
the O 0 6.790588091831751e-10
disorder O 0 0.00011510644253576174
in O 0 1.5881243542459345e-10
8 O 0 8.254928296480557e-09
patients O 0 2.674997445772931e-10
originating O 0 4.9346284003437546e-11
from O 0 2.208523468272272e-11
3 O 0 3.9229406390006716e-09
unrelated O 0 2.6210052794795047e-08
families O 0 2.3639130652952645e-09
, O 0 1.1963213752963497e-10
all O 0 6.200928225758018e-12
Palestinian O 0 2.465129433915081e-08
Arabs O 0 1.4953647209381415e-08
from O 0 6.044899823753891e-12
the O 0 2.1540779576723068e-11
region O 0 3.192296149645557e-10
of O 0 1.1393310340307439e-12
Jerusalem O 0 0.00014234904665499926
. O 0 3.5500640649388515e-08

The O 0 6.19671922663656e-08
clinical O 0 7.188983090600232e-06
diagnosis O 0 0.28872060775756836
of O 0 2.668915044523601e-08
AGU B-Disease 1 1.0
is O 0 1.2371175216685515e-05
often O 0 1.7153932958535734e-06
difficult O 0 1.7680184782875585e-06
, O 0 1.3260015307992035e-10
in O 0 3.897241904193827e-12
particular O 0 2.97720945119373e-11
early O 0 1.575060082359414e-09
in O 0 1.2779424740649858e-10
the O 0 8.202910017907072e-10
course O 0 7.37758966806723e-07
of O 0 1.8892628780853293e-11
the O 0 1.191140313494543e-06
disease O 1 0.9317981600761414
, O 0 3.311640406344907e-10
and O 0 1.8395115430891451e-09
most O 0 2.7022930768061393e-11
of O 0 6.7488228547296636e-12
the O 0 1.8541204127586752e-08
patients O 0 1.1369930774662862e-08
are O 0 1.1112596953744003e-10
diagnosed O 0 6.843814389867475e-06
after O 0 4.2182055071116054e-10
the O 0 2.0627256847038922e-10
age O 0 4.145298548863252e-10
of O 0 8.360235247140135e-13
5 O 0 8.113627991690464e-09
years O 0 1.1193287408062247e-09
. O 0 1.9022856623251982e-09

However O 0 7.741489866930351e-07
, O 0 3.696467021363503e-10
since O 0 4.784614926478525e-10
these O 0 5.986375284372514e-11
patients O 0 2.396708942420389e-10
excrete O 0 8.161584741372963e-10
early O 0 4.803384426321777e-11
large O 0 2.1248228870840435e-12
amounts O 0 1.1742205298370667e-11
of O 0 4.814159054039591e-12
aspartylglucosamine O 0 5.119349680171581e-06
in O 0 8.02691690893198e-10
urine O 0 9.881943041634145e-10
, O 0 5.022811593730081e-13
biochemical O 0 2.6940294439725676e-10
screening O 0 1.1176051195604941e-09
is O 0 7.687507574960506e-11
easy O 0 2.998613624072277e-08
by O 0 4.6930986874471614e-11
urine O 0 5.1952575574887305e-09
chromatography O 0 3.5736018588750085e-09
. O 0 2.4800106412925516e-10
. O 0 1.729934417937784e-09

Detection O 0 4.985932946510729e-07
of O 0 7.855426378822195e-12
heterozygous O 0 4.38060698826348e-09
carriers O 0 1.299983010127903e-09
of O 0 7.406326940628816e-11
the O 0 5.440317909233272e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999996423721313
telangiectasia I-Disease 1 0.9999998807907104
( O 0 2.103258900376659e-08
ATM O 0 2.7658691124088364e-06
) O 0 7.042364087717079e-12
gene O 0 1.520390063847188e-10
by O 0 4.722161463938113e-12
G2 O 0 5.114637815495371e-07
phase O 0 1.499654977976661e-08
chromosomal O 0 0.0005515660159289837
radiosensitivity O 0 4.277634070604108e-05
of O 0 8.537636153604922e-10
peripheral O 0 0.2696729004383087
blood O 0 8.522442658431828e-05
lymphocytes O 0 0.00017732528795022517
. O 0 6.686093456664821e-08

In O 0 0.00027686840621754527
ataxia B-Disease 1 0.9999996423721313
- I-Disease 1 0.999996542930603
telangiectasia I-Disease 1 0.9999998807907104
( O 0 0.0011750109260901809
A B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
) O 0 1.323034098277276e-06
patients O 0 6.063768864805752e-07
, O 0 1.548733780110112e-10
mutations O 0 1.0514248316439989e-07
in O 0 1.9062026263005905e-11
a O 0 6.834112442621887e-11
single O 0 6.679755415461841e-09
gene O 0 1.4909852552591474e-07
, O 0 7.656854594806362e-10
ATM O 0 8.301261004817206e-06
, O 0 3.5304328349639036e-09
result O 0 7.355443809586859e-09
in O 0 1.8269184920427506e-07
an O 0 0.4490005373954773
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 3.210128488717601e-05
embraces O 0 8.198426257877145e-07
a O 0 1.14663600836451e-09
variety O 0 9.705861114817083e-11
of O 0 6.065897350387983e-12
clinical O 0 8.841495855449466e-07
features O 0 2.6258196612616302e-06
and O 0 1.753276137606008e-06
manifests O 0 1.5576025589325582e-06
extreme O 0 4.87276622607169e-07
radiosensitivity O 0 4.648840331356041e-05
and O 0 1.351202083554881e-08
a O 0 2.1958102003338809e-10
strong O 0 1.642880415042569e-10
pre O 0 2.2970527879806468e-07
- O 0 3.5459306673146784e-05
disposition O 0 4.359597824077355e-06
to O 0 1.0723480770025162e-08
malignancy B-Disease 0 7.996704516699538e-05
. O 0 2.2219321937910763e-09

Heterozygotes O 0 7.169013542807079e-07
for O 0 7.857588191217957e-11
the O 0 1.8987492134137085e-11
ATM O 0 2.713839421630837e-06
gene O 0 2.1894113615417155e-06
have O 0 1.0641981873504847e-07
no O 0 6.186714252010006e-09
clinical O 0 8.30312600896832e-08
expression O 0 4.722411794944037e-09
of O 0 1.0199500133367678e-09
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
but O 0 0.12947577238082886
may O 0 2.9045934297755593e-06
be O 0 2.1157021024009737e-07
cancer B-Disease 0 1.9757324480451643e-05
prone O 0 7.47426611269475e-06
with O 0 6.759828113933608e-11
a O 0 2.5107969037208022e-09
moderate O 0 4.8777224037621636e-08
increase O 0 6.16491857563517e-10
in O 0 2.988327363340204e-10
in O 0 2.7898949817029006e-09
vitro O 0 1.2141979823354632e-05
radiosensitivity O 0 6.747729003109271e-06
. O 0 4.2081946816097116e-09

We O 0 2.887002210627543e-06
performed O 0 1.4162582218091302e-08
a O 0 6.244382788622715e-11
blind O 0 1.4523126701249112e-08
chromosomal O 0 4.0113363866112195e-06
analysis O 0 1.961813378414945e-09
on O 0 1.2719755249079867e-09
G2 O 0 3.2618618206470273e-06
- O 0 4.418768185132649e-06
phase O 0 2.538689436448749e-08
lymphocytes O 0 4.40847891525209e-08
from O 0 1.1140837384571167e-11
7 O 0 2.1537678307481656e-09
unrelated O 0 2.5810012971305696e-07
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 0.002059309044852853
, O 0 1.6492852916716316e-10
13 O 0 8.89749801613604e-11
obligate O 0 6.194060802044987e-07
A B-Disease 1 0.999998927116394
- I-Disease 1 0.9999971389770508
T I-Disease 1 0.9999998807907104
heterozygotes O 0 1.6350177247659303e-05
( O 0 2.2846230463002826e-10
parents O 0 9.392918387529647e-11
of O 0 2.7805397415960054e-13
the O 0 7.783620414869574e-10
patients O 0 1.1298891600119987e-08
) O 0 7.71620874834289e-12
, O 0 2.1093231328261908e-10
and O 0 1.0847567288863047e-08
14 O 0 6.845178868175594e-10
normal O 0 1.4017882410399807e-09
controls O 0 5.873150143997918e-07
following O 0 1.5495196792336685e-10
X O 0 3.5889024729840457e-06
- O 0 3.7142598330319743e-07
irradiation O 0 8.295730324903161e-09
with O 0 1.069887733962105e-09
1 O 0 1.1263705523845147e-09
Gy O 0 1.1987357538600918e-05
in O 0 4.842064596499718e-11
order O 0 3.292379216479624e-11
to O 0 2.793586325808284e-12
evaluate O 0 1.910854807718465e-11
this O 0 2.0606070018705513e-13
cytogenetic O 0 3.0256948058138278e-09
method O 0 1.696907198089903e-10
as O 0 3.387817153546746e-12
a O 0 1.3142716082104045e-12
tool O 0 6.985488298916209e-10
for O 0 2.1398211165219588e-13
detection O 0 7.4653311310513e-10
of O 0 1.2062412700630798e-12
ATM O 0 8.735460141906515e-05
carriers O 0 2.848403539701394e-07
. O 0 1.23467467361138e-08

Both O 0 5.074049568065675e-06
A B-Disease 1 0.9997182488441467
- I-Disease 1 0.9999605417251587
T I-Disease 1 0.9999991655349731
homozygotes O 0 0.00047770378296263516
and O 0 1.1469646565842595e-08
heterozygotes O 0 1.389723891520589e-08
showed O 0 5.597466490314673e-09
significantly O 0 3.793614589131522e-10
increased O 0 3.604396295320278e-11
levels O 0 2.1967977784087545e-11
of O 0 1.1178826961333321e-12
radiation O 0 4.388896195450798e-05
- O 0 0.1106710135936737
induced O 0 0.1783216893672943
chromatid O 0 0.0021989585366100073
damage O 0 6.46428597974591e-05
relative O 0 6.5143623828589625e-09
to O 0 2.155681882998195e-10
that O 0 2.9510782706410055e-11
of O 0 2.1034393844765464e-12
normal O 0 4.9773049681789416e-08
controls O 0 0.000132478991872631
. O 0 5.840508876531203e-08

These O 0 2.8008265928747278e-08
results O 0 2.223203843243482e-09
show O 0 6.177300893028814e-10
that O 0 8.09455714262386e-12
the O 0 4.6886678567448214e-12
G2 O 0 1.4854839491817984e-07
- O 0 2.427175616048771e-07
phase O 0 9.113075627453782e-09
chromosomal O 0 3.783220745390281e-05
radiosensitivity O 0 1.256583914255316e-06
assay O 0 2.0709556736164814e-07
can O 0 1.7797289197929445e-09
be O 0 3.0249340358945442e-12
used O 0 2.5489181945670403e-11
for O 0 2.7939898116467743e-13
the O 0 1.82331471969277e-12
detection O 0 2.938977772259932e-08
of O 0 4.646863727142403e-10
A B-Disease 1 0.9999995231628418
- I-Disease 1 0.9999959468841553
T I-Disease 1 0.9999994039535522
heterozygotes O 0 7.61018309276551e-05
. O 0 1.3555903954909354e-08

In O 0 5.0921298289097194e-09
combination O 0 9.255932909013609e-09
with O 0 2.0587941074179383e-11
molecular O 0 9.081118435005919e-08
genetic O 0 1.080200217984384e-05
analyses O 0 2.6349407562520355e-06
, O 0 3.502789724940669e-10
this O 0 1.3120086961304622e-10
test O 0 3.6223346455699357e-07
may O 0 1.2162071350019232e-09
be O 0 1.3928584847999748e-11
of O 0 8.02443574370211e-14
value O 0 5.713930439910087e-10
in O 0 5.900327448848941e-10
studies O 0 3.0242389148504856e-10
of O 0 8.635725056056753e-13
familial B-Disease 0 0.00012769768363796175
and I-Disease 0 2.524128376535373e-06
sporadic I-Disease 0 0.005474225617945194
cancers I-Disease 1 0.9972793459892273
aimed O 0 2.9252925415335085e-08
at O 0 3.487959432391108e-08
determination O 0 2.7893682919000184e-09
of O 0 1.6293406511144748e-13
the O 0 5.236366895644551e-12
potential O 0 6.752530826159564e-12
involvement O 0 4.2621101092876756e-11
of O 0 3.882610812716569e-12
ATM O 0 0.0027167934458702803
mutations O 0 3.603081131586805e-05
in O 0 5.7923720930830314e-08
tumor B-Disease 0 0.08896391093730927
risk O 0 2.3941399263094354e-07
or O 0 2.029577617079781e-09
development O 0 7.475152052904832e-09
. O 0 1.0438327979755968e-09
. O 0 3.478895171937779e-09

Ataxia B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999845027923584
telangiectasia I-Disease 1 0.9999983310699463
: O 0 2.3893811373909557e-08
identification O 0 9.848661441935747e-09
and O 0 4.161371802702263e-10
detection O 0 7.455832218283831e-08
of O 0 2.6373430349335703e-12
founder O 0 3.0001697837178654e-07
- O 0 7.039838237687945e-06
effect O 0 1.8195351003669202e-08
mutations O 0 8.257813988166163e-08
in O 0 7.51800791759516e-12
the O 0 4.630826538204458e-12
ATM O 0 6.839194384156144e-07
gene O 0 2.528772924392797e-08
in O 0 3.3033886737143803e-10
ethnic O 0 1.0294550101264122e-08
populations O 0 7.186359312072454e-07
. O 0 6.273314756555237e-09

To O 0 9.811251810987187e-10
facilitate O 0 1.1937731358990789e-10
the O 0 4.3832749929695325e-12
evaluation O 0 8.885384615575642e-12
of O 0 6.070729178684828e-14
ATM O 0 1.7832610410550842e-07
heterozygotes O 0 1.1377393249745182e-08
for O 0 2.415430268992713e-12
susceptibility O 0 9.840870234256727e-07
to O 0 1.2707660701494206e-08
other O 0 2.0089583330218375e-08
diseases O 1 0.5839262008666992
, O 0 2.6202279235221226e-10
such O 0 6.176915867683874e-09
as O 0 0.013879133388400078
breast B-Disease 1 0.9999927282333374
cancer I-Disease 1 0.9942187070846558
, O 0 2.8988264233476002e-08
we O 0 2.851520832791721e-07
have O 0 1.7818482245246514e-09
attempted O 0 2.6832535127141455e-07
to O 0 1.1713467695795288e-10
define O 0 1.9999889744326538e-08
the O 0 1.4551171378940353e-10
most O 0 4.121762653408467e-11
common O 0 1.2885780220628362e-09
mutations O 0 2.508754732843954e-07
and O 0 1.1097944785376512e-09
their O 0 8.884406405007539e-11
frequencies O 0 7.390109999505512e-07
in O 0 0.00010584277333691716
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999996423721313
telangiectasia I-Disease 1 1.0
( O 0 6.424274033633992e-05
A B-Disease 1 0.9999994039535522
- I-Disease 1 0.9999982118606567
T I-Disease 1 0.9999998807907104
) O 0 1.5886825188715648e-09
homozygotes O 0 2.6693376398156943e-08
from O 0 1.3729967683617783e-11
10 O 0 2.4862516559420733e-11
ethnic O 0 8.288403297029845e-10
populations O 0 3.2273527494908194e-07
. O 0 6.311949629633773e-09

Both O 0 1.3085862171635654e-08
genomic O 0 4.8943006731860805e-06
mutations O 0 8.78171413205564e-05
and O 0 1.4536290393607487e-08
their O 0 7.795428885737365e-11
effects O 0 4.272899367663285e-09
on O 0 3.293059158693268e-10
cDNA O 0 4.024100164201627e-08
were O 0 5.1361515041037364e-09
characterized O 0 5.132227443027659e-07
. O 0 1.497365609282042e-08

Protein O 0 8.740223051972862e-07
- O 0 2.8542933705466567e-07
truncation O 0 5.35395372480707e-07
testing O 0 2.053283409964024e-08
of O 0 3.138480686275258e-13
the O 0 1.4777352952410894e-11
entire O 0 3.543113025195055e-10
ATM O 0 3.8607897323572615e-08
cDNA O 0 3.786604363398283e-09
detected O 0 3.0331328559896065e-08
92 O 0 1.2227220347327261e-09
( O 0 4.1648776441527424e-12
66 O 0 6.545124886514486e-09
% O 0 3.406049314119697e-12
) O 0 8.082184227431455e-12
truncating O 0 3.358429125910334e-07
mutations O 0 3.929248180156719e-07
in O 0 1.4516569370182086e-11
140 O 0 6.964039761525598e-11
mutant O 0 2.7265114610486307e-08
alleles O 0 1.0252772852936687e-08
screened O 0 1.3190958270570263e-05
. O 0 1.2250406911107348e-08

The O 0 1.0899998237334785e-08
haplotyping O 0 2.873235644074157e-06
of O 0 6.654747586321008e-11
patients O 0 3.955845073733144e-08
with O 0 7.212649366650226e-10
identical O 0 7.960123912198469e-05
mutations O 0 0.00044105463894084096
indicates O 0 3.1585045690007973e-07
that O 0 4.539351561305693e-09
almost O 0 4.128517083756833e-09
all O 0 5.02371755306541e-11
of O 0 1.6638019087467093e-12
these O 0 1.437703706086424e-10
represent O 0 1.7573099919676594e-10
common O 0 3.2381148429294626e-08
ancestry O 0 6.1561040638480335e-06
and O 0 3.282784462044219e-07
that O 0 1.3915116170437614e-08
very O 0 8.473785229057285e-09
few O 0 5.2495745528347015e-09
spontaneously O 0 2.1062215083134106e-08
recurring O 0 5.76973491206445e-08
ATM O 0 0.0002887743466999382
mutations O 0 0.00014207186177372932
exist O 0 1.3147327990736812e-06
. O 0 2.3573722529590668e-08

Assays O 0 1.358831127618032e-06
requiring O 0 1.2426025763900839e-09
minimal O 0 8.197482692651192e-10
amounts O 0 4.784263263335475e-12
of O 0 2.509747780692767e-13
genomic O 0 8.212811763996797e-08
DNA O 0 0.000130671716760844
were O 0 1.7520297435069665e-09
designed O 0 5.956770365855846e-08
to O 0 1.564972804124487e-11
allow O 0 3.577267301824172e-11
rapid O 0 3.1786256959875914e-10
screening O 0 4.561440114514426e-09
for O 0 1.0207975090215093e-11
common O 0 2.5898507782784463e-09
ethnic O 0 1.4845323903500685e-07
mutations O 0 4.726307815872133e-05
. O 0 1.7735757751324854e-08

These O 0 5.072974040842837e-09
rapid O 0 8.112467142495916e-09
assays O 0 1.3992352165814737e-08
detected O 0 3.7658484330904685e-08
mutations O 0 4.871223069358166e-08
in O 0 4.7393079044555364e-11
76 O 0 1.1674690547636146e-08
% O 0 1.4377496589113026e-11
of O 0 1.2017820766319076e-11
Costa O 0 9.848035006143618e-06
Rican O 0 4.923579410842649e-08
patients O 0 3.965543005080008e-09
( O 0 4.9737243403708e-13
3 O 0 1.6457721296880834e-10
) O 0 3.2273073102828675e-11
, O 0 7.127148177188403e-11
50 O 0 4.162608452373817e-11
% O 0 5.005437037075566e-12
of O 0 6.8442708098248595e-12
Norwegian O 0 0.26551535725593567
patients O 0 3.58297462810242e-08
( O 0 4.2318747247790944e-13
1 O 0 5.814856582353478e-11
) O 0 3.520832930758999e-11
, O 0 1.0739229644451953e-10
25 O 0 2.263300311056149e-11
% O 0 7.302560249208834e-13
of O 0 2.5178953973886697e-12
Polish O 0 0.05815031751990318
patients O 0 5.865347674216537e-08
( O 0 8.586927284677526e-13
4 O 0 4.649346185825465e-10
) O 0 1.6662077273466025e-10
, O 0 8.913503823926305e-10
and O 0 6.0300884285879874e-09
14 O 0 4.278752907538319e-10
% O 0 3.5606829984491384e-12
of O 0 2.602727061651322e-12
Italian O 0 7.711706530244555e-06
patients O 0 1.2441685015573967e-08
( O 0 7.529225723792998e-13
1 O 0 2.0250524868092867e-10
) O 0 4.487345772741236e-10
, O 0 4.812034104517693e-10
as O 0 2.052341629976695e-10
well O 0 5.166617689233988e-10
as O 0 2.119275865908321e-10
in O 0 1.8893718534140902e-10
patients O 0 6.328904761376819e-11
of O 0 7.867113265089959e-14
Amish O 0 0.0003930538659915328
/ O 0 5.624881305266172e-05
Mennonite O 0 1.0710176866268739e-05
and O 0 1.484206677559996e-07
Irish O 0 1.9285913310795877e-07
English O 0 5.382170797929575e-08
backgrounds O 0 1.485307787874035e-08
. O 0 2.2299904145484106e-09

Additional O 0 3.34521077505201e-10
mutations O 0 1.6555817694552388e-07
were O 0 1.136315555538836e-10
observed O 0 8.220279457127333e-10
in O 0 2.3675070584538993e-11
Japanese O 0 3.460485942241576e-08
, O 0 1.0906464533583238e-12
Utah O 0 1.2314912978261816e-10
Mormon O 0 9.965218927820985e-11
, O 0 5.908590977599104e-11
and O 0 3.2120361925791485e-10
African O 0 1.2917122926836555e-10
American O 0 3.760391553697673e-09
patients O 0 2.0620185559039328e-09
. O 0 2.458018510953508e-10

These O 0 1.2394449910857475e-09
assays O 0 1.5696297595013675e-08
should O 0 2.3745347701997765e-11
facilitate O 0 4.5535051423906125e-12
screening O 0 1.5983202539260333e-09
for O 0 2.216141020694451e-10
A B-Disease 1 0.9999974966049194
- I-Disease 1 0.9999977350234985
T I-Disease 1 0.9999998807907104
heterozygotes O 0 1.3457076420309022e-05
in O 0 5.91062254695629e-10
the O 0 3.2550025175215325e-11
populations O 0 7.346228070304051e-10
studied O 0 2.7631883448009376e-09
. O 0 4.665155761696127e-11
. O 0 4.820596144483602e-10

The O 0 6.803959990975272e-07
von B-Disease 1 0.9833599328994751
Hippel I-Disease 1 0.9984470009803772
- I-Disease 1 0.9941370487213135
Lindau I-Disease 1 0.994437575340271
tumor I-Disease 0 0.0001756194542394951
suppressor O 0 1.70892917594756e-07
gene O 0 2.3534596493846038e-07
is O 0 6.045433598167449e-11
required O 0 6.292898927645618e-12
for O 0 1.0065920536331263e-12
cell O 0 2.4762755401752656e-06
cycle O 0 5.053984750702512e-07
exit O 0 8.233860882000954e-08
upon O 0 6.81145626013624e-11
serum O 0 5.198690473662282e-07
withdrawal O 0 2.2022766188456444e-07
. O 0 6.438479971393463e-09

The O 0 6.945263919533318e-09
inactivation O 0 9.884380460789544e-07
of O 0 9.793032704208393e-12
the O 0 6.309686995109587e-09
von B-Disease 1 0.999795138835907
Hippel I-Disease 1 0.9999401569366455
- I-Disease 1 0.999882698059082
Lindau I-Disease 1 0.9996938705444336
( I-Disease 0 2.1038887965119102e-08
VHL I-Disease 0 7.666939927730709e-05
) I-Disease 0 7.345962171889653e-10
tumor I-Disease 0 6.792938052058162e-07
suppressor O 0 1.2050224995618919e-06
gene O 0 1.692331898084376e-05
predisposes O 0 0.00014190828369464725
affected O 0 6.197109314598492e-07
individuals O 0 4.512267642864387e-11
to O 0 7.297071835665747e-10
the O 0 4.8854410295007256e-08
human O 0 0.06855380535125732
VHL B-Disease 1 0.9999973773956299
cancer I-Disease 1 0.9999984502792358
syndrome I-Disease 1 0.9999994039535522
and O 0 1.890167453666436e-07
is O 0 5.511810563518793e-09
associated O 0 6.598713753191987e-08
with O 0 1.3475684568220458e-07
sporadic B-Disease 1 0.9960495829582214
renal I-Disease 1 0.999931812286377
cell I-Disease 1 0.9999840259552002
carcinomas I-Disease 1 1.0
( O 0 3.1501167541136965e-06
RCC B-Disease 1 0.9102891683578491
) O 0 3.2238921221505734e-07
and O 0 4.634535343939206e-06
brain B-Disease 0 0.28441566228866577
hemangioblastomas I-Disease 0 0.006132291164249182
. O 0 1.1481601802643127e-07

VHL O 0 0.006489686667919159
- O 0 0.00034233080805279315
negative O 0 1.80502127022919e-07
786 O 0 3.408260056403378e-07
- O 0 6.605504313483834e-05
0 O 0 5.52092522809744e-08
RCC B-Disease 0 5.935640274401521e-06
cells O 0 2.4576326040914864e-07
are O 0 5.3393924698275086e-11
tumorigenic O 0 5.432197212940082e-06
in O 0 2.7725235440811957e-08
nude O 0 0.19008897244930267
mice O 0 0.06522798538208008
which O 0 1.640496094523769e-08
is O 0 6.002289637541125e-11
suppressed O 0 2.928488285203201e-10
by O 0 7.96741687382474e-13
the O 0 3.4429137058672454e-12
reintroduction O 0 5.5876025584211675e-08
of O 0 2.058759690504175e-10
VHL B-Disease 0 0.0004084326501470059
. O 0 7.3421557722497255e-09

Remarkably O 0 1.6252704881480895e-05
, O 0 2.5073032539069118e-09
this O 0 2.992546835334231e-11
occurs O 0 2.591544201457907e-10
without O 0 9.531517068672724e-12
affecting O 0 2.1472366940056276e-10
the O 0 4.2879030881515234e-10
growth O 0 1.0553100615595667e-08
rate O 0 3.609141430160889e-08
and O 0 8.062576717371428e-10
cell O 0 1.865647959675698e-06
cycle O 0 6.665364082891756e-08
profile O 0 3.304926332603486e-10
of O 0 5.862167305401011e-13
these O 0 1.0491696400549699e-10
cells O 0 6.1585874178149425e-09
in O 0 1.012126077393205e-10
culture O 0 6.549610276351814e-08
. O 0 9.03965613474611e-09

The O 0 4.849278312235583e-09
786 O 0 2.6012385134777105e-08
- O 0 4.132760750508169e-06
0 O 0 2.844151758552016e-08
cell O 0 1.391754540236434e-05
line O 0 2.6525374778429978e-05
, O 0 1.391988052601434e-10
like O 0 7.524302070294198e-09
many O 0 2.3010149341473607e-09
cancer B-Disease 0 3.374183506821282e-06
cells O 0 5.587133244944198e-08
, O 0 3.2922253812017743e-09
fails O 0 1.510555875938735e-07
to O 0 1.3176784316448753e-11
exit O 0 6.026813537118869e-08
the O 0 5.686269163862612e-11
cell O 0 4.34895082435105e-06
cycle O 0 5.546192483052437e-08
upon O 0 5.747199244288126e-11
serum O 0 2.1114067294547567e-07
withdrawal O 0 1.1328471316573996e-07
. O 0 5.241100442532343e-09

Here O 0 9.225178132510337e-07
, O 0 4.0976216864052617e-10
it O 0 4.4861964837439317e-11
is O 0 3.5055133709022135e-12
shown O 0 3.1553065282102777e-12
that O 0 3.776989029695421e-13
reintroduction O 0 1.6147597703408678e-09
of O 0 1.0919453275609614e-12
the O 0 4.468231618037777e-10
wild O 0 1.8886622683567111e-06
- O 0 0.00010959717474179342
type O 0 4.181436906947056e-06
VHL B-Disease 0 5.748584499087883e-06
gene O 0 1.2533962490124395e-07
restores O 0 1.1265406101301778e-05
the O 0 1.185672560133355e-09
ability O 0 7.2694725794519854e-09
of O 0 1.5325770166829678e-11
VHL O 0 0.0007659532711841166
- O 0 0.0031536512542515993
negative O 0 1.0102679652845836e-06
RCC B-Disease 0 0.006972139701247215
cancer I-Disease 0 8.614321995992213e-05
cells O 0 2.0923435428699122e-08
to O 0 4.759399818698995e-11
exit O 0 6.283484310642962e-08
the O 0 8.605134660388813e-11
cell O 0 2.5020384782692418e-05
cycle O 0 9.54377583184396e-07
and O 0 9.93035098595385e-10
enter O 0 6.817841291528737e-10
G0 O 0 2.6152579835070355e-07
/ O 0 3.278316853538854e-07
quiescence O 0 2.1849550080332847e-07
in O 0 1.8067696228030172e-09
low O 0 1.5801633708178997e-06
serum O 0 1.0534383363847155e-05
. O 0 3.0798030792311692e-09

Both O 0 4.546199079413782e-07
VHL O 0 0.00031389581272378564
- O 0 0.00016030902042984962
positive O 0 3.2414209982789544e-08
and O 0 2.562224210578279e-08
VHL O 0 6.630375719396397e-05
- O 0 4.204544529784471e-05
negative O 0 1.3498063822225959e-07
RCC B-Disease 0 6.027933523000684e-06
cells O 0 8.029665821140952e-08
exit O 0 3.420731076175798e-08
the O 0 9.356382855985057e-12
cell O 0 1.0067803941637976e-06
cycle O 0 2.087954342755438e-08
by O 0 7.297134251016413e-12
contact O 0 7.938176338484482e-08
inhibition O 0 1.129844449110351e-07
. O 0 6.313285894066212e-09

The O 0 7.93237564522542e-09
cyclin O 0 1.127587665905594e-06
- O 0 2.4606296733509225e-07
dependent O 0 2.81927858836184e-09
kinase O 0 5.4827062001550075e-08
inhibitor O 0 1.799273441349669e-08
, O 0 4.0022611960677246e-12
p27 O 0 1.1190065540844785e-09
, O 0 1.8029182747431038e-12
accumulates O 0 2.787468311726826e-10
upon O 0 1.693019530991935e-12
serum O 0 2.5711193174515756e-08
withdrawal O 0 8.087889824537342e-08
, O 0 1.583140146754758e-10
only O 0 1.1260413435021377e-10
in O 0 2.160558537633861e-11
the O 0 3.7556287940665456e-11
presence O 0 9.523186683679796e-10
of O 0 1.0278210574310442e-11
VHL B-Disease 0 5.131560828885995e-05
, O 0 6.170412514272527e-10
as O 0 5.082092038866115e-11
a O 0 1.193670579047179e-10
result O 0 6.419702547333372e-10
of O 0 3.922341509747518e-13
the O 0 1.930703860675287e-11
stabilization O 0 1.551477418759717e-10
of O 0 2.543985801097687e-13
the O 0 2.6305168113194277e-11
protein O 0 2.738221560605325e-08
. O 0 3.6321563534613688e-09

We O 0 1.4141505744191818e-07
propose O 0 6.583696920969828e-10
that O 0 1.3052446623529335e-10
the O 0 4.9580915761904265e-11
loss O 0 1.7731226265027544e-08
of O 0 1.607628613564671e-11
wild O 0 0.0004207538440823555
- O 0 0.14980469644069672
type O 0 0.002453869441524148
VHL B-Disease 0 0.0003475851262919605
gene O 0 6.807193130953237e-06
results O 0 1.7951498065826854e-08
in O 0 4.29100765336754e-12
a O 0 3.1255206756064524e-11
specific O 0 2.6686833298761314e-10
cellular O 0 0.0008518828544765711
defect O 0 0.0027912266086786985
in O 0 9.484543816995483e-09
serum O 0 4.4607120798900723e-05
- O 0 1.4753128198208287e-05
dependent O 0 1.7332122581592557e-07
growth O 0 9.204809714447038e-08
control O 0 3.745880121641676e-06
, O 0 3.3201785765157865e-10
which O 0 3.5974148104855885e-09
may O 0 5.913512790556297e-09
initiate O 0 1.2010185734823153e-08
tumor B-Disease 0 2.5841536626103334e-06
formation O 0 1.0730887289867042e-08
. O 0 2.3687798389460113e-08

This O 0 5.023962135197735e-09
is O 0 3.8067323598900416e-11
corrected O 0 2.1370087210925703e-07
by O 0 6.35501417114992e-13
the O 0 1.3057662590076902e-12
reintroduction O 0 1.006912864198739e-08
of O 0 1.5072746870070652e-11
wild O 0 7.472270226571709e-05
- O 0 0.45344915986061096
type O 0 0.03274095803499222
VHL B-Disease 0 0.006204187870025635
, O 0 3.4418423666693343e-09
implicating O 0 1.0337788580727647e-06
VHL B-Disease 0 2.50613629759755e-05
as O 0 8.009436447409257e-10
the O 0 4.8363972549037015e-11
first O 0 2.507527963047096e-09
tumor B-Disease 0 3.626205113960168e-08
suppressor O 0 7.98240051835819e-09
involved O 0 3.162762829411747e-10
in O 0 1.0236875930269562e-10
the O 0 6.559027626584779e-11
regulation O 0 3.2545093286984184e-09
of O 0 5.730336452743068e-13
cell O 0 2.6579844416119158e-05
cycle O 0 1.2271966625121422e-06
exit O 0 1.1268771231698338e-06
, O 0 1.485023659597573e-09
which O 0 2.6694635391066868e-09
is O 0 9.285417573723365e-11
consistent O 0 5.852635598380118e-10
with O 0 3.4231259320172125e-12
its O 0 4.084011948068955e-11
gatekeeper O 0 1.7055917851394042e-05
function O 0 2.3504809121277503e-07
in O 0 3.43582784445573e-09
the O 0 9.918376520090533e-08
kidney O 0 5.792664978798712e-06
. O 0 2.6855950796544903e-10
. O 0 4.100860540035001e-09

Piebaldism B-Disease 1 0.9999822378158569
with O 0 0.015580391511321068
deafness B-Disease 1 0.9999998807907104
: O 0 6.619182535416712e-09
molecular O 0 4.095531380698958e-08
evidence O 0 8.871342771499258e-09
for O 0 4.908915635093436e-11
an O 0 9.935830824758796e-09
expanded O 1 0.7557375431060791
syndrome O 1 0.999992847442627
. O 0 1.8707771332060474e-08

In O 0 4.485909865792337e-09
a O 0 7.067480489730826e-10
South O 0 1.749149873830902e-07
African O 0 1.0395764110660011e-10
girl O 0 4.9548161129564505e-09
of O 0 2.633929532813717e-12
Xhosa O 0 0.000914065632969141
stock O 0 3.585463446142967e-07
with O 0 4.95994090243812e-09
severe O 0 2.12522581932717e-06
piebaldism B-Disease 0 0.0020197404082864523
and O 0 7.911594366305508e-06
profound O 0 1.5269211871782318e-05
congenital O 1 0.9999980926513672
sensorineural B-Disease 1 0.9999972581863403
deafness I-Disease 1 1.0
we O 1 0.5093375444412231
identified O 0 1.2157667015344487e-06
a O 0 5.499340219317084e-11
novel O 0 2.6327882096666144e-09
missense O 0 2.9493560305127176e-07
substitution O 0 4.148076548915469e-09
at O 0 4.291963673352939e-09
a O 0 2.3272217486436375e-11
highly O 0 1.4809575440977163e-11
conserved O 0 4.5425303518698e-09
residue O 0 2.9934992085145495e-07
in O 0 2.492576284263137e-11
the O 0 8.892895968226622e-12
intracellular O 0 4.06686062603967e-09
kinase O 0 3.059856013010176e-08
domain O 0 4.820690513440695e-09
of O 0 4.573071522157024e-12
the O 0 6.981984990162005e-10
KIT O 0 8.443749720754568e-06
proto O 0 2.6046898256026907e-06
- O 0 8.897424095266615e-07
oncogene O 0 2.5206401232935605e-07
, O 0 1.6262320656768026e-10
R796G O 0 2.294101086874889e-08
. O 0 4.5051148922503614e-10

Though O 0 3.4039723573187075e-07
auditory B-Disease 0 7.702951734245289e-06
anomalies I-Disease 0 0.00037225388223305345
have O 0 3.274947601994427e-08
been O 0 1.3518252073296821e-09
observed O 0 5.359600319110314e-09
in O 0 3.1072858175384965e-10
mice O 0 2.3240385417011566e-05
with O 0 3.664596126551345e-10
dominant O 0 7.039448519208236e-06
white O 0 1.7413020714229788e-06
spotting O 0 3.0069239073782228e-05
( O 0 1.060681942277597e-08
W O 1 0.9993436932563782
) O 0 4.3380918302027283e-10
due O 0 1.2059785392537492e-09
to O 0 5.285159865309197e-09
KIT O 0 0.0024789045564830303
mutations O 0 0.021312382072210312
, O 0 2.669114337550127e-06
deafness B-Disease 1 1.0
is O 0 4.175813501205994e-06
not O 0 6.370831329149951e-08
typical O 0 5.171799344338979e-08
in O 0 9.663128075487748e-09
human O 0 9.15578226567959e-08
piebaldism B-Disease 0 0.0002925377048086375
. O 0 2.740478777241151e-08

Thus O 0 7.63784129276246e-08
, O 0 5.873231068154183e-11
the O 0 1.5171295209698288e-12
occurrence O 0 1.71764860112944e-08
of O 0 3.418177685343693e-10
sensorineural B-Disease 1 0.9999949932098389
deafness I-Disease 1 1.0
in O 0 2.2236530639929697e-05
this O 0 1.9852199883985122e-08
patient O 0 3.884500756612397e-07
extends O 0 1.3196842507667839e-09
considerably O 0 1.724564491212277e-09
the O 0 8.683976281120831e-12
phenotypic O 0 1.796183313196309e-09
range O 0 7.459968642820058e-09
of O 0 1.1836965435607638e-11
piebaldism B-Disease 0 3.292029578005895e-05
due O 0 1.6673085134755183e-09
to O 0 1.448615116750318e-10
KIT O 0 3.879828796016227e-07
gene O 0 1.1752714357271543e-07
mutation O 0 8.977151821909501e-08
in O 0 3.8570616145428005e-10
humans O 0 2.2405826882732072e-07
and O 0 8.562069275797057e-09
tightens O 0 0.0023677856661379337
the O 0 1.4359663458307637e-10
clinical O 0 1.1014567924405583e-08
similarity O 0 2.47314368984064e-09
between O 0 8.656236283322016e-10
piebaldism B-Disease 0 0.00011244632332818583
and O 0 3.945399118521209e-09
the O 0 4.0152061363263325e-12
various O 0 1.8932912963093296e-12
forms O 0 2.0235949804714437e-08
of O 0 2.2596293547394453e-07
Waardenburg B-Disease 1 0.9999985694885254
syndrome I-Disease 1 0.9999911785125732
. O 0 1.420765172177596e-09
. O 0 2.5707109774231185e-09

Cycloheximide O 0 4.2936917452607304e-05
facilitates O 0 3.863117115088244e-08
the O 0 1.1708279311350989e-11
identification O 0 5.10480546722647e-11
of O 0 1.5768161516077628e-12
aberrant O 0 7.109927651072212e-07
transcripts O 0 1.2828696526412386e-05
resulting O 0 5.585353690662487e-08
from O 0 2.2525510970372586e-11
a O 0 5.41843236945283e-10
novel O 0 2.1611640477203764e-07
splice O 0 0.003899363335222006
- O 0 0.0001371214457321912
site O 0 3.4428273920639185e-06
mutation O 0 2.598922890229005e-07
in O 0 9.240065657056817e-11
COL17A1 O 0 9.057901479536667e-06
in O 0 6.076009140265626e-11
a O 0 1.555211404102863e-09
patient O 0 3.881538361838466e-07
with O 0 2.128054399364032e-09
generalized O 0 0.0029472257010638714
atrophic B-Disease 1 0.9998992681503296
benign I-Disease 1 0.9989373087882996
epidermolysis I-Disease 1 0.9983525276184082
bullosa I-Disease 1 0.9922500848770142
. O 0 5.7224165175284725e-06

Patients O 0 9.02567189768888e-05
with O 0 5.680131920371423e-08
generalized O 0 0.0022861568722873926
atrophic B-Disease 1 0.9998125433921814
benign I-Disease 1 0.9995818734169006
epidermolysis I-Disease 1 0.9991254210472107
bullosa I-Disease 1 0.9946446418762207
often O 0 7.938285125419497e-05
show O 0 1.1969827085067664e-07
decreased O 0 6.750187253601325e-08
expression O 0 1.3877285987007326e-09
of O 0 4.848339438257021e-11
type O 0 0.0052831522189080715
XVII O 0 0.0013732446823269129
collagen O 0 0.019398918375372887
, O 0 3.789711211510394e-09
a O 0 6.926765827586223e-10
transmembrane O 0 2.238336094251281e-07
hemidesmosomal O 0 2.7161458859836785e-08
protein O 0 2.5278443227527703e-10
encoded O 0 2.2377440178633634e-10
by O 0 1.7136971008913093e-10
COL17A1 O 0 7.690928759984672e-05
. O 0 7.476092633851295e-09

This O 0 5.24774224075486e-09
report O 0 3.272914994578713e-10
documents O 0 7.86757534121385e-11
a O 0 1.520413239752827e-10
novel O 0 8.784799376826413e-08
splice O 0 0.008211511187255383
- O 0 0.00021330690651666373
site O 0 2.9518985229515238e-06
mutation O 0 3.1790449384061503e-07
in O 0 1.1873739491630175e-10
COL17A1 O 0 1.2600623449543491e-05
in O 0 5.4466344628911756e-11
a O 0 1.5587096058311545e-09
patient O 0 5.460476586449658e-07
with O 0 8.475789847750548e-09
generalized O 0 0.01866098679602146
atrophic B-Disease 1 0.9999661445617676
benign I-Disease 1 0.999545156955719
epidermolysis I-Disease 1 0.9972852468490601
bullosa I-Disease 1 0.8815398216247559
, O 0 2.2396106658106874e-07
and O 0 3.4631500445136965e-10
applies O 0 2.0053077254278406e-10
a O 0 5.056929701374724e-12
new O 0 1.238016633653416e-11
methodology O 0 7.178092564785743e-10
to O 0 9.878503397231508e-12
define O 0 1.3435950130258334e-08
and O 0 8.93610963004221e-10
characterize O 0 7.408810347442341e-07
the O 0 1.49873835564307e-10
resulting O 0 7.173794891457419e-10
mRNA O 0 1.2687753070395047e-08
splice O 0 1.2457742741389666e-05
variants O 0 2.7001617581845494e-06
. O 0 4.071169712460687e-08

Mutational O 0 8.01572241471149e-05
analysis O 0 8.265424611408889e-08
of O 0 3.372642096155509e-11
COL17A1 O 0 2.1810419639223255e-05
identified O 0 1.4862038710816705e-07
a O 0 1.134979665806668e-09
maternally O 0 1.2502947356551886e-05
inherited O 0 0.0006787171005271375
G O 0 0.001938555622473359
- O 0 4.712971713161096e-05
to O 0 1.020762496750649e-07
- O 0 8.306250674650073e-05
T O 0 0.00021392526105046272
transversion O 0 5.214440648160235e-07
at O 0 3.038678419997609e-09
the O 0 6.359164930747063e-12
- O 0 1.3687889932612052e-08
1 O 0 1.5149270726766417e-11
position O 0 4.36315809870802e-11
of O 0 5.892993883670206e-14
exon O 0 1.4831228156708676e-07
32 O 0 5.71029765694675e-08
. O 0 4.831441469121955e-09

This O 0 1.5737328107334747e-09
acceptor O 0 3.1844105130574007e-09
splice O 0 4.5099786802893505e-05
- O 0 4.013669240521267e-05
site O 0 2.811022739024338e-07
mutation O 0 1.794327033621812e-07
led O 0 9.48477407725079e-10
to O 0 1.0151299939531455e-11
the O 0 2.3636661204695653e-12
formation O 0 5.022239568663878e-12
of O 0 1.3194426020518568e-13
aberrant O 0 2.9527491562930663e-08
transcripts O 0 2.6348951109866903e-07
present O 0 1.1276065636778299e-09
at O 0 1.3317819735902958e-08
extremely O 0 1.5091748961637563e-09
low O 0 1.1345066752710409e-07
levels O 0 2.7749891273742833e-08
. O 0 2.599089610200167e-09

Based O 0 5.866030150514234e-08
on O 0 3.646434931781073e-09
our O 0 5.944662123669175e-11
recent O 0 1.3947299912220323e-11
finding O 0 1.4314754243072159e-11
that O 0 7.48921549775794e-11
cycloheximide O 0 1.123422975979338e-06
stabilized O 0 5.20077082910575e-06
mutant O 0 7.394858947407101e-09
COL17A1 O 0 1.1616810979830916e-07
transcripts O 0 3.180799978963478e-08
in O 0 1.0501301217491488e-11
keratinocytes O 0 8.543570295671543e-09
homozygous O 0 5.275287429107323e-10
for O 0 8.093287325039444e-13
a O 0 1.8213353047968894e-10
frameshift O 0 0.00026905350387096405
mutation O 0 7.178186024248134e-06
, O 0 3.928666836294781e-10
the O 0 1.261202808855444e-10
effects O 0 5.9134251273462723e-08
of O 0 4.373871057006262e-12
the O 0 5.669940628116876e-10
splice O 0 0.0017295394791290164
- O 0 2.781623834380298e-06
site O 0 1.9469188927700998e-08
mutation O 0 3.0042263121643487e-10
on O 0 6.757500917338455e-13
splicing O 0 2.49747916791776e-10
of O 0 4.310364185803467e-13
COL17A1 O 0 5.052418572404349e-08
transcripts O 0 1.378684721942136e-09
were O 0 9.239655048010054e-12
determined O 0 2.0906013031840587e-11
using O 0 4.828747124374644e-11
reverse O 0 2.772206926238141e-06
transcriptase O 0 3.2481035304954275e-05
polymerase O 0 6.095372555137146e-06
chain O 0 2.831858864738024e-06
reaction O 0 4.024671707014704e-10
of O 0 2.347808362654358e-13
total O 0 2.0419659019221825e-11
RNA O 0 9.797961411095457e-07
from O 0 1.4682307453162124e-11
keratinocytes O 0 3.963457828604078e-08
incubated O 0 3.1541618206176736e-09
for O 0 2.2841329522238496e-12
2 O 0 3.50242412849866e-09
. O 0 2.7959146109424182e-09

5 O 0 9.493234642832249e-08
h O 0 2.5697554519865662e-05
in O 0 9.865629146954547e-11
the O 0 4.414892756932076e-11
presence O 0 5.106746137073515e-10
or O 0 3.912611346024164e-10
absence O 0 2.7952452852364473e-11
of O 0 2.008822931132484e-13
10 O 0 3.752778643395516e-11
microg O 0 1.6354385934391757e-07
cycloheximide O 0 2.2004500976890995e-07
per O 0 1.5562520716549955e-10
ml O 0 6.3443479803027e-07
. O 0 1.1098500785067245e-08

Using O 0 1.7082740777496497e-09
this O 0 4.9457847539624566e-11
approach O 0 1.1315283821033972e-08
, O 0 4.577044299125532e-11
an O 0 1.2028851872902813e-11
abnormally O 0 5.58703732167487e-08
spliced O 0 0.0009779754327610135
transcript O 0 0.037156108766794205
was O 0 4.357390480436152e-06
identified O 0 7.592408479695223e-08
that O 0 1.6610029324182207e-11
contains O 0 4.285568427908615e-12
an O 0 8.164390387713216e-13
extra O 0 7.72877335047939e-12
264 O 0 4.5891010436172053e-10
bases O 0 2.2579053293725337e-08
upstream O 0 1.2588985409678344e-09
from O 0 5.700597871353963e-13
exon O 0 3.965029193864211e-09
32 O 0 6.592370649372015e-09
, O 0 3.46429794573222e-11
resulting O 0 1.365017543442093e-10
in O 0 1.3971056256334435e-10
a O 0 3.911300172632082e-09
premature O 0 6.484265924200372e-08
termination O 0 2.188494274690811e-09
codon O 0 3.064020148713098e-08
27 O 0 7.236271581945175e-09
bp O 0 6.69800215291616e-08
downstream O 0 8.81890915849226e-09
from O 0 4.999463950466909e-12
the O 0 3.637463594219348e-11
cryptic O 0 1.9171081078184216e-07
splice O 0 0.00015644484665244818
site O 0 7.165963324951008e-06
. O 0 1.402906946168514e-08

Three O 0 2.9994240424713325e-09
other O 0 3.483909775253702e-12
splice O 0 6.354411539177818e-07
variants O 0 1.3139150212282402e-07
, O 0 1.3117536223905546e-10
including O 0 4.8345134319449645e-12
one O 0 8.248982226455315e-12
derived O 0 1.6124305666706529e-12
from O 0 2.8424471435438414e-13
the O 0 5.611554515332073e-13
skipping O 0 1.1896793272736517e-10
of O 0 8.448507870942659e-14
exon O 0 5.413324899450345e-08
32 O 0 2.00368486247271e-08
, O 0 7.1405506507638e-11
were O 0 1.4347426025018706e-10
also O 0 3.47428663616256e-09
identified O 0 1.5210390813535923e-07
. O 0 3.4980511820492666e-09

These O 0 1.7499999671599653e-08
results O 0 1.7983325939496808e-09
indicate O 0 2.496864937029386e-10
the O 0 3.2932064193691435e-12
usefulness O 0 1.5789733964766128e-09
of O 0 4.417720963351135e-12
cycloheximide O 0 3.445106995059177e-05
treatment O 0 1.758945700203185e-07
in O 0 1.2660410914078213e-12
evaluating O 0 5.333102362503617e-11
the O 0 1.5335652886472317e-11
abnormal O 0 8.999190836966875e-10
processing O 0 1.0847391040957888e-10
of O 0 3.509947053056267e-13
mRNA O 0 1.5903902195191222e-08
due O 0 1.7352549397386952e-09
to O 0 1.897240559101121e-10
splice O 0 0.009256182238459587
- O 0 0.0003389025223441422
site O 0 1.2697681995632593e-05
mutations O 0 9.065367521543521e-06
, O 0 6.380675432460237e-10
because O 0 4.995458713352718e-09
( O 0 6.79703723860392e-11
i O 0 7.142589311115444e-07
) O 0 3.0476821153563316e-12
aberrant O 0 6.964069876325141e-10
splicing O 0 6.186657230955461e-08
often O 0 7.828898640482862e-10
generates O 0 2.135790676260907e-11
a O 0 3.1947386402997324e-10
premature O 0 5.043221396050512e-09
termination O 0 9.78968017761872e-10
codon O 0 4.130354369635825e-08
, O 0 1.8450098393518743e-10
( O 0 1.0500299414684111e-11
ii O 0 8.07669877644912e-08
) O 0 1.875307895082834e-11
transcripts O 0 3.0422523167317195e-08
with O 0 1.8689003677963e-09
premature O 0 7.709309812753418e-08
termination O 0 3.288290528757898e-09
codons O 0 1.574217662891897e-07
can O 0 1.471670856290075e-07
occur O 0 8.117919492178771e-08
at O 0 1.0831941210653895e-07
low O 0 4.9352192945661955e-06
or O 0 4.527913404217543e-07
undetectable O 0 0.0001413884456269443
levels O 0 1.90865758753489e-08
due O 0 1.534379290291099e-10
to O 0 3.6817116022547225e-10
nonsense O 0 3.5434995879768394e-06
- O 0 4.088929017598275e-07
mediated O 0 1.7796821794036077e-08
mRNA O 0 8.776517845809906e-10
decay O 0 2.1115960180395632e-07
, O 0 1.6465004359922375e-10
and O 0 3.3180957981215897e-10
( O 0 2.96333313790087e-12
iii O 0 5.30747747973237e-08
) O 0 4.460174590770194e-11
the O 0 8.973698173431188e-11
levels O 0 9.186871402500074e-11
of O 0 4.8712922394835226e-14
these O 0 2.716689503565184e-12
transcripts O 0 2.585296776658197e-08
can O 0 2.8974596055775237e-09
be O 0 1.2677065994171066e-11
increased O 0 4.902111268995091e-12
by O 0 2.8853128219985535e-11
cycloheximide O 0 2.776626388367731e-05
. O 0 2.1834670960174662e-08

A O 0 3.29578959679111e-08
deletion O 0 1.7331242361251498e-06
mutation O 0 1.103978661376459e-06
in O 0 4.123502372888055e-10
COL17A1 O 0 6.106409273343161e-05
in O 0 9.172815840230442e-10
five O 0 9.56978163380029e-10
Austrian O 0 0.0012894166866317391
families O 0 4.630816174966412e-09
with O 0 1.4814541593466402e-08
generalized O 0 0.008781099691987038
atrophic B-Disease 1 0.9999297857284546
benign I-Disease 1 0.9990230798721313
epidermolysis I-Disease 1 0.9963339567184448
bullosa I-Disease 0 0.1525605320930481
represents O 0 1.9170052212302835e-08
propagation O 0 6.820995679390762e-08
of O 0 5.471538153112299e-12
an O 0 1.3614339690326549e-11
ancestral O 0 1.177290073428594e-06
allele O 0 6.801079166507407e-07
. O 0 1.1347182748977502e-08

Patients O 0 0.00031754266819916666
with O 0 8.999387546282378e-08
generalized O 0 0.017870543524622917
atrophic B-Disease 1 0.9999167919158936
benign I-Disease 1 0.9996359348297119
epidermolysis I-Disease 1 0.9990192651748657
bullosa I-Disease 1 0.9941568374633789
, O 0 2.2461452431343787e-07
a O 0 8.437751053413933e-10
usually O 0 1.3311150792727489e-10
nonlethal O 0 5.9506013450061346e-09
form O 0 2.536713283873837e-09
of O 0 5.255512691704212e-10
junctional B-Disease 1 0.9992744326591492
epidermolysis I-Disease 1 0.9951474070549011
bullosa I-Disease 0 0.32236674427986145
, O 0 1.0324478161294337e-08
have O 0 7.539181501314829e-10
generalized O 0 1.0384481186065386e-07
blistering B-Disease 0 0.0002410265733487904
, O 0 1.232573936249537e-07
nail B-Disease 1 0.9999517202377319
dystrophy I-Disease 1 0.9991247057914734
, O 0 2.5332527187060805e-08
patchy B-Disease 0 0.38806816935539246
alopecia I-Disease 1 0.9999796152114868
, O 0 3.11886196868727e-07
and O 0 2.4063501768978313e-06
dental B-Disease 1 0.999169111251831
abnormalities I-Disease 1 0.9992460012435913
. O 0 8.424652975236313e-08

Skin B-Disease 1 0.999913215637207
fragility I-Disease 0 0.039487097412347794
in O 0 9.212722806850593e-10
most O 0 1.9625375977105897e-11
cases O 0 4.0066416850947917e-10
is O 0 4.4743292404447743e-10
due O 0 6.009475694845889e-10
to O 0 6.702968180505309e-10
mutations O 0 5.729979690727305e-08
in O 0 6.98492175557619e-12
the O 0 2.1485536873949718e-12
gene O 0 3.1879412443203137e-09
encoding O 0 4.485424653921655e-08
type O 0 0.0027651451528072357
XVII O 0 0.0002748047118075192
collagen O 0 0.0008325065136887133
( O 0 4.145522147780412e-09
COL17A1 O 0 7.233224459923804e-05
) O 0 2.0331112349225577e-09
. O 0 3.7121470342071916e-09

Recently O 0 5.141700603417121e-05
, O 0 1.8438357507477576e-09
we O 0 8.377231131007079e-10
reported O 0 1.6388305990044927e-10
five O 0 3.333247913794857e-11
Austrian O 0 7.088989514159039e-05
families O 0 1.2697720652710132e-09
with O 0 6.713514189016223e-09
generalized O 0 0.010299795307219028
atrophic B-Disease 1 0.9999380111694336
benign I-Disease 1 0.9983800649642944
epidermolysis I-Disease 1 0.9949747323989868
bullosa I-Disease 1 0.9828051924705505
who O 0 6.080017192289233e-05
share O 0 5.287226656491839e-09
the O 0 1.33639141419728e-10
same O 0 1.510444880281625e-09
COL17A1 O 0 7.142528193071485e-05
mutation O 0 9.530569400340028e-07
. O 0 4.792572561029829e-09

Affected O 0 2.7682388008543057e-06
individuals O 0 1.0846976788991824e-10
in O 0 2.096854981314955e-11
three O 0 6.081771891652821e-11
families O 0 7.735026161248548e-12
are O 0 1.8286704073743054e-13
homozygous O 0 5.782506071194682e-11
for O 0 1.4810019530187013e-12
4003delTC O 0 1.4904648537594767e-07
, O 0 1.0346488249490804e-10
whereas O 0 8.753313074372215e-10
those O 0 3.972988951717049e-11
in O 0 1.0698279762078045e-10
two O 0 1.9023679853624742e-10
others O 0 2.1156168483749127e-10
are O 0 4.260295675267978e-12
compound O 0 2.149497362324837e-07
heterozygotes O 0 8.982424333225936e-07
. O 0 6.599617297098348e-09

To O 0 5.371676881082976e-09
determine O 0 1.3020078348802144e-09
if O 0 1.2275187810661947e-10
the O 0 3.927403974951504e-12
occurrence O 0 1.5661845154113507e-08
of O 0 1.638845309459569e-11
4003delTC O 0 7.673977052036207e-06
in O 0 7.436949944761295e-10
these O 0 4.0886884156154935e-11
unrelated O 0 1.6288314030887818e-09
families O 0 1.5345894693874484e-11
signifies O 0 1.8325337775015882e-11
propagation O 0 1.2376260016822016e-09
of O 0 1.0629398836808912e-12
an O 0 2.065453016952823e-11
ancestral O 0 3.8380662203962856e-07
allele O 0 4.400834185958047e-08
or O 0 1.239452096513105e-09
a O 0 3.46241035842354e-10
mutational O 0 5.433824298961554e-06
hot O 0 7.487735729228007e-06
spot O 0 4.196761437924579e-06
, O 0 8.312320970427223e-11
haplotypes O 0 1.4937883818788578e-08
were O 0 2.0889598384421504e-10
determined O 0 5.630260702105261e-10
for O 0 5.019843048181816e-13
polymorphisms O 0 8.046865218602761e-07
both O 0 6.384014650251402e-09
within O 0 9.735295236623642e-09
and O 0 4.544915910287273e-08
flanking O 0 0.05818328261375427
COL17A1 O 0 0.06474589556455612
. O 0 1.0161954122622774e-07

Five O 0 5.237652533907067e-09
intragenic O 0 8.251815586390876e-08
polymorphisms O 0 9.076892837356354e-08
were O 0 2.3628343726045387e-10
chosen O 0 1.2288556457129562e-11
based O 0 1.350501741687049e-11
on O 0 9.374613307855384e-10
their O 0 7.873794949375679e-10
informativeness O 0 3.836906762444414e-05
. O 0 6.152634846046112e-09

One O 0 1.4472578691027138e-08
of O 0 3.518414509393053e-12
these O 0 6.879441460938551e-11
, O 0 1.0515877751915426e-10
not O 0 1.1754676121356056e-09
previously O 0 3.367389211916816e-08
reported O 0 7.487055597721337e-08
, O 0 2.7370700150797234e-10
was O 0 1.4187185648495415e-08
2988 O 0 3.286699623572531e-08
A O 0 1.0558194318832648e-08
or O 0 6.4802332389035655e-09
C O 0 1.3331945410754997e-05
that O 0 1.398150623055372e-10
introduces O 0 2.9116015154428965e-10
a O 0 2.338274018853781e-11
new O 0 4.9501638899052125e-11
restriction O 0 5.100457833862038e-10
site O 0 8.008417040628046e-09
for O 0 1.9684457189250715e-11
Eco0109 O 0 4.129855426526774e-07
I O 0 7.214961806312203e-05
. O 0 1.1061427329650542e-09

All O 0 9.150606383734328e-10
the O 0 2.051170518158063e-11
4003delTC O 0 7.236437227220449e-09
alleles O 0 1.61323510106115e-10
showed O 0 1.401972649084371e-09
the O 0 3.1963673244664315e-13
same O 0 3.669229850511435e-12
haplotype O 0 2.0264918632051376e-08
for O 0 4.921297310639394e-12
these O 0 4.5532098057188275e-12
five O 0 1.9295148812048524e-11
polymorphic O 0 1.0916105708247414e-07
markers O 0 0.0005958736874163151
. O 0 7.248209499266522e-08

Fourteen O 0 6.015238085410601e-08
microsatellite O 0 7.866316877880308e-07
polymorphisms O 0 3.971161675053736e-07
were O 0 7.29662608112136e-10
selected O 0 1.80406471012029e-11
based O 0 1.6435627164801403e-11
on O 0 1.2556229389559803e-09
their O 0 1.6151070758585462e-10
high O 0 1.2783208935829293e-09
heterozygosity O 0 1.9447445254172635e-07
and O 0 4.839502576459154e-09
their O 0 2.4088847236369837e-11
location O 0 6.89518913077336e-08
within O 0 1.148833805864058e-09
10q23 O 0 1.6449584450128896e-07
- O 0 5.372117357183015e-06
q25 O 0 2.46872474463089e-07
near O 0 1.6554600961171673e-06
COL17A1 O 0 7.56763038225472e-05
. O 0 7.631634879601279e-09

Three O 0 6.534936147772896e-08
families O 0 1.5501915306970204e-09
shared O 0 4.097936212588138e-09
microsatellite O 0 2.2541831640410237e-05
polymorphisms O 0 6.47448978270404e-05
covering O 0 2.705786573642399e-05
at O 0 2.458938297422719e-07
most O 0 1.4434052564293864e-10
19 O 0 4.553859955791495e-09
cM O 0 3.520636937537347e-08
, O 0 1.3042548152597533e-09
whereas O 0 1.466204047062547e-08
the O 0 1.4985162000158425e-09
others O 0 1.1466365634760223e-08
shared O 0 2.1942623273929485e-09
smaller O 0 7.958878001090852e-10
regions O 0 1.794150250589155e-08
consistent O 0 4.784263651913534e-08
with O 0 5.447052808804642e-10
cross O 0 3.93369055018411e-06
- O 0 2.692576526897028e-05
over O 0 4.0149387814381043e-07
events O 0 5.565464977763668e-09
during O 0 3.123394598514295e-10
passage O 0 3.392668784796271e-11
of O 0 1.7284664097141217e-13
this O 0 1.4084331791119897e-11
mutation O 0 2.938403131924616e-10
through O 0 1.2422198686357078e-11
several O 0 5.0517267452532266e-11
generations O 0 8.802171436173012e-09
. O 0 1.2560037454534267e-09

These O 0 2.987486880101642e-08
results O 0 3.3483722461369325e-09
indicate O 0 1.6655286039224393e-09
that O 0 1.0537642286534421e-10
4003delTC O 0 4.936471782457375e-07
occurs O 0 3.734531794918894e-09
on O 0 6.459161677740966e-11
a O 0 4.3763687118669736e-11
single O 0 6.650211936687356e-09
ancestral O 0 1.8612122403283138e-06
allele O 0 6.210160563568934e-08
. O 0 1.1771549290884309e-09
. O 0 1.664350435248707e-09

The O 0 3.880455068383526e-09
haptoglobin O 0 6.054627874618745e-07
- O 0 4.971508360540611e-07
gene O 0 9.768258024678289e-08
deletion O 0 4.123129713207163e-07
responsible O 0 6.618071868302877e-09
for O 0 5.438008376934533e-11
anhaptoglobinemia B-Disease 0 8.420174708589911e-05
. O 0 1.2840201790709216e-08

We O 0 1.2252227179487818e-06
have O 0 7.654310518745433e-11
found O 0 5.398569178499679e-12
an O 0 3.0238930527311594e-14
allelic O 0 5.302150385411153e-10
deletion O 0 3.3098697826972057e-07
of O 0 1.0750619144905826e-11
the O 0 1.3103389484570016e-09
haptoglobin O 0 8.62443528149015e-07
( O 0 7.982236399639575e-12
Hp O 0 3.8604325292013186e-10
) O 0 6.126195904732068e-12
gene O 0 8.807847784453315e-09
from O 0 1.512882701060203e-11
an O 0 7.471951529725018e-11
individual O 0 1.4215938148876006e-10
with O 0 1.95075022801916e-09
anhaptoglobinemia B-Disease 0 0.0011680439347401261
. O 0 3.643197032943135e-08

The O 0 2.830005341181163e-09
Hp O 0 7.850929684138919e-09
gene O 0 1.1030061308758832e-08
cluster O 0 1.7080273195801965e-08
consists O 0 2.8215514993878976e-11
of O 0 3.4661134639540903e-12
coding O 0 0.047957729548215866
regions O 0 1.1444338952060207e-06
of O 0 6.455318918296982e-11
the O 0 3.952379534766237e-10
alpha O 0 1.4021243888162616e-10
chain O 0 4.361843366496032e-06
and O 0 1.1293974644388527e-09
beta O 0 1.1590252195492479e-11
chain O 0 6.799354679287717e-08
of O 0 9.715779613131414e-13
the O 0 2.0128751096470943e-11
haptoglobin O 0 6.877270308791594e-09
gene O 0 2.8632280990592562e-09
( O 0 1.9882929937903304e-12
Hp O 0 5.056414176252133e-10
) O 0 2.5815528534312016e-11
and O 0 2.84830742325326e-10
of O 0 1.0746575070802455e-12
the O 0 7.748703068077845e-11
alpha O 0 6.761504550700792e-11
chain O 0 5.600786153081572e-06
and O 0 2.9074354035429906e-09
beta O 0 5.4549101347056705e-11
chain O 0 8.54782840065127e-08
of O 0 1.5467955692335944e-12
the O 0 8.15168557655177e-11
haptoglobin O 0 6.46461870701387e-08
- O 0 3.053629171745342e-08
related O 0 1.435605412325458e-09
gene O 0 2.0081810703231895e-07
( O 0 1.062150020714192e-11
Hpr O 0 8.452803967884392e-08
) O 0 3.6522364993407663e-11
, O 0 3.5915149326770646e-11
in O 0 4.31214508544997e-11
tandem O 0 1.7065901829482755e-06
from O 0 1.490737741582926e-11
the O 0 6.468744984111652e-10
5 O 0 2.3474294508218918e-08
side O 0 6.459740689024329e-06
. O 0 1.3913363794415545e-08

Southern O 0 2.4119509589581867e-07
blot O 0 0.0005677854642271996
and O 0 5.92019044898251e-10
PCR O 0 8.57372242535348e-07
analyses O 0 3.275684790082778e-08
have O 0 4.409399512184109e-10
indicated O 0 5.158851124065222e-09
that O 0 1.9472956580557366e-10
the O 0 1.9052938046715262e-11
individual O 0 4.64237676078838e-12
with O 0 7.976406861398555e-12
anhaptoglobinemia B-Disease 0 1.0919079613813665e-06
was O 0 3.385716595971644e-09
homozygous O 0 4.346189033666015e-11
for O 0 2.024439237123879e-13
the O 0 2.4046600214516767e-12
gene O 0 9.21049636559701e-09
deletion O 0 3.0407272788579576e-07
and O 0 3.5970646461436218e-09
that O 0 7.430494414206734e-11
the O 0 3.883929202558312e-12
gene O 0 6.7213172805224985e-09
deletion O 0 2.1321616827663092e-07
was O 0 9.221485441912591e-08
included O 0 1.6354456677802887e-10
at O 0 2.97093838419471e-09
least O 0 5.568939406841444e-12
from O 0 4.1275958887788955e-13
the O 0 8.398821568778025e-12
promoter O 0 3.1976932746147213e-07
region O 0 2.784704966618534e-10
of O 0 3.960448234554409e-13
Hp O 0 9.252786314917216e-10
to O 0 7.3368255915085e-12
Hpr O 0 2.884358307753132e-09
alpha O 0 7.987352966531969e-12
but O 0 1.1144073858160297e-10
not O 0 2.9000440937565486e-11
to O 0 1.8550477126622056e-11
Hpr O 0 1.4589531360797992e-07
beta O 0 1.3070558524397313e-10
( O 0 2.197510229340338e-11
Hpdel O 0 1.5160500197453075e-06
) O 0 5.187512086557433e-10
. O 0 1.9569101894489904e-09

In O 0 8.439264287396497e-10
addition O 0 9.221701874340127e-11
, O 0 3.742601506484533e-10
we O 0 1.568847607380519e-09
found O 0 3.987945043637531e-11
seven O 0 5.161392147012833e-12
individuals O 0 6.058098223375372e-14
with O 0 2.6970036447193646e-12
hypohaptoglobinemia B-Disease 0 4.093820734851761e-06
in O 0 1.6858909823724844e-09
three O 0 1.250126668850271e-09
families O 0 7.088432618651552e-10
, O 0 1.187863141183243e-10
and O 0 8.943185636489659e-10
the O 0 1.4298544119550893e-11
genotypes O 0 7.670375445911759e-10
of O 0 1.0105279243596832e-12
six O 0 3.765011635792348e-10
of O 0 1.0290387248909627e-12
the O 0 4.65967986418292e-10
seven O 0 1.2626710788055107e-10
individuals O 0 2.093927245136462e-13
were O 0 1.8092851869488946e-11
found O 0 1.827006601562431e-10
to O 0 4.99611151061341e-11
be O 0 6.36165786715992e-10
Hp2 O 0 4.59458606201224e-05
/ O 0 2.5630912205087952e-05
Hpdel O 0 0.0002078370889648795
. O 0 2.0718992743695708e-08

The O 0 1.0204778355671351e-08
phenotypes O 0 3.1671189049120585e-07
and O 0 1.423201378969452e-08
genotypes O 0 1.0916584614051317e-07
in O 0 2.670047793973396e-10
one O 0 5.435314975876793e-10
of O 0 3.027000308394867e-12
these O 0 1.9090269642862978e-10
three O 0 2.441971624911332e-10
families O 0 3.1532443323101234e-11
showed O 0 1.9951119867300804e-08
the O 0 5.2557506957651157e-11
father O 0 9.16052922406152e-09
to O 0 4.1333509531726875e-11
be O 0 7.314612110453922e-11
hypohaptoglobinemic B-Disease 0 7.394594803145083e-08
( O 0 4.044884219234213e-12
Hp2 O 0 2.1129477545400732e-07
) O 0 2.023595700728631e-11
and O 0 3.7881775494241765e-10
Hp2 O 0 4.015661488665501e-06
/ O 0 8.058575986069627e-06
Hpdel O 0 1.365489424642874e-05
, O 0 3.082910871032851e-10
the O 0 8.992546290942371e-11
mother O 0 9.031973746687072e-08
to O 0 3.1490251378718526e-11
be O 0 1.663513944649697e-11
Hp2 O 0 8.740008894392304e-08
- O 0 2.1916827463996924e-08
1 O 0 2.0681306667214017e-10
and O 0 6.542312802615413e-10
Hp1 O 0 2.4356954781978857e-06
/ O 0 1.09259337932599e-06
Hp2 O 0 3.157277888021781e-06
, O 0 9.211365697980867e-11
one O 0 4.81465518495372e-12
of O 0 1.5939605592461131e-13
the O 0 1.3299630841068222e-10
two O 0 3.238741497213482e-10
children O 0 2.2442453451176902e-10
to O 0 1.8251945094194255e-11
be O 0 6.465941670974473e-11
hypohaptoglobinemic B-Disease 0 1.7943904140338418e-07
( O 0 1.454103764481074e-11
Hp2 O 0 8.458753768536553e-07
) O 0 4.28828535181669e-11
and O 0 2.1300443631133703e-09
Hp2 O 0 1.3883742212783545e-05
/ O 0 1.336315744993044e-05
Hpdel O 0 0.00015677980263717473
, O 0 2.854410929842288e-09
and O 0 2.973006008044621e-10
the O 0 1.1493959430064482e-11
other O 0 2.1122690402330946e-11
child O 0 4.868833780591331e-09
to O 0 2.7923623482917215e-11
be O 0 5.772466879494509e-11
Hp1 O 0 5.131772127242584e-07
and O 0 1.3414203081651976e-09
Hp1 O 0 6.219457645784132e-06
/ O 0 8.719428478798363e-06
Hpdel O 0 1.2292780411371496e-05
, O 0 7.939118806810086e-11
showing O 0 7.044158034652526e-10
an O 0 8.530949384411013e-13
anomalous O 0 1.4723714469866422e-09
inheritance O 0 1.6052716489411978e-08
of O 0 2.839930374198829e-11
Hp O 0 1.3677316701432574e-06
phenotypes O 0 7.511629291911959e-07
in O 0 8.39975922151126e-10
the O 0 1.5531599339979607e-09
child O 0 3.265859618295508e-07
with O 0 1.5420906773755405e-09
Hp1 O 0 0.0009644492529332638
. O 0 2.4453719049688516e-08

The O 0 4.46446222213126e-08
Hp2 O 0 4.838014137931168e-05
/ O 0 0.00010966114496113732
Hpdel O 0 7.047793042147532e-05
individuals O 0 1.118857118065364e-09
had O 0 1.799023578996639e-07
an O 0 1.874517555067179e-11
extremely O 0 4.626649285910389e-09
low O 0 1.487026111135492e-07
level O 0 6.670814456377627e-10
of O 0 3.321592133287421e-13
Hp O 0 2.768036022615661e-09
( O 0 3.0262498236510726e-12
mean O 0 7.287780379172659e-10
+ O 0 1.369441227083712e-09
/ O 0 1.3555201121562277e-06
- O 0 2.149412239305093e-06
SD O 0 1.4039439520274755e-05
= O 0 1.3854858593731478e-07
0 O 0 2.8589849238036535e-11
. O 0 3.722647190507189e-13
049 O 0 1.0378174986058752e-09
+ O 0 2.481572169976687e-10
/ O 0 9.161406921975868e-08
- O 0 1.3286806677115237e-07
0 O 0 3.519283753306013e-10
. O 0 1.3323051429453558e-12
043 O 0 7.520812306260893e-10
mg O 0 2.0733600947231423e-10
/ O 0 7.0519585726458445e-09
ml O 0 4.664252539754443e-09
; O 0 3.820712843327634e-11
n O 0 2.1157021024009737e-07
= O 0 3.699793467148993e-07
6 O 0 1.542319189029584e-10
) O 0 1.901626208930529e-12
, O 0 1.3958416670775686e-12
compared O 0 9.679678066032427e-12
with O 0 1.9104466272845677e-11
the O 0 2.274579274930133e-10
level O 0 3.779574431206356e-10
( O 0 2.765444665799033e-13
1 O 0 2.525961861551962e-12
. O 0 2.1961724973318386e-12
64 O 0 4.1806860057169715e-11
+ O 0 2.0402501910155024e-10
/ O 0 1.742456845477136e-07
- O 0 1.3504218543403113e-07
1 O 0 2.208739302567153e-10
. O 0 9.685606483511577e-12
07 O 0 8.887796054679598e-11
mg O 0 7.227408949095349e-11
/ O 0 2.2060291371417406e-09
ml O 0 2.0211590734398044e-10
) O 0 3.3372523494668016e-13
obtained O 0 1.4166803147253049e-11
from O 0 1.7637690353372593e-12
52 O 0 8.114634297839984e-09
healthy O 0 3.9110070737535807e-10
volunteers O 0 4.812488515332225e-12
having O 0 6.53249676574319e-11
phenotype O 0 2.7648821898651477e-08
Hp2 O 0 9.280752237827983e-07
, O 0 2.2432640814362692e-11
whereas O 0 9.863295596934663e-11
the O 0 2.6429591154508714e-11
serum O 0 4.313195844929396e-08
Hp O 0 5.656621837601961e-10
level O 0 1.6422099791135736e-10
of O 0 2.679808957205265e-13
an O 0 4.5531602793635884e-11
individual O 0 4.1020770114030825e-11
with O 0 1.1296430457718998e-09
Hp1 O 0 0.0008125508320517838
/ O 0 6.459060386987403e-05
Hpdel O 0 0.00012828153558075428
was O 0 5.409402206169034e-07
0 O 0 1.8805151213996396e-08
. O 0 1.1898909635377208e-09

50 O 0 4.445858792223589e-09
mg O 0 1.0209217471413012e-08
/ O 0 4.483850943870493e-07
ml O 0 6.591404826394864e-07
, O 0 4.67768546119629e-10
which O 0 5.418750170793629e-11
was O 0 9.029606506949506e-10
approximately O 0 7.615861066789797e-12
half O 0 5.334987451810491e-10
the O 0 1.256608705979545e-11
level O 0 2.1182361420457596e-11
of O 0 5.0672658479184243e-14
Hp O 0 7.954936265264223e-09
in O 0 4.3486378387136426e-10
control O 0 3.297163493698463e-05
sera O 0 1.9663460193442006e-07
from O 0 8.926181191762361e-13
the O 0 8.547517728330067e-12
Hp1 O 0 1.3473027138388716e-06
phenotype O 0 1.1391443344166419e-08
( O 0 1.854720397447343e-13
1 O 0 1.9512570812590946e-12
. O 0 3.66951651356584e-12
26 O 0 3.128598075052835e-11
+ O 0 2.0070795025972643e-10
/ O 0 2.5867575459415093e-07
- O 0 2.9958584946143674e-07
0 O 0 3.333262277305238e-10
. O 0 4.107866661846177e-13
33 O 0 6.407964436849767e-12
mg O 0 5.288462029406915e-11
/ O 0 2.8847930710895753e-09
ml O 0 1.4405702186692793e-09
; O 0 3.0495560937593424e-11
n O 0 4.1948143802983395e-07
= O 0 4.5989727368578315e-06
9 O 0 1.4270659098869487e-09
) O 0 1.640930880758562e-12
, O 0 9.64447488885356e-13
showing O 0 2.9857904343399966e-11
a O 0 3.884032852286001e-12
gene O 0 9.320560323544669e-09
- O 0 7.73148485677666e-07
dosage O 0 1.659710875401288e-07
effect O 0 4.681008025642086e-09
. O 0 3.026843442555105e-09

The O 0 1.5072734171894808e-09
other O 0 1.509415162304073e-11
allele O 0 3.2904093338892437e-10
( O 0 3.66236338131265e-12
Hp2 O 0 3.06721602783e-07
) O 0 1.5633162082570595e-12
of O 0 6.394174469417924e-14
individuals O 0 1.631070278840241e-12
with O 0 3.008439330987045e-11
Hp2 O 0 5.438730295281857e-05
/ O 0 9.133905223279726e-06
Hpdel O 0 2.3935785065987147e-05
was O 0 1.9659728422993794e-07
found O 0 2.060489334709814e-09
to O 0 1.6044374162582642e-10
have O 0 1.1429894808401286e-09
, O 0 3.7652755913164526e-11
in O 0 1.549022542179923e-11
all O 0 6.02222872264635e-12
exons O 0 3.205582856935507e-07
, O 0 4.514491003249077e-10
no O 0 1.6805479230441733e-10
mutation O 0 2.8921906536361064e-10
, O 0 2.7035123272012296e-13
by O 0 2.622068686307377e-13
DNA O 0 3.3668439414213935e-07
sequencing O 0 3.0799111527812784e-07
. O 0 5.327262186938242e-09

On O 0 4.805323250423044e-09
the O 0 2.5226687058732544e-12
basis O 0 1.873365828783391e-12
of O 0 2.868234350115323e-13
the O 0 6.844443761755414e-11
present O 0 7.709900773367195e-11
study O 0 1.171590324755556e-10
, O 0 4.449924369959168e-12
the O 0 4.75092664861676e-12
mechanism O 0 2.8311969435534934e-10
of O 0 7.842637129995556e-13
anhaptoglobinemia B-Disease 0 2.8817927159252577e-05
and O 0 8.469746681782908e-09
the O 0 1.8708314411530758e-11
mechanism O 0 1.8222734432526977e-10
of O 0 7.312383256416824e-14
anomalous O 0 4.042846502017028e-09
inheritance O 0 1.9522511607306114e-08
of O 0 2.1279427872555878e-11
Hp O 0 2.0464146643917047e-07
phenotypes O 0 4.375991409233393e-07
were O 0 1.0264082028754729e-08
well O 0 2.4439124501896003e-08
explained O 0 3.045624907827005e-06
. O 0 2.6027109356618894e-09

However O 0 4.290689048502827e-07
, O 0 5.3762019142089557e-11
the O 0 5.488219687738161e-12
mechanism O 0 3.0227914615821305e-10
of O 0 1.8215455185877083e-12
hypohaptoglobinemia B-Disease 0 6.344779103528708e-05
remains O 0 3.668474732876348e-07
unknown O 0 4.896785412711324e-07

ATM O 0 0.00037749105831608176
mutations O 0 0.0008246906800195575
and O 0 2.3013460292986565e-07
phenotypes O 0 0.00013087395927868783
in O 0 1.4802849364059512e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
telangiectasia I-Disease 1 1.0
families O 0 0.0005807204288430512
in O 0 1.0646159509519748e-08
the O 0 5.9012310593686834e-09
British O 0 0.00011316400195937604
Isles O 0 1.046968282025773e-05
: O 0 4.08739968954519e-12
expression O 0 1.9471488223871125e-12
of O 0 2.398331946722957e-14
mutant O 0 1.5704074707301174e-09
ATM O 0 6.317245606624056e-07
and O 0 4.756827820528997e-09
the O 0 2.0493999552950726e-10
risk O 0 5.255505808321459e-09
of O 0 1.5416545817714677e-10
leukemia B-Disease 1 0.9989084005355835
, O 0 9.933652472682297e-05
lymphoma B-Disease 1 1.0
, O 0 1.5298801372409798e-05
and O 0 0.020611586049199104
breast B-Disease 1 0.9998531341552734
cancer I-Disease 0 0.45863139629364014
. O 0 9.880331219846994e-08

We O 0 5.343466114027251e-07
report O 0 1.2399835325194175e-10
the O 0 5.933396135526792e-13
spectrum O 0 4.697209288195836e-11
of O 0 1.396054712804462e-12
59 O 0 3.356392141995457e-08
ATM O 0 3.093036139034666e-05
mutations O 0 1.1878904842888005e-05
observed O 0 2.2304525373328943e-06
in O 0 1.7365195162710734e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 0 0.010841972194612026
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999994039535522
T I-Disease 1 1.0
) O 0 4.211457280689501e-07
patients O 0 4.404133946422917e-08
in O 0 2.8754788480855886e-11
the O 0 4.425011190800632e-10
British O 0 6.0021884564775974e-05
Isles O 0 0.0009758039959706366
. O 0 8.704270193504726e-09

Of O 0 8.201986867462097e-10
51 O 0 1.451222289006182e-07
ATM O 0 2.1242867660475895e-05
mutations O 0 1.5295767298084684e-05
identified O 0 4.1114364535133063e-07
in O 0 3.74906022893029e-10
families O 0 2.4488466809913234e-10
native O 0 2.09856154675947e-09
to O 0 6.588219414460639e-10
the O 0 2.4116625363390654e-10
British O 0 6.55165349598974e-05
Isles O 0 0.00034964169026352465
, O 0 2.0399699984796626e-10
11 O 0 3.409873425286314e-11
were O 0 3.22311170808387e-11
founder O 0 1.2225920720254635e-08
mutations O 0 1.0726384971349034e-06
, O 0 3.159446593237192e-10
and O 0 1.193646181896213e-09
2 O 0 2.9450350491622146e-10
of O 0 1.5020277773294954e-12
these O 0 4.8312433914565744e-11
11 O 0 4.1084899371490735e-11
conferred O 0 4.695623750938793e-11
a O 0 3.764815889595319e-11
milder O 0 4.290578772270237e-07
clinical O 0 1.9719188912858954e-06
phenotype O 0 4.463346954253211e-07
with O 0 9.019635038853835e-11
respect O 0 5.855896323403442e-10
to O 0 3.3881970562532615e-09
both O 0 4.567380074149696e-08
cerebellar B-Disease 0 0.023636074736714363
degeneration I-Disease 1 0.9997416138648987
and O 0 2.455755918617797e-07
cellular O 0 4.041041393065825e-05
features O 0 8.443113620160148e-05
. O 0 3.176938321303169e-07

We O 0 5.799375685455743e-06
report O 0 4.907525941177937e-09
, O 0 1.8789419672926577e-11
in O 0 1.4650249763326073e-11
two O 0 2.562819068074873e-09
A B-Disease 1 0.9999978542327881
- I-Disease 1 0.9999985694885254
T I-Disease 1 1.0
families O 0 1.0507972802997756e-07
, O 0 3.025720646254726e-11
an O 0 1.1363144583262375e-12
ATM O 0 1.4216909676179057e-06
mutation O 0 3.028600303878193e-08
( O 0 2.0452860325509414e-12
7271T O 0 2.157904299693314e-09
- O 0 3.169844546846434e-07
- O 0 9.22521337543003e-07
> O 0 6.334672342234171e-09
G O 0 2.4973353447421687e-06
) O 0 1.8139810833983638e-11
that O 0 1.1093541640860849e-09
may O 0 3.6680314341452913e-09
be O 0 3.58580630466232e-11
associated O 0 2.5110874490863466e-10
with O 0 2.801345787284415e-11
an O 0 1.0940583161644923e-10
increased O 0 5.636218602944609e-08
risk O 0 5.955100164101168e-07
of O 0 1.3397410292270706e-08
breast B-Disease 1 0.9997071623802185
cancer I-Disease 0 0.30526530742645264
in O 0 2.6468158775827533e-09
both O 0 5.485289733542231e-08
homozygotes O 0 4.244354568072595e-05
and O 0 2.645182028970794e-08
heterozygotes O 0 8.993553279879052e-08
( O 0 4.945331991135227e-11
relative O 0 6.373745975452039e-09
risk O 0 1.584425568523784e-08
12 O 0 4.3665300542006236e-11
. O 0 2.3945739488495654e-11
7 O 0 6.315429956771368e-09
; O 0 6.668222862771245e-09
P O 1 0.8166981339454651
= O 0 0.000873179582413286
. O 0 3.2477853739720786e-10
0025 O 0 1.1157828794239322e-07
) O 0 2.618053343561577e-11
, O 0 2.187866034175645e-11
although O 0 1.6454738960280935e-10
there O 0 1.90150464818295e-10
is O 0 6.788123535494961e-11
a O 0 4.033448020024366e-10
less O 0 2.373119922793876e-09
severe O 0 6.438937998609617e-05
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999996423721313
T I-Disease 1 1.0
phenotype O 0 0.0018771671457216144
in O 0 6.275283070955595e-11
terms O 0 8.914973793905379e-12
of O 0 1.0653079167508711e-13
the O 0 1.3357943223768487e-11
degree O 0 2.70602845686696e-10
of O 0 9.594870731266525e-11
cerebellar B-Disease 0 0.19198405742645264
degeneration I-Disease 1 0.9998363256454468
. O 0 1.459269043380118e-07

This O 0 6.046684930538504e-09
mutation O 0 3.481093813206826e-08
( O 0 1.520850459457712e-11
7271T O 0 1.4326083430660219e-08
- O 0 1.7739533859639778e-06
- O 0 1.8062961316900328e-05
> O 0 7.817476443960913e-08
G O 0 7.193008514150279e-06
) O 0 5.663687401014084e-12
also O 0 2.4381819480057132e-11
allows O 0 3.1495702313560914e-12
expression O 0 1.3800093012772408e-11
of O 0 1.0692123320618988e-13
full O 0 3.1266593480960836e-11
- O 0 1.281842827438595e-07
length O 0 1.0008164075259174e-08
ATM O 0 3.2719324849495024e-07
protein O 0 2.3750818201051516e-08
at O 0 1.2148206884887713e-09
a O 0 2.016587244413337e-11
level O 0 3.164716405601453e-11
comparable O 0 8.8745163995263e-11
with O 0 1.354454465252175e-10
that O 0 4.2524921362030454e-09
in O 0 9.263133593506723e-10
unaffected O 0 5.931051418883726e-06
individuals O 0 4.353731264394867e-11
. O 0 8.057934319793958e-10

In O 0 1.2547035632692882e-09
addition O 0 9.773182957362181e-11
, O 0 2.8116464712013567e-10
we O 0 1.91645233016402e-09
have O 0 3.702159065421817e-11
studied O 0 9.029369252289143e-09
18 O 0 9.357681740596036e-09
A B-Disease 1 0.9999946355819702
- I-Disease 1 0.9999992847442627
T I-Disease 1 1.0
patients O 0 0.015057791024446487
, O 0 4.842731771148578e-10
in O 0 8.385028782420534e-11
15 O 0 1.4443994611479383e-10
families O 0 5.154272147978034e-11
, O 0 5.323957941172353e-10
who O 0 7.957304433148238e-07
developed O 0 0.0018218627665191889
leukemia B-Disease 1 0.9975021481513977
, O 0 2.7054979000240564e-05
lymphoma B-Disease 1 1.0
, O 0 4.217019267116484e-08
preleukemic O 0 0.0022851349785923958
T O 1 0.559772789478302
- O 0 0.0020462418906390667
cell O 0 0.04944577440619469
proliferation O 0 0.00825961772352457
, O 0 9.775452980420596e-08
or O 0 0.0009284954285249114
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 7.428096893136171e-08
mostly O 0 1.126897020142792e-09
in O 0 7.907906507398366e-08
childhood O 0 0.00013650854816660285
. O 0 2.1769299252127894e-08

A O 0 5.592091056882964e-08
wide O 0 7.083800657170514e-09
variety O 0 1.7215202874343305e-10
of O 0 6.592549423034555e-12
ATM O 0 3.519018355291337e-05
mutation O 0 3.1401657452079235e-07
types O 0 2.511736774124529e-08
, O 0 6.681877273706505e-11
including O 0 6.27662297136844e-11
missense O 0 5.294768561725505e-05
mutations O 0 0.000670095905661583
and O 0 1.682556529658541e-07
in O 0 1.5716269397003657e-09
- O 0 9.975665307138115e-05
frame O 0 0.003231217386201024
deletions O 0 5.643970780511154e-06
, O 0 1.6798533675199678e-09
were O 0 7.480169261775416e-10
seen O 0 1.5427268351686507e-08
in O 0 1.3682342758780663e-10
these O 0 3.5480632321061023e-10
patients O 0 5.237063227525596e-09
. O 0 3.528357328530518e-10

We O 0 1.8665128891370841e-06
also O 0 2.7670582491978735e-10
show O 0 2.323745501575658e-10
that O 0 2.666310748578038e-11
25 O 0 3.73264570294185e-12
% O 0 1.167109892888027e-13
of O 0 1.7100601804823784e-13
all O 0 6.129758478579106e-09
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999996423721313
T I-Disease 1 1.0
patients O 0 2.3601769498782232e-05
carried O 0 4.1443140474939355e-08
in O 0 4.981079992916193e-10
- O 0 2.1827775071869837e-06
frame O 0 0.0002661475446075201
deletions O 0 2.0499785478023114e-06
or O 0 2.174025404144686e-08
missense O 0 1.6223499187617563e-05
mutations O 0 5.619450894300826e-05
, O 0 2.384675512612233e-10
many O 0 1.619501191138517e-12
of O 0 4.094430090112455e-12
which O 0 1.4251985192004213e-07
were O 0 9.471025919083331e-08
also O 0 1.1269733590779651e-07
associated O 0 3.76105191435272e-09
with O 0 6.001408398015329e-11
expression O 0 2.0279358747821163e-10
of O 0 8.583078909066288e-13
mutant O 0 2.7819259784678252e-08
ATM O 0 6.806088208577421e-07
protein O 0 2.0303265557686245e-07
. O 0 4.711031564852419e-09

The O 0 3.9526453221583324e-09
DMPK O 0 1.0182048981732805e-06
gene O 0 8.948568108735344e-08
of O 0 1.8879859897680262e-09
severely O 1 0.997055172920227
affected O 0 0.0723913386464119
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
patients O 0 0.008265389129519463
is O 0 1.8029278070486043e-09
hypermethylated O 0 1.1016080861736555e-05
proximal O 0 1.5095058643055381e-06
to O 0 4.8893911142045e-09
the O 0 1.5709579470613022e-10
largely O 0 2.0999069150207106e-09
expanded O 0 1.15869802641555e-07
CTG O 0 7.078782073222101e-05
repeat O 0 2.4626309823361225e-05
. O 0 5.662432300823639e-09

Using O 0 7.900199605614944e-09
methylation O 0 4.5067022256262135e-06
- O 0 4.205198820272926e-06
sensitive O 0 9.59380258791498e-07
restriction O 0 2.1162489360904146e-07
enzymes O 0 1.4323001096272492e-07
, O 0 1.2262152404574067e-10
we O 0 3.527697856053891e-10
characterized O 0 6.322305179384813e-11
the O 0 6.85426108232301e-13
methylation O 0 1.5976300460351922e-07
pattern O 0 5.29154976902646e-06
on O 0 9.25184195921247e-08
the O 0 4.152659993650332e-09
5 O 0 2.440083690657957e-08
side O 0 7.777335753189618e-08
of O 0 4.706234859284952e-13
the O 0 8.857419658836463e-11
CTG O 0 1.0710315336837084e-06
repeat O 0 5.6757350819225394e-08
in O 0 2.7167944977035674e-11
the O 0 1.0260446138554702e-11
DMPK O 0 2.867870705358655e-07
gene O 0 5.9644187366814094e-09
of O 0 4.056697686105615e-12
normal O 0 4.814288345755813e-08
individuals O 0 1.4768138101306505e-11
and O 0 4.319934687746496e-10
of O 0 2.4203986037640846e-11
patients O 0 2.241967820282298e-07
affected O 0 4.8143068198669425e-08
with O 0 6.054239293007413e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 0.9999998807907104
, O 0 1.1736149829744136e-09
showing O 0 1.5098313710382172e-09
expansions O 0 1.777972258310001e-08
of O 0 4.0784051483222505e-12
the O 0 4.3294701157492455e-10
repetitive O 0 0.00010837109584826976
sequence O 0 1.3607317669084296e-05
. O 0 2.0062396188791354e-08

The O 0 9.880699591846565e-10
gene O 0 4.272011189243585e-09
segment O 0 3.053697739119343e-09
analyzed O 0 8.360981906818665e-10
corresponds O 0 1.4396274450323432e-10
to O 0 1.2247841629786649e-11
the O 0 4.984296829435575e-12
genomic O 0 6.396803087227454e-07
SacI O 0 3.759433457162231e-05
- O 0 9.419480875294539e-07
HindIII O 0 3.9618487335246755e-07
fragment O 0 1.5164239641762833e-08
carrying O 0 1.4219600497078488e-10
exons O 0 8.086455238753842e-08
11 O 0 6.285735043576324e-09
- O 0 2.1825151179655222e-06
15 O 0 3.207856202891435e-09
. O 0 6.003243457897156e-10

There O 0 6.142761410643516e-09
is O 0 4.2979374399731984e-12
constitutive O 0 1.4793320735062565e-10
methylation O 0 5.39687050604698e-07
in O 0 1.8403108204001484e-10
intron O 0 0.0010834375862032175
12 O 0 3.345480559246994e-09
at O 0 6.866018170681443e-11
restriction O 0 9.666122763318796e-11
sites O 0 2.351271677358824e-10
of O 0 1.2742026401016404e-12
SacII O 0 0.0001763058389769867
and O 0 1.9090800051912993e-08
HhaI O 0 4.416282536112703e-06
, O 0 1.0874979736175128e-11
localized O 0 1.5732706248883233e-09
1 O 0 2.845489122105249e-10
, O 0 1.985625899814103e-11
159 O 0 1.7463379631266207e-09
- O 0 7.463516027428341e-08
1 O 0 2.7312396788659044e-10
, O 0 1.0409865677796226e-11
232 O 0 2.5561773184246128e-11
bp O 0 8.95279461676779e-10
upstream O 0 9.074595241909122e-11
of O 0 2.0620340829800854e-13
the O 0 1.2462066968643715e-11
CTG O 0 2.8956497999388375e-07
repeat O 0 8.648867577676356e-08
, O 0 3.6378432818201523e-12
whereas O 0 2.480245869795894e-11
most O 0 9.023916162920198e-12
, O 0 9.870522454935582e-11
if O 0 6.574966349148781e-09
not O 0 2.1811474848476564e-09
all O 0 1.1838613422909816e-11
, O 0 1.2303637275667967e-11
of O 0 6.773279311554636e-14
the O 0 3.212271811395273e-12
other O 0 1.6189783888509446e-13
sites O 0 6.810117747502176e-11
of O 0 5.018244392078486e-13
SacII O 0 4.455272573977709e-06
, O 0 1.0508659914476581e-10
HhaI O 0 8.725182283342292e-07
, O 0 7.812665792084061e-11
and O 0 6.574649713542158e-10
HpaII O 0 2.5244846710847924e-06
in O 0 1.8782406185913203e-10
this O 0 6.509287553413401e-11
region O 0 3.884572219448046e-09
are O 0 5.3096333753333e-12
unmethylated O 0 4.811296548723476e-06
, O 0 3.178134699854951e-10
in O 0 2.8660717896200616e-11
normal O 0 5.972546901489295e-09
individuals O 0 1.968489824269448e-12
and O 0 1.5533251074284493e-10
most O 0 2.953633214744511e-12
of O 0 1.0571452567498252e-12
the O 0 8.099727999422157e-09
patients O 0 5.429021143754653e-08
. O 0 1.0904983582804562e-09

In O 0 2.383767183644636e-09
a O 0 6.330800467191366e-11
number O 0 9.977105946967768e-11
of O 0 6.034500676932453e-11
young O 0 6.860149710519181e-07
and O 0 2.554334969318006e-06
severely O 1 0.8454675078392029
affected O 0 8.82781364452967e-07
patients O 0 2.9947042889943987e-07
, O 0 1.0000883454708287e-10
however O 0 3.3691846534900094e-10
, O 0 4.578464777443836e-12
complete O 0 1.480353895022546e-10
methylation O 0 1.230021098308498e-07
of O 0 1.889024093398861e-12
these O 0 4.9496916981750516e-11
restriction O 0 1.2837844121094122e-09
sites O 0 4.124041552699964e-08
was O 0 5.571043288910005e-07
found O 0 1.668905680318744e-09
in O 0 7.455406084155847e-12
the O 0 2.5035827577735148e-11
mutated O 0 9.955601143474269e-08
allele O 0 2.1985449905059795e-08
. O 0 5.6109237256407596e-09

In O 0 1.738269306272855e-09
most O 0 6.621357108438364e-12
of O 0 5.681103374191587e-13
these O 0 1.1872561267445292e-10
patients O 0 2.259024300954593e-09
, O 0 1.0386165885667431e-11
the O 0 4.078360218984223e-11
onset O 0 1.0142218798137037e-06
of O 0 3.0251448568385797e-10
the O 0 1.515469284640858e-05
disease O 1 0.998374342918396
was O 0 0.00036356874625198543
congenital O 1 0.999981164932251
. O 0 4.6661682517878944e-07

Preliminary O 0 9.310388691119442e-07
in O 0 1.743475808169137e-09
vivo O 0 1.8353038058194215e-06
footprinting O 0 4.88609748572344e-06
data O 0 3.143669324856546e-09
gave O 0 1.1918824260881422e-10
evidence O 0 3.7587368113822794e-12
for O 0 8.601938063755588e-14
protein O 0 6.701421084720494e-10
- O 0 5.0940739129146095e-06
DNA O 0 0.02002047374844551
contact O 0 1.774373117768846e-06
in O 0 7.929951140184244e-10
normal O 0 2.6599149549610956e-08
genes O 0 1.0960080842892239e-08
at O 0 3.9700989162838596e-09
an O 0 5.881739539859154e-11
Sp1 O 0 2.3827105906093493e-05
consensus O 0 5.520684950854893e-11
binding O 0 2.911307306341371e-10
site O 0 7.79091813285504e-09
upstream O 0 8.972659282235895e-10
of O 0 4.838680996675782e-13
the O 0 3.4849085422949955e-11
CTG O 0 8.754362852414488e-07
repeat O 0 8.202039794014127e-07
and O 0 4.018857191478986e-10
for O 0 2.5226964072387614e-13
a O 0 4.412466052261532e-12
significant O 0 1.2782093092300606e-12
reduction O 0 1.5974509215421762e-10
of O 0 3.687919110720306e-13
this O 0 9.513051457687993e-11
interaction O 0 6.48730028030009e-11
in O 0 1.0602903971479449e-10
cells O 0 2.9588476113673323e-09
with O 0 7.292960506333213e-12
a O 0 8.391208283775597e-10
hypermethylated O 0 4.802041075890884e-06
DMPK O 0 2.508936859157984e-06
gene O 0 1.7138009411610255e-07
. O 0 2.900460427390783e-10
. O 0 9.237444698051434e-10

The O 0 3.307749238956603e-07
hemochromatosis B-Disease 1 0.9999716281890869
gene O 0 1.9587952920119278e-05
product O 0 6.724179257844298e-08
complexes O 0 1.2475361188535317e-07
with O 0 1.5680720610866672e-10
the O 0 1.2428674756037594e-10
transferrin O 0 6.67107471485906e-08
receptor O 0 2.8352622472027633e-09
and O 0 7.707302573933816e-10
lowers O 0 9.842843695651027e-08
its O 0 1.1449339740177145e-12
affinity O 0 1.0310609137309523e-11
for O 0 2.2537002917089738e-13
ligand O 0 1.9088049196813728e-10
binding O 0 1.9646755333724286e-08
. O 0 9.505570552903464e-09

We O 0 2.63645392806211e-06
recently O 0 1.4551353011427182e-08
reported O 0 3.528976555422503e-10
the O 0 6.332557091551227e-13
positional O 0 2.25602736492192e-09
cloning O 0 4.989193058690944e-09
of O 0 1.922052740490482e-13
a O 0 5.689958226806624e-11
candidate O 0 1.2394685278138695e-09
gene O 0 1.6316683968398138e-06
for O 0 6.118547162259347e-07
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 0.5334376096725464
HFE O 1 0.9774819016456604
. O 0 5.404946818998724e-07

The O 0 2.006261601295023e-09
gene O 0 2.0604943529178854e-08
product O 0 9.887566321253871e-09
, O 0 1.1382721848418598e-10
a O 0 5.698755703442693e-11
member O 0 9.684664528664122e-12
of O 0 4.386041226392412e-13
the O 0 1.3558451583683961e-10
major O 0 3.3691011092074064e-10
histocompatibility O 0 2.0365588326853867e-08
complex O 0 4.582694046462166e-08
class O 0 1.9045124588501494e-07
I O 0 0.0025414314586669207
- O 0 9.73884311861184e-07
like O 0 4.3141670857949066e-07
family O 0 1.0342714062971936e-07
, O 0 1.1833495294766294e-10
was O 0 8.22690271462534e-09
found O 0 3.908315060474621e-10
to O 0 2.1175738246226317e-11
have O 0 3.954194610633621e-11
a O 0 4.297980374379229e-11
mutation O 0 1.1034164693057846e-08
, O 0 1.656838902186486e-11
Cys O 0 4.9788327487476636e-06
- O 0 8.803888107422608e-08
282 O 0 1.9446178001203407e-08
- O 0 2.226915739811375e-06
- O 0 2.4394939828198403e-06
> O 0 9.332514316895413e-09
Tyr O 0 6.670080043846838e-09
( O 0 5.059792645631389e-13
C282Y O 0 8.533740381011512e-11
) O 0 7.714203624845095e-13
, O 0 9.741312574293448e-13
in O 0 1.067346406570524e-12
85 O 0 2.1445425296695575e-11
% O 0 6.02624720957845e-13
of O 0 3.620137392981726e-12
patient O 0 2.3152417725214036e-06
chromosomes O 0 8.284552563964098e-07
. O 0 6.359598625493845e-09

This O 0 7.434826088115187e-09
mutation O 0 4.2439378233893876e-08
eliminates O 0 1.4995768538028642e-07
the O 0 4.797828800917614e-10
ability O 0 2.256690168067621e-09
of O 0 2.792361177353375e-12
HFE O 0 0.0002819335204549134
to O 0 1.2547035632692882e-09
associate O 0 6.962476151173291e-10
with O 0 9.109225179715352e-11
beta2 O 0 4.7195695515256375e-05
- O 0 0.0001562589459354058
microglobulin O 0 5.0586699217092246e-05
( O 0 1.0117555404587364e-10
beta2m O 0 3.2772601343822316e-07
) O 0 3.0137344009251166e-11
and O 0 1.172996838549878e-10
prevents O 0 1.6042057682241762e-09
cell O 0 3.4709639294305816e-05
- O 0 0.00047466938849538565
surface O 0 4.5012471673544496e-05
expression O 0 1.987733639907674e-06
. O 0 9.463870576098543e-09

A O 0 1.6004236158551066e-07
second O 0 1.4770499490168731e-08
mutation O 0 6.730055446269034e-08
that O 0 1.324258258605937e-09
has O 0 4.3199119836856426e-09
no O 0 1.3042242286154249e-10
effect O 0 4.726464220006221e-10
on O 0 1.1831046364818576e-08
beta2m O 0 6.364303408190608e-05
association O 0 2.8330390811071027e-10
, O 0 2.8131094675920565e-11
H63D O 0 7.248927431646734e-07
, O 0 6.775357358490552e-11
was O 0 2.8249752759279545e-08
found O 0 9.41249389541099e-09
in O 0 4.0605546702821016e-11
eight O 0 2.511063579291317e-10
out O 0 5.493189236815965e-10
of O 0 5.697761056369655e-13
nine O 0 4.905776229691128e-09
patients O 0 4.980441059565521e-11
heterozygous O 0 1.6130742575004575e-11
for O 0 4.166591659367225e-13
the O 0 3.3969618784546185e-11
C282Y O 0 7.570139359813766e-08
mutant O 0 1.8014958413914428e-07
. O 0 5.4864175424995665e-09

In O 0 2.334354931576854e-09
this O 0 8.854851574202627e-11
report O 0 9.240352372152927e-10
, O 0 1.798769813654566e-11
we O 0 3.476047782946523e-10
demonstrate O 0 3.5524021224642155e-11
in O 0 7.343209373900095e-12
cultured O 0 9.980522186481267e-09
293 O 0 1.7597595602936167e-09
cells O 0 1.3773187035326373e-08
overexpressing O 0 6.341220455396979e-07
wild O 0 2.0175065174043993e-07
- O 0 3.1033243431011215e-05
type O 0 3.2472617021994665e-05
or O 0 1.0083696544427312e-08
mutant O 0 1.3553298572333006e-07
HFE O 0 5.132216301717563e-06
proteins O 0 2.4160113909488246e-08
that O 0 7.259963186179164e-10
both O 0 1.3925695319105813e-10
the O 0 1.80489151402341e-10
wild O 0 5.113193992656306e-07
- O 0 0.00016600711387582123
type O 0 0.0013569669099524617
and O 0 1.1923654028578312e-06
H63D O 0 0.00013531444710679352
HFE O 0 0.00016521818179171532
proteins O 0 6.564455361512955e-07
form O 0 6.097204874322415e-08
stable O 0 5.214042531065388e-08
complexes O 0 3.2587468723477286e-08
with O 0 3.733416700790748e-11
the O 0 1.9559390218581996e-10
transferrin O 0 2.2947909883441753e-07
receptor O 0 3.5659692976253154e-09
( O 0 1.2833210882856605e-10
TfR O 0 2.1695454051950946e-05
) O 0 3.590927555308099e-10
. O 0 1.0733276489816035e-09

The O 0 1.8402493751068505e-08
C282Y O 0 2.477569580605632e-07
mutation O 0 4.6945069698267616e-07
nearly O 0 6.546822639563743e-09
completely O 0 5.401512225944316e-06
prevents O 0 3.007004636401689e-07
the O 0 9.457316041405761e-10
association O 0 1.3761218727037505e-11
of O 0 1.4863042979533503e-13
the O 0 3.242677307224717e-11
mutant O 0 1.269627425415365e-08
HFE O 0 6.201341875566868e-07
protein O 0 1.0108768933037027e-08
with O 0 8.370982379490854e-11
the O 0 1.1352719875290518e-09
TfR O 0 0.022834639996290207
. O 0 9.78751923952359e-09

Studies O 0 7.756062814223696e-08
on O 0 5.607347919323047e-10
cell O 0 9.365842856823292e-07
- O 0 2.754697106865933e-06
associated O 0 5.719909434986903e-09
transferrin O 0 3.9614775459995144e-08
at O 0 4.440305900743624e-10
37 O 0 4.463646466335014e-11
degrees O 0 1.400051408140257e-09
C O 0 3.161736094625667e-05
suggest O 0 2.1031866026532953e-08
that O 0 6.004457486774584e-10
the O 0 6.550675279992646e-11
overexpressed O 0 7.259220001287758e-05
wild O 0 2.580154614406638e-06
- O 0 9.230399155057967e-05
type O 0 7.492635631933808e-06
HFE O 0 7.504865152441198e-06
protein O 0 1.5849485279773035e-08
decreases O 0 1.0414860085461441e-09
the O 0 1.5880592197162202e-12
affinity O 0 6.063282688428817e-12
of O 0 7.384386071368487e-13
the O 0 8.23257712001535e-11
TfR O 0 1.1736864507838618e-05
for O 0 2.82615111868445e-11
transferrin O 0 7.725824389126501e-07
. O 0 3.761216671449574e-09

The O 0 2.270524568359633e-08
overexpressed O 0 1.6022018826333806e-05
H63D O 0 1.823444472393021e-05
protein O 0 8.177920562957297e-07
does O 0 9.162560132836006e-08
not O 0 1.3702041723462344e-09
have O 0 9.185013860601998e-11
this O 0 5.329865888914487e-12
effect O 0 3.5982772317311174e-10
, O 0 1.9343198917609605e-11
providing O 0 2.118122083977214e-12
the O 0 6.397339689240278e-12
first O 0 4.6294516831135724e-11
direct O 0 1.1072835356951138e-11
evidence O 0 6.382635531210212e-10
for O 0 3.694313518293191e-12
a O 0 6.22029094898835e-10
functional O 0 2.3564939510833938e-07
consequence O 0 3.231967582451034e-09
of O 0 1.0861747699181246e-12
the O 0 1.3487166938830342e-09
H63D O 0 0.001349207479506731
mutation O 0 2.274799953738693e-06
. O 0 3.475764565052941e-09

Addition O 0 9.594002037260907e-09
of O 0 9.567185238479325e-11
soluble O 0 1.2169058436484192e-06
wild O 0 3.4749225505947834e-06
- O 0 0.000737841532099992
type O 0 0.0002311592543264851
HFE O 0 0.16235437989234924
/ O 0 0.0289956945925951
beta2m O 0 0.0002109065535478294
heterodimers O 0 2.0158806819381425e-06
to O 0 2.025169587582809e-09
cultured O 0 1.3270407350773894e-07
cells O 0 3.1483398288401077e-07
also O 0 6.923519535462219e-09
decreased O 0 1.0788514082094025e-08
the O 0 9.16165147218928e-12
apparent O 0 7.693287673582461e-11
affinity O 0 2.5084581981027476e-11
of O 0 1.1875334699970597e-12
the O 0 1.225072127075677e-10
TfR O 0 3.784213276958326e-06
for O 0 3.04735511998111e-13
its O 0 3.2713249969139324e-13
ligand O 0 3.849115123855107e-11
under O 0 1.0356379642750824e-10
steady O 0 2.820036870687659e-09
- O 0 6.11570030173425e-08
state O 0 3.577734997151083e-09
conditions O 0 1.6895507997105597e-06
, O 0 6.986574079687058e-12
both O 0 5.7346805255875655e-12
in O 0 9.001962369969974e-12
293 O 0 6.064677093853277e-10
cells O 0 4.049761415103603e-09
and O 0 3.3013983213869835e-10
in O 0 3.0753052882026566e-10
HeLa O 0 5.1158764108549803e-05
cells O 0 1.232985340493542e-07
. O 0 7.527600209833452e-10

Furthermore O 0 2.37903606148393e-07
, O 0 1.034374530473059e-10
at O 0 4.8781614164772336e-11
4 O 0 2.7124089432839504e-11
degrees O 0 1.2378390756850877e-08
C O 0 0.007007646840065718
, O 0 2.2427542489822372e-08
the O 0 6.898080329165168e-09
added O 0 5.137504558661021e-06
soluble O 0 7.16660792932089e-08
complex O 0 1.0734818367552634e-08
of O 0 5.065350222599463e-11
HFE O 0 0.0008915033540688455
/ O 0 4.491951040108688e-05
beta2m O 0 1.1975688494203496e-06
inhibited O 0 2.0131611933038585e-09
binding O 0 6.28612439879106e-11
of O 0 5.080768705062466e-13
transferrin O 0 3.29362777051756e-08
to O 0 2.580249625072639e-10
HeLa O 0 4.937676749250386e-06
cell O 0 6.625868991250172e-06
TfR O 0 0.00012219742347951978
in O 0 1.4424611505248208e-10
a O 0 3.6932745750561935e-10
concentration O 0 1.1813776836788747e-05
- O 0 1.2596394299180247e-05
dependent O 0 4.432068934079325e-08
manner O 0 1.6387421908348188e-07
. O 0 1.7902012094950237e-09

Scatchard O 0 0.002822034526616335
plots O 0 4.519898993748939e-06
of O 0 2.827768574853451e-11
these O 0 1.6759088908302466e-11
data O 0 4.4258724463119847e-10
indicate O 0 2.1396784344318576e-09
that O 0 3.366589507169948e-10
the O 0 5.138373615487524e-10
added O 0 1.9429758424394095e-07
heterodimer O 0 7.363037735075295e-09
substantially O 0 6.364051508001012e-09
reduced O 0 7.602801721517949e-11
the O 0 1.6368546058506683e-12
affinity O 0 2.3939345297763204e-11
of O 0 3.0795693686108683e-12
TfR O 0 2.3438902644556947e-05
for O 0 3.5353480559718875e-11
transferrin O 0 7.227570222312352e-07
. O 0 5.0690567299227496e-09

These O 0 1.1580971204239177e-07
results O 0 1.0930269134235004e-08
establish O 0 3.7042727218938865e-10
a O 0 2.0419154214690316e-11
molecular O 0 3.217908073338549e-08
link O 0 0.00012980413157492876
between O 0 5.166564065461898e-08
HFE O 0 0.39886167645454407
and O 0 3.4648845570472986e-08
a O 0 2.135070731323907e-10
key O 0 3.03104918941699e-09
protein O 0 7.382062960914482e-09
involved O 0 7.246281352735195e-10
in O 0 3.782504531812947e-09
iron O 0 0.0006098211160860956
transport O 0 5.8249341350347095e-08
, O 0 1.8615314845149555e-10
the O 0 1.1541174960161271e-10
TfR O 0 0.0008801427320577204
, O 0 1.2552182626635044e-09
and O 0 2.096953055641393e-09
raise O 0 1.068736835141415e-10
the O 0 4.655509051182394e-12
possibility O 0 2.250438203843519e-11
that O 0 3.2072305922170585e-10
alterations O 0 4.682242717990448e-07
in O 0 4.748156728906494e-11
this O 0 6.45785577790825e-11
regulatory O 0 2.762425843627625e-08
mechanism O 0 7.452860728562882e-08
may O 0 6.081128489654475e-09
play O 0 2.190929215828419e-09
a O 0 8.388670834358347e-12
role O 0 2.7073501773777764e-10
in O 0 6.81373013566855e-11
the O 0 1.591811960022227e-10
pathogenesis O 0 1.4475564967142418e-05
of O 0 2.288742706468838e-08
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 8.095612429315224e-06
. O 0 1.99373868525754e-08

Genomic O 0 1.7517286323709413e-05
organization O 0 7.820083247622733e-09
of O 0 1.3683849192647202e-11
the O 0 1.4040511808754985e-10
UBE3A O 0 3.637122745203669e-06
/ O 0 2.2367407837009523e-06
E6 O 0 8.829446755953541e-07
- O 0 9.71943445620127e-05
AP O 0 9.852482617134228e-05
gene O 0 6.065388191700549e-08
and O 0 1.9374853110765144e-10
related O 0 2.2266913313195857e-10
pseudogenes O 0 5.988518978483626e-07
. O 0 1.863569032423129e-08

The O 0 2.3040552576958362e-08
UBE3A O 0 4.516678870913893e-07
gene O 0 9.139342616037993e-09
encodes O 0 1.9347019541982036e-09
the O 0 1.984782477260083e-10
E6 O 0 6.551040883095993e-07
- O 0 0.00013571683666668832
AP O 0 6.557891902048141e-05
ubiquitin O 0 1.7165112664585536e-09
- O 0 3.6388566826417446e-08
protein O 0 6.192023005446856e-10
ligase O 0 2.5496685318593393e-10
and O 0 4.860000846207413e-09
has O 0 4.51753390251497e-09
recently O 0 1.636420954298501e-08
been O 0 1.307412234030636e-10
shown O 0 4.9431916893105665e-11
to O 0 1.5482988155457456e-11
be O 0 2.942126819949209e-10
mutated O 0 0.00045568105997517705
in O 1 0.84654301404953
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.00027670105919241905
who O 0 2.9795316436320718e-08
lack O 0 7.799403345387645e-10
15q11 O 0 3.6415997328731464e-07
- O 0 7.054718480503652e-06
q13 O 0 3.326235855638515e-07
deletions O 0 1.4622656863139127e-06
or O 0 6.471292834930864e-08
chromosome O 0 0.000655431067571044
15 O 0 4.243516471547082e-08
paternal O 0 4.9642007070360705e-05
uniparental B-Disease 1 0.5199941396713257
disomy I-Disease 0 0.08774524182081223
. O 0 2.78929604746736e-07

Previous O 0 4.4735656956618186e-08
UBE3A O 0 2.0651042120789498e-07
cDNA O 0 1.900864710080441e-08
analysis O 0 1.436197827331398e-08
has O 0 5.489020349358498e-10
shown O 0 3.168177178936027e-11
a O 0 2.571772655945992e-11
coding O 0 8.175068069249392e-05
region O 0 3.520388602851199e-08
of O 0 3.4921796357445523e-12
approximately O 0 5.456473606280099e-10
2 O 0 3.989875807519638e-08
. O 0 1.3840761425853998e-08

6 O 0 1.7228860826890013e-07
kb O 0 1.858741234173067e-05
and O 0 1.6804758473654147e-08
a O 0 1.5526446794922322e-09
3 O 0 2.1352038004351925e-07
- O 0 0.015735574066638947
untranslated O 1 0.9743536114692688
region O 0 3.058885704376735e-05
( O 0 8.052844502337564e-11
UTR O 0 2.229637061645917e-07
) O 0 1.7991942571210506e-12
of O 0 1.441848214173841e-13
< O 0 3.889102373477726e-09
50 O 0 2.3126649206783867e-10
bp O 0 2.497605677831416e-08
, O 0 1.2242282708407881e-11
whereas O 0 2.3532625501032634e-11
Northern O 0 5.57333690309747e-09
analysis O 0 3.873915910279635e-10
has O 0 1.3015329092258554e-10
indicated O 0 2.516945853126007e-11
mRNA O 0 1.0813300775625034e-11
sizes O 0 7.529808027095797e-11
of O 0 3.1322984570675283e-12
5 O 0 3.2255629278665765e-09
- O 0 9.894746654026676e-06
8 O 0 3.027924577736485e-08
kb O 0 5.4534331866307184e-05
. O 0 1.1246988229629551e-08

We O 0 1.1643052033605272e-07
have O 0 1.0124827191926311e-11
analyzed O 0 1.140194622745172e-11
additional O 0 2.6531386679642943e-13
cDNA O 0 2.9482345453857306e-09
clones O 0 8.152052828336309e-07
and O 0 6.574336075537701e-10
provide O 0 5.745157821701596e-12
evidence O 0 1.5679993761730238e-11
for O 0 7.534465130791534e-14
an O 0 3.528816507666205e-13
additional O 0 1.3331725480514311e-11
0 O 0 2.4441087020932173e-07
. O 0 4.136636366780522e-09

5 O 0 5.024077154303086e-09
kb O 0 1.3991208902552899e-07
of O 0 2.917453778561452e-11
5 O 0 4.569416400812543e-09
- O 0 4.275480023352429e-06
UTR O 0 5.525505184778012e-05
and O 0 1.333993715491033e-08
> O 0 6.959727794075832e-10
2 O 0 9.607983159076738e-11
kb O 0 3.1396507438330445e-07
of O 0 2.6097275382386265e-11
3 O 0 7.332111096047811e-08
- O 0 0.0001345624914392829
UTR O 0 0.0016129700234159827
. O 0 2.414339128620213e-08

We O 0 6.5902008827833924e-06
have O 0 3.5114924856749496e-10
established O 0 3.192732883627869e-11
the O 0 1.6236828504975764e-12
genomic O 0 1.5586808288503562e-08
organization O 0 1.697116752685801e-11
of O 0 2.0430663725482662e-13
UBE3A O 0 4.178763219897519e-07
and O 0 7.542744900890241e-11
the O 0 1.0112007802279277e-12
sequence O 0 3.529972980587104e-10
of O 0 2.9817882104404836e-12
intron O 0 0.0005458665546029806
- O 0 2.4979517547762953e-05
exon O 0 9.432367733097635e-06
borders O 0 0.00010040082997875288
. O 0 3.642356460886731e-08

We O 0 3.096595173701644e-05
have O 0 3.2578255648729737e-09
also O 0 3.2062519306208515e-10
mapped O 0 1.330735358351376e-06
two O 0 1.1547206940631938e-10
highly O 0 2.1790381998787467e-10
homologous O 0 1.3251880703890606e-09
processed O 0 1.6941212876986356e-08
pseudogenes O 0 9.977328829791077e-08
, O 0 1.7279360164934587e-09
UBE3AP1 O 0 1.708359195617959e-05
and O 0 4.66165550605524e-09
UBE3AP2 O 0 3.5834405025525484e-06
, O 0 7.255031991837413e-11
to O 0 1.310345061622531e-11
chromosomes O 0 2.2973136726278653e-09
2 O 0 6.717020273327989e-10
and O 0 1.3902170081792065e-08
21 O 0 2.856976433207592e-09
, O 0 2.914679886334426e-10
respectively O 0 3.5128611131085563e-09
, O 0 1.2875780441845563e-09
and O 0 6.5225429501936105e-09
determined O 0 1.2729056031446362e-08
their O 0 2.5221408295195147e-11
genomic O 0 9.394020707986783e-07
organization O 0 4.8164809918205265e-09
. O 0 3.3213329864167918e-09

These O 0 2.5714578910651653e-08
results O 0 5.044955742050661e-08
will O 0 3.0351088309288343e-10
form O 0 2.1931638796712782e-11
the O 0 3.0944838705360134e-12
basis O 0 1.176664321533849e-11
for O 0 1.05094708977016e-12
studies O 0 1.962859562387731e-11
of O 0 1.36938623960213e-13
mutation O 0 1.3765807160837085e-08
and O 0 4.000326736530724e-10
imprinting O 0 2.0683712591562653e-06
of O 0 1.8608037333223137e-10
UBE3A O 0 0.0002309209230588749
. O 0 1.5796549845958907e-08

Mutation O 0 3.8029136248951545e-06
spectrum O 0 1.2172129970622336e-07
and O 0 2.948813637715375e-09
genotype O 0 3.119563984910201e-07
- O 0 2.083291474264115e-05
phenotype O 0 1.2417322068358772e-05
analyses O 0 9.351384733236046e-07
in O 0 5.22010967785036e-09
Cowden B-Disease 1 0.9994718432426453
disease I-Disease 1 0.9998564720153809
and O 0 1.2557763966469793e-06
Bannayan B-Disease 1 0.9995367527008057
- I-Disease 1 0.9999877214431763
Zonana I-Disease 1 0.9999949932098389
syndrome I-Disease 1 0.9999982118606567
, O 0 2.8360140902350395e-09
two O 0 9.05321950739335e-09
hamartoma B-Disease 1 0.8563897013664246
syndromes I-Disease 1 0.9319432973861694
with O 0 1.0268703221072428e-08
germline O 0 0.0008479974931105971
PTEN O 0 0.0045227063819766045
mutation O 0 0.0004848488315474242
. O 0 5.048844542443476e-08

The O 0 1.9205938315280946e-06
tumour B-Disease 1 0.9999023675918579
suppressor O 0 1.0143950021301862e-05
gene O 0 2.3047114154906012e-06
PTEN O 0 5.257029897620669e-06
, O 0 5.184821461057254e-10
which O 0 3.368084283694728e-11
maps O 0 5.121988806422451e-07
to O 0 6.35330632547948e-09
10q23 O 0 4.211965915601468e-06
. O 0 3.897129285945766e-09

3 O 0 1.4310135298956084e-08
and O 0 1.0032579628171945e-10
encodes O 0 2.425196432565002e-10
a O 0 7.500165766227695e-11
403 O 0 3.526224590100213e-10
amino O 0 1.6792959245393035e-09
acid O 0 4.370748485360565e-10
dual O 0 2.8259506734684692e-08
specificity O 0 4.46168741063957e-07
phosphatase O 0 0.00023776014859322459
( O 0 6.046632639034044e-11
protein O 0 9.873657447201367e-09
tyrosine O 0 3.490722235710564e-07
phosphatase O 0 0.00010309346544090658
; O 0 9.077698592818706e-10
PTPase O 0 1.0130659120477503e-06
) O 0 4.092651911813405e-11
, O 0 3.8093177917586374e-11
was O 0 8.993891853492642e-09
shown O 0 8.285511166050696e-10
recently O 0 1.7242601302314142e-07
to O 0 4.735190572979775e-10
play O 0 1.0515848636316605e-08
a O 0 6.962074666772011e-11
broad O 0 6.922595385816521e-09
role O 0 5.464444008396185e-09
in O 0 4.599005176686433e-09
human O 0 2.061511139572758e-07
malignancy B-Disease 0 0.0008955980301834643
. O 0 8.602271783786364e-09

Somatic O 0 4.654515578295104e-06
PTEN O 0 1.0328248208679724e-05
deletions O 0 5.509355560207041e-06
and O 0 4.3471576560705216e-08
mutations O 0 3.1316301374317845e-07
were O 0 2.8682661801227027e-10
observed O 0 4.9531339030295385e-09
in O 0 1.152921202951518e-09
sporadic B-Disease 0 0.19491428136825562
breast I-Disease 1 0.9999619722366333
, I-Disease 0 6.506960926344618e-05
brain I-Disease 1 0.999098539352417
, I-Disease 0 0.0001969052682397887
prostate I-Disease 1 0.999967098236084
and I-Disease 1 0.7618527412414551
kidney I-Disease 1 0.866002082824707
cancer I-Disease 0 0.01599971577525139
cell O 0 0.17823636531829834
lines O 1 0.9925445318222046
and O 0 1.7972324712900445e-05
in O 0 8.023400610568387e-09
several O 0 4.29746815910903e-09
primary O 0 7.215463847387582e-05
tumours B-Disease 1 0.9999997615814209
such O 0 1.2977194430163763e-08
as O 0 9.821639832807705e-05
endometrial B-Disease 1 0.9998125433921814
carcinomas I-Disease 1 1.0
, O 1 0.999954104423523
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9999632835388184
thyroid B-Disease 1 0.9999951124191284
tumours I-Disease 1 0.9999997615814209
. O 0 2.1557289073825814e-06

In O 0 1.7895388504385323e-09
addition O 0 1.732442939106349e-10
, O 0 3.2289945023356026e-11
PTEN O 0 1.4617118893056613e-07
was O 0 4.064262704162047e-09
identified O 0 4.247804330503868e-10
as O 0 1.7143360299051724e-12
the O 0 1.2400011573099334e-12
susceptibility O 0 1.1526359422475707e-08
gene O 0 2.7400083979500778e-08
for O 0 6.782303052510485e-10
two O 0 5.976839020149782e-06
hamartoma B-Disease 1 0.9999431371688843
syndromes I-Disease 1 0.9999746084213257
Cowden B-Disease 1 0.9999685287475586
disease I-Disease 1 0.9999561309814453
( O 0 2.3279865535297262e-10
CD B-Disease 0 3.6005030779051594e-06
; O 0 2.2865828341878114e-08
MIM O 0 0.21757422387599945
158350 O 0 4.1036710172193125e-06
) O 0 2.0449487936335942e-10
and O 0 1.1011710654429407e-08
Bannayan B-Disease 0 0.0052163805812597275
- I-Disease 0 0.016678640618920326
Zonana I-Disease 0 0.4539715647697449
( I-Disease 0 1.584118808350965e-10
BZS I-Disease 0 4.070424779456516e-07
) I-Disease 0 3.160349412723029e-11
or I-Disease 0 1.5727898150519337e-10
Ruvalcaba I-Disease 0 6.480258889496326e-05
- I-Disease 0 9.676394984126091e-05
Riley I-Disease 0 9.536406287224963e-05
- I-Disease 1 0.9943332672119141
Smith I-Disease 1 0.9858402013778687
syndrome I-Disease 1 0.9995988011360168
( O 0 1.9201613910002635e-10
MIM O 0 0.0009223154629580677
153480 O 0 1.3429938690023846e-06
) O 0 8.716792843088683e-10
. O 0 1.2108163360835533e-09

Constitutive O 0 4.564705946563663e-08
DNA O 0 6.200884854479227e-06
from O 0 1.5669949712804332e-11
37 O 0 6.893525195117434e-10
CD B-Disease 0 1.3801830789361702e-07
families O 0 4.989430646418214e-09
and O 0 1.5312257017896513e-09
seven O 0 7.32901031530453e-11
BZS B-Disease 0 3.369323451352102e-07
families O 0 8.886033575628005e-11
was O 0 9.896410357868035e-10
screened O 0 3.4636357781892e-08
for O 0 1.5222231461442526e-11
germline O 0 3.161166887366562e-06
PTEN O 0 3.8734353438485414e-05
mutations O 0 1.729574978526216e-05
. O 0 8.51594528228361e-09

PTEN O 0 2.6526462534093298e-05
mutations O 0 0.00015580754552502185
were O 0 2.4808635146200686e-09
identified O 0 1.1699121671426838e-08
in O 0 2.05691002425068e-11
30 O 0 4.6358309552241295e-11
of O 0 6.88116664343541e-13
37 O 0 1.7492224557713598e-08
( O 0 2.2901978924405597e-11
81 O 0 8.151927133326353e-09
% O 0 1.1803620580952412e-11
) O 0 7.556275917475208e-12
CD B-Disease 0 8.027092945894765e-08
families O 0 8.943851215192922e-10
, O 0 9.076390680706758e-12
including O 0 7.824218703489372e-12
missense O 0 4.32216256740503e-06
and O 0 3.141878579526747e-08
nonsense O 0 9.167275493382476e-06
point O 0 7.672972657246646e-08
mutations O 0 8.683049657065567e-08
, O 0 5.588710483978021e-12
deletions O 0 1.532827731409725e-08
, O 0 6.385956347054744e-11
insertions O 0 1.4488409760815557e-07
, O 0 9.554474572626148e-11
a O 0 5.259139998492479e-11
deletion O 0 2.2429824184655445e-06
/ O 0 9.968610538635403e-05
insertion O 0 2.9327843549253885e-06
and O 0 1.7401718821474788e-07
splice O 0 0.10668358951807022
site O 0 0.00019559319480322301
mutations O 0 9.653409506427124e-05
. O 0 2.062900961163905e-08

These O 0 7.902942300574978e-09
mutations O 0 1.7429721310691093e-07
were O 0 1.9786178251379738e-10
scattered O 0 1.0589636723068452e-08
over O 0 5.814898429434834e-08
the O 0 9.291232783148473e-10
entire O 0 2.0693795121928815e-08
length O 0 3.5064630310444045e-08
of O 0 1.911878424673552e-12
PTEN O 0 8.025039619496965e-07
, O 0 1.9642462656399573e-10
with O 0 1.0989160102725659e-11
the O 0 1.1364189103635347e-11
exception O 0 1.0892421686836684e-10
of O 0 3.0787631016652994e-13
the O 0 2.218822625632555e-10
first O 0 3.250354652095666e-08
, O 0 1.3926261255292616e-09
fourth O 0 3.2437219488201663e-07
and O 0 1.8079967523121354e-09
last O 0 3.2227340795998316e-09
exons O 0 8.449735105386935e-06
. O 0 2.0255953359082923e-08

A O 0 9.555599689292649e-08
hot O 0 8.009961334209947e-07
spot O 0 6.999538726404353e-08
for O 0 4.3152859757755735e-12
PTEN O 0 5.883930498384871e-07
mutation O 0 2.588045617812895e-07
in O 0 5.7185940011139635e-11
CD B-Disease 0 3.042043772438774e-07
was O 0 1.1798578469779386e-07
identified O 0 1.0695985430686505e-08
in O 0 1.0672248675069884e-11
exon O 0 1.3865458470263547e-07
5 O 0 2.4723605385190695e-09
that O 0 1.2494418000219554e-10
contains O 0 1.3675298393689417e-10
the O 0 4.732526592832187e-10
PTPase O 0 4.297710347600514e-06
core O 0 1.4660447078540528e-08
motif O 0 1.2246573533047922e-06
, O 0 2.3518817449108553e-10
with O 0 1.0186618909502343e-11
13 O 0 9.080321564103322e-12
of O 0 2.7932598725341484e-13
30 O 0 4.389443322705411e-11
( O 0 1.7377695419804051e-12
43 O 0 7.962719372756055e-10
% O 0 2.6973377958289246e-12
) O 0 2.6417785060212085e-12
CD B-Disease 0 2.932985765369267e-08
mutations O 0 2.7695327275978343e-07
identified O 0 2.1451226572821724e-08
in O 0 3.2855978354673354e-11
this O 0 3.135162962575322e-11
exon O 0 7.757919775031041e-06
. O 0 7.109603217259064e-08

Seven O 0 4.969505251750661e-09
of O 0 3.0645516506389026e-12
30 O 0 1.0327757399286597e-10
( O 0 4.341364941151671e-12
23 O 0 4.264364694694933e-10
% O 0 1.8228556684929398e-12
) O 0 2.2626559913890842e-12
were O 0 3.665887732262618e-11
within O 0 2.9883314572876074e-11
the O 0 8.400776602135451e-12
core O 0 2.5072983689256034e-09
motif O 0 3.957109981911344e-07
, O 0 3.7030298272178186e-10
the O 0 2.6044813875025774e-11
majority O 0 4.183224877607472e-10
( O 0 5.967322556227339e-12
five O 0 5.64343623915553e-12
of O 0 5.829042218526148e-13
seven O 0 2.2991712700370925e-10
) O 0 6.010658550742454e-13
of O 0 9.350183252437513e-14
which O 0 8.361013548174867e-10
were O 0 3.147681837400995e-10
missense O 0 2.759429889920284e-06
mutations O 0 2.7924045298277633e-06
, O 0 1.045862979554002e-10
possibly O 0 9.41494451844882e-11
pointing O 0 3.3569556023849145e-08
to O 0 2.484337735531028e-10
the O 0 2.09345422941265e-11
functional O 0 7.151557568363387e-09
significance O 0 1.1811176481302255e-09
of O 0 2.509740852640885e-11
this O 0 4.291488941987609e-09
region O 0 7.321224302359042e-07
. O 0 2.075435290294081e-08

Germline O 0 0.0002818669017869979
PTEN O 0 8.55497273732908e-06
mutations O 0 1.6734136806917377e-05
were O 0 1.3671549448091014e-09
identified O 0 2.5259044633685335e-08
in O 0 4.912999868045276e-11
four O 0 1.3329953807428296e-10
of O 0 1.6973069000628116e-12
seven O 0 1.1582992343051046e-09
( O 0 9.776870285582717e-12
57 O 0 3.302924156400877e-09
% O 0 9.203897192999744e-12
) O 0 3.215878258133742e-11
BZS B-Disease 0 1.0121619880010257e-06
families O 0 1.804010413275492e-10
studied O 0 3.7002024555476964e-08
. O 0 9.999000516458523e-10

Interestingly O 0 4.599298335961066e-05
, O 0 6.16339335124394e-09
none O 0 1.7954526754238032e-10
of O 0 9.664817367640091e-14
these O 0 1.78435634323737e-11
mutations O 0 1.5467389857803937e-07
was O 0 2.8798632811799507e-08
observed O 0 2.766389339825537e-09
in O 0 6.393732071563463e-11
the O 0 1.0900402802604958e-10
PTPase O 0 8.726616215426475e-06
core O 0 1.3871979831492354e-07
motif O 0 3.121012559859082e-05
. O 0 3.8193125107000014e-08

It O 0 1.1191968951607123e-06
is O 0 5.002120939678889e-10
also O 0 1.7577525546208506e-10
worthy O 0 2.6510776213184428e-11
of O 0 7.424735197318622e-13
note O 0 4.548202170440163e-08
that O 0 5.758965526680981e-10
a O 0 7.825073228273638e-11
single O 0 2.108593122329694e-08
nonsense O 0 7.451861165463924e-06
point O 0 4.360552452453703e-08
mutation O 0 2.3692001249742134e-08
, O 0 3.0143380846947565e-11
R233X O 0 2.8514726135853152e-09
, O 0 8.271484885913338e-11
was O 0 2.8836322218950272e-09
observed O 0 5.273345649037253e-10
in O 0 7.74847807444301e-12
the O 0 3.3159033244883895e-12
germline O 0 3.6958061055969438e-09
DNA O 0 3.2499071949132485e-06
from O 0 1.485160193610835e-12
two O 0 5.151164217398474e-12
unrelated O 0 5.874903341585025e-10
CD B-Disease 0 4.93302604809287e-06
families O 0 1.3498033801795373e-08
and O 0 3.269852832943343e-09
one O 0 1.5090252381000369e-09
BZS B-Disease 0 1.0393480806669686e-05
family O 0 5.50212888583701e-08
. O 0 3.049186902970291e-09

Genotype O 0 0.00022099939815234393
- O 0 8.581117435824126e-05
phenotype O 0 7.058917617541738e-06
studies O 0 2.474837668131613e-09
were O 0 2.3445542729483293e-10
not O 0 1.045743824867884e-09
performed O 0 1.2319488007506152e-07
on O 0 3.350544286462309e-09
this O 0 7.624614134504881e-11
small O 0 4.794810104513658e-10
group O 0 4.147167054213696e-09
of O 0 1.0101507304238755e-11
BZS B-Disease 0 1.806085856514983e-05
families O 0 1.5586976154224885e-09
. O 0 9.088925168043716e-10

However O 0 3.875988952017906e-08
, O 0 7.068649832131513e-11
genotype O 0 2.365226769995843e-08
- O 0 1.4697482129122363e-06
phenotype O 0 4.59814799569358e-07
analysis O 0 1.3533214548999695e-09
inthe O 0 5.695297318197845e-07
group O 0 1.4064274189706794e-08
of O 0 2.0462108570040716e-12
CD B-Disease 0 7.483737135771662e-05
families O 0 2.1400182959041558e-08
revealed O 0 2.4794817932161095e-07
two O 0 3.067208292906187e-11
possible O 0 7.514427968757786e-11
associations O 0 8.776520634377893e-13
worthy O 0 6.657588109276746e-12
of O 0 1.4388840054342655e-13
follow O 0 3.204914555965388e-09
- O 0 9.096960980059521e-07
up O 0 1.9964977227004965e-08
in O 0 1.8119764022550555e-10
independent O 0 5.326700192043177e-10
analyses O 0 2.702549650734909e-08
. O 0 7.113692412907824e-10

The O 0 2.5019350147204023e-08
first O 0 8.328420619818644e-09
was O 0 2.372587104559898e-08
an O 0 2.8966926513690483e-12
association O 0 2.6431707517149405e-11
noted O 0 2.820456534990967e-09
in O 0 6.737945618118246e-11
the O 0 7.403375829051484e-11
group O 0 4.165175704340385e-10
of O 0 1.494630970638039e-13
CD B-Disease 0 5.652060735883424e-06
families O 0 3.257827430047655e-08
with O 0 1.709150524220604e-06
breast B-Disease 1 0.9996911287307739
disease I-Disease 1 0.9933686852455139
. O 0 5.207790820804803e-08

A O 0 4.152018728831308e-09
correlation O 0 4.890783245059538e-08
was O 0 1.0490726509715387e-08
observed O 0 3.5827044109204564e-10
between O 0 2.950762897913073e-11
the O 0 5.72256582398456e-11
presence O 0 1.612163380571019e-08
/ O 0 6.362834392348304e-05
absence O 0 4.664028052658864e-10
of O 0 1.9859874649755943e-13
a O 0 1.514084135845195e-10
PTEN O 0 1.1143572464789031e-06
mutation O 0 2.0071605888460908e-07
and O 0 8.31660684763591e-10
the O 0 1.3767788298313377e-10
type O 0 1.1382274351490196e-05
of O 0 7.808933943920238e-09
breast O 1 0.501673698425293
involvement O 0 6.5702702158887405e-06
( O 0 8.59721982493511e-09
unaffected O 0 0.00010451426351210102
versus O 0 3.0237458759074798e-06
benign O 0 0.00450588995590806
versus O 0 7.707140866841655e-06
malignant O 1 0.8371771574020386
) O 0 1.6539649649871535e-08
. O 0 1.0961460183978033e-08

Specifically O 0 2.3581641528380715e-07
and O 0 1.4488590327488282e-09
more O 0 8.850638321192261e-13
directly O 0 3.039366813784028e-10
, O 0 1.0934136235318803e-10
an O 0 5.211409775940368e-11
association O 0 7.613122909866377e-10
was O 0 8.687569561516284e-07
also O 0 1.67857621136136e-08
observed O 0 5.081747911361845e-09
between O 0 5.7208085491033955e-11
the O 0 6.827268785036811e-12
presence O 0 2.7857395210051372e-11
of O 0 1.1831896953081594e-13
a O 0 8.593870615136723e-10
PTEN O 0 0.00013870751718059182
mutation O 0 0.00032369839027523994
and O 0 0.006815093103796244
malignant B-Disease 1 0.9999896287918091
breast I-Disease 1 0.9999837875366211
disease I-Disease 1 0.99993896484375
. O 0 6.128247491687944e-07

Secondly O 0 0.00041521189268678427
, O 0 2.0038903869590285e-09
there O 0 1.105618999130975e-10
appeared O 0 4.4196344362035234e-08
to O 0 3.5373262652349524e-10
be O 0 5.504862676808386e-10
an O 0 4.861015756585374e-11
interdependent O 0 4.6142660721670836e-05
association O 0 5.375917488947834e-10
between O 0 8.162409637080259e-10
mutations O 0 4.095433268958004e-06
upstream O 0 3.37554382667804e-07
and O 0 4.113535734262541e-09
within O 0 1.8827167602708528e-10
the O 0 1.0587505178127898e-10
PTPase O 0 2.6643126602721168e-06
core O 0 9.483675178501016e-09
motif O 0 1.8960651004817919e-06
, O 0 1.587736608854584e-10
the O 0 2.945071270188393e-12
core O 0 2.004360455387655e-09
motif O 0 7.334543994375053e-08
containing O 0 1.626802859089338e-10
the O 0 6.973158162004722e-11
majority O 0 2.133064003206897e-10
of O 0 1.4856616371156095e-12
missense O 0 1.7251220924663357e-05
mutations O 0 8.97152567631565e-05
, O 0 4.393141406211498e-09
and O 0 1.904747248815397e-09
the O 0 3.188412381338601e-11
involvement O 0 1.2710514862845912e-09
of O 0 5.352257699542395e-12
all O 0 1.4851107843494304e-10
major O 0 4.1232425807002926e-10
organ O 0 5.357508712222625e-07
systems O 0 1.0009300694946432e-06
( O 0 9.556407054578386e-11
central O 0 1.83603589221093e-07
nervous O 0 3.1803159799892455e-05
system O 0 7.303135021174967e-07
, O 0 2.4504098306010746e-08
thyroid O 0 0.0008757433970458806
, O 0 1.0528194138714753e-07
breast O 1 0.9859310388565063
, O 0 0.023905426263809204
skin O 1 0.9999998807907104
and O 1 0.9981220364570618
gastrointestinal O 1 0.9999896287918091
tract O 1 0.9998492002487183
) O 0 1.877555320106694e-07
. O 0 7.96710182271454e-08

However O 0 2.0957151036782307e-07
, O 0 2.127070394819519e-11
these O 0 3.629621288855217e-13
observations O 0 1.3843123869428098e-10
would O 0 1.2632810353352397e-09
need O 0 1.949202049766896e-10
to O 0 8.104169418876594e-11
be O 0 6.45677261656985e-11
confirmed O 0 3.4895064615625415e-10
by O 0 3.9675928558205453e-13
studying O 0 3.5349889248442734e-12
a O 0 7.017397947450821e-12
larger O 0 5.881624614428871e-12
number O 0 4.2148579765255434e-11
of O 0 3.119182429706102e-12
CD B-Disease 0 6.5437311604910064e-06
families O 0 2.4243943741453222e-08
. O 0 2.8810869245887716e-09

Molecular O 0 0.060243088752031326
defects O 1 0.9993003606796265
leading O 0 5.553786763812241e-07
to O 0 4.300426403869295e-10
human O 0 7.667015466950033e-09
complement B-Disease 0 5.682218215952162e-06
component I-Disease 1 0.949556827545166
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 2.3048421837756905e-08
an O 0 1.2262931781137354e-09
African O 0 2.138939914075877e-09
- O 0 2.3998554752324708e-06
American O 0 9.773345510666331e-08
family O 0 1.5424303967392916e-07
. O 0 2.5390223257204525e-09

Complement B-Disease 0 0.0008361775544472039
component I-Disease 1 0.7203400731086731
C6 I-Disease 1 0.999998927116394
deficiency I-Disease 1 0.9999998807907104
( O 0 9.423145819198453e-09
C6D B-Disease 0 0.007052503060549498
) O 0 6.312770750582786e-08
was O 0 6.966273213038221e-05
diagnosed O 0 0.0006038958090357482
in O 0 1.8165476067810715e-10
a O 0 1.778493574633444e-09
16 O 0 5.272946079770691e-09
- O 0 1.099911628443806e-06
year O 0 4.718483936905216e-10
- O 0 2.2633482785749948e-06
old O 0 1.7430551451980136e-05
African O 0 2.1837689989645526e-10
- O 0 3.849625507257315e-09
American O 0 5.296075800131916e-10
male O 0 6.997517010276511e-10
with O 0 2.161372636422243e-09
meningococcal B-Disease 1 0.9999977350234985
meningitis I-Disease 1 0.9999995231628418
. O 0 4.7237929123866707e-08

The O 0 4.060933349592233e-07
patients O 0 6.728899961672141e-07
father O 0 3.0386601679310843e-07
and O 0 6.4962093482279215e-09
two O 0 3.3661933240836106e-09
brothers O 0 2.343358391954098e-05
also O 0 5.5500020579302145e-08
had O 0 5.259539648250211e-07
C6D B-Disease 0 1.725377114780713e-05
, O 0 1.2964018747396722e-10
but O 0 3.4805325288544964e-10
gave O 0 2.094402873353829e-09
no O 0 1.8617551944544175e-10
history O 0 3.5793851216325834e-10
of O 0 2.33071006938701e-10
meningitis B-Disease 1 1.0
or O 0 1.0089991775430462e-07
other O 0 1.3256968856012463e-08
neisserial B-Disease 1 0.5570774674415588
infection I-Disease 0 0.35045138001441956
. O 0 1.2776293800698113e-08

By O 0 1.2462335330365448e-10
using O 0 8.680122592918948e-11
exon O 0 6.778065220203189e-09
- O 0 1.523251427215655e-07
specific O 0 1.3568901557903246e-10
polymerase O 0 6.052052867744351e-07
chain O 0 2.682777449081186e-07
reaction O 0 2.698591072824996e-10
( O 0 7.234034877200146e-13
PCR O 0 1.4469513587300753e-08
) O 0 2.559229954693376e-12
/ O 0 8.18093059962166e-09
single O 0 1.6183487883125736e-09
- O 0 1.3152903477475775e-07
strand O 0 2.1566727355093462e-06
conformation O 0 3.22793680673783e-10
polymorphism O 0 6.885312320292769e-10
as O 0 1.7248940990810535e-12
a O 0 1.870716255514271e-12
screening O 0 7.838401594462141e-10
step O 0 1.54022031240153e-10
and O 0 1.119557680069605e-12
nucleotide O 0 3.087776215271454e-11
sequencing O 0 9.638305431547423e-11
of O 0 3.8914834896153216e-13
target O 0 4.256015984083206e-08
exons O 0 1.529611381556606e-06
, O 0 8.084709790523448e-09
we O 0 5.327536634069929e-09
determined O 0 3.1955005308503814e-10
that O 0 1.3428294934336726e-11
the O 0 1.0377888652601808e-11
proband O 0 9.812137022890965e-07
was O 0 4.5232240175607785e-09
a O 0 2.651086164831562e-12
compound O 0 2.863391745933086e-09
heterozygote O 0 2.5522679525380454e-09
for O 0 2.541135487796331e-12
two O 0 2.2729920723385533e-10
C6 O 0 3.679858491523191e-05
gene O 0 2.969245997519465e-06
mutations O 0 4.541821908787824e-05
. O 0 1.8577983595946534e-08

The O 0 9.712352699864368e-09
first O 0 7.072429863974605e-10
, O 0 7.122768954509473e-12
1195delC O 0 2.060119852487219e-09
located O 0 9.204345619018284e-10
in O 0 1.1511270235631255e-11
exon O 0 1.5932570818222302e-07
7 O 0 3.944273316847102e-07
, O 0 6.815137343352262e-10
is O 0 5.923801726925859e-11
a O 0 7.6234213386428e-11
novel O 0 5.128606517246226e-08
mutation O 0 1.0021443586083478e-07
, O 0 1.8084374275861848e-10
while O 0 2.6232432892570046e-10
the O 0 1.0786198323398111e-10
second O 0 9.398124056758661e-09
, O 0 1.6724219231711857e-11
1936delG O 0 1.0642378089897875e-09
in O 0 1.6800686276213783e-12
exon O 0 6.835399091187355e-08
12 O 0 1.73303291717275e-08
, O 0 6.695952681212702e-10
has O 0 3.605919340898822e-09
been O 0 4.675491660499631e-10
described O 0 3.0279636575869517e-09
before O 0 8.964208819683961e-10
to O 0 3.5446945378936334e-10
cause O 0 1.905324786832807e-09
C6D B-Disease 0 5.403367140388582e-06
in O 0 1.9276877316620755e-10
an O 0 3.8160662130248824e-11
unrelated O 0 2.3483876177010643e-08
African O 0 5.769193123228433e-09
- O 0 2.843924846729351e-07
American O 0 8.522931693732971e-09
individual O 0 3.1567481961758403e-10
. O 0 1.0882003076417845e-09

Both O 0 3.057137973883073e-07
mutations O 0 1.4219731383491307e-05
result O 0 1.4607497433871686e-08
in O 0 6.228874638303239e-10
premature O 0 9.138317835777343e-08
termination O 0 1.9604050294219633e-07
codons O 0 9.594355105946306e-06
and O 0 3.910765826731222e-07
C6 O 0 0.0009985326323658228
null O 0 3.97226722270716e-05
alleles O 0 8.303045433422085e-07
. O 0 6.450996181683877e-08

Allele O 0 3.089144797741028e-07
- O 0 1.6381765988171537e-07
specific O 0 1.8695410497482357e-10
PCR O 0 1.2297730336285895e-06
indicated O 0 2.5935149139399982e-08
that O 0 7.913281835358887e-11
the O 0 4.479493165288062e-11
probands O 0 5.6188448070315644e-05
two O 0 1.794599171489608e-07
brothers O 0 0.0057056257501244545
also O 0 1.762882106959296e-07
inherited O 0 4.375242042442551e-06
the O 0 3.1987613946515836e-11
1195delC O 0 6.910553906891437e-08
mutation O 0 1.0157938490351626e-08
from O 0 4.461874012623435e-12
their O 0 5.0062225198654886e-11
heterozygous O 0 1.1646561404177191e-07
mother O 0 3.2483654877069057e-07
and O 0 2.877137139645214e-10
the O 0 7.481359282079936e-12
1936delG O 0 1.677862293547605e-08
mutation O 0 4.397592956451035e-09
from O 0 2.2658042976575477e-12
their O 0 2.2562231596912063e-11
homozygous O 0 1.3778889140780848e-08
father O 0 2.1182112064366265e-08
. O 0 4.996092081710479e-11
. O 0 7.180296912601136e-10

PAX6 O 0 0.0018247213447466493
mutations O 0 0.0002895824145525694
reviewed O 0 6.960795872146264e-06
. O 0 1.3833746947966574e-07

Mutations O 0 0.0012052847305312753
in O 0 6.974119060032535e-10
PAX6 O 0 6.805557404732099e-06
are O 0 6.175708555655746e-11
responsible O 0 1.3159793255113073e-09
for O 0 1.0539350642213563e-10
human O 0 1.3365503264139988e-06
aniridia B-Disease 1 1.0
and O 0 9.07412832020782e-05
have O 0 2.1451762677315855e-07
also O 0 1.5282502374702744e-08
been O 0 2.2768940066697496e-09
found O 0 4.1588981147810955e-09
in O 0 1.0909310121931526e-09
patients O 0 7.739789253946583e-09
with O 0 2.0237176379112043e-09
Peters B-Disease 1 1.0
anomaly I-Disease 1 0.9999998807907104
, O 0 2.4065889192570467e-06
with O 0 0.0002370471484027803
congenital B-Disease 1 0.9999998807907104
cataracts I-Disease 1 0.9999994039535522
, O 0 8.761871868046001e-07
with O 0 2.429844471407705e-06
autosomal B-Disease 1 0.9999409914016724
dominant I-Disease 1 0.7409095764160156
keratitis I-Disease 1 0.9998154044151306
, O 0 2.386740561632905e-06
and O 0 2.420042903850117e-07
with O 0 5.277441346152045e-07
isolated B-Disease 1 0.9999016523361206
foveal I-Disease 1 0.9999992847442627
hypoplasia I-Disease 1 0.9999995231628418
. O 0 6.7951286837342195e-06

No O 0 9.261957956141487e-08
locus O 0 1.67262861339168e-08
other O 0 7.292184911467103e-11
than O 0 3.885679972226441e-11
chromosome O 0 0.00012986564252059907
11p13 O 0 3.1761433092469815e-06
has O 0 4.872635983588225e-08
been O 0 1.923178949425619e-09
implicated O 0 2.7023693505157098e-08
in O 0 2.0070777040359644e-08
aniridia B-Disease 1 1.0
, O 0 2.464570343363448e-07
and O 0 1.350586220638661e-08
PAX6 O 0 9.78911884885747e-06
is O 0 8.840971510437612e-09
clearly O 0 1.0909982250950634e-08
the O 0 1.4255002560303875e-11
major O 0 5.046807971531564e-10
, O 0 1.0833914876329231e-09
if O 0 1.1015114154133698e-08
not O 0 4.002662368218779e-10
only O 0 2.7035096383798418e-11
, O 0 4.855277638271538e-12
gene O 0 2.1502675195961274e-08
responsible O 0 1.457647158531472e-07
. O 0 9.494933728149135e-09

Twenty O 0 1.5212944504128245e-07
- O 0 2.9269167498569004e-06
eight O 0 1.254607751022263e-09
percent O 0 3.29600444159972e-11
of O 0 3.1819390330055375e-13
identified O 0 2.2085140827243777e-08
PAX6 O 0 3.0554581371688982e-06
mutations O 0 2.0312948834089184e-07
are O 0 8.942175472315128e-11
C O 0 0.0005425160634331405
- O 0 0.0016802857862785459
T O 0 0.0007087073172442615
changes O 0 1.9376933391157536e-09
at O 0 1.4343355392298918e-09
CpG O 0 3.217808625777252e-06
dinucleotides O 0 3.072500476264395e-07
, O 0 2.33417903061639e-11
20 O 0 1.3038523169126015e-12
% O 0 1.1427429911625014e-13
are O 0 9.202588777817988e-14
splicing O 0 2.2007270672474988e-07
errors O 0 6.394392403308302e-05
, O 0 8.379724136808875e-10
and O 0 1.336901145343461e-10
more O 0 1.148636578646861e-13
than O 0 4.73430019146126e-12
30 O 0 4.3911263514218035e-11
% O 0 1.5883287523763001e-12
are O 0 1.6017909654914009e-12
deletion O 0 3.0600020295423747e-08
or O 0 6.143777708800258e-10
insertion O 0 7.812080582425551e-08
events O 0 4.648491014336287e-08
. O 0 4.0566824566212745e-08

There O 0 2.8395554352300678e-08
is O 0 3.611924995206017e-11
a O 0 5.083633514146868e-11
noticeably O 0 1.2467833698792674e-07
elevated O 0 1.7286871525357128e-06
level O 0 6.025497878425767e-10
of O 0 7.463810385716085e-13
mutation O 0 8.119715744214773e-08
in O 0 9.002242007394301e-11
the O 0 1.3337023152537597e-10
paired O 0 1.0426816032804709e-07
domain O 0 2.806826948642538e-08
compared O 0 3.2827947027413984e-09
with O 0 2.748254401829797e-10
the O 0 3.4161506956564835e-10
rest O 0 2.643646135336297e-10
of O 0 8.66095864189391e-14
the O 0 1.6411037459529432e-11
gene O 0 1.0456190580043767e-07
. O 0 3.946219795381012e-09

Increased O 0 8.14821561334611e-08
mutation O 0 1.4930085967534978e-07
in O 0 4.971727890490385e-11
the O 0 2.2848311784229303e-11
homeodomain O 0 4.428630120401067e-07
is O 0 1.1958765921971093e-10
accounted O 0 1.4816878834977842e-09
for O 0 2.352165229084491e-13
by O 0 4.260360293717458e-12
the O 0 1.300131113879388e-10
hypermutable O 0 6.059773568267701e-06
CpG O 0 3.951663529733196e-06
dinucleotide O 0 3.765022782431515e-08
in O 0 2.7223757970151752e-11
codon O 0 1.1282181411331749e-08
240 O 0 8.046415755913472e-10
. O 0 9.298643521837846e-10

Very O 0 2.696916290290119e-08
nearly O 0 3.609619270150688e-10
all O 0 3.38770296537394e-11
mutations O 0 3.3361283158228616e-07
appear O 0 4.3258509663246514e-08
to O 0 2.9729635642183894e-08
cause O 0 4.380083282740088e-07
loss O 0 5.868894845661998e-07
of O 0 4.538201845566414e-12
function O 0 1.1498560326117513e-08
of O 0 7.7514448852678e-13
the O 0 3.464317721579846e-11
mutant O 0 4.817840792981087e-09
allele O 0 9.052005811582831e-10
, O 0 8.66298699442325e-11
and O 0 9.357471394966232e-12
more O 0 1.7264689704992245e-14
than O 0 7.059817682709968e-13
80 O 0 1.8244844871007082e-11
% O 0 5.763659948615496e-13
of O 0 4.0412112675344836e-13
exonic O 0 4.385509782878216e-06
substitutions O 0 1.4558126260055815e-08
result O 0 2.671607823856448e-09
in O 0 6.838732358183108e-10
nonsense O 0 4.2655439756345004e-05
codons O 0 2.199444224970648e-06
. O 0 8.454896338605522e-09

In O 0 7.773235388697231e-10
a O 0 1.447874025534146e-11
gene O 0 1.5781543849513469e-09
with O 0 1.700976338947502e-11
such O 0 1.8487603808958752e-11
extraordinarily O 0 7.27757454299649e-09
high O 0 1.4826209149276792e-09
sequence O 0 7.537779111999043e-08
conservation O 0 3.3127520171483127e-10
throughout O 0 3.313635130175463e-11
evolution O 0 1.3116491226483618e-09
, O 0 9.292876190780675e-11
there O 0 2.337142701591688e-10
are O 0 3.6065692099462865e-11
presumed O 0 1.4997556263551814e-07
undiscovered O 0 1.5302358633562108e-06
missense O 0 2.9161035854485817e-05
mutations O 0 4.9323578423354775e-05
, O 0 2.0128146371867217e-10
these O 0 1.22877125141585e-11
are O 0 2.898986606325593e-12
hypothesized O 0 3.257013503343842e-08
to O 0 1.1946301725629382e-09
exist O 0 2.400934562274415e-08
in O 0 1.6142909231575686e-10
as O 0 4.1681658125014565e-09
- O 0 4.8584071919322014e-05
yet O 0 3.767896217254929e-08
unidentified O 0 1.7181301714686015e-08
phenotypes O 0 1.071125677043483e-08
. O 0 7.067072621547155e-11
. O 0 5.101829514408962e-10

Genetic O 0 0.001116690575145185
heterogeneity O 0 2.168027094739955e-05
and O 0 1.45682381713641e-08
penetrance O 0 1.6692077906554914e-06
analysis O 0 3.9577603416773854e-09
of O 0 5.181237383578008e-12
the O 0 1.058423904076733e-09
BRCA1 O 0 0.00027055368991568685
and O 0 2.387563995398523e-07
BRCA2 O 0 7.00484961271286e-05
genes O 0 3.2241187000181526e-05
in O 0 2.5233068299712613e-05
breast B-Disease 1 0.9999411106109619
cancer I-Disease 1 0.7988488674163818
families O 0 4.042863466224844e-08
. O 0 3.154987737730153e-08

The O 0 0.0009140612673945725
Breast B-Disease 1 0.9999983310699463
Cancer I-Disease 1 0.9999946355819702
Linkage O 1 0.5918945670127869
Consortium O 0 2.0539142497000284e-05
. O 0 2.3269233651035393e-08

The O 0 6.505704308601423e-10
contribution O 0 1.8013311328668458e-11
of O 0 7.717871480794614e-12
BRCA1 O 0 0.0004891178105026484
and O 0 1.1345470738888253e-05
BRCA2 O 1 0.9850599765777588
to O 1 0.6767719984054565
inherited B-Disease 1 1.0
breast I-Disease 1 0.9999998807907104
cancer I-Disease 1 1.0
was O 0 4.5263856009114534e-05
assessed O 0 4.357008531741258e-09
by O 0 1.6697922558539524e-11
linkage O 0 0.00022127623378764838
and O 0 2.48680080972008e-08
mutation O 0 9.0540828168173e-09
analysis O 0 6.037991773233387e-10
in O 0 8.61832046700206e-12
237 O 0 1.212521971716285e-09
families O 0 2.2478183203666902e-10
, O 0 3.6016536975047586e-11
each O 0 1.7956495665383265e-12
with O 0 4.3564246654526073e-10
at O 0 1.7931853335539927e-08
least O 0 2.5932688288432537e-11
four O 0 6.546778397176212e-11
cases O 0 6.38427921639817e-10
of O 0 1.1061643157006529e-08
breast B-Disease 1 0.9999254941940308
cancer I-Disease 0 0.1256784200668335
, O 0 1.1988705861387672e-10
collected O 0 3.496435085903471e-10
by O 0 2.0849656223731472e-08
the O 0 0.03964715451002121
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.9999997615814209
Linkage O 0 0.05249929800629616
Consortium O 0 9.198261068377178e-07
. O 0 3.3260876275420515e-09

Families O 0 3.060871733850945e-08
were O 0 7.518097255854173e-11
included O 0 6.021700499347915e-12
without O 0 4.076002122627154e-12
regard O 0 1.457952855665745e-11
to O 0 1.5961891530746897e-11
the O 0 1.525088562381871e-11
occurrence O 0 1.5273899407475255e-06
of O 0 6.305033650733094e-08
ovarian B-Disease 1 0.9988456964492798
or I-Disease 0 3.1868310657046095e-07
other I-Disease 0 3.996804025518941e-07
cancers I-Disease 1 0.9833906888961792
. O 0 6.712006239695256e-08

Overall O 0 0.004122880287468433
, O 0 5.507469722942915e-06
disease O 0 0.12985558807849884
was O 0 3.29485274619401e-08
linked O 0 6.125705453996488e-07
to O 0 3.880795684807481e-09
BRCA1 O 0 2.4181265416700626e-06
in O 0 7.379845345933944e-11
an O 0 2.429842568471563e-12
estimated O 0 3.032840367733769e-10
52 O 0 6.65855104386992e-09
% O 0 7.892341294390981e-12
of O 0 1.4914594082329757e-12
families O 0 1.0393488292237407e-09
, O 0 9.200233630490828e-11
to O 0 9.142297335840155e-11
BRCA2 O 0 1.6722871976071474e-08
in O 0 4.467070463531897e-11
32 O 0 1.5138684750226616e-09
% O 0 5.4068646261618e-12
of O 0 1.2095819137969421e-12
families O 0 2.0217501006669636e-09
, O 0 2.0585044779863892e-10
and O 0 9.932056288519675e-10
to O 0 3.5936458669949545e-11
neither O 0 1.567647400779748e-10
gene O 0 1.2119646397579231e-09
in O 0 5.2091539415322075e-11
16 O 0 3.104275170251469e-11
% O 0 3.504347961987009e-13
( O 0 7.373168915691952e-13
95 O 0 5.4801945204019376e-09
% O 0 4.953434329380002e-10
confidence O 0 5.93530103287776e-07
interval O 0 1.6137096281454433e-06
[ O 0 8.75505357100792e-09
CI O 0 0.0001582728436915204
] O 0 3.1711366865749824e-09
6 O 0 1.460575549394605e-10
% O 0 7.538857559052925e-12
- O 0 3.4782185593940085e-06
28 O 0 2.3304499663368006e-08
% O 0 5.5066216343713226e-12
) O 0 1.617059676266297e-12
, O 0 2.4714375511381004e-12
suggesting O 0 2.5100821421375485e-10
other O 0 5.172057920832529e-11
predisposition O 0 8.870600822774577e-07
genes O 0 2.6292929078408633e-07
. O 0 1.9842355314381166e-08

The O 0 4.197277192474758e-09
majority O 0 3.570547746356567e-10
( O 0 9.592816992143316e-12
81 O 0 7.747716912476221e-10
% O 0 1.3410883731648782e-12
) O 0 1.275386805714429e-12
of O 0 1.9370631834658703e-11
the O 0 0.001394841237924993
breast B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.2391761394781042e-08
were O 0 1.8162402692922797e-09
due O 0 8.649601590526856e-10
to O 0 8.332166623326032e-10
BRCA1 O 0 6.461555699388555e-07
, O 0 1.1320323151098322e-10
with O 0 3.427165148894851e-11
most O 0 1.923955716964798e-10
others O 0 9.378852139363403e-10
( O 0 1.0857651583373595e-11
14 O 0 2.7015215064984943e-10
% O 0 5.220599993971398e-12
) O 0 1.5514292975304933e-11
due O 0 6.480315728474295e-10
to O 0 9.910184672889955e-09
BRCA2 O 0 4.6870074584148824e-05
. O 0 2.6175731804300995e-08

Conversely O 0 9.198329280479811e-06
, O 0 5.55959500658787e-10
the O 0 6.612434558239677e-12
majority O 0 3.89563138691873e-11
of O 0 1.1824502965315786e-12
families O 0 1.324224757626169e-10
with O 0 8.995175160286806e-10
male B-Disease 0 8.20822947389388e-07
and I-Disease 0 1.2937127848999808e-06
female I-Disease 0 1.9680826881085522e-05
breast I-Disease 0 0.24363267421722412
cancer I-Disease 0 0.0015128158265724778
were O 0 1.0586950871527279e-08
due O 0 7.701222770606364e-09
to O 0 3.597244813136058e-08
BRCA2 O 0 1.294304365728749e-05
( O 0 4.753215598896077e-10
76 O 0 3.085897049004416e-07
% O 0 9.959804508907766e-11
) O 0 8.229566472728322e-10
. O 0 1.193309806524212e-08

The O 0 1.4632893785559986e-09
largest O 0 1.4174944551470503e-10
proportion O 0 3.979847007506976e-10
( O 0 1.727594803324628e-11
67 O 0 1.455076272804945e-07
% O 0 9.83319849157116e-12
) O 0 9.068759632135936e-12
of O 0 2.2074148064987753e-12
families O 0 1.579895214653959e-09
due O 0 6.098036520185701e-10
to O 0 8.665961698239855e-11
other O 0 6.651267644292025e-12
genes O 0 2.9888092001328914e-08
was O 0 2.831707661243854e-06
found O 0 8.023801711942724e-08
in O 0 2.2230512985998985e-09
families O 0 9.563427133540969e-11
with O 0 8.102052362346512e-11
four O 0 1.4083183230706453e-10
or O 0 2.6194282853886364e-10
five O 0 3.8459815193681024e-11
cases O 0 6.606210023463177e-11
of O 0 5.109074274756153e-10
female O 0 0.0068981582298874855
breast B-Disease 1 0.9426565170288086
cancer I-Disease 0 0.014781850390136242
only O 0 5.2500276126465906e-08
. O 0 3.509105894750064e-08

These O 0 1.2541323535231186e-08
estimates O 0 3.818125549059914e-08
were O 0 1.9675094886650868e-09
not O 0 3.5221581207167674e-10
substantially O 0 2.930586617821973e-08
affected O 0 6.894419479763769e-10
either O 0 2.177641053591195e-11
by O 0 3.902329848148867e-12
changing O 0 2.622604133861728e-09
the O 0 1.6627535459612375e-10
assumed O 0 6.984532952003519e-09
penetrance O 0 1.9729468192508648e-07
model O 0 2.440646973411731e-08
for O 0 9.703450716547213e-12
BRCA1 O 0 5.070452857580676e-07
or O 0 4.4165626711389905e-10
by O 0 1.4003918684390992e-11
including O 0 1.9672082018917791e-10
or O 0 1.4024628569586639e-08
excluding O 0 2.1351671364300273e-07
BRCA1 O 0 0.00012338798842392862
mutation O 0 1.352877802673902e-06
data O 0 4.076668176367093e-07
. O 0 2.688119238314357e-08

Among O 0 7.423589298838351e-09
those O 0 5.482345133422939e-10
families O 0 1.6138054226289e-09
with O 0 2.3492394518598303e-07
disease O 0 0.4424336552619934
due O 0 1.1936734933826187e-09
to O 0 1.2235291668716286e-09
BRCA1 O 0 1.3781137568003032e-05
that O 0 2.4538143961194692e-08
were O 0 1.0834250829816483e-08
tested O 0 2.9493833153537707e-08
by O 0 2.0582423569323605e-13
one O 0 3.5016707415624904e-12
of O 0 5.0384968820847004e-14
the O 0 3.012221548581717e-12
standard O 0 4.1495384905942956e-10
screening O 0 2.7812760428069794e-10
methods O 0 1.4772717493727328e-09
, O 0 1.079957390875963e-11
mutations O 0 1.8518468980488478e-09
were O 0 3.819663682569363e-11
detected O 0 2.407175259122596e-08
in O 0 1.0672838481051716e-11
the O 0 3.661261571696883e-11
coding O 0 1.0355665835959371e-05
sequence O 0 1.6438401644336409e-06
or O 0 6.807134855790764e-10
splice O 0 3.0883102226653136e-06
sites O 0 9.203387918432782e-08
in O 0 4.7600083596943676e-11
an O 0 1.4207439478358674e-12
estimated O 0 6.652792899908277e-11
63 O 0 2.5154127669679838e-09
% O 0 1.3480665151874294e-12
( O 0 1.159539803584353e-12
95 O 0 2.5871105258090665e-09
% O 0 1.869202292947847e-10
CI O 0 0.049263883382081985
51 O 0 1.5595259128531325e-07
% O 0 1.7053367051822477e-10
- O 0 6.328005838440731e-06
77 O 0 5.757642185244549e-08
% O 0 1.6793517965130178e-11
) O 0 3.913632265484246e-11
. O 0 5.36436339793056e-10

The O 0 1.8451338235081494e-09
estimated O 0 1.1287206586052534e-10
sensitivity O 0 5.7387596896774085e-09
was O 0 3.890534117090283e-09
identical O 0 4.60521731859842e-10
for O 0 1.8614541060901074e-13
direct O 0 7.066651083742492e-12
sequencing O 0 3.89622414331825e-08
and O 0 2.7199328900273656e-10
other O 0 2.9847357224666027e-12
techniques O 0 2.644224252890126e-07
. O 0 7.841007843012449e-09

The O 0 3.979476748128263e-09
penetrance O 0 1.0177525382459862e-06
of O 0 4.8682249204068384e-11
BRCA2 O 0 7.268072295119055e-06
was O 0 3.780758817129026e-09
estimated O 0 7.755323293279215e-12
by O 0 3.570188307315536e-13
maximizing O 0 7.51871842563645e-10
the O 0 1.108434122265578e-09
LOD O 1 0.8357186913490295
score O 0 2.3978922399692237e-05
in O 0 1.1631965390890286e-09
BRCA2 O 0 3.592244183892035e-06
- O 0 1.1637290299404413e-05
mutation O 0 1.1456066886239569e-06
families O 0 4.930754693432959e-10
, O 0 1.4571050963030352e-11
over O 0 1.0118153537241881e-10
all O 0 4.1017484547767324e-11
possible O 0 1.3151454925086625e-10
penetrance O 0 2.350519707761123e-06
functions O 0 2.7995927354140804e-08
. O 0 8.093689274346616e-09

The O 0 1.1142740063974088e-09
estimated O 0 9.928261684999384e-11
cumulative O 0 5.477498454808938e-09
risk O 0 3.1653979704060475e-07
of O 0 1.6713010975166753e-09
breast B-Disease 1 0.9998688697814941
cancer I-Disease 1 0.8254673480987549
reached O 0 7.887508104431618e-07
28 O 0 3.146362503869682e-09
% O 0 2.1413777868961592e-12
( O 0 1.151592059558948e-12
95 O 0 1.4145621340944103e-09
% O 0 9.386148108747605e-11
CI O 0 0.004202880430966616
9 O 0 9.363395392369966e-09
% O 0 2.0431737898785052e-11
- O 0 8.44632381813426e-07
44 O 0 2.732825299389674e-09
% O 0 5.350703604148355e-13
) O 0 3.577773656764788e-14
by O 0 3.0087290623335983e-13
age O 0 2.899557503821537e-11
50 O 0 2.786290729389629e-12
years O 0 4.269617645547008e-12
and O 0 7.821641251348765e-11
84 O 0 8.819791424974355e-11
% O 0 4.811311397033557e-13
( O 0 4.946808479337761e-13
95 O 0 1.2526781834054646e-09
% O 0 5.2537862949009195e-11
CI O 0 0.0006025077309459448
43 O 0 5.017545934293821e-09
% O 0 4.192152527893178e-11
- O 0 2.2563196466762747e-07
95 O 0 6.1023213149269395e-09
% O 0 4.4475824932666e-12
) O 0 5.346336979898669e-13
by O 0 2.4127689863401303e-12
age O 0 3.4259056702623525e-10
70 O 0 1.316023817699019e-10
years O 0 1.144005168374207e-10
. O 0 5.709725470204319e-10

The O 0 2.147155100828968e-05
corresponding O 1 0.7783762812614441
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
risks O 0 0.0001215620432049036
were O 0 3.287571104237941e-08
0 O 0 6.603120255022077e-07
. O 0 1.671678262482601e-08

4 O 0 4.158366539996905e-09
% O 0 1.5071884712503092e-11
( O 0 4.383450633721475e-12
95 O 0 5.635299449302522e-10
% O 0 6.109675265708603e-11
CI O 0 0.004129047505557537
0 O 0 8.999418099620016e-09
% O 0 1.6841056327265846e-11
- O 0 2.9785525157421944e-07
1 O 0 9.109126786199795e-10
% O 0 1.0865892604086658e-12
) O 0 7.413934375276321e-14
by O 0 2.398438706755629e-13
age O 0 2.0844138914899446e-11
50 O 0 4.5626948400046e-12
years O 0 2.3075482497025845e-11
and O 0 1.0122882393437393e-10
27 O 0 2.0507490150478702e-10
% O 0 1.457039648438893e-13
( O 0 1.2121311170499444e-13
95 O 0 4.5602371878672443e-10
% O 0 2.4099326700888213e-11
CI O 0 0.00023201289877761155
0 O 0 2.115173813876936e-09
% O 0 1.2958821515862695e-11
- O 0 2.5080083787543117e-07
47 O 0 1.805964267020954e-08
% O 0 2.820651481480474e-12
) O 0 2.728866395004803e-13
by O 0 1.1344520158343419e-12
age O 0 9.855096599897806e-11
70 O 0 9.934626732377438e-11
years O 0 8.689713532072929e-11
. O 0 4.531727770817895e-10

The O 0 2.8830507758925705e-08
lifetime O 0 9.440761061796366e-08
risk O 0 2.4541989773751993e-07
of O 0 3.441120277614118e-09
breast B-Disease 1 0.9994359612464905
cancer I-Disease 0 0.01444474421441555
appears O 0 2.7648082934206286e-08
similar O 0 1.614544276051788e-09
to O 0 7.73666020137398e-09
the O 0 9.780073639831244e-09
risk O 0 1.1512719311213004e-07
in O 0 2.571455270938827e-10
BRCA1 O 0 2.6072993932757527e-06
carriers O 0 7.702534077225209e-08
, O 0 2.146373967448767e-09
but O 0 1.0174440845389654e-08
there O 0 4.253138952137192e-10
was O 0 7.3098775921209835e-09
some O 0 6.022685605441835e-13
suggestion O 0 8.504594806169052e-10
of O 0 1.7731866322479028e-12
a O 0 7.664252343886346e-09
lower O 0 2.533171482355101e-06
risk O 0 6.779645644883203e-08
in O 0 2.9808927548558017e-10
BRCA2 O 0 1.6450212569907308e-07
carriers O 0 2.3204060894954637e-10
< O 0 2.286559830366741e-09
50 O 0 5.339272912685544e-10
years O 0 1.70641608482347e-11
of O 0 1.8354994173880312e-12
age O 0 7.941731716698541e-09
. O 0 8.080003888188969e-10

Eye B-Disease 1 0.8532591462135315
movement I-Disease 0 2.9085937057971023e-05
abnormalities I-Disease 0 0.015033907257020473
correlate O 0 2.8622912395803723e-07
with O 0 2.3206019328370076e-09
genotype O 0 3.162393477396108e-05
in O 0 2.5826409455476096e-07
autosomal O 1 0.9997753500938416
dominant O 1 0.9922704696655273
cerebellar B-Disease 1 0.9995096921920776
ataxia I-Disease 1 0.9999951124191284
type I-Disease 1 0.999954342842102
I I-Disease 1 0.9992263317108154
. O 0 1.7717135847306054e-07

We O 0 1.5118484952836297e-06
compared O 0 9.817958890323553e-09
horizontal O 0 8.190658991225064e-05
eye O 0 0.177339106798172
movements O 0 5.116842658026144e-05
( O 0 3.490799649341625e-09
visually O 0 1.0112435120390728e-06
guided O 0 8.689310107001802e-07
saccades O 0 0.00013649383618030697
, O 0 2.6356319349218893e-09
antisaccades O 0 2.968883336507133e-06
, O 0 7.442597649287563e-10
and O 0 2.34313368707717e-09
smooth O 0 2.5008287707350974e-07
pursuit O 0 1.0011909523655049e-07
) O 0 5.1532302730583623e-11
in O 0 9.758542585114327e-11
control O 0 3.0322532893478638e-06
subjects O 0 2.1592805765635603e-08
( O 0 3.563986952781484e-11
n O 0 1.8253515008836985e-05
= O 0 0.0004550811427179724
14 O 0 7.663330414686698e-09
) O 0 9.521909649645721e-11
and O 0 1.4600757047844581e-08
patients O 0 4.105008333255e-09
with O 0 1.5342527595607613e-11
three O 0 1.856655801324436e-10
forms O 0 4.507781703466662e-09
of O 0 1.767031188038004e-09
autosomal O 1 0.9973204731941223
dominant O 0 0.057744551450014114
cerebellar B-Disease 0 0.01825975626707077
ataxias I-Disease 0 0.05138895660638809
type I-Disease 1 0.7190848588943481
I I-Disease 0 0.3844795227050781
spinocerebellar B-Disease 1 0.9989963173866272
ataxias I-Disease 0 0.000994983478449285
1 I-Disease 0 2.4162002176808528e-08
and I-Disease 0 1.3737846416006505e-08
2 I-Disease 0 1.0261532734645584e-09
( O 0 3.215436597536758e-11
SCA1 B-Disease 0 2.4297817162732827e-06
, O 0 1.2057387033248546e-10
n O 0 6.854826324342866e-07
= O 0 1.4528218343912158e-06
11 O 0 1.808299482375375e-10
; O 0 6.596801230274174e-12
SCA2 B-Disease 0 2.2640210772806313e-07
, O 0 1.7072756403058165e-11
n O 0 2.2443765601565246e-07
= O 0 3.896889211318921e-06
10 O 0 7.633956661257102e-11
) O 0 1.473530152062974e-11
and O 0 1.780398406481254e-08
SCA3 B-Disease 1 0.9999988079071045
/ O 0 0.013079189695417881
Machado B-Disease 0 4.465001984499395e-05
- I-Disease 0 0.0001862916542449966
Joseph I-Disease 0 0.014047040604054928
disease I-Disease 0 0.49143821001052856
( O 0 2.0483682805494396e-10
MJD B-Disease 1 0.9999967813491821
) O 0 4.650419493934521e-10
( O 0 2.473282689763323e-11
n O 0 1.3424595636024605e-05
= O 0 8.880629320628941e-05
16 O 0 1.640927060897468e-09
) O 0 2.122665931914014e-10
. O 0 8.846989252297988e-10

In O 0 6.936658802914053e-09
SCA1 B-Disease 0 1.3878479876439087e-06
, O 0 2.0734063771454814e-11
saccade O 0 9.332870476441713e-09
amplitude O 0 7.810136426478209e-10
was O 0 2.800333742669636e-09
significantly O 0 4.943448428385011e-10
increased O 0 2.0000862077651504e-10
, O 0 6.851248735006976e-11
resulting O 0 2.478837968222791e-10
in O 0 1.599485321968075e-09
hypermetria B-Disease 0 0.0002517267130315304
. O 0 2.135459808982887e-08

The O 0 4.369941741799721e-09
smooth O 0 5.1096549213980325e-08
pursuit O 0 3.08676781912709e-08
gain O 0 1.849038433476835e-08
was O 0 1.3602115700450668e-07
decreased O 0 1.1790743883466348e-06
. O 0 1.7522411965842366e-08

In O 0 7.102118448898409e-09
SCA2 B-Disease 0 1.9327869722474134e-06
, O 0 4.478878032343481e-11
saccade O 0 2.0053098737093933e-08
velocity O 0 1.3376651786245475e-08
was O 0 6.746413649949545e-09
markedly O 0 1.6686684034539212e-07
decreased O 0 3.325453462821315e-06
. O 0 1.3745840021783806e-08

The O 0 8.179369181959828e-09
percentage O 0 1.8755279551641024e-09
of O 0 8.667544980356379e-12
errors O 0 8.527921636414248e-06
in O 0 4.465982306189886e-10
antisaccades O 0 0.00021397853561211377
was O 0 2.531031952912599e-07
greatly O 0 1.0436376207678677e-09
increased O 0 1.5097824102028312e-09
and O 0 2.6597106739245646e-09
was O 0 1.575003771847605e-08
significantly O 0 1.5556177457298759e-09
correlated O 0 4.679294285381275e-09
with O 0 7.460452700058795e-09
age O 0 1.5063033060869202e-06
at O 0 7.979548172443174e-06
disease O 0 0.01072909776121378
onset O 0 4.1158950807584915e-06
. O 0 2.166946266868308e-08

In O 0 1.8909229737573696e-09
addition O 0 2.6631597968562737e-11
, O 0 8.811766420702138e-12
a O 0 3.009132222911437e-12
correlation O 0 5.800296243307912e-09
between O 0 4.180379153950753e-09
smooth O 0 2.0354148091428215e-06
pursuit O 0 1.3335582025320036e-06
gain O 0 3.0940773854126746e-07
and O 0 2.7531246171719204e-09
the O 0 3.4441947991542543e-12
number O 0 1.6791021698048247e-11
of O 0 1.422119193239535e-11
trinucleotide O 0 0.00021723929967265576
repeats O 0 2.2746678951079957e-05
was O 0 7.520517897319223e-08
found O 0 2.6068842640114553e-09
. O 0 7.996858175651766e-10

In O 0 3.0818443974567344e-07
SCA3 B-Disease 1 0.9999358654022217
, O 0 6.056856705072278e-08
gaze B-Disease 0 3.2132586056832224e-05
- I-Disease 0 7.074861059663817e-05
evoked I-Disease 0 1.838553544075694e-06
nystagmus I-Disease 0 0.00016404212510678917
was O 0 1.923351078403357e-07
often O 0 2.204160604035721e-10
present O 0 8.443566484016285e-13
as O 0 1.3459988332242823e-11
was O 0 3.092193168185986e-09
saccade O 0 6.257900508899183e-07
hypometria O 0 1.852621790021658e-05
and O 0 1.3421760591825205e-08
smooth O 0 4.7220453325280687e-07
pursuit O 0 2.3597974063704896e-07
gain O 0 2.1927071713889745e-08
was O 0 9.675211032345032e-08
markedly O 0 4.608020560681325e-07
decreased O 0 1.7399208900314989e-06
. O 0 8.702560450046803e-09

Three O 0 8.197798884168606e-09
major O 0 3.2548427841838645e-10
criteria O 0 2.0260183808407106e-10
, O 0 4.187251673865022e-12
saccade O 0 6.527160145708422e-09
amplitude O 0 2.857726832949936e-10
, O 0 4.898064592806506e-12
saccade O 0 2.7183728601443136e-09
velocity O 0 5.996105834071841e-09
, O 0 1.6375995004480615e-10
and O 0 1.0611220235823282e-10
presence O 0 1.1530415511273873e-10
of O 0 8.546523731778333e-12
gaze B-Disease 0 4.167690349277109e-05
- I-Disease 0 5.239141955826199e-06
evoked I-Disease 0 5.952886183990813e-08
nystagmus I-Disease 0 2.680721422620991e-07
, O 0 3.0006554966460763e-12
permitted O 0 5.093540172973476e-12
the O 0 1.1663806856118675e-12
correct O 0 2.3497708223629843e-09
assignment O 0 1.2999896992216264e-10
of O 0 7.500425925959994e-14
90 O 0 7.407994356833925e-11
% O 0 2.45586992582425e-12
of O 0 2.1221404895941515e-13
the O 0 1.769765722858807e-10
SCA1 B-Disease 0 2.05305832423619e-06
, O 0 1.789264049423256e-11
90 O 0 9.59166426839353e-12
% O 0 1.3151511943278876e-13
of O 0 5.22243686284455e-14
the O 0 7.093893528153927e-11
SCA2 B-Disease 0 8.838614121486899e-06
, O 0 2.2291900270143827e-10
and O 0 2.4373553175749407e-10
93 O 0 7.709066718319946e-10
% O 0 1.341584720919442e-12
of O 0 4.324404603937154e-13
the O 0 6.140547181843203e-09
patients O 0 5.564427851822984e-08
with O 0 3.984740537532616e-09
SCA3 B-Disease 1 1.0
to O 0 1.7887076353417797e-07
their O 0 2.742557292378933e-10
genetically O 0 4.8946372288583007e-08
confirmed O 0 1.407655986440659e-06
patient O 0 1.5866021385591011e-06
group O 0 4.663089470113846e-08
and O 0 5.1838874526310974e-08
, O 0 1.3825741662643054e-09
therefore O 0 5.316025841750616e-09
, O 0 5.51034606832701e-10
may O 0 7.325984707762245e-09
help O 0 2.49961440434987e-10
orient O 0 2.9459872621373506e-06
diagnoses O 0 1.953776882146485e-05
of O 0 1.0384144932817918e-11
SCA1 B-Disease 0 0.00023490165767725557
, O 0 1.3961846123677901e-09
SCA2 B-Disease 0 1.0468485015735496e-05
, O 0 2.0650257059884325e-09
and O 0 6.85759999896618e-08
SCA3 B-Disease 1 0.9999994039535522
at O 0 1.401722613536549e-07
early O 0 2.6876769698702674e-09
clinical O 0 4.408218501339434e-08
stages O 0 1.1313124659295681e-08
of O 0 1.0627965521536886e-11
the O 0 4.6282931975838437e-07
diseases O 1 0.7159920930862427
. O 0 1.1613365824558741e-09
. O 0 9.5675414257812e-09

Genetic O 0 1.8951228412333876e-05
basis O 0 2.342923632880911e-09
and O 0 5.461013308227791e-10
molecular O 0 1.4259628642321331e-06
mechanism O 0 4.2031413613585755e-05
for O 0 6.863696739856096e-07
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999896287918091
fibrillation I-Disease 1 0.9999998807907104
. O 0 0.00029492450994439423

Ventricular B-Disease 1 0.7210344672203064
fibrillation I-Disease 0 0.18506364524364471
causes O 0 2.0136063483278122e-07
more O 0 1.8360456384425294e-12
than O 0 2.240765515845733e-12
300 O 0 2.414390735949734e-11
, O 0 1.7591234025005065e-11
000 O 0 3.481002291971791e-11
sudden O 0 6.861491930187924e-10
deaths O 0 2.372535945482923e-09
each O 0 3.870691961394002e-12
year O 0 1.1647339343001661e-11
in O 0 3.4667303749902345e-11
the O 0 1.0209718626086328e-09
USA O 0 1.957297899934929e-05
alone O 0 9.171844794764183e-08
. O 0 8.623985969791192e-10

In O 0 7.41689099026388e-10
approximately O 0 1.4047102370184916e-10
5 O 0 4.572744405351159e-10
- O 0 8.975625291895994e-07
12 O 0 8.674135298925023e-10
% O 0 4.886677542649542e-13
of O 0 2.8790416096080226e-14
these O 0 8.623944440511178e-12
cases O 0 1.9497337078178134e-10
, O 0 8.258845829445249e-10
there O 0 8.782412574959153e-10
are O 0 9.253980914891713e-11
no O 0 2.362791917676077e-08
demonstrable O 0 0.0007337745628319681
cardiac O 0 0.044499535113573074
or O 0 4.3792309156742704e-07
non O 0 2.413640686427243e-06
- O 1 0.9996747970581055
cardiac O 1 0.7576394081115723
causes O 0 2.7378254685572756e-07
to O 0 8.372088577957015e-10
account O 0 8.723129996113244e-10
for O 0 1.5350226298394e-11
the O 0 3.9502845439187695e-10
episode O 0 2.4732710244279588e-06
, O 0 1.3932405451555496e-08
which O 0 1.2336806021195912e-09
is O 0 3.772571838256411e-11
therefore O 0 1.4925537195065175e-10
classified O 0 2.5049484975170344e-07
as O 0 8.552784856874496e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999767541885376
fibrillation I-Disease 1 0.9999998807907104
( O 0 0.00011168076889589429
IVF B-Disease 1 0.9999992847442627
) O 0 1.3060208914339455e-07
. O 0 2.573096580249512e-08

A O 0 7.3606081230082054e-09
distinct O 0 1.189595977280078e-09
group O 0 1.1253511900122248e-08
of O 0 1.9007033447149269e-10
IVF B-Disease 1 0.9999998807907104
patients O 0 5.940201663179323e-05
has O 0 1.3615191640781177e-08
been O 0 1.3793396425043625e-09
found O 0 3.3980862568228076e-09
to O 0 1.1497276741767593e-10
present O 0 1.406900203976269e-11
with O 0 1.4740614978636657e-11
a O 0 1.0462006816425173e-09
characteristic O 0 2.0551817669911543e-06
electrocardiographic O 0 9.353864152217284e-05
pattern O 0 0.00013414613204076886
. O 0 4.418783206006083e-08

Because O 0 8.788201455445233e-08
of O 0 2.3471378920308927e-12
the O 0 3.073773180428674e-11
small O 0 3.881568677588376e-11
size O 0 6.350613368510949e-10
of O 0 2.466116503715976e-12
most O 0 5.258498150806368e-11
pedigrees O 0 1.4219185118236055e-07
and O 0 2.291231204765154e-09
the O 0 3.081421923178951e-11
high O 0 2.388719222423674e-09
incidence O 0 1.0278940862917807e-05
of O 0 1.1083003959022619e-10
sudden B-Disease 0 1.2736004464386497e-05
death I-Disease 0 2.930508571807877e-06
, O 0 8.016313723935298e-10
however O 0 9.380730636721069e-10
, O 0 4.7737074709841565e-12
molecular O 0 1.4183505925302597e-08
genetic O 0 1.1157375183756812e-06
studies O 0 7.995470951982497e-10
of O 0 4.371254747059794e-11
IVF B-Disease 1 1.0
have O 0 3.7273357520462014e-06
not O 0 7.377671362718274e-09
yet O 0 1.0877748701787482e-09
been O 0 1.4066199316431494e-09
done O 0 4.9588273043355e-08
. O 0 7.654401557033452e-10

Because O 0 0.00013982714153826237
IVF B-Disease 1 0.9999879598617554
causes O 0 2.767305340967141e-05
cardiac O 0 0.029225114732980728
rhythm O 0 0.04307589307427406
disturbance O 0 3.88707521778997e-05
, O 0 2.8077142832927393e-09
we O 0 1.0061252941895305e-09
investigated O 0 5.436714411999333e-10
whether O 0 6.00766172920153e-11
malfunction O 0 2.0290754036977887e-06
of O 0 1.494095103714288e-13
ion O 0 1.5680683418395347e-07
channels O 0 0.00024811082403175533
could O 0 0.002137938514351845
cause O 0 3.1902243335935054e-07
the O 0 9.851103932589922e-09
disorder O 0 8.715139301784802e-06
by O 0 1.1513195995530023e-12
studying O 0 6.944700370326018e-11
mutations O 0 1.564778955298607e-07
in O 0 4.29774271726302e-11
the O 0 4.907785844388002e-10
cardiac O 0 7.23917310097022e-07
sodium O 0 3.387182756497964e-09
channel O 0 5.227881956670899e-06
gene O 0 1.2750527275784407e-05
SCN5A O 0 0.00013293644587974995
. O 0 7.1331660578266565e-09

We O 0 3.027947423106525e-05
have O 0 1.0830754071378124e-09
now O 0 1.7055480638905607e-10
identified O 0 9.484376617407975e-10
a O 0 7.424247328025046e-11
missense O 0 1.4392190678336192e-05
mutation O 0 3.956950422434602e-06
, O 0 5.4300793028705385e-11
a O 0 8.433868881052575e-11
splice O 0 0.03623397648334503
- O 0 0.005377567373216152
donor O 0 3.2766329649547288e-09
mutation O 0 4.337740122650757e-08
, O 0 1.8358513320659853e-10
and O 0 3.3300404100877756e-10
a O 0 6.192318324771406e-10
frameshift O 0 2.9428616471705027e-05
mutation O 0 1.3471520787788904e-07
in O 0 3.052361141619997e-11
the O 0 4.4594512110807116e-11
coding O 0 6.16693650954403e-05
region O 0 1.552657380443634e-08
of O 0 9.367400952142724e-12
SCN5A O 0 3.4125849197153e-05
in O 0 4.894483152106943e-10
three O 0 1.7616443415136018e-08
IVF B-Disease 1 0.9999945163726807
families O 0 1.8825463854454938e-08
. O 0 2.7757551812612746e-09

We O 0 1.6761136123477627e-07
show O 0 3.0681751583827577e-10
that O 0 1.2099833938614135e-12
sodium O 0 1.032217887553255e-11
channels O 0 4.837248379629955e-10
with O 0 1.2550492763108156e-11
the O 0 4.548698570583376e-11
missense O 0 7.458757409040118e-06
mutation O 0 1.854426500358386e-06
recover O 0 8.039212673338625e-08
from O 0 3.763930573469354e-12
inactivation O 0 5.945940415585937e-07
more O 0 1.1780155843854612e-12
rapidly O 0 1.2478847954966454e-09
than O 0 2.824981741589294e-11
normal O 0 7.640828414423595e-08
and O 0 3.578226381861782e-09
that O 0 1.7417407516262529e-09
the O 0 9.13074837960437e-10
frameshift O 0 0.003178613493219018
mutation O 0 4.7686535253888e-07
causes O 0 4.2284847845408535e-10
the O 0 1.1261352961255966e-11
sodium O 0 6.511517991469873e-09
channel O 0 6.561315331055084e-06
to O 0 5.421588511467235e-09
be O 0 4.865972069723057e-10
non O 0 1.7097140370125885e-10
- O 0 1.9369792880752357e-06
functional O 0 4.381304734124569e-06
. O 0 1.4794069969070733e-08

Our O 0 3.294489090421848e-07
results O 0 6.4978946667793025e-09
indicate O 0 1.102082425319395e-09
that O 0 1.2859796560960035e-10
mutations O 0 1.1620333850714815e-07
in O 0 5.085592710840636e-11
cardiac O 0 7.516114806094265e-07
ion O 0 9.53586294372144e-08
- O 0 0.004070311319082975
channel O 0 8.133328083204105e-05
genes O 0 1.9057735300975764e-07
contribute O 0 6.829551507658849e-11
to O 0 3.6658384661159005e-11
the O 0 1.376822787724219e-11
risk O 0 1.7423479325984204e-10
of O 0 3.4553984023036333e-13
developing O 0 7.394961443196735e-08
IVF B-Disease 1 0.9999939203262329
. O 0 1.259117143881383e-09
. O 0 1.0168790254283522e-09

Molecular O 0 2.4949119961092947e-06
heterogeneity O 0 6.310510798357427e-06
in O 0 9.081027485535742e-09
mucopolysaccharidosis B-Disease 0 0.00014064068091101944
IVA I-Disease 1 0.976720929145813
in O 0 8.68626045757992e-07
Australia O 0 0.00022810438531450927
and O 0 1.1487779261187825e-07
Northern O 0 7.913826266303658e-05
Ireland O 0 2.70962409558706e-05
: O 0 8.190351868941903e-11
nine O 0 6.232840632502956e-11
novel O 0 2.2838924085277768e-09
mutations O 0 1.0563732999457898e-08
including O 0 1.090547183807411e-11
T312S O 0 8.368950688009136e-08
, O 0 3.570437001609861e-11
a O 0 9.244538294594928e-12
common O 0 5.55322315909379e-11
allele O 0 2.6129265418006753e-10
that O 0 1.6220005893963219e-10
confers O 0 4.9028670012774e-09
a O 0 1.720619202671969e-08
mild O 0 5.006162609788589e-06
phenotype O 0 8.342019282281399e-05
. O 0 1.5521569807219748e-08

Mucopolysaccharidosis B-Disease 0 0.1890059858560562
IVA I-Disease 1 0.9982499480247498
( O 0 5.217100624577142e-05
MPS B-Disease 1 0.9999895095825195
IVA I-Disease 1 0.9999998807907104
) O 0 5.011551706957107e-07
is O 0 1.135197109647379e-07
an O 0 1.887400600253386e-07
autosomal B-Disease 1 0.999997615814209
recessive I-Disease 1 0.999998927116394
lysosomal I-Disease 1 0.9999995231628418
storage I-Disease 1 0.9999984502792358
disorder I-Disease 1 0.9999926090240479
caused O 0 2.0724132809846196e-06
by O 0 2.1276273798331857e-10
a O 0 9.279938240069896e-07
genetic B-Disease 1 0.9999998807907104
defect I-Disease 1 0.999998927116394
in O 0 2.6942363895443577e-09
N O 0 0.000205747113795951
- O 0 0.00028248297167010605
acetylgalactosamine O 0 0.00044154509669169784
- O 0 0.0002155199326807633
6 O 0 7.731470645921945e-07
- O 0 0.0006239110371097922
sulfate O 0 2.0348003090475686e-05
sulfatase O 0 7.941838703118265e-06
( O 0 1.528712295639778e-10
GALNS O 0 8.467615657536953e-07
) O 0 2.5263596770130903e-10
. O 0 7.721399075677482e-10

Previous O 0 1.1924207399260922e-07
studies O 0 9.868532657719697e-10
of O 0 2.3787900902544346e-12
patients O 0 3.320319796884519e-09
from O 0 3.2905319094500562e-12
a O 0 2.884776639788811e-09
British O 0 0.0011093387147411704
- O 0 0.01952226087450981
Irish O 0 9.124590860665194e-07
population O 0 9.649599869154812e-11
showed O 0 1.7130834528700234e-09
that O 0 8.863143725890144e-12
the O 0 9.022745224573914e-12
I113F O 0 1.1494678986423423e-08
mutation O 0 5.852515805315761e-09
is O 0 1.980636661624846e-11
the O 0 9.134849994485439e-12
most O 0 7.1162234091537435e-12
common O 0 1.6767955079988184e-10
single O 0 1.0705047515102706e-08
mutation O 0 4.041592376324843e-07
among O 0 1.1950910483449206e-08
MPS B-Disease 1 0.9999938011169434
IVA I-Disease 1 1.0
patients O 0 0.21224170923233032
and O 0 3.8579557326556824e-08
produces O 0 2.06430197380314e-08
a O 0 6.33832428320602e-07
severe O 0 9.465612674830481e-05
clinical O 0 2.7595522624324076e-05
phenotype O 0 0.00010319929424440488
. O 0 2.3349349120849183e-08

We O 0 3.459767299318628e-07
studied O 0 6.583662948145275e-09
mutations O 0 3.6748399878661075e-08
in O 0 9.051306579244134e-12
the O 0 5.4172495482507355e-12
GALNS O 0 2.2448089964655082e-07
gene O 0 2.526163500604639e-09
from O 0 2.914393552877481e-12
23 O 0 2.071344068488301e-10
additional O 0 4.2113082465711216e-10
MPS B-Disease 1 0.9999951124191284
IVA I-Disease 1 1.0
patients O 0 0.00019135627371724695
( O 0 1.5553877630303248e-11
15 O 0 2.8065455515147164e-10
from O 0 2.50783629973661e-11
Australia O 0 3.6751487186847953e-07
, O 0 2.386362288331334e-11
8 O 0 1.8116758093711383e-10
from O 0 2.829385814182017e-12
Northern O 0 2.5624208319641184e-06
Ireland O 0 1.161961904472264e-06
) O 0 1.7540207133959207e-11
, O 0 1.1010805982258898e-12
with O 0 1.3117172278920286e-12
various O 0 4.0620496549736984e-11
clinical O 0 6.064455646992428e-06
phenotypes O 0 1.6352435068256455e-06
( O 0 3.941714066257873e-09
severe O 0 7.488849405490328e-06
, O 0 4.2726691629191293e-10
16 O 0 9.512724635785119e-11
cases O 0 5.390988697118182e-11
; O 0 7.743281016381331e-11
intermediate O 0 2.1773149949666504e-09
, O 0 2.8758079251289814e-11
4 O 0 9.606448969634585e-10
cases O 0 1.6823392456899455e-08
; O 0 7.867151907703374e-08
mild O 0 2.2578078642254695e-06
, O 0 9.748389873109886e-10
3 O 0 2.5694464333980704e-09
cases O 0 7.121067735482711e-09
) O 0 5.9189630974287866e-09
. O 0 3.337133236414047e-08

We O 0 5.258052624412812e-06
found O 0 6.901182403318273e-10
two O 0 1.073764775011421e-11
common O 0 1.1591937826294085e-10
mutations O 0 7.387242249023984e-07
that O 0 2.811862298557344e-09
together O 0 6.599966684284198e-10
accounted O 0 7.793444112280667e-09
for O 0 3.2143862224720543e-12
32 O 0 1.0781534554027417e-09
% O 0 1.2378365476725661e-12
of O 0 2.19030644858266e-13
the O 0 1.0795213334358067e-10
44 O 0 1.7141089936334453e-10
unrelated O 0 1.5338380565665943e-10
alleles O 0 1.49647599867464e-10
in O 0 3.523031311125635e-10
these O 0 9.793041932937285e-10
patients O 0 1.4303640050172817e-08
. O 0 1.088713119656859e-09

One O 0 2.2957379997023963e-08
is O 0 9.152312241411664e-11
the O 0 1.0551494573907139e-11
T312S O 0 4.083924665110317e-08
mutation O 0 6.682319053652463e-08
, O 0 1.5823061610964473e-11
a O 0 4.406706943793637e-11
novel O 0 2.1892470059015068e-08
mutation O 0 1.5888720383827604e-07
found O 0 4.0934269862624717e-10
exclusively O 0 7.62800378417694e-11
in O 0 7.942302926444711e-10
milder O 0 1.9874185454682447e-05
patients O 0 7.124792773538502e-07
. O 0 3.0225626446167553e-09

The O 0 7.592115380816722e-09
other O 0 2.229499224126741e-11
is O 0 2.3192147854955714e-11
the O 0 8.78113033675465e-12
previously O 0 1.0433874209070382e-08
described O 0 1.9536219753035766e-08
I113F O 0 2.6994534607638343e-08
that O 0 2.1249911552612133e-10
produces O 0 4.826502530974608e-10
a O 0 5.789743084960719e-08
severe O 0 1.746470843499992e-05
phenotype O 0 6.32526571280323e-05
. O 0 1.946681216224988e-08

The O 0 3.815626481440404e-09
I113F O 0 1.0596166788445771e-07
and O 0 4.24189378067652e-10
T312S O 0 4.762074734543376e-09
mutations O 0 6.231325677674704e-09
accounted O 0 9.057186667327244e-10
for O 0 9.387160103055403e-13
8 O 0 1.210483824287678e-09
( O 0 2.3091905124172918e-11
18 O 0 3.616000554540477e-10
% O 0 2.8245546093014218e-12
) O 0 1.467771737484469e-11
and O 0 1.948013750308064e-09
6 O 0 2.565866408232864e-09
( O 0 1.251621202513764e-11
14 O 0 1.2573908581003934e-10
% O 0 3.85850531213483e-13
) O 0 1.9615102456790184e-13
of O 0 8.110466508462477e-14
44 O 0 1.260736098851467e-10
unrelated O 0 3.201729714685797e-10
alleles O 0 9.124185296194298e-10
, O 0 3.8812675295929466e-10
respectively O 0 4.2804693123343895e-09
. O 0 5.079015430453637e-09

The O 0 3.8330671969788455e-09
relatively O 0 7.7643297347052e-10
high O 0 5.865833929696862e-10
residual O 0 3.5315522950440936e-08
GALNS O 0 4.587242983689066e-06
activity O 0 1.7290050280394098e-08
seen O 0 6.415213693600208e-09
when O 0 1.2375334090819479e-10
the O 0 1.0378852725173582e-12
T312S O 0 3.313169461005572e-10
mutant O 0 1.2508200031291494e-10
cDNA O 0 7.962112080761585e-10
is O 0 2.72200716827653e-11
overexpressed O 0 9.774426956710158e-08
in O 0 2.4482008434412172e-11
mutant O 0 7.022178039051141e-08
cells O 0 8.377571525386429e-09
provides O 0 8.81899674815001e-12
an O 0 6.794269465613956e-13
explanation O 0 6.778497901871461e-11
for O 0 1.3679379894451782e-12
the O 0 4.719212798320882e-10
mild O 0 7.303601137209625e-07
phenotype O 0 8.85836016095709e-06
in O 0 2.4271689103017025e-09
patients O 0 2.4052602132229595e-09
with O 0 6.1543621761306344e-12
this O 0 1.0855550902633126e-09
mutation O 0 4.312749751989031e-06
. O 0 1.4473764409217438e-08

The O 0 3.373428481001639e-10
distribution O 0 5.249752299540944e-10
and O 0 1.4502565814922264e-11
relative O 0 2.728586670844302e-12
frequencies O 0 2.4044228413844237e-11
of O 0 2.74860673500979e-13
the O 0 2.465191592526672e-11
I113F O 0 1.1517919951131717e-08
and O 0 3.217039412639622e-10
T312S O 0 2.1402621896982055e-09
mutations O 0 2.616140548639123e-08
in O 0 4.080873833300913e-11
Australia O 0 6.419963227699554e-09
corresponded O 0 6.106774114167379e-11
to O 0 9.147908992812592e-12
those O 0 1.0429595555250248e-12
observed O 0 7.554771253026615e-10
in O 0 1.613293665325699e-10
Northern O 0 7.688026926189195e-06
Ireland O 0 1.769907794368919e-05
and O 0 4.516043095037503e-09
are O 0 1.1398614257335238e-12
unique O 0 1.9232906933730476e-11
to O 0 3.0339511458699064e-10
these O 0 2.199355281229387e-11
two O 0 1.7825001197291357e-10
populations O 0 3.606402643185902e-08
, O 0 1.5522937102385725e-11
suggesting O 0 9.284194940617496e-11
that O 0 8.529656841949063e-11
both O 0 1.1578436820425253e-10
mutations O 0 2.109007368744642e-08
were O 0 1.3688658540012e-10
probably O 0 4.389454077990962e-10
introduced O 0 2.8875826729723997e-10
to O 0 5.995908214373458e-10
Australia O 0 7.926265865876303e-09
by O 0 1.2765695618643935e-12
Irish O 0 1.880374300711196e-09
migrants O 0 9.698866709761944e-11
during O 0 1.2087983392028434e-11
the O 0 4.821712907415732e-12
19th O 0 1.6004840119876462e-08
century O 0 3.844689615561947e-07
. O 0 4.590407609583735e-09

Haplotype O 0 1.1755862033169251e-05
analysis O 0 1.5157935351339802e-08
using O 0 1.838743379778407e-09
6 O 0 4.0594900774237885e-09
RFLPs O 0 7.67019116665324e-07
provides O 0 6.4839075948619485e-12
additional O 0 4.232706307845391e-13
data O 0 3.743803045352934e-09
that O 0 3.163547201978645e-10
the O 0 8.111190191728568e-11
I113F O 0 4.226553684816281e-08
mutation O 0 1.7387667972101895e-09
originated O 0 3.2013572348610353e-10
from O 0 6.420366083399742e-13
a O 0 1.2911918929880972e-11
common O 0 1.3843969026705594e-10
ancestor O 0 1.3833398426754684e-08
. O 0 6.693300136362268e-09

The O 0 8.315897304100872e-09
other O 0 2.8905456153638376e-11
9 O 0 6.870947144577144e-10
novel O 0 4.329059333230134e-09
mutations O 0 3.60832956403101e-07
identified O 0 1.7552659414832306e-07
in O 0 4.357031402335565e-10
these O 0 5.153448778827396e-10
23 O 0 1.2769448609617484e-08
patients O 0 6.611557967772796e-10
were O 0 4.765077221691172e-11
each O 0 4.568189576614756e-12
limited O 0 1.2086066369931814e-08
to O 0 1.574420371852625e-09
a O 0 7.132971990841952e-10
single O 0 1.3923074675403768e-06
family O 0 6.989025678194594e-07
. O 0 2.909800222994363e-08

These O 0 7.374235111434757e-10
data O 0 7.297781823289995e-10
provide O 0 1.152612207067083e-11
further O 0 1.5837245794306232e-12
evidence O 0 4.999531171001603e-12
for O 0 2.723676861306201e-13
extensive O 0 1.554125939051687e-09
allelic O 0 2.1612260070469347e-07
heterogeneity O 0 7.103945245034993e-05
in O 0 4.698426891991403e-06
MPS B-Disease 1 0.9999911785125732
IVA I-Disease 1 0.9999998807907104
in O 0 1.3746307558903936e-06
British O 0 0.07701945304870605
- O 0 0.3459184765815735
Irish O 0 0.00016730731294956058
patients O 0 8.617335112148794e-08
and O 0 6.232579036202779e-11
provide O 0 2.473522038234921e-12
evidence O 0 2.1963915061706807e-11
for O 0 2.7274355191876654e-13
their O 0 1.202405796457695e-11
transmission O 0 7.3407331910857465e-06
to O 0 4.626682093000767e-10
Australia O 0 8.474222212839777e-09
by O 0 3.825020161718484e-12
British O 0 5.661797217726416e-07
- O 0 2.5567380816937657e-06
Irish O 0 3.6761434785148595e-08
migrants O 0 1.4584208840595636e-10
. O 0 6.501071382614132e-12
. O 0 1.2289641526663786e-10

Identification O 0 4.199529257675749e-08
of O 0 7.356895648236161e-11
constitutional O 0 2.490346595607207e-08
WT1 O 0 0.0005562287988141179
mutations O 0 0.00022616141359321773
, O 0 5.252746571038358e-10
in O 0 1.2829784457046856e-10
patients O 0 3.6784986168214573e-09
with O 0 1.870333887765696e-09
isolated O 1 0.980090320110321
diffuse B-Disease 1 0.9999088048934937
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 5.020975635261493e-08
and O 0 1.681724620672398e-10
analysis O 0 6.6634350814887e-11
of O 0 1.1533087852788615e-12
genotype O 0 1.5592850104440004e-06
/ O 0 0.00014260907482821494
phenotype O 0 8.916213118936867e-07
correlations O 0 5.012505077672813e-09
by O 0 3.7313502981861646e-12
use O 0 1.2993700559960075e-10
of O 0 2.24322014956424e-12
a O 0 9.016389301841343e-10
computerized O 0 2.214648156950716e-05
mutation O 0 2.580115278760786e-06
database O 0 3.8179396142368205e-06
. O 0 2.8547717079163704e-08

Constitutional O 0 3.867261284540291e-07
mutations O 0 8.13514532183035e-07
of O 0 8.798700483481081e-12
the O 0 4.412728862868143e-11
WT1 O 0 1.0622346735544852e-06
gene O 0 1.0776338932316776e-08
, O 0 2.6293919298814306e-12
encoding O 0 1.2078056610409504e-10
a O 0 2.6953838272447683e-08
zinc O 0 0.010053218342363834
- O 0 0.00012457471166271716
finger O 0 4.9143109208671376e-05
transcription O 0 4.121691006275796e-07
factor O 0 2.8182503553075833e-10
involved O 0 7.140200097843774e-10
in O 0 6.067575242241219e-08
renal O 0 0.008054635487496853
and O 0 1.5985443724275683e-07
gonadal O 0 0.0011500129476189613
development O 0 6.589720413785471e-08
, O 0 1.4905736367420985e-10
are O 0 3.212700504934274e-12
found O 0 7.004540836241802e-10
in O 0 4.886169940876428e-11
most O 0 4.009240717195439e-10
patients O 0 6.9874377395251486e-09
with O 0 2.3361643286534672e-08
Denys B-Disease 1 0.9999985694885254
- I-Disease 1 0.9999990463256836
Drash I-Disease 1 0.9999982118606567
syndrome I-Disease 1 0.9999995231628418
( O 0 3.1737747985260967e-09
DDS B-Disease 1 0.9999997615814209
) O 0 4.4149331301923667e-08
, O 0 6.5098784141071064e-09
or O 0 9.111199688049965e-07
diffuse B-Disease 1 0.9997897744178772
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 1.8440375981754187e-07
DMS B-Disease 1 0.9245766401290894
) O 0 4.813778264889379e-10
associated O 0 1.93290290440018e-08
with O 0 4.4878039062723474e-08
pseudohermaphroditism B-Disease 1 1.0
and O 0 0.0010423740604892373
/ O 1 0.9361196160316467
or O 0 7.574128539999947e-05
Wilms B-Disease 1 0.9998892545700073
tumor I-Disease 1 0.939074695110321
( O 0 8.665958262099593e-08
WT B-Disease 1 0.9999971389770508
) O 0 5.436551653303923e-09
. O 0 5.697261773462969e-09

Most O 0 2.0142607581874472e-08
mutations O 0 1.1203096619283315e-05
in O 0 2.5916754964327993e-08
DDS B-Disease 1 0.9999998807907104
patients O 0 0.2844833433628082
lie O 0 0.00016156566562131047
in O 0 1.7625255421815922e-11
exon O 0 9.209902884776966e-08
8 O 0 3.31689520294276e-09
or O 0 1.182561965018536e-10
exon O 0 1.0100158220893718e-07
9 O 0 2.4935500775313812e-08
, O 0 4.755915453125148e-11
encoding O 0 1.8350059249883088e-08
zinc O 0 0.3536009192466736
finger O 1 0.9424616694450378
2 O 0 3.0608720180680393e-07
or O 0 5.506684601641609e-07
zinc O 0 0.06258688867092133
finger O 1 0.8102070689201355
3 O 0 6.870914148748852e-08
, O 0 3.2062963395418365e-09
respectively O 0 5.0926152184160856e-09
, O 0 2.0630402941534953e-10
with O 0 8.413031382659142e-11
a O 0 1.1327720983445033e-08
hot O 0 1.856395829236135e-05
spot O 0 5.571198471443495e-06
( O 0 4.043027024280832e-11
R394W O 0 9.532672429202194e-10
) O 0 8.854724137079273e-13
in O 0 2.3466636620006476e-12
exon O 0 6.35066754739455e-08
9 O 0 5.569619787593183e-08
. O 0 4.094397265674843e-09

We O 0 1.336890278480496e-07
analyzed O 0 1.0994307686473803e-09
a O 0 8.139749291258269e-12
series O 0 1.99893923635841e-09
of O 0 2.1258737825657903e-11
24 O 0 6.587031720073355e-08
patients O 0 6.0746017105373085e-09
, O 0 1.1278592643160223e-11
10 O 0 5.3732289451158266e-11
with O 0 3.215022914559995e-09
isolated B-Disease 1 0.8576510548591614
DMS I-Disease 1 0.9992474317550659
( O 0 2.8664355333773983e-09
IDMS B-Disease 0 0.0005431116442196071
) O 0 1.0238926373418167e-10
, O 0 7.23400089830406e-11
10 O 0 1.6483410122947184e-11
with O 0 3.131443104820164e-09
DDS B-Disease 1 1.0
, O 0 1.0403518899693154e-06
and O 0 2.1487711165946166e-08
4 O 0 4.215215732017441e-09
with O 0 2.7803400470816086e-08
urogenital B-Disease 1 0.9937729239463806
abnormalities I-Disease 1 0.9997199177742004
and O 0 1.601493863745418e-06
/ O 1 0.8315420746803284
or O 0 0.0019239801913499832
WT B-Disease 1 0.9999986886978149
. O 0 3.436813358348445e-07

We O 0 1.2193373777336092e-06
report O 0 4.126415209526613e-09
WT1 O 0 1.5658224583603442e-06
heterozygous O 0 3.113559898793028e-08
mutations O 0 1.324551590187184e-06
in O 0 2.7856239537271676e-10
16 O 0 6.102566008081567e-09
patients O 0 6.820251030603686e-09
, O 0 1.3551773418718494e-11
4 O 0 6.392808504784853e-10
of O 0 2.5126626473914726e-11
whom O 0 6.913190730983843e-08
presented O 0 5.430789151716908e-09
with O 0 4.0084191965661375e-08
IDMS B-Disease 1 0.932646632194519
. O 0 1.005661758313181e-07

One O 0 1.240595537410627e-07
male O 0 6.457040058194252e-08
and O 0 1.5854375590151903e-09
two O 0 1.036818408906015e-09
female O 0 2.1423549867449765e-07
IDMS B-Disease 0 0.12799663841724396
patients O 0 5.224973733675142e-07
with O 0 3.3906020213692045e-09
WT1 O 1 0.957578182220459
mutations O 1 0.5931384563446045
underwent O 0 0.0008476900984533131
normal O 0 1.4904556337569375e-05
puberty O 0 0.00035591109190136194
. O 0 1.7099472060522203e-08

Two O 0 1.5821221666101337e-07
mutations O 0 5.803889962407993e-06
associated O 0 1.881067568376693e-08
with O 0 4.592973557038249e-09
IDMS B-Disease 0 0.0678604245185852
are O 0 1.4346604459980483e-10
different O 0 9.389026882355989e-12
from O 0 7.018227578953207e-12
those O 0 4.277184162404524e-11
described O 0 7.751005171030556e-08
in O 0 2.1518272319553944e-07
DDS B-Disease 1 1.0
patients O 0 0.0013550040312111378
. O 0 7.530978507475083e-09

No O 0 1.602922594656775e-07
WT1 O 0 6.395646778400987e-06
mutations O 0 2.3138998130889377e-06
were O 0 5.050496132419369e-10
detected O 0 1.2809654492684786e-07
in O 0 8.045351884700125e-11
the O 0 3.120113889476528e-10
six O 0 7.792582579213558e-09
other O 0 1.986461217740043e-09
IDMS B-Disease 1 0.9352253675460815
patients O 0 1.1196201654684046e-07
, O 0 4.800891021533582e-12
suggesting O 0 2.3260780801503955e-10
genetic O 0 6.488645709623597e-08
heterogeneity O 0 1.4946012072414305e-07
of O 0 6.669517160773353e-10
this O 0 8.100168997771107e-06
disease O 1 0.8857865929603577
. O 0 1.3997636827411952e-08

We O 0 2.3409555183206976e-07
analyzed O 0 1.241311622379726e-07
genotype O 0 2.0660674238115462e-07
/ O 0 8.381653060496319e-06
phenotype O 0 8.147110293066362e-07
correlations O 0 2.7978424554930825e-07
, O 0 3.283913974083674e-10
on O 0 2.7047541983904466e-10
the O 0 5.876757847717018e-12
basis O 0 2.1526771684654555e-11
of O 0 2.362498651570233e-12
the O 0 8.465865231066516e-10
constitution O 0 4.607469072936965e-09
of O 0 2.4736352289417285e-12
a O 0 1.6836416705245938e-09
WT1 O 0 2.8818696591770276e-05
mutation O 0 1.7294008003432282e-08
database O 0 5.2522284299527655e-09
of O 0 7.50691783041324e-12
84 O 0 6.544578212697161e-08
germ O 0 0.005994377192109823
- O 0 0.0017605327302590013
line O 0 0.006653574761003256
mutations O 0 1.6600987464698846e-06
, O 0 2.3933729997871467e-11
to O 0 5.982502687684743e-12
compare O 0 1.1516815279222214e-09
the O 0 3.4828667727637708e-12
distribution O 0 2.0606121253763376e-08
and O 0 1.8620127661961305e-08
type O 0 2.7230507271269744e-07
of O 0 1.6398554389396303e-11
mutations O 0 5.624048299068818e-06
, O 0 1.1331772326039768e-10
according O 0 1.029861959600531e-11
to O 0 2.7939874372440165e-11
the O 0 4.820391308335559e-11
different O 0 8.538259876900156e-09
symptoms O 0 1.7278320001423708e-06
. O 0 9.617008300821794e-10

This O 0 2.38910180527796e-09
demonstrated O 0 8.830804421045002e-10
( O 0 2.3441628412695925e-12
1 O 0 7.002774055075989e-11
) O 0 8.293981473839196e-11
the O 0 2.8625641787516365e-11
association O 0 1.0225845344102868e-11
between O 0 2.091506655366171e-11
mutations O 0 1.7562864940146028e-08
in O 0 7.060736544051149e-12
exons O 0 4.517424088135158e-07
8 O 0 4.0083886432285e-08
and O 0 1.131144244936877e-08
9 O 0 3.856285601955278e-08
and O 0 7.458193351794762e-08
DMS B-Disease 0 0.1973567008972168
; O 0 6.763365978379454e-10
( O 0 8.024857688082587e-12
2 O 0 2.337112725570023e-09
) O 0 1.470588512075821e-10
among O 0 3.277136201296216e-11
patients O 0 4.323940927530856e-10
with O 0 2.242827798482061e-11
DMS B-Disease 0 0.077371746301651
, O 0 1.2875349224283905e-11
a O 0 3.472503859978937e-13
higher O 0 3.3136695969625263e-13
frequency O 0 3.860842895386796e-11
of O 0 2.8185150068894826e-13
exon O 0 3.487088804376981e-07
8 O 0 3.134994486231335e-08
mutations O 0 4.082908731106727e-07
among O 0 4.3042399505699436e-11
46 O 0 6.721062817405254e-08
, O 0 7.354040487683733e-09
XY O 0 0.00016664784925524145
patients O 0 1.566053065005235e-08
with O 0 3.223241118455178e-11
female O 0 5.805941505343526e-09
phenotype O 0 2.033391588440736e-08
than O 0 2.0448540430373363e-11
among O 0 3.2245137115971545e-11
46 O 0 1.2142982086515985e-07
, O 0 2.926235609379546e-08
XY O 0 0.000712631328497082
patients O 0 1.6244976919210785e-08
with O 0 2.1044516823609527e-11
sexual O 0 7.566253401591894e-09
ambiguity O 0 1.405317817670948e-07
or O 0 6.933036900136358e-08
male O 0 1.809700762578359e-07
phenotype O 0 1.3739467021878227e-06
; O 0 4.484079774158545e-09
and O 0 1.1332068794445149e-07
( O 0 3.9669478812953685e-10
3 O 0 7.427597648046458e-09
) O 0 2.740213438101602e-11
statistically O 0 1.9093511494094884e-10
significant O 0 1.216637381118435e-11
evidence O 0 6.2278200374521475e-09
that O 0 6.9605414765305795e-09
mutations O 0 3.303694882106356e-07
in O 0 1.516552439184693e-10
exons O 0 6.519624548673164e-06
8 O 0 1.3941289012109337e-07
and O 0 1.14486642388556e-08
9 O 0 1.6435684813131957e-08
preferentially O 0 7.130339696459487e-08
affect O 0 1.2066672105959242e-08
amino O 0 2.9096209885892677e-09
acids O 0 1.3563908329849994e-10
with O 0 8.593890573130314e-13
different O 0 6.693771513639757e-13
functions O 0 1.227748180898658e-10
. O 0 3.676743076663769e-10
. O 0 1.6625324450458834e-09

The O 0 2.742131144373161e-08
185delAG O 0 3.279278189438628e-06
BRCA1 O 0 5.522068931895774e-06
mutation O 0 4.005064369039246e-08
originated O 0 2.0268542400003753e-09
before O 0 1.870920605939741e-11
the O 0 4.652239964791915e-13
dispersion O 0 1.4503106493535256e-09
of O 0 1.4920995211956112e-12
Jews O 0 7.204653940107164e-08
in O 0 3.177637875051431e-10
the O 0 1.4111713186881758e-10
diaspora O 0 3.90407750572308e-09
and O 0 3.1252613830190512e-09
is O 0 5.889912862988567e-11
not O 0 2.9724320227408896e-11
limited O 0 7.896922699091036e-11
to O 0 2.0301689496182718e-10
Ashkenazim O 0 4.096753400517628e-06
. O 0 3.1725524429759844e-09

The O 0 9.339886197778924e-09
185delAG O 0 7.970504611876095e-07
mutation O 0 3.460958453160856e-07
in O 0 1.6460670326789995e-10
BRCA1 O 0 1.3865409300706233e-06
is O 0 1.4522141822403967e-10
detected O 0 2.3233982915371598e-07
in O 0 1.0209266071425915e-10
Ashkenazi O 0 2.5742606339917984e-06
Jews O 0 1.0937651673259552e-08
both O 0 1.2573075913735465e-09
in O 0 7.423280834473189e-08
familial B-Disease 1 0.9999172687530518
breast I-Disease 1 0.9999997615814209
and I-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 4.46193189418409e-06
in O 0 2.883016270160965e-09
the O 0 2.087589823229763e-10
general O 0 9.35796329315508e-10
population O 0 4.309589629603039e-10
. O 0 2.158686562836465e-09

All O 0 3.069325416049651e-08
tested O 0 2.3683963945586584e-07
Ashkenazi O 0 3.39816011774019e-07
mutation O 0 1.586176523460381e-08
carriers O 0 9.35466260010287e-10
share O 0 2.8517266326133495e-10
the O 0 1.6558279053446867e-11
same O 0 5.954955278886231e-11
allelic O 0 1.5695938770932116e-08
pattern O 0 1.5125136997085065e-05
at O 0 1.2945846172840447e-08
the O 0 9.386279531398145e-10
BRCA1 O 0 7.566684416815406e-06
locus O 0 2.3409183995681815e-06
. O 0 7.956138148301761e-08

Our O 0 1.8319693140256277e-07
previous O 0 1.0094969304930146e-09
study O 0 8.70967534205569e-11
showed O 0 2.749944272295579e-09
that O 0 1.473836677701179e-11
this O 0 1.6572025002270507e-11
Ashkenazi O 0 2.6205356334685348e-05
mutation O 0 9.668990514910547e-07
also O 0 9.9785850693479e-08
occurs O 0 1.636432545026878e-09
in O 0 1.9306709009292433e-11
Iraqi O 0 6.706996624750161e-10
Jews O 0 5.439826367137357e-10
with O 0 4.1374187062515055e-12
a O 0 1.602454974269918e-11
similar O 0 6.949311959214555e-11
allelic O 0 6.528619422851989e-08
pattern O 0 5.530650742002763e-05
. O 0 4.698408062608905e-08

We O 0 9.58862415245676e-07
extended O 0 5.074287656725573e-10
our O 0 1.1381065360971387e-11
analysis O 0 6.668339491699982e-12
to O 0 1.4183234664857935e-12
other O 0 2.2494101037124486e-13
non O 0 4.0958382518940795e-11
- O 0 6.504035354737425e-07
Ashkenazi O 0 6.680803039671446e-07
subsets O 0 4.171585743506512e-09
354 O 0 2.669579279857004e-10
of O 0 1.040378612253423e-12
Moroccan O 0 9.57875627705107e-08
origin O 0 4.514643520137085e-11
, O 0 6.411264748262813e-12
200 O 0 1.159186028415471e-12
Yemenites O 0 8.071012302934832e-09
and O 0 3.578029582687603e-12
150 O 0 3.195113444653952e-12
Iranian O 0 2.640818674848333e-10
Jews O 0 1.8348861319239518e-09
. O 0 8.199640966211064e-10

Heteroduplex O 0 3.4219439839944243e-05
analysis O 0 1.652139403063302e-08
complemented O 0 1.4646128754236543e-09
by O 0 7.115893703273091e-13
direct O 0 2.748850799760838e-11
DNA O 0 1.7077414327104634e-07
sequencing O 0 6.105068894868282e-09
of O 0 4.78532187833669e-12
abnormally O 0 3.0551834395708966e-09
migrating O 0 1.2387683934189653e-10
bands O 0 1.7436145582916396e-10
were O 0 2.3502000345843044e-10
employed O 0 8.515051774793392e-09
. O 0 1.1894235596443536e-09

Four O 0 2.192053649707759e-09
of O 0 3.4109902402601477e-12
Moroccan O 0 4.77682355892739e-08
origin O 0 2.3261921902606453e-11
( O 0 6.756675839485193e-13
1 O 0 3.312161309110273e-12
. O 0 3.3861117035294264e-12
1 O 0 1.0979271311550853e-11
% O 0 1.0777637463044165e-11
) O 0 2.7668350249809848e-11
and O 0 6.507569150215886e-09
none O 0 1.5316141688259677e-09
of O 0 4.2476032456953416e-13
the O 0 1.4543430348901154e-10
Yemenites O 0 2.0676444023592921e-07
or O 0 1.1435514341018305e-10
Iranians O 0 2.650431818462806e-10
was O 0 1.3933559861456501e-10
a O 0 1.5271311775907903e-12
carrier O 0 9.04468375195755e-11
of O 0 1.9642956965854053e-13
the O 0 3.976710974407105e-11
185delAG O 0 2.069735529630634e-07
mutation O 0 8.006084328826546e-08
. O 0 1.5557928279008593e-09

BRCA1 O 0 2.8121081413701177e-05
allelic O 0 3.7190378066043195e-07
patterns O 0 5.1639210141729563e-05
were O 0 1.5156106369929034e-09
determined O 0 4.759141969401526e-09
for O 0 4.5590497523007034e-12
four O 0 6.66231722568078e-11
of O 0 1.0922620230155444e-12
these O 0 8.455468963886048e-11
individuals O 0 3.893779396135777e-12
and O 0 8.702269460592049e-11
for O 0 1.2162725254033502e-12
12 O 0 4.39754396092118e-12
additional O 0 1.489725118437868e-12
non O 0 1.0506320258230062e-09
- O 0 1.2571733350341674e-05
Ashkenazi O 0 3.243596802349202e-05
185delAG O 0 5.050819140706153e-08
mutation O 0 5.1785971066919956e-09
carriers O 0 5.246111545176291e-09
who O 0 6.938209480722435e-06
had O 0 0.3436475694179535
breast B-Disease 1 0.9999935626983643
/ I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 7.444307357218349e-07

Six O 0 1.7768711302323936e-07
non O 0 1.5731364655380276e-08
- O 0 0.00016429289826191962
Ashkenazi O 0 0.00026059133233502507
individuals O 0 9.453236110568142e-11
shared O 0 3.8224351461835226e-10
the O 0 2.6010112466612334e-11
common O 0 1.120488701822353e-09
Ashkenazi O 0 6.565985131601337e-06
haplotype O 0 3.939822636311874e-05
, O 0 2.964751111278474e-09
four O 0 1.877854760579112e-09
had O 0 1.263082225477774e-07
a O 0 3.745563234569538e-11
closely O 0 2.220555295195936e-09
related O 0 5.289917393014321e-10
pattern O 0 0.00012964998313691467
, O 0 1.79069381545105e-08
and O 0 8.79337846981798e-09
the O 0 2.899586404314647e-10
rest O 0 3.357985001173347e-09
( O 0 5.843293730822818e-12
n O 0 1.8899055476140347e-06
= O 0 3.199312777724117e-05
6 O 0 4.553651233862865e-09
) O 0 2.0104118023112072e-11
displayed O 0 5.356490806462944e-10
a O 0 3.25531462896933e-10
distinct O 0 7.707747329277481e-09
BRCA1 O 0 6.275295163504779e-06
allelic O 0 9.729828889248893e-07
pattern O 0 0.0005718686152249575
. O 0 1.3129718468007923e-07

We O 0 4.180604662451515e-07
conclude O 0 1.420553674691405e-09
that O 0 7.318920643151205e-12
the O 0 8.783508642640214e-12
185delAG O 0 2.587162043710123e-06
BRCA1 O 0 1.9262623027316295e-05
mutation O 0 1.0889129953284282e-06
occurs O 0 7.692165127082262e-09
in O 0 1.0483929696603056e-11
some O 0 9.054656330276245e-12
non O 0 5.387457591154998e-09
- O 0 0.0007334948168136179
Ashkenazi O 0 0.0005102457362227142
populations O 0 5.2969902242239186e-08
at O 0 1.2109734326415378e-09
rates O 0 3.113752589101182e-10
comparable O 0 1.471757958559916e-11
with O 0 3.909004630403556e-12
that O 0 7.927587752920573e-11
of O 0 1.0741109390810522e-11
Ashkenazim O 0 5.793515083496459e-05
. O 0 7.622949382835031e-09

The O 0 5.999331254002982e-09
majority O 0 2.29770702464549e-10
of O 0 2.081862026520609e-12
Jewish O 0 2.2322087289694537e-08
185delAG O 0 8.90958347099513e-07
mutation O 0 3.8746069463968524e-08
carriers O 0 2.2215296269223472e-09
have O 0 9.702997294525062e-10
a O 0 7.889273956340759e-11
common O 0 3.243563473365185e-10
allelic O 0 2.204541260653059e-08
pattern O 0 0.00016141030937433243
, O 0 1.0850914611282292e-09
supporting O 0 7.692982917362201e-10
the O 0 3.32269989300471e-10
founder O 0 1.922098036288844e-08
effect O 0 4.0442479920521635e-10
notion O 0 6.188023871089854e-09
, O 0 1.034118679577034e-09
but O 0 3.165382123082594e-10
dating O 0 1.4237253154192331e-08
the O 0 3.5890838911978307e-11
mutations O 0 8.68770122508522e-09
origin O 0 3.555689770395887e-11
to O 0 5.0987918748246486e-11
an O 0 5.561729462394416e-13
earlier O 0 1.4442065598974096e-10
date O 0 1.501583302143672e-09
than O 0 8.452174724005168e-12
currently O 0 3.057630260094868e-10
estimated O 0 1.4962684424801864e-09
. O 0 7.246657940385148e-09

However O 0 1.2602210119894153e-07
, O 0 1.70398330862076e-11
the O 0 8.038809418478565e-13
different O 0 1.5067106633528948e-12
allelic O 0 8.555947950128484e-09
pattern O 0 1.2097193575755227e-05
at O 0 2.7937041124914685e-08
the O 0 4.6562062538946236e-10
BRCA1 O 0 6.365345143422019e-06
locus O 0 3.252507099205104e-07
even O 0 4.0315367044740924e-08
in O 0 1.8509339894112742e-11
some O 0 3.245639651136556e-12
Jewish O 0 5.5360462880571504e-08
mutation O 0 9.000176959261807e-08
carriers O 0 3.845325391438337e-09
, O 0 4.787727436728062e-10
might O 0 3.596042574827152e-09
suggest O 0 3.39357653089678e-10
that O 0 2.7798107565812913e-11
the O 0 5.524832761422127e-12
mutation O 0 6.664484963891937e-09
arose O 0 5.7469907305263135e-11
independently O 0 1.2196055276803008e-09
. O 0 5.655313717323196e-11
. O 0 1.0451276510892171e-09

Crystal O 0 0.000201255374122411
structure O 0 1.8982782989951374e-07
of O 0 5.947373149517432e-11
the O 0 5.268766400945424e-08
hemochromatosis B-Disease 1 0.9999997615814209
protein O 0 8.696744043845683e-05
HFE O 0 0.0018953101243823767
and O 0 1.8454093364539403e-08
characterization O 0 1.0774663223855896e-06
of O 0 6.3876464881373884e-12
its O 0 1.4935610040400782e-11
interaction O 0 6.296419635676287e-11
with O 0 3.9478642577250866e-11
transferrin O 0 5.657479391629749e-07
receptor O 0 2.5390573199501887e-08
. O 0 5.6461577635502636e-09

HFE O 0 0.0037199200596660376
is O 0 3.218141131355878e-08
an O 0 8.264088718901164e-11
MHC O 0 4.4533385334943887e-07
- O 0 2.179058583351434e-06
related O 0 3.6697109795369443e-09
protein O 0 8.618008706662295e-08
that O 0 9.82882109035188e-10
is O 0 1.8227662434977532e-11
mutated O 0 4.4843385893500454e-08
in O 0 1.376254554763534e-09
the O 0 1.1306032376978692e-07
iron B-Disease 1 0.9998891353607178
- I-Disease 1 0.9999939203262329
overload I-Disease 1 0.9999809265136719
disease I-Disease 1 0.999994158744812
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.00015470877406187356

HFE O 0 8.275291475001723e-05
binds O 0 5.052910410086042e-07
to O 0 1.6556023219038707e-09
transferrin O 0 1.0981553799638277e-07
receptor O 0 2.9950908420062206e-09
( O 0 7.574056659631623e-11
TfR O 0 4.129048829781823e-05
) O 0 3.977183304915144e-10
and O 0 4.936024367019343e-10
reduces O 0 1.3342500437829585e-09
its O 0 3.0077090991398325e-12
affinity O 0 1.0883201978506563e-10
for O 0 2.022790407396613e-10
iron O 0 0.00022779643768444657
- O 0 5.981173217151081e-06
loaded O 0 3.2580633302359274e-08
transferrin O 0 2.3651544722724793e-08
, O 0 3.315936414338694e-11
implicating O 0 1.2545837080324418e-07
HFE O 0 5.380052971304394e-05
in O 0 2.0175598081095814e-08
iron O 0 0.00038335155113600194
metabolism O 0 0.00011982436990365386
. O 0 5.435037753187544e-09

The O 0 1.1328909366170592e-08
2 O 0 2.2757184581223555e-08
. O 0 7.854239925109141e-09

6 O 0 8.913815463529318e-07
A O 0 6.227715942941359e-08
crystal O 0 4.244209048920311e-05
structure O 0 1.508987679699203e-06
of O 0 4.001080369797627e-11
HFE O 0 0.0021181663032621145
reveals O 0 5.315395128491218e-07
the O 0 3.907761614296845e-11
locations O 0 1.992168918718562e-08
of O 0 1.7357977277754344e-09
hemochromatosis B-Disease 1 1.0
mutations O 1 0.9961763620376587
and O 0 4.522165397702338e-07
a O 0 5.860234519872165e-09
patch O 1 0.7669711112976074
of O 0 6.427727794466875e-10
histidines O 0 0.0005842101527377963
that O 0 4.803162667599281e-08
could O 0 8.595190337246095e-08
be O 0 5.4147724498632144e-11
involved O 0 2.1129058572211257e-11
in O 0 2.075497551601302e-09
pH O 0 1.7403972378815524e-05
- O 0 8.340556632902008e-06
dependent O 0 1.0876368605750031e-07
interactions O 0 1.6389197554644852e-08
. O 0 3.041658702684913e-09

We O 0 4.996670668333536e-06
also O 0 1.9505863591007255e-09
demonstrate O 0 1.0273184525289025e-09
that O 0 2.449748182087319e-10
soluble O 0 1.1728388926712796e-06
TfR O 0 0.008624495938420296
and O 0 1.683241777072908e-07
HFE O 0 0.0009518462466076016
bind O 0 2.233563645859249e-05
tightly O 0 2.482444870111067e-05
at O 0 1.6260290891523255e-08
the O 0 2.7956772313819656e-11
basic O 0 3.088550526442191e-09
pH O 0 1.9789668570524555e-08
of O 0 2.972700753091362e-13
the O 0 5.2515821552523434e-11
cell O 0 4.517722572927596e-06
surface O 0 8.29654345579911e-06
, O 0 1.1581711145680629e-09
but O 0 3.7069110003784544e-09
not O 0 1.043639619169312e-09
at O 0 2.016473876764735e-09
the O 0 1.759916379295845e-10
acidic O 0 3.214595949430077e-07
pH O 0 2.3611880450857825e-08
of O 0 6.734716517103889e-12
intracellular O 0 5.700389465346234e-06
vesicles O 0 3.318196831969544e-05
. O 0 8.552900254699125e-08

TfR O 0 0.024663254618644714
HFE O 0 0.00021334942721296102
stoichiometry O 0 1.1848387657664716e-06
( O 0 3.629315736830563e-10
2 O 0 1.282618733444707e-10
1 O 0 3.027411654699108e-11
) O 0 4.506485462574261e-12
differs O 0 3.9399755680236126e-10
from O 0 2.0081660292992076e-11
TfR O 0 3.674521576613188e-05
transferrin O 0 1.182010755940155e-08
stoichiometry O 0 1.157283491259875e-09
( O 0 6.386623001286562e-12
2 O 0 9.176259058163438e-11
2 O 0 7.767989029794364e-10
) O 0 5.078003295633238e-11
, O 0 7.457368056407176e-12
implying O 0 5.481359810488584e-11
a O 0 2.3823998329675078e-12
different O 0 1.141094190708694e-13
mode O 0 4.0739290413371876e-11
of O 0 3.6336232823617684e-14
binding O 0 6.914723654771748e-11
for O 0 2.2144107294369553e-12
HFE O 0 2.284999209223315e-05
and O 0 7.499229681684483e-09
transferrin O 0 6.822570242093207e-08
to O 0 6.644997330162994e-10
TfR O 0 5.288975444273092e-05
, O 0 2.2097970675538647e-10
consistent O 0 1.643131852802071e-09
with O 0 3.257853362081953e-11
our O 0 8.385668548438474e-11
demonstration O 0 3.161833850295892e-10
that O 0 1.712820336952081e-11
HFE O 0 9.734720833876054e-07
, O 0 6.21927925825716e-11
transferrin O 0 2.4806423581935633e-08
, O 0 3.209268129023002e-10
and O 0 7.476435470721299e-09
TfR O 0 0.0005544862360693514
form O 0 4.154917743193209e-09
a O 0 8.33935309696443e-10
ternary O 0 1.621790829631209e-06
complex O 0 4.8238660383503884e-05
. O 0 9.617713914167325e-08

Identification O 0 7.398558921067888e-08
of O 0 1.4708879947367137e-11
three O 0 2.780183305794992e-10
novel O 0 1.949586980742879e-08
mutations O 0 1.7319857761322055e-06
and O 0 8.697478293129279e-10
a O 0 2.0192236771521266e-11
high O 0 3.971927994839142e-11
frequency O 0 9.123141131439638e-10
of O 0 2.0275161757843385e-12
the O 0 7.340261731769715e-10
Arg778Leu O 0 5.4219053708948195e-05
mutation O 0 6.785272148590593e-07
in O 0 4.466325531637949e-09
Korean O 0 9.473476893617772e-06
patients O 0 8.906811288511562e-09
with O 0 1.1323697535203792e-09
Wilson B-Disease 0 0.06668643653392792
disease I-Disease 0 0.2738921046257019
. O 0 4.7935504454699185e-09

Four O 0 1.0144719198024177e-07
mutations O 0 1.1691414556480595e-06
- O 0 1.4123196706350427e-05
- O 0 1.9289867850602604e-05
R778L O 0 2.266055929567301e-07
, O 0 1.7444353253570632e-11
A874V O 0 6.458105716866669e-10
, O 0 1.7808228849891528e-12
L1083F O 0 2.8834548637668433e-10
, O 0 2.8217868579955008e-12
and O 0 1.3749413066421745e-11
2304delC O 0 1.3408556931437943e-08
- O 0 4.419171091285534e-07
- O 0 8.448595281151938e-07
in O 0 3.890398558858976e-10
the O 0 2.952091349150976e-11
copper O 0 1.0612322576264432e-08
- O 0 2.4217217120536816e-09
transporting O 0 4.6548986887273713e-11
enzyme O 0 2.806802568144917e-10
, O 0 1.0755583056132334e-11
P O 0 2.0103132101212395e-06
- O 0 6.837706791884557e-07
type O 0 1.4387773035196005e-06
ATPase O 0 1.628781433282711e-06
( O 0 4.3217290857100465e-11
ATP7B O 0 2.5541837089804176e-07
) O 0 6.294927686750773e-12
, O 0 2.4107311199367265e-12
were O 0 1.640962886406694e-11
identified O 0 8.174971810603893e-09
in O 0 1.3309406909911559e-09
Korean O 0 2.486344237695448e-05
Patients O 0 1.641106273098103e-08
with O 0 1.258240733825744e-09
Wilson B-Disease 0 0.09043341875076294
disease I-Disease 1 0.558108925819397
. O 0 7.416569580698251e-09

Arg778Leu O 0 0.0001881495991256088
, O 0 7.56646922894788e-09
the O 0 3.42156095123336e-11
most O 0 1.457655350589615e-11
frequently O 0 1.1783100717366324e-08
reported O 0 2.7005850888883742e-09
mutation O 0 1.3156731260011156e-09
of O 0 1.2110726646790554e-13
this O 0 3.406122606186557e-11
enzyme O 0 6.466589486109342e-09
, O 0 4.2763542706936164e-10
was O 0 9.120191180045367e-08
found O 0 3.967405959315329e-08
in O 0 6.713036793115634e-10
six O 0 2.5026480887646585e-10
of O 0 1.248759234039054e-12
eight O 0 8.067007062351195e-10
unrelated O 0 7.031168536286714e-09
patients O 0 2.172055646454396e-09
studied O 0 2.7454044593255844e-10
, O 0 2.9119024899659784e-13
an O 0 9.396894578379746e-15
allele O 0 8.438934447074775e-12
frequency O 0 3.6579270168424216e-10
of O 0 1.4288866097278419e-11
37 O 0 9.854903737505083e-08
. O 0 5.566070271356693e-09

5 O 0 4.455147717408181e-08
% O 0 3.0793201322154573e-10
, O 0 1.56956517227691e-10
which O 0 5.999211544205352e-11
is O 0 1.6711041187986164e-12
considerably O 0 2.6926424978590546e-10
higher O 0 8.387615255123215e-12
than O 0 3.673529362646644e-12
those O 0 6.62164767462059e-12
in O 0 4.9616488001502645e-11
other O 0 9.435024289627947e-11
Asian O 0 1.2205625843364487e-08
populations O 0 1.757278411673724e-08
. O 0 1.1962899559847529e-09

The O 0 2.00135397143697e-09
novel O 0 1.6420980131215401e-09
single O 0 2.540294918862429e-10
nucleotide O 0 4.80429651616987e-09
deletion O 0 1.3622873495933163e-07
, O 0 6.180728151505832e-11
2304delC O 0 6.35844870089386e-08
, O 0 1.6496563837176126e-10
was O 0 1.572545293981875e-08
found O 0 2.6809086062229426e-09
in O 0 1.3930398501393881e-10
one O 0 1.0528472316195803e-08
patient O 0 9.44065106978087e-07
. O 0 1.232833946041012e-09

Since O 0 1.9563291431268226e-08
a O 0 1.1620362311282051e-10
mutation O 0 2.7028730364975218e-09
at O 0 1.456461062865344e-10
cDNA O 0 2.8277082009253718e-08
nucleotide O 0 2.958565232802357e-07
2302 O 0 2.9350840122788213e-05
( O 0 7.387577355411068e-11
2302insC O 0 9.403148482078905e-08
) O 0 1.1143330008733798e-10
had O 0 4.029776619063341e-07
been O 0 5.8291429461121425e-09
previously O 0 1.0302176178811351e-07
described O 0 2.0342105244708364e-07
, O 0 3.324500397194896e-10
this O 0 1.2540849435305201e-11
region O 0 8.775379312098153e-10
of O 0 1.2611485206842632e-12
the O 0 2.34089025941131e-10
ATP7B O 0 1.4836882655799855e-05
gene O 0 2.3827649329177802e-06
may O 0 5.256550394960868e-08
be O 0 3.4425495787360205e-10
susceptible O 0 2.9145770241711944e-08
to O 0 1.054325238225573e-10
gene O 0 4.968142093275674e-06
rearrangements O 0 0.038409896194934845
causing O 0 0.004264294169843197
Wilson B-Disease 1 0.9725445508956909
disease I-Disease 1 0.9891797304153442
. O 0 1.967431728644442e-08

Disruption O 0 2.273993004564545e-06
of O 0 8.208144233745607e-12
splicing O 0 3.679707560877432e-08
regulated O 0 1.392321369309002e-08
by O 0 4.737986045166842e-12
a O 0 4.668289019238436e-11
CUG O 0 2.9253510547277983e-06
- O 0 4.177806829375186e-07
binding O 0 6.543813935167009e-09
protein O 0 3.235732037865091e-07
in O 0 1.1192544207005994e-06
myotonic B-Disease 1 0.9999970197677612
dystrophy I-Disease 1 0.999997615814209
. O 0 1.408022285431798e-07

Myotonic B-Disease 1 0.9999909400939941
dystrophy I-Disease 1 0.9999986886978149
( O 0 0.00018604118668008596
DM B-Disease 1 0.9999997615814209
) O 0 1.0533512977417558e-06
is O 0 5.409245051879452e-09
caused O 0 5.958949333972896e-09
by O 0 5.9920718560591e-12
a O 0 1.172893865364344e-10
CTG O 0 4.162107245520019e-07
expansion O 0 3.3053124681714507e-09
in O 0 3.6954730942007075e-10
the O 0 1.6791573687058303e-10
3 O 0 1.3331078463352242e-09
untranslated O 0 3.1755636882735416e-05
region O 0 1.1118352460925962e-08
of O 0 9.717971219402877e-12
the O 0 9.112572030289812e-09
DM B-Disease 1 0.9999974966049194
gene O 0 7.833997369743884e-05
. O 0 1.7877487934470082e-08

One O 0 6.575279876130935e-09
model O 0 1.017442130546442e-08
of O 0 3.459815767214991e-10
DM B-Disease 1 0.9999980926513672
pathogenesis O 0 0.08435254544019699
suggests O 0 1.1244590325532045e-07
that O 0 7.143670377462996e-11
RNAs O 0 4.495720133945724e-07
from O 0 1.0200093374101993e-11
the O 0 6.698704958785218e-12
expanded O 0 1.7895185333571817e-09
allele O 0 1.9268688866702632e-09
create O 0 3.8881062258688814e-10
a O 0 2.352254224735617e-10
gain O 0 7.4052755039133444e-09
- O 0 8.145199217324262e-07
of O 0 5.268788530465862e-11
- O 0 1.307618003920652e-05
function O 0 7.197756168864089e-09
mutation O 0 7.58785478893742e-10
by O 0 3.59923299931425e-13
the O 0 1.8696177418731086e-12
inappropriate O 0 2.3799770487720195e-10
binding O 0 1.7383702116680055e-11
of O 0 1.8174979750373854e-13
proteins O 0 1.830020801563137e-09
to O 0 1.7904666638202116e-10
the O 0 6.016678266718145e-10
CUG O 0 0.00012261082883924246
repeats O 0 3.9865855796961114e-05
. O 0 1.5028104982661716e-08

Data O 0 2.1644889613980922e-07
presented O 0 1.4696891481591479e-09
here O 0 1.3612996840883795e-10
indicate O 0 2.3303900476001616e-10
that O 0 1.4940682371844538e-11
the O 0 6.501976474587723e-12
conserved O 0 2.8108182448249863e-08
heterogeneous O 0 4.407100675507536e-07
nuclear O 0 2.5796871341299266e-06
ribonucleoprotein O 0 1.4314589691366564e-07
, O 0 1.4714218732336803e-10
CUG O 0 1.2153286661487073e-06
- O 0 6.546188302536393e-08
binding O 0 8.723895494888723e-10
protein O 0 2.705710100414649e-09
( O 0 4.718929240421499e-12
CUG O 0 6.344680514303036e-07
- O 0 1.1885236972375424e-06
BP O 0 6.676942803096608e-07
) O 0 1.3172612306489029e-11
, O 0 4.2022635371452566e-11
may O 0 8.927761863120054e-10
mediate O 0 1.0506709458013574e-07
the O 0 6.737611163432078e-11
trans O 0 3.7736003832833376e-07
- O 0 1.657790198805742e-05
dominant O 0 3.492866653687088e-07
effect O 0 2.13296630358073e-10
of O 0 4.433689743468805e-13
the O 0 4.3955675904649993e-11
RNA O 0 4.457087470655097e-06
. O 0 4.152874044649479e-09

CUG O 0 0.0002177486167056486
- O 0 7.258126424858347e-05
BP O 0 1.0552562343946192e-05
was O 0 8.452461841557124e-09
found O 0 5.835634059314643e-11
to O 0 2.4194556948187174e-12
bind O 0 3.613492616239e-09
to O 0 4.122564442599064e-11
the O 0 7.870817886335146e-11
human O 0 4.572504863631366e-08
cardiac O 0 2.1801561160827987e-05
troponin O 0 1.7591079085832462e-05
T O 0 0.00020802387734875083
( O 0 2.772651552795935e-11
cTNT O 0 6.790202622397601e-09
) O 0 7.042766977244375e-12
pre O 0 3.0553288787871224e-09
- O 0 6.869118465147039e-07
messenger O 0 1.295691376412833e-08
RNA O 0 7.06298521890858e-07
and O 0 9.793597183227476e-11
regulate O 0 1.7845888655720898e-10
its O 0 3.4186434065552884e-12
alternative O 0 2.279103121505255e-11
splicing O 0 7.014895686552336e-08
. O 0 3.822320238100474e-09

Splicing O 0 4.883656856691232e-07
of O 0 2.134696031053096e-10
cTNT O 0 1.5234359125315677e-06
was O 0 1.5856386426094105e-07
disrupted O 0 8.518168033333495e-05
in O 0 1.0589540266892072e-07
DM B-Disease 1 0.9999994039535522
striated O 1 0.9972773194313049
muscle O 0 0.48417606949806213
and O 0 1.1632485552581784e-07
in O 0 2.626497352942181e-10
normal O 0 5.434854344343876e-08
cells O 0 6.514225603382329e-09
expressing O 0 4.905104534352889e-12
transcripts O 0 7.468069718186143e-09
that O 0 3.854958019466892e-10
contain O 0 2.585089475815039e-08
CUG O 0 0.0003839859564322978
repeats O 0 7.516078039770946e-05
. O 0 1.0604411571080163e-08

Altered O 0 0.0001318160502705723
expression O 0 2.81160108528411e-08
of O 0 1.2135086338571632e-11
genes O 0 1.3813096444437178e-08
regulated O 0 4.0256892930301547e-08
posttranscriptionally O 0 3.250274573929346e-07
by O 0 5.981044826075532e-11
CUG O 0 1.1513192475831602e-05
- O 0 9.98883660940919e-06
BP O 0 5.882931873202324e-06
therefore O 0 3.270682391587343e-09
may O 0 9.487464980306726e-11
contribute O 0 5.9381202212327455e-12
to O 0 7.690650338787464e-10
DM B-Disease 1 0.9999990463256836
pathogenesis O 0 0.17241446673870087
. O 0 7.726367101668075e-09
. O 0 2.9981142013468798e-09

Identification O 0 1.3596480386013354e-08
of O 0 2.9855783643950584e-12
a O 0 3.12259634815959e-10
novel O 0 2.363667022109439e-07
nonsense O 0 4.881893619312905e-05
mutation O 0 1.928793551542185e-07
and O 0 7.140360525070832e-11
a O 0 1.978555340398369e-12
missense O 0 3.5376652718355217e-09
substitution O 0 6.378628181202828e-11
in O 0 2.861547587426627e-12
the O 0 4.41816722096533e-12
vasopressin O 0 2.336505433575553e-10
- O 0 8.018429866751831e-07
neurophysin O 0 1.9406199953664327e-06
II O 0 1.4501584928439115e-06
gene O 0 2.9350786689974484e-08
in O 0 7.643441435334353e-11
two O 0 9.635511138972319e-11
Spanish O 0 5.190602614391082e-09
kindreds O 0 3.1805141134100268e-06
with O 0 9.0374330241616e-09
familial B-Disease 1 0.9169713258743286
neurohypophyseal I-Disease 1 0.9997941851615906
diabetes I-Disease 1 0.9999786615371704
insipidus I-Disease 1 0.9974162578582764
. O 0 8.976772392088606e-07

Familial B-Disease 1 0.9996486902236938
neurohypophyseal I-Disease 1 0.9998400211334229
diabetes I-Disease 1 0.9999922513961792
insipidus I-Disease 1 0.999906063079834
( O 0 5.160149885341525e-05
FNDI B-Disease 1 0.9999997615814209
) O 0 1.1920342046778387e-07
is O 0 3.751567589915794e-08
an O 0 1.1309990810559611e-07
autosomal B-Disease 1 0.9999966621398926
dominant I-Disease 1 0.9999984502792358
disease I-Disease 1 0.9999991655349731
caused O 0 0.0003536554577294737
by O 0 1.029344957714784e-06
deficiency O 1 0.6075537800788879
in O 0 2.2868640314754884e-10
the O 0 1.1053475912348176e-09
antidiuretic O 0 6.956256015655526e-07
hormone O 0 7.305009375180305e-10
arginine O 0 2.5224753397168342e-09
vasopressin O 0 1.3305567758692405e-10
( O 0 3.760486280007802e-12
AVP O 0 7.735180829193666e-10
) O 0 7.571488602102841e-14
encoded O 0 1.581526901626995e-12
by O 0 1.896337904414014e-12
the O 0 7.578204036517988e-11
AVP O 0 1.5295238426915603e-06
- O 0 1.9921626517316326e-05
neurophysin O 0 1.0131362614629325e-05
II O 0 3.7101922316651326e-06
( O 0 5.3873596556064385e-11
AVP O 0 7.027671244941303e-08
- O 0 7.330907010327792e-07
NPII O 0 3.537381019214081e-07
) O 0 3.2265791601038263e-12
gene O 0 5.267535296837877e-10
on O 0 7.351260156163164e-10
chromosome O 0 1.0307762750016991e-05
20p13 O 0 4.99553777899564e-07
. O 0 4.706630640782805e-09

In O 0 5.503322686450929e-09
this O 0 3.028665165882849e-11
study O 0 4.852567306312672e-11
, O 0 4.127253747099324e-11
we O 0 4.170867817787638e-10
analyzed O 0 1.0351606238856448e-09
two O 0 2.982836200260408e-11
families O 0 2.5289907321091043e-11
with O 0 9.227561076352586e-11
FNDI B-Disease 1 0.9999865293502808
using O 0 6.31256921734824e-11
direct O 0 1.1563159284244673e-11
automated O 0 2.757781114581803e-09
fluorescent O 0 5.556756832447718e-09
, O 0 2.2882908068400099e-10
solid O 0 1.7450992872980464e-09
phase O 0 4.427310074106572e-09
, O 0 3.203426066078485e-11
single O 0 3.494481648491643e-10
- O 0 1.580317920968355e-08
stranded O 0 5.150049275925994e-10
DNA O 0 1.1289666979052981e-09
sequencing O 0 1.4311258775268065e-11
of O 0 2.0330217815212742e-13
PCR O 0 2.216194587845166e-07
- O 0 5.977928196898574e-08
amplified O 0 8.790699723704165e-08
AVP O 0 3.9584273281434434e-07
- O 0 1.890946350613376e-07
NPII O 0 6.49254559448309e-07
DNA O 0 2.9264588192745578e-06
. O 0 1.8949595226303018e-09

In O 0 2.5414594873041096e-09
one O 0 3.988386357289819e-11
of O 0 4.474049169339578e-13
the O 0 3.4361014034089976e-10
families O 0 6.03396221876551e-10
, O 0 1.8109709565283794e-10
affected O 0 6.145770004017947e-10
individuals O 0 3.845104573282909e-13
presented O 0 8.495198468294607e-12
a O 0 5.1625169417146566e-11
novel O 0 5.568727701188436e-08
nonsense O 0 9.552003575663548e-06
mutation O 0 1.2770982493748306e-08
in O 0 2.01222155257752e-12
exon O 0 2.922370434532695e-08
3 O 0 2.0328398964153394e-09
of O 0 1.3627218927933504e-12
the O 0 9.708508996730814e-11
gene O 0 4.9743345442720965e-08
, O 0 2.235490438595722e-11
consisting O 0 1.1096995718162805e-12
in O 0 1.517364879577432e-11
a O 0 4.518401486297563e-10
G O 0 8.000023080967367e-05
to O 0 5.341516562396009e-09
T O 0 3.892720997100696e-05
transition O 0 1.0343478962226982e-08
at O 0 2.985309555114668e-09
nucleotide O 0 3.209834531503475e-08
2101 O 0 2.5646061203588033e-06
, O 0 2.0204614370467056e-10
which O 0 8.6872063362331e-12
produces O 0 2.2334903024279207e-12
a O 0 8.117640240556945e-12
stop O 0 6.844059097232957e-09
signal O 0 3.907735468544615e-09
in O 0 3.518584035244743e-11
codon O 0 9.274598511410659e-08
82 O 0 1.0734572342130377e-08
( O 0 2.3901977619367187e-11
Glu O 0 4.718781838164432e-06
) O 0 1.009195418205655e-11
of O 0 9.938299315448429e-12
NPII O 0 0.0003091183607466519
. O 0 1.1244091879802909e-08

The O 0 2.38845618838468e-08
premature O 0 5.24743519747517e-08
termination O 0 1.6153151705111668e-08
eliminates O 0 1.8643119048533663e-08
part O 0 4.829098787517694e-10
of O 0 6.494180193605814e-12
the O 0 5.606751507514218e-09
C O 0 0.0016303888987749815
- O 0 3.3246037673961837e-06
terminal O 0 6.803946916988934e-07
domain O 0 5.894189136768091e-09
of O 0 9.587398149685233e-13
NPII O 0 1.4867525806039339e-06
, O 0 1.8200764246439904e-12
including O 0 7.323996416936859e-14
a O 0 9.558766538714236e-13
cysteine O 0 3.612848215039932e-11
residue O 0 8.156623820809727e-09
in O 0 4.991301469359222e-11
position O 0 1.4634464307050621e-08
85 O 0 1.1745600048129745e-09
, O 0 1.5840161127211871e-10
which O 0 8.868936141048778e-10
could O 0 2.30808421264328e-08
be O 0 3.485799496272257e-11
involved O 0 7.294546043590255e-12
in O 0 5.2274476414204685e-11
the O 0 1.435982721620377e-10
correct O 0 6.809659112150257e-07
folding O 0 6.097344567024265e-07
of O 0 7.24974420773794e-12
the O 0 9.152001934076281e-10
prohormone O 0 3.458471110207029e-05
. O 0 1.8588403705166456e-08

In O 0 1.982457575877561e-08
the O 0 9.026489555807871e-10
second O 0 2.379008279262962e-08
family O 0 4.81471473801065e-10
, O 0 9.49841008797414e-13
a O 0 2.9498820920681457e-13
G279A O 0 3.3216970840577176e-11
substitution O 0 6.1126212598516805e-12
at O 0 2.1959066509591452e-10
position O 0 1.0662615235190742e-09
- O 0 5.495266908184249e-09
1 O 0 5.0828360617649615e-12
of O 0 1.7204597799582236e-14
the O 0 7.450326705397969e-13
signal O 0 1.3586538838428197e-10
peptide O 0 1.0073036849078676e-10
was O 0 3.5400191111811807e-10
observed O 0 1.1931107490870119e-10
in O 0 9.043557569476945e-12
all O 0 4.62855066774015e-11
affected O 0 1.4205022713653648e-09
individuals O 0 1.0027275017254755e-11
. O 0 8.571117149358543e-10

This O 0 4.732565006548839e-09
missense O 0 4.917244496027706e-06
mutation O 0 7.333673238463234e-06
, O 0 1.0343316203531572e-09
which O 0 1.4285529426061316e-09
replaces O 0 4.067137524543796e-06
Ala O 0 6.689553993055597e-05
with O 0 7.032844528964688e-09
Thr O 1 0.9243553280830383
, O 0 8.578808774473146e-09
is O 0 8.539618318037512e-11
frequent O 0 2.299787560389177e-08
among O 0 6.411482900148258e-09
FNDI B-Disease 1 1.0
patients O 0 0.00011756542517105117
and O 0 7.736247198408819e-09
is O 0 4.0056558070489245e-10
thought O 0 6.516030026659791e-08
to O 0 3.9423939807159414e-11
reduce O 0 1.134271426783684e-10
the O 0 1.8245218703916155e-12
efficiency O 0 3.5959086402970186e-11
of O 0 3.3443381527650806e-13
cleavage O 0 6.88722394670549e-08
by O 0 9.8158651345992e-12
signal O 0 6.83481005125941e-09
peptidases O 0 6.047598333225324e-08
. O 0 2.0732097982811837e-10
. O 0 1.2813380356746507e-09

Genetic O 0 3.860458673443645e-05
heterogeneity O 0 1.379259629175067e-06
of O 0 3.2713500797143524e-09
Saethre B-Disease 1 0.9977532029151917
- I-Disease 1 0.9999810457229614
Chotzen I-Disease 1 0.9999898672103882
syndrome I-Disease 1 0.9999983310699463
, O 0 4.97742347338459e-10
due O 0 2.38625424975325e-10
to O 0 1.2775987212609863e-10
TWIST O 0 1.709382740955334e-05
and O 0 2.3854474306972406e-07
FGFR O 0 0.00047990569146350026
mutations O 0 1.1940873264393304e-05
. O 0 9.421222912919802e-09

Thirty O 0 5.381872369980556e-07
- O 0 6.872841368021909e-06
two O 0 5.933857849527158e-10
unrelated O 0 8.877876211954572e-09
patients O 0 3.9945340368774396e-09
with O 0 6.9373890312918185e-12
features O 0 1.4011105520239653e-07
of O 0 2.9661029188332577e-09
Saethre B-Disease 1 0.9999102354049683
- I-Disease 1 0.9999803304672241
Chotzen I-Disease 1 0.9999904632568359
syndrome I-Disease 1 0.9999977350234985
, O 0 1.7114823447350602e-10
a O 0 3.881476473566181e-09
common O 0 1.1221381100767758e-05
autosomal B-Disease 1 0.9992955923080444
dominant I-Disease 1 0.9673272967338562
condition I-Disease 0 0.17905418574810028
of O 0 1.8215585706471416e-09
craniosynostosis B-Disease 1 0.9999469518661499
and O 0 8.765382517594844e-05
limb B-Disease 1 0.9993808269500732
anomalies I-Disease 0 0.006358968559652567
, O 0 2.347995686768911e-10
were O 0 1.0933218913544707e-10
screened O 0 4.957371402269928e-07
for O 0 3.1936404909505e-11
mutations O 0 1.2992083497920248e-07
in O 0 5.077598896896518e-10
TWIST O 0 8.023670488910284e-06
, O 0 2.0976331782662783e-09
FGFR2 O 0 1.3651040717377327e-05
, O 0 6.479178860097079e-10
and O 0 6.1465703637964e-09
FGFR3 O 0 0.00015104655176401138
. O 0 1.2294179008165429e-08

Nine O 0 2.78262717756661e-07
novel O 0 2.3754607525461324e-07
and O 0 5.236316980017364e-08
three O 0 6.6894423333963e-10
recurrent O 0 5.357525878935121e-05
TWIST O 0 0.00011491923942230642
mutations O 0 6.786687299609184e-05
were O 0 1.8453356176451052e-08
found O 0 2.642569896238456e-08
in O 0 9.486221808074902e-10
12 O 0 2.9633320242083983e-09
families O 0 1.3626407779909755e-09
. O 0 1.6040986317022998e-09

Seven O 0 4.772825334953268e-08
families O 0 1.0275982148533203e-10
were O 0 3.453306737788431e-11
found O 0 2.1902137048446235e-10
to O 0 3.1147608797743587e-11
have O 0 9.453690053007335e-10
the O 0 1.2434649143688858e-10
FGFR3 O 0 1.580664684297517e-05
P250R O 0 2.0618859508658716e-08
mutation O 0 7.930382395215929e-08
, O 0 4.973020328868927e-10
and O 0 4.0726435557303375e-09
one O 0 1.3173554469503301e-09
individual O 0 3.254232647242894e-11
was O 0 1.4031336093012214e-07
found O 0 1.0310172271488227e-08
to O 0 4.4018455547245594e-10
have O 0 3.2953836881510767e-10
an O 0 1.1686660320031628e-11
FGFR2 O 0 3.076979965044302e-06
VV269 O 0 4.7890544863093965e-09
- O 0 2.496672202312311e-08
270 O 0 1.8269308288410002e-09
deletion O 0 4.738728023312433e-07
. O 0 6.857988843478324e-09

To O 0 3.646031698778529e-09
date O 0 3.452941488291117e-09
, O 0 8.0288536236095e-12
our O 0 1.6033804058762646e-12
detection O 0 7.396491752409418e-10
rate O 0 9.444535153946276e-10
for O 0 4.1802111360074445e-13
TWIST O 0 1.2266186786291655e-06
or O 0 1.348954015156778e-08
FGFR O 0 2.9334134524106048e-05
mutations O 0 7.359332698797516e-07
is O 0 3.9324826728304174e-10
68 O 0 3.476535681556925e-08
% O 0 9.323213208400905e-12
in O 0 7.999161888427864e-10
our O 0 2.7311341455060756e-07
Saethre B-Disease 1 0.9816513061523438
- I-Disease 1 0.999964714050293
Chotzen I-Disease 1 0.9999840259552002
syndrome I-Disease 1 0.9999983310699463
patients O 0 5.468220365401066e-07
, O 0 2.315930260066157e-11
including O 0 1.9843661436258486e-10
our O 0 3.84489453608694e-08
five O 0 1.0782624793037598e-09
patients O 0 1.5352752402719716e-10
elsewhere O 0 1.1774327346447677e-10
reported O 0 2.2861019743913857e-09
with O 0 3.199794318398119e-10
TWIST O 0 0.00012581842020154
mutations O 0 6.136811862234026e-05
. O 0 1.4719791607831212e-08

More O 0 6.46963038697379e-11
than O 0 3.2207689206614765e-12
35 O 0 3.722381430870669e-11
different O 0 3.896156834659603e-12
TWIST O 0 6.471972255894798e-07
mutations O 0 7.734611813248193e-07
are O 0 8.164211667827104e-11
now O 0 3.5894232031097317e-09
known O 0 1.0442410269817515e-09
in O 0 6.84175494036765e-11
the O 0 8.603592144273975e-11
literature O 0 6.534459640050727e-09
. O 0 4.290040322985078e-09

The O 0 3.0329516675919876e-09
most O 0 8.3368633177483e-12
common O 0 7.723688875971302e-12
phenotypic O 0 1.5504783013042811e-09
features O 0 1.4462804074355518e-06
, O 0 1.5916192808163032e-08
present O 0 4.698161304439452e-10
in O 0 3.8807915214711386e-11
more O 0 1.0102619695667725e-12
than O 0 2.3698832826712923e-11
a O 0 2.247982022751671e-09
third O 0 1.984604523386224e-06
of O 0 3.152673261341832e-11
our O 0 2.1757927015642053e-08
patients O 0 3.626353939356619e-10
with O 0 6.335750066949197e-12
TWIST O 0 9.436795153305866e-06
mutations O 0 8.098207217699382e-06
, O 0 1.7184659251157086e-10
are O 0 8.733526055126895e-12
coronal B-Disease 0 2.9030982204858446e-06
synostosis I-Disease 0 4.9788024625740945e-05
, O 0 1.6245651490720547e-09
brachycephaly B-Disease 0 1.508979494246887e-05
, O 0 1.0494709989927742e-08
low B-Disease 0 6.466863123932853e-05
frontal I-Disease 1 0.9999598264694214
hairline I-Disease 1 0.9999990463256836
, O 0 3.07430382235907e-05
facial B-Disease 1 0.9998646974563599
asymmetry I-Disease 1 0.8078586459159851
, O 0 1.8546351157056051e-06
ptosis B-Disease 1 0.9937352538108826
, O 0 8.26657569064082e-08
hypertelorism B-Disease 0 0.03315531834959984
, O 0 8.584115818166538e-08
broad B-Disease 0 8.09606135590002e-05
great I-Disease 0 5.017792864236981e-05
toes I-Disease 0 0.4046000838279724
, O 0 2.2835264790188603e-09
and O 0 9.2503915638531e-09
clinodactyly B-Disease 0 0.00010311018559150398
. O 0 1.0632036584468096e-08

Significant O 0 3.268152326540985e-08
intra O 0 2.527987419398414e-07
- O 0 0.0003087492659687996
and O 0 2.114045827283917e-08
interfamilial O 0 8.625710847809387e-07
phenotypic O 0 3.2285065287851467e-08
variability O 0 3.3492656825728773e-07
is O 0 7.623625342123574e-11
present O 0 8.541634413661292e-12
for O 0 2.2076084450067812e-12
either O 0 6.0130100898447836e-09
TWIST O 0 7.292426016647369e-05
mutations O 0 4.3704432755475864e-05
or O 0 7.834582760324338e-08
FGFR O 0 0.01335723977535963
mutations O 0 0.00026296015130355954
. O 0 2.8082407510510166e-08

The O 0 9.768496234130453e-09
overlap O 0 2.615507810332929e-07
in O 0 6.80652423312722e-10
clinical O 0 1.6986260220619442e-07
features O 0 5.170497274775698e-07
and O 0 2.387841675499658e-07
the O 0 2.12078932193549e-09
presence O 0 1.6980809647293427e-08
, O 0 2.0782617293768624e-10
in O 0 1.3277877061734777e-11
the O 0 1.0540351577659202e-11
same O 0 3.183629748715333e-11
genes O 0 6.189496137842809e-10
, O 0 4.75682947892464e-12
of O 0 6.473138268892759e-14
mutations O 0 1.4471363662948988e-08
for O 0 1.9744037134394876e-13
more O 0 3.9452260360527125e-13
than O 0 3.7449272849432447e-11
one O 0 1.0402636974049528e-08
craniosynostotic B-Disease 0 0.002088729524984956
condition I-Disease 0 5.482309643412009e-05
- O 0 5.6789183133787446e-08
such O 0 1.501819502092161e-11
as O 0 1.045386888165467e-09
Saethre B-Disease 0 4.628682290785946e-06
- I-Disease 0 1.6113690435304306e-06
Chotzen I-Disease 0 3.5850025597028434e-06
, I-Disease 0 2.169052992773146e-10
Crouzon I-Disease 0 3.554607701516943e-06
, I-Disease 0 2.348699901233431e-09
and I-Disease 0 2.1190076893162768e-07
Pfeiffer I-Disease 1 0.9987906813621521
syndromes I-Disease 1 0.6183517575263977
- O 0 5.795615379611263e-06
support O 0 1.4252400648562258e-10
the O 0 4.067189640633018e-11
hypothesis O 0 8.14903522439181e-09
that O 0 6.887529435672946e-11
TWIST O 0 5.170862209524785e-07
and O 0 5.153844906402583e-09
FGFRs O 0 4.041399677134905e-07
are O 0 1.8443606017437553e-12
components O 0 4.765061678568827e-10
of O 0 8.403239584210687e-13
the O 0 6.813054287402309e-11
same O 0 3.9880210245257786e-11
molecular O 0 2.4542954335515788e-09
pathway O 0 1.3464213077796217e-09
involved O 0 3.325638375795137e-12
in O 0 2.3573133462601037e-12
the O 0 7.629018076993344e-12
modulation O 0 1.3784882568756984e-08
of O 0 7.087324616072976e-10
craniofacial O 1 0.9998294115066528
and O 0 1.3992711501487065e-05
limb O 1 0.9925855994224548
development O 0 1.2083395972695143e-07
in O 0 2.0902244379783497e-09
humans O 0 2.2230864260563976e-08
. O 0 4.2595826171831774e-11
. O 0 1.0295271302140918e-09

Mutation O 0 2.26794213631365e-06
analysis O 0 1.1389161613806209e-08
of O 0 1.3004294308061048e-09
UBE3A O 1 0.8321614861488342
in O 0 0.23931021988391876
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.003966540563851595
. O 0 3.944220239304741e-08

Angelman B-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
( O 0 2.8744070732500404e-05
AS B-Disease 1 0.9999958276748657
) O 0 1.4620067823045702e-08
is O 0 1.980196895345898e-09
caused O 0 1.7697066923005877e-08
by O 0 2.864040393735223e-10
chromosome O 0 0.002584826434031129
15q11 O 0 4.090343736606883e-06
- O 0 1.2197211617603898e-05
q13 O 0 7.663246748279562e-08
deletions O 0 8.701966436319708e-08
of O 0 6.474629860031555e-11
maternal O 0 5.855555400557932e-07
origin O 0 3.6383601687006717e-10
, O 0 5.5104594498534e-11
by O 0 3.439738771593426e-11
paternal O 0 4.48300534117152e-06
uniparental B-Disease 0 0.039697811007499695
disomy I-Disease 0 0.05809913948178291
( O 0 4.436213174585646e-08
UPD B-Disease 1 0.9999977350234985
) O 0 1.0402670946874082e-09
15 O 0 1.0520913307221491e-10
, O 0 5.597788725608677e-12
by O 0 1.5880628409514763e-11
imprinting O 0 0.4653375446796417
defects O 1 0.9999494552612305
, O 0 2.791113784539334e-09
and O 0 1.050900588772663e-09
by O 0 1.00383597267939e-10
mutations O 0 3.9994156963985006e-07
in O 0 2.1352540569008482e-10
the O 0 5.895501864472408e-10
UBE3A O 0 1.0979174476233311e-05
gene O 0 1.0208807452727342e-06
. O 0 2.100284390849083e-08

UBE3A O 0 5.72054268559441e-05
encodes O 0 6.934862284424526e-08
a O 0 6.093106574844853e-10
ubiquitin O 0 1.630460921830945e-08
- O 0 1.564689284805354e-07
protein O 0 3.606311249626515e-09
ligase O 0 2.2979536051792593e-09
and O 0 1.3353531613802261e-08
shows O 0 4.2260779764546896e-07
brain O 0 6.678610225208104e-05
- O 0 1.0708681656979024e-06
specific O 0 1.978973651617366e-09
imprinting O 0 0.00035313767148181796
. O 0 3.768334622122893e-08

Here O 0 2.059021682043749e-07
we O 0 3.858468655693059e-09
describe O 0 4.304868017612762e-09
UBE3A O 0 2.7124344796902733e-06
coding O 0 0.003041965188458562
- O 0 0.004143118392676115
region O 0 8.135239113471471e-07
mutations O 0 2.2113009379154391e-07
detected O 0 8.161292974762091e-09
by O 0 2.0481318464132814e-12
SSCP O 0 9.710093991088797e-07
analysis O 0 3.878974919047096e-09
in O 0 1.011950967466646e-09
13 O 0 2.871000504001131e-08
AS B-Disease 1 0.9999920129776001
individuals O 0 1.7500449700502685e-10
or O 0 3.6264937719465706e-09
families O 0 2.0049686355605445e-09
. O 0 3.065439013738569e-09

Two O 0 4.6717428148213e-08
identical O 0 6.403370775842632e-07
de O 0 5.446715789503287e-08
novo O 0 6.725666708007338e-07
5 O 0 5.146857939841709e-10
- O 0 2.0308688419845566e-07
bp O 0 2.3164815843301767e-08
duplications O 0 3.324344888255837e-08
in O 0 4.1731652855592216e-11
exon O 0 7.76541853042545e-08
16 O 0 6.1513087956655e-09
were O 0 5.889398968506043e-10
found O 0 6.986251577245639e-09
. O 0 3.4330960296813373e-09

Among O 0 2.59283106096575e-09
the O 0 2.891957506800935e-11
other O 0 3.589438208467799e-12
11 O 0 5.3904127689241577e-11
unique O 0 1.115562156539518e-10
mutations O 0 8.839296015139553e-07
, O 0 1.1939232935631594e-10
8 O 0 2.271553084520761e-10
were O 0 4.144948620443678e-11
small O 0 5.922740076158561e-11
deletions O 0 2.3621977618404344e-07
or O 0 1.1718462644694227e-08
insertions O 0 2.3991731723072007e-05
predicted O 0 6.272233440540731e-05
to O 0 1.3541535892613865e-08
cause O 0 2.3275360305774484e-08
frameshifts O 0 3.5085700801573694e-05
, O 0 9.921377053245806e-10
1 O 0 3.0465230338450056e-10
was O 0 4.311608492457708e-08
a O 0 1.3094662854040706e-10
mutation O 0 1.7724056888823725e-08
to O 0 2.457365734509498e-11
a O 0 2.9834849868404234e-11
stop O 0 4.8044821454595876e-08
codon O 0 1.4753464228078883e-08
, O 0 3.5976169959761606e-11
1 O 0 4.479407816893044e-11
was O 0 3.0602222977904603e-09
a O 0 2.2610824670921126e-11
missense O 0 1.0336547120459727e-06
mutation O 0 1.5040282050904352e-06
, O 0 1.3556337163933563e-09
and O 0 3.6020286753313258e-09
1 O 0 3.6161540428736316e-09
was O 0 1.7666278608885477e-06
predicted O 0 9.681234587333165e-07
to O 0 3.4715558205888897e-10
cause O 0 1.0242754561184952e-10
insertion O 0 2.770867535417665e-09
of O 0 4.393220509602003e-11
an O 0 8.164281695144382e-09
isoleucine O 1 0.8667418956756592
in O 0 5.843678874128955e-10
the O 0 4.148950974447452e-11
hect O 0 7.976605331805331e-08
domain O 0 1.95077998199622e-09
of O 0 1.4876948414496716e-12
the O 0 1.4769667433522926e-10
UBE3A O 0 5.106566618451325e-07
protein O 0 1.2120833225992556e-08
, O 0 1.4472942809484746e-11
which O 0 1.982400571823306e-12
functions O 0 3.350008638547397e-12
in O 0 9.546236197366387e-12
E2 O 0 2.9206875140630473e-08
binding O 0 2.375450947056379e-10
and O 0 3.504692716593816e-11
ubiquitin O 0 7.518617395341209e-10
transfer O 0 1.2978770280724916e-09
. O 0 6.3154903529039075e-09

Eight O 0 7.0283792119596455e-09
of O 0 1.3656959677726954e-12
the O 0 1.6424096457856585e-11
cases O 0 1.877567129549007e-10
were O 0 1.2491041534445912e-09
familial O 0 2.7269405109109357e-05
, O 0 1.7490455306301556e-08
and O 0 3.929568226368474e-09
five O 0 9.270623158030844e-11
were O 0 1.8437151805272833e-10
sporadic O 0 2.4304600287905487e-07
. O 0 1.9967643538620905e-08

In O 0 1.7808638119731768e-08
two O 0 2.959111566891437e-10
familial O 0 5.369346126826713e-06
cases O 0 4.685512422497595e-08
and O 0 1.8009215452252647e-08
one O 0 3.7767569627256137e-10
sporadic O 0 3.008645137470012e-07
case O 0 2.189759129578306e-07
, O 0 5.665918845210172e-10
mosaicism O 0 1.3571370800491422e-06
for O 0 2.6512899514719024e-11
UBE3A O 0 4.9978621063928585e-06
mutations O 0 3.0699102353537455e-06
was O 0 1.7765044546536046e-08
detected O 0 3.281576255176333e-07
in O 0 2.110550623157792e-10
the O 0 3.1983438120164465e-09
mother O 0 3.925857527065091e-06
of O 0 1.0097634534078637e-11
three O 0 2.6435714062245097e-07
AS B-Disease 1 0.9999998807907104
sons O 0 2.941186357929837e-05
, O 0 1.360998397315072e-10
in O 0 2.4184971733620664e-11
the O 0 4.847833245946731e-10
maternal O 0 4.099127579593187e-07
grandfather O 0 5.075647990793186e-08
of O 0 1.6559660543855048e-12
two O 0 5.078076181774804e-09
AS B-Disease 1 0.9999964237213135
first O 0 6.02721570430731e-08
cousins O 0 6.449288775911555e-06
, O 0 2.1458295140774908e-09
and O 0 4.40761915854182e-09
in O 0 9.53136347625616e-10
the O 0 2.348377270422475e-09
mother O 0 5.605374440165178e-07
of O 0 1.124902579939524e-12
an O 0 8.417533337023997e-09
AS B-Disease 1 0.9999991655349731
daughter O 0 0.0049973903223872185
. O 0 1.972944296824153e-08

The O 0 3.469338150097201e-10
frequencies O 0 1.7700163557066162e-09
with O 0 1.1898336482740746e-10
which O 0 5.542358794130564e-10
we O 0 3.479324606203704e-10
detected O 0 1.3279561894563585e-09
mutations O 0 2.86881474131917e-09
were O 0 2.7046856074242065e-11
5 O 0 5.6281642540900734e-11
( O 0 4.064395955211131e-12
14 O 0 1.7705049926153293e-10
% O 0 1.0075409473744856e-12
) O 0 6.030984630971126e-13
of O 0 2.668195525634687e-13
35 O 0 1.1314889025726416e-09
in O 0 1.3297898372732764e-11
sporadic O 0 3.175326668269918e-08
cases O 0 5.461859853284068e-09
and O 0 9.495585651109195e-09
8 O 0 2.0256754051928283e-09
( O 0 3.1772830894061244e-12
80 O 0 7.441912364125614e-11
% O 0 7.973775285885498e-12
) O 0 2.1194192234563758e-12
of O 0 4.5386841529028443e-13
10 O 0 1.705271618357429e-10
in O 0 1.595648196905941e-10
familial O 0 2.828544438671088e-06
cases O 0 1.8747421393072727e-08
. O 0 6.33234908953284e-10
. O 0 2.946705324191612e-09

The O 0 1.2499036472490843e-07
hemochromatosis B-Disease 1 0.9999303817749023
845 O 0 1.9150411390000954e-06
G O 0 3.1185340048978105e-05
- O 0 1.048402509695734e-06
- O 0 5.570926191467152e-07
> O 0 1.5327362712369563e-09
A O 0 5.239888523078662e-10
and O 0 3.722963604069207e-11
187 O 0 1.278656763803454e-10
C O 0 1.2804686093659257e-06
- O 0 1.5195673768175766e-06
- O 0 1.595684625499416e-05
> O 0 1.2559820561364177e-07
G O 0 2.834079168678727e-05
mutations O 0 1.045595695359225e-06
: O 0 1.5408196940569496e-10
prevalence O 0 1.5416081851071795e-06
in O 0 4.491318705834857e-10
non O 0 1.3335561988014888e-08
- O 0 0.002414492890238762
Caucasian O 0 0.0014187617925927043
populations O 0 2.275281531183282e-06
. O 0 2.0513564180646426e-09

Hemochromatosis B-Disease 1 0.9980499744415283
, O 0 1.818599230318796e-05
the O 0 2.561971814429853e-05
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 0 1.7341573510520902e-08
iron I-Disease 1 0.937693178653717
metabolism I-Disease 0 0.3548004925251007
, O 0 1.6173004269148805e-08
leads O 0 6.676153248008632e-07
, O 0 6.118031414814595e-09
if O 0 5.273130341265642e-07
untreated O 0 1.8908820493379608e-05
, O 0 4.420647875535977e-11
to O 0 5.63177504631085e-10
progressive O 0 1.0880120271394844e-06
iron B-Disease 1 0.9726203083992004
overload I-Disease 1 0.6469014286994934
and O 0 6.699413575006474e-07
premature B-Disease 0 7.691140240240202e-07
death I-Disease 0 2.51797558803446e-07
. O 0 4.1439407461041355e-09

The O 0 4.486931004521466e-07
hemochromatosis B-Disease 1 0.999984860420227
gene O 0 0.00039593243855051696
, O 0 5.556799020922654e-09
HFE O 0 0.00029628348420374095
, O 0 7.0429395648829995e-09
recently O 0 2.930123912392446e-07
has O 0 7.453994754769155e-09
been O 0 2.918000840956836e-10
identified O 0 1.448613762278228e-08
, O 0 4.099480130359545e-11
and O 0 1.1949531641963773e-10
characterization O 0 1.3200428838899825e-07
of O 0 1.964551568298112e-12
this O 0 5.4667111115680456e-11
gene O 0 3.149883696096367e-07
has O 0 2.992374845689483e-07
shown O 0 7.1182295613425595e-09
that O 0 1.435638274926987e-09
it O 0 7.180844807663789e-10
contains O 0 1.430941060087676e-10
two O 0 1.940659632992947e-09
mutations O 0 1.3480198504112195e-06
that O 0 1.755816714243963e-09
result O 0 8.327813993957989e-10
in O 0 1.757547232750234e-11
amino O 0 1.904796875784598e-10
acid O 0 3.878105475640936e-11
substitutions O 0 5.794791296115376e-12
- O 0 1.17938658839023e-09
cDNA O 0 7.036168314655811e-10
nucleotides O 0 6.971712096515148e-10
845 O 0 2.9753033370383264e-10
G O 0 2.6528323360253125e-07
- O 0 1.7880223879274126e-07
- O 0 5.441854682430858e-07
> O 0 1.3104562990307045e-09
A O 0 3.0087796143440926e-10
( O 0 5.050315092340607e-13
C282Y O 0 6.076020936385262e-11
) O 0 1.4311953857280846e-13
and O 0 7.340698144828184e-13
187 O 0 3.0888715196741856e-11
C O 0 7.441396974172676e-07
- O 0 1.7957630689124926e-06
- O 0 1.0594429113552906e-05
> O 0 7.434318405330487e-08
G O 0 8.860979505698197e-06
( O 0 4.096768063677203e-11
H63D O 0 6.349504815261753e-07
) O 0 9.402525286139607e-11
. O 0 3.3611935457145137e-10

Although O 0 1.6063877410488203e-05
hemochromatosis B-Disease 1 0.9999982118606567
is O 0 5.753525655904923e-08
common O 0 1.4482843813112822e-09
in O 0 5.5935013565378e-11
Caucasians O 0 1.4311602853922523e-06
, O 0 8.831457093405604e-11
affecting O 0 1.0044378662144027e-09
> O 0 5.58677086814896e-08
= O 0 2.5977858513215324e-06
1 O 0 3.656252800521287e-10
/ O 0 1.153577045442944e-06
300 O 0 2.3284561778691426e-11
individuals O 0 3.454240582803636e-12
of O 0 2.1361356693921918e-12
northern O 0 2.3974785108293872e-06
European O 0 4.9556692971464145e-08
origin O 0 5.338223751927273e-10
, O 0 1.5995097468746167e-09
it O 0 7.1148766878081915e-09
has O 0 7.223116327281787e-09
not O 0 5.581663464759856e-10
been O 0 9.507282461296285e-11
recognized O 0 2.188800876656849e-11
in O 0 1.0437601304091881e-11
other O 0 4.3444071257114913e-11
populations O 0 4.10877021295164e-08
. O 0 3.2497702306955034e-09

The O 0 9.620126917297966e-10
present O 0 3.1100042246351434e-12
study O 0 1.066381900317881e-12
used O 0 1.7752179934382717e-11
PCR O 0 1.3943645171821117e-06
and O 0 1.0550137430342943e-09
restriction O 0 8.849242760788911e-08
- O 0 1.4910917798260925e-06
enzyme O 0 4.474257053743713e-08
digestion O 0 6.384260586855817e-08
to O 0 3.4506581619853094e-12
analyze O 0 2.7883070852219305e-11
the O 0 1.799598610321279e-13
frequency O 0 5.708905917445328e-11
of O 0 2.0456984088472463e-13
the O 0 4.6052653877859395e-12
845 O 0 4.414002496844205e-10
G O 0 4.0820248159434414e-07
- O 0 8.939544215991191e-08
- O 0 9.69989670807081e-08
> O 0 3.681809856992402e-10
A O 0 2.848024871493493e-10
and O 0 3.8635240839912655e-11
187 O 0 4.636060979557044e-11
C O 0 1.488214991240966e-07
- O 0 2.0175757242668624e-07
- O 0 4.212425324112701e-07
> O 0 5.771889188821433e-09
G O 0 3.8894455656190985e-07
mutations O 0 1.64754201392725e-08
in O 0 1.3815341232126244e-11
HLA O 0 1.063588911165425e-06
- O 0 8.328043321625955e-08
typed O 0 1.6235064848046932e-08
samples O 0 8.623245451033767e-10
from O 0 7.768881024605712e-13
non O 0 1.0198678707107334e-10
- O 0 1.7127908904512879e-06
Caucasian O 0 1.0302102054993156e-05
populations O 0 9.100902786940424e-08
, O 0 3.841653991448757e-12
comprising O 0 6.949092451642713e-13
Australian O 0 3.557190653147302e-10
Aboriginal O 0 1.8810368540567168e-10
, O 0 1.267964682902245e-12
Chinese O 0 5.437725356799428e-12
, O 0 2.137843504654291e-12
and O 0 9.659138072715123e-11
Pacific O 0 1.7896796933314363e-08
Islanders O 0 7.039060534452801e-08
. O 0 2.351428496361052e-10

Results O 0 3.3645856092334725e-06
showed O 0 3.1939013211967904e-08
that O 0 2.1502357186453658e-11
the O 0 3.8079431101400996e-12
845 O 0 7.276824920410263e-09
G O 0 1.3515029422705993e-05
- O 0 2.3583986603625817e-06
- O 0 1.3448740219246247e-06
> O 0 4.164788514060547e-09
A O 0 1.7091931203694344e-09
mutation O 0 4.390111030261323e-08
was O 0 7.284462810730474e-09
present O 0 6.452878596047151e-12
in O 0 6.0586128128314876e-12
these O 0 2.216121817305572e-12
populations O 0 1.4052481400739225e-11
( O 0 2.6623785438100768e-14
allele O 0 2.001740353335668e-12
frequency O 0 3.045332042095339e-10
0 O 0 5.830404908868658e-11
. O 0 1.0195613884406152e-12
32 O 0 2.5545007081850812e-11
% O 0 7.357701687499274e-13
) O 0 1.467698879098478e-11
, O 0 4.0498210340800256e-10
and O 0 1.5425943189484315e-08
, O 0 6.050973611060328e-10
furthermore O 0 1.0661135974032732e-08
, O 0 1.1428492874276941e-10
it O 0 8.477244684002017e-09
was O 0 2.396266438609018e-07
always O 0 9.524934618809766e-09
seen O 0 2.1248208748048114e-10
in O 0 4.051391112782493e-13
conjunction O 0 2.3029182727452024e-11
with O 0 1.5944130737910456e-10
HLA O 0 7.524440297856927e-05
haplotypes O 0 9.71516897152469e-07
common O 0 3.391160063870302e-08
in O 0 4.244143925191679e-10
Caucasians O 0 6.271175152505748e-07
, O 0 8.318502137116823e-12
suggesting O 0 1.0836823105542237e-10
that O 0 6.071607105972987e-11
845 O 0 8.859320388410197e-09
G O 0 0.000373198272427544
- O 0 0.0001486281689722091
- O 0 7.385588833130896e-05
> O 0 1.1385864695512282e-07
A O 0 2.9668973411389743e-07
may O 0 2.6019531418342012e-08
have O 0 9.413920337708603e-11
been O 0 4.128434399897074e-11
introduced O 0 8.151856273341807e-11
into O 0 3.1989261933818014e-11
these O 0 6.798317551265365e-12
populations O 0 2.1403834260524945e-10
by O 0 1.0932128466367708e-11
Caucasian O 0 2.8273659609112656e-06
admixture O 0 2.542120682846871e-07
. O 0 1.3170949664242926e-08

187 O 0 1.874320787464967e-07
C O 0 1.5531717508565634e-05
- O 0 1.73517503299081e-06
- O 0 4.250453002896393e-06
> O 0 9.850224813590103e-08
G O 0 1.5006447029008996e-05
was O 0 1.0439885400614912e-08
present O 0 3.177598375397883e-12
at O 0 6.3540605069190015e-12
an O 0 2.374204890846776e-14
allele O 0 5.20390805100468e-12
frequency O 0 2.477136551437553e-10
of O 0 2.5842956247190685e-12
2 O 0 9.082708807284234e-09
. O 0 4.798563768559916e-09

68 O 0 4.555683517537545e-06
% O 0 3.351405541973662e-10
in O 0 1.1884788292393367e-11
the O 0 2.6940331909752757e-11
two O 0 7.899513682074755e-11
populations O 0 4.125101149554666e-09
analyzed O 0 1.4417557814283555e-08
( O 0 1.4624424934939206e-11
Australian O 0 3.0694952357634975e-08
Aboriginal O 0 5.928897905960184e-08
and O 0 3.6365443989438972e-09
Chinese O 0 3.5724825875327326e-10
) O 0 4.6359107525040244e-11
. O 0 4.316549617744414e-10

In O 0 1.33906608024148e-09
the O 0 2.1351713799799832e-11
Australian O 0 2.3396404258413384e-10
Aboriginal O 0 1.2661462156504655e-10
samples O 0 2.8081292499648747e-11
, O 0 8.563942198620833e-14
187 O 0 1.5299103997556962e-11
C O 0 3.173077800511237e-07
- O 0 3.807638790931378e-07
- O 0 1.0825482377185836e-06
> O 0 1.1662539378676229e-08
G O 0 1.1432042811065912e-05
was O 0 2.919228414555164e-08
found O 0 1.7148611697326288e-10
to O 0 1.1611604906758277e-11
be O 0 7.657693923412978e-12
associated O 0 5.008734746403398e-11
with O 0 1.0751526752228457e-10
HLA O 0 0.0015171379782259464
haplotypes O 0 1.0889358463828103e-06
common O 0 1.6162520211082665e-08
in O 0 2.73352257496029e-10
Caucasians O 0 2.947929033325636e-06
, O 0 1.5334461478389017e-10
suggesting O 0 1.391685988672009e-09
that O 0 6.793333673371649e-10
it O 0 7.419537206843074e-10
was O 0 7.552826142287472e-10
introduced O 0 1.9663293562843798e-11
by O 0 1.4047516405310545e-12
recent O 0 1.352758183248426e-10
admixture O 0 6.687917419867517e-08
. O 0 7.597562579064743e-09

In O 0 1.8136888657593886e-09
the O 0 2.0835951020092836e-11
Chinese O 0 1.6125451668402846e-11
samples O 0 3.778923701736048e-11
analyzed O 0 4.915249110504227e-11
, O 0 7.222495713478383e-13
187 O 0 4.1126685390580064e-11
C O 0 3.473805065823399e-07
- O 0 4.0892760466704203e-07
- O 0 2.2507219910039566e-06
> O 0 2.87757924155585e-08
G O 0 0.00014356688188854605
was O 0 7.478505494873389e-07
present O 0 1.0344494705272211e-10
in O 0 1.0647732695545642e-10
association O 0 4.772487526699676e-12
with O 0 4.272526343135352e-12
a O 0 2.0298671077334518e-10
wide O 0 3.9075866986593155e-09
variety O 0 8.757622405042298e-10
of O 0 2.0653870280717967e-10
HLA O 0 0.0016198286321014166
haplotypes O 0 2.1731937067670515e-06
, O 0 1.359405504830491e-10
showing O 0 1.913712743828455e-09
this O 0 1.1748814594814139e-11
mutation O 0 8.877369062076923e-09
to O 0 1.9483693824984272e-10
be O 0 9.531322259226371e-11
widespread O 0 1.7727658230271004e-10
and O 0 8.326883715881195e-08
likely O 0 3.6300926709031955e-09
to O 0 1.6670205146840367e-11
predate O 0 1.5980506873347622e-07
the O 0 2.2613499614521082e-11
more O 0 4.4591828602009997e-13
genetically O 0 1.5907383188462632e-09
restricted O 0 1.6188830276320232e-09
845 O 0 1.548829864361778e-08
G O 0 5.682374467141926e-05
- O 0 1.0586289135972038e-05
- O 0 7.59272097639041e-06
> O 0 6.15367889977847e-09
A O 0 6.8990537727131596e-09
mutation O 0 4.238315796101233e-07
. O 0 3.1069200545630338e-09

Genotype O 0 0.00023345527006313205
- O 0 0.00045816480997018516
phenotype O 0 8.078369864961132e-05
correlations O 0 4.552715108729899e-05
in O 0 3.64189844503926e-07
attenuated B-Disease 1 0.9986876845359802
adenomatous I-Disease 1 0.99998939037323
polyposis I-Disease 1 0.9999589920043945
coli I-Disease 1 0.9999943971633911
. O 0 2.3809161575627513e-05

Germ O 0 0.0771736204624176
- O 0 0.0021350577007979155
line O 0 7.223463762784377e-05
mutations O 0 1.0962886420884388e-07
of O 0 2.030461302565678e-12
the O 0 2.384493713591951e-10
tumor B-Disease 0 1.9436556613072753e-06
suppressor O 0 2.0149337842667592e-07
APC O 0 1.3299165857461048e-07
are O 0 2.4918361818393464e-10
implicated O 0 1.0789068483063602e-06
in O 0 3.1729341571917757e-06
attenuated B-Disease 1 0.9999750852584839
adenomatous I-Disease 1 0.9999994039535522
polyposis I-Disease 1 0.9999961853027344
coli I-Disease 1 0.9999998807907104
( O 0 0.00024639585171826184
AAPC B-Disease 1 0.9999994039535522
) O 0 1.230762247672601e-08
, O 0 4.439024842151085e-11
a O 0 2.556441724976821e-10
variant O 0 0.008064680732786655
of O 0 2.478196438460145e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999850988388062
polyposis I-Disease 1 0.9999988079071045
( O 0 1.213156224366685e-06
FAP B-Disease 0 2.6655616238713264e-05
) O 0 8.40781044786354e-09
. O 0 1.0686115103908378e-08

AAPC B-Disease 1 0.9998784065246582
is O 0 2.4834070799784058e-08
recognized O 0 5.3960086399129636e-11
by O 0 3.913689684831301e-12
the O 0 6.009446846394484e-12
occurrence O 0 6.414919706543287e-09
of O 0 7.892566808442858e-12
< O 0 8.0078530118044e-07
100 O 0 2.334461735031823e-09
colonic B-Disease 0 0.00011465566058177501
adenomas I-Disease 0 0.00011743063805624843
and O 0 1.616973577256431e-08
a O 0 1.8676351576374373e-09
later O 0 1.6562527207497624e-06
onset O 0 0.0032845342066138983
of O 0 0.00041129448800347745
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.2731241838537244e-08
age O 0 9.304094383821848e-09
> O 0 2.9710855997677754e-09
40 O 0 1.7193685364347289e-09
years O 0 4.001410314202758e-10
) O 0 2.0092551233918954e-10
. O 0 1.8393081502310338e-09

The O 0 1.5739948011628258e-08
aim O 0 1.470146226978386e-09
of O 0 3.790383263334307e-13
this O 0 2.0876354030890942e-12
study O 0 8.586424106449275e-12
was O 0 1.175263081298894e-10
to O 0 2.7707788320674442e-12
assess O 0 7.497909515485901e-10
genotype O 0 1.6866669838577764e-08
- O 0 3.82778353014146e-06
phenotype O 0 2.825104502335307e-06
correlations O 0 5.722977789446304e-07
in O 0 1.5005655029654008e-07
AAPC B-Disease 1 0.9999954700469971
families O 0 3.3645264352344384e-07
. O 0 5.999960972502549e-09

By O 0 4.924523011595738e-10
protein O 0 9.810358747586179e-09
- O 0 1.4267027381720254e-06
truncation O 0 3.220925646019168e-05
test O 0 2.5272211132687517e-06
( O 0 5.223309198360004e-12
PTT O 0 6.464653701243606e-09
) O 0 2.768581154263816e-12
assay O 0 1.1067272653875193e-09
, O 0 9.340937311835829e-13
the O 0 9.73521935808408e-13
entire O 0 1.375871194753131e-09
coding O 0 3.343735443195328e-05
region O 0 3.895167299816649e-09
of O 0 2.1850946887395223e-13
the O 0 9.26301830378451e-12
APC B-Disease 0 1.573771779561639e-09
gene O 0 2.0609109085967248e-08
was O 0 5.221755827733432e-08
screened O 0 3.971616138187528e-07
in O 0 1.7482233716226148e-10
affected O 0 2.263466525320723e-09
individuals O 0 1.2748760380709712e-12
from O 0 3.5314123153495913e-11
11 O 0 7.289245900210517e-07
AAPC B-Disease 1 0.9999995231628418
kindreds O 0 0.01806574873626232
, O 0 1.8029769677241347e-08
and O 0 1.7597595602936167e-09
their O 0 1.468762958478642e-11
phenotypic O 0 1.2718183839410813e-08
differences O 0 4.1341930767657686e-08
were O 0 5.054025198347745e-09
examined O 0 5.112889994052239e-06
. O 0 8.350976798965348e-09

Five O 0 5.19861096393015e-08
novel O 0 1.0873858968807326e-07
germ O 0 0.0011661212192848325
- O 0 0.000721293909009546
line O 0 2.903084532590583e-05
APC B-Disease 0 3.708079532316333e-08
mutations O 0 5.972628969175275e-08
were O 0 1.0906517355913081e-10
identified O 0 1.4985511498366577e-08
in O 0 4.438968081998951e-10
seven O 0 1.0360776236950642e-08
kindreds O 0 0.00013855856377631426
. O 0 1.521842207807822e-08

Mutations O 0 0.0004753925313707441
were O 0 1.0186343324392055e-08
located O 0 6.510797234682286e-09
in O 0 2.5757441318718932e-11
three O 0 1.6628287288766863e-11
different O 0 9.420610992683098e-13
regions O 0 1.6948209502487543e-10
of O 0 4.451331339118403e-13
the O 0 7.084671044266244e-11
APC B-Disease 0 1.6201370245383373e-09
gene O 0 5.927277779704809e-09
( O 0 2.1978864041261037e-12
1 O 0 3.644915619327449e-11
) O 0 3.925504019064441e-11
at O 0 1.962876527983326e-09
the O 0 7.664156809195077e-11
5 O 0 6.873071001223252e-10
end O 0 1.099525026582171e-09
spanning O 0 3.4873057774831295e-09
exons O 0 6.228689812814991e-07
4 O 0 6.710262567821701e-09
and O 0 6.458294343758553e-09
5 O 0 6.573508959384355e-10
, O 0 5.156524165994547e-11
( O 0 1.0489765523216676e-12
2 O 0 7.1364893161618426e-12
) O 0 7.159595724441636e-13
within O 0 6.297121569846797e-13
exon O 0 5.670083957909355e-09
9 O 0 1.973471164262719e-08
, O 0 3.4035721463432367e-10
and O 0 2.7328670437754e-09
( O 0 4.262652730790961e-12
3 O 0 7.407645052914802e-10
) O 0 1.2164337592768248e-10
at O 0 1.0986870968565654e-08
the O 0 6.364542920467287e-11
3 O 0 1.7863538426254877e-09
distal O 0 1.729586358578672e-07
end O 0 4.170195921915365e-08
of O 0 1.8810996597201646e-12
the O 0 1.5302059619415331e-10
gene O 0 8.214760782720987e-07
. O 0 8.915973737089189e-09

Variability O 0 0.00018199675832875073
in O 0 5.556605731094066e-10
the O 0 4.911144754760066e-11
number O 0 1.4755286992240713e-09
of O 0 5.709208039661462e-07
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 0.09917769581079483
most O 0 1.901498514200739e-09
apparent O 0 2.9389607192342737e-08
in O 0 6.333871205299602e-10
individuals O 0 4.8936007156219485e-12
with O 0 3.961511396699535e-10
mutations O 0 3.486148671072442e-06
in O 0 1.4498597877832253e-09
region O 0 1.0335280364870414e-07
1 O 0 7.005747093558057e-09
, O 0 2.0938207612175574e-08
and O 0 1.2470762840166572e-06
upper O 1 0.9854075312614441
- O 1 0.9999436140060425
gastrointestinal O 1 0.5439922213554382
manifestations O 0 8.397778401558753e-07
were O 0 6.691155629567902e-09
more O 0 1.6498673260922914e-10
severe O 0 4.987311967852293e-07
in O 0 6.119568740636794e-10
them O 0 6.916313299853982e-09
. O 0 1.9754482494249714e-08

In O 0 1.015940664927939e-09
individuals O 0 7.675489584191286e-12
with O 0 3.021764088950718e-11
mutations O 0 1.9711619358986354e-07
in O 0 2.1685565843032606e-10
either O 0 4.831868238852621e-08
region O 0 2.3305885576974106e-07
2 O 0 2.7753964459975577e-08
or O 0 4.532250841293717e-08
region O 0 1.258954966942838e-07
3 O 0 1.3351951544393614e-08
, O 0 7.285500536191591e-10
the O 0 8.62121832256868e-11
average O 0 3.2962907958733467e-09
number O 0 5.8030902999606226e-11
of O 0 3.491794700605233e-11
adenomas B-Disease 0 0.00016612430044915527
tended O 0 5.29375574842561e-06
to O 0 1.5233864170127731e-09
be O 0 4.038628598213023e-10
lower O 0 1.9012809104879125e-09
than O 0 3.8266275564913244e-11
those O 0 3.831908401696893e-11
in O 0 1.0719113791024526e-10
individuals O 0 1.9181717846039614e-12
with O 0 1.0611401340954174e-10
mutations O 0 8.982201507024001e-07
in O 0 1.5008529974380735e-09
region O 0 6.302857258333461e-08
1 O 0 1.9900792125326916e-09
, O 0 5.470833785992113e-10
although O 0 8.972731890821706e-09
age O 0 2.056464998290153e-09
at O 0 1.3541149535001296e-08
diagnosis O 0 5.2194347517797723e-05
was O 0 3.955964000823542e-09
similar O 0 9.796330413536225e-10
. O 0 1.7709425037537585e-08

In O 0 8.173088872354128e-08
all O 0 8.922285132939578e-09
AAPC B-Disease 1 0.9999587535858154
kindreds O 0 0.000632463488727808
, O 0 6.135768004789099e-10
a O 0 1.376352764398403e-11
predominance O 0 2.8915041028199084e-08
of O 0 3.523837888153025e-10
right O 1 0.7751208543777466
- O 1 0.9999842643737793
sided O 1 0.9999991655349731
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999998807907104
and O 0 0.057611264288425446
rectal B-Disease 1 0.9999138116836548
polyp I-Disease 0 0.3612513840198517
sparing O 0 3.049023291623598e-07
was O 0 8.499365122816016e-08
observed O 0 3.969722328633907e-08
. O 0 2.1696169305585045e-09

No O 0 0.00010697209654608741
desmoid B-Disease 1 0.9579319357872009
tumors I-Disease 1 1.0
were O 0 1.0048488263691979e-07
found O 0 1.2278828620537752e-08
in O 0 1.7009837982584486e-10
these O 0 2.0439738790400952e-10
kindreds O 0 0.00012654972670134157
. O 0 1.840354713067427e-08

Our O 0 1.0431764785323594e-08
data O 0 1.2276949457046271e-09
suggest O 0 4.830564281910199e-10
that O 0 2.94967272829183e-10
, O 0 1.343747335624812e-10
in O 0 3.292294437073906e-09
AAPC B-Disease 1 0.9999998807907104
families O 0 1.8962984071890787e-08
, O 0 6.516204242856816e-12
the O 0 5.375140436914005e-13
location O 0 4.490773086729405e-09
of O 0 1.4122685226131138e-12
the O 0 5.511407996650064e-10
APC B-Disease 0 5.056003828940447e-06
mutation O 0 2.6657191483536735e-05
may O 0 2.826787124377006e-07
partially O 0 2.0350034901639447e-06
predict O 0 2.689739808658942e-08
specific O 0 1.2604405019711606e-10
phenotypic O 0 7.307133955691825e-07
expression O 0 5.492081072588917e-06
. O 0 9.8684651561598e-08

This O 0 1.006246641566122e-08
should O 0 2.193040637976651e-09
help O 0 9.461041325375952e-12
in O 0 3.3870402684800516e-13
the O 0 1.810105776205162e-12
design O 0 2.0181909476946203e-08
of O 0 9.027341374423514e-12
tailored O 0 1.2210456588945817e-05
clinical O 0 2.054059223155491e-05
- O 0 3.432120865909383e-05
management O 0 2.204081397394475e-07
protocols O 0 1.3591995084993869e-08
in O 0 3.1757140320221033e-12
this O 0 5.150778349845286e-13
subset O 0 3.8872979835069543e-10
of O 0 2.1823480522709104e-11
FAP B-Disease 0 2.7552225674298825e-06
patients O 0 1.1034737212867185e-07
. O 0 8.194727535437707e-11
. O 0 3.0073121770612943e-09

Wilms B-Disease 0 0.09598343819379807
' I-Disease 0 2.3311684344662353e-05
tumor I-Disease 0 7.421043119393289e-05
1 O 0 2.2330466364905988e-09
and O 0 2.240492413818629e-08
Dax O 1 0.9321079254150391
- O 0 1.1881771570187993e-05
1 O 0 1.0471830069747057e-09
modulate O 0 3.90546574635664e-07
the O 0 5.010906134472748e-10
orphan O 0 2.053381962241474e-07
nuclear O 0 3.798353631623286e-08
receptor O 0 1.7135926011491165e-10
SF O 0 0.0004417745512910187
- O 0 3.506742132231011e-06
1 O 0 3.433755779713721e-10
in O 0 1.562095071350189e-11
sex O 0 1.8467958273760132e-09
- O 0 5.168798722365864e-09
specific O 0 2.2248689002246635e-11
gene O 0 2.8542981311829863e-08
expression O 0 2.8729779444347514e-08
. O 0 3.018546967936686e-09

Products O 0 1.9032306397548382e-07
of O 0 1.5429098970676236e-11
steroidogenic O 0 2.4935056330832595e-07
factor O 0 8.084042324441043e-10
1 O 0 1.3008703836359103e-10
( O 0 2.0955526203181307e-10
SF O 1 0.8823736310005188
- O 0 0.0005565056344494224
1 O 0 2.481744942883779e-08
) O 0 1.669758997735471e-09
and O 0 1.4045836849163607e-07
Wilms B-Disease 0 0.03732099384069443
tumor I-Disease 0 5.280176264932379e-05
1 O 0 9.250262777982243e-10
( O 0 1.2287508510677725e-10
WT1 O 0 2.3463426259695552e-06
) O 0 3.699533387968579e-11
genes O 0 3.0258853200848534e-09
are O 0 1.8937715978717407e-12
essential O 0 1.646088300388815e-11
for O 0 6.34864123078005e-13
mammalian O 0 7.50836104401742e-09
gonadogenesis O 0 2.0583188131695351e-07
prior O 0 9.721683874586162e-11
to O 0 1.5839005454432176e-11
sexual O 0 1.681262906672032e-10
differentiation O 0 8.208944279886055e-08
. O 0 1.4187835795098636e-08

In O 0 5.5295004131039605e-09
males O 0 2.9853495231435545e-09
, O 0 3.5968228395688584e-10
SF O 0 0.10375943779945374
- O 0 2.394039802311454e-05
1 O 0 1.864961962638745e-09
participates O 0 1.7992005663103328e-09
in O 0 1.8171089632978976e-10
sexual O 0 7.264644996674008e-10
development O 0 4.920940824965081e-12
by O 0 1.2721911740211367e-13
regulating O 0 2.0092627561751897e-10
expression O 0 6.54020448909165e-10
of O 0 1.5197216315238071e-12
the O 0 1.1936369670451086e-09
polypeptide O 0 7.2053253461490385e-06
hormone O 0 1.6931642754514087e-09
Mullerian O 0 4.1118198623735225e-08
inhibiting O 0 4.344370196918135e-09
substance O 0 1.9315024246679968e-08
( O 0 1.7450652034511904e-10
MIS O 0 0.00035105753340758383
) O 0 4.093629879520222e-10
. O 0 6.809991459633125e-10

Here O 0 4.300012506064377e-07
, O 0 4.4322082115577643e-10
we O 0 2.4532223474871273e-10
show O 0 4.784687646086638e-10
that O 0 6.920674450183739e-11
WT1 O 0 1.1970724699494895e-05
- O 0 3.5207958717364818e-06
KTS O 0 1.49588311160187e-06
isoforms O 0 5.38462996413358e-10
associate O 0 5.0293982312155094e-09
and O 0 1.5775877826307294e-10
synergize O 0 6.547550128743751e-07
with O 0 2.89529400454569e-09
SF O 1 0.9972803592681885
- O 0 0.0012777048395946622
1 O 0 2.065901227865652e-08
to O 0 8.537962004062649e-10
promote O 0 5.211832299067964e-09
MIS O 0 0.002060109516605735
expression O 0 6.850474676411977e-08
. O 0 3.778624968475697e-09

In O 0 8.223718594990714e-09
contrast O 0 1.7618829062371333e-08
, O 0 5.192807850384895e-10
WT1 O 0 3.27233829011675e-05
missense O 0 7.405173528240994e-05
mutations O 0 8.634800178697333e-05
, O 0 1.608917860052017e-10
associated O 0 1.7174577315870465e-09
with O 0 5.267045466439413e-09
male B-Disease 0 3.793053838307969e-05
pseudohermaphroditism I-Disease 1 0.9999992847442627
in O 0 1.1391591215215158e-05
Denys B-Disease 1 0.9999904632568359
- I-Disease 1 0.9999971389770508
Drash I-Disease 1 0.9999960660934448
syndrome I-Disease 1 0.9999994039535522
, O 0 9.610485740552122e-09
fail O 0 4.534663560207264e-07
to O 0 4.501384681665499e-11
synergize O 0 5.339850758900866e-06
with O 0 2.4111546537142203e-08
SF O 1 0.9991363883018494
- O 0 0.02296711690723896
1 O 0 3.3140452160296263e-07
. O 0 1.6445939721165814e-08

Additionally O 0 2.154640554863363e-07
, O 0 1.8357149134118345e-10
the O 0 4.463485137051748e-11
X O 0 0.0002692629350349307
- O 0 5.746754686697386e-05
linked O 0 4.614398130797781e-05
, O 0 4.492055893923208e-10
candidate O 0 4.7093558219746257e-11
dosage O 0 1.1963584567453722e-09
- O 0 2.749939165269666e-09
sensitive O 0 2.5961581329170258e-08
sex O 0 9.906329978548456e-09
- O 0 3.2792730308983664e-08
reversal O 0 1.5520643659172606e-09
gene O 0 6.392226747919949e-09
, O 0 1.7709508859375944e-10
Dax O 0 0.007012778427451849
- O 0 9.294712413066009e-07
1 O 0 4.036125877959762e-10
, O 0 2.406248811315237e-11
antagonizes O 0 1.1446714154317306e-07
synergy O 0 1.6434453797842252e-09
between O 0 1.4087435662446524e-09
SF O 1 0.5959628820419312
- O 0 5.98411716055125e-05
1 O 0 6.577324462853085e-09
and O 0 5.323554486125204e-09
WT1 O 0 4.220642949803732e-06
, O 0 1.459447840357342e-10
most O 0 4.015520121275484e-12
likely O 0 3.948195589908998e-11
through O 0 9.51696187134754e-13
a O 0 2.1983307101763883e-12
direct O 0 2.5459398478311357e-11
interaction O 0 3.531009928892104e-10
with O 0 1.365075608106281e-09
SF O 1 0.9984557628631592
- O 0 0.000708076055161655
1 O 0 3.333964926355293e-08
. O 0 8.838172860237137e-09

We O 0 8.203716106436332e-08
propose O 0 6.152013121152322e-09
that O 0 1.4275715332079386e-10
WT1 O 0 2.967009777421481e-06
and O 0 1.827242002150342e-08
Dax O 0 0.265559583902359
- O 0 9.715941814647522e-06
1 O 0 2.793706377346439e-10
functionally O 0 2.563224965612676e-09
oppose O 0 2.5288038330018026e-10
each O 0 7.929126105699069e-12
other O 0 1.2873925016310128e-11
in O 0 5.71031388840737e-10
testis O 0 8.380390681850258e-06
development O 0 4.3312353703583995e-11
by O 0 2.511156864046238e-12
modulating O 0 3.711440754727846e-08
SF O 0 0.16759565472602844
- O 0 1.641736162127927e-05
1 O 0 4.95698060376526e-09
- O 0 6.965350394239067e-07
mediated O 0 1.748446010196858e-07
transactivation O 0 1.2059444998158142e-06
. O 0 3.4724828568144517e-10
. O 0 3.916255097990984e-10

A O 0 5.8612993569795435e-08
mouse O 0 1.4536174148815917e-06
model O 0 2.812886634728784e-07
for O 0 9.788232802065977e-08
Prader B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999997615814209
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999991655349731
imprinting O 1 0.888161838054657
- O 1 0.7274218201637268
centre O 0 0.000324565771734342
mutations O 0 1.3981292795506306e-05
. O 0 3.968463779813192e-09

Imprinting O 0 0.00013017300807405263
in O 0 2.3232147317031604e-09
the O 0 1.145385106204877e-10
15q11 O 0 2.50348222152752e-07
- O 0 6.168710115161957e-06
q13 O 0 1.705049754718857e-07
region O 0 9.893184049758474e-10
involves O 0 3.4371418905498885e-11
an O 0 2.5068308973780207e-12
imprinting O 0 1.4431499039346818e-05
centre O 0 1.1895147054019617e-06
( O 0 1.165673352114538e-12
IC O 0 6.741782687669229e-09
) O 0 6.993240188324368e-12
, O 0 3.2367190525017797e-12
mapping O 0 2.990542569136778e-08
in O 0 7.209276231545658e-11
part O 0 5.176185591260207e-10
to O 0 1.0441548320416771e-10
the O 0 4.056209795127996e-12
promoter O 0 1.1022453350051364e-07
and O 0 1.5124419772138964e-10
first O 0 1.0465110548973922e-11
exon O 0 1.2630594348195245e-09
of O 0 7.158673653862024e-11
SNRPN O 0 0.0021828203462064266
. O 0 1.637460478320918e-08

Deletion O 0 1.244484792550793e-05
of O 0 1.0848860004797345e-10
this O 0 1.2975300001105694e-10
IC O 0 2.2976275886321673e-06
abolishes O 0 9.985369615606032e-06
local O 0 7.490419395850267e-10
paternally O 0 4.874904036000771e-08
derived O 0 7.162730131238249e-11
gene O 0 1.1913676267738538e-08
expression O 0 1.879876876387243e-08
and O 0 1.612569278108822e-08
results O 0 3.04043425103373e-07
in O 0 4.561458626994863e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
( O 0 1.0509971843930543e-06
PWS B-Disease 1 0.9999954700469971
) O 0 4.912004669677117e-08
. O 0 9.228608988109954e-09

We O 0 4.1196844904334284e-06
have O 0 3.352300659287266e-10
created O 0 2.114574834677363e-11
two O 0 9.014436766485723e-12
deletion O 0 4.957304895469861e-07
mutations O 0 3.859829121211078e-06
in O 0 3.424169614518746e-09
mice O 0 0.015035699121654034
to O 0 4.041098122797848e-08
understand O 0 6.919964107510168e-06
PWS B-Disease 1 0.9999997615814209
and O 0 2.0703733127902524e-07
the O 0 1.2289406992049834e-10
mechanism O 0 9.463811956322843e-10
of O 0 5.830131841709496e-13
this O 0 2.2841700753062355e-10
IC O 0 1.2307208635320421e-05
. O 0 8.649787552883481e-09

Mice O 0 0.008134124800562859
harbouring O 0 5.8863661251962185e-06
an O 0 2.7570065674886735e-10
intragenic O 0 8.055533726292197e-06
deletion O 0 3.7332742067519575e-05
in O 0 2.814770638792652e-09
Snrpn O 0 0.0011362030636519194
are O 0 5.509053768726346e-10
phenotypically O 0 4.5584678787236044e-07
normal O 0 1.1079933415203413e-07
, O 0 5.29370991486644e-11
suggesting O 0 9.283509516677668e-10
that O 0 4.3990755482781196e-10
mutations O 0 9.668662670492267e-08
of O 0 9.29464491483678e-12
SNRPN O 0 0.0022871731780469418
are O 0 3.981196622371286e-11
not O 0 1.691220358202017e-10
sufficient O 0 1.8888196562372173e-11
to O 0 1.1811328304300872e-10
induce O 0 1.2903699371236144e-06
PWS B-Disease 1 0.9999924898147583
. O 0 2.2779121877647412e-07

Mice O 0 0.0008139500860124826
with O 0 1.3977347057547718e-10
a O 0 1.296517494059346e-11
larger O 0 3.556585234654186e-11
deletion O 0 1.380608267709249e-07
involving O 0 1.0740751621440836e-09
both O 0 5.942344394327392e-09
Snrpn O 0 0.0003777752863243222
and O 0 1.1714416991992493e-08
the O 0 9.116478683068863e-10
putative O 0 2.6975731088896282e-05
PWS O 1 0.9999973773956299
- O 0 0.044662512838840485
IC O 0 3.870312139042653e-05
lack O 0 6.5658807280044584e-09
expression O 0 1.0240337466882465e-09
of O 0 2.6613609319797726e-12
the O 0 2.8926208650581486e-10
imprinted O 0 7.72817566030426e-06
genes O 0 2.8600209134310717e-07
Zfp127 O 0 3.03018919112219e-06
( O 0 5.7765861538605634e-11
mouse O 0 1.0167363484470116e-07
homologue O 0 9.623545516035392e-09
of O 0 3.1564820202056865e-11
ZNF127 O 0 4.542896567727439e-05
) O 0 4.1075751133767824e-10
, O 0 2.762486073226711e-10
Ndn O 0 3.524270505295135e-05
and O 0 7.315312799960338e-10
Ipw O 0 1.0868723165913252e-06
, O 0 2.1877097911016108e-09
and O 0 1.0155357665908582e-09
manifest O 0 1.3827350375805736e-09
several O 0 1.9991773861360862e-11
phenotypes O 0 1.749536977513344e-07
common O 0 1.5810255149517616e-07
to O 0 2.848842996172607e-06
PWS B-Disease 1 0.9999996423721313
infants O 0 0.046800244599580765
. O 0 8.517797134288685e-09

These O 0 1.128815929618554e-09
data O 0 9.50979073266467e-10
demonstrate O 0 9.368709280588305e-11
that O 0 3.715621213484788e-11
both O 0 5.6936816372754606e-11
the O 0 2.859095460383543e-10
position O 0 3.13992565281751e-08
of O 0 8.621571338796041e-13
the O 0 1.54327842172286e-10
IC O 0 1.1008130513801007e-06
and O 0 6.335856284067631e-09
its O 0 2.138558427566828e-11
role O 0 8.492243019908585e-10
in O 0 3.9855879013783735e-11
the O 0 1.4860026403828996e-11
coordinate O 0 2.1723001175644185e-09
expression O 0 4.494746796979143e-10
of O 0 1.0320481448611307e-12
genes O 0 7.672661617164067e-09
is O 0 5.871629571441161e-11
conserved O 0 5.768015398643911e-09
between O 0 4.349244964174659e-09
mouse O 0 0.002607106463983655
and O 0 2.453141405567294e-07
human O 0 1.3517438901544665e-07
, O 0 2.617826400097556e-09
and O 0 2.059542314469809e-09
indicate O 0 7.618328190517332e-09
that O 0 1.3854674074664786e-09
the O 0 4.5863010611491006e-10
mouse O 0 8.149844688887242e-06
is O 0 1.4517738400332547e-10
a O 0 2.5344377638236715e-11
suitable O 0 3.8698982907092727e-10
model O 0 2.5318568575016798e-08
system O 0 4.160265021369014e-08
in O 0 1.5795659225048553e-10
which O 0 9.520280119801328e-10
to O 0 1.0581040384149976e-11
investigate O 0 2.972624577046723e-11
the O 0 8.37510995884555e-13
molecular O 0 2.992903702647709e-09
mechanisms O 0 1.5081879078948646e-09
of O 0 4.051978479309437e-13
imprinting O 0 4.368279405753128e-06
in O 0 2.2104096331077017e-09
this O 0 1.7414408803873016e-10
region O 0 5.349211629201989e-10
of O 0 5.296239250114632e-13
the O 0 4.153788771277256e-11
genome O 0 2.0906043118884554e-08
. O 0 1.0191503196921303e-10
. O 0 6.652593476097479e-10

Mutations O 0 1.7810030840337276e-05
of O 0 1.6706205863137313e-11
the O 0 2.202234748727161e-11
ATM O 0 2.4199687231885036e-07
gene O 0 6.225744186849624e-08
detected O 0 3.0495602914015763e-06
in O 0 3.447573604375975e-08
Japanese O 1 0.9870966672897339
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.9561399817466736
: O 0 1.6154397264322995e-10
possible O 0 6.347534303730029e-11
preponderance O 0 3.5369993156564306e-08
of O 0 4.0709983127606986e-12
the O 0 4.820540633332371e-10
two O 0 4.4979542312972853e-10
founder O 0 7.978994176482956e-08
mutations O 0 2.2792508502789133e-07
4612del165 O 0 4.14711358587283e-08
and O 0 1.2866451237769638e-09
7883del5 O 0 1.4205753018359246e-07
. O 0 4.226809569018997e-09

The O 0 6.552856923747186e-09
ATM O 0 6.253603260120144e-06
( O 0 2.6570752709176304e-08
A O 1 0.9999885559082031
- O 1 0.9999964237213135
T O 1 1.0
, O 0 1.2097412849243483e-08
mutated O 0 1.2268252191915963e-07
) O 0 1.0792449399443793e-11
gene O 0 6.194507129464455e-09
on O 0 1.0815050188739406e-08
human O 0 5.9539193131286083e-08
chromosome O 0 0.00018953751714434475
11q22 O 0 2.5170131721097277e-06
. O 0 5.170178951630078e-09

3 O 0 6.18284161646443e-07
has O 0 4.0042316129529354e-08
recently O 0 3.7421770571199886e-08
been O 0 3.022780081796128e-10
identified O 0 1.0798575367232388e-09
as O 0 2.3358389875105523e-12
the O 0 5.47951441165484e-13
gene O 0 3.3867628701500507e-09
responsible O 0 5.198526054073227e-10
for O 0 1.4581280627368187e-11
the O 0 3.541008553042957e-08
human O 0 0.012313039042055607
recessive B-Disease 1 0.9999977350234985
disease I-Disease 1 0.9999998807907104
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 0 0.12848863005638123
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999991655349731
T I-Disease 1 0.9999998807907104
) O 0 1.8740847451681475e-07
. O 0 1.0670188288486315e-08

In O 0 1.1648083608761794e-09
order O 0 1.6342825703841157e-10
to O 0 9.032990501423033e-12
define O 0 2.4529802633566078e-09
the O 0 8.556428482409117e-11
types O 0 1.037088281918841e-07
of O 0 1.731453735942523e-08
disease O 1 0.9993565678596497
- O 0 0.009480513632297516
causing O 0 2.4501161988155218e-06
ATM O 0 0.0007034111185930669
mutations O 0 9.30086480366299e-06
in O 0 5.12719555700869e-09
Japanese O 0 0.008989174850285053
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 7.581932004541159e-05
as O 0 3.392075231811731e-10
well O 0 7.7321571367861e-10
as O 0 1.7886166159275518e-10
to O 0 3.353194111266333e-11
look O 0 1.6755742626717307e-10
for O 0 1.281763323951468e-13
possible O 0 5.495499888485966e-12
mutational O 0 2.2714688796554583e-08
hotspots O 0 1.9896701175525777e-08
, O 0 2.2790783149595484e-10
reverse O 0 2.18712830246659e-06
- O 0 5.719660407521587e-07
transcribed O 0 1.0266460321872728e-06
RNA O 0 1.2907034943054896e-06
derived O 0 1.8464840767506985e-11
from O 0 3.504891472536076e-12
ten O 0 4.573230683035945e-11
patients O 0 4.404043449368622e-11
belonging O 0 3.232149270449014e-11
to O 0 2.3842797181039543e-10
eight O 0 7.612321190064719e-11
unrelated O 0 3.4271161464261013e-09
Japanese O 0 0.0030614049173891544
A B-Disease 1 0.9999995231628418
- I-Disease 1 0.9999992847442627
T I-Disease 1 1.0
families O 0 1.6020210580336425e-07
was O 0 8.925177930052541e-09
analyzed O 0 9.542350243307851e-10
for O 0 2.9892120679761436e-13
mutations O 0 1.8040895166659965e-10
by O 0 1.4486488723007562e-13
the O 0 1.0411151107891925e-12
restriction O 0 2.5065940989499325e-10
endonuclease O 0 2.3300765761291586e-08
fingerprinting O 0 1.4642763801475667e-07
method O 0 2.363008277939116e-08
. O 0 1.816174322044617e-09

As O 0 1.3711570545638097e-07
has O 0 3.5929164088344123e-09
been O 0 6.955477166448176e-11
reported O 0 4.74765227131968e-10
by O 0 4.8298032240268185e-12
others O 0 3.882814902933518e-10
, O 0 2.232946466618202e-11
mutations O 0 7.901389764697342e-09
that O 0 1.0466193189895279e-10
lead O 0 1.7178811262397176e-08
to O 0 4.49649128694829e-12
exon O 0 6.629760918031025e-08
skipping O 0 1.50437824686378e-06
or O 0 7.354576325724338e-08
premature O 0 2.595286652251616e-08
protein O 0 1.5153562848979618e-09
truncation O 0 1.6511303329025395e-06
were O 0 2.760904180831858e-07
also O 0 7.962164971786478e-08
predominant O 0 4.111871589884686e-07
in O 0 2.4840596246633595e-09
our O 0 4.613088133709198e-09
mutants O 0 9.054534899632927e-08
. O 0 8.46840098045476e-10

Six O 0 4.863469182936342e-09
different O 0 7.345225989940918e-12
mutations O 0 1.3911905405450398e-08
were O 0 7.869346840827518e-11
identified O 0 5.340987208057868e-09
on O 0 2.168764723364802e-09
12 O 0 7.313914057727189e-11
of O 0 2.938163221836293e-13
the O 0 1.436114144270917e-10
16 O 0 2.9212304797354705e-10
alleles O 0 8.525822270399885e-10
examined O 0 3.1415615353580506e-07
. O 0 3.830523898074034e-09

Four O 0 1.6901706700878094e-08
were O 0 7.452608669078487e-11
deletions O 0 1.176708774863755e-08
involving O 0 2.354149097882896e-09
a O 0 4.013129384361491e-09
loss O 0 1.016422217503532e-07
of O 0 2.3529011313090653e-13
a O 0 8.731498163383478e-11
single O 0 1.340770605651187e-09
exon O 0 1.5301665712286194e-08
exon O 0 3.184713079917856e-07
7 O 0 9.243688481319623e-09
, O 0 9.765892088064998e-12
exon O 0 2.4210025983961714e-08
16 O 0 1.3194124681703556e-09
, O 0 5.187131106587639e-12
exon O 0 6.584228273709414e-09
33 O 0 5.500572886063537e-09
or O 0 6.103433036752648e-11
exon O 0 2.156605631853381e-07
35 O 0 2.133453307351374e-07
. O 0 9.55904155830467e-09

The O 0 1.6441915606790758e-09
others O 0 4.807509251802955e-11
were O 0 5.697491957390444e-12
minute O 0 6.080821263187985e-11
deletions O 0 5.594595009483783e-09
, O 0 2.3270264187802425e-11
4649delA O 0 3.94424048977271e-09
in O 0 2.9221861475720035e-12
exon O 0 1.0906924252651606e-08
33 O 0 3.4104377988342094e-08
and O 0 2.823787037531389e-10
7883del5 O 0 4.524458141474952e-09
in O 0 2.1257157492571288e-11
exon O 0 3.564217365692457e-07
55 O 0 1.1397163746096339e-07
. O 0 5.359825472339708e-09

The O 0 9.103625409068172e-09
mutations O 0 1.962155664614329e-07
4612del165 O 0 2.989846947798469e-08
and O 0 1.6607408503954701e-10
7883del5 O 0 2.4261230802125056e-09
were O 0 3.008859827957622e-10
found O 0 3.8540318159085984e-10
in O 0 1.2953427393214145e-12
more O 0 1.0340159446991376e-13
than O 0 1.897966376077087e-12
two O 0 4.5947195700946075e-12
unrelated O 0 3.399601433695665e-10
families O 0 4.2369593944435735e-11
; O 0 9.116886932891699e-12
44 O 0 3.261789102704249e-11
% O 0 1.0402576152909737e-12
( O 0 3.3629728776046752e-12
7 O 0 1.2349661293598047e-09
of O 0 9.715395155041051e-12
16 O 0 5.919335244186641e-09
) O 0 5.850275125451887e-12
of O 0 6.709823668904491e-14
the O 0 1.0089684296388235e-11
mutant O 0 1.6464761776191494e-09
alleles O 0 9.073487794442059e-11
had O 0 9.616906737619502e-08
one O 0 1.2369969631942368e-11
of O 0 7.52218857406721e-14
the O 0 9.018344404587708e-11
two O 0 2.039916680018905e-09
mutations O 0 1.1963736596953822e-06
. O 0 5.10587216950853e-09

The O 0 5.505789602011646e-09
4612del165 O 0 9.900005437657455e-08
mutations O 0 2.65170427837802e-07
in O 0 1.6261195515121507e-11
three O 0 1.5931719485329232e-11
different O 0 1.584464764253779e-12
families O 0 1.512270864090226e-11
were O 0 1.7006746705350295e-11
all O 0 4.982374105302889e-13
ascribed O 0 1.99710900594674e-10
to O 0 3.493806979837366e-11
the O 0 3.0938875593411463e-12
same O 0 1.45384662642023e-10
T O 0 1.6688813047949225e-05
- O 0 5.408081165114709e-07
- O 0 1.616272697901877e-07
> O 0 5.1154198932312767e-11
A O 0 1.2306288800500997e-11
substitution O 0 9.37580221793688e-12
at O 0 7.143152735977765e-11
the O 0 1.079293772410228e-12
splice O 0 1.045177896230598e-06
donor O 0 5.118708928941729e-11
site O 0 7.067130214366557e-10
in O 0 4.002308900963314e-11
intron O 0 0.00012419586710166186
33 O 0 1.3424735811895516e-07
. O 0 2.9422630998254817e-09

Microsatellite O 0 7.163728878367692e-05
genotyping O 0 8.473144589515869e-06
around O 0 8.419557495642493e-09
the O 0 1.3163199696908379e-10
ATM O 0 2.07712014343997e-06
locus O 0 1.1550176282071334e-07
also O 0 7.850603367387521e-08
indicated O 0 5.370890576728016e-08
that O 0 7.545953445431408e-11
a O 0 7.532738321991417e-11
common O 0 2.6306701261802345e-09
haplotype O 0 0.00012910163786727935
was O 0 2.1137811927474104e-06
shared O 0 7.803911961090648e-10
by O 0 2.1465875951753866e-12
the O 0 3.0547298631583564e-12
mutant O 0 4.289614885522042e-09
alleles O 0 1.1572298674877857e-10
in O 0 9.921258259382171e-11
both O 0 1.4182363061721048e-09
mutations O 0 5.1042957238678355e-06
. O 0 8.521371164249558e-09

This O 0 5.215094134314313e-09
suggests O 0 4.970718947561181e-09
that O 0 5.504020156310574e-11
these O 0 4.237635849863031e-12
two O 0 6.072823494074342e-11
founder O 0 1.2378529845591402e-06
mutations O 0 4.972311944584362e-05
may O 0 1.5324740587630004e-08
be O 0 1.2957561239257398e-11
predominant O 0 1.0202495515088117e-09
among O 0 1.6682610154417077e-11
Japanese O 0 1.546020023113215e-08
ATM O 0 5.818149020342389e-07
mutant O 0 1.1288319967661664e-07
alleles O 0 2.236167517821741e-08
. O 0 4.295706457213555e-09

W474C O 0 4.04263937525684e-06
amino O 0 7.774266208571134e-08
acid O 0 2.550681221791251e-09
substitution O 0 1.541157756967948e-10
affects O 0 2.1477608580511287e-10
early O 0 1.6725112614301985e-11
processing O 0 5.203811340170894e-11
of O 0 5.347935636001999e-14
the O 0 4.2288489875662305e-13
alpha O 0 9.467860523360017e-13
- O 0 3.730875330898442e-11
subunit O 0 6.195963013488903e-12
of O 0 1.958601602300783e-13
beta O 0 2.1941219674470602e-11
- O 0 2.2850176861766158e-08
hexosaminidase O 0 6.69186022150825e-08
A O 0 4.6309045487191725e-09
and O 0 1.720221409762246e-09
is O 0 1.9986474281141753e-11
associated O 0 5.486215370886782e-10
with O 0 5.761756072253377e-10
subacute O 1 0.7259682416915894
G B-Disease 0 0.0023471175227314234
( I-Disease 0 1.8592499761993508e-10
M2 I-Disease 0 1.8531061868998222e-05
) I-Disease 0 2.468583026882243e-08
gangliosidosis I-Disease 0 0.0001240011042682454
. O 0 5.142692671711302e-08

Mutations O 0 0.0006824394222348928
in O 0 6.352745551829742e-10
the O 0 7.232690835135003e-11
HEXA O 0 4.1222197069146205e-06
gene O 0 1.0747027268109832e-08
, O 0 1.83635376869995e-12
encoding O 0 5.727094579827119e-12
the O 0 1.0935794370753316e-12
alpha O 0 8.115329697307161e-13
- O 0 3.9417847458311783e-11
subunit O 0 1.2978808132391162e-11
of O 0 4.423924334501228e-13
beta O 0 4.399308348168596e-11
- O 0 1.8734343143478327e-07
hexosaminidase O 0 1.2117115488763375e-07
A O 0 2.2913535513424677e-09
( O 0 4.985722772132828e-12
Hex O 0 1.6184824147558174e-08
A O 0 2.0532902045289347e-09
) O 0 6.972875402078138e-12
, O 0 2.2882754718844822e-12
that O 0 4.5382538872706935e-12
abolish O 0 1.571376095910182e-08
Hex O 0 6.883454517492282e-08
A O 0 1.7768109206173222e-10
enzyme O 0 1.2612209054907453e-08
activity O 0 1.6004663905277994e-07
cause O 0 0.00037383465678431094
Tay B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9999362230300903
( O 0 5.0940678758548685e-11
TSD B-Disease 0 2.3033931029203814e-06
) O 0 2.795454701054467e-10
, O 0 2.3716481556412816e-10
the O 0 3.600283848825825e-09
fatal O 0 0.014066152274608612
infantile B-Disease 0 0.04956395551562309
form I-Disease 0 3.485186184093436e-08
of I-Disease 0 8.060942885412814e-11
G I-Disease 0 0.011135656386613846
( I-Disease 0 1.0832483521294733e-10
M2 I-Disease 0 1.198141308123013e-05
) I-Disease 0 1.1118114207064878e-09
gangliosidosis I-Disease 0 7.30809574633895e-07
, I-Disease 0 2.337534887875137e-10
Type I-Disease 0 1.3479929066306795e-06
1 I-Disease 0 1.0265256200625572e-08
. O 0 1.611354782937724e-08

Less O 0 5.050545155427244e-07
severe O 0 7.074638415360823e-05
, O 0 3.3958185152727083e-09
subacute O 0 0.20919077098369598
( O 0 2.2554777601158094e-08
juvenile O 0 0.08564668893814087
- O 1 0.9929733276367188
onset O 1 0.9921742677688599
) O 0 1.2411971965775592e-06
and O 0 0.0001695993560133502
chronic O 0 0.22718305885791779
( O 0 5.04429609193835e-10
adult O 0 6.725052116962615e-06
- O 1 0.5100449323654175
onset O 0 0.00021684322564397007
) O 0 3.545687007888709e-11
variants O 0 3.973962936498765e-09
are O 0 8.339141877033995e-11
characterized O 0 8.390124150992051e-09
by O 0 4.0404810573713146e-12
a O 0 1.1077551376192929e-10
broad O 0 1.5767170680192066e-08
spectrum O 0 1.28914896535548e-08
of O 0 1.1324166604431696e-10
clinical O 0 8.804122444416862e-06
manifestations O 0 1.8349345509705017e-06
and O 0 9.597995642707247e-08
are O 0 7.327304735182949e-11
associated O 0 1.3146979505052059e-08
with O 0 6.117071849054412e-10
residual O 0 2.19324829231482e-06
levels O 0 6.9556307380480575e-09
of O 0 6.461631902286713e-13
Hex O 0 8.166214797711291e-07
A O 0 2.9392004385897508e-09
enzyme O 0 1.2954936678966078e-08
activity O 0 1.0717754683753355e-08
. O 0 1.7751926595366285e-09

We O 0 1.6001703784240817e-07
identified O 0 1.7491315063011825e-09
a O 0 6.08954831005093e-11
1422 O 0 1.3985220448375912e-07
G O 0 9.29127236304339e-06
- O 0 4.179164534434676e-06
- O 0 9.693119864095934e-06
> O 0 7.034672222516747e-08
C O 0 1.125205130847462e-06
( O 0 1.6391509460519926e-12
amino O 0 6.313557315840157e-11
acid O 0 1.8814415303491927e-11
W474C O 0 3.4784120028774623e-12
) O 0 7.745111721565133e-15
substitution O 0 1.987435010401134e-13
in O 0 5.943805560584825e-13
the O 0 6.677299772134271e-12
first O 0 4.039923118259736e-10
position O 0 3.268036952164266e-10
of O 0 6.400555676829359e-14
exon O 0 9.479266793732677e-08
13 O 0 1.349673928174866e-09
of O 0 2.6264246853757722e-12
HEXA O 0 2.680126272025518e-05
of O 0 9.378967220918799e-12
a O 0 8.654453265144468e-10
non O 0 8.327654676953955e-10
- O 0 3.1010363272798713e-06
Jewish O 0 8.468891792290378e-07
proband O 0 6.824490264989436e-05
who O 0 6.237095107053392e-08
manifested O 0 3.251684199678806e-10
a O 0 8.938590319307327e-12
subacute O 0 3.683440581880859e-06
variant O 0 1.482280367781641e-06
of O 0 2.2673239674642076e-10
G B-Disease 0 0.009272518567740917
( I-Disease 0 3.5509067908279235e-10
M2 I-Disease 0 5.48371062905062e-05
) I-Disease 0 1.6189979135106114e-08
gangliosidosis I-Disease 0 0.00018911706865765154
. O 0 8.390176020611761e-08

On O 0 1.2126248805088835e-07
the O 0 1.4369697654004199e-09
second O 0 1.210547253549521e-07
maternally O 0 4.09423091696226e-06
inherited O 0 1.1020159035979304e-05
allele O 0 8.203215173807621e-08
, O 0 2.6232296335138017e-09
we O 0 5.743544750913543e-09
identified O 0 9.421618152316569e-09
the O 0 2.4094062300861196e-09
common O 0 0.0001417195308022201
infantile O 1 0.9999847412109375
disease O 1 0.9999876022338867
- O 0 0.03788286820054054
causing O 0 2.676488520592102e-06
4 O 0 2.0550700696730928e-08
- O 0 1.730247504383442e-06
bp O 0 3.96801915769629e-08
insertion O 0 1.1894076834551015e-09
, O 0 3.476623156029035e-11
+ O 0 8.14117107061918e-10
TATC O 0 2.3117549119433534e-07
1278 O 0 3.384020175190017e-08
, O 0 1.5729150620868992e-11
in O 0 3.446974693524507e-12
exon O 0 1.7560662968207907e-07
11 O 0 1.9394173378373125e-08
. O 0 2.618970151857525e-09

Pulse O 0 0.0001255500828847289
- O 0 1.984123855436337e-06
chase O 0 1.673398344337329e-07
analysis O 0 1.4947472426474206e-10
using O 0 3.7791131335396244e-10
proband O 0 2.7487506031320663e-06
fibroblasts O 0 3.529738137331151e-07
revealed O 0 1.9332465228671936e-07
that O 0 6.563657950486856e-11
the O 0 5.429393046263442e-12
W474C O 0 2.3668185189507085e-09
- O 0 3.637513623644395e-10
containing O 0 3.0047390357085257e-12
alpha O 0 3.938356151617084e-12
- O 0 4.640413747702965e-11
subunit O 0 1.8221093037174008e-11
precursor O 0 2.892157624501124e-10
was O 0 6.4455205617264255e-09
normally O 0 1.0047664956991387e-11
synthesized O 0 7.096536136508291e-10
, O 0 4.43623783541458e-12
but O 0 4.718698001782151e-11
not O 0 6.564180622670168e-12
phosphorylated O 0 1.5984140400160385e-10
or O 0 1.522386383623342e-10
secreted O 0 1.2498857504539274e-09
, O 0 2.2783885889055e-09
and O 0 4.440587453302669e-09
the O 0 3.7300662558692466e-10
mature O 0 8.053600564217334e-10
lysosomal O 0 1.9739228918069784e-08
alpha O 0 1.503679646075451e-11
- O 0 4.289165023152464e-09
subunit O 0 9.7620467265358e-10
was O 0 3.5232567086040945e-08
not O 0 6.002751073985735e-10
detected O 0 2.7681959835490488e-08
. O 0 4.5893461253498913e-10

When O 0 2.7670662205991903e-08
the O 0 2.809489967059431e-11
W474C O 0 1.1149713374791759e-09
- O 0 5.05976205378289e-10
containing O 0 4.1522341120980855e-12
alpha O 0 1.0606539951885097e-11
- O 0 6.328244039899289e-10
subunit O 0 4.439094924979514e-10
was O 0 2.552965305824273e-08
transiently O 0 5.135781933063299e-08
co O 0 1.5870894287672854e-07
- O 0 1.583060260657021e-08
expressed O 0 1.0733362983128547e-12
with O 0 8.10855289162804e-13
the O 0 4.843658026748576e-13
beta O 0 7.737751411829308e-13
- O 0 1.0993630311650904e-10
subunit O 0 4.3611527583697907e-11
to O 0 1.7764543308596004e-11
produce O 0 1.655063759653519e-11
Hex O 0 9.292620006817742e-09
A O 0 6.034330812809685e-10
( O 0 5.61287431463664e-12
alphabeta O 0 6.61489352182798e-08
) O 0 1.5098413838621205e-11
in O 0 1.3590632785831502e-10
COS O 0 0.0002282717323396355
- O 0 1.0509478670428507e-05
7 O 0 2.080008343341433e-08
cells O 0 4.941539799574457e-08
, O 0 8.156269930281734e-12
the O 0 1.1496870079216737e-12
mature O 0 1.853515604888223e-12
alpha O 0 1.4144135624012677e-13
- O 0 3.087010508329158e-11
subunit O 0 1.6901208210740037e-10
was O 0 6.478369840579035e-08
present O 0 1.2557772530175093e-11
, O 0 1.4855236832311824e-11
but O 0 5.4041864733234135e-11
its O 0 3.741712668869912e-12
level O 0 2.453100778065931e-10
was O 0 1.2887449996057398e-09
much O 0 1.4932818870327935e-11
lower O 0 4.1947781359574776e-10
than O 0 3.1789805163273677e-12
that O 0 6.687397857696453e-11
from O 0 4.572327759466699e-13
normal O 0 2.5124036531765093e-11
alpha O 0 6.260511315088479e-13
- O 0 1.1704512359322905e-10
subunit O 0 7.50440126706664e-11
transfections O 0 4.048728641237176e-08
, O 0 1.4389759349364706e-11
although O 0 1.760065509136266e-12
higher O 0 3.3736679899351585e-13
than O 0 5.448332757174157e-13
in O 0 1.4650249763326073e-11
those O 0 2.7776694139225455e-11
cells O 0 1.4648392498983753e-09
transfected O 0 1.8384742617172378e-08
with O 0 2.330263152577894e-12
an O 0 2.0153931962977462e-13
alpha O 0 7.185811407711684e-12
- O 0 8.541288565311334e-09
subunit O 0 2.8191549095168966e-09
associated O 0 1.2781173097664578e-07
with O 0 3.6501386802001434e-08
infantile O 0 0.05614199861884117
TSD B-Disease 0 0.0006341674597933888
. O 0 3.638849932485755e-08

Furthermore O 0 9.308248536399333e-07
, O 0 5.6020320327032636e-11
the O 0 1.4334473278504456e-12
precursor O 0 1.429658891272112e-10
level O 0 1.0705689806878027e-10
of O 0 1.4455545593004826e-13
the O 0 3.5442313146838433e-12
W474C O 0 1.1364759133769553e-10
alpha O 0 5.066147154564327e-13
- O 0 5.199654248833063e-11
subunit O 0 1.0109916376288552e-10
was O 0 1.2623688760982077e-08
found O 0 2.5365184952441666e-10
to O 0 5.292679836066405e-11
accumulate O 0 3.887359323329065e-09
in O 0 3.779181394908404e-12
comparison O 0 1.1715590997329883e-10
to O 0 2.5305252684959534e-11
the O 0 3.092837401116877e-12
normal O 0 6.432115257082316e-11
alpha O 0 2.3869755998162656e-12
- O 0 4.0479369856072367e-10
subunit O 0 2.958852052259431e-10
precursor O 0 3.3400737731170693e-09
levels O 0 1.986597553127467e-09
. O 0 3.495921885310338e-10

We O 0 8.082984095381107e-07
conclude O 0 4.532620501151996e-09
that O 0 1.3334777726470293e-11
the O 0 7.914047889245879e-12
1422 O 0 1.0376206205364724e-07
G O 0 1.8035269022220746e-05
- O 0 5.846627573191654e-06
- O 0 6.888435746077448e-05
> O 0 6.109603418735787e-07
C O 0 2.8248538001207635e-05
mutation O 0 2.0088094743186957e-07
is O 0 1.8223464404165668e-10
the O 0 3.1918988285806194e-11
cause O 0 5.904425837144345e-10
of O 0 3.175992671980432e-12
Hex B-Disease 0 0.01030311081558466
A I-Disease 0 0.008019818924367428
enzyme I-Disease 1 0.9999997615814209
deficiency I-Disease 1 0.9999997615814209
in O 0 5.729187124714485e-10
the O 0 9.661058619769847e-10
proband O 0 3.401096546440385e-05
. O 0 5.64175506312381e-09

The O 0 1.7758158277203506e-09
resulting O 0 4.307469658737517e-10
W474C O 0 4.462417102502059e-09
substitution O 0 1.1659908594197077e-09
clearly O 0 1.0579557230272485e-09
interferes O 0 1.7671558660836695e-09
with O 0 3.9604856395293597e-13
alpha O 0 9.979361087486538e-13
- O 0 3.5185975660878555e-11
subunit O 0 1.675474169127167e-11
processing O 0 8.231894277344054e-09
, O 0 5.888912274487623e-11
but O 0 3.1591441268519205e-11
because O 0 9.808037628594724e-13
the O 0 6.099071578726314e-14
base O 0 5.553106585676204e-11
substitution O 0 6.789004775020757e-11
falls O 0 4.594220683884487e-07
at O 0 8.049731436976515e-10
the O 0 5.969815787543187e-12
first O 0 1.8003633306395983e-10
position O 0 2.9694072201102983e-10
of O 0 9.527872468859805e-14
exon O 0 6.182150968925271e-08
13 O 0 1.0199674438382544e-09
, O 0 9.080511516323941e-12
aberrant O 0 7.871335583331529e-09
splicing O 0 4.072260253451532e-06
may O 0 1.9920288707453437e-07
also O 0 1.3385859087833296e-09
contribute O 0 1.9719068392043404e-11
to O 0 1.3395558273732178e-10
Hex B-Disease 0 8.499028626829386e-05
A I-Disease 0 2.3421454898198135e-05
deficiency I-Disease 0 0.0075324228964746
in O 0 1.803462414129431e-11
this O 0 7.4773541525186e-11
proband O 0 8.615018487034831e-06
. O 0 9.63055524216827e-10
. O 0 1.7627324044866555e-09

Two O 0 1.1611334116423677e-08
frequent O 0 2.565799945841718e-07
missense O 0 0.0010624212445691228
mutations O 0 0.38439419865608215
in O 0 0.0008694137213751674
Pendred B-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
. O 0 7.742360708107299e-07

Pendred B-Disease 1 0.9999978542327881
syndrome I-Disease 1 1.0
is O 0 0.0006098917801864445
an O 0 0.008787793107330799
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9815459847450256
by O 0 3.0980902465671534e-07
early O 0 0.0010086864931508899
childhood O 1 0.9998308420181274
deafness B-Disease 1 1.0
and O 1 0.9943622350692749
goiter B-Disease 1 0.9999997615814209
. O 0 4.688087756221648e-06

A O 0 6.462227730708037e-08
century O 0 2.2515793673960616e-08
after O 0 7.074706098730843e-11
its O 0 1.089241110502348e-12
recognition O 0 1.8646329272287154e-11
as O 0 2.014175271014551e-09
a O 0 6.694515377603238e-07
syndrome O 1 0.9715889692306519
by O 0 3.6104372963530196e-11
Vaughan O 0 1.6373707694583572e-05
Pendred O 0 2.900267645600252e-05
, O 0 5.468917319007005e-09
the O 0 1.8052341843599606e-08
disease O 0 0.0011524623259902
gene O 0 1.916322247552671e-07
( O 0 1.8351757613555009e-10
PDS O 0 1.3160099115339108e-05
) O 0 5.909458339337093e-11
was O 0 1.4037019546719876e-08
mapped O 0 2.5197770810336806e-05
to O 0 5.608965736314531e-09
chromosome O 0 5.188948125578463e-05
7q22 O 0 5.043830242357217e-07
- O 0 1.8992081095348112e-05
q31 O 0 1.8263659740114235e-06
. O 0 7.066082829965126e-09

1 O 0 8.162245990206429e-08
and O 0 3.860731112581561e-08
, O 0 1.6433379657065927e-10
recently O 0 5.693223670277803e-08
, O 0 2.1615684936415747e-11
found O 0 2.1214020123894173e-11
to O 0 8.802656954048915e-13
encode O 0 4.0200071049767416e-10
a O 0 6.288465859149994e-10
putative O 0 2.031201944419081e-07
sulfate O 0 3.2815210033732e-06
transporter O 0 0.0003865071339532733
. O 0 3.6446500928377645e-08

We O 0 5.054837970419612e-07
performed O 0 1.1023977286583886e-09
mutation O 0 1.3516904262544926e-10
analysis O 0 1.9380091281773204e-11
of O 0 4.62042242573707e-13
the O 0 1.237455415914468e-10
PDS B-Disease 0 1.2790999790013302e-05
gene O 0 3.0553249530385074e-07
in O 0 1.496317070248665e-09
patients O 0 8.596432898855255e-09
from O 0 3.88627107925088e-12
14 O 0 1.0483980350528554e-09
Pendred B-Disease 0 6.138528533483623e-06
families O 0 1.1151877338244631e-10
originating O 0 4.322835978065598e-10
from O 0 2.4359320116573713e-11
seven O 0 2.3866777998371447e-10
countries O 0 3.4094942581025522e-12
and O 0 4.090888044983032e-11
identified O 0 3.1564608704570674e-09
all O 0 6.231081622898316e-11
mutations O 0 4.01330083832363e-07
. O 0 1.8977954763244043e-09

The O 0 5.299948924175624e-09
mutations O 0 1.3011252519845584e-07
include O 0 9.969344794136248e-11
three O 0 2.4679969179430827e-10
single O 0 3.357466082931637e-09
base O 0 3.174872631461767e-08
deletions O 0 1.3122299833412399e-06
, O 0 1.2290538586867683e-09
one O 0 1.8333844165052682e-10
splice O 0 7.53697968320921e-05
site O 0 1.0601044095892576e-06
mutation O 0 7.402044275295339e-07
and O 0 2.8249464989471562e-09
10 O 0 1.3426842970787334e-10
missense O 0 2.2811980670667253e-05
mutations O 0 0.00017215214029420167
. O 0 3.5153895794337586e-08

One O 0 1.3965422596129429e-08
missense O 0 3.1435683922609314e-06
mutation O 0 1.318587578680308e-06
( O 0 4.487266114239219e-11
L236P O 0 1.9603520584610123e-08
) O 0 5.0673406443157987e-11
was O 0 1.2946685501447064e-08
found O 0 2.121242292929537e-09
in O 0 4.512618143742708e-12
a O 0 1.0904347737261677e-11
homozygous O 0 1.913760261373909e-09
state O 0 1.2984038844088275e-10
in O 0 4.517770532674881e-11
two O 0 3.615419422176025e-11
consanguineous O 0 8.579123544905087e-08
families O 0 6.519442763419647e-10
and O 0 4.0422967750863847e-10
in O 0 6.234668597365767e-12
a O 0 1.8532937337556454e-11
heterozygous O 0 4.149720567170334e-10
state O 0 1.4526346271692692e-11
in O 0 6.433878603495646e-12
five O 0 1.943471859139345e-12
additional O 0 1.0907213717284425e-12
non O 0 5.372862710295578e-10
- O 0 5.12364795213216e-06
consanguineous O 0 2.382153797952924e-05
families O 0 4.0655052657712076e-08
. O 0 3.3590610293288137e-09

Another O 0 1.4051946095605672e-07
missense O 0 2.8662883778451942e-05
mutation O 0 3.920679318980547e-06
( O 0 4.828305116832965e-11
T416P O 0 3.205441956311006e-08
) O 0 9.390463406866445e-11
was O 0 3.564611006368068e-08
found O 0 1.2128411608358647e-09
in O 0 2.8000572780545463e-12
a O 0 6.018508174471249e-12
homozygous O 0 5.429460769867944e-10
state O 0 9.829884822787349e-11
in O 0 1.8388651712442083e-10
one O 0 4.70146277464778e-09
family O 0 2.1255528892538678e-08
and O 0 1.1006141553693283e-09
in O 0 8.534012906069588e-12
a O 0 1.0946526671218315e-11
heterozygous O 0 4.89878859699644e-10
state O 0 3.5579695439880155e-11
in O 0 8.22918608256451e-11
four O 0 4.6536047237921707e-10
families O 0 4.2325271065735137e-10
. O 0 7.3223488383789e-10

Pendred B-Disease 0 0.010827927850186825
patients O 0 5.657049405272119e-05
in O 0 5.634321342817827e-10
three O 0 6.886061165722879e-10
non O 0 1.968222695936106e-09
- O 0 1.9711103504960192e-06
consanguineous O 0 4.036361360704177e-07
families O 0 2.82459500233756e-10
were O 0 3.674203649661756e-11
shown O 0 3.434546744229827e-11
to O 0 2.67961607763878e-12
be O 0 1.227746962255416e-12
compound O 0 4.999707314823354e-10
heterozygotes O 0 2.5978108553204038e-09
for O 0 4.169169350032309e-12
L236P O 0 4.485595894720973e-08
and O 0 2.2680735067837077e-09
T416P O 0 5.547365731217724e-07
. O 0 4.91059681806405e-09

In O 0 3.2584719367179105e-09
total O 0 1.7199383584021177e-10
, O 0 1.7283702247183896e-10
one O 0 3.393511860405596e-10
or O 0 6.243076056122732e-10
both O 0 1.1806575161976696e-10
of O 0 6.944666738374627e-13
these O 0 1.0183574816746699e-10
mutations O 0 6.037605970732329e-08
were O 0 8.101052051401325e-10
found O 0 1.640552405035578e-08
in O 0 5.370024980244636e-10
nine O 0 1.1982379533037602e-09
of O 0 1.0137807477175742e-12
the O 0 3.9041356258984194e-10
14 O 0 1.1689079704169103e-09
families O 0 3.812894097676711e-11
analyzed O 0 3.7745355285778714e-08
. O 0 1.4515060264841395e-09

The O 0 2.9192198658378743e-10
identification O 0 1.3226572614932763e-10
of O 0 1.4268623175356376e-12
two O 0 1.0463278854455638e-10
frequent O 0 2.175150228822531e-07
PDS B-Disease 0 0.0011131492210552096
mutations O 0 1.2613367289304733e-05
will O 0 1.8940841950421117e-10
facilitate O 0 5.0686652791620546e-11
the O 0 2.224482750778911e-11
molecular O 0 7.2097795964509714e-06
diagnosis O 1 0.9600563049316406
of O 0 1.3451125369101646e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 5.222841537033673e-07

Insertional O 0 3.553717033355497e-05
mutation O 0 1.50872736526253e-07
by O 0 2.396086280775922e-11
transposable O 0 8.258081862777544e-08
element O 0 4.373463013962464e-08
, O 0 1.4596711617187452e-09
L1 O 0 3.1547424441669136e-05
, O 0 3.726148001259588e-10
in O 0 4.368570782897763e-11
the O 0 1.20060805741673e-09
DMD B-Disease 1 0.9999997615814209
gene O 0 6.730165478074923e-05
results O 0 6.015421405436427e-08
in O 0 7.889944697581086e-09
X B-Disease 1 0.9999252557754517
- I-Disease 1 0.9999898672103882
linked I-Disease 1 0.9999963045120239
dilated I-Disease 1 0.9999775886535645
cardiomyopathy I-Disease 1 0.9999995231628418
. O 0 1.7103081972891232e-06

X B-Disease 1 0.9993835687637329
- I-Disease 1 0.9998618364334106
linked I-Disease 1 0.9999169111251831
dilated I-Disease 1 0.9999735355377197
cardiomyopathy I-Disease 1 0.9999998807907104
( O 0 3.335689484629256e-07
XLDCM B-Disease 0 0.00793895497918129
) O 0 5.180195161713641e-10
is O 0 9.163875908102526e-11
a O 0 8.279507635045036e-10
clinical O 0 9.778116236702772e-07
phenotype O 0 5.904971658310387e-07
of O 0 3.033591086665233e-11
dystrophinopathy B-Disease 0 0.028716396540403366
which O 0 5.24630401343984e-08
is O 0 1.3775616758415765e-10
characterized O 0 1.3527260200874025e-08
by O 0 1.2589292108788896e-10
preferential O 0 1.8986056602443568e-06
myocardial B-Disease 1 0.8232030868530273
involvement I-Disease 0 9.730490546644432e-08
without O 0 1.8594342732214386e-10
any O 0 2.2870025317978104e-11
overt O 0 1.9336589218710287e-08
clinical O 0 3.403690698178252e-06
signs O 0 1.7591638368230633e-07
of O 0 6.655835704805213e-08
skeletal B-Disease 1 0.9999998807907104
myopathy I-Disease 1 1.0
. O 0 5.0178594392491505e-05

To O 0 2.8261861739764527e-09
date O 0 1.2736627308385096e-09
, O 0 3.818277725248231e-12
several O 0 4.254083630500505e-12
mutations O 0 5.4622997680553453e-08
in O 0 8.045341060025635e-10
the O 0 2.133455296871034e-07
Duchenne B-Disease 1 0.999951958656311
muscular I-Disease 0 0.0185915008187294
dystrophy I-Disease 0 0.0056555140763521194
gene O 0 1.535917544970289e-05
, O 0 5.501184574541185e-08
DMD O 1 0.9999998807907104
, O 0 8.716900623539914e-08
have O 0 1.4642784762486372e-08
been O 0 1.981557140595669e-09
identified O 0 3.642155661509605e-07
in O 0 2.5570185968604164e-09
patients O 0 7.95586174717755e-09
with O 0 1.0884364243235467e-10
XLDCM B-Disease 0 0.13134224712848663
, O 0 6.4387499776330515e-09
but O 0 3.1472913164520833e-10
a O 0 1.5348521065217113e-12
pathogenic O 0 3.5717651059030686e-11
correlation O 0 5.478237863343338e-10
of O 0 5.289841047834143e-12
these O 0 5.976053540912574e-10
cardiospecific O 0 2.0930014215991832e-05
mutations O 0 9.322746336692944e-06
in O 0 2.459620240813365e-08
DMD O 1 0.9999996423721313
with O 0 2.863098558236743e-08
the O 0 3.5896576378036116e-08
XLDCM B-Disease 0 0.09369779378175735
phenotype O 0 0.00024863419821485877
has O 0 2.4958276867437235e-07
remained O 0 7.612968033754441e-09
to O 0 6.835416260786431e-11
be O 0 4.797015007440564e-10
elucidated O 0 9.811419658944942e-06
. O 0 3.0322924171599652e-09

We O 0 7.94580137153389e-06
report O 0 1.4723939845140421e-09
here O 0 4.435434224764334e-12
the O 0 8.181034517364127e-14
identification O 0 1.0724528036465397e-11
of O 0 3.0425577964184047e-13
a O 0 7.100381393954081e-10
unique O 0 2.8804880702892888e-09
de O 0 5.707790240450095e-09
novo O 0 1.7684287456631864e-07
L1 O 0 1.5467210801034526e-07
insertion O 0 5.587663221007233e-09
in O 0 8.517625493809078e-11
the O 0 2.0853841223300584e-11
muscle O 0 1.5038159606461932e-09
exon O 0 1.35462894235161e-08
1 O 0 2.7714277539558907e-09
in O 0 1.795488735467643e-08
DMD O 1 1.0
in O 0 8.91074165565442e-08
three O 0 1.21605685521331e-08
XLDCM B-Disease 0 0.000540329550858587
patients O 0 9.379160559319644e-09
from O 0 2.7892296220084767e-13
two O 0 8.462675872566994e-12
unrelated O 0 8.427204711836112e-09
Japanese O 0 1.3444247997540515e-05
families O 0 2.884517957824073e-09
. O 0 1.702211482879079e-09

The O 0 5.266851954566221e-10
insertion O 0 5.298230298933504e-09
was O 0 6.326244417209637e-09
a O 0 6.199311897159276e-11
5 O 0 8.383225780228543e-10
- O 0 1.228475412062835e-06
truncated O 0 2.423064188405988e-06
form O 0 2.3224894007967123e-08
of O 0 7.472317903323145e-12
human O 0 1.46275924706174e-09
L1 O 0 1.550849475506766e-07
inversely O 0 8.006885710010181e-10
integrated O 0 1.885820779534697e-07
in O 0 8.65821747630946e-10
the O 0 4.0666259248922643e-10
5 O 0 2.850863323189401e-09
- O 0 3.386365960977855e-06
untranslated O 0 0.0007168503361754119
region O 0 1.3947181969342637e-06
in O 0 3.911163892755809e-10
the O 0 2.710671097305717e-11
muscle O 0 7.373475163774401e-10
exon O 0 1.4008580961899497e-09
1 O 0 3.4159550188483934e-10
, O 0 2.3713722652196623e-10
which O 0 3.7515210382643716e-10
affected O 0 6.10045278182092e-11
the O 0 1.7253184558113643e-12
transcription O 0 1.0556829010965885e-07
or O 0 2.1369633174117553e-08
the O 0 2.7544273528690155e-09
stability O 0 6.135211805258223e-08
of O 0 1.4903276095851181e-12
the O 0 1.2221716971794194e-09
muscle O 0 3.802224313176339e-08
form O 0 4.383093540893945e-11
of O 0 9.965627498567664e-13
dystrophin O 0 1.81864393766773e-07
transcripts O 0 4.915116278425558e-07
but O 0 1.141125416381783e-08
not O 0 9.908322773366507e-11
that O 0 1.0400398424426083e-11
of O 0 1.2439240176104205e-12
the O 0 1.7934967289079395e-08
brain O 0 0.0001862483040895313
or O 0 1.4112750079675607e-08
Purkinje O 0 0.007114089094102383
cell O 1 0.5553541779518127
form O 0 1.3007922461838461e-05
, O 0 1.9890978819603333e-07
probably O 0 5.3037006182421464e-06
due O 0 4.24442125890323e-09
to O 0 4.5515907709514636e-10
its O 0 1.808501959299491e-11
unique O 0 3.267555323538396e-11
site O 0 1.6599887686652437e-08
of O 0 1.3670023446543667e-11
integration O 0 7.873081386833292e-08
. O 0 1.1208269867779563e-08

We O 0 8.795848316367483e-08
speculate O 0 1.4249607049876545e-09
that O 0 3.6780301027050655e-12
this O 0 7.693436951958579e-14
insertion O 0 5.762368707196153e-11
of O 0 5.107936643100608e-13
an O 0 9.744592632809912e-11
L1 O 0 0.00035285146441310644
sequence O 0 0.00010636982187861577
in O 0 1.336507011728827e-06
DMD O 1 1.0
is O 0 2.0839722481014178e-07
responsible O 0 2.584792380133649e-09
for O 0 1.2966455166518731e-12
some O 0 4.692557106777961e-13
of O 0 2.304383626191425e-13
the O 0 2.3702087167953856e-11
population O 0 5.114431881475534e-12
of O 0 5.787509685904746e-13
Japanese O 0 5.56661007067305e-06
patients O 0 3.3933370002792174e-10
with O 0 8.04085357325457e-12
XLDCM B-Disease 0 1.4962718523747753e-05
. O 0 3.6560018901177216e-10
. O 0 1.2404524074582923e-09

Severe O 0 0.0019790336955338717
early O 0 3.1101405966182938e-06
- O 1 0.9923831820487976
onset O 1 0.9999008178710938
obesity B-Disease 1 1.0
, O 0 0.031534574925899506
adrenal B-Disease 1 0.999998927116394
insufficiency I-Disease 1 0.9999996423721313
and O 0 0.00013234805373940617
red O 0 0.007758906111121178
hair O 1 0.9999566078186035
pigmentation O 1 0.8897125720977783
caused O 0 3.0551725558325415e-06
by O 0 3.694902162010294e-10
POMC O 0 0.0005914014182053506
mutations O 0 1.5422496289829724e-05
in O 0 1.6347168063646222e-09
humans O 0 4.0942438772617606e-07
. O 0 3.1166598191134653e-09

Sequential O 0 1.3716660305362893e-06
cleavage O 0 1.5164582691795658e-05
of O 0 2.918945293806097e-11
the O 0 8.47277109583544e-12
precursor O 0 8.843104026823312e-11
protein O 0 8.402307183352775e-10
pre O 0 9.560394431673558e-08
- O 0 1.929082463902887e-05
pro O 0 3.372223318365286e-07
- O 0 8.4943778347224e-05
opiomelanocortin O 0 5.760515705333091e-06
( O 0 2.2055430398681963e-11
POMC O 0 2.2260225662762423e-08
) O 0 4.775644940266388e-13
generates O 0 3.3141013804777186e-12
the O 0 9.430341056659852e-12
melanocortin O 0 1.3179497670989804e-07
peptides O 0 1.6734677643626128e-08
adrenocorticotrophin O 0 4.4248895392229315e-07
( O 0 8.838534765187589e-11
ACTH O 0 7.345941099856645e-08
) O 0 2.1261901961278085e-11
, O 0 2.5934220049261825e-11
melanocyte O 0 1.4605027445213636e-06
- O 0 0.00018836573872249573
stimulating O 0 6.242902941266948e-07
hormones O 0 3.9505954063656645e-09
( O 0 7.576115841449738e-13
MSH O 0 6.808566599403321e-09
) O 0 2.6343201708564634e-13
alpha O 0 2.849123660522007e-13
, O 0 1.277387348458045e-13
beta O 0 1.0803744644781801e-13
and O 0 7.19728503141212e-14
gamma O 0 4.935602165682951e-13
as O 0 4.79582996579242e-12
well O 0 2.838591124307288e-12
as O 0 4.3950598911136896e-13
the O 0 2.7439343657474635e-13
opioid O 0 2.4048860125525096e-11
- O 0 1.4434966555398887e-09
receptor O 0 1.798241590356131e-11
ligand O 0 9.306729692459825e-11
beta O 0 3.462694297962088e-10
- O 0 8.396689850087569e-07
endorphin O 0 3.909858605766203e-06
. O 0 4.966255406912978e-09

While O 0 7.739007656937247e-09
a O 0 2.6873716793551772e-11
few O 0 2.5700025441111052e-11
cases O 0 3.581459087631522e-11
of O 0 3.4692987371798267e-10
isolated O 1 0.999924898147583
ACTH B-Disease 1 0.9994280934333801
deficiency I-Disease 1 0.9266470670700073
have O 0 1.527792647948445e-08
been O 0 3.185979480235801e-08
reported O 0 4.0519972799302195e-07
( O 0 7.365660303904065e-10
OMIM O 0 0.02577322907745838
201400 O 0 5.8780751714948565e-06
) O 0 5.31313382179377e-10
, O 0 7.293662340757123e-10
an O 0 4.527134223053508e-09
inherited O 1 0.9532010555267334
POMC O 1 0.9984966516494751
defect O 1 0.9301058650016785
has O 0 1.1899300034201588e-06
not O 0 9.304786274810795e-09
been O 0 1.2445285912932036e-09
described O 0 1.2818912153989004e-08
so O 0 1.1654395226656789e-09
far O 0 5.310125117397035e-10
. O 0 1.0523809601536982e-09

Recent O 0 1.7744225999649643e-07
studies O 0 4.833211164623208e-09
in O 0 1.2538673224704588e-11
animal O 0 3.361586342620626e-09
models O 0 2.6930340180086887e-09
elucidated O 0 1.5593444402384193e-07
a O 0 5.612052836334591e-11
central O 0 3.2306959885097797e-10
role O 0 1.42956263146643e-11
of O 0 2.5779779786599955e-13
alpha O 0 3.091618280826047e-11
- O 0 2.824464218065259e-07
MSH O 0 4.751543656311696e-06
in O 0 6.829851267875497e-11
the O 0 6.10405823109339e-12
regulation O 0 6.032144228562686e-10
of O 0 1.6328686449837426e-13
food O 0 4.114106277874896e-10
intake O 0 2.6201915637180662e-11
by O 0 6.763803384567113e-14
activation O 0 3.0075371446752763e-12
of O 0 7.8211558323521e-13
the O 0 1.448151820682142e-09
brain O 0 1.9203630472475197e-06
melanocortin O 0 4.8219249038083944e-08
- O 0 4.56643931556755e-07
4 O 0 2.379787478190565e-09
- O 0 3.830921002645482e-07
receptor O 0 2.3064405940687038e-10
( O 0 5.161707433004592e-12
MC4 O 0 5.731718033530342e-08
- O 0 5.860427165771398e-08
R O 0 3.2419842455055914e-07
; O 0 4.739741932269226e-11
refs O 0 1.7862115342381912e-08
3 O 0 7.51864265291502e-11
- O 0 8.605049117704766e-08
5 O 0 1.197234533734104e-10
) O 0 2.8652067697587658e-12
and O 0 3.750431562532519e-11
the O 0 9.0486481155172e-12
linkage O 0 4.261399681126932e-06
of O 0 1.788739573127529e-10
human O 0 8.3615341281984e-06
obesity B-Disease 1 0.9999998807907104
to O 0 2.129761078606407e-08
chromosome O 0 3.546221705619246e-05
2 O 0 4.925568397595725e-09
in O 0 3.8527162016244176e-10
close O 0 3.352137767365093e-08
proximity O 0 2.8734882562275743e-07
to O 0 1.5345587023318785e-09
the O 0 2.922707353913978e-10
POMC O 0 1.4265668141888455e-05
locus O 0 4.925768237740158e-08
, O 0 2.120061237675941e-09
led O 0 1.1613410233479726e-09
to O 0 2.574427823698322e-11
the O 0 4.9008587986454355e-12
proposal O 0 9.721665139572622e-11
of O 0 5.300878551210697e-13
an O 0 3.0154479607746865e-11
association O 0 1.2003388734360687e-11
of O 0 9.951306272071303e-13
POMC O 0 0.0003041150339413434
with O 0 4.928850927399253e-08
human O 0 6.449544889619574e-05
obesity B-Disease 1 0.9999992847442627
. O 0 2.1466456701091374e-07

The O 0 5.316996842807953e-10
dual O 0 2.0188983818059114e-09
role O 0 1.588675718755539e-10
of O 0 1.71611249516479e-12
alpha O 0 2.6714486178747165e-10
- O 0 2.274127382406732e-06
MSH O 0 1.2885468095191754e-05
in O 0 4.201470074627345e-11
regulating O 0 2.574808588562405e-09
food O 0 4.528299513140155e-09
intake O 0 3.414849292227018e-09
and O 0 4.96222896106957e-10
influencing O 0 3.6475082509923595e-08
hair O 1 0.9240432381629944
pigmentation O 0 0.0004164662677794695
predicts O 0 1.4668302128484356e-06
that O 0 8.461813472138147e-10
the O 0 1.2780033975534622e-10
phenotype O 0 1.3872260069547337e-06
associated O 0 5.6414428684092854e-09
with O 0 3.1435179459471385e-10
a O 0 6.065469193572426e-08
defect O 0 0.00022968818666413426
in O 0 3.3612126970616885e-10
POMC O 0 0.00014286547957453877
function O 0 1.8900249187936424e-07
would O 0 2.2779246933168906e-08
include O 0 1.0509836556593655e-07
obesity B-Disease 1 0.9999998807907104
, O 0 2.2232432783653167e-08
alteration O 0 2.244941242679488e-05
in O 0 1.9454864741419442e-07
pigmentation O 1 0.9983931183815002
and O 0 0.021052293479442596
ACTH B-Disease 1 0.9914002418518066
deficiency I-Disease 1 0.8166922330856323
. O 0 8.25702262119421e-09

The O 0 1.2870009502563562e-09
observation O 0 1.5943119535677397e-07
of O 0 1.3270003151877319e-11
these O 0 1.2370224844460154e-08
symptoms O 0 3.153128318444942e-06
in O 0 2.7706425695384063e-11
two O 0 2.3491736333980384e-10
probands O 0 3.6717508464789717e-06
prompted O 0 4.923076946106164e-10
us O 0 1.0132077121749461e-10
to O 0 4.53867802716057e-12
search O 0 5.6752068322563076e-11
for O 0 2.8847061458309176e-12
mutations O 0 5.5417086031184226e-08
within O 0 2.9827298964058e-10
their O 0 1.114388803458155e-09
POMC O 0 8.682441693963483e-05
genes O 0 7.235984185172128e-07
. O 0 1.1551449574653816e-08

Patient O 0 0.00035877045593224466
1 O 0 1.8199958207176792e-09
was O 0 2.0870821515472926e-08
found O 0 2.8952151787109415e-10
to O 0 2.2848879038805947e-11
be O 0 5.394822175791569e-12
a O 0 8.591399076537942e-13
compound O 0 1.8941790358439903e-09
heterozygote O 0 5.876808484295282e-10
for O 0 7.676042418879037e-13
two O 0 2.3504812679542297e-11
mutations O 0 5.992561558088028e-09
in O 0 5.324237144915811e-12
exon O 0 1.0557634055885501e-07
3 O 0 6.4189591419960834e-09
( O 0 2.2385752973530515e-11
G7013T O 0 4.724648761111894e-08
, O 0 1.4701649619919266e-10
C7133delta O 0 5.854756750522938e-07
) O 0 9.620558689971137e-12
which O 0 3.5051805208352604e-11
interfere O 0 3.6597971875274027e-10
with O 0 1.2055833761848156e-12
appropriate O 0 2.177075360265679e-12
synthesis O 0 1.6141984970907686e-10
of O 0 5.663611940542879e-12
ACTH O 0 3.814086255715665e-07
and O 0 2.7391697243750457e-10
alpha O 0 7.767855247919897e-10
- O 0 8.267384146165568e-06
MSH O 0 0.00016908715770114213
. O 0 5.536128000471763e-09

Patient O 0 0.00021446340542752296
2 O 0 4.3278292061188495e-09
was O 0 4.132927333699854e-10
homozygous O 0 1.8923689004690658e-10
for O 0 4.1350503208158196e-13
a O 0 2.7536259730731594e-11
mutation O 0 5.0976298737737125e-09
in O 0 1.1980926667432001e-11
exon O 0 6.17780187894823e-07
2 O 0 3.834794881640846e-08
( O 0 2.2205669247821191e-10
C3804A O 0 9.105070120085657e-08
) O 0 9.6720798037353e-11
which O 0 8.022921771377867e-10
abolishes O 0 2.8894624847453088e-05
POMC O 0 0.0009086754289455712
translation O 0 1.6366414001822704e-06
. O 0 2.3506371960024808e-08

These O 0 4.987537494116623e-09
findings O 0 3.7669656283156883e-10
represent O 0 1.454128744499128e-11
the O 0 6.520831791201331e-11
first O 0 5.402396308085144e-10
examples O 0 1.9366466763592882e-10
of O 0 1.0507592192177118e-11
a O 0 2.5001470476126997e-06
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999995231628418
within O 0 8.687265351525753e-10
the O 0 8.738529344576307e-11
POMC O 0 5.929733561060857e-06
gene O 0 2.1924148541074828e-07
and O 0 4.979645584768377e-10
define O 0 1.29889317079801e-08
a O 0 3.4496698830821515e-09
new O 0 3.086438482569065e-07
monogenic B-Disease 1 0.9924579858779907
endocrine I-Disease 1 0.8066806793212891
disorder I-Disease 0 0.02442866936326027
resulting O 0 3.673562565253974e-09
in O 0 3.775426193897147e-09
early O 0 3.443365858402103e-05
- O 1 0.9999604225158691
onset O 1 0.9999854564666748
obesity B-Disease 1 1.0
, O 0 0.014717289246618748
adrenal B-Disease 1 0.9999986886978149
insufficiency I-Disease 1 0.9999992847442627
and O 0 1.8509441360947676e-05
red O 0 6.876523548271507e-05
hair O 1 0.9979152083396912
pigmentation O 0 0.017068324610590935
. O 0 1.1311658276724756e-08
. O 0 1.8771062482159095e-09

A O 0 1.818990824631328e-07
European O 0 7.044486949325801e-08
multicenter O 0 6.937825673958287e-06
study O 0 2.7531681823234067e-08
of O 0 3.831921446817432e-08
phenylalanine B-Disease 1 0.9999997615814209
hydroxylase I-Disease 1 0.9999969005584717
deficiency I-Disease 1 1.0
: O 0 1.8888261621441416e-08
classification O 0 2.829127936365694e-07
of O 0 8.534566282858425e-12
105 O 0 3.417307681274906e-08
mutations O 0 3.3542278288223315e-06
and O 0 7.661675183179284e-10
a O 0 9.569552615606991e-12
general O 0 1.2338912877551955e-11
system O 0 1.7587552247899652e-10
for O 0 8.885515478777861e-13
genotype O 0 7.60542118172225e-09
- O 0 6.518640560670974e-08
based O 0 9.443453796720291e-10
prediction O 0 1.1497753860112425e-07
of O 0 5.859309131633905e-12
metabolic O 0 5.8316065405961126e-05
phenotype O 0 1.4100681255513337e-05
. O 0 6.725112466909877e-09

Phenylketonuria B-Disease 0 0.010204343125224113
( O 0 2.18891171854807e-09
PKU B-Disease 0 3.2105992886499735e-06
) O 0 1.6378250977666653e-09
and O 0 3.424230783366511e-07
mild B-Disease 0 0.029857132583856583
hyperphenylalaninemia I-Disease 1 0.9999998807907104
( O 0 3.2461157388752326e-05
MHP B-Disease 1 1.0
) O 0 1.3368291718052205e-07
are O 0 1.6393011392779044e-08
allelic B-Disease 0 0.014808624982833862
disorders I-Disease 1 0.9997007846832275
caused O 0 9.084755703270275e-08
by O 0 2.4092935979602714e-11
mutations O 0 6.016614975123957e-07
in O 0 3.315771962553171e-11
the O 0 7.176679389653273e-11
gene O 0 3.9029563936310296e-07
encoding O 0 2.5922595341398846e-06
phenylalanine O 0 0.15953592956066132
hydroxylase O 0 0.010082230903208256
( O 0 5.972626837547068e-09
PAH O 0 3.938282679882832e-05
) O 0 4.945334697303849e-10
. O 0 8.943936147254306e-10

Previous O 0 7.680482667637989e-07
studies O 0 9.123006350364449e-09
have O 0 3.876746701436673e-10
suggested O 0 6.944346209181163e-10
that O 0 2.4340742962869477e-11
the O 0 9.274916772106234e-12
highly O 0 8.107683413527411e-10
variable O 0 5.83820849442418e-07
metabolic O 0 0.06039039418101311
phenotypes O 0 0.0001233783405041322
of O 0 3.196870181909617e-07
PAH B-Disease 1 0.999902606010437
deficiency I-Disease 1 0.9980564713478088
correlate O 0 8.316189632751048e-05
with O 0 9.357521548736258e-07
PAH O 1 0.5829275846481323
genotypes O 0 0.0001236544194398448
. O 0 3.4760184064452915e-08

We O 0 5.05382615756389e-07
identified O 0 2.3124104853167182e-09
both O 0 4.136616396643866e-11
causative O 0 2.9573186566267395e-07
mutations O 0 3.2572797863394953e-06
in O 0 8.864302070143992e-10
686 O 0 1.8259376020068885e-06
patients O 0 3.858600337025564e-07
from O 0 2.0158449562379666e-11
seven O 0 1.7706039967535503e-09
European O 0 7.007030067285314e-09
centers O 0 4.249113487730938e-07
. O 0 5.939137626143065e-09

On O 0 1.2149603101363482e-08
the O 0 3.0998417808320022e-12
basis O 0 1.0530861122362567e-12
of O 0 2.992199790350335e-14
the O 0 2.1427586267830367e-12
phenotypic O 0 1.3509023899516137e-09
characteristics O 0 3.0755999969045433e-09
of O 0 4.604018555287581e-12
297 O 0 1.6875397079729737e-07
functionally O 0 9.37040567805525e-06
hemizygous O 0 0.0008716110023669899
patients O 0 1.0578371529845754e-06
, O 0 2.6412847603518586e-12
105 O 0 6.9354876008898e-11
of O 0 3.4705902431445e-13
the O 0 8.359510306199525e-11
mutations O 0 1.35301760906259e-08
were O 0 3.046974825227089e-11
assigned O 0 3.8862377205184373e-10
to O 0 2.2810342156787122e-11
one O 0 3.513820744788232e-12
of O 0 8.597230593447927e-14
four O 0 2.0695896385536372e-11
arbitrary O 0 2.4843126311679953e-07
phenotype O 0 8.621149390819483e-06
categories O 0 3.559903234418016e-07
. O 0 4.122256314076367e-08

We O 0 4.462266076643573e-07
proposed O 0 7.003298496677246e-10
and O 0 3.0304827536298262e-09
tested O 0 8.386380478953015e-09
a O 0 1.582365748847847e-12
simple O 0 3.503556472717051e-11
model O 0 2.7845298289363996e-10
for O 0 1.9895590979823047e-13
correlation O 0 1.522157844213723e-09
between O 0 1.668602478410719e-10
genotype O 0 5.155253646194069e-08
and O 0 5.397411406704578e-10
phenotypic O 0 6.60436754174043e-08
outcome O 0 5.5979924695748196e-08
. O 0 1.0182788834356415e-08

The O 0 2.435442070236604e-09
observed O 0 7.594345596828589e-09
phenotype O 0 2.178172451294813e-07
matched O 0 1.5048159696107177e-07
the O 0 7.904004534209363e-11
predicted O 0 1.5447857037997892e-07
phenotype O 0 9.767938990989933e-07
in O 0 3.2919539316722535e-10
79 O 0 5.266073799248261e-08
% O 0 3.777552923245331e-12
of O 0 4.775089286652989e-13
the O 0 1.565329532660087e-09
cases O 0 2.7015550685405287e-08
, O 0 1.3812043064831414e-08
and O 0 1.1456309678692378e-08
in O 0 2.955073130639363e-10
only O 0 1.647772890356336e-10
5 O 0 4.17463633106685e-12
of O 0 1.621874428378925e-13
184 O 0 1.385565218114948e-09
patients O 0 7.22343296288841e-09
was O 0 2.8971667287436276e-09
the O 0 1.0598915842208179e-11
observed O 0 2.65334132443229e-09
phenotype O 0 2.375198482340579e-09
more O 0 1.4775702363023502e-13
than O 0 6.312518216478047e-12
one O 0 2.693495149141967e-10
category O 0 1.1366505070498079e-08
away O 0 2.474914495564917e-08
from O 0 8.388223275701545e-12
that O 0 2.141943566957849e-10
expected O 0 5.208808939727305e-10
. O 0 1.7362613569105179e-09

Among O 0 2.3488970768426043e-09
the O 0 6.52212589491441e-11
seven O 0 2.3210953992158778e-11
contributing O 0 1.7701732440977835e-11
centers O 0 4.259863128908137e-09
, O 0 1.1810764866115875e-10
the O 0 1.3379309812822093e-11
proportion O 0 1.5761862648400182e-10
of O 0 4.8236631702835986e-12
patients O 0 2.1961756857535875e-09
for O 0 5.78619617497278e-13
whom O 0 9.222863445179641e-11
the O 0 5.373390100926745e-12
observed O 0 1.7314000233525917e-09
phenotype O 0 4.3239285929530524e-08
did O 0 1.1726941551160053e-07
not O 0 1.7323380507860975e-09
match O 0 3.17305044461591e-08
the O 0 2.9586246647062e-11
predicted O 0 9.774930020967076e-08
phenotype O 0 1.9287752195396024e-07
was O 0 3.318713126532202e-08
4 O 0 1.1215316175761103e-10
% O 0 2.406097369955784e-11
- O 0 3.6640096823248314e-06
23 O 0 1.504826840914575e-08
% O 0 6.377603306573221e-12
( O 0 1.7064127888488656e-11
P O 0 6.544971984112635e-05
< O 0 1.26306545666921e-07
. O 0 1.1245352427025068e-09
0001 O 0 3.2290120088873664e-07
) O 0 6.083427598474467e-12
, O 0 1.6686930700074432e-12
suggesting O 0 8.270097107132557e-11
that O 0 7.88995119238578e-11
differences O 0 2.1462048804821166e-10
in O 0 1.1650021225495522e-12
methods O 0 6.228740440095137e-11
used O 0 6.94568083603464e-11
for O 0 1.0374359791370802e-12
mutation O 0 1.7787378236988616e-09
detection O 0 2.1723640486470686e-07
or O 0 1.2048438691181218e-07
phenotype O 0 0.0025467542000114918
classification O 0 0.03316644951701164
may O 0 2.749086434050696e-07
account O 0 8.353123193138856e-10
for O 0 3.02699467054357e-12
a O 0 6.787502504490561e-11
considerable O 0 6.1096258260895375e-12
proportion O 0 8.309277571560969e-11
of O 0 4.577015849660526e-12
genotype O 0 1.4359316082845908e-06
- O 0 0.00015480470028705895
phenotype O 0 4.263278242433444e-05
inconsistencies O 0 1.0837994523171801e-05
. O 0 2.338839522053604e-08

Our O 0 2.0713144976980402e-08
data O 0 3.568840778456206e-09
indicate O 0 2.7863586993248646e-09
that O 0 2.6140631326221353e-10
the O 0 4.1833680963776487e-10
PAH O 0 5.147872070665471e-05
- O 0 1.0377040780440439e-05
mutation O 0 1.565552025795114e-07
genotype O 0 1.9131187301013597e-08
is O 0 3.349531416119156e-11
the O 0 2.554947572952493e-12
main O 0 4.895762129031311e-10
determinant O 0 8.25581025765132e-09
of O 0 3.16107869047233e-11
metabolic O 0 0.00012102850450901315
phenotype O 0 6.848737939435523e-06
in O 0 8.633004311420223e-10
most O 0 4.539498554834154e-09
patients O 0 3.312964338419988e-07
with O 0 1.0347464467486134e-06
PAH B-Disease 1 0.9999195337295532
deficiency I-Disease 1 0.9989872574806213
. O 0 2.361746709311774e-08

In O 0 4.417769705611363e-09
the O 0 3.7033317384915776e-11
present O 0 5.6580191920563294e-12
study O 0 1.585181812202574e-11
, O 0 2.9828860735603424e-12
the O 0 8.48051576879394e-12
classification O 0 3.994985675603857e-08
of O 0 1.0977219133678773e-11
105 O 0 6.450393357226858e-07
PAH O 0 4.520187576417811e-05
mutations O 0 1.5367790183518082e-05
may O 0 1.6014634063310496e-09
allow O 0 7.737446100497536e-12
the O 0 9.137010592574768e-12
prediction O 0 7.117702693903993e-08
of O 0 2.99817679363934e-13
the O 0 1.0599972288805048e-10
biochemical O 0 3.122397629340412e-07
phenotype O 0 2.486492611808444e-08
in O 0 1.6871825117559247e-11
> O 0 1.880327671344162e-09
10 O 0 9.947786344666198e-11
, O 0 4.138731371505777e-11
000 O 0 1.0238223463465701e-10
genotypes O 0 3.7652885254146895e-08
, O 0 1.6449349660163648e-09
which O 0 2.7967482552071488e-08
may O 0 2.0923035748410257e-08
be O 0 2.645278961155295e-11
useful O 0 1.1247935742531023e-11
for O 0 1.0875035681007228e-12
the O 0 1.5223285132481834e-10
management O 0 7.542666047299917e-09
of O 0 1.8841778831601985e-11
hyperphenylalaninemia B-Disease 1 0.9999995231628418
in O 0 1.0984272194036748e-06
newborns O 0 1.9396600691834465e-05
. O 0 1.101178925821955e-09

Somatic O 0 1.836782212194521e-05
instability O 0 4.696531959780259e-06
of O 0 2.2355246126481987e-11
the O 0 2.638075036198728e-10
CTG O 0 1.6642719856463373e-05
repeat O 0 2.064398586298921e-06
in O 0 9.159611957798575e-11
mice O 0 2.0207801298965933e-07
transgenic O 0 6.385064210689961e-08
for O 0 6.936761165476923e-10
the O 0 4.582564542943146e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 0.0003599995980039239
is O 0 6.369761962332632e-08
age O 0 2.323423231587185e-09
dependent O 0 4.521143182056875e-10
but O 0 1.1669631927446744e-09
not O 0 1.2413836451841131e-11
correlated O 0 1.1028515600752797e-10
to O 0 4.310432653170659e-12
the O 0 4.513384457838221e-12
relative O 0 1.5056721147654883e-10
intertissue O 0 1.6524789714367216e-07
transcription O 0 6.133673196018208e-07
levels O 0 3.9783479621746665e-08
and O 0 7.56638307564117e-09
proliferative O 0 0.005622771102935076
capacities O 0 3.4471574963390594e-06
. O 0 1.3172104296188536e-08

A O 0 7.551579983555712e-08
( O 0 2.1136244143793448e-10
CTG O 0 9.376570631047798e-08
) O 0 3.723077054984536e-11
nexpansion O 0 1.8467972040525638e-07
in O 0 1.5938018960159894e-10
the O 0 2.4249838248557865e-10
3 O 0 1.284905124521174e-07
- O 0 0.0060343206860125065
untranslated O 0 0.4974097013473511
region O 0 1.1253703632974066e-05
( O 0 4.417942053858148e-11
UTR O 0 2.3727098152903636e-07
) O 0 3.899443268284841e-12
of O 0 2.9968733115774693e-13
the O 0 1.7099691662636474e-09
DM O 1 0.9999988079071045
protein O 0 1.6523133581358707e-06
kinase O 0 1.5147002159210388e-06
gene O 0 2.2992846879787976e-06
( O 0 9.267316775085632e-11
DMPK O 0 3.4008160127996234e-06
) O 0 1.2831270768121072e-11
is O 0 8.95924220228883e-12
responsible O 0 1.7632468818362668e-09
for O 0 1.105006086632443e-09
causing O 0 0.005325707141309977
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 0.9999998807907104
( O 0 1.986797542485874e-06
DM B-Disease 1 0.999998927116394
) O 0 6.101742400232979e-08
. O 0 1.3008592425478582e-08

Major O 0 3.828148692264222e-06
instability O 0 4.019249900011346e-05
, O 0 9.566442082942217e-10
with O 0 4.982626464200557e-11
very O 0 3.580414090209594e-11
large O 0 7.643160410131244e-12
expansions O 0 9.779144960475605e-08
between O 0 3.0635978198745306e-09
generations O 0 5.838979966199531e-09
and O 0 5.062812391543048e-10
high O 0 1.6154613757812797e-10
levels O 0 2.482962793703969e-11
of O 0 2.648012560092783e-13
somatic O 0 6.339821112533173e-09
mosaicism O 0 1.9206413526262622e-06
, O 0 5.958295662411572e-11
is O 0 9.275747704651227e-12
observed O 0 1.34730759882018e-09
in O 0 1.3517065244883497e-09
patients O 0 2.5154955451966998e-08
. O 0 8.096016079761625e-10

There O 0 1.4523077140893292e-07
is O 0 9.464060785058237e-11
a O 0 1.4478519078098273e-11
good O 0 8.646248994548245e-11
correlation O 0 3.693013950201163e-10
between O 0 3.24805821128038e-10
repeat O 0 2.0176462385279592e-06
size O 0 9.348405605180687e-09
( O 0 5.0927661393584955e-11
at O 0 4.0121959088423864e-09
least O 0 3.105109919188109e-11
in O 0 7.108331978589177e-11
leucocytes O 0 5.883335688849911e-06
) O 0 2.7829674328905263e-11
, O 0 2.311032441804084e-11
clinical O 0 4.756893190460687e-08
severity O 0 3.8006585327821085e-06
and O 0 3.1624466600987944e-08
age O 0 3.466032794108287e-09
of O 0 4.875054873676454e-11
onset O 0 0.0001721902226563543
. O 0 8.093707748457746e-08

The O 0 4.167436529201041e-08
trinucleotide O 0 0.0006687867571599782
repeat O 0 0.0003832320508081466
instability O 0 2.6025793431472266e-06
mechanisms O 0 5.250167944836903e-08
involved O 0 2.882410143900671e-10
in O 0 1.0716323828319219e-08
DM B-Disease 1 1.0
and O 0 0.00033924225135706365
other O 0 9.405749068491787e-08
human O 0 0.009017945267260075
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 2.5836683903435187e-09
unknown O 0 2.4143304244717e-07
. O 0 7.207056285096769e-09

We O 0 2.959812945846352e-07
studied O 0 5.9336686675237615e-09
somatic O 0 2.8280641828359876e-08
instability O 0 5.936162139619228e-08
by O 0 4.083480081851221e-12
measuring O 0 5.477688205246523e-07
the O 0 2.3885809996571084e-10
CTG O 0 6.802805728511885e-06
repeat O 0 3.3054577670554863e-06
length O 0 2.490729684723192e-07
at O 0 1.2009177652316794e-08
several O 0 7.338647745047666e-11
ages O 0 3.428301553753954e-08
in O 0 7.024217318907233e-11
various O 0 3.027891132267868e-11
tissues O 0 3.115395585950864e-08
of O 0 3.9829240166405766e-13
transgenic O 0 3.981282134191133e-06
mice O 0 1.393791421833157e-06
carrying O 0 3.121648078918682e-11
a O 0 2.026640660846013e-10
( O 0 3.426812306139837e-11
CTG O 0 5.864720833415049e-07
) O 0 1.6603503294465582e-11
55expansion O 0 8.344018809225417e-09
surrounded O 0 6.305641009340945e-10
by O 0 5.569874422794996e-12
45 O 0 2.500294936369496e-11
kb O 0 8.190363587345928e-08
of O 0 8.490695126150971e-12
the O 0 1.6839210026375895e-09
human O 0 1.0478147487447131e-06
DM B-Disease 1 0.9999998807907104
region O 0 1.9199162579752738e-06
, O 0 1.6329979035667463e-11
using O 0 2.8844324498344953e-11
small O 0 6.884025571807229e-10
- O 0 3.980009933002293e-05
pool O 0 2.5209141085724696e-07
PCR O 0 3.8208432329156494e-07
. O 0 6.105647654131019e-10

These O 0 4.672910236536154e-08
mice O 0 7.476026894437382e-06
have O 0 6.842411637286716e-10
been O 0 4.747504819824222e-11
shown O 0 1.491668594200135e-10
to O 0 5.162723720752993e-11
reproduce O 0 2.5340898446302162e-06
the O 0 4.449290241792525e-11
intergenerational O 0 2.8512627636700927e-07
and O 0 2.3885824429470404e-09
somatic O 0 3.725368458162848e-09
instability O 0 3.732639086706513e-08
of O 0 2.429740870307784e-12
the O 0 2.0065130112989493e-10
55 O 0 7.658713663261096e-09
CTG O 0 1.4963197827455588e-06
repeat O 0 5.72917109309401e-08
suggesting O 0 1.9176323029501674e-10
that O 0 3.970411239367921e-12
surrounding O 0 1.064131768813148e-10
sequences O 0 2.0543507162074093e-06
and O 0 1.0952933671148912e-08
the O 0 4.450792512322721e-11
chromatin O 0 7.707148341751235e-08
environment O 0 5.475652287145749e-08
are O 0 1.1836213432980802e-12
involved O 0 1.5574005626795007e-11
in O 0 1.907723840011144e-10
instability O 0 2.7946211389462405e-07
mechanisms O 0 5.192050878122245e-08
. O 0 2.3224349110506637e-09

As O 0 2.2063826321527813e-09
observed O 0 1.0893798085831463e-09
in O 0 1.841755480763707e-12
some O 0 4.209647767091512e-13
of O 0 1.5598373287462053e-12
the O 0 3.0037579090702593e-09
tissues O 0 5.017978992327699e-07
of O 0 1.31594157792847e-09
DM B-Disease 1 1.0
patients O 0 0.11271680891513824
, O 0 5.590069518390806e-10
there O 0 2.125591092028145e-10
is O 0 3.8853836814567444e-11
a O 0 6.166715055266891e-11
tendency O 0 2.984542391004652e-08
for O 0 1.2639136265368833e-11
repeat O 0 7.902823426775285e-07
length O 0 8.660951777983428e-08
and O 0 2.4940147724805684e-09
somatic O 0 6.66049104758315e-10
mosaicism O 0 5.214938028075267e-07
to O 0 2.0633748876175417e-10
increase O 0 5.838926564472047e-12
with O 0 1.1829025259313397e-10
the O 0 8.441373156031773e-10
age O 0 4.63664689975829e-10
of O 0 4.150727613179417e-13
the O 0 5.684450687937215e-10
mouse O 0 5.134487946634181e-05
. O 0 1.8811464386203625e-08

Furthermore O 0 8.12717462395085e-06
, O 0 2.282324773617006e-09
we O 0 6.061623980535558e-10
observed O 0 4.9001504243140204e-11
no O 0 7.296160203784652e-12
correlation O 0 5.217349885455747e-10
between O 0 1.0716777291974733e-11
the O 0 4.204562479431795e-12
somatic O 0 2.469391580106617e-09
mutation O 0 8.042968033805664e-07
rate O 0 3.494660177238984e-06
and O 0 4.078623874192999e-07
tissue O 0 0.0026970377657562494
proliferation O 0 4.253763472661376e-05
capacity O 0 2.307642965604373e-09
. O 0 2.774516394410398e-09

The O 0 1.3301640899854306e-09
somatic O 0 1.0777552184038086e-08
mutation O 0 3.0010681939529604e-07
rates O 0 2.6114599904758506e-07
in O 0 1.5788936130745057e-11
different O 0 5.1158494107639285e-11
tissues O 0 6.925886282260763e-07
were O 0 7.456923967197326e-09
also O 0 9.86778392331189e-09
not O 0 5.182191897823429e-10
correlated O 0 1.2763718970631999e-09
to O 0 2.719113267879436e-10
the O 0 3.0160535180456804e-10
relative O 0 4.8911189765021845e-08
inter O 0 1.9012909433513414e-06
- O 0 0.0004849251126870513
tissue O 0 2.3049551600706764e-05
difference O 0 6.450891487652655e-10
in O 0 6.215940305878687e-13
transcriptional O 0 3.34577254790247e-10
levels O 0 6.762020804407243e-11
of O 0 3.7498392520436685e-14
the O 0 3.462963249489803e-11
three O 0 3.711649321225252e-10
genes O 0 3.1925111443342757e-09
( O 0 1.2513944741554539e-11
DMAHP O 0 8.692840651747247e-07
, O 0 1.747973293886318e-10
DMPK O 0 4.7152147999440785e-06
and O 0 2.2453692238855183e-08
59 O 0 1.3152121169923703e-08
) O 0 6.089905489614633e-12
surrounding O 0 4.593707636502131e-10
the O 0 1.743163280387705e-09
repeat O 0 3.7005274862167425e-06
. O 0 2.6425420185383075e-10
. O 0 1.1481854356176768e-09

A O 0 2.742465810001704e-08
novel O 0 4.790354068973102e-08
missense O 0 6.4086998463608325e-06
mutation O 0 1.404056547471555e-05
in O 0 2.448903968499394e-09
patients O 0 2.3499739043586487e-08
from O 0 3.830824980149972e-12
a O 0 2.354315409291985e-09
retinoblastoma B-Disease 0 0.02271861396729946
pedigree O 0 0.00012115008576074615
showing O 0 2.0775469522504864e-07
only O 0 4.202323822255494e-09
mild O 0 1.3334646276064177e-08
expression O 0 4.993322422208735e-10
of O 0 5.223637928458702e-12
the O 0 1.1637496299954364e-08
tumor B-Disease 0 9.644999954616651e-05
phenotype O 0 2.081432830891572e-05
. O 0 8.84343442919544e-09

We O 0 3.4876541121775517e-07
have O 0 1.505608311636042e-11
used O 0 8.691747842293207e-12
single O 0 3.8368374449815335e-11
strand O 0 3.2500076940777944e-07
conformation O 0 1.3127604558960115e-09
polymorphism O 0 2.6769637617718445e-09
analysis O 0 8.958397912373073e-10
to O 0 1.6409566414021803e-11
study O 0 1.379180450400419e-11
the O 0 5.442612506512123e-12
27 O 0 4.290921784555479e-10
exons O 0 1.5573256462175777e-08
of O 0 5.794106080342365e-12
the O 0 1.4557285377136964e-09
RB1 O 0 4.493663709581597e-06
gene O 0 4.321999469425464e-08
in O 0 1.428094448252537e-10
individuals O 0 2.3236900684869832e-12
from O 0 7.488236376460011e-13
a O 0 6.629097826227337e-10
family O 0 3.106933377239329e-08
showing O 0 1.0135319428172807e-07
mild O 0 1.1696087653945142e-08
expression O 0 3.3975336433123005e-10
of O 0 1.7996817144178001e-12
the O 0 3.889547350865996e-09
retinoblastoma B-Disease 0 0.0006233678432181478
phenotype O 0 4.221845301799476e-05
. O 0 6.269163854710769e-09

In O 0 1.6895551624429572e-08
this O 0 5.241487799345634e-10
family O 0 9.116291721511516e-09
affected O 0 3.11512038386752e-09
individuals O 0 6.052009587920182e-11
developed O 0 4.9544672947376966e-05
unilateral B-Disease 1 0.9999092817306519
tumors I-Disease 1 1.0
and O 0 0.0005537666147574782
, O 0 5.944622571973923e-09
as O 0 6.45074382799038e-10
a O 0 5.763558519333856e-10
result O 0 6.576982847228408e-10
of O 0 7.922712507747731e-13
linkage O 0 0.00011601577716646716
analysis O 0 1.0272977846170761e-07
, O 0 3.0165828168726705e-10
unaffected O 0 3.946086621908762e-07
mutation O 0 3.8224754916882375e-08
carriers O 0 4.560013255883177e-09
were O 0 5.9523044271259096e-09
also O 0 5.558518978432403e-08
identified O 0 6.57075673871077e-08
within O 0 7.096562781860882e-10
the O 0 1.0687191132063845e-09
pedigree O 0 2.625668639666401e-05
. O 0 4.2424304069754726e-09

A O 0 1.8994983363995743e-08
single O 0 5.796322866125081e-10
band O 0 7.959360254217174e-11
shift O 0 6.888251774528342e-11
using O 0 4.242256199105121e-11
SSCP O 0 1.3788926480629016e-06
was O 0 6.3262923788443e-09
identified O 0 2.5291089222889696e-09
in O 0 7.0263174618834245e-12
exon O 0 9.461778063268866e-07
21 O 0 8.944797258436665e-08
which O 0 6.114062034434653e-10
resulted O 0 5.192976604284638e-10
in O 0 1.8757228409382876e-11
a O 0 1.5312744128248568e-10
missense O 0 1.5242438848872553e-06
mutation O 0 1.7364808257980258e-08
converting O 0 1.203104504909902e-09
a O 0 5.250793688738042e-10
cys O 0 0.00018172938143834472
- O 0 8.327888281201012e-06
- O 0 5.18765364176943e-06
> O 0 3.5091847205848126e-09
arg O 0 5.046098205951921e-09
at O 0 1.3595455317094718e-10
nucleotide O 0 1.328858134641564e-09
position O 0 4.171203826786041e-09
28 O 0 7.654397254919232e-11
in O 0 2.107089459510436e-12
the O 0 1.0609756996571296e-11
exon O 0 1.1312778269711998e-06
. O 0 1.9393395334077468e-08

The O 0 1.3874408288927498e-08
mutation O 0 4.909242079520482e-07
destroyed O 0 1.3922623338658013e-06
an O 0 5.863302898756473e-11
NdeI O 0 2.0492187104537152e-05
restriction O 0 5.390564439267109e-08
enzyme O 0 3.056840114368242e-08
site O 0 2.983814226809045e-07
. O 0 9.567997949488927e-09

Analysis O 0 5.52107266571511e-08
of O 0 1.7894824511088814e-11
all O 0 9.513323462329026e-11
family O 0 1.874682908908909e-10
members O 0 1.456025648357076e-13
demonstrated O 0 8.212185272082895e-12
that O 0 2.28327036097542e-12
the O 0 4.796085837505126e-12
missense O 0 4.891324351774529e-06
mutation O 0 4.734536105388543e-06
co O 0 1.1543778782652225e-05
- O 0 4.927708687318955e-06
segregated O 0 2.134635542461183e-05
with O 0 3.0202009781987726e-08
patients O 0 4.4518310460262e-07
with O 0 2.0873626453976613e-06
tumors B-Disease 1 1.0
or O 0 0.0005819871439598501
who O 0 0.001969633623957634
, O 0 1.0235890357535027e-08
as O 0 1.553995598868596e-09
a O 0 6.480711522982574e-10
result O 0 1.1078339356984657e-09
of O 0 4.0914924985362144e-13
linkage O 0 0.00011929537868127227
analysis O 0 1.4137232540178957e-07
had O 0 4.608214112522546e-07
been O 0 9.432868930403515e-10
predicted O 0 4.374645534710453e-09
to O 0 3.698529330020683e-12
carry O 0 2.0889033558457726e-11
the O 0 3.211672941483279e-11
predisposing O 0 1.7461964318954415e-07
mutation O 0 2.641940568537393e-07
. O 0 6.1222809044636506e-09

These O 0 8.70015004483804e-10
observations O 0 1.3371772578096852e-09
point O 0 5.226206578612391e-09
to O 0 2.2569375188186136e-11
another O 0 1.1061505184040143e-10
region O 0 1.631726309625492e-09
of O 0 2.6416525217287656e-12
the O 0 3.2513119974098004e-10
RB1 O 0 2.2805952539783902e-06
gene O 0 1.0257427796034335e-08
where O 0 1.1487988338387822e-09
mutations O 0 1.55702863935403e-08
only O 0 4.5772972218083297e-11
modify O 0 7.389448342109972e-08
the O 0 1.3041048796402777e-10
function O 0 1.0223242252749287e-09
of O 0 5.680106450293987e-13
the O 0 2.4560503630866037e-10
gene O 0 1.1226316019019578e-06
and O 0 2.015621269890744e-08
raise O 0 1.8784375444003132e-10
important O 0 2.1042017954442382e-12
questions O 0 5.4069266425260665e-12
for O 0 4.815883477594929e-13
genetic O 0 9.720565685711335e-08
counseling O 0 6.356527526563127e-10
in O 0 2.7689203360714565e-11
families O 0 2.8183835473760688e-11
with O 0 4.018349195056281e-11
these O 0 3.3681438194044233e-10
distinctive O 0 1.0849205978047394e-07
phenotypes O 0 9.140214842773275e-07
. O 0 7.806621460382246e-10
. O 0 1.432476470775157e-09

Maternal B-Disease 0 0.03765869140625
disomy I-Disease 0 0.0476631261408329
and O 0 0.028591739013791084
Prader B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999997615814209
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999994039535522
consistent O 0 1.8784664916893234e-06
with O 0 1.5054482660481483e-10
gamete O 0 3.1394886690350177e-08
complementation O 0 4.925965185975656e-06
in O 0 2.5786787635762032e-11
a O 0 5.35076982721705e-11
case O 0 1.3202835491554765e-09
of O 0 1.927840265897318e-12
familial O 0 4.561017249216093e-06
translocation O 0 1.8156257283408195e-05
( O 0 6.690242804197055e-11
3 O 0 1.3511883834027572e-09
; O 0 4.2212319750767335e-10
15 O 0 2.8306679222822595e-10
) O 0 7.770292222153419e-12
( O 0 1.0867156783819776e-12
p25 O 0 2.5685240045980606e-10
; O 0 7.082735873492618e-12
q11 O 0 9.57628198960947e-10
. O 0 1.1127713334113665e-11
2 O 0 1.3325707204359105e-10
) O 0 3.0959745878078593e-10
. O 0 2.0692523250431805e-09

Maternal B-Disease 0 0.03179984912276268
uniparental I-Disease 0 0.07202412933111191
disomy I-Disease 0 0.2551192045211792
( I-Disease 0 7.033141855572467e-07
UPD I-Disease 1 0.9999884366989136
) I-Disease 0 6.992583845288891e-09
for I-Disease 0 1.2983740471650407e-10
chromosome I-Disease 0 0.0017373261507600546
15 I-Disease 0 5.8552513948484375e-09
is O 0 6.25103233065083e-11
responsible O 0 3.2834507335266494e-10
for O 0 9.830793947993022e-13
an O 0 1.3654199298995806e-12
estimated O 0 1.2627841827761443e-10
30 O 0 1.9007278390104076e-11
% O 0 2.2241919677562505e-13
of O 0 1.1930929334769136e-13
cases O 0 2.4496513706395717e-09
of O 0 9.473208706367586e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
( O 0 2.1405455186140898e-07
PWS B-Disease 1 0.9999959468841553
) O 0 2.220653883000523e-08
. O 0 8.466531475903594e-09

We O 0 3.838893462670967e-06
report O 0 3.720246610772193e-10
on O 0 2.2338270556226947e-12
an O 0 2.573559854807117e-14
unusual O 0 5.061098241887496e-12
case O 0 3.549796290247542e-10
of O 0 2.4677600241052033e-11
maternal B-Disease 0 1.4301930605142843e-05
disomy I-Disease 0 9.25089480006136e-05
15 I-Disease 0 2.37605153330378e-08
in O 0 3.020696937028333e-08
PWS B-Disease 1 0.9999998807907104
that O 0 2.9404671408883587e-07
is O 0 1.8304457949369635e-10
most O 0 1.1176722741756961e-11
consistent O 0 2.6817470466511395e-09
with O 0 1.3636612672396353e-11
adjacent O 0 1.6675818415023969e-06
- O 0 2.1339915292628575e-06
1 O 0 1.823389494948202e-10
segregation O 0 7.199845697414275e-08
of O 0 2.0955813310758603e-13
a O 0 4.110866924644796e-10
paternal O 0 5.112804046802921e-07
t O 0 2.243667040602304e-06
( O 0 7.276203077555277e-12
3 O 0 2.397147758070872e-10
; O 0 8.878579815796428e-11
15 O 0 3.711095319935964e-11
) O 0 2.255223785496696e-12
( O 0 3.5433374984128463e-13
p25 O 0 5.4320579284672377e-11
; O 0 1.6492111495902684e-12
q11 O 0 5.012693593542394e-10
. O 0 2.6105428582723356e-12
2 O 0 4.388126580850971e-12
) O 0 7.672983342449369e-13
with O 0 3.9167740231715875e-12
simultaneous O 0 2.673097476701969e-08
maternal O 0 4.44480292571825e-06
meiotic O 0 2.5090946564887417e-06
nondisjunction O 0 5.865576895303093e-06
for O 0 2.682815081200829e-10
chromosome O 0 5.517607496585697e-05
15 O 0 2.165871926251839e-08
. O 0 9.564074865409111e-09

The O 0 2.9856071392941885e-08
patient O 0 1.283859063505588e-07
( O 0 3.0857920385596316e-11
J O 0 6.163344369269907e-05
. O 0 1.0955226725783973e-09
B O 0 9.47817534324713e-06
. O 0 1.9943786205844916e-11
) O 0 2.334725295038975e-12
, O 0 3.3080385219291797e-12
a O 0 9.20602621912181e-11
17 O 0 3.807215431805844e-09
- O 0 3.280124474258628e-07
year O 0 3.73334724246277e-10
- O 0 9.429058081877884e-06
old O 0 0.0016827445942908525
white O 0 5.856013558513951e-07
male O 0 5.669726910184636e-09
with O 0 3.1699859404099584e-10
PWS B-Disease 1 0.9999985694885254
, O 0 3.265776760130734e-09
was O 0 2.3225602774346044e-08
found O 0 9.770019238075633e-10
to O 0 1.6641749089885138e-10
have O 0 1.0891409996105494e-09
47 O 0 4.6496233530035624e-09
chromosomes O 0 2.2014276623849582e-08
with O 0 2.1221802093407405e-10
a O 0 4.104256934311934e-09
supernumerary O 0 0.00024587204097770154
, O 0 6.659950457788e-08
paternal O 0 2.378646604483947e-05
der O 0 0.38254448771476746
( O 0 8.124072248261172e-11
15 O 0 2.1479822087666633e-10
) O 0 1.926891805836828e-12
consisting O 0 3.309660488379218e-12
of O 0 3.1046186454997127e-11
the O 0 6.882548575504188e-08
short O 0 0.00043621897930279374
arm O 1 0.5495002865791321
and O 0 4.7153847049230535e-08
the O 0 5.935476554697061e-10
proximal O 0 6.1224395722092595e-06
long O 0 8.354448254976887e-06
arm O 0 4.133792026550509e-05
of O 0 8.867303592785536e-12
chromosome O 0 6.866026524221525e-05
15 O 0 1.0555858409588836e-08
, O 0 7.690019176997964e-10
and O 0 1.448285047445097e-08
distal O 0 0.0005342435324564576
chromosome O 1 0.9977274537086487
arm O 0 0.4288109242916107
3p O 0 0.0017276149010285735
. O 0 1.0836818375992152e-07

The O 0 1.2204858457209866e-08
t O 0 1.4067406937101623e-06
( O 0 1.1603235733348427e-11
3 O 0 1.0352330798157894e-10
; O 0 2.3473540819440863e-11
15 O 0 2.010043693989605e-11
) O 0 3.6081910029239772e-12
was O 0 1.2862066078866974e-08
present O 0 3.487342359331791e-11
in O 0 1.1714198187851022e-11
the O 0 7.458353379341531e-11
balanced O 0 1.069793920116524e-09
state O 0 1.7278198316539317e-10
in O 0 3.454237451627762e-10
the O 0 1.41054234958915e-09
patients O 0 1.0951721307606022e-08
father O 0 7.389614253838772e-09
and O 0 2.079015848366339e-09
a O 0 3.593553898895152e-09
sister O 0 7.982297393027693e-05
. O 0 8.78310313368047e-09

Fluorescent O 0 3.617743118411454e-07
in O 0 1.8290498282613754e-10
situ O 0 2.4489739125499455e-09
hybridization O 0 3.7994293822229963e-10
analysis O 0 2.0112335408217774e-10
demonstrated O 0 1.1392626425577035e-10
that O 0 4.0142812685051155e-11
the O 0 1.4267692582947689e-09
PWS B-Disease 1 0.9999992847442627
critical O 0 7.466376246156869e-07
region O 0 4.946622667034717e-08
resided O 0 1.402859339805218e-07
on O 0 3.6697508920546795e-10
the O 0 1.445798775839835e-11
derivative O 0 1.1709418856753473e-07
chromosome O 0 2.978413067467045e-05
3 O 0 1.387522985396572e-08
and O 0 1.533260451935803e-08
that O 0 1.574216090816094e-09
there O 0 7.87609255592514e-10
was O 0 2.3990486042180237e-08
no O 0 7.010551861252878e-11
deletion O 0 1.326488607844567e-08
of O 0 8.87088926621038e-12
the O 0 1.1874752203766548e-07
PWS B-Disease 1 0.9999998807907104
region O 0 1.9148383216816e-06
on O 0 1.864084353542239e-08
the O 0 2.0339170625494063e-10
normal O 0 4.9209387675830385e-09
pair O 0 7.615030384044985e-09
of O 0 8.507777273479566e-13
15s O 0 1.181811037920255e-10
present O 0 4.385217189373236e-11
in O 0 1.7407544294911759e-09
J O 0 0.11593570560216904
. O 0 2.1951510831286214e-08

B O 0 0.002287889365106821
. O 0 8.280967733753641e-08

Methylation O 0 6.151194611447863e-07
analysis O 0 1.8251684608117102e-09
at O 0 2.7359935497739407e-11
exon O 0 2.3975091356653877e-10
alpha O 0 1.9160775396875884e-11
of O 0 2.948779458458728e-13
the O 0 2.050368555495119e-11
small O 0 1.0459393351425206e-09
nuclear O 0 4.591295237332815e-06
ribonucleoprotein O 0 1.10352004867309e-07
- O 0 2.3715160750725772e-06
associated O 0 1.4130581149629506e-08
polypeptide O 0 2.3274743909951212e-07
N O 0 1.9027311282115988e-06
( O 0 2.5998604311072704e-11
SNRPN O 0 4.485553262156827e-08
) O 0 2.2587450573124945e-12
gene O 0 1.6738340713473576e-09
showed O 0 1.119275960803634e-08
a O 0 6.95122084892752e-11
pattern O 0 5.1016240831813775e-06
characteristic O 0 2.8630091719605844e-07
of O 0 2.5484225840699537e-11
only O 0 1.414271544319945e-08
the O 0 1.0776374237408959e-09
maternal O 0 8.938230280364223e-07
chromosome O 0 7.50566641727346e-06
15 O 0 1.2681891092825026e-09
in O 0 3.887329569352005e-09
J O 1 0.540834903717041
. O 0 3.548770877159768e-08

B O 0 0.004457998089492321
. O 0 1.359036758685761e-07

Maternal B-Disease 0 0.0019263401627540588
disomy I-Disease 0 8.695699216332287e-05
was O 0 2.190040504501667e-08
confirmed O 0 1.352696288314803e-10
by O 0 1.5037075317553272e-12
polymerase O 0 4.3297555407662003e-07
chain O 0 7.891887889854843e-07
reaction O 0 8.813821894548823e-11
analysis O 0 3.628538441935447e-11
of O 0 1.0518173788540142e-12
microsatellite O 0 1.6687094102962874e-05
repeats O 0 6.160015345813008e-06
at O 0 5.234204736304093e-10
the O 0 1.6523567453533006e-12
gamma O 0 2.7495652976661233e-10
- O 0 1.9505857835611096e-06
aminobutyric O 0 1.5941249102979782e-06
acid O 0 3.4873322007911156e-09
receptor O 0 3.7033756616899893e-10
beta3 O 0 1.1230803842465775e-08
subunit O 0 1.940989147186656e-09
( O 0 1.0705893810358802e-10
GABRB3 O 0 6.350679768729606e-07
) O 0 9.953366603143721e-11
locus O 0 7.795796364007401e-08
. O 0 1.3108694574270885e-08

A O 0 1.0427512364685754e-07
niece O 0 5.634838544210652e-06
( O 0 2.340247440280052e-10
B O 0 5.279779998090817e-06
. O 0 1.9401034945243367e-10
B O 0 2.0814788967982167e-06
. O 0 8.777110982460812e-12
) O 0 6.611989601668089e-13
with O 0 3.840095602614113e-11
45 O 0 7.487905850922516e-10
chromosomes O 0 3.208775822827192e-08
and O 0 9.711754733743305e-10
the O 0 2.373131031963016e-11
derivative O 0 2.9257110512048712e-08
3 O 0 3.9812535490568735e-09
but O 0 1.0619430668157293e-08
without O 0 7.153296704975887e-11
the O 0 2.614222449626169e-10
der O 0 0.14908795058727264
( O 0 1.422981957960312e-11
15 O 0 3.268876835882395e-11
) O 0 3.0832782074025067e-12
demonstrated O 0 8.12566888774846e-11
a O 0 6.258643603374026e-11
phenotype O 0 2.1894855706250382e-07
consistent O 0 1.5403326392160466e-09
with O 0 1.6253538445698545e-11
that O 0 5.620507392833929e-10
reported O 0 7.739080487567662e-09
for O 0 2.616844024458387e-12
haploinsufficiency O 0 6.080145453779551e-07
of O 0 7.912387758879369e-12
distal O 0 4.113697286811657e-06
3 O 0 5.721040565731528e-07
p O 0 0.009344837628304958
. O 0 4.3493553647522276e-08

Uniparental B-Disease 1 0.9995996356010437
disomy I-Disease 1 0.9997664093971252
associated O 0 4.260622972651618e-06
with O 0 4.218763116625723e-09
unbalanced O 0 2.0801706341444515e-05
segregation O 0 1.1018907571269665e-05
of O 0 2.6638812683499324e-11
non O 0 2.2356003270829206e-08
- O 0 0.0001130073142121546
Robertsonian O 0 7.039348565740511e-05
translocations O 0 0.00011386172263883054
has O 0 1.1653687579382677e-06
been O 0 5.364223287784853e-09
reported O 0 1.9840312504015856e-08
previously O 0 2.432505539218255e-07
but O 0 1.5759300708850787e-07
has O 0 5.2191570176773894e-08
not O 0 2.442803115343395e-08
, O 0 7.764715537206257e-10
to O 0 5.45830547427073e-10
our O 0 7.378874594676788e-11
knowledge O 0 1.4472335656268154e-11
, O 0 2.998555830718841e-12
been O 0 3.144799698429068e-11
observed O 0 1.4715059726277957e-10
in O 0 1.309707333904675e-12
a O 0 1.2021030872111371e-11
case O 0 6.113365369486701e-09
of O 0 4.13159534362606e-10
PWS B-Disease 1 0.9999985694885254
. O 0 1.5206866521566553e-07

Furthermore O 0 5.8190351410303265e-05
, O 0 3.475578935763224e-09
our O 0 1.893148693365987e-10
findings O 0 8.830968595274769e-11
are O 0 7.274063079307225e-13
best O 0 2.376575047868812e-10
interpreted O 0 9.337133843878576e-11
as O 0 2.781237219695587e-11
true O 0 1.3986840852187044e-10
gamete O 0 1.1172881286825032e-08
complementation O 0 1.1147218401674763e-06
resulting O 0 5.685646176090131e-09
in O 0 1.6846575690010468e-08
maternal B-Disease 0 0.007414410822093487
UPD I-Disease 1 0.9999970197677612
15 I-Disease 0 7.416525477310643e-06
and O 0 2.748922270257026e-05
PWS B-Disease 1 0.9999915361404419

Schwartz B-Disease 1 0.9939683675765991
- I-Disease 1 0.99906986951828
Jampel I-Disease 1 0.9995929598808289
syndrome I-Disease 1 0.9999785423278809
type I-Disease 0 5.018692172598094e-05
2 I-Disease 0 4.170720657725724e-08
and O 0 2.1786472643725574e-06
Stuve B-Disease 1 0.9998058676719666
- I-Disease 1 0.9999983310699463
Wiedemann I-Disease 1 0.9999996423721313
syndrome I-Disease 1 0.9999985694885254
: O 0 3.652348215532619e-11
a O 0 3.3604978608853253e-12
case O 0 1.9110198146155e-10
for O 0 3.0393753919916167e-12
" O 0 2.6318580648165835e-10
lumping O 0 4.4561506484797064e-08
" O 0 4.819945775835777e-09
. O 0 5.70044345060694e-10

Recent O 0 2.809929071645456e-07
studies O 0 1.4315704177647604e-08
demonstrated O 0 1.2087765233204095e-09
the O 0 6.294507449988718e-12
existence O 0 1.0131690625359013e-10
of O 0 4.1044988588478937e-13
a O 0 3.5503106010637e-10
genetically O 0 1.0895258917287265e-08
distinct O 0 1.222167034242716e-09
, O 0 6.064665991623031e-10
usually O 0 2.2968613122564818e-10
lethal O 0 1.0408838374553753e-10
form O 0 6.78836986622855e-11
of O 0 8.416061250682283e-12
the O 0 1.2115498293496785e-07
Schwartz B-Disease 1 0.9999661445617676
- I-Disease 1 0.9999868869781494
Jampel I-Disease 1 0.9999690055847168
syndrome I-Disease 1 0.9999839067459106
( O 0 9.541908929655563e-11
SJS B-Disease 0 7.992624887265265e-05
) O 0 2.495049652995185e-11
of O 0 1.3160156991931515e-11
myotonia B-Disease 1 0.9842069149017334
and O 0 2.0944189600413665e-05
skeletal B-Disease 1 0.9925340414047241
dysplasia I-Disease 1 0.9999488592147827
, O 0 1.3623659533834598e-08
which O 0 8.398097328665699e-09
we O 0 1.6377699196823414e-08
called O 0 3.635117451494807e-08
SJS B-Disease 0 0.09199649840593338
type I-Disease 0 1.0960124200209975e-05
2 I-Disease 0 3.5288252320242464e-08
. O 0 1.0996074273350587e-08

This O 0 3.706132702063769e-06
disorder O 0 0.0006253708270378411
is O 0 3.853757937766211e-11
reminiscent O 0 4.025604738444599e-08
of O 0 6.3453886242625934e-12
another O 0 5.507788358727339e-08
rare O 0 4.5801340320394957e-07
condition O 0 1.8576638467493467e-05
, O 0 1.1699467783454764e-10
the O 0 1.9074921642214804e-09
Stuve B-Disease 1 0.9989843964576721
- I-Disease 1 0.9999971389770508
Wiedemann I-Disease 1 0.9999990463256836
syndrome I-Disease 1 0.9999983310699463
( O 0 3.4916500246673365e-10
SWS B-Disease 0 0.0011250328971073031
) O 0 7.147499953008563e-11
, O 0 2.7881794095740986e-11
which O 0 1.0247288434461765e-10
comprises O 0 4.702608302764588e-10
campomelia B-Disease 0 2.022426633629948e-05
at O 0 9.071977302710366e-08
birth O 0 5.812692194240299e-08
with O 0 3.6556202509530067e-09
skeletal B-Disease 1 0.957843542098999
dysplasia I-Disease 1 0.9987429976463318
, O 0 1.2789850067917996e-08
contractures B-Disease 0 0.001331463921815157
, O 0 1.0879062095625613e-08
and O 0 1.1613217054673441e-08
early B-Disease 0 1.012517500953436e-07
death I-Disease 0 7.548641178800608e-07
. O 0 6.732260970920834e-09

To O 0 1.886748535184779e-08
test O 0 2.5787945112654143e-09
for O 0 3.629413935189729e-13
possible O 0 7.849199762377523e-11
nosologic O 0 6.193450644786935e-06
identity O 0 5.51415780591924e-07
between O 0 4.361891683402064e-07
these O 0 3.6701962358165474e-07
disorders O 0 0.023192500695586205
, O 0 2.588491365695944e-10
we O 0 4.215360949189062e-09
reviewed O 0 3.7473104619323294e-09
the O 0 2.4211927601713867e-11
literature O 0 9.147517188168308e-10
and O 0 3.035971474218968e-10
obtained O 0 1.4591611252612324e-10
a O 0 5.332319308326561e-11
follow O 0 5.216125864571097e-10
- O 0 3.590424313415497e-08
up O 0 2.9765763187583616e-09
of O 0 4.3532535974437347e-13
the O 0 8.620626434918677e-11
only O 0 6.961095033730658e-10
two O 0 1.5461718017029114e-10
surviving O 0 2.907199530000071e-07
patients O 0 2.6255256302398777e-10
, O 0 3.6525115072218173e-13
one O 0 4.71391849166114e-12
with O 0 1.191173409909041e-10
SJS B-Disease 0 0.004002944566309452
type I-Disease 0 2.3654265532968566e-06
2 I-Disease 0 1.4819939941901339e-08
at O 0 3.587001984328708e-08
age O 0 1.2232631574349284e-09
10 O 0 6.115665265871151e-12
years O 0 2.284678696229392e-11
and O 0 9.632276920523708e-11
another O 0 2.2440997671235863e-10
with O 0 2.8116586836546276e-09
SWS B-Disease 1 0.5818582773208618
at O 0 5.496643140645574e-08
age O 0 5.738056141346703e-10
7 O 0 3.604638254550707e-10
years O 0 1.582566577784661e-10
. O 0 6.03213312633244e-10

Patients O 0 7.933365850476548e-05
reported O 0 4.141453757711133e-08
as O 0 9.201584633133919e-11
having O 0 5.107401168658043e-09
either O 0 3.2422494911088506e-08
neonatal O 1 0.9999442100524902
SJS B-Disease 1 0.9997910857200623
or O 0 1.7442005173506914e-06
SWS B-Disease 0 0.04054257646203041
presented O 0 3.7395048169130973e-10
a O 0 2.8348863187477313e-11
combination O 0 8.270037987756496e-10
of O 0 2.7321851378547812e-12
a O 0 6.688886600159094e-08
severe O 0 3.8435496207966935e-06
, O 0 2.549538358209702e-09
prenatal O 0 0.19820518791675568
- O 1 0.993062436580658
onset O 1 0.9929221868515015
neuromuscular B-Disease 1 0.9999959468841553
disorder I-Disease 1 0.9999444484710693
( O 0 3.388843650142803e-09
with O 0 1.1807373994088266e-06
congenital B-Disease 1 0.9999978542327881
joint I-Disease 0 0.011818488128483295
contractures I-Disease 1 0.9999881982803345
, O 0 0.05368441343307495
respiratory O 1 0.9999949932098389
and O 0 0.00010425854270579293
feeding O 0 0.0008170132641680539
difficulties O 0 1.0658959581633098e-06
, O 0 1.2984929798065536e-10
tendency O 0 3.357166988848803e-08
to O 0 6.717096878716688e-10
hyperthermia B-Disease 0 6.688182475045323e-05
, O 0 2.188093706223526e-09
and O 0 6.774420580057949e-09
frequent O 0 4.33553623224725e-07
death O 0 1.0222076525678858e-05
in O 0 5.904904654130405e-08
infancy O 0 4.7848757276369724e-06
) O 0 2.632051260970103e-12
with O 0 2.8885051902433068e-12
a O 0 2.582085933955369e-10
distinct O 0 1.2306637486858563e-08
campomelic B-Disease 0 0.00423061940819025
- I-Disease 1 0.5548651814460754
metaphyseal I-Disease 0 0.10327622294425964
skeletal I-Disease 1 0.9688042998313904
dysplasia I-Disease 1 0.9988791346549988
. O 0 1.308265922261853e-07

The O 0 3.9999376033605927e-10
similarity O 0 5.257156932003682e-10
of O 0 9.49024387721098e-13
the O 0 1.020796086548259e-10
clinical O 0 6.57621058053337e-07
and O 0 6.248904949046619e-09
radiographic O 0 0.0004248145269230008
findings O 0 4.481636892705865e-07
is O 0 1.9094650305362393e-09
so O 0 1.069740851455947e-09
extensive O 0 5.770736422050504e-08
that O 0 5.969462790744728e-07
these O 0 8.816877539175039e-08
disorders O 0 0.0022400037851184607
appear O 0 1.5548821119537592e-09
to O 0 9.245111898259495e-10
be O 0 5.712394446355518e-10
a O 0 2.7560337345633457e-10
single O 0 1.1280378231504073e-07
entity O 0 9.257520105165895e-06
. O 0 2.831579024586972e-07

The O 0 4.293830624391148e-09
follow O 0 2.269215926276047e-09
- O 0 1.417399175807077e-07
up O 0 7.489409092897858e-09
observation O 0 7.376421962135282e-08
of O 0 3.51033546848456e-13
an O 0 2.2765919358014308e-11
identical O 0 1.3355565897654742e-06
and O 0 1.0985488074766181e-08
unique O 0 4.972536826741702e-10
pattern O 0 1.2235587746545207e-05
of O 0 1.0860480292862462e-09
progressive O 0 0.011163534596562386
bone B-Disease 1 0.9995790123939514
dysplasia I-Disease 1 0.9999486207962036
in O 0 3.271719606345869e-08
the O 0 7.433890392150033e-09
two O 0 5.841990713406631e-08
patients O 0 2.221420558612408e-08
( O 0 1.7970611977669027e-12
one O 0 6.424709375618676e-11
with O 0 9.045119098161081e-10
SJS B-Disease 1 0.682892382144928
type I-Disease 0 3.092393308179453e-05
2 I-Disease 0 1.5409799658527845e-08
, O 0 1.373280933414378e-09
one O 0 2.0135260125897503e-09
with O 0 1.3522591046921661e-08
SWS B-Disease 1 0.8012614250183105
) O 0 8.841270493498143e-10
surviving O 0 8.411390695073351e-08
beyond O 0 1.8194448614394787e-08
infancy O 0 3.727068929038069e-07
adds O 0 2.1469684696739932e-08
to O 0 3.872406562077657e-11
the O 0 3.0860433566232137e-12
evidence O 0 5.921881734982648e-11
in O 0 2.6978833663621193e-12
favor O 0 6.5564598021594644e-12
of O 0 1.2971055436336587e-12
identity O 0 1.388860653150914e-07
. O 0 5.564138483293846e-09

The O 0 4.660393404520846e-09
hypothesis O 0 5.086910093154984e-08
that O 0 3.082457900038804e-10
SWS B-Disease 0 0.00020864639373030514
and O 0 3.2271383343385196e-09
SJS B-Disease 0 0.0007132452446967363
type I-Disease 0 3.7451375192176783e-06
2 I-Disease 0 1.8262445999894794e-09
are O 0 6.218662390589103e-11
the O 0 1.0413272466536228e-09
same O 0 7.40152927392046e-07
disorder O 0 0.002181827323511243
should O 0 2.602625337466691e-10
be O 0 1.083487032732533e-12
testable O 0 3.0484104823758074e-11
by O 0 3.324171721306307e-13
molecular O 0 7.090082410066145e-10
methods O 0 4.280487786445519e-08
. O 0 7.224545406359084e-10
. O 0 3.4168234908094064e-09

A O 0 6.627750792631559e-08
mouse O 0 3.082551529587363e-06
model O 0 2.3749150557250687e-07
of O 0 6.340631575341149e-09
severe O 1 0.9994927644729614
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 1 0.5344884991645813
defects O 1 0.99998939037323
in O 0 2.5536385237501236e-06
hemostasis O 1 0.9996527433395386
and O 0 0.00024249231501016766
thrombosis B-Disease 1 0.7680302858352661
. O 0 1.1197035831855828e-07

von B-Disease 1 0.9830114841461182
Willebrand I-Disease 1 0.9518733024597168
factor I-Disease 0 1.1112543688795995e-05
( I-Disease 0 8.644563109783121e-08
vWf I-Disease 0 0.002761283190920949
) I-Disease 0 0.0029908132273703814
deficiency I-Disease 1 0.9999423027038574
causes O 0 0.4262208640575409
severe O 1 0.9999856948852539
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 8.22020519990474e-05
humans O 0 0.00013893427967559546
. O 0 3.2257492676990296e-08

We O 0 1.0082331414196233e-08
generated O 0 1.4659195732291685e-11
a O 0 1.3785019133127907e-11
mouse O 0 1.9104902548860991e-07
model O 0 2.707895241371716e-08
for O 0 1.6209329017913277e-11
this O 0 8.301883624994844e-10
disease O 0 5.238854896560952e-07
by O 0 6.887649765851059e-14
using O 0 6.904733729218293e-11
gene O 0 2.685255253709329e-07
targeting O 0 7.460312190232798e-07
. O 0 2.1637992730916267e-08

vWf B-Disease 0 0.000674875162076205
- I-Disease 1 0.9732816815376282
deficient I-Disease 1 0.5777507424354553
mice O 0 0.003765513887628913
appeared O 0 4.4230293383407115e-07
normal O 0 6.059248391920846e-08
at O 0 7.080099617695623e-09
birth O 0 2.279306698937944e-08
; O 0 9.610182094554887e-11
they O 0 1.1851954972996737e-09
were O 0 5.652059931193776e-10
viable O 0 7.139907154396496e-08
and O 0 1.962289886137114e-08
fertile O 0 1.1088872042819276e-06
. O 0 2.7292427873248926e-08

Neither O 0 9.30624173633987e-06
vWf O 0 2.7681129722623155e-05
nor O 0 9.489805051998701e-06
vWf O 0 1.7055592252290808e-05
propolypeptide O 0 0.0006368202739395201
( O 0 2.820495481614671e-08
von B-Disease 1 0.5690078735351562
Willebrand I-Disease 1 0.9250544309616089
antigen O 0 0.0013683841098099947
II O 0 0.009480240754783154
) O 0 6.454534684507962e-10
were O 0 8.850279953342977e-10
detectable O 0 2.8906548266149912e-08
in O 0 2.7759110982072954e-11
plasma O 0 6.143830546534446e-07
, O 0 4.163104527776795e-09
platelets O 0 4.4279033772909315e-08
, O 0 1.6620949061518786e-09
or O 0 1.6271017866387183e-09
endothelial O 0 4.537038245100433e-10
cells O 0 4.3325926180060037e-10
of O 0 1.4557312874672462e-13
the O 0 3.489857361427262e-11
homozygous O 0 1.6250339740508934e-08
mutant O 0 9.873112958302954e-07
mice O 0 6.500957533717155e-05
. O 0 1.8172485738432442e-09

The O 0 8.583898924996447e-09
mutant O 0 1.8265227481606416e-06
mice O 0 0.0007516443147324026
exhibited O 0 1.1060440556320827e-05
defects O 0 0.49599143862724304
in O 0 2.078100136415628e-09
hemostasis O 0 0.0015026008477434516
with O 0 1.2653532444062421e-08
a O 0 1.3153632494322665e-07
highly O 0 6.703805865981849e-06
prolonged O 0 0.006723830476403236
bleeding O 1 0.9654420018196106
time O 0 2.065379248961108e-06
and O 0 8.340791168848227e-07
spontaneous O 0 4.6107768980618857e-07
bleeding O 0 0.005612595472484827
events O 0 4.563813493785318e-10
in O 0 7.837665239041058e-11
approximately O 0 4.832201999649399e-11
10 O 0 3.282434740681239e-11
% O 0 4.690152780040258e-12
of O 0 2.1328921268048973e-11
neonates O 0 0.00012058924767188728
. O 0 8.998061851173134e-09

As O 0 3.514954016736738e-08
in O 0 3.90515592085805e-10
the O 0 1.6787291556852324e-09
human O 0 1.7933176366113912e-07
disease O 0 0.0006156989256851375
, O 0 5.844943452848472e-12
the O 0 1.4987004692823547e-11
factor O 0 6.644909067432536e-10
VIII O 0 8.624866495665628e-06
level O 0 1.1432128133037622e-07
in O 0 3.358816003107279e-10
these O 0 3.188942998555433e-10
mice O 0 5.729007625632221e-06
was O 0 2.5944849824099947e-08
reduced O 0 1.2422637363229683e-09
strongly O 0 1.543473682197316e-09
as O 0 4.1313669152387433e-10
a O 0 1.7499290905220732e-09
result O 0 4.460740221645665e-09
of O 0 1.2783092726703638e-12
the O 0 7.143238223150661e-10
lack O 0 1.4240851553548595e-10
of O 0 1.0793322751398784e-13
protection O 0 1.080865286162691e-09
provided O 0 2.5632320918567153e-11
by O 0 1.3662516430701377e-11
vWf O 0 1.9322806110722013e-07
. O 0 3.2538778782509326e-08

Defective O 1 0.6357091069221497
thrombosis B-Disease 0 0.1461986005306244
in O 0 1.7495118687094191e-09
mutant O 0 1.352635194962204e-06
mice O 0 0.009289979003369808
was O 0 5.007614731766807e-07
also O 0 5.37749977880253e-09
evident O 0 1.2692562556537723e-09
in O 0 1.4410085104332726e-11
an O 0 1.7141236346995825e-12
in O 0 3.964283762369902e-11
vivo O 0 2.880427132367913e-07
model O 0 4.113551277384886e-09
of O 0 1.4414709703647333e-10
vascular B-Disease 1 0.9875389337539673
injury I-Disease 0 0.1642419993877411
. O 0 1.766270507630452e-08

In O 0 9.664007372123251e-10
this O 0 1.5346245108016632e-11
model O 0 1.7322225875915365e-09
, O 0 8.034491474906424e-12
the O 0 1.8433943607676362e-11
exteriorized O 0 1.7235086033906555e-06
mesentery O 0 1.8141104192181956e-06
was O 0 5.217066956220151e-08
superfused O 0 3.2235445246442396e-07
with O 0 3.3201025262385997e-10
ferric O 0 1.0635742910380941e-05
chloride O 0 5.397652671490505e-07
and O 0 3.961628891602231e-08
the O 0 1.1684014866730763e-10
accumulation O 0 5.073341746708593e-09
of O 0 7.379066975510273e-12
fluorescently O 0 1.9890721887350082e-05
labeled O 0 4.742832970805466e-06
platelets O 0 1.2756794376400649e-07
was O 0 6.710275446408787e-09
observed O 0 6.058269164110897e-11
by O 0 4.974068466140347e-12
intravital O 0 1.1710334035797132e-07
microscopy O 0 1.3520403285838256e-07
. O 0 4.588840862851384e-09

We O 0 8.353532393812202e-06
conclude O 0 5.6547179383414914e-08
that O 0 1.226732326831126e-10
these O 0 5.2984876902639755e-11
mice O 0 4.004624315712135e-06
very O 0 7.369679311253208e-10
closely O 0 3.532839798481291e-07
mimic O 0 0.06023573875427246
severe O 0 0.059384118765592575
human O 1 0.8575214147567749
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 1 0.6761864423751831
will O 0 4.3673048821801785e-06
be O 0 2.7707300898072162e-09
very O 0 3.516041277573656e-11
useful O 0 8.798733443227125e-12
for O 0 8.765992760232516e-14
investigating O 0 7.648979540031409e-12
the O 0 2.2652684849439053e-12
role O 0 2.354021144679308e-11
of O 0 2.4966468237415385e-13
vWf O 0 6.840796373808189e-09
in O 0 1.8150626557300598e-09
normal O 0 5.521166599464777e-07
physiology O 0 3.6850003652943997e-06
and O 0 9.61455910442055e-08
in O 0 3.963609174206795e-08
disease O 0 0.0004664655134547502
models O 0 2.5636467171352706e-08
. O 0 1.4767702616325096e-09
. O 0 9.45591338563645e-09

Oral O 0 0.00018104379705619067
contraceptives O 0 0.01329931803047657
and O 0 4.107909035155899e-07
the O 0 2.648452124276446e-09
risk O 0 1.0634935279085767e-06
of O 0 3.1839115877119184e-07
hereditary B-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
. O 0 5.257864472696383e-07

Hereditary B-Disease 1 0.9999833106994629
Ovarian I-Disease 1 0.9999920129776001
Cancer I-Disease 1 0.998790442943573
Clinical O 0 0.0006658057100139558
Study O 0 2.3284114547550416e-07
Group O 0 1.2103942026442382e-06
. O 0 1.2273912552984712e-08

BACKGROUND O 0 0.0005628662765957415
Women O 0 3.39470716426149e-07
with O 0 2.1517176929108928e-10
mutations O 0 1.025030769596924e-06
in O 0 7.920272770967074e-11
either O 0 3.333594511545357e-09
the O 0 1.6116459278237016e-09
BRCA1 O 0 2.4992052203742787e-05
or O 0 2.370714469179802e-08
the O 0 3.0125593131202777e-09
BRCA2 O 0 8.502070159011055e-07
gene O 0 1.5840109313103312e-07
have O 0 3.9996495004857024e-09
a O 0 1.0441851827636128e-09
high O 0 1.289491251554864e-07
lifetime O 0 1.5636197758794879e-07
risk O 0 6.037587809260003e-06
of O 0 1.4308969184639864e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
. O 0 2.114286132837151e-07

Oral O 0 0.0006773911300115287
contraceptives O 1 0.9768121838569641
protect O 1 0.7990826964378357
against O 1 0.9999269247055054
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 1.644506042453031e-08
general O 0 3.384748037404961e-09
, O 0 3.1467422445530246e-08
but O 0 1.7526865292438742e-07
it O 0 1.0512740011847654e-08
is O 0 8.586035354918309e-11
not O 0 4.922999161105501e-11
known O 0 2.599701877381566e-11
whether O 0 3.157940575704288e-10
they O 0 9.036036807685832e-09
also O 0 1.868530574711258e-08
protect O 0 3.238349677303631e-08
against O 0 1.1325953153118462e-07
hereditary B-Disease 0 0.018710436299443245
forms I-Disease 0 1.859603071352467e-05
of I-Disease 0 0.019155964255332947
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
. O 0 4.3019483086936816e-07

METHODS O 0 2.125785385942436e-06
We O 0 9.61327284443314e-09
enrolled O 0 5.365611843721751e-10
207 O 0 4.4253792452764174e-07
women O 0 1.7456915202274104e-06
with O 0 0.002269951393827796
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 2.4345667952729855e-06
161 O 0 3.250286795264401e-07
of O 0 1.2784867609028083e-09
their O 0 4.892126526101492e-07
sisters O 0 1.6835589121910743e-05
as O 0 4.665460795472143e-10
controls O 0 1.3067314057479962e-06
in O 0 7.147949593333536e-11
a O 0 1.5437671974094513e-10
case O 0 2.5935198877391485e-08
- O 0 1.7938677046913654e-05
control O 0 1.2046767551510129e-05
study O 0 3.2417468709411423e-09
. O 0 5.7694982125156e-10

All O 0 7.65025998106239e-09
the O 0 2.5738106090855695e-10
patients O 0 4.0472034057437156e-10
carried O 0 1.95278557213463e-10
a O 0 1.0864592212000979e-11
pathogenic O 0 3.306334095398711e-09
mutation O 0 2.462981640860562e-08
in O 0 1.0613061124375989e-10
either O 0 2.0112587151288608e-08
BRCA1 O 0 5.404242983786389e-06
( O 0 9.415482976615763e-11
179 O 0 2.1037003250512498e-08
women O 0 2.372003393702471e-08
) O 0 3.3515717978716e-10
or O 0 1.0991863774734156e-07
BRCA2 O 0 4.150706809014082e-05
( O 0 2.0313941639926725e-09
28 O 0 2.835632244568842e-07
women O 0 2.2584567105354836e-08
) O 0 4.2473913275387076e-10
. O 0 3.6786671486765954e-09

The O 0 4.106866313691171e-08
control O 0 2.5830158847384155e-05
women O 0 4.567185740711466e-09
were O 0 2.6333480535045695e-11
enrolled O 0 2.058220781309128e-11
regardless O 0 1.8349542371676186e-11
of O 0 8.13091252855648e-14
whether O 0 4.106039952489482e-10
or O 0 9.092640418373321e-09
not O 0 1.0151121720980427e-08
they O 0 2.693501643946661e-09
had O 0 5.4695561857442954e-08
either O 0 1.2745862143503928e-09
mutation O 0 1.2426049522673566e-07
. O 0 2.601787896239216e-09

Lifetime O 0 6.602352300433267e-07
histories O 0 2.1896400426157925e-07
of O 0 1.0496615729382874e-11
oral O 0 9.878823448161711e-08
- O 0 4.737742642646481e-07
contraceptive O 0 1.939404455697513e-06
use O 0 9.316800109182566e-11
were O 0 1.1331615333565193e-11
obtained O 0 1.5834111799506445e-11
by O 0 3.875914780099299e-12
interview O 0 4.990752131561749e-07
or O 0 7.307946608969829e-11
by O 0 1.2663429332926412e-12
written O 0 1.9642611148729117e-10
questionnaire O 0 1.5977220935159409e-10
and O 0 7.917040634186634e-11
were O 0 5.066335892478513e-11
compared O 0 3.1620814300303834e-10
between O 0 5.363333333008313e-09
patients O 0 6.982537570365821e-08
and O 0 1.7279303321515727e-08
control O 0 0.1682949662208557
women O 0 1.9517193550200318e-07
, O 0 1.7341521274527594e-10
after O 0 1.6524907830994806e-10
adjustment O 0 7.109948740868788e-10
for O 0 5.787907046000962e-13
year O 0 2.472281494109163e-12
of O 0 1.713538490787092e-12
birth O 0 1.9646327586997359e-07
and O 0 8.907847792727352e-09
parity O 0 2.5408389774383977e-06
. O 0 5.498506538970105e-09

RESULTS O 0 2.0552679416141473e-06
The O 0 1.0000870132031991e-09
adjusted O 0 1.930951839312911e-06
odds O 0 1.7049364032573067e-05
ratio O 0 5.501871055457741e-05
for O 0 0.013217901811003685
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 7.434800295413879e-07
with O 0 5.614818054944237e-10
any O 0 1.695710100113601e-10
past O 0 7.4145756201460244e-09
use O 0 2.4276958221491896e-10
of O 0 7.666258253213876e-12
oral O 0 1.6073511233116733e-06
contraceptives O 0 0.003349001519382
was O 0 6.173373208184785e-07
0 O 0 3.9581394162269135e-08
. O 0 1.1914352837649744e-09

5 O 0 3.64334828972801e-09
( O 0 2.531790055382288e-11
95 O 0 3.697413708536601e-09
percent O 0 1.708982111381374e-08
confidence O 0 1.5326968139106611e-07
interval O 0 1.8279816060839948e-07
, O 0 4.6437935961873844e-12
0 O 0 9.165903452901247e-11
. O 0 1.4319935211573598e-12
3 O 0 1.427884026294901e-11
to O 0 6.256495321821376e-11
0 O 0 9.232125064428942e-10
. O 0 3.40777961405081e-11
8 O 0 5.159901395046518e-10
) O 0 8.830765979572774e-11
. O 0 1.1434996283199439e-09

The O 0 1.4518590774059703e-07
risk O 0 1.3256645559067692e-07
decreased O 0 1.7217780978739938e-08
with O 0 4.241404102933721e-12
increasing O 0 7.548122717138117e-12
duration O 0 3.831142902921414e-10
of O 0 1.6093234329796896e-13
use O 0 2.4495159234305675e-09
( O 0 8.333227163870305e-11
P O 0 8.685484317538794e-06
for O 0 9.572145159841838e-12
trend O 0 4.593563218691088e-08
, O 0 1.3134778854839713e-11
< O 0 2.937030063598911e-10
0 O 0 7.685822117631247e-11
. O 0 4.268785303539191e-13
001 O 0 2.1520285553577878e-11
) O 0 8.411814403667603e-14
; O 0 6.572166584822153e-14
use O 0 1.0308327975938614e-11
for O 0 1.6932658400414802e-11
six O 0 9.416277757523517e-10
or O 0 4.1539177653149295e-10
more O 0 2.1612099262990903e-11
years O 0 8.566573006518752e-10
was O 0 2.037529966969487e-08
associated O 0 2.5108529144723946e-10
with O 0 5.796925005990827e-12
a O 0 5.421386603532419e-11
60 O 0 4.530552599746329e-10
percent O 0 4.1710426779140164e-10
reduction O 0 1.8870101037293807e-09
in O 0 1.0099171277033747e-08
risk O 0 4.1764445768421865e-07
. O 0 2.2920705333717706e-09

Oral O 0 8.95384255272802e-06
- O 0 1.0332838428439572e-05
contraceptive O 0 0.0001165491048595868
use O 0 3.943531282857293e-06
protected O 1 0.9777314066886902
against O 1 0.9999276399612427
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
both O 0 1.9793169325765803e-09
for O 0 1.6855100648527355e-11
carriers O 0 1.7434158561258073e-09
of O 0 3.631063548795166e-12
the O 0 7.442615856945167e-09
BRCA1 O 0 7.666997589694802e-06
mutation O 0 9.801160416600396e-08
( O 0 2.0980512466239887e-11
odds O 0 2.0286755386678124e-07
ratio O 0 4.438910572446275e-09
, O 0 2.915445662665661e-11
0 O 0 2.903687568167612e-10
. O 0 3.2437210469721256e-12
5 O 0 7.875994995076852e-12
; O 0 9.698547520642364e-12
95 O 0 3.200192777441657e-09
percent O 0 3.9160870102250556e-08
confidence O 0 1.2409434191340551e-07
interval O 0 8.440559895461774e-08
, O 0 1.721498811557698e-12
0 O 0 2.6443456799252196e-11
. O 0 2.5301172290083385e-13
3 O 0 2.832928119519962e-12
to O 0 1.2749180183790898e-11
0 O 0 3.138234117017191e-10
. O 0 8.433270574925711e-12
9 O 0 1.716163322562636e-10
) O 0 2.0668352012503943e-12
and O 0 4.458634850212917e-11
for O 0 6.190549375201249e-13
carriers O 0 6.515511047355815e-11
of O 0 9.329078308473182e-13
the O 0 5.594979146650303e-09
BRCA2 O 0 4.7712055675219744e-06
mutation O 0 1.8044286065332926e-08
( O 0 4.633565666573025e-12
odds O 0 1.0080966283965154e-08
ratio O 0 1.7083523484728858e-09
, O 0 1.347974596527246e-11
0 O 0 4.8641136257687734e-11
. O 0 4.404828552687784e-13
4 O 0 8.466179146626729e-12
; O 0 8.410300234018564e-12
95 O 0 4.467006764485859e-09
percent O 0 3.1940842859512486e-08
confidence O 0 9.440167758612006e-08
interval O 0 1.5670876507556386e-07
, O 0 3.6267031044978637e-12
0 O 0 7.272876745290091e-11
. O 0 1.2354967309641252e-12
2 O 0 9.565920972010034e-12
to O 0 1.5449684934165653e-11
1 O 0 3.504666001852286e-11
. O 0 4.3036654101547e-11
1 O 0 2.572612955997755e-10
) O 0 2.858037695396831e-10
. O 0 2.3114137270852098e-09

CONCLUSIONS O 0 1.0924193247774383e-06
Oral O 0 4.346198238636134e-06
- O 0 8.315435479744337e-06
contraceptive O 0 9.995127766160294e-05
use O 0 1.0810393291649234e-07
may O 0 4.7065615405017525e-08
reduce O 0 5.972375927143503e-09
the O 0 1.6499162924787925e-08
risk O 0 0.00010856657172553241
of O 0 0.00016587025311309844
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 2.8818853934353683e-06
women O 0 7.327944473445314e-08
with O 0 1.265028498620424e-10
pathogenic O 0 3.956931493576121e-08
mutations O 0 3.4580719443511043e-07
in O 0 2.66500072010345e-10
the O 0 2.1033421671035057e-09
BRCA1 O 0 0.00011093471403000876
or O 0 3.35921072291967e-07
BRCA2 O 0 0.0004591262259054929
gene O 0 0.00017628917703405023

A O 0 1.14867276579389e-07
Japanese O 0 1.455651045034756e-06
family O 0 1.3282760669142135e-08
with O 0 1.7042255384680516e-09
adrenoleukodystrophy B-Disease 1 0.9999982118606567
with O 0 6.29151342135259e-10
a O 0 2.3181677410999413e-10
codon O 0 7.109900934665347e-08
291 O 0 1.6117450485353402e-08
deletion O 0 3.313183697173372e-06
: O 0 1.685693945541189e-10
a O 0 4.308447487666456e-10
clinical O 0 1.2315745152591262e-06
, O 0 1.4988613128430472e-10
biochemical O 0 6.694974672427634e-07
, O 0 1.2313838837485491e-09
pathological O 0 1.596579750184901e-05
, O 0 5.729495988759936e-09
and O 0 1.0159958208078024e-07
genetic O 0 6.31997172604315e-05
report O 0 6.280608033648605e-08
. O 0 3.0161875219647527e-09

We O 0 1.9251085632276954e-06
report O 0 5.622158849583059e-10
a O 0 2.0441093262490995e-11
Japanese O 0 8.081327109721315e-07
family O 0 4.261011099515599e-08
with O 0 1.9604011924911902e-07
adrenoleukodystrophy B-Disease 1 1.0
( O 0 1.0899561857513618e-06
ALD B-Disease 1 0.9999998807907104
) O 0 1.4351483335062198e-09
with O 0 1.089273393706236e-10
a O 0 8.079772406688335e-10
three O 0 8.23074441935745e-10
base O 0 1.27250316950267e-07
pair O 0 6.578757165698335e-07
deletion O 0 1.870303094619885e-07
( O 0 2.2077948844123618e-11
delGAG O 0 6.07042061062657e-09
291 O 0 9.55181933548488e-10
) O 0 1.2252817684077488e-11
in O 0 1.3324462366792744e-10
the O 0 2.077922722776293e-08
ALD B-Disease 1 0.9999980926513672
gene O 0 0.00014971787459217012
. O 0 4.158337318926897e-08

A O 0 2.0960543523074193e-08
variety O 0 5.264441660379759e-10
of O 0 5.824888748423573e-12
phenotypes O 0 6.358473569889611e-08
were O 0 4.043445855916872e-10
observed O 0 8.416293217905491e-10
within O 0 1.2716765140918795e-10
this O 0 3.1412161760613344e-10
family O 0 3.252072389159366e-08
. O 0 7.519295408542348e-09

While O 0 2.675229637816301e-08
the O 0 9.170923048751334e-11
proband O 0 2.8420588478184072e-06
( O 0 1.6457876728104281e-10
patient O 0 1.4866687081394048e-07
1 O 0 2.5736240916174324e-10
) O 0 2.706204149660607e-10
was O 0 2.2078738837194578e-08
classified O 0 1.2726282250241638e-07
as O 0 1.2618922795581966e-08
having O 0 6.987837419814014e-09
a O 0 5.243704775947933e-11
rare O 0 3.1390123833574535e-10
intermediate O 0 1.3741771054398555e-09
type O 0 2.9603688744828105e-07
of O 0 1.2647101421681128e-10
adult O 0 3.2255575206363574e-05
cerebral O 0 0.008563361130654812
and O 0 1.679063416304416e-06
cerebello O 1 0.5832081437110901
- O 1 0.9998021721839905
brain O 1 0.7382023930549622
stem O 0 9.967115488507261e-08
forms O 0 5.590224461116122e-08
, O 0 6.568248167582169e-09
his O 0 3.92846075669695e-08
younger O 0 1.640987257189863e-08
brother O 0 2.6970088384814517e-08
( O 0 1.3113076596793505e-11
patient O 0 2.2830050738775753e-08
2 O 0 5.612376674513087e-10
) O 0 7.515449373940442e-10
and O 0 1.0795928773177366e-07
nephew O 0 0.0002546602045185864
( O 0 1.0567617891865666e-09
patient O 0 5.215812848291534e-07
3 O 0 3.03823211034171e-09
) O 0 1.987575437567557e-09
had O 0 7.029881999187637e-06
a O 0 5.663363253916032e-07
childhood O 1 0.7075004577636719
ALD B-Disease 1 0.9999996423721313
type O 0 0.3033629357814789
. O 0 1.923433501360705e-07

Another O 0 2.100198770449424e-07
nephew O 0 8.121642167679965e-06
( O 0 4.297810440867522e-10
patient O 0 3.8870058460815926e-07
4 O 0 1.2834122653515578e-09
) O 0 1.8287636682767783e-10
of O 0 4.418253957139129e-11
patient O 0 1.3833993762091268e-05
1 O 0 5.100995181805956e-09
was O 0 3.1719312687528145e-07
classified O 0 3.212793728835095e-07
as O 0 3.927614145027292e-08
having O 0 7.858078987510453e-08
an O 0 1.6909816602517225e-10
adolescent O 0 3.7677564250770956e-06
form O 0 3.7472482006251084e-08
. O 0 1.0533995009609498e-08

The O 0 2.336283611015233e-09
tau O 0 1.1423137991073418e-09
level O 0 1.296907137238179e-09
in O 0 4.2394084770469576e-11
the O 0 4.340104720057525e-09
cerebrospinal O 0 0.05618312209844589
fluid O 0 1.1216695384064224e-05
( O 0 1.3043700342052489e-08
CSF O 0 0.008123724721372128
) O 0 4.5312265051222766e-10
in O 0 6.545470832008959e-10
patient O 0 5.898706945117738e-07
1 O 0 9.265342937325727e-10
was O 0 1.7683375119759148e-07
as O 0 3.0550825758091094e-10
high O 0 5.044892836814086e-10
as O 0 1.079809575088575e-10
that O 0 1.716585762423506e-10
of O 0 2.677619757862626e-11
patients O 0 5.30248939867306e-07
with O 0 7.809978228578984e-07
Alzheimers B-Disease 1 0.9999996423721313
disease I-Disease 1 0.9998297691345215
( O 0 5.904489397412505e-11
AD B-Disease 0 1.6076992892521957e-07
) O 0 3.730046493899408e-09
. O 0 5.557159621361052e-09

His O 0 6.246273898113941e-08
brain O 0 6.463977797466214e-08
magnetic O 0 2.4554986932656675e-09
resonance O 0 1.1022595280962832e-08
image O 0 3.9686923969384225e-08
( O 0 2.1436878314129437e-11
MRI O 0 1.3560425031755585e-06
) O 0 3.4545866167690065e-10
showed O 0 2.406657813480706e-06
abnormalities B-Disease 0 0.08019799739122391
in I-Disease 0 1.87780102578472e-09
the I-Disease 0 9.599954609029737e-08
bilateral I-Disease 0 1.8414999431115575e-05
cerebellar I-Disease 1 0.778046190738678
hemispheres I-Disease 1 0.79323810338974
and O 0 1.9683247955981642e-05
brain O 0 0.0014270294923335314
stem O 0 2.048644489605067e-07
, O 0 1.0036718123274113e-09
but O 0 3.148645433270758e-08
not O 0 3.2719367215605644e-09
in O 0 2.1686807905041405e-10
the O 0 6.206736014036096e-09
cerebral O 0 4.930157501803478e-06
white O 0 1.2724363784855086e-07
matter O 0 2.7527782275882373e-09
, O 0 4.715054041648514e-11
where O 0 1.2905548851804838e-10
marked O 0 5.448036813349155e-11
reductions O 0 1.6938553892842378e-09
of O 0 7.335621693416172e-12
the O 0 8.585032418295668e-08
cerebral O 0 0.006544787436723709
blood O 0 4.618531193045783e-07
flow O 0 1.5531851715877565e-07
and O 0 2.7647590172819037e-07
oxygen O 0 2.127799980655709e-08
metabolism O 0 1.272264512408583e-06
were O 0 5.608427611214495e-10
clearly O 0 4.3610387523429495e-10
demonstrated O 0 3.427340009021229e-12
by O 0 4.0391135396186315e-14
positron O 0 6.810381147914768e-10
emission O 0 5.045470707898403e-10
tomography O 0 2.75342586064653e-06
( O 0 4.308603751557172e-10
PET O 0 1.1350535942256101e-06
) O 0 9.637647346849576e-10
. O 0 2.5251469804032922e-09

In O 0 3.7816409559354724e-08
patients O 0 8.334590262393249e-08
2 O 0 2.0563000191486935e-09
and O 0 2.341874960620771e-08
3 O 0 5.021356219714335e-09
, O 0 2.8251714856430965e-10
the O 0 7.785324468434496e-11
autopsy O 0 9.405983291799203e-05
findings O 0 4.954740173701566e-09
showed O 0 1.374563680656138e-07
massive O 0 2.8277952424105024e-07
demyelination B-Disease 1 0.9999998807907104
of I-Disease 0 2.9009781243871657e-08
the I-Disease 0 1.0883815093620797e-06
cerebral I-Disease 0 0.0001849236141424626
white I-Disease 0 5.543389747231231e-08
matter I-Disease 0 9.041234427797917e-11
with O 0 1.950096117572797e-12
sparing O 0 8.999787026731099e-11
of O 0 1.5746971868818571e-12
the O 0 9.732097350223512e-10
U O 0 0.001010376843623817
- O 0 0.0003958120651077479
fibers O 0 0.0002188824291806668
, O 0 1.4913187351695e-10
compatible O 0 2.659247544389842e-10
with O 0 3.273250420710028e-11
the O 0 6.642041777693564e-11
findings O 0 1.105566860282181e-09
of O 0 1.5271676978567683e-10
childhood O 0 0.36941683292388916
ALD B-Disease 1 0.9999984502792358
. O 0 2.2795639154082892e-07

Oleic O 0 0.012245784513652325
and O 0 4.736234018309915e-07
erucic O 0 0.0001842073688749224
acids O 0 4.3790433323920297e-07
( O 0 2.4956779698381837e-11
Lorenzos O 0 3.5205906101509754e-07
Oil O 0 1.7622114878435013e-09
) O 0 5.6961657612930594e-12
were O 0 2.0949601428621456e-11
administered O 0 6.581613032352607e-10
to O 0 2.5577490125883173e-10
patients O 0 3.1988178772479614e-10
1 O 0 8.611587831719447e-11
and O 0 2.591033165799672e-08
4 O 0 2.190078163266662e-08
, O 0 1.6346294318125842e-09
but O 0 1.096145507695212e-09
sufficient O 0 1.3072645396738913e-11
effectiveness O 0 1.604165134061475e-10
was O 0 2.4479605009730676e-09
not O 0 3.521117009075425e-10
obtained O 0 1.7822697762071016e-09
. O 0 2.7671123170591727e-09

The O 0 9.82069359167781e-09
findings O 0 5.026060900803486e-09
in O 0 4.5615657084940864e-11
this O 0 3.08370308454986e-11
family O 0 6.388018447545107e-10
suggest O 0 7.159715043059123e-10
that O 0 7.350933750593924e-11
delGAG291 O 0 9.950912271960988e-08
is O 0 7.791325917771985e-11
part O 0 4.007480458589896e-11
of O 0 4.498541730096894e-12
the O 0 6.323405687957973e-10
cause O 0 9.048639615372167e-10
of O 0 5.835886895261266e-12
Japanese O 0 0.0014242295874282718
ALD B-Disease 1 0.9999984502792358
with O 0 9.112219312434888e-10
phenotypic O 0 1.7437633914596518e-07
variations O 0 1.919004716910422e-06
. O 0 7.509552091278238e-08

Moreover O 0 8.660866797072231e-07
, O 0 3.7166081323647404e-10
although O 0 4.314432144880698e-11
the O 0 4.380525456260109e-12
scale O 0 2.0770299613559473e-07
of O 0 2.100321305764652e-11
the O 0 1.4845649154437979e-09
study O 0 1.789201009572139e-09
is O 0 7.01819088955169e-11
limited O 0 3.807004933520375e-09
, O 0 8.351355162972141e-10
there O 0 1.1598157989567426e-09
is O 0 1.1782611344934857e-11
a O 0 1.7929947457306916e-11
possibility O 0 2.1194296317972317e-10
that O 0 4.252751484301598e-09
PET O 0 1.219993350787263e-06
can O 0 2.0361042629701842e-08
detect O 0 2.0393774491367367e-07
an O 0 1.5018288002099922e-10
insidious B-Disease 0 0.0023285888601094484
lesion I-Disease 1 0.9999574422836304
which O 0 1.069900463335216e-06
is O 0 3.4982179375475653e-09
undetectable O 0 1.6565886440389477e-08
by O 0 3.9737120928820535e-13
computed O 0 3.4949567684350313e-09
tomogram O 0 7.342060257542471e-07
( O 0 1.0339203451725787e-11
CT O 0 2.7276792025077157e-05
) O 0 1.969061719231391e-11
or O 0 5.288694135408001e-11
MRI O 0 2.3236177071339625e-07
analysis O 0 2.850732760961705e-09
, O 0 2.882761807043721e-10
and O 0 1.523075554565878e-09
that O 0 4.2248407550182776e-10
the O 0 7.87370030286283e-11
higher O 0 1.5161273625441396e-10
level O 0 1.4006329429605557e-10
of O 0 7.571055598860205e-14
tau O 0 9.119321617290232e-12
reflects O 0 5.6943846339641e-12
the O 0 6.155591986654885e-13
process O 0 2.6132128145422984e-12
of O 0 1.368253709117806e-12
neuronal B-Disease 0 4.521234950516373e-05
degeneration I-Disease 1 0.9995414018630981
in O 0 5.75756030229968e-06
ALD B-Disease 1 0.9999991655349731
. O 0 6.881444960527006e-07

Lorenzos O 0 4.087453635293059e-05
Oil O 0 6.986800116237646e-08
should O 0 1.4239065482257729e-09
be O 0 2.5547868941905305e-12
given O 0 1.3138975855659513e-13
in O 0 6.23805531969196e-13
the O 0 1.2085793303640013e-11
early O 0 2.8139546248695524e-09
stage O 0 2.7211194719711784e-07
. O 0 1.1660837573312932e-10
. O 0 8.136389340052119e-10

Nonsense O 0 9.306469291914254e-05
mutation O 0 7.303065672203957e-07
in O 0 1.1242145235568213e-11
exon O 0 2.9475385687760536e-08
4 O 0 5.71615732525288e-09
of O 0 2.4797256262254486e-11
human O 0 7.737062190926736e-08
complement O 0 1.8583902416935416e-08
C9 O 0 4.85649195525184e-07
gene O 0 2.797714387270389e-06
is O 0 1.4000433035121773e-09
the O 0 4.827835006770975e-11
major O 0 5.901047983591923e-10
cause O 0 1.907357605190896e-09
of O 0 1.6679366221517e-11
Japanese O 0 0.00019252282800152898
complement B-Disease 0 9.998806490330026e-06
C9 I-Disease 0 0.02454284578561783
deficiency I-Disease 1 0.7560928463935852
. O 0 6.28524299273181e-09

Deficiency B-Disease 1 0.9995877146720886
of I-Disease 0 1.0035622333148808e-10
the I-Disease 0 2.666464826717174e-10
ninth I-Disease 0 1.0132342254109972e-07
component I-Disease 0 1.361837975721869e-09
of I-Disease 0 1.0029456432025796e-11
human I-Disease 0 4.00825115320913e-08
complement I-Disease 0 1.8488691466700402e-08
( O 0 3.840146950429002e-11
C9 O 0 6.243926975457725e-08
) O 0 7.71869998472674e-11
is O 0 1.895203438628812e-11
the O 0 1.6732769683724946e-11
most O 0 8.547526020308283e-10
common O 0 3.237585769966245e-05
complement B-Disease 1 0.9999998807907104
deficiency I-Disease 1 1.0
in O 0 1.5327136893006355e-08
Japan O 0 5.0276114052394405e-05
but O 0 8.018306019152988e-09
is O 0 3.9901058151992075e-11
rare O 0 2.2424011258959098e-10
in O 0 1.6632546728789777e-10
other O 0 4.5633843925863005e-11
countries O 0 9.93919460623438e-11
. O 0 8.666808937185522e-10

We O 0 2.3655499603592034e-07
studied O 0 6.372429806056346e-10
the O 0 4.705472123056609e-13
molecular O 0 4.4425510492551723e-10
basis O 0 9.29817750572326e-11
of O 0 1.790623760378196e-10
C9 B-Disease 1 0.8800994157791138
deficiency I-Disease 1 0.9936895370483398
in O 0 6.470657343271569e-10
four O 0 1.9588446420470973e-09
Japanese O 0 2.739371439020033e-06
C9 B-Disease 0 6.274968473007903e-05
- I-Disease 0 0.09446760267019272
deficient I-Disease 1 0.5938397645950317
patients O 0 1.3706297977478243e-05
who O 0 3.889448635163717e-06
had O 0 0.00016800110461190343
suffered O 0 0.04121285676956177
from O 0 1.0196630029213338e-07
meningococcal B-Disease 1 0.9999998807907104
meningitis I-Disease 1 0.9999998807907104
. O 0 1.0188110763920122e-06

Direct O 0 4.045731749613424e-09
sequencing O 0 2.076999372491173e-08
of O 0 2.538685581199296e-11
amplified O 0 7.42194998792911e-08
C9 O 0 1.6776935751749988e-07
cDNA O 0 5.051695950442081e-08
and O 0 2.686298294918288e-09
DNA O 0 4.5264082473295275e-06
revealed O 0 6.1259717298867145e-09
a O 0 1.3276610713597314e-11
nonsense O 0 2.1156351337481283e-08
substitution O 0 8.785691618662383e-11
( O 0 7.502761975065886e-13
CGA O 0 3.3227143259040304e-09
- O 0 4.107654660856497e-07
- O 0 6.14070870597061e-07
> O 0 1.149682127277174e-09
TGA O 0 7.450814365483893e-08
) O 0 1.266813910716369e-12
at O 0 1.0413355290908588e-12
codon O 0 3.2046237191662996e-11
95 O 0 1.5749294229872035e-11
in O 0 8.656850193286547e-13
exon O 0 1.3708112867050204e-08
4 O 0 1.269162552830494e-08
in O 0 4.6005468878895783e-10
the O 0 2.188636161193358e-09
four O 0 1.963229401269473e-08
C9 B-Disease 0 2.6362769858678803e-05
- I-Disease 0 0.0011343882651999593
deficient I-Disease 0 0.0009347621235065162
individuals O 0 1.9200405154684574e-10
. O 0 1.0169022290895668e-09

An O 0 3.740517895423068e-10
allele O 0 5.39814504207925e-09
- O 0 1.1633594709792305e-07
specific O 0 2.6041896417083876e-10
polymerase O 0 2.941156026281533e-06
chain O 0 3.7985096241754945e-06
reaction O 0 2.946542343451597e-09
system O 0 2.1936106264774935e-08
designed O 0 2.1511542058760824e-07
to O 0 2.900465978505906e-10
detect O 0 5.354964471848689e-08
exclusively O 0 6.780682959561801e-11
only O 0 1.393202553323647e-09
one O 0 1.4060236308566232e-10
of O 0 4.57600103642708e-13
the O 0 2.254150893721274e-10
normal O 0 6.624411685862697e-09
and O 0 4.746038284597631e-11
mutant O 0 3.8860303863685886e-10
alleles O 0 1.2204536860294102e-11
indicated O 0 2.368602425306676e-09
that O 0 7.349419683944092e-11
all O 0 1.1763276984433357e-11
the O 0 4.997140895524055e-11
four O 0 1.6489706822220285e-10
patients O 0 3.133238460351073e-11
were O 0 4.452316065741563e-13
homozygous O 0 3.635590439809988e-11
for O 0 4.2802317679752067e-13
the O 0 9.624081913350846e-12
mutation O 0 7.582039440734434e-10
in O 0 4.208317288395547e-12
exon O 0 5.712301458515867e-07
4 O 0 7.761566962471989e-07
and O 0 1.80603720423278e-07
that O 0 1.5977695611013587e-08
the O 0 7.294816972702733e-10
parents O 0 1.1260161691950543e-09
of O 0 9.290723572419335e-13
patient O 0 2.3456747655359322e-08
2 O 0 1.0511647108302213e-10
were O 0 7.999940154768126e-10
heterozygous O 0 2.144255830671682e-07
. O 0 3.4245417612766005e-09

The O 0 1.5387000562583353e-09
common O 0 3.3512267960666975e-10
mutation O 0 3.5998375391699255e-09
at O 0 5.596745636382572e-11
codon O 0 7.205733787429836e-10
95 O 0 6.006163899563433e-10
in O 0 5.791056870152467e-12
exon O 0 3.57975096676455e-07
4 O 0 8.788050109842516e-08
might O 0 3.934114545245393e-08
be O 0 8.540303186865827e-11
responsible O 0 5.6650947821701436e-11
for O 0 1.1550500139678732e-12
most O 0 2.7387098144870947e-10
Japanese O 0 0.00027266237884759903
C9 B-Disease 0 0.04874604195356369
deficiency I-Disease 0 0.34221214056015015
. O 0 1.574131242021437e-10
. O 0 1.1482204076429525e-09

BRCA1 O 0 1.59683568199398e-05
required O 0 1.1435564717388047e-09
for O 0 4.098657177542542e-12
transcription O 0 3.6157466638542246e-06
- O 0 0.0035298913717269897
coupled O 0 1.1206901035620831e-05
repair O 0 9.099094313569367e-06
of O 0 5.0659272783637466e-12
oxidative O 0 6.383091886164038e-07
DNA O 0 0.006721823941916227
damage O 0 0.00013359262084122747
. O 0 3.671588899578637e-08

The O 0 0.00010226396261714399
breast B-Disease 1 0.9999550580978394
and I-Disease 1 0.9999516010284424
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
susceptibility O 0 0.04509034752845764
gene O 0 0.00029719556914642453
BRCA1 O 0 0.0008867168216966093
encodes O 0 2.08638721233001e-06
a O 0 9.886483894661069e-06
zinc O 1 0.9749218821525574
finger O 0 0.35292959213256836
protein O 0 3.7267847119437647e-07
of O 0 2.463457042523043e-11
unknown O 0 7.255651013338138e-08
function O 0 1.3043131730228197e-07
. O 0 6.000704821929048e-09

Association O 0 2.5450697549445067e-08
of O 0 1.195618170440893e-11
the O 0 4.102014214413252e-11
BRCA1 O 0 1.8517988564781263e-07
protein O 0 1.6066614705323445e-09
with O 0 2.7877753924765436e-11
the O 0 1.5326946656291085e-10
DNA O 0 0.00031814721296541393
repair O 0 1.8943675968330353e-05
protein O 0 1.6240113254184507e-08
Rad51 O 0 1.0660693078534678e-05
and O 0 3.5570770773318827e-09
changes O 0 3.780144253173745e-10
in O 0 6.5371549319570565e-12
the O 0 2.3755390016200195e-12
phosphorylation O 0 3.599361919626176e-10
and O 0 2.2950046030256743e-10
cellular O 0 7.851876659970003e-08
localization O 0 3.639696544155413e-08
of O 0 9.498519592393562e-13
the O 0 4.3088067835928e-11
protein O 0 7.820306180406078e-09
after O 0 3.453460017954768e-10
exposure O 0 1.1479364125932534e-08
to O 0 3.0431199227187733e-10
DNA O 0 0.0024966446217149496
- O 0 1.0971062692988198e-05
damaging O 0 1.1130875776643734e-07
agents O 0 4.65818938977236e-09
are O 0 1.7744021529875198e-11
consistent O 0 3.7035663424944687e-10
with O 0 4.924337847211913e-13
a O 0 6.083578519416877e-12
role O 0 7.834302651055225e-11
for O 0 7.755515847585048e-12
BRCA1 O 0 3.6755133692167874e-07
in O 0 1.8613797170274893e-09
DNA O 0 0.009244395419955254
repair O 0 0.01066281832754612
. O 0 1.3945406607263067e-08

Here O 0 9.430446539226978e-07
, O 0 2.2936610943879998e-10
it O 0 2.4661085673560734e-11
is O 0 1.8699779138348083e-12
shown O 0 6.667274371485732e-11
that O 0 2.1747201262023452e-10
mouse O 0 1.80764382093912e-05
embryonic O 0 6.791104851799901e-07
stem O 0 3.569367379441246e-07
cells O 0 1.7117328070526128e-06
deficient B-Disease 0 2.509465230104979e-05
in I-Disease 0 3.9702105492089856e-10
BRCA1 I-Disease 0 3.0327882996061817e-06
are O 0 1.1267266980530266e-10
defective O 0 1.2463344774005236e-06
in O 0 4.709746814768323e-09
the O 0 3.00048252910301e-09
ability O 0 3.296977979516669e-08
to O 0 4.4870523963069786e-11
carry O 0 1.004812899552121e-10
out O 0 8.014769958819556e-10
transcription O 0 1.6464572354379925e-06
- O 0 2.7140746169607155e-05
coupled O 0 4.930872137265396e-07
repair O 0 4.853407517657615e-06
of O 0 1.2892397652924936e-12
oxidative O 0 1.0647829640220152e-07
DNA O 1 0.5048446655273438
damage O 0 0.014582577161490917
, O 0 8.142136742605999e-09
and O 0 8.010434093819185e-09
are O 0 2.491996366205118e-11
hypersensitive O 0 8.314297019751393e-07
to O 0 5.592284968436445e-11
ionizing O 0 4.644916451468362e-09
radiation O 0 6.620321357786452e-08
and O 0 2.8076752034422725e-10
hydrogen O 0 1.8880830232603785e-09
peroxide O 0 7.403975359920878e-06
. O 0 1.8121129485848542e-08

These O 0 1.389071968560529e-08
results O 0 4.702466860351251e-09
suggest O 0 1.9637378390058302e-09
that O 0 7.48202333422654e-10
BRCA1 O 0 2.665741021701251e-06
participates O 0 3.549093685606408e-09
, O 0 2.395287856948869e-10
directly O 0 2.6829632959746164e-10
or O 0 4.237688810970752e-10
indirectly O 0 9.82146097783243e-09
, O 0 5.1312409182768803e-11
in O 0 6.446568105722417e-12
transcription O 0 1.0728573442975176e-06
- O 0 0.00024328597646672279
coupled O 0 9.351981589134084e-07
repair O 0 6.8693152570631355e-06
of O 0 1.0558213374770031e-12
oxidative O 0 1.2704346374903253e-07
DNA O 0 0.017927853390574455
damage O 0 2.0540670448099263e-05
. O 0 1.0463563349105698e-09
. O 0 3.563745964996201e-09

Truncation O 0 0.00014735377044416964
mutations O 0 0.00019718916155397892
in O 0 3.7607342240342234e-10
the O 0 1.806086530331541e-10
transactivation O 0 9.248724381905049e-05
region O 0 1.9047051580400876e-07
of O 0 5.1800150974168346e-11
PAX6 O 0 0.000593232165556401
result O 0 5.524179513827221e-08
in O 0 2.5435045736266204e-10
dominant O 0 1.6714890307412134e-06
- O 0 3.2228152122115716e-05
negative O 0 2.21398028799058e-08
mutants O 0 3.206592111837381e-07
. O 0 1.860364751138377e-09

PAX6 O 0 6.577971362276003e-05
is O 0 7.952731806426527e-10
a O 0 1.2495079623753291e-11
transcription O 0 5.6251110436278395e-09
factor O 0 4.0740143897322056e-11
with O 0 8.171530292699902e-12
two O 0 3.936961173733877e-11
DNA O 0 2.305399175384082e-05
- O 0 1.4326788004836999e-06
binding O 0 7.469779461644066e-09
domains O 0 1.1240859265626568e-07
( O 0 9.051897426060052e-11
paired O 0 2.3345080535364104e-07
box O 0 2.166224930988392e-06
and O 0 2.0034633507748367e-08
homeobox O 0 7.636982246594926e-08
) O 0 7.463746981573038e-11
and O 0 4.37799657637683e-11
a O 0 1.4138971243804477e-11
proline O 0 1.7771729687865445e-07
- O 0 1.2457979892133153e-07
serine O 0 5.6371867174220824e-08
- O 0 1.3862035075362655e-07
threonine O 0 1.2185643072371022e-06
( O 0 1.9076065380096985e-11
PST O 0 2.513812660254189e-07
) O 0 8.003003815204579e-11
- O 0 1.6482168518905382e-07
rich O 0 1.8141939062132906e-09
transactivation O 0 1.1444644769653678e-06
domain O 0 1.0762806113007173e-07
. O 0 3.229687406403059e-09

PAX6 O 0 0.006233638618141413
regulates O 0 0.0004455442540347576
eye O 0 0.2032291740179062
development O 0 3.214748289792624e-08
in O 0 1.1788799103573666e-10
animals O 0 5.413536285914233e-10
ranging O 0 2.041775082339825e-11
from O 0 2.9800825435827294e-12
jellyfish O 0 6.943683961146974e-10
to O 0 7.039920296020297e-12
Drosophila O 0 9.13795636381387e-11
to O 0 1.3104574717037742e-11
humans O 0 1.1190320892140448e-09
. O 0 3.606605292194587e-10

Heterozygous O 0 1.7281372493016534e-05
mutations O 0 8.58171479194425e-05
in O 0 5.101985500743922e-10
the O 0 1.2191607445810604e-10
human O 0 1.890602119303253e-09
PAX6 O 0 7.86508826422505e-06
gene O 0 3.3619810437812703e-06
result O 0 3.6068135145228553e-09
in O 0 8.830458933517527e-12
various O 0 1.2118548352313407e-11
phenotypes O 0 2.1147963025214267e-07
, O 0 9.295961223010352e-11
including O 0 1.449218300919597e-09
aniridia B-Disease 1 1.0
, O 0 6.008660056977533e-05
Peters B-Disease 1 0.9999998807907104
anomaly I-Disease 1 0.9999995231628418
, O 0 1.1926360912184464e-06
autosomal B-Disease 1 0.8324604034423828
dominant I-Disease 0 0.033333346247673035
keratitis I-Disease 1 0.9995635151863098
, O 0 2.1725015812990023e-06
and O 0 2.199895106969052e-06
familial B-Disease 1 0.9873635172843933
foveal I-Disease 1 0.99787437915802
dysplasia I-Disease 1 0.9999232292175293
. O 0 1.0670655683497898e-06

It O 0 8.484302327360638e-08
is O 0 3.5953257732090904e-11
believed O 0 4.684167498325564e-10
that O 0 2.6318504667277587e-12
the O 0 8.507160904544508e-13
mutated O 0 8.30770119364388e-09
allele O 0 5.294994998017444e-10
of O 0 7.410633738602623e-12
PAX6 O 0 1.5221523426589556e-05
produces O 0 1.7152478326565301e-09
an O 0 5.649222409309651e-11
inactive O 0 1.699791951637053e-08
protein O 0 8.916247224988183e-07
and O 0 6.5930044002016075e-06
aniridia B-Disease 1 1.0
is O 0 2.1859939351998037e-06
caused O 0 3.952648057747865e-07
due O 0 1.0614200629532888e-09
to O 0 1.5204719705508296e-09
genetic O 0 1.9793686078628525e-05
haploinsufficiency O 0 0.00040051370160654187
. O 0 5.955123327794354e-08

However O 0 1.1534962141013239e-07
, O 0 1.9428873440641148e-11
several O 0 1.889824017761721e-12
truncation O 0 7.619724442520237e-07
mutations O 0 2.5754303351277485e-05
have O 0 1.8066671714223048e-08
been O 0 5.788702850395566e-09
found O 0 4.5565182738016574e-09
to O 0 4.4256531772646213e-10
occur O 0 9.407212786527452e-10
in O 0 1.8351643121805594e-11
the O 0 7.676302926640233e-10
C O 0 0.0005991596844978631
- O 0 2.0772567950189114e-05
terminal O 0 3.816443950199755e-06
half O 0 2.4852905844419126e-10
of O 0 1.0623521376831868e-12
PAX6 O 0 4.595395239448408e-06
in O 0 8.636100723435902e-10
patients O 0 3.469823095514357e-09
with O 0 1.1197921478967032e-09
Aniridia B-Disease 1 1.0
resulting O 0 1.0722379784056102e-07
in O 0 2.4832200185009867e-10
mutant O 0 5.3708085090420354e-08
proteins O 0 1.396385140850498e-08
that O 0 6.514122574685643e-10
retain O 0 1.330895749163119e-08
the O 0 8.897430014975782e-11
DNA O 0 4.860469562117942e-05
- O 0 9.100205602408096e-07
binding O 0 3.067339937601332e-09
domains O 0 1.5111696427538845e-07
but O 0 7.071788843404647e-08
have O 0 4.897651173507711e-09
lost O 0 1.008458298201731e-06
most O 0 3.3887090182538326e-12
of O 0 6.601492898335171e-13
the O 0 9.375144410794789e-11
transactivation O 0 6.388454039552016e-06
domain O 0 1.0009118796006078e-06
. O 0 1.1181835013474029e-08

It O 0 1.8182900873853214e-07
is O 0 1.6168515137859885e-10
not O 0 4.952052656825856e-11
clear O 0 2.8948272598472435e-11
whether O 0 1.2464652790825093e-12
such O 0 3.5904718868190466e-12
mutants O 0 5.283852146931167e-07
really O 0 1.6873498509539786e-07
behave O 0 1.199806809459858e-09
as O 0 2.8674333740763558e-11
loss O 0 1.1202820004996283e-08
- O 0 3.843802574010624e-07
of O 0 2.305925866918912e-10
- O 0 1.6441741536254995e-05
function O 0 8.452365030109377e-09
mutants O 0 1.7883855507605517e-09
as O 0 5.2929297229831196e-12
predicted O 0 4.402139208714573e-10
by O 0 2.383892042101543e-11
haploinsufficiency O 0 7.4135982686129864e-06
. O 0 7.340125396382291e-09

Contrary O 0 9.126783879764844e-07
to O 0 4.377063989036145e-10
this O 0 3.638849638276653e-12
theory O 0 4.295452438185521e-09
, O 0 2.7750586550912004e-11
our O 0 8.04933897313731e-12
data O 0 1.785903230855368e-10
showed O 0 7.85690623672508e-09
that O 0 2.327563489168405e-11
these O 0 1.5513693845184418e-12
mutants O 0 4.016023513742084e-09
are O 0 1.0522849952510072e-12
dominant O 0 3.4452330766043815e-08
- O 0 2.900314484577393e-06
negative O 0 1.5687010579412686e-09
in O 0 9.10480892069021e-12
transient O 0 3.114738467147049e-10
transfection O 0 1.4564660943960916e-07
assays O 0 2.561012557578124e-08
when O 0 5.016790094458656e-09
they O 0 4.241091158818655e-11
are O 0 5.883618787484723e-13
coexpressed O 0 8.208113655427951e-08
with O 0 1.872610261299812e-10
wild O 0 1.380471644552017e-06
- O 0 0.00038677715929225087
type O 0 4.644887303584255e-05
PAX6 O 0 0.0003903810866177082
. O 0 1.859946863191908e-08

We O 0 3.0244843856053194e-06
found O 0 8.358079783832295e-10
that O 0 1.4848238957809734e-11
the O 0 1.1715762908426353e-11
dominant O 0 5.905670263928187e-07
- O 0 4.008146424894221e-05
negative O 0 8.793177741495128e-09
effects O 0 2.4867439663012192e-08
result O 0 4.00251498611226e-11
from O 0 9.318723093523773e-14
the O 0 5.718152188728676e-13
enhanced O 0 1.913784825058329e-10
DNA O 0 2.3414586394210346e-06
binding O 0 8.81722250767325e-10
ability O 0 2.658268882793635e-10
of O 0 3.294247741345707e-13
these O 0 4.0705033094168286e-11
mutants O 0 5.664616864464733e-08
. O 0 6.904078420078008e-10

Kinetic O 0 5.4322633502579265e-08
studies O 0 1.2198567711507735e-09
of O 0 1.2518020474361347e-12
binding O 0 3.2823265883052954e-08
and O 0 7.306587779254414e-09
dissociation O 0 6.715502109955196e-08
revealed O 0 2.5488201771395325e-08
that O 0 7.918683070373689e-12
various O 0 2.0244933117072317e-13
truncation O 0 8.745394808329365e-08
mutants O 0 2.63223057572759e-07
have O 0 1.6518487688799155e-09
3 O 0 5.646488832056207e-10
- O 0 1.956862888619071e-06
5 O 0 1.3628910444651865e-08
- O 0 1.600182486072299e-06
fold O 0 1.2087310707897814e-08
higher O 0 6.246452140257208e-12
affinity O 0 3.2020380270891824e-12
to O 0 4.511488567709304e-13
various O 0 8.427987311949298e-14
DNA O 0 2.2547449418652832e-07
- O 0 8.600779644041268e-09
binding O 0 1.5298644295835828e-10
sites O 0 1.3410775823174959e-09
when O 0 6.417217313092749e-10
compared O 0 5.580433684593267e-12
with O 0 2.431103712438598e-12
the O 0 1.6147805315114283e-10
wild O 0 6.055643666513788e-07
- O 0 4.279654240235686e-05
type O 0 9.031316949403845e-06
PAX6 O 0 7.0176538429223e-05
. O 0 2.4223050232308196e-08

These O 0 2.1122884774626982e-08
results O 0 1.0524130455991099e-09
provide O 0 1.5146207205107842e-11
a O 0 1.469979346579997e-11
new O 0 1.2208943578340126e-10
insight O 0 8.690211050765839e-11
into O 0 8.02899153412584e-12
the O 0 4.201660287056486e-12
role O 0 1.9222821251441147e-11
of O 0 4.181351445642356e-13
mutant O 0 1.6900321142543362e-08
PAX6 O 0 1.2141376828367356e-06
in O 0 1.3606434867696748e-09
causing O 0 3.4657114156289026e-07
aniridia B-Disease 1 0.9999970197677612
. O 0 8.629716496955098e-09
. O 0 2.2825250578506484e-09

Reversal O 0 2.3717428121017292e-05
of O 0 9.541430756598857e-08
severe O 0 0.47020959854125977
hypertrophic B-Disease 1 0.9999840259552002
cardiomyopathy I-Disease 1 1.0
and O 0 5.681507900590077e-05
excellent O 0 6.781183969906124e-07
neuropsychologic O 0 0.00014619104331359267
outcome O 0 2.7164884386365884e-07
in O 0 2.37489961030235e-09
very B-Disease 0 4.863406388722069e-08
- I-Disease 0 0.002299857558682561
long I-Disease 0 1.3597446013591252e-05
- I-Disease 0 4.190410254523158e-05
chain I-Disease 0 0.00018242972146254033
acyl I-Disease 0 2.4895486561149482e-08
- I-Disease 0 2.619336783027393e-07
coenzyme I-Disease 0 4.021588839719925e-09
A I-Disease 0 3.4398752291053825e-08
dehydrogenase I-Disease 0 0.0001763713953550905
deficiency I-Disease 0 0.048386286944150925
. O 0 2.7067423857829453e-09

Very B-Disease 0 3.5557877708924934e-06
- I-Disease 0 0.00022302688739728183
long I-Disease 0 3.681951284306706e-06
- I-Disease 0 5.7804634707281366e-05
chain I-Disease 0 5.424252958619036e-05
acyl I-Disease 0 2.776370600088285e-08
- I-Disease 0 3.4858246067415166e-08
coenzyme I-Disease 0 1.7292935139412435e-10
A I-Disease 0 5.150461723779642e-10
dehydrogenase I-Disease 0 5.947881120960119e-08
( I-Disease 0 3.5301817025157334e-10
VLCAD I-Disease 0 0.00016751163639128208
) I-Disease 0 4.094305339208404e-08
deficiency I-Disease 0 0.0006295593921095133
is O 0 6.732630009054219e-10
a O 0 1.3663115794315672e-07
disorder O 0 0.02857127971947193
of O 0 4.260899272301444e-11
fatty O 0 1.3945552382210735e-05
acid O 0 2.9216904451345727e-08
beta O 0 1.7356404508062084e-11
oxidation O 0 1.2145501493421307e-08
that O 0 3.6448217777262926e-09
reportedly O 0 3.53342613834684e-07
has O 0 8.15744805038321e-09
high O 0 1.1887227868712102e-09
rates O 0 4.804445552508696e-08
of O 0 2.539872132056864e-11
morbidity O 1 0.9074532985687256
and O 0 2.6099114620592445e-06
mortality O 0 0.00020265454077161849
. O 0 9.725699356977202e-09

We O 0 9.047992222122048e-08
describe O 0 4.82109241417561e-10
the O 0 9.782502932709214e-12
outcome O 0 4.716239117991128e-12
of O 0 4.6867135958814435e-14
a O 0 7.769852122807563e-11
5 O 0 2.4042052793049606e-09
- O 0 3.170732043145108e-06
year O 0 1.1188826531949303e-09
- O 0 3.0412422347581014e-05
old O 0 0.021447381004691124
girl O 0 0.00028628413565456867
with O 0 2.118131760653341e-06
VLCAD B-Disease 1 0.9999998807907104
deficiency I-Disease 1 1.0
who O 0 2.0962588109796343e-07
was O 0 1.0632422053902246e-08
first O 0 1.0924630644559841e-10
seen O 0 4.362280314751388e-09
at O 0 1.165672891545455e-09
5 O 0 1.7059929857676792e-11
months O 0 4.3889553449916185e-12
of O 0 7.353142075262886e-13
age O 0 2.0741213191399765e-08
with O 0 1.483496276932783e-07
severe O 0 0.0507061667740345
hypertrophic B-Disease 1 0.9999879598617554
cardiomyopathy I-Disease 1 1.0
, O 0 0.022108102217316628
hepatomegaly B-Disease 1 1.0
, O 0 0.000709309009835124
encephalopathy B-Disease 1 0.9883902072906494
, O 0 3.387694746948e-08
and O 0 1.2633761059532844e-07
hypotonia B-Disease 0 0.2343931794166565
. O 0 3.933859460403255e-08

Biochemical O 0 0.0006610409473069012
studies O 0 9.496377970208414e-06
indicated O 1 0.7526678442955017
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 2.5397524950676598e-05
by O 0 2.724174497092946e-10
a O 0 3.67460835093425e-08
stable O 0 2.0177540136501193e-06
yet O 0 1.3655443442672777e-09
inactive O 0 9.071991158293713e-09
enzyme O 0 1.1545098743681592e-07
. O 0 2.5683293269906926e-09

Molecular O 0 4.818803972739261e-06
genetic O 0 8.445730600215029e-06
analysis O 0 1.0392363414268857e-08
of O 0 5.306487887990485e-11
her O 0 2.127655307049281e-06
VLCAD O 0 0.001218247227370739
gene O 0 5.964363936072914e-06
revealed O 0 3.6357667454467446e-07
a O 0 4.552051235950927e-10
T1372C O 0 2.9872165896449587e-07
( O 0 3.635888812247856e-11
F458L O 0 8.084309222056163e-09
) O 0 3.9498227605294645e-11
missense O 0 1.249197453034867e-06
mutation O 0 1.537909520266112e-05
and O 0 1.4174560192259378e-07
a O 0 3.145464688714128e-07
1668 O 0 0.10145973414182663
ACAG O 0 0.03154681250452995
1669 O 0 8.741758392716292e-06
splice O 0 0.0006687227287329733
site O 0 1.1590064787014853e-05
mutation O 0 6.3834900174697395e-06
. O 0 1.3780702801113875e-08

After O 0 3.6904104216972655e-09
initial O 0 2.0911565534742493e-10
treatment O 0 1.2961898221419688e-09
with O 0 1.8506409946161817e-11
intravenous O 0 1.987546767168169e-07
glucose O 0 1.4765430023544468e-05
and O 0 5.0948724350519115e-08
carnitine O 0 5.9941689869447146e-06
, O 0 3.954168548148118e-09
the O 0 1.0659910731902755e-09
patient O 0 3.999578439106699e-06
has O 0 1.4330674424911649e-08
thrived O 0 8.169478746822278e-07
on O 0 9.304818027189299e-10
a O 0 9.014514690264264e-10
low O 0 7.298386321963335e-07
- O 0 8.5442097770283e-06
fat O 0 1.7105234064729302e-06
diet O 0 8.89772788781329e-09
supplemented O 0 8.641797694108888e-11
with O 0 2.6260351532192416e-11
medium O 0 4.627198677553679e-07
- O 0 1.0991944691340905e-05
chain O 0 1.890265593829099e-05
triglyceride O 0 8.951811736324089e-08
oil O 0 2.441884250359294e-09
and O 0 1.9212932633738689e-10
carnitine O 0 5.148323545256517e-09
and O 0 7.649041816604196e-11
avoidance O 0 2.405874832689392e-09
of O 0 1.726945843272265e-11
fasting O 0 1.1590936566108212e-07
. O 0 2.2128603394122592e-09

Her O 0 0.003441369626671076
ventricular O 0 0.0005484455614350736
hypertrophy O 0 5.449435775517486e-05
resolved O 0 1.316545450436024e-07
significantly O 0 1.6154784177047077e-08
over O 0 5.2559365748550135e-09
1 O 0 1.0780553338918253e-08
year O 0 1.1902814289754815e-09
, O 0 1.7386605488667328e-09
and O 0 2.1379703341040113e-08
cognitively O 0 4.22246284870198e-06
, O 0 6.573060762349314e-09
she O 0 1.0724154435592936e-06
is O 0 2.810610078007869e-11
in O 0 4.581042142848268e-12
the O 0 2.8698994136017175e-12
superior O 0 1.1196463894913578e-10
range O 0 6.240075678398682e-10
for O 0 5.131407104785879e-11
age O 0 2.9518538724460086e-08
. O 0 2.4536823683973807e-09

Clinical O 0 9.160119952866808e-05
recognition O 0 7.022553205615623e-08
of O 0 6.1797154558007605e-06
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 2.767035596207279e-07
important O 0 6.830392251799822e-09
because O 0 7.588948136572071e-08
it O 0 1.1219649209692761e-08
is O 0 1.7575749189369105e-10
one O 0 3.634724118906085e-11
of O 0 5.355665997491821e-13
the O 0 1.9601864575946593e-09
few O 0 3.7578985256914166e-08
directly O 0 9.388843977831129e-07
treatable O 1 0.5538591742515564
causes O 0 2.282230049388545e-08
of O 0 3.174321250298817e-08
cardiomyopathy B-Disease 1 1.0
in O 0 1.6462186067656148e-06
children O 0 4.0595315908831253e-07
. O 0 1.3531562537139052e-09
. O 0 3.798467762550217e-09

Cloning O 0 1.986327561098733e-06
of O 0 2.1733297453363498e-11
a O 0 3.2563080010206136e-10
novel O 0 2.898655004912598e-08
member O 0 2.763485967838264e-11
of O 0 4.4617865717182237e-13
the O 0 1.4396191183596585e-10
low O 0 1.9573953125018306e-07
- O 0 9.11785832613532e-07
density O 0 2.1609821487800218e-08
lipoprotein O 0 7.784318768244702e-06
receptor O 0 8.51812558266829e-08
family O 0 1.3434238610443572e-07
. O 0 2.925151454391539e-09

A O 0 3.4004916660279605e-09
gene O 0 5.135377900700178e-09
encoding O 0 1.2420007244884346e-09
a O 0 1.3225871509092713e-09
novel O 0 1.6402808000748337e-07
transmembrane O 0 3.162681991852878e-07
protein O 0 8.340681034724184e-08
was O 0 5.861587215605368e-09
identified O 0 2.026420281575625e-10
by O 0 2.5172458518671337e-13
DNA O 0 4.846359047405713e-08
sequence O 0 1.7765611204367815e-09
analysis O 0 1.1390583615211725e-10
within O 0 3.990417718480188e-11
the O 0 5.52503021111761e-09
insulin B-Disease 0 0.03191308304667473
- I-Disease 1 0.999971866607666
dependent I-Disease 1 0.9999254941940308
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 7.493970599625754e-08
IDDM B-Disease 0 0.00020156477694399655
) O 0 3.325109076968147e-10
locus O 0 5.0517151350959466e-08
IDDM4 O 0 1.242390771949431e-05
on O 0 3.3443591007653595e-08
chromosome O 0 0.00012462816084735096
11q13 O 0 2.5034394184331177e-06
. O 0 1.3492936545844714e-08

Based O 0 1.1175779413008513e-08
on O 0 1.1787906206706111e-09
its O 0 3.019090880074238e-11
chromosomal O 0 0.08807101845741272
position O 0 1.1034617273253389e-05
, O 0 9.510583293126373e-11
this O 0 1.9137172315580875e-12
gene O 0 6.648727790548037e-09
is O 0 1.9752080179791243e-11
a O 0 8.547289612192976e-12
candidate O 0 8.59922376361677e-12
for O 0 1.2075551062556977e-13
conferring O 0 5.760890875450286e-09
susceptibility O 0 0.0012285214615985751
to O 0 8.816826266411226e-06
diabetes B-Disease 1 0.99843829870224
. O 0 7.173883886935073e-08

The O 0 8.333120304904185e-10
gene O 0 1.3515164987154549e-08
, O 0 1.1360771351442978e-10
termed O 0 2.1174152209368913e-08
low O 0 9.989933005272178e-07
- O 0 6.562642283824971e-06
density O 0 7.245348143669617e-08
lipoprotein O 0 3.7171339499764144e-06
receptor O 0 4.690714039412569e-09
related O 0 2.211809624341754e-09
protein O 0 8.660323658205016e-08
5 O 0 9.72818159361566e-10
( O 0 3.4122024650251603e-11
LRP5 O 0 1.7160591596621089e-06
) O 0 6.7720846291807746e-12
, O 0 8.987220689871123e-13
encodes O 0 1.2759349132807074e-11
a O 0 7.175597616093654e-11
protein O 0 7.388387679441166e-09
of O 0 2.7164628185749606e-11
1615 O 0 2.382201500950032e-06
amino O 0 1.7053254808274687e-08
acids O 0 9.906891973443521e-10
that O 0 3.413541801652875e-12
contains O 0 7.565058822434079e-12
conserved O 0 1.1390095977503734e-08
modules O 0 2.7418809622759e-07
which O 0 1.5138453823837494e-09
are O 0 3.884655184333008e-12
characteristic O 0 2.145485789029067e-09
of O 0 4.444953519838757e-12
the O 0 2.470357252093436e-09
low O 0 4.7911680667311884e-06
- O 0 7.084611570462584e-05
density O 0 7.515842526117922e-07
lipoprotein O 0 0.00017182037117891014
( O 0 1.955940076570073e-09
LDL O 0 8.366911060875282e-06
) O 0 3.328408659797333e-10
receptor O 0 4.231689665346039e-09
family O 0 1.0892458846001318e-07
. O 0 4.7281711879065824e-09

These O 0 3.5536576459271885e-10
modules O 0 6.494967341730273e-10
include O 0 5.307466705711805e-12
a O 0 4.338236367362747e-12
putative O 0 3.8083608489003495e-10
signal O 0 5.387660317879295e-10
peptide O 0 1.1636886593224816e-10
for O 0 3.0102903134619774e-13
protein O 0 6.390796780664232e-10
export O 0 3.1301174985287616e-09
, O 0 2.411331412321971e-10
four O 0 8.16971004735656e-11
epidermal O 0 6.087281576583337e-07
growth O 0 7.450011163534498e-10
factor O 0 4.052554472555592e-11
( O 0 3.826012423546743e-12
EGF O 0 2.98237416984648e-08
) O 0 1.4060229543144676e-11
repeats O 0 7.107203003897666e-08
with O 0 8.040427351696522e-11
associated O 0 7.980421656839098e-09
spacer O 0 2.9131686460459605e-05
domains O 0 1.7255480315725436e-06
, O 0 5.812308967456659e-10
three O 0 1.1021743934191974e-10
LDL O 0 5.059621344116749e-06
- O 0 7.336709131777752e-06
receptor O 0 5.213284026694964e-09
( O 0 2.6518766349514777e-11
LDLR O 0 5.298344945003919e-07
) O 0 2.011033180260302e-11
repeats O 0 1.2561054063553456e-07
, O 0 1.758999369771974e-11
a O 0 3.7478787434652716e-11
single O 0 1.2343380539903137e-08
transmembrane O 0 1.5729384017504344e-08
spanning O 0 4.0603286066698274e-08
domain O 0 2.864514101474924e-07
, O 0 6.034446276004246e-10
and O 0 1.4868029030168373e-10
a O 0 6.360987431230924e-11
cytoplasmic O 0 2.129177801180049e-06
domain O 0 2.5172485038638115e-06
. O 0 1.051426412601586e-08

The O 0 3.3004285415749735e-10
encoded O 0 2.7177235462083615e-10
protein O 0 6.977771249694342e-08
has O 0 5.203865782732464e-09
a O 0 2.278764156538049e-11
unique O 0 5.31683169713304e-11
organization O 0 6.472209573837873e-11
of O 0 2.3569041683602077e-12
EGF O 0 4.266201813152293e-06
and O 0 4.059097236108755e-08
LDLR O 0 2.7678173864842393e-05
repeats O 0 1.3563965694629587e-05
; O 0 7.396308010498842e-10
therefore O 0 4.85177453768415e-10
, O 0 2.7871158506109772e-11
LRP5 O 0 2.2236879431147827e-06
likely O 0 2.6031365951695307e-10
represents O 0 2.1611425756601355e-12
a O 0 8.149707471372114e-12
new O 0 1.7621029635428442e-10
category O 0 8.989381683477404e-09
of O 0 1.0797184327171472e-11
the O 0 1.1107331054915903e-08
LDLR O 0 0.0018194891745224595
family O 0 2.3289487671718234e-07
. O 0 4.827443778054885e-09

Both O 0 1.7618702941035735e-07
human O 0 7.80717712700607e-09
and O 0 6.660735518693173e-09
mouse O 0 1.631142913538497e-05
LRP5 O 0 7.878074939071666e-06
cDNAs O 0 2.1960727281111758e-07
have O 0 2.4705801848767805e-08
been O 0 1.080381384355178e-08
isolated O 0 2.5606381313991733e-05
and O 0 7.997209006127548e-10
the O 0 1.9335923921032228e-12
encoded O 0 3.063584663731689e-10
mature O 0 5.876775177604543e-10
proteins O 0 1.7840647015265887e-10
are O 0 2.1098359604537764e-12
95 O 0 1.2422044504134533e-09
% O 0 1.8578982102779307e-11
identical O 0 1.652716861144654e-07
, O 0 3.3361119422536945e-10
indicating O 0 5.215687881587883e-10
a O 0 8.284511271439143e-11
high O 0 1.9621081148724073e-10
degree O 0 4.2123023819007344e-11
of O 0 2.992589357743436e-13
evolutionary O 0 6.203457747488983e-09
conservation O 0 1.4783118063022016e-09
. O 0 5.7004408138272566e-11
. O 0 4.5625514477620754e-10

The O 0 5.892042409527676e-09
APC B-Disease 0 1.2087287615258901e-08
variants O 0 1.1130850019469563e-08
I1307K O 0 2.3926472181301506e-07
and O 0 1.545677252856592e-09
E1317Q O 0 7.385629885447997e-08
are O 0 5.16551412754751e-10
associated O 0 3.962876508012414e-05
with O 1 0.999887228012085
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 0.011823461391031742
but O 0 4.911371888738358e-06
not O 0 2.0436490899555793e-07
always O 0 4.4120962883198445e-08
with O 0 5.936266062045448e-11
a O 0 3.1156315305480575e-09
family O 0 5.7012869092432084e-08
history O 0 4.2252960241739856e-08
. O 0 3.3258211740161414e-09

Classical O 1 0.676383912563324
familial B-Disease 1 0.9999911785125732
adenomatous I-Disease 1 0.9998379945755005
polyposis I-Disease 1 0.999997615814209
( O 0 1.6568167211516993e-06
FAP B-Disease 0 1.3641620171256363e-05
) O 0 1.1385984377554337e-09
is O 0 2.1856816356802256e-10
a O 0 3.5955214361393928e-09
high O 0 1.1164315765199717e-05
- O 1 0.9999407529830933
penetrance O 1 0.9999572038650513
autosomal B-Disease 1 0.999996542930603
dominant I-Disease 1 0.9998219609260559
disease I-Disease 1 0.9998809099197388
that O 0 1.0439124009664624e-09
predisposes O 0 5.692180593541707e-07
to O 0 7.53828596766759e-11
hundreds O 0 1.5270503611608532e-11
or O 0 6.828200227460002e-10
thousands O 0 1.6508157063555018e-09
of O 0 3.3526350762258517e-06
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9998619556427002
carcinoma I-Disease 1 1.0
and O 0 0.0021234650630503893
that O 0 8.365391579445713e-08
results O 0 1.9935068706899983e-08
from O 0 4.785358307529686e-12
truncating O 0 5.847804004588397e-06
mutations O 0 1.243578390131006e-05
in O 0 1.823229484054778e-10
the O 0 1.2217235556555295e-10
APC B-Disease 0 1.1016336998181941e-07
gene O 0 6.318625196399807e-07
. O 0 6.019734488660333e-09

A O 0 9.515456866893146e-09
variant O 0 2.38284627585017e-07
of O 0 1.3335420268045795e-10
FAP B-Disease 0 1.4494627976091579e-05
is O 0 6.269530672398105e-07
attenuated B-Disease 1 0.9997264742851257
adenomatous I-Disease 1 0.9999991655349731
polyposis I-Disease 1 0.9999939203262329
coli I-Disease 1 0.9999998807907104
, O 0 1.4084965869187727e-06
which O 0 1.1538963562429672e-08
results O 0 2.215559069540518e-09
from O 0 6.7978248897981874e-12
germ O 0 0.001450041774660349
- O 0 0.0003724709094967693
line O 0 0.010037782602012157
mutations O 0 1.109161075873999e-06
in O 0 6.140541547461353e-11
the O 0 1.6634164878848168e-10
5 O 0 9.332171702070013e-10
and O 0 1.2563056150938223e-09
3 O 0 7.081081832005509e-10
regions O 0 1.2336830446102454e-09
of O 0 2.1652647123199253e-12
the O 0 1.5316864443448708e-10
APC B-Disease 0 6.432296117964142e-08
gene O 0 1.8702390036651195e-07
. O 0 6.108493266765436e-09

Attenuated B-Disease 1 0.9972761273384094
adenomatous I-Disease 1 0.9999548196792603
polyposis I-Disease 1 0.9999353885650635
coli I-Disease 1 0.999998927116394
patients O 1 0.9920686483383179
have O 0 4.046940830448875e-06
" O 0 1.3828444878072332e-07
multiple O 0 0.00013589891023002565
" O 1 0.9444674849510193
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999998807907104
( O 0 7.782633559827445e-08
typically O 0 2.506633789423063e-09
fewer O 0 1.1624235428386864e-11
than O 0 1.4133632632307158e-11
100 O 0 2.7638445351807484e-11
) O 0 1.2121553760735537e-11
without O 0 2.229388722241321e-11
the O 0 3.339650084255297e-11
florid O 0 5.140377106727101e-05
phenotype O 0 3.9627630599170516e-07
of O 0 8.86179150894062e-12
classical O 0 1.4993995023360185e-07
FAP B-Disease 0 2.62456273958378e-06
. O 0 5.3937605493104e-09

Another O 0 8.12284497442306e-08
group O 0 6.392884888128947e-09
of O 0 1.0556769000635846e-11
patients O 0 5.24546095448386e-09
with O 0 3.790316671636873e-10
multiple O 0 4.518536570685683e-06
adenomas B-Disease 1 0.7198969721794128
has O 0 3.1120431231101975e-05
no O 0 6.458333956516071e-08
mutations O 0 5.042156772105955e-07
in O 0 9.395157568592438e-11
the O 0 1.3380287156028459e-10
APC B-Disease 0 7.67238717003238e-08
gene O 0 1.4012269957675016e-06
, O 0 1.0668276040348701e-08
and O 0 1.3250623709382126e-08
their O 0 6.391723816889794e-10
phenotype O 0 4.5493564471144055e-07
probably O 0 5.7991154989167626e-08
results O 0 1.0333254391037272e-10
from O 0 2.7231106367216207e-13
variation O 0 2.7432399463123147e-08
at O 0 8.464953538123154e-08
a O 0 3.380838053956836e-09
locus O 0 4.13841462432174e-07
, O 0 6.247081518750974e-09
or O 0 5.360620281003037e-10
loci O 0 1.6923949741620703e-10
, O 0 6.320714091012647e-11
elsewhere O 0 6.301132393637943e-10
in O 0 6.898125820553602e-11
the O 0 1.4337112053119938e-10
genome O 0 5.573413091042312e-07
. O 0 6.0799449919102244e-09

Recently O 0 3.332845153636299e-05
, O 0 2.2811148525647695e-09
however O 0 1.1185663506552146e-10
, O 0 4.869956976745471e-13
a O 0 2.965368619059494e-12
missense O 0 4.234106256717496e-07
variant O 0 4.401691967359511e-06
of O 0 1.191491488805596e-10
APC B-Disease 0 3.2596724395261845e-06
( O 0 2.6898397398333884e-10
I1307K O 0 6.963610843513379e-08
) O 0 3.3447626612836956e-11
was O 0 1.3814546839796549e-08
described O 0 2.6930135899050356e-09
that O 0 4.9204081781217823e-11
confers O 0 7.733632068074314e-10
an O 0 1.9451157698413546e-11
increased O 0 5.7300781008962076e-08
risk O 0 4.250105848768726e-05
of O 0 0.006882867775857449
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 4.7234325961653667e-07
including O 0 9.567463488124872e-10
multiple O 0 1.619250269868644e-06
adenomas B-Disease 0 0.007166869007050991
, O 0 1.101614355292213e-08
in O 0 2.5110184154186754e-08
Ashkenazim O 0 0.00967168714851141
. O 0 4.787075269518937e-08

We O 0 4.560130491881864e-06
have O 0 8.404883039547784e-11
studied O 0 7.11716380275007e-11
a O 0 2.8542704224449045e-12
set O 0 5.851084061703204e-10
of O 0 1.3733095606885404e-13
164 O 0 1.827502273954451e-07
patients O 0 1.662295368021205e-08
with O 0 6.9080341447147475e-09
multiple O 1 0.9931890964508057
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.8764873743057251
/ I-Disease 1 0.9999815225601196
or I-Disease 1 0.9044785499572754
carcinoma I-Disease 1 1.0
and O 0 0.00010364338231738657
analyzed O 0 3.2537926017539576e-05
codons O 0 2.386460437264759e-05
1263 O 0 4.4568068915396e-06
- O 0 1.113603138946928e-05
1377 O 0 4.29507394983375e-07
( O 0 2.750235282567015e-11
exon O 0 1.6424904103473636e-08
15G O 0 3.538882538123289e-07
) O 0 4.034259037943855e-12
of O 0 1.4564839948254943e-13
the O 0 9.252229191125672e-12
APC B-Disease 0 3.811974735867807e-09
gene O 0 4.471780723491747e-09
for O 0 1.861385004464644e-11
germ O 0 0.00047038632328622043
- O 0 7.15433488949202e-05
line O 0 7.346441634581424e-06
variants O 0 1.7121918460816232e-07
. O 0 9.502469922040291e-09

Three O 0 8.753755764701054e-08
patients O 0 8.150186303623741e-09
with O 0 7.22050154042253e-12
the O 0 4.577103019515194e-12
I1307K O 0 1.4547570925671494e-09
allele O 0 1.8035493931645163e-10
were O 0 1.921519714176423e-11
detected O 0 5.826474858139363e-09
, O 0 1.306972325504363e-12
each O 0 2.4780492328263515e-13
of O 0 4.972000675756982e-12
Ashkenazi O 0 0.003971849102526903
descent O 0 1.2800065633200575e-05
. O 0 2.1539248606927686e-08

Four O 0 2.2700790225371748e-07
patients O 0 2.0818548307488527e-07
had O 0 1.9721317912058112e-08
a O 0 3.818572957836608e-10
germ O 0 0.06992803514003754
- O 0 0.003680590773001313
line O 0 8.357689512195066e-05
E1317Q O 0 2.439888113769939e-08
missense O 0 4.5616513233426303e-08
variant O 0 1.642337679186312e-07
of O 0 1.4612602794450424e-11
APC O 0 1.03682486951584e-06
that O 0 2.33055228449075e-08
was O 0 3.845261744572781e-07
not O 0 3.25132010203788e-09
present O 0 5.1806472306514806e-11
in O 0 1.6075404896120915e-10
controls O 0 0.0016047086101025343
; O 0 5.906861666460372e-09
one O 0 9.474481615923125e-11
of O 0 4.3989093509270993e-13
these O 0 6.25444640522943e-10
individuals O 0 2.312849044228127e-11
had O 0 3.717725860497012e-07
an O 0 1.4466897298170966e-11
unusually O 0 1.3887314909144521e-10
large O 0 3.5442739021451786e-11
number O 0 4.5561424077966706e-10
of O 0 5.559327304061057e-11
metaplastic B-Disease 0 0.0009160448680631816
polyps I-Disease 0 4.18658419221174e-06
of I-Disease 0 3.0165453468455894e-12
the I-Disease 0 2.171202551082274e-09
colorectum I-Disease 0 0.00012318931112531573
. O 0 1.3776050522551486e-08

There O 0 1.2672992966145102e-07
is O 0 2.133278623195345e-11
increasing O 0 3.103071402263402e-12
evidence O 0 3.623560618226662e-10
that O 0 3.1832006475163155e-10
there O 0 1.9668967843333718e-10
exist O 0 3.757782085500594e-09
germ O 0 3.482585452729836e-05
- O 0 3.0722151223017136e-06
line O 0 1.047862610903394e-06
variants O 0 8.07559685789272e-10
of O 0 1.6030226191593444e-12
the O 0 6.577619005021518e-11
APC B-Disease 0 8.203321577582301e-09
gene O 0 9.44187483753467e-09
that O 0 1.5585839563403425e-10
predispose O 0 3.4504399337720315e-09
to O 0 1.5144156761959238e-11
the O 0 1.149352054502506e-11
development O 0 3.879794263639269e-10
of O 0 1.7687474818117721e-09
multiple O 1 0.9998652935028076
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9999693632125854
carcinoma I-Disease 1 1.0
, O 0 2.4350114472326823e-05
but O 0 9.00373109402608e-08
without O 0 6.363584659219157e-11
the O 0 2.2387675047141897e-11
florid O 0 4.926453766529448e-05
phenotype O 0 3.4316516916987894e-07
of O 0 1.1823194333293596e-12
classical O 0 3.494525202540899e-08
FAP B-Disease 0 8.328551359682024e-08
, O 0 2.069860283171465e-09
and O 0 2.3461208531472266e-09
possibly O 0 1.849763259231807e-10
with O 0 8.040243471008068e-11
importance O 0 4.946981135844908e-08
for O 0 0.003667989280074835
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 0.00018377756350673735
in O 0 4.37279962239856e-10
the O 0 2.5774704592862463e-10
general O 0 3.0706223674847877e-10
population O 0 1.1722206538777868e-10
. O 0 5.299185049101318e-11
. O 0 8.056981193327317e-10

Genomic O 0 9.7563033705228e-06
structure O 0 1.7262478024804295e-07
of O 0 6.070668967517179e-11
the O 0 3.124643299656782e-08
human O 0 0.0005187715287320316
congenital B-Disease 1 0.9999995231628418
chloride I-Disease 1 0.9999887943267822
diarrhea I-Disease 1 1.0
( O 0 4.662840922264877e-07
CLD B-Disease 0 0.059001799672842026
) O 0 9.643992271435309e-10
gene O 0 1.4213940175977768e-06
. O 0 1.5978670830918418e-08

Congenital B-Disease 1 0.9999966621398926
chloride I-Disease 1 0.9999713897705078
diarrhea I-Disease 1 1.0
( O 0 2.932311144832056e-05
CLD B-Disease 1 0.9969614148139954
) O 0 5.525180668541907e-08
is O 0 5.184942253322333e-09
caused O 0 1.6392512236507173e-08
by O 0 5.868170532830064e-11
mutations O 0 8.622354812359845e-07
in O 0 6.915369665794202e-11
a O 0 2.646249330773287e-10
gene O 0 3.0119352345536754e-07
which O 0 3.229909228963379e-09
encodes O 0 9.410378964958e-08
an O 0 8.098201931261428e-08
intestinal O 0 0.0019912526477128267
anion O 0 6.34802745480556e-07
transporter O 0 0.0009014329989440739
. O 0 7.597347462251491e-08

We O 0 2.06297954719048e-05
report O 0 2.9746125562724046e-09
here O 0 6.747552516728206e-11
the O 0 1.7214855842911936e-12
complete O 0 7.299006399286156e-10
genomic O 0 1.592128455740749e-07
organization O 0 1.5924345175832855e-10
of O 0 2.5695407173537133e-12
the O 0 1.3613107308074746e-09
human O 0 3.3355235018461826e-08
CLD B-Disease 0 4.307755079935305e-05
gene O 0 4.4170894852868514e-07
which O 0 1.4809787840519562e-09
spans O 0 5.2200427091975143e-08
approximately O 0 1.9848128696153822e-10
39kb O 0 5.610665994026931e-06
, O 0 1.1637513175344338e-09
and O 0 1.977866898039693e-10
comprises O 0 3.9209413493779266e-10
21 O 0 1.3806820131634367e-09
exons O 0 1.7997938357439125e-06
. O 0 1.4434974993093874e-08

All O 0 2.6210540404747462e-09
exon O 0 2.1191007704146614e-07
/ O 0 0.00012231657456140965
intron O 0 0.0017681815661489964
boundaries O 0 7.010881290625548e-06
conform O 0 2.540712671361689e-07
to O 0 4.0469773365803263e-11
the O 0 1.129600926685903e-11
GT O 0 3.792692382376117e-08
/ O 0 1.5289699149434455e-05
AG O 0 0.10897675901651382
rule O 0 1.7196208546010894e-06
. O 0 5.381316281471982e-09

An O 0 1.3146589372681206e-10
analysis O 0 1.6881876452323752e-10
of O 0 3.9244890432006685e-13
the O 0 1.535388656492831e-11
putative O 0 1.6407902592163737e-08
promoter O 0 1.5537851822955417e-06
region O 0 1.3436513235376424e-08
sequence O 0 7.431738424656942e-08
shows O 0 5.339112707503091e-09
a O 0 5.286759918732287e-10
putative O 0 1.5794960006587644e-07
TATA O 0 4.940408871334512e-06
box O 0 5.198886356083676e-06
and O 0 1.1889341955395594e-08
predicts O 0 1.0871225697428599e-07
multiple O 0 1.7182965050821508e-09
transcription O 0 3.1552289669889433e-07
factor O 0 5.708505890211768e-10
binding O 0 2.2703761093367802e-09
sites O 0 3.0198390277291765e-07
. O 0 1.2322303177825233e-08

The O 0 1.3004739507493923e-09
genomic O 0 1.4459008923495276e-07
structure O 0 2.5452402496739523e-07
was O 0 2.4858748393086216e-09
determined O 0 4.7386029128348994e-11
using O 0 2.7243081054950657e-11
DNA O 0 1.0835225111804903e-05
from O 0 2.0231587672531193e-12
several O 0 5.322386411807378e-13
sources O 0 3.2973797303714747e-12
including O 0 6.9300619930101615e-12
multiple O 0 2.6993902668692726e-09
large O 0 2.4781218854741383e-08
- O 0 0.002370574278756976
insert O 0 0.0004031822318211198
libaries O 0 6.212877451616805e-06
and O 0 3.493695333034452e-10
genomic O 0 3.276947069252856e-08
DNA O 0 1.4287315025285352e-05
from O 0 7.867785589699139e-11
Finnish O 0 0.00043871186790056527
CLD B-Disease 1 0.9387372732162476
patients O 0 1.921877083077561e-05
and O 0 7.676073110474135e-09
controls O 0 0.00039886924787424505
. O 0 9.647882848184963e-08

Exon O 0 2.445955544772005e-07
- O 0 1.5948091913742246e-06
specific O 0 2.7375923750128095e-10
primers O 0 5.60601256438531e-06
developed O 0 4.389089838241489e-07
in O 0 3.940243964439816e-11
this O 0 1.5303569175784126e-11
study O 0 4.369437450746361e-11
will O 0 9.099531891876289e-12
facilitate O 0 1.845269249900472e-11
mutation O 0 1.2392558090823513e-09
screening O 0 2.739693583109215e-09
studies O 0 8.805688123114663e-11
of O 0 1.625582372703771e-12
patients O 0 3.249486368872567e-08
with O 0 1.5379665319059654e-09
the O 0 3.3684607387840515e-06
disease O 1 0.8361409902572632
. O 0 2.4451152214055583e-08

Genomic O 0 1.3207850315666292e-06
sequencing O 0 9.020318003649663e-08
of O 0 2.3841557200698915e-11
a O 0 2.746023630706418e-09
BAC O 0 0.0002236938598798588
clone O 0 0.01939181052148342
H O 1 0.9999997615814209
_ O 0 1.6327794227777304e-08
RG364P16 O 0 4.366994588167472e-08
revealed O 0 4.1437214548523116e-08
the O 0 8.679753964180303e-12
presence O 0 6.975153787891486e-11
of O 0 8.481319487864403e-13
another O 0 5.169873418253701e-09
, O 0 1.186479664516682e-10
highly O 0 7.422232967124742e-12
homologous O 0 9.232367648159823e-11
gene O 0 1.5027703526016012e-08
3 O 0 4.939226250222362e-10
of O 0 7.002997574195868e-12
the O 0 1.1573745517523548e-08
CLD B-Disease 0 0.0021418780088424683
gene O 0 1.3539827250497183e-06
, O 0 1.805060267923153e-10
with O 0 6.393143826832759e-12
a O 0 5.6998208236569425e-11
similar O 0 2.874284976694952e-10
genomic O 0 3.3523442652949598e-06
structure O 0 1.590273495821748e-05
, O 0 5.295479610367693e-10
recently O 0 1.5976718614751917e-08
identified O 0 3.0186406263510435e-08
as O 0 6.282642406318928e-09
the O 0 5.443118880066322e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 8.283847819257062e-06
( O 0 1.300004687232459e-10
PDS B-Disease 0 2.589501946204109e-06
) O 0 6.549163988900375e-11
. O 0 1.359275886292366e-10
. O 0 1.267318583408894e-09

The O 0 2.0652510812624314e-08
APCI1307K O 0 1.8810314941219985e-05
allele O 0 1.6833201925692265e-06
and O 0 1.631192753848154e-05
cancer B-Disease 0 0.0030103703029453754
risk O 0 3.9880353597254725e-07
in O 0 3.4447500407708276e-10
a O 0 1.5932890562453395e-09
community O 0 3.854215557819174e-10
- O 0 1.627991252917127e-07
based O 0 1.131850932423184e-10
study O 0 1.1052010001622037e-11
of O 0 6.800765462930403e-13
Ashkenazi O 0 3.906176061718725e-06
Jews O 0 3.1001142986042396e-08
. O 0 1.971258267730036e-09

Mutations O 0 0.0006497709546238184
in O 0 5.208530828859637e-10
APC O 0 9.364309505599522e-08
are O 0 2.1114604509264723e-10
classically O 0 0.00046685896813869476
associated O 0 1.6906511518754996e-05
with O 0 0.0011348179541528225
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999946355819702
polyposis I-Disease 1 0.9999996423721313
( O 0 1.2492904488681233e-06
FAP B-Disease 0 1.1043429367418867e-05
) O 0 1.329826693208247e-09
, O 0 3.117615332559609e-10
a O 0 2.821523281681948e-08
highly O 0 0.00016418124141637236
penetrant O 1 0.9999629259109497
autosomal B-Disease 1 1.0
dominant I-Disease 1 0.9999997615814209
disorder I-Disease 1 1.0
characterized O 0 0.053788334131240845
by O 0 9.743620665858543e-08
multiple O 0 0.31417790055274963
intestinal O 1 0.9999556541442871
polyps B-Disease 1 0.9484331011772156
and O 0 6.099577944951307e-07
, O 0 7.515577604699786e-10
without O 0 1.5639113615240063e-10
surgical O 0 2.779681199172046e-05
intervention O 0 1.3245242236337162e-08
, O 0 1.5808462178190652e-11
the O 0 2.020306144601136e-11
development O 0 5.8536574698564436e-08
of O 0 1.631438499316573e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 3.838124484900618e-08
CRC B-Disease 0 0.010368646122515202
) O 0 2.56093302120064e-09
. O 0 6.363031879175196e-09

APC B-Disease 0 5.55350288777845e-06
is O 0 7.185219530470022e-09
a O 0 4.121170960047493e-08
tumour O 1 0.9999973773956299
- O 0 2.066413617285434e-05
suppressor O 0 2.66582242147706e-06
gene O 0 1.2521528560682782e-06
, O 0 5.272802194866699e-10
and O 0 2.3376106605965674e-10
somatic O 0 4.0440976789568595e-08
loss O 0 2.280208263982786e-06
occurs O 0 1.0142764494958101e-07
in O 0 1.7419399966911442e-07
tumours B-Disease 1 0.9999997615814209
. O 0 3.38859365456301e-07

The O 0 9.888037943994732e-09
germline O 0 1.3156859495211393e-06
T O 0 0.004045865032821894
- O 0 1.471468567615375e-05
to O 0 4.926930863291545e-09
- O 0 2.4290559963446867e-07
A O 0 1.7334520485690064e-09
transversion O 0 1.9229125314268458e-07
responsible O 0 2.330047821352821e-10
for O 0 5.416368308724939e-13
the O 0 2.8073726069527405e-12
APC O 0 3.1140079403968457e-10
I1307K O 0 6.885821773883194e-11
allele O 0 7.632234254317805e-12
converts O 0 7.729835001246688e-12
the O 0 7.189540195823296e-12
wild O 0 5.69767433233892e-09
- O 0 5.112091798764595e-07
type O 0 5.884228357899701e-07
sequence O 0 9.480222047386633e-07
to O 0 5.602945662985803e-09
a O 0 3.251700064765828e-08
homopolymer O 0 0.1979307234287262
tract O 1 0.9928538203239441
( O 0 4.6117856200567076e-09
A8 O 0 0.31285661458969116
) O 0 1.8200686513480946e-09
that O 0 5.3111306463904384e-09
is O 0 5.297715155450078e-09
genetically O 0 5.943848464085022e-06
unstable O 0 0.3543083667755127
and O 0 9.775459375305218e-07
prone O 0 1.7844799003796652e-05
to O 0 8.086212255342673e-11
somatic O 0 8.830943976079197e-09
mutation O 0 4.6586404778281576e-07
. O 0 4.88790874442202e-09

The O 0 2.160119860761256e-09
I1307K O 0 2.7455328677206126e-08
allele O 0 3.0370213011110536e-09
was O 0 5.857272888931675e-09
found O 0 2.071059573838241e-10
in O 0 1.1161027657635714e-10
6 O 0 4.7565485772338434e-08
. O 0 9.00912144885524e-09

1 O 0 3.4337377385895707e-09
% O 0 3.1513566062235654e-11
of O 0 1.728526610039749e-12
unselected O 0 1.6693014913471416e-05
Ashkenazi O 0 0.0001692978839855641
Jews O 0 2.300635060237255e-07
and O 0 2.4256880948314574e-09
higher O 0 2.3146903838089372e-10
proportions O 0 1.4576110629604955e-07
of O 0 1.286342039830135e-11
Ashkenazim O 0 0.00047710444778203964
with O 0 2.487707106979542e-08
family O 0 2.3919443492559367e-07
or O 0 3.750749932862618e-09
personal O 0 1.0324512356163495e-09
histories O 0 2.3693610273767263e-07
of O 0 5.762203908465935e-11
CRC B-Disease 0 0.00038957063225097954
( O 0 1.2751642797237395e-10
ref O 0 5.3219220717437565e-05
. O 0 1.2989934128349034e-10
2 O 0 3.881763244173442e-10
) O 0 1.186497705640832e-10
. O 0 1.0314612497452913e-09

To O 0 3.824012217990003e-09
evaluate O 0 1.690099060702721e-09
the O 0 4.620504066160658e-12
role O 0 2.2397157045661586e-11
of O 0 1.6472400700406897e-12
I1307K O 0 9.62841227192257e-07
in O 0 3.1279885348567404e-08
cancer B-Disease 0 0.00014120209380052984
, O 0 3.35807937013044e-10
we O 0 5.067017472271118e-09
genotyped O 0 3.401664798730053e-07
5 O 0 3.490871203215562e-10
, O 0 1.529978227443607e-10
081 O 0 7.302804988285061e-06
Ashkenazi O 0 1.2883722774859052e-05
volunteers O 0 1.5524573293568267e-10
in O 0 4.972920512880119e-12
a O 0 2.7265330618253536e-11
community O 0 1.5472220726842068e-10
survey O 0 2.3196960796667554e-08
. O 0 8.709247767413331e-10

Risk O 0 2.3396183678414673e-05
of O 0 2.589232162009125e-10
developing O 0 7.625287707924144e-06
colorectal B-Disease 1 1.0
, I-Disease 0 0.0008434030460193753
breast I-Disease 1 0.999031662940979
and I-Disease 0 0.00012924290786031634
other I-Disease 0 1.3448543256799894e-07
cancers I-Disease 1 0.8280411958694458
were O 0 5.827197835372999e-09
compared O 0 9.609967266399622e-10
between O 0 1.875774868764779e-09
genotyped O 0 1.5938474462018348e-05
I1307K O 0 3.82537095333646e-08
carriers O 0 5.068757413795311e-09
and O 0 1.9002945883528355e-09
non O 0 9.464005967796396e-11
- O 0 1.4689746876683785e-06
carriers O 0 1.6989913476095353e-08
and O 0 3.3446638791900796e-09
their O 0 2.8383219385919034e-11
first O 0 2.466274406920377e-10
- O 0 2.647145436185383e-08
degree O 0 7.855178729698764e-10
relatives O 0 2.801797682749907e-09
. O 0 5.214783049822813e-10

Sperm O 0 2.1822269502536074e-07
DNA O 0 1.3633933804158005e-07
analysis O 0 8.405384721577036e-10
in O 0 5.275334682974808e-11
a O 0 2.33647643455015e-08
Friedreich B-Disease 1 0.9999384880065918
ataxia I-Disease 1 0.9999639987945557
premutation O 0 0.29078975319862366
carrier O 0 6.910474439791869e-06
suggests O 0 3.657505232013136e-08
both O 0 2.3497742640543606e-10
meiotic O 0 5.246174055173469e-07
and O 0 1.8911430199608503e-09
mitotic O 0 1.095546551255211e-07
expansion O 0 1.6561084947852578e-08
in O 0 3.1086849761052804e-10
the O 0 2.768283102749791e-10
FRDA B-Disease 0 2.2361848095897585e-05
gene O 0 1.2250276313352515e-06
. O 0 7.422046088834122e-09

Friedreich B-Disease 1 0.9994924068450928
ataxia I-Disease 1 0.999980092048645
is O 0 4.970368172507733e-05
usually O 0 1.3385147212829906e-06
caused O 0 4.3020467188625844e-08
by O 0 6.579096208797486e-12
an O 0 4.2695855531627025e-12
expansion O 0 3.5967904210565393e-09
of O 0 2.255302368470158e-11
a O 0 5.9732215618169e-08
GAA O 0 8.951519703259692e-06
trinucleotide O 0 2.4721115551074035e-05
repeat O 0 4.784774887411913e-07
in O 0 2.1158094373752157e-11
intron O 0 4.552664904622361e-06
1 O 0 6.062083474089874e-11
of O 0 1.652489126438561e-12
the O 0 2.0268532685552287e-10
FRDA B-Disease 0 1.6015083019738086e-05
gene O 0 5.010720087739173e-07
. O 0 6.190054246957288e-09

Occasionally O 0 0.00012373509525787085
, O 0 7.568429216675554e-10
a O 0 9.269332523764717e-11
fully O 0 1.1365149793496343e-10
expanded O 0 1.574209373966795e-10
allele O 0 2.7883432451858425e-08
has O 0 2.3103041257854784e-08
been O 0 7.095737331042073e-10
found O 0 1.121506443269027e-09
to O 0 4.947577417202531e-11
arise O 0 6.328482876627461e-11
from O 0 8.683122444804944e-14
a O 0 7.829637979628323e-12
premutation O 0 3.7279075826290864e-08
of O 0 7.261254314841481e-13
100 O 0 2.3888214323308787e-11
or O 0 3.20100307371618e-10
less O 0 2.1036421216091838e-10
triplet O 0 0.015984533354640007
repeats O 0 0.0009019941207952797
. O 0 2.0877392259421867e-08

We O 0 2.912337777161156e-06
have O 0 1.49336806809508e-10
examined O 0 1.175337605019422e-09
the O 0 1.9927577383366257e-12
sperm O 0 4.598781078168912e-11
DNA O 0 4.431804700999464e-09
of O 0 2.834710276840985e-13
a O 0 4.808126119471012e-10
premutation O 0 1.2644994967558887e-05
carrier O 0 4.4847578806184174e-07
. O 0 9.123668043287125e-09

This O 0 4.063293701506154e-09
mans O 0 8.960626729503929e-08
leucocyte O 0 4.6304475631586683e-07
DNA O 0 2.7554448024602607e-05
showed O 0 3.181279595310116e-08
one O 0 2.3321140157905873e-11
normal O 0 4.222923122298994e-10
allele O 0 7.605416296740941e-10
and O 0 2.3576665619806647e-10
one O 0 4.2161100999305035e-12
allele O 0 1.1112336745222606e-11
of O 0 2.262598745514377e-13
approximately O 0 5.5590834019403346e-11
100 O 0 4.884122550841141e-10
repeats O 0 3.802933861152269e-05
. O 0 1.9653800364949348e-08

His O 0 4.906321038333772e-08
sperm O 0 2.4500172557395672e-08
showed O 0 1.4792058689039322e-09
an O 0 3.3126461101117e-13
expanded O 0 5.677797121350636e-10
allele O 0 3.5350886662399716e-09
in O 0 1.285332257294769e-10
a O 0 4.740540182623931e-10
tight O 0 1.556344841446844e-06
range O 0 7.1117256528197e-10
centering O 0 1.3919992936095582e-09
on O 0 9.689663515999314e-10
a O 0 1.4762899236409055e-11
size O 0 4.2483693646344634e-11
of O 0 5.872609256524219e-13
approximately O 0 1.5955173293669134e-10
320 O 0 1.0980607534349929e-08
trinucleotide O 0 0.00013809558004140854
repeats O 0 2.540600144129712e-05
. O 0 4.222747929105708e-09

His O 0 2.908518581534736e-06
affected O 0 2.6470652869647893e-07
son O 0 3.297556929737766e-07
has O 0 2.47948217513283e-09
repeat O 0 1.7343557701110512e-08
sizes O 0 2.2033787294706286e-10
of O 0 2.9951833114411075e-12
1040 O 0 8.952748089541274e-07
and O 0 4.370491968330725e-09
540 O 0 3.606856324722685e-08
. O 0 5.258031787747086e-09

These O 0 7.634368137665604e-10
data O 0 4.490633698228663e-10
suggest O 0 9.682766394236708e-11
that O 0 3.0336761748517294e-12
expansion O 0 8.980535204372586e-10
occurs O 0 5.19256282416336e-09
in O 0 2.479536541366567e-11
two O 0 3.791950919929121e-10
stages O 0 1.1981521197412803e-07
, O 0 2.1598538929579192e-11
the O 0 5.6847157189898745e-12
first O 0 5.7118165752712e-10
during O 0 2.656858413829788e-11
meiosis O 0 8.991362515642365e-11
followed O 0 3.131481879359299e-11
by O 0 6.475908134392916e-13
a O 0 3.374077059414837e-11
second O 0 3.848561025421304e-09
mitotic O 0 1.5822956811462063e-07
expansion O 0 1.5763930605317e-07
. O 0 2.2816861289243207e-08

We O 0 5.479828359966632e-06
also O 0 1.076064237715002e-09
show O 0 2.8455069411847944e-09
that O 0 1.0811038175795318e-10
in O 0 1.0363685604142248e-11
all O 0 4.067459043188837e-12
informative O 0 9.988712079689321e-09
carrier O 0 1.746885942566223e-07
father O 0 1.6804060010144894e-07
to O 0 3.549728289087284e-10
affected O 0 7.965696435796588e-10
child O 0 2.4446662472144e-09
transmissions O 0 5.843194230692461e-07
, O 0 9.105230458494873e-11
with O 0 2.3327145770579705e-11
the O 0 1.5409394246712615e-11
notable O 0 9.191073249703585e-12
exception O 0 1.4303679074512132e-10
of O 0 1.5200290028397068e-12
the O 0 2.0221808949560938e-10
premutation O 0 1.100308168133779e-06
carrier O 0 6.209115444022473e-09
, O 0 1.2584723194097869e-11
the O 0 7.925373139879011e-13
expansion O 0 1.579370106918887e-10
size O 0 6.530419538464116e-10
decreases O 0 1.2184017350591603e-08
. O 0 1.9983854848693028e-10
. O 0 7.066846552383765e-10

The O 0 2.6383983886546503e-09
R496H O 0 5.0605777346390823e-08
mutation O 0 1.2429397955315835e-08
of O 0 3.805002753848319e-12
arylsulfatase O 0 1.339916889264714e-05
A O 0 3.197351645667368e-07
does O 0 7.019392000984226e-07
not O 0 1.5390155283512286e-07
cause O 0 3.925835244444897e-06
metachromatic B-Disease 1 0.9999971389770508
leukodystrophy I-Disease 1 0.9999924898147583
. O 0 1.5797053265487193e-06

Deficiency B-Disease 1 0.9988982677459717
of I-Disease 0 1.776153668586744e-10
arylsulfatase I-Disease 0 5.125691677676514e-05
A I-Disease 0 1.694052684797498e-07
( O 0 1.5954664256412343e-09
ARSA O 0 0.0016807792708277702
) O 0 3.0328980993310495e-10
enzyme O 0 5.982992945519072e-08
activity O 0 1.479733668929839e-06
causes O 0 0.00011623612226685509
metachromatic B-Disease 1 0.9999990463256836
leukodystrophy I-Disease 1 0.9999980926513672
( O 0 3.5529437809600495e-06
MLD B-Disease 1 0.9999617338180542
) O 0 1.5769035854873437e-08
. O 0 8.438302501190265e-09

A O 0 2.9181188576643535e-09
number O 0 1.0370315717267431e-10
of O 0 3.2065683441828696e-11
ARSA O 1 0.6094227433204651
gene O 0 2.0585421225405298e-05
mutations O 0 2.1330035451683216e-05
responsible O 0 9.118817700937143e-08
for O 0 3.891840627545662e-09
MLD B-Disease 1 0.9999991655349731
have O 0 9.077989489014726e-07
been O 0 1.291156959126738e-08
identified O 0 1.384821359806665e-07
. O 0 3.9097933779430605e-09

Recently O 0 5.464463811222231e-06
, O 0 2.68793182156557e-10
the O 0 1.710202292282137e-11
R496H O 0 2.436724599874651e-09
mutation O 0 1.6587790030442306e-09
of O 0 3.674825634764067e-12
ARSA O 0 0.000828273594379425
was O 0 7.1620407382511075e-09
proposed O 0 4.452745464011976e-11
to O 0 1.746140732006296e-10
be O 0 5.893002752443977e-11
a O 0 2.608434856998798e-10
cause O 0 1.5028792432758564e-08
of O 0 4.386541407885858e-10
MLD B-Disease 1 0.9999997615814209
( O 0 7.807101631840396e-09
Draghia O 0 8.589991921326146e-05
et O 0 1.4832942270004423e-06
al O 0 2.2521392111229943e-06
. O 0 1.4003772585979846e-09
, O 0 3.294125389130542e-11
1997 O 0 1.0194865784907137e-10
) O 0 6.416577685852687e-11
. O 0 9.14933240281357e-10

We O 0 1.1177365877301781e-06
have O 0 1.5493098470820144e-10
investigated O 0 1.6232704069807369e-09
the O 0 1.5471565001368148e-11
R496H O 0 3.9713960120479896e-08
mutation O 0 1.2738691168578953e-07
and O 0 1.203175559183478e-09
found O 0 1.1270668842655596e-09
this O 0 1.884001808727387e-11
mutation O 0 1.3310150315248848e-08
at O 0 5.866953034505684e-10
a O 0 4.332291036329705e-12
relatively O 0 8.134860840502967e-12
high O 0 2.1837554334269704e-11
frequency O 0 2.819488420513494e-09
in O 0 8.217203306681853e-11
an O 0 7.334782954615537e-12
African O 0 8.607675336391729e-12
American O 0 1.523783009493851e-11
population O 0 1.163909355179904e-12
( O 0 1.0413534184267048e-12
f O 0 1.0830077599166543e-06
= O 0 1.7560840888108942e-06
0 O 0 4.4154191414236266e-09
. O 0 5.417169143817624e-11
09 O 0 2.096480072877327e-10
, O 0 1.1431168511766288e-11
n O 0 5.565987066802336e-07
= O 0 6.3860052250674926e-06
61 O 0 1.8866622042423842e-08
subjects O 0 3.1429333802179826e-08
) O 0 4.492141103540348e-10
. O 0 9.768883479921442e-10

The O 0 2.9936188639112515e-08
ARSA O 0 4.579092637868598e-05
enzyme O 0 1.5772885220144417e-08
activity O 0 9.777070708594238e-09
in O 0 6.65977620273317e-11
subjects O 0 9.276402579416754e-08
with O 0 1.9276491514119698e-08
and O 0 7.636531051957718e-08
without O 0 1.3319380320897523e-10
the O 0 8.224192160621868e-12
R496H O 0 2.5818065463312223e-09
mutation O 0 6.7685825833052604e-09
was O 0 1.946695959986755e-08
determined O 0 1.2662368931160017e-08
and O 0 7.906285626191334e-10
found O 0 9.510666032497284e-09
to O 0 3.7269939912043526e-10
be O 0 5.418070436746802e-10
normal O 0 2.0553640567300135e-08
. O 0 4.108125839508148e-09

It O 0 6.341383596009109e-07
is O 0 4.0855099858738697e-10
therefore O 0 1.0525650490089689e-10
concluded O 0 8.572261234185419e-10
that O 0 1.5341504108756787e-11
the O 0 6.838372750006538e-12
R496H O 0 2.067008786355018e-08
mutation O 0 3.493177302971162e-09
of O 0 1.131470524912137e-11
ARSA O 0 0.4942404627799988
does O 0 1.1685477829814772e-07
not O 0 6.365550447862134e-11
negatively O 0 5.450892341662961e-12
influence O 0 3.2849192116435333e-12
the O 0 2.1350562377092652e-12
activity O 0 4.225928496026654e-10
of O 0 7.021401255552506e-12
ARSA O 1 0.7486955523490906
and O 0 1.253214492180632e-07
is O 0 9.46865030826416e-10
not O 0 3.378077262361501e-10
a O 0 3.474424081773009e-10
cause O 0 1.652123771123115e-08
of O 0 2.4114719110457372e-08
MLD B-Disease 1 0.9999954700469971

Down O 0 0.0002287632814841345
- O 0 1.413367613167793e-06
regulation O 0 2.080286165551115e-08
of O 0 5.570979441649193e-12
transmembrane O 0 3.8471250718430383e-07
carbonic O 0 3.6912646805831173e-07
anhydrases O 0 4.4481639633886516e-05
in O 0 9.464001493597607e-08
renal B-Disease 0 0.1953931450843811
cell I-Disease 1 0.9975045323371887
carcinoma I-Disease 1 1.0
cell O 1 0.9971778392791748
lines O 0 0.005871658679097891
by O 0 7.0813959140991756e-09
wild O 0 4.9367157771484926e-05
- O 0 0.4517909288406372
type O 0 0.1599481850862503
von B-Disease 1 0.9992546439170837
Hippel I-Disease 1 0.9975923895835876
- I-Disease 1 0.9541864395141602
Lindau I-Disease 1 0.9105431437492371
transgenes O 0 0.0005932784988544881
. O 0 8.008970553419203e-08

To O 0 3.331085451918625e-08
discover O 0 2.5303648953922675e-08
genes O 0 5.29255439474241e-09
involved O 0 3.2056160503834974e-10
in O 0 1.9730496347847293e-08
von B-Disease 1 0.9999008178710938
Hippel I-Disease 1 0.9999616146087646
- I-Disease 1 0.9999314546585083
Lindau I-Disease 1 0.9997733235359192
( O 0 3.031802364716896e-08
VHL B-Disease 0 8.225255442084745e-05
) O 0 4.4802561660617357e-10
- O 0 3.1607812616130104e-06
mediated O 0 1.6114358004415408e-05
carcinogenesis O 0 9.43144696066156e-05
, O 0 2.3560764450536453e-09
we O 0 2.7480160369464102e-08
used O 0 4.792657364305342e-07
renal B-Disease 0 0.03171225264668465
cell I-Disease 1 0.9995872378349304
carcinoma I-Disease 1 1.0
cell O 1 0.9999366998672485
lines O 1 0.9950389266014099
stably O 1 0.6262187361717224
transfected O 0 0.0009891536319628358
with O 0 6.187801915302771e-08
wild O 0 2.6755602448247373e-05
- O 1 0.5673245191574097
type O 0 0.04268544539809227
VHL O 0 0.02530764788389206
- O 0 4.758452996611595e-05
expressing O 0 2.674432453275699e-09
transgenes O 0 5.362673164199805e-06
. O 0 1.9119585914495474e-08

Large O 0 1.1749483164180674e-08
- O 0 3.75569186417124e-07
scale O 0 5.1680324020253465e-08
RNA O 0 9.762518402567366e-07
differential O 0 1.319703102353742e-07
display O 0 6.2441869452811716e-09
technology O 0 1.985863740117111e-08
applied O 0 3.097429202014723e-09
to O 0 7.289430864476643e-11
these O 0 9.873981840491375e-12
cell O 0 1.767580101841304e-06
lines O 0 1.748100658005569e-05
identified O 0 3.3348337069583067e-07
several O 0 2.1728573801338413e-11
differentially O 0 1.4666326819678943e-07
expressed O 0 1.8722521796799008e-11
genes O 0 1.2092792323059598e-09
, O 0 1.8417836700201917e-12
including O 0 4.120814746291085e-13
an O 0 4.980904143997433e-12
alpha O 0 2.67348254645583e-10
carbonic O 0 3.6360106037136575e-09
anhydrase O 0 3.5705769452221148e-09
gene O 0 9.172558712577938e-09
, O 0 1.0547314410747077e-10
termed O 0 1.2103441804356407e-07
CA12 O 0 0.00028809733339585364
. O 0 8.836487985774966e-09

The O 0 1.0865411903537847e-09
deduced O 0 1.5066554670539745e-09
protein O 0 5.776765732434797e-10
sequence O 0 1.1469322913626456e-07
was O 0 7.3925603416569174e-09
classified O 0 9.000602929631896e-09
as O 0 2.590042069705589e-10
a O 0 1.4417357308005307e-09
one O 0 6.837433375039836e-08
- O 0 0.08240044116973877
pass O 0 3.0696686735609546e-05
transmembrane O 0 8.743626494833734e-06
CA O 0 6.657614903815556e-06
possessing O 0 3.3203544080873115e-11
an O 0 3.480146032464049e-11
apparently O 0 3.2254355630811915e-08
intact O 0 2.0357304730822534e-09
catalytic O 0 1.1122228693594138e-09
domain O 0 2.1157640972546687e-08
in O 0 4.9296611931426426e-11
the O 0 5.0920181265956543e-11
extracellular O 0 3.034949713764945e-06
CA O 0 0.0005015293718315661
module O 0 8.806792720861267e-06
. O 0 6.11517325666e-09

Reintroduced O 0 2.1708698113798164e-05
wild O 0 1.3076117284072097e-05
- O 0 0.007595794275403023
type O 0 0.00038010062417015433
VHL B-Disease 0 0.0001955609186552465
strongly O 0 7.208417862614169e-09
inhibited O 0 1.6113087752955835e-08
the O 0 1.3792409922497306e-11
overexpression O 0 5.2984625575902555e-09
of O 0 1.857206445923798e-12
the O 0 1.4615370025339303e-10
CA12 O 0 2.9247346446936717e-06
gene O 0 2.4324908309836246e-08
in O 0 1.21335649860832e-10
the O 0 8.516330418650853e-10
parental O 0 0.00017032230971381068
renal B-Disease 1 0.7323852777481079
cell I-Disease 1 0.9997034668922424
carcinoma I-Disease 1 1.0
cell O 1 0.9996224641799927
lines O 1 0.8523404002189636
. O 0 1.5699881714681396e-06

Similar O 0 2.9154834990663403e-08
results O 0 4.43155112606064e-09
were O 0 2.127358532388879e-11
obtained O 0 9.162372943682939e-11
with O 0 2.7339174327178917e-11
CA9 O 0 2.3298794985748827e-05
, O 0 5.008046755072826e-11
encoding O 0 3.6859997276650347e-09
another O 0 7.988311381268431e-07
transmembrane O 0 0.0013850457035005093
CA O 0 0.013385070487856865
with O 0 6.121316648011188e-11
an O 0 1.3071673084230628e-11
intact O 0 2.3649969094208245e-08
catalytic O 0 1.8000148926944348e-08
domain O 0 7.386220204352867e-07
. O 0 7.738696794490352e-09

Although O 0 1.3877551907626184e-07
both O 0 1.9238528825571422e-10
domains O 0 3.6273657411101112e-09
of O 0 5.484703403252356e-12
the O 0 1.6271700653547327e-09
VHL B-Disease 0 1.266662457055645e-05
protein O 0 1.536067628649107e-08
contribute O 0 4.871559752817056e-11
to O 0 2.2874212940449112e-11
regulation O 0 1.7886517822418568e-09
of O 0 1.6901673203367773e-12
CA12 O 0 2.895602665375918e-05
expression O 0 4.702960687552604e-09
, O 0 1.791975769160903e-11
the O 0 9.864682855298401e-12
elongin O 0 1.3359139927615615e-07
binding O 0 1.7329263579668464e-09
domain O 0 7.177023917392944e-07
alone O 0 1.8365928156072187e-07
could O 0 9.63557678090865e-09
effectively O 0 2.6529935581720565e-08
regulate O 0 1.1839290436910233e-07
CA9 O 0 0.0001690667268121615
expression O 0 1.5701050415373174e-06
. O 0 1.5800106112351386e-08

We O 0 2.634172005855362e-06
mapped O 0 1.947140299307648e-05
CA12 O 0 0.0001978532236535102
and O 0 1.2470265708941497e-08
CA9 O 0 2.5124920284724794e-05
loci O 0 2.8482995517720155e-08
to O 0 4.5685949467966225e-10
chromosome O 0 2.348514044570038e-06
bands O 0 9.408903878238561e-09
15q22 O 0 1.1695373132170062e-06
and O 0 8.756139813215214e-09
17q21 O 0 1.0292468459738302e-06
. O 0 8.721653621535097e-09

2 O 0 4.6317989443878105e-08
respectively O 0 4.349759663568875e-09
, O 0 1.3325580916490054e-10
regions O 0 4.327631142331256e-09
prone O 0 2.4037304683588445e-05
to O 0 5.325011612211661e-11
amplification O 0 1.7550407349631314e-08
in O 0 4.164156866548474e-11
some O 0 2.586024172579471e-10
human O 0 2.2148772131913574e-06
cancers B-Disease 1 0.581179141998291
. O 0 2.696134515645099e-08

Additional O 0 5.855639306773242e-10
experiments O 0 3.930746927949258e-08
are O 0 9.543905596376412e-12
needed O 0 2.2843268943084638e-10
to O 0 3.1197954376144255e-12
define O 0 1.7359699233665538e-09
the O 0 2.4112841931489548e-11
role O 0 3.295666795022356e-10
of O 0 3.5201213471891535e-11
CA O 0 0.021771376952528954
IX O 0 1.9983695892733522e-05
and O 0 3.2567390917392913e-06
CA O 0 0.005320485681295395
XII O 0 9.205720630234282e-07
enzymes O 0 5.0577600774204257e-08
in O 0 2.0812714399132126e-11
the O 0 1.5180653609170314e-11
regulation O 0 6.581766687219215e-09
of O 0 3.175938028190939e-12
pH O 0 4.590541493598721e-07
in O 0 1.1771610075594907e-10
the O 0 7.894121467622028e-11
extracellular O 0 9.314556592698864e-08
microenvironment O 0 5.7661982282297686e-06
and O 0 1.796673254617076e-09
its O 0 1.4096103624627876e-11
potential O 0 4.965643868315439e-11
impact O 0 4.0806735768228464e-10
on O 0 1.2659886294841272e-07
cancer B-Disease 0 1.3886059605283663e-05
cell O 0 1.3091127584630158e-05
growth O 0 6.235465122017558e-08
. O 0 4.56557458505813e-09

A O 0 1.988182063428212e-09
gene O 0 1.5427200628082005e-09
encoding O 0 5.161830407551804e-10
a O 0 2.690080935785488e-10
transmembrane O 0 2.1235953440168487e-08
protein O 0 7.551374636705077e-09
is O 0 3.949566368399715e-11
mutated O 0 7.562994710497151e-07
in O 0 7.546972113914308e-08
patients O 0 2.0213641619193368e-05
with O 0 0.01586364209651947
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.9983377456665039
optic B-Disease 1 0.9999997615814209
atrophy I-Disease 1 0.9999951124191284
( O 0 0.053802650421857834
Wolfram B-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
) O 0 1.1309784753166241e-07
. O 0 2.2924258047396506e-08

Wolfram B-Disease 1 0.9999854564666748
syndrome I-Disease 1 0.9999998807907104
( O 0 1.7750060123944422e-06
WFS B-Disease 0 0.06726717203855515
; O 0 1.1988242931693094e-07
OMIM O 0 0.008899777196347713
222300 O 0 2.6547011657385156e-05
) O 0 6.74334810213395e-10
is O 0 1.0846409104203758e-08
an O 0 3.618940525029757e-07
autosomal B-Disease 1 0.9999988079071045
recessive I-Disease 1 0.9999996423721313
neurodegenerative I-Disease 1 0.9999998807907104
disorder I-Disease 1 0.9999816417694092
defined O 0 1.5386427776320488e-06
by O 0 8.949704310978746e-10
young O 0 7.197182583240647e-08
- O 0 0.0005251872353255749
onset O 0 0.0016207742737606168
non O 0 9.848099580267444e-07
- O 1 0.986880898475647
immune O 0 0.12145622074604034
insulin B-Disease 0 0.004876253195106983
- I-Disease 1 0.9931455850601196
dependent I-Disease 1 0.9947904348373413
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.00037868268555030227
progressive O 0 0.0001681517605902627
optic B-Disease 1 0.999962568283081
atrophy I-Disease 1 0.9986215829849243
. O 0 5.761464194620203e-07

Linkage O 0 5.203620457905345e-05
to O 0 3.042697427346752e-09
markers O 0 6.890100394230103e-06
on O 0 2.4683052046725606e-08
chromosome O 0 0.0006034252000972629
4p O 0 0.00047528400318697095
was O 0 3.6673379781859694e-06
confirmed O 0 2.4531084363843547e-07
in O 0 2.488292905056255e-10
five O 0 1.5535748243422631e-09
families O 0 2.0348569496064783e-09
. O 0 3.0467104394915623e-09

On O 0 1.854055797778642e-09
the O 0 1.8224733788069214e-12
basis O 0 1.6046868694941097e-12
of O 0 1.1298050169028517e-12
meiotic O 0 5.6212938943644986e-05
recombinants O 1 0.9697192907333374
and O 0 0.13146059215068817
disease O 1 0.999377429485321
- O 0 0.0006736696232110262
associated O 0 1.2961296533831046e-06
haplotypes O 0 5.930363840889186e-05
, O 0 9.5256935672694e-10
the O 0 6.835572385899269e-11
WFS B-Disease 0 2.12432814805652e-06
gene O 0 3.286655925194282e-08
was O 0 2.13336215360016e-09
localized O 0 1.2355463319124738e-08
to O 0 2.535773535594643e-10
a O 0 6.094083015995011e-10
BAC O 0 9.124136340687983e-06
/ O 0 1.8567941424407763e-06
P1 O 0 3.7375586998678045e-06
contig O 0 1.8252693223530514e-07
of O 0 3.062902308084009e-13
less O 0 7.262902844244745e-13
than O 0 1.4039693886636062e-12
250 O 0 3.545355675704798e-11
kb O 0 1.8646393073140644e-05
. O 0 8.72671179763529e-09

Mutations O 0 0.0004335603734944016
in O 0 5.964939098213051e-10
a O 0 1.6108951672588745e-10
novel O 0 1.24363710440889e-08
gene O 0 3.1370106512440543e-07
( O 0 7.877125340893798e-11
WFS1 O 0 8.98369250990072e-07
) O 0 1.4839001338459723e-12
encoding O 0 9.083998830927698e-11
a O 0 5.658963297960895e-10
putative O 0 4.37691767274373e-08
transmembrane O 0 1.1312153880282949e-08
protein O 0 1.5669076702806706e-08
were O 0 5.581801687526422e-10
found O 0 8.76183658959917e-09
in O 0 1.718541420281383e-10
all O 0 1.5836686129144795e-10
affected O 0 3.453620056603768e-09
individuals O 0 3.3482329322293003e-12
in O 0 1.3319609304396351e-10
six O 0 3.8056762186045034e-09
WFS B-Disease 0 1.6118199710035697e-05
families O 0 2.3034523177756228e-09
, O 0 9.702973841063667e-11
and O 0 2.628722517439286e-10
these O 0 7.988222062993433e-12
mutations O 0 3.944641591147047e-08
were O 0 6.568018906527584e-10
associated O 0 7.480029928785825e-09
with O 0 1.281886330417592e-08
the O 0 3.7007146147516323e-06
disease O 1 0.8769909739494324
phenotype O 0 3.4468092053430155e-05
. O 0 1.1311398928626204e-08

WFS1 O 0 8.852827886585146e-05
appears O 0 2.520495741009654e-07
to O 0 2.9374838672602266e-10
function O 0 1.6717218720430083e-09
in O 0 3.5651581686835243e-10
survival O 0 5.126834821567172e-06
of O 0 6.387999938045619e-12
islet O 0 0.0008498089737258852
beta O 0 1.9759569980237757e-08
- O 0 7.903660298325121e-05
cells O 0 1.2363948371785227e-06
and O 0 3.6453481899734186e-10
neurons O 0 2.2665338494931575e-09
. O 0 4.423507393713777e-11
. O 0 4.134882991557731e-10

Stable O 0 1.4062443369766697e-06
interaction O 0 8.117400640550443e-10
between O 0 5.13790017475646e-11
the O 0 9.489993860190005e-12
products O 0 1.094023316383641e-09
of O 0 6.172266257126191e-12
the O 0 3.7020779775076562e-09
BRCA1 O 0 9.390927152708173e-05
and O 0 1.1253273441980127e-06
BRCA2 O 0 1.4761966667720117e-05
tumor B-Disease 0 4.734391438887542e-07
suppressor O 0 9.253676580556203e-08
genes O 0 2.7914559552755236e-08
in O 0 3.6655187218848084e-10
mitotic O 0 4.451658696780214e-06
and O 0 1.324941649727407e-07
meiotic O 0 0.00010726033360697329
cells O 0 0.00010250452760374174
. O 0 2.30810179857599e-08

BRCA1 O 0 0.1851668804883957
and O 0 1.960903773579048e-06
BRCA2 O 0 7.507556347263744e-06
account O 0 2.0602810568703944e-09
for O 0 1.7235950080379814e-12
most O 0 5.436232193567481e-12
cases O 0 1.1029771714021752e-11
of O 0 2.5000980018868857e-12
familial O 0 0.00012443176819942892
, O 0 1.1181664483217446e-08
early O 0 1.9513471727350407e-07
onset O 0 0.0002881294349208474
breast B-Disease 1 0.989793062210083
and I-Disease 0 0.36852389574050903
/ I-Disease 1 0.9999997615814209
or I-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 4.044336776587443e-08
encode O 0 6.152730946951124e-08
products O 0 2.392182295807288e-06
that O 0 6.3222755919412066e-09
each O 0 9.70422787266445e-12
interact O 0 1.1836609470350368e-10
with O 0 7.041105198890563e-11
hRAD51 O 0 3.784332420764258e-06
. O 0 4.3099457336381874e-09

Results O 0 4.0205793538916623e-07
presented O 0 6.744724778684485e-10
here O 0 7.923597195036436e-11
show O 0 1.022622653223948e-09
that O 0 2.847177771325704e-10
BRCA1 O 0 5.5350074035231955e-06
and O 0 6.376946544150996e-07
BRCA2 O 0 4.679459016188048e-05
coexist O 0 1.5708474165876396e-05
in O 0 3.297570203009137e-11
a O 0 1.0002734057712459e-10
biochemical O 0 1.454414473300858e-07
complex O 0 7.204296537111077e-08
and O 0 7.186537942516225e-08
colocalize O 0 1.3424339158518706e-05
in O 0 1.0367808833677827e-09
subnuclear O 0 3.3999015158769907e-06
foci O 0 3.013412026575679e-07
in O 0 1.628503408512838e-11
somatic O 0 1.5661240082565087e-09
cells O 0 2.1170686181903875e-07
and O 0 2.337914029038046e-10
on O 0 5.160784646851546e-11
the O 0 1.7759486372823097e-12
axial O 0 6.548926678728861e-11
elements O 0 1.9899568104442267e-10
of O 0 8.564800778321224e-12
developing O 0 4.821888310857503e-08
synaptonemal O 0 7.93511571828276e-06
complexes O 0 9.367716302222107e-06
. O 0 1.5492522820181875e-08

Like O 0 2.475102064636303e-06
BRCA1 O 0 3.21842308039777e-05
and O 0 2.741283822160767e-08
RAD51 O 0 0.00014131295029073954
, O 0 1.5523454743870957e-09
BRCA2 O 0 1.9440714993379515e-07
relocates O 0 4.357617555683646e-08
to O 0 1.3946507837481192e-10
PCNA O 0 1.7414945432392415e-06
+ O 0 3.5643576978827696e-09
replication O 0 2.786687787192932e-07
sites O 0 3.498011436064985e-09
following O 0 4.516279711319626e-11
exposure O 0 5.673123748550779e-09
of O 0 4.072210017108668e-12
S O 0 4.191953848931007e-06
phase O 0 3.6450025220347015e-09
cells O 0 2.2060628879216893e-09
to O 0 6.201566603997177e-12
hydroxyurea O 0 1.346421996117897e-08
or O 0 3.8443995209469506e-10
UV O 0 1.2878558663942385e-06
irradiation O 0 4.0373163301410386e-07
. O 0 1.3917398788976243e-08

Thus O 0 2.0244431198079837e-07
, O 0 1.3404714005460505e-09
BRCA1 O 0 3.863412530336063e-06
and O 0 2.8812586094772996e-08
BRCA2 O 0 4.219552465656307e-06
participate O 0 1.6956971937709397e-10
, O 0 5.100457833862038e-10
together O 0 2.019684197662741e-09
, O 0 4.0382332894273176e-11
in O 0 8.546653836039031e-12
a O 0 1.826553769346262e-10
pathway O 0 3.644663948421112e-08
( O 0 8.524288913625e-11
s O 0 5.056562713434687e-06
) O 0 5.6871479747755416e-11
associated O 0 7.606663632309107e-10
with O 0 1.9268633563718218e-11
the O 0 6.555459734075564e-12
activation O 0 6.721242486185108e-12
of O 0 9.519104254840371e-13
double O 0 3.865966391458642e-06
- O 0 0.0007828085799701512
strand O 1 0.9458214044570923
break O 0 0.00107998913154006
repair O 0 0.0003669637080747634
and O 0 1.529297044555733e-08
/ O 0 1.4787744930799818e-06
or O 0 5.839088657033642e-10
homologous O 0 6.497362203816692e-09
recombination O 0 1.9263259432023006e-08
. O 0 5.0055404265947345e-09

Dysfunction O 0 0.009084994904696941
of O 0 2.064540205459764e-10
this O 0 3.916112989443832e-10
pathway O 0 5.393155788624426e-07
may O 0 1.600603027895886e-08
be O 0 3.736337281234903e-11
a O 0 5.213000170423143e-11
general O 0 2.1963045271355952e-10
phenomenon O 0 2.8013243991154013e-07
in O 0 2.9964264403048446e-10
the O 0 6.273823127678213e-11
majority O 0 5.5526402920058615e-11
of O 0 1.5972169604711733e-13
cases O 0 2.5227675504169156e-10
of O 0 2.651003028208976e-10
hereditary B-Disease 1 0.9999549388885498
breast I-Disease 1 0.999950647354126
and I-Disease 1 0.8418471813201904
/ I-Disease 1 0.9999992847442627
or I-Disease 1 0.9999983310699463
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 2.7509530653446745e-08
. O 0 1.7833315268944716e-08

A O 0 8.591240430178004e-08
novel O 0 8.880201107785979e-08
Arg362Ser O 0 1.031840201903833e-05
mutation O 0 2.197229207467899e-07
in O 0 2.967695880706778e-11
the O 0 1.4997728753352035e-11
sterol O 0 4.104570962226717e-06
27 O 0 6.667398366744237e-08
- O 0 5.915816814194841e-07
hydroxylase O 0 4.458958301256644e-06
gene O 0 6.019484430908051e-07
( O 0 3.0209570955896936e-11
CYP27 O 0 7.615902859470225e-07
) O 0 1.380654271465609e-11
: O 0 3.3609527921169002e-12
its O 0 2.722810909031037e-12
effects O 0 2.8772701998747152e-09
on O 0 3.781665813828994e-10
pre O 0 1.3743978399816115e-08
- O 0 8.479799973315494e-09
mRNA O 0 1.3528123066208764e-10
splicing O 0 3.5296918721172688e-09
and O 0 1.5076377646305872e-10
enzyme O 0 3.2573146957481924e-10
activity O 0 6.676287855889029e-10
. O 0 5.894905674708184e-10

A O 0 3.908304080368907e-08
novel O 0 8.247283744822198e-08
C O 0 4.397995871840976e-05
to O 0 8.835686349240035e-11
A O 0 4.1534028993872596e-10
mutation O 0 8.142572838210071e-09
in O 0 2.6060466284949513e-11
the O 0 1.6677425065947382e-11
sterol O 0 3.066928456973983e-06
27 O 0 3.2794918780609805e-08
- O 0 5.861846830157447e-07
hydroxylase O 0 2.809706074913265e-06
gene O 0 5.197847485760576e-07
( O 0 1.7898578452690828e-11
CYP27 O 0 9.534132914268412e-07
) O 0 1.577797788254731e-11
was O 0 2.709587276772396e-10
identified O 0 6.557401149853703e-11
by O 0 2.6322658787901465e-13
sequencing O 0 8.323243427810212e-09
amplified O 0 3.315087937494354e-08
CYP27 O 0 3.09032628820205e-07
gene O 0 5.818093740117547e-08
products O 0 1.98033358600469e-08
from O 0 2.0188193131098764e-11
a O 0 6.169062594096886e-09
patient O 0 7.012887635937659e-06
with O 0 1.5632275562893483e-07
cerebrotendinous B-Disease 1 0.9999990463256836
xanthomatosis I-Disease 1 0.9999951124191284
( O 0 1.635185320481014e-08
CTX B-Disease 0 0.0004229529877193272
) O 0 4.4697001655436e-09
. O 0 7.918559141728565e-09

The O 0 3.939398585117715e-09
mutation O 0 1.4323132901949975e-08
changed O 0 4.3426862106343833e-10
the O 0 1.2724619968818018e-11
adrenodoxin O 0 2.2234086571870648e-08
cofactor O 0 6.014532760723057e-10
binding O 0 2.4146359911547677e-10
residue O 0 1.0767359448493607e-08
362Arg O 0 2.49139180397151e-08
to O 0 8.174495802482085e-11
362Ser O 0 7.432164039755662e-08
( O 0 3.7809422259726944e-11
CGT O 0 1.5023495336663473e-07
362Arg O 0 4.6596134950505075e-08
to O 0 9.285913704637494e-11
AGT O 0 1.878540416555552e-07
362Ser O 0 1.3976833201923e-07
) O 0 5.838573374772338e-11
, O 0 3.298903858417468e-11
and O 0 1.2583344366490223e-09
was O 0 7.075363583908256e-08
responsible O 0 1.6101473931939836e-08
for O 0 2.7363720178641415e-09
deficiency O 0 6.136285082902759e-05
in O 0 1.6207195308037825e-11
the O 0 2.1810954084489076e-11
sterol O 0 7.480113254132448e-06
27 O 0 8.247346983125681e-08
- O 0 2.0630707808777515e-07
hydroxylase O 0 4.781162488143309e-07
activity O 0 3.33777627758991e-08
, O 0 9.277163239007624e-12
as O 0 2.0406217948049088e-12
confirmed O 0 4.902506178794397e-11
by O 0 9.368426986868655e-14
expression O 0 2.0011219244164824e-12
of O 0 1.7632054670480013e-14
mutant O 0 1.5228743266426648e-10
cDNA O 0 3.8254985290642196e-10
into O 0 9.388355648454194e-10
COS O 0 4.850856930715963e-05
- O 0 1.643841756049369e-06
1 O 0 4.4537098453645285e-09
cells O 0 1.1302949332048229e-07
. O 0 1.2116549985563552e-09

Quantitative O 0 4.02420056389019e-07
analysis O 0 1.1324048365679573e-08
showed O 0 1.4275621573744957e-08
that O 0 1.5557319321679586e-11
the O 0 2.8699870171372543e-12
expression O 0 4.756695384799947e-11
of O 0 8.560304700332144e-13
CYP27 O 0 1.10982466594578e-06
gene O 0 2.360907691567604e-09
mRNA O 0 6.338971014763217e-10
in O 0 5.524498219999785e-11
the O 0 6.330172497293063e-11
patient O 0 1.922328962677966e-08
represented O 0 1.052227888154178e-10
52 O 0 9.78136469598212e-08
. O 0 8.894249781121744e-09

5 O 0 9.346854845659891e-09
% O 0 4.335715467207457e-11
of O 0 1.4820643627275198e-12
the O 0 1.0552828055843122e-10
normal O 0 5.4501764878978065e-08
level O 0 1.6376386469119097e-08
. O 0 2.3760684531026754e-09

As O 0 3.0285123298057215e-09
the O 0 1.5414391985046905e-11
mutation O 0 5.809648873089657e-10
occurred O 0 1.029163976262737e-09
at O 0 3.094007688941858e-11
the O 0 2.923795645697058e-13
penultimate O 0 9.805335710044716e-11
nucleotide O 0 1.651910032374193e-11
of O 0 4.472281106646797e-14
exon O 0 1.9577624854605347e-08
6 O 0 7.176946592579725e-09
( O 0 3.233752501885512e-11
- O 0 2.475779297128611e-07
2 O 0 1.090993517749439e-09
position O 0 5.312657536116205e-10
of O 0 9.801711444443542e-14
exon O 0 5.326716063791537e-07
6 O 0 1.0293101126990223e-07
- O 0 7.814560376573354e-06
intron O 0 0.00039632708649151027
6 O 0 8.19589196510151e-09
splice O 0 2.6484076443011872e-05
site O 0 4.466106133804715e-07
) O 0 1.5058659614403114e-12
of O 0 3.421327687846455e-14
the O 0 6.885200742878794e-12
gene O 0 9.569132686237936e-08
, O 0 3.8329628360145307e-10
we O 0 2.640541674203689e-10
hypothesized O 0 1.9433440967553395e-10
that O 0 6.602896701624061e-11
the O 0 1.6924563139841808e-10
mutation O 0 2.2061390154703986e-06
may O 0 9.508638498800792e-08
partially O 0 9.008778647512372e-07
affect O 0 2.8802462637145254e-09
the O 0 8.265598275269959e-12
normal O 0 1.0552526213958302e-10
splicing O 0 1.6792510715291087e-09
efficiency O 0 3.227887401813234e-10
in O 0 4.369726802622154e-12
exon O 0 1.8448309901941684e-07
6 O 0 2.578580335921288e-07
and O 0 5.086790988428902e-09
cause O 0 6.3624189250433e-11
alternative O 0 9.213205719171835e-12
splicing O 0 3.489004285484043e-08
elsewhere O 0 5.051686358115148e-08
, O 0 6.584070788573371e-11
which O 0 4.1233114145278194e-11
resulted O 0 8.348802899016405e-11
in O 0 3.1294754981869843e-11
decreased O 0 2.5732733277550324e-08
transcript O 0 3.9084156924218405e-06
in O 0 1.3784243746428615e-09
the O 0 1.7362944415566517e-09
patient O 0 1.438225808669813e-06
. O 0 1.7560243259495678e-09

Transfection O 0 0.00012070417869836092
of O 0 1.0266857364271686e-09
constructed O 0 8.971124429990596e-07
minigenes O 0 1.2849977792939171e-05
, O 0 9.151304158905305e-10
with O 0 1.0220858187581783e-10
or O 0 6.645187178300205e-10
without O 0 2.954412409161833e-11
the O 0 1.9908059575857173e-11
mutation O 0 1.3826698008756466e-08
, O 0 3.242683552229231e-11
into O 0 1.4533343417610922e-09
COS O 0 0.010984611697494984
- O 0 1.3921952813689131e-05
1 O 0 2.340681426460378e-09
cells O 0 3.065750675546042e-08
confirmed O 0 2.9989206673519675e-09
that O 0 8.532450787579471e-12
the O 0 2.7169226070322683e-12
mutant O 0 2.7872477659229844e-08
minigene O 0 4.7075670295271266e-07
was O 0 1.369844149223809e-08
responsible O 0 1.0770081354527505e-10
for O 0 1.334713047550229e-13
a O 0 5.169273863125934e-12
mRNA O 0 5.316469486871256e-10
species O 0 2.794369770298122e-12
alternatively O 0 5.343623321607538e-10
spliced O 0 7.626600563526154e-05
at O 0 2.7080406539425894e-07
an O 0 2.7535522473254304e-11
activated O 0 9.355847652159355e-08
cryptic O 0 6.10429111702615e-08
5 O 0 1.0518145382443223e-10
splice O 0 5.758450242865365e-06
site O 0 4.915374347547186e-07
88 O 0 2.077866101402037e-09
bp O 0 4.3988093167968145e-09
upstream O 0 4.5399209391838724e-10
from O 0 8.002049001719358e-13
the O 0 2.480651534880751e-12
3 O 0 5.647918938089802e-11
end O 0 3.719592342465994e-11
of O 0 2.840712962168951e-13
exon O 0 1.6783702676548273e-06
6 O 0 4.402454578666948e-07
. O 0 1.111430325551055e-08

Our O 0 3.5845106882703703e-09
data O 0 7.485164155163204e-10
suggest O 0 1.7316237332920537e-10
that O 0 1.1677167913171083e-11
the O 0 1.3487383952737186e-11
C O 0 2.4698460947547574e-06
to O 0 4.2633865188212994e-11
A O 0 4.250243768044726e-10
mutation O 0 9.567212799765912e-09
at O 0 8.23112134007431e-10
the O 0 4.888805939934349e-12
penultimate O 0 7.414910907499461e-10
nucleotide O 0 4.915464910104639e-11
of O 0 7.632532572545564e-14
exon O 0 4.250061635957536e-08
6 O 0 4.393065911045824e-09
of O 0 1.5441897977322427e-12
the O 0 2.9321381433966565e-10
CYP27 O 0 1.022688411467243e-05
gene O 0 6.586855079149245e-07
not O 0 1.035026819806717e-08
only O 0 5.843009964756618e-10
causes O 0 3.9234118176523225e-09
the O 0 2.212385084021662e-07
deficiency B-Disease 0 0.024213489145040512
in I-Disease 0 7.014350211775877e-11
the I-Disease 0 2.804758370000826e-10
sterol I-Disease 0 6.245837084861705e-06
27 I-Disease 0 1.3271191789954173e-07
- I-Disease 0 8.102063731030285e-08
hydroxylase I-Disease 0 1.5427937114509405e-06
activity I-Disease 0 4.473105263969046e-07
, O 0 5.909092770650659e-09
but O 0 4.760660488045687e-08
also O 0 4.5136602011552895e-08
partially O 0 2.8261338229640387e-06
leads O 0 1.0318375487372577e-08
to O 0 3.3770690237300283e-12
alternative O 0 6.821880300239558e-12
pre O 0 2.76947104138614e-10
- O 0 1.0679244155653578e-09
mRNA O 0 1.8528270931406077e-11
splicing O 0 2.7617907960575394e-10
of O 0 1.1190795469115389e-12
the O 0 2.9747686952630303e-11
gene O 0 4.787897367464211e-08
. O 0 2.8413094099732916e-09

To O 0 1.2531046422736836e-07
our O 0 1.6164845850763498e-10
knowledge O 0 5.015588985801678e-11
, O 0 9.969054227954022e-12
this O 0 1.1719065388243743e-12
is O 0 4.764111414395922e-12
the O 0 6.376532548507674e-12
first O 0 8.336315526769056e-10
report O 0 8.197713341484558e-11
regarding O 0 6.171168177165898e-13
effects O 0 9.847455073597189e-10
on O 0 9.98236493465754e-10
pre O 0 8.906455128965263e-09
- O 0 6.210181702215323e-09
mRNA O 0 5.3138406869157606e-11
splicing O 0 7.842200222540896e-10
of O 0 3.024355668245632e-13
a O 0 2.0798864366899927e-11
mutation O 0 5.382076118110035e-09
at O 0 3.176050256126217e-10
the O 0 4.0014998259341183e-11
- O 0 1.2661132586799795e-06
2 O 0 6.849335321135186e-09
position O 0 5.484345866335616e-09
of O 0 2.6258522808388085e-13
a O 0 1.4802663261814786e-10
5 O 0 1.0865820743166665e-10
splice O 0 1.4626542906626128e-05
site O 0 7.275499683601083e-06
. O 0 9.332087103075537e-09

ATM O 0 0.00017923668201547116
germline O 0 0.0001396354055032134
mutations O 0 0.00028420021408237517
in O 0 9.762088915010736e-09
classical O 0 0.049052346497774124
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
telangiectasia I-Disease 1 1.0
patients O 1 0.9963739514350891
in O 0 9.636972997384419e-09
the O 0 1.831511942107511e-09
Dutch O 0 5.517144381883554e-05
population O 0 1.9241144233461682e-09
. O 0 6.703939625651856e-10

Germline O 0 0.0008579370332881808
mutations O 0 0.0002497541718184948
in O 0 1.560877677109218e-10
the O 0 3.1020613161514277e-11
ATM O 0 1.0528641496421187e-06
gene O 0 4.4511981656114585e-08
are O 0 5.311457003387421e-12
responsible O 0 1.652214254299622e-09
for O 0 6.707664645944078e-09
the O 1 0.9126021862030029
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.05122201517224312
A B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999990463256836
T I-Disease 1 0.9999998807907104
) O 0 1.9395271522171242e-07
. O 0 8.079730662302609e-09

In O 0 1.711883186317209e-07
our O 0 9.852677562705026e-10
study O 0 7.517796107858743e-11
, O 0 2.497887660601883e-11
we O 0 2.1393835314409415e-10
have O 0 5.5080501791537895e-12
determined O 0 2.4150676250500602e-11
the O 0 3.7922559515367327e-13
ATM O 0 1.030895688813871e-07
mutation O 0 1.3437352341938436e-09
spectrum O 0 8.070115686820145e-10
in O 0 1.3523737685261494e-10
19 O 0 1.0271088424218533e-09
classical O 0 6.406619945664715e-07
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 0.0009025106555782259
, O 0 2.1679807254981753e-11
including O 0 1.0529214219262562e-12
some O 0 5.524031319176226e-12
immigrant O 0 9.351654739475634e-08
populations O 0 1.0342354528347641e-08
, O 0 1.1644517815267985e-11
as O 0 2.8049495018334092e-11
well O 0 7.458709344598802e-11
as O 0 2.4443188792466763e-11
12 O 0 8.857330667522145e-12
of O 0 5.712919286943174e-13
Dutch O 0 9.712723567645298e-07
ethnic O 0 2.355141859311516e-09
origin O 0 4.104687256756279e-09
. O 0 2.9972568871272642e-09

Both O 0 4.172302059402e-09
the O 0 3.6605215386620316e-11
protein O 0 1.4404576420545823e-09
truncation O 0 2.5865206225716975e-06
test O 0 2.652200009833905e-06
( O 0 1.0209027200003273e-11
PTT O 0 6.841621313924406e-08
) O 0 1.3345591125257794e-11
and O 0 3.927561401106949e-12
the O 0 6.047825543316343e-13
restriction O 0 2.1365902103109846e-10
endonuclease O 0 5.875447328662631e-08
fingerprinting O 0 1.951002559508197e-06
( O 0 6.556722612766075e-12
REF O 0 2.728140202634677e-07
) O 0 1.0479200921722706e-13
method O 0 5.632317095355388e-12
were O 0 2.957139524570329e-12
used O 0 6.867409974020688e-10
and O 0 1.2730361209634111e-09
compared O 0 3.540422469083815e-11
for O 0 3.6681080265235644e-13
their O 0 1.7704493470230287e-12
detection O 0 1.2019346629088545e-09
efficiency O 0 5.092163496422941e-11
, O 0 8.50119182948389e-13
identifying O 0 1.4093792105596137e-11
76 O 0 1.7945909203120891e-09
% O 0 2.030879587763823e-12
and O 0 1.6236875732822398e-10
60 O 0 2.78364303829548e-10
% O 0 1.7396930250546117e-12
of O 0 3.928226288089226e-13
the O 0 1.1094727359051149e-09
mutations O 0 5.958133897365769e-07
, O 0 7.800456114370746e-11
respectively O 0 3.4255542846750586e-09
. O 0 2.638982365965603e-09

Most O 0 1.4146491089661595e-08
patients O 0 2.7200652397141312e-08
were O 0 3.954217162038809e-11
found O 0 1.85115381357015e-10
to O 0 1.6326088050910847e-11
be O 0 3.456925024014623e-11
compound O 0 9.580309523471442e-08
heterozygote O 0 1.5647834743504063e-06
. O 0 4.701139921792219e-09

Seventeen O 0 2.2637445340478735e-07
mutations O 0 2.490067572580301e-06
were O 0 3.0628308222979683e-10
distinct O 0 1.2800671633783622e-10
, O 0 1.6732140672992557e-10
of O 0 4.072893498158203e-12
which O 0 1.5758091720385892e-08
10 O 0 5.464323785120406e-11
were O 0 2.344742178195247e-10
not O 0 1.3080390104391881e-09
reported O 0 5.8292988214248e-09
previously O 0 1.6869316254997102e-07
. O 0 1.0860112809041311e-08

Mutations O 0 0.0015059183351695538
are O 0 3.539533111052151e-10
small O 0 2.2562027246486593e-10
deletions O 0 7.134500719985226e-06
or O 0 1.9775950477196602e-06
point O 0 1.8316603018320166e-05
mutations O 0 0.0004223305149935186
frequently O 0 3.7931124552414985e-07
affecting O 0 2.8676840457819708e-08
splice O 0 0.00850876048207283
sites O 0 4.132893081987277e-05
. O 0 6.086398940396975e-08

Moreover O 0 2.718701580306515e-06
, O 0 8.189949829429111e-10
a O 0 2.1863655330633947e-10
16 O 0 3.180719909678942e-09
. O 0 1.1953616985138638e-09

7 O 0 9.783715171352014e-08
- O 0 9.650364063418237e-07
kb O 0 8.529536330570409e-07
genomic O 0 3.614956369801803e-07
deletion O 0 1.70735040683212e-06
of O 0 2.0496883704201885e-11
the O 0 8.061639134027132e-10
3 O 0 1.0068956335373969e-08
end O 0 1.865737564443748e-09
of O 0 2.099638144554758e-13
the O 0 1.9526281633264198e-11
gene O 0 7.273442292898835e-08
, O 0 3.58014284884689e-10
most O 0 1.2891494295674821e-11
likely O 0 4.322028013259427e-10
a O 0 1.0674447437075685e-11
result O 0 2.988747790921842e-11
of O 0 5.151895281370854e-14
recombination O 0 1.68697417146646e-10
between O 0 9.504278475347405e-10
two O 0 1.5555079446727405e-09
LINE O 0 1.3292259609443136e-05
elements O 0 4.195478453539181e-08
, O 0 1.8784780397851364e-09
was O 0 7.997720530283914e-08
identified O 0 2.554836555646034e-07
. O 0 3.783492630304863e-09

The O 0 9.833739156306365e-09
most O 0 6.33444824371665e-11
frequently O 0 6.282271147739493e-09
found O 0 4.980909018570401e-10
mutation O 0 2.2564758950238684e-08
, O 0 4.053984578589187e-11
identified O 0 3.191562925053404e-08
in O 0 1.792612586148934e-10
three O 0 1.3371390661376381e-09
unrelated O 0 1.9710248011506337e-07
Turkish O 0 0.0023706327192485332
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999994039535522
T I-Disease 1 1.0
individuals O 0 1.4937171499695978e-08
, O 0 5.753497678284702e-10
was O 0 2.3347922706307145e-08
previously O 0 7.897985376814631e-09
described O 0 1.2372678881433785e-08
to O 0 2.19187695771339e-10
be O 0 5.565491470460593e-11
a O 0 2.2689118639451777e-10
Turkish O 0 6.779089744668454e-06
A B-Disease 1 0.9999985694885254
- I-Disease 1 0.9999865293502808
T I-Disease 1 0.9999994039535522
founder O 0 2.272751044074539e-05
mutation O 0 1.8115845250576967e-06
. O 0 3.158689310112095e-09

The O 0 6.7747043530630435e-09
presence O 0 3.944705118108516e-10
of O 0 1.8177173091368792e-12
a O 0 5.024093363559246e-10
founder O 0 1.2066711008174025e-07
mutation O 0 2.5446327711620143e-08
among O 0 4.3280791277300334e-12
relatively O 0 1.3426662559545832e-10
small O 0 3.1616412266011196e-10
ethnic O 0 1.8823453018512737e-08
population O 0 9.818665880345634e-10
groups O 0 3.121701508401742e-11
in O 0 2.5229972624996044e-11
Western O 0 1.0177510745279505e-07
Europe O 0 5.930198199166625e-08
could O 0 5.762371135809019e-10
indicate O 0 5.4580086110422865e-12
a O 0 4.638179488918037e-13
high O 0 5.192515688257071e-12
carrier O 0 2.7507754754574343e-11
frequency O 0 1.0312428688763475e-09
in O 0 4.8429697752094825e-11
such O 0 1.9568336534492303e-11
communities O 0 1.541115146608263e-08
. O 0 9.037519177468312e-09

In O 0 5.8287014326197095e-08
patients O 0 5.878025532979336e-08
of O 0 2.6681614816864707e-12
Dutch O 0 1.3401571777649224e-05
ethnic O 0 2.0407620482387756e-08
origin O 0 1.9139035245530067e-08
, O 0 2.08200412465942e-09
however O 0 1.397372773048744e-09
, O 0 2.2812864444721193e-11
no O 0 4.234446820960969e-11
significant O 0 3.254380055370265e-12
founder O 0 9.52631662443082e-09
effect O 0 7.207207719517328e-09
could O 0 1.1204748062709768e-07
be O 0 2.2728187387688337e-10
identified O 0 4.778955897677406e-08
. O 0 2.737969628796577e-09

The O 0 4.740045245199553e-09
observed O 0 3.530378878124907e-09
genetic O 0 3.275659921087026e-08
heterogeneity O 0 3.159679096143009e-08
including O 0 1.7736824509118065e-10
the O 0 2.701753265554885e-10
relative O 0 5.016005388824851e-09
high O 0 3.5293823419380033e-09
percentage O 0 3.0525504346456955e-09
of O 0 2.9908675362733117e-12
splice O 0 0.06263191252946854
- O 0 0.004002290312200785
site O 0 2.8345009923214093e-05
mutations O 0 2.79269261227455e-05
had O 0 5.274674208521901e-07
no O 0 7.784269756561102e-11
reflection O 0 4.084229829337538e-11
on O 0 4.1987563426104657e-10
the O 0 2.920149955176754e-10
phenotype O 0 1.705311319710745e-06
. O 0 1.4473620080224237e-09

All O 0 5.348002929395079e-08
patients O 0 1.1198355132080451e-08
manifested O 0 2.1657096116456387e-09
classical O 0 7.880756243139331e-07
A B-Disease 1 0.9999899864196777
- I-Disease 1 0.9999958276748657
T I-Disease 1 1.0
and O 0 3.5524419672583463e-07
increased O 0 9.370895170945914e-10
cellular O 0 3.1401359024130215e-07
radioresistant O 0 4.204538583962858e-07
DNA O 0 1.6783318415036774e-06
synthesis O 0 1.1578519121258068e-07
. O 0 4.143743570494962e-09

Determination O 0 6.997829586907756e-07
of O 0 1.02185534339716e-11
the O 0 1.4440983131525087e-11
genomic O 0 5.943231684568673e-08
structure O 0 4.43508803016357e-08
of O 0 2.1065469247433244e-12
the O 0 1.5583105639205286e-10
COL4A4 O 0 9.772217708814424e-06
gene O 0 1.5059615066093102e-07
and O 0 1.1903812380253953e-09
of O 0 4.04035971346417e-11
novel O 0 0.00013739366841036826
mutations O 1 0.8112753033638
causing O 0 0.15846993029117584
autosomal B-Disease 1 0.9999949932098389
recessive I-Disease 1 0.9999979734420776
Alport I-Disease 1 0.9999992847442627
syndrome I-Disease 1 0.9999990463256836
. O 0 3.9522060433228035e-06

Autosomal B-Disease 1 0.9999744892120361
recessive I-Disease 1 0.9999901056289673
Alport I-Disease 1 0.9999986886978149
syndrome I-Disease 1 0.9999995231628418
is O 0 1.219228806803585e-07
a O 0 3.245070701041186e-08
progressive O 0 0.00013166504504624754
hematuric B-Disease 1 0.9994107484817505
glomerulonephritis I-Disease 1 0.9999997615814209
characterized O 0 0.309457927942276
by O 0 1.7859908041373274e-07
glomerular B-Disease 1 0.9992393255233765
basement I-Disease 1 0.9999006986618042
membrane I-Disease 1 0.9997380375862122
abnormalities I-Disease 1 0.9999866485595703
and O 0 1.9017682006960968e-07
associated O 0 2.8154005349279032e-08
with O 0 1.0600366806556849e-08
mutations O 0 0.00010376037971582264
in O 0 2.3458524012198723e-09
either O 0 3.0773854575727455e-08
the O 0 5.294523042209676e-09
COL4A3 O 0 0.0004110525769647211
or O 0 4.941716369444293e-09
the O 0 2.0943617673463422e-10
COL4A4 O 0 2.3025979771773564e-06
gene O 0 5.973551964189028e-08
, O 0 1.814517459897136e-11
which O 0 2.5193605882045667e-12
encode O 0 1.3249447372576384e-10
the O 0 1.7313034339494493e-10
alpha3 O 0 4.021263976028422e-06
and O 0 7.853520500589184e-09
alpha4 O 0 4.220240498398198e-06
type O 0 8.178655843948945e-05
IV O 0 0.0003743570705410093
collagen O 0 0.010995925404131413
chains O 0 0.10469964146614075
, O 0 3.55406797325486e-08
respectively O 0 2.4808221255057106e-08
. O 0 2.1474424460876662e-09

To O 0 3.197154319067863e-09
date O 0 5.355040855192783e-10
, O 0 5.700285295867635e-12
mutation O 0 1.170498142855081e-10
screening O 0 1.4107206069979839e-08
in O 0 1.0389736987415077e-10
the O 0 1.0157856777937013e-09
two O 0 6.151390952169322e-09
genes O 0 8.647908202874532e-07
has O 0 7.122584975149948e-07
been O 0 5.84572461548305e-08
hampered O 0 3.5687514809978893e-06
by O 0 6.996298679284862e-11
the O 0 2.1704021913038218e-10
lack O 0 2.6131258268335955e-10
of O 0 5.224323035811496e-13
genomic O 0 1.899978542496683e-06
structure O 0 1.5315790733438917e-06
information O 0 2.434412316176804e-08
. O 0 1.1540812749899487e-08

We O 0 1.3493418009602465e-05
report O 0 3.6738008191150584e-09
here O 0 2.0022148869425216e-11
the O 0 4.808063669425877e-13
complete O 0 1.0160099150891e-10
characterization O 0 9.405839307419228e-08
of O 0 2.200075841993221e-12
the O 0 5.723068199903203e-11
48 O 0 7.101288446165199e-10
exons O 0 2.3259961068333723e-08
of O 0 4.327517511004686e-12
the O 0 3.119590141764661e-10
COL4A4 O 0 4.403388174978318e-06
gene O 0 1.2764972723289247e-07
, O 0 2.5675626555421438e-11
a O 0 6.2539027775865286e-12
comprehensive O 0 4.3940107108397797e-10
gene O 0 7.379363609061329e-08
screen O 0 3.4890872484538704e-05
, O 0 1.9113533866743637e-08
and O 0 6.933824070465278e-10
the O 0 3.2987135158840664e-12
subsequent O 0 2.5937288775090828e-11
detection O 0 8.467742951268065e-09
of O 0 1.2386017775659064e-12
10 O 0 1.4196131770116693e-10
novel O 0 4.2593779170374546e-08
mutations O 0 1.6405919041062589e-06
in O 0 3.442091722760665e-09
eight O 0 3.2114826353790704e-07
patients O 0 2.689894472496235e-06
diagnosed O 0 0.003044647630304098
with O 0 6.469758773164358e-06
autosomal B-Disease 1 0.999998927116394
recessive I-Disease 1 0.9999994039535522
Alport I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999996423721313
. O 0 2.634488510011579e-06

Furthermore O 0 1.5727815707577975e-06
, O 0 5.371151301503119e-10
we O 0 2.0263817013255192e-10
identified O 0 2.078989931597608e-11
a O 0 7.899536060007595e-13
glycine O 0 1.3635195195149663e-09
to O 0 8.086084753167189e-12
alanine O 0 2.504669582847896e-09
substitution O 0 1.201127391992074e-10
in O 0 9.372458538436934e-12
the O 0 1.0859972643384452e-11
collagenous O 0 8.862552022037562e-06
domain O 0 1.383851042646711e-07
that O 0 1.7115451278471028e-09
is O 0 2.339542171103659e-10
apparently O 0 6.362085525069006e-09
silent O 0 2.702431167733721e-08
in O 0 8.234504224324812e-12
the O 0 5.6052033674258706e-12
heterozygous O 0 5.621997867244488e-10
carriers O 0 1.033751348411549e-10
, O 0 1.1476960007361647e-11
in O 0 6.245073208566154e-11
11 O 0 4.1210905799005104e-09
. O 0 1.7293735332657434e-09

5 O 0 7.21383663915276e-09
% O 0 9.191108811534843e-12
of O 0 2.349546338736852e-13
all O 0 3.3698772938794974e-11
control O 0 5.928076461714227e-06
individuals O 0 3.0977099357842874e-11
, O 0 7.665271195556045e-10
and O 0 2.4599240422418234e-09
in O 0 3.5233604922524364e-10
one O 0 4.659504337922726e-09
control O 0 1.2039931789331604e-06
individual O 0 1.1602189478251979e-12
homozygous O 0 1.924402477648801e-11
for O 0 8.75372907840899e-14
this O 0 7.755230377153033e-13
glycine O 0 3.1573399450479656e-09
substitution O 0 1.3954923883119363e-09
. O 0 2.2793056331238404e-09

There O 0 9.301628551838803e-07
has O 0 1.3131792542253606e-08
been O 0 3.3328301229929025e-10
no O 0 8.768331200004198e-11
previous O 0 8.394085426743914e-11
finding O 0 1.9868826636043613e-12
of O 0 9.312855357484964e-15
a O 0 1.06491844422546e-12
glycine O 0 4.645809292824765e-10
substitution O 0 2.6070460026894615e-11
that O 0 2.6940705222244787e-10
is O 0 2.9275223911717774e-10
not O 0 6.47532416575558e-10
associated O 0 3.1432120795038543e-10
with O 0 3.558810884873864e-11
any O 0 1.8605988971742704e-09
obvious O 0 2.549666078266455e-08
phenotype O 0 1.738645636351066e-07
in O 0 7.896049092348534e-11
homozygous O 0 4.185032409509404e-08
individuals O 0 3.2200167532359103e-10
. O 0 2.0886781193496518e-09

Founder O 0 1.0846762961591594e-05
BRCA1 O 0 0.00044541325769387186
and O 0 3.2468912536387506e-07
BRCA2 O 0 4.619989704224281e-05
mutations O 0 2.6009141947724856e-05
in O 0 1.4473571674500363e-08
French O 0 0.00032887133420445025
Canadian O 0 0.48959556221961975
breast B-Disease 1 0.9999992847442627
and I-Disease 1 0.9999995231628418
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 1.7525060513889912e-07
. O 0 1.4088088029495793e-08

We O 0 2.158635879823123e-06
have O 0 3.461756714617792e-10
identified O 0 4.511607198942613e-10
four O 0 3.4141422328159976e-11
mutations O 0 1.4841069706506005e-08
in O 0 1.507602549744025e-11
each O 0 3.567569200127463e-12
of O 0 2.7645614963933696e-11
the O 0 4.5252386371430475e-06
breast B-Disease 1 0.9960189461708069
cancer I-Disease 0 0.2076634019613266
- O 0 0.012306459248065948
susceptibility O 0 0.001316606649197638
genes O 0 2.5190208816638915e-06
, O 0 8.282023067351929e-09
BRCA1 O 0 6.400998972821981e-05
and O 0 5.298900305206189e-07
BRCA2 O 0 2.097941433021333e-05
, O 0 2.064517667932364e-09
in O 0 4.275875209458491e-09
French O 0 0.00018741229723673314
Canadian O 0 0.0053325314074754715
breast B-Disease 1 0.9997307658195496
cancer I-Disease 1 0.9987545013427734
and O 1 0.9840906262397766
breast B-Disease 1 0.9999997615814209
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.571890149738465e-07
from O 0 1.0501711722454843e-09
Quebec O 0 6.0298807511571795e-05
. O 0 4.6041765955351366e-08

To O 0 3.0338732415202685e-08
identify O 0 2.8819513886446657e-08
founder O 0 1.644618841112333e-08
effects O 0 2.323735998288612e-06
, O 0 1.6060395235939495e-09
we O 0 9.947150658717874e-09
examined O 0 3.351945920826438e-08
independently O 0 2.4251342267689324e-08
ascertained O 0 4.184951649222057e-06
French O 0 1.7372782167512923e-05
Canadian O 0 3.557630043360405e-05
cancer B-Disease 0 0.05623361095786095
families O 0 1.2352011080629666e-10
for O 0 1.9141734638322694e-12
the O 0 1.0759727310516443e-11
distribution O 0 1.687264661320853e-09
of O 0 2.7671081571922773e-12
these O 0 8.864636108496526e-11
eight O 0 1.131659432829224e-09
mutations O 0 5.571840233642433e-07
. O 0 4.530675390412853e-09

Mutations O 0 0.00018638047913555056
were O 0 2.383317099230453e-09
found O 0 1.3270035070789277e-10
in O 0 3.741634172632624e-12
41 O 0 8.392777028909393e-10
of O 0 1.9092325376918184e-12
97 O 0 1.6931690538513067e-07
families O 0 7.229608467440585e-09
. O 0 4.588140534167451e-09

Six O 0 8.81097328431224e-09
of O 0 1.9956863852449436e-12
eight O 0 1.215000877685668e-10
mutations O 0 1.836252394582516e-08
were O 0 6.074468011929568e-11
observed O 0 3.0577134157994124e-09
at O 0 3.6706140349451744e-09
least O 0 5.389767521180033e-10
twice O 0 4.325942200011923e-07
. O 0 1.1909133235121772e-08

The O 0 4.062389180603532e-08
BRCA1 O 0 6.666853096248815e-06
C4446T O 0 1.368904491982903e-07
mutation O 0 9.894491768136504e-07
was O 0 2.597911397117514e-08
the O 0 5.185409827218601e-12
most O 0 9.119670296708904e-12
common O 0 1.8568019344300524e-09
mutation O 0 1.4684688665056456e-07
found O 0 3.123093961221457e-08
, O 0 3.213443747207556e-11
followed O 0 6.478335229376242e-11
by O 0 8.507522811229684e-12
the O 0 6.77683353877967e-10
BRCA2 O 0 5.704174327547662e-06
8765delAG O 0 5.62564991923864e-07
mutation O 0 9.46833097259514e-07
. O 0 4.449014490148784e-09

Together O 0 8.680896712576214e-08
, O 0 3.873093859518839e-11
these O 0 1.1242418671356114e-12
mutations O 0 4.967799505095627e-09
were O 0 4.415231791288221e-10
found O 0 6.395238560941152e-09
in O 0 4.833983213714532e-10
28 O 0 1.8887171826520444e-09
of O 0 2.0826918748634293e-12
41 O 0 2.2171711577811948e-07
families O 0 2.183473263306368e-10
identified O 0 2.521125175292127e-08
to O 0 1.1760860341158974e-10
have O 0 9.047927684857626e-11
a O 0 2.9072452778500235e-10
mutation O 0 1.8245400212890672e-07
. O 0 4.747926052317553e-09

The O 0 4.035619838305138e-09
odds O 0 4.753752946839995e-09
of O 0 2.126374434602979e-13
detection O 0 1.7791798256894253e-08
of O 0 3.2375694464757687e-13
any O 0 2.2205234179173416e-11
of O 0 2.038894443903705e-12
the O 0 9.33030319671957e-10
four O 0 4.482147097917277e-09
BRCA1 O 0 3.0825133308098884e-06
mutations O 0 8.456971158921078e-07
was O 0 3.2499954727427394e-07
18 O 0 1.9270636197887825e-09
. O 0 1.9347905499955687e-09

7x O 0 1.1780395652749576e-05
greater O 0 4.551663046470367e-09
if O 0 1.3716690894227668e-08
one O 0 2.093146836412707e-11
or O 0 1.0781009765481464e-11
more O 0 1.504832391509281e-12
cases O 0 1.265000904027147e-08
of O 0 0.0003520361497066915
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 7.575020504191343e-07
also O 0 1.0577987268334255e-06
present O 0 3.360137723618095e-09
in O 0 1.5580260415148928e-09
the O 0 1.6649440714999741e-09
family O 0 1.8928659528683056e-07
. O 0 4.661886876533572e-09

The O 0 3.2821811934979905e-09
odds O 0 6.831304411036854e-09
of O 0 1.4312527129179548e-13
detection O 0 9.366699416091251e-09
of O 0 4.225922183801606e-13
any O 0 6.187191731177322e-11
of O 0 5.511475824337975e-12
the O 0 6.430012078340042e-09
four O 0 1.768269441981829e-08
BRCA2 O 0 4.369846010376932e-06
mutations O 0 7.937371151456318e-07
was O 0 1.4769463518859993e-07
5 O 0 2.4453892244480357e-09
. O 0 4.36242197920933e-09

3x O 0 4.4769467422156595e-06
greater O 0 1.4638364964625339e-09
if O 0 4.7885153620086385e-09
there O 0 4.023004152031717e-11
were O 0 1.931576947000746e-11
at O 0 7.056768364099852e-11
least O 0 6.117913792756668e-13
five O 0 4.725143887274186e-12
cases O 0 7.035440285907413e-11
of O 0 4.902642292137216e-09
breast B-Disease 1 0.9999325275421143
cancer I-Disease 0 0.4860488176345825
in O 0 2.084202144203573e-08
the O 0 5.3091785190417795e-08
family O 0 1.6177683619389427e-06
. O 0 2.2301279045677802e-08

Interestingly O 0 7.248538167914376e-06
, O 0 5.458805629743324e-10
the O 0 3.1860946173023486e-12
presence O 0 5.513560441539056e-11
of O 0 5.552722344426275e-12
a O 0 5.983815185572894e-07
breast B-Disease 1 0.7068871855735779
cancer I-Disease 0 3.763673157664016e-05
case O 0 3.236680701235173e-09
< O 0 7.648775124380336e-08
36 O 0 1.3109969998481574e-08
years O 0 2.4163900047557973e-11
of O 0 7.977209387846629e-13
age O 0 5.278732118085827e-09
was O 0 7.45906836296939e-10
strongly O 0 8.444505511517875e-12
predictive O 0 1.154052076124401e-09
of O 0 2.975856323514381e-12
the O 0 1.4735591913339618e-10
presence O 0 1.5518325513497189e-10
of O 0 9.017952535975496e-14
any O 0 1.0291786520233437e-11
of O 0 1.1632080932147404e-12
the O 0 1.2347677047497285e-10
eight O 0 9.288274038787847e-10
mutations O 0 6.456129142407008e-08
screened O 0 2.698172238524421e-06
. O 0 5.211196363319459e-09

Carriers O 0 1.7109952921146032e-07
of O 0 6.909894097878455e-12
the O 0 1.0835681310550349e-11
same O 0 3.716039628787193e-11
mutation O 0 9.960878344372759e-09
, O 0 8.760737794932805e-12
from O 0 4.4712765933339893e-13
different O 0 1.0911567656368693e-11
families O 0 1.469823013300342e-10
, O 0 3.4791173414427945e-11
shared O 0 2.2841613322999166e-10
similar O 0 1.3109881236150756e-10
haplotypes O 0 2.1927201032667654e-07
, O 0 7.264502888126856e-11
indicating O 0 2.4616123028842196e-10
that O 0 5.4456165271554724e-11
the O 0 3.687365083410166e-12
mutant O 0 1.5889249915801429e-09
alleles O 0 5.865159746765158e-11
were O 0 4.6242470963520077e-10
likely O 0 1.3993145531188134e-09
to O 0 9.854307647660931e-11
be O 0 9.291618169315896e-11
identical O 0 6.240591154949016e-09
by O 0 1.2471966515104072e-10
descent O 0 2.3735246656997333e-07
for O 0 5.0619505115312435e-11
a O 0 4.053965607653254e-09
mutation O 0 2.76583250524709e-07
in O 0 6.43555431167897e-10
the O 0 4.213750737225297e-10
founder O 0 4.0320449556929816e-07
population O 0 8.746204316345541e-10
. O 0 9.707514792012262e-10

The O 0 3.5284380972555596e-10
identification O 0 3.621605237924541e-10
of O 0 7.411425639869407e-12
common O 0 2.0623422969379135e-08
BRCA1 O 0 0.0004970132722519338
and O 0 1.080509036910371e-06
BRCA2 O 0 7.297893898794428e-05
mutations O 0 1.3932577530795243e-05
will O 0 4.726040669922327e-10
facilitate O 0 1.4884939114612195e-10
carrier O 0 7.088247322428742e-09
detection O 0 1.2626212537725223e-06
in O 0 5.088538035380452e-09
French O 0 4.401104888529517e-05
Canadian O 0 0.006108275149017572
breast B-Disease 1 0.9999086856842041
cancer I-Disease 1 0.9993845224380493
and O 1 0.962536096572876
breast B-Disease 1 0.9999996423721313
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.273599878004461e-06
. O 0 3.941851289823717e-08

Are O 0 2.8158298803759862e-08
Dp71 O 0 0.0001097354106605053
and O 0 1.1151659151664717e-07
Dp140 O 0 3.2671543976903195e-06
brain O 0 5.619405328616267e-06
dystrophin O 0 1.9122145999972417e-07
isoforms O 0 1.6842647276860134e-09
related O 0 8.538552087600237e-09
to O 0 2.3042432406583657e-09
cognitive B-Disease 0 8.210153282561805e-06
impairment I-Disease 0 2.0692530597443692e-05
in O 0 1.2331788639130536e-06
Duchenne B-Disease 1 0.9999735355377197
muscular I-Disease 1 0.9988442659378052
dystrophy I-Disease 1 0.9994382262229919
? O 0 2.199200571340043e-05

Molecular O 0 4.0567247197031975e-06
study O 0 1.0258641047755646e-08
and O 0 2.017315481328552e-10
neuropsychological O 0 1.3656388908600547e-08
analysis O 0 6.004924335556439e-11
were O 0 2.315674041408755e-11
performed O 0 2.401180587696672e-09
concurrently O 0 1.2940852833764893e-09
on O 0 3.669103776360316e-08
49 O 0 5.045772468292853e-06
patients O 0 3.900529748079862e-07
with O 0 3.9373281879306887e-07
Duchenne B-Disease 1 0.9999915361404419
muscular I-Disease 1 0.9867838621139526
dystrophy I-Disease 1 0.9835184812545776
( O 0 4.783935025898245e-08
DMD B-Disease 1 0.9999998807907104
) O 0 3.613777010968988e-08
in O 0 3.3079552430592685e-09
order O 0 1.315257325273933e-08
to O 0 4.625005656233583e-10
find O 0 1.4311211937734214e-10
a O 0 1.6970089613058126e-12
molecular O 0 2.460834425122016e-09
explanation O 0 2.484655259316071e-10
for O 0 5.587377782667602e-12
the O 0 1.7970903931630033e-10
cognitive B-Disease 0 6.9698495508419e-07
impairment I-Disease 0 2.9413609325956713e-08
observed O 0 3.5479161830664907e-09
in O 0 1.4848764440245077e-09
most O 0 1.876527733202238e-07
DMD B-Disease 1 1.0
patients O 0 0.0016279140254482627
. O 0 7.060289686222632e-09

Complete O 0 9.812851686774593e-08
analysis O 0 6.548917519388908e-10
of O 0 6.44522467081049e-13
the O 0 3.200347972742712e-11
dystrophin O 0 6.140269306342816e-07
gene O 0 1.9331814655743074e-06
was O 0 3.269287560669909e-07
performed O 0 3.199352249794174e-08
to O 0 7.321168844776071e-12
define O 0 1.5753214288594108e-09
the O 0 5.286411933203006e-12
localization O 0 6.271747565733676e-09
of O 0 9.927002796172868e-13
deletions O 0 4.209749022265896e-06
and O 0 5.232912414498969e-08
duplications O 0 4.567537871480454e-06
in O 0 1.5188025281887008e-09
relation O 0 1.644195535277504e-08
to O 0 1.3439575841101004e-10
the O 0 7.348116559668938e-11
different O 0 6.6976673096519335e-09
DMD B-Disease 1 0.9999985694885254
promoters O 0 6.154846050776541e-05
. O 0 1.593302023650267e-08

Qualitative O 0 1.0427074670360525e-07
analysis O 0 1.3294970679922358e-09
of O 0 1.6020689549284262e-12
the O 0 2.2196258719908712e-11
Dp71 O 0 1.3705833907806664e-06
transcript O 0 2.380275873292703e-06
and O 0 2.595364145818735e-09
testing O 0 8.741034007719861e-10
for O 0 4.634913126585517e-14
the O 0 2.9499438915919773e-13
specific O 0 8.79852831217609e-13
first O 0 2.3954418310045966e-11
exon O 0 4.523647234577766e-09
of O 0 1.0528015091659793e-11
Dp140 O 0 3.097809440077981e-07
were O 0 2.5095756583937145e-09
also O 0 2.176625990557568e-09
carried O 0 3.161174078059048e-08
out O 0 3.313532914717143e-08
. O 0 4.41410552554089e-09

Neuropsychological O 0 1.804677776817698e-05
analysis O 0 2.3951713501446648e-08
assessed O 0 2.244576080556726e-09
verbal O 0 2.1484500223323266e-07
and O 0 1.079569766915256e-08
visuospatial O 0 2.3668844733037986e-05
intelligence O 0 1.250707271083229e-07
, O 0 2.7288443726902756e-10
verbal O 0 5.4192756948623355e-08
memory O 0 1.9329054339323193e-05
, O 0 4.623350147170413e-09
and O 0 3.779605073361836e-09
reading O 0 7.158875092727612e-08
skills O 0 1.9614373059084755e-07
. O 0 1.6423611359783763e-09

Comparison O 0 4.707190015551532e-08
of O 0 6.763087485872621e-12
molecular O 0 8.218782454605389e-08
and O 0 7.567653170781341e-09
psychometric O 0 3.302015466033481e-05
findings O 0 8.019193309394268e-09
demonstrated O 0 3.2670396943323965e-10
that O 0 1.7513164529692204e-11
deletions O 0 3.816858793470601e-07
and O 0 1.4638373180275721e-08
duplications O 0 5.69604253541911e-06
that O 0 4.3870478805274615e-08
were O 0 1.835663177018887e-09
localized O 0 1.4884095662637264e-06
in O 0 2.238463459036666e-08
the O 0 2.117696906722699e-09
distal O 0 1.0839501101145288e-06
part O 0 1.530306725783248e-08
of O 0 6.379890105795427e-12
the O 0 2.376348284816032e-10
gene O 0 1.3634141282636847e-07
seemed O 0 9.525479960359462e-09
to O 0 2.335345805626332e-11
be O 0 1.3379642879729481e-11
preferentially O 0 5.79845671477841e-10
associated O 0 1.2779211022717618e-09
with O 0 3.96233756916331e-09
cognitive B-Disease 0 3.195132376276888e-05
impairment I-Disease 0 5.492081072588917e-06
. O 0 6.635564986368081e-09

Two O 0 7.574064930793156e-09
altered O 0 5.773884481641289e-07
Dp71 O 0 3.7955403513478814e-06
transcripts O 0 1.0771570941869868e-06
and O 0 4.309055612328194e-10
two O 0 3.831380091662284e-12
deleted O 0 1.223037582320785e-08
Dp140 O 0 3.1080460427546086e-09
DNA O 0 9.033403358671421e-08
sequences O 0 1.373182101360726e-08
were O 0 8.122000849652977e-10
found O 0 3.0180000720747557e-09
in O 0 1.5212545112497367e-10
four O 0 8.560338216057062e-09
patients O 0 3.9079687041976285e-08
with O 0 9.958146307553761e-08
severe O 0 0.21837469935417175
cerebral B-Disease 1 0.9554947018623352
dysfunction I-Disease 0 0.06051729619503021
. O 0 1.0949010231797729e-07

These O 0 3.738978904266332e-09
findings O 0 6.344705316685406e-10
suggest O 0 1.1314731790390553e-10
that O 0 2.030856385837332e-12
some O 0 2.069966512649804e-13
sequences O 0 9.421766122841291e-08
located O 0 4.300865441564383e-07
in O 0 1.1813880984590241e-09
the O 0 1.0591463817100077e-10
distal O 0 9.251824195644076e-08
part O 0 1.26929988741864e-09
of O 0 3.566297214138703e-12
the O 0 1.3304198021035774e-10
gene O 0 5.462632657327049e-07
and O 0 1.0594792598794811e-07
, O 0 2.58070231851093e-10
in O 0 9.862688790662766e-12
particular O 0 5.4683379352438166e-11
, O 0 1.4665012260106636e-11
some O 0 9.640745667061079e-12
DMD B-Disease 1 0.9999978542327881
isoforms O 0 1.3456569192271672e-08
expressed O 0 3.210909038653398e-10
in O 0 3.7173669698020717e-10
the O 0 5.1411599422124254e-09
brain O 0 0.000716737937182188
may O 0 8.02588040471619e-09
be O 0 1.2800909637844526e-11
related O 0 7.196802181974604e-11
to O 0 9.64055280050502e-10
the O 0 2.4222852612609813e-09
cognitive B-Disease 0 5.161859007785097e-06
impairment I-Disease 0 1.20259855407312e-07
associated O 0 2.872928561714616e-08
with O 0 1.0984842901962111e-07
DMD B-Disease 1 1.0
. O 0 8.519926950611989e-07
. O 0 1.816923678177318e-08

I1307K O 0 9.29423185880296e-06
APC O 0 1.9441749827819876e-06
and O 0 3.0028662223458014e-08
hMLH1 O 0 1.278674858440354e-06
mutations O 0 8.728380635147914e-06
in O 0 2.2321554327131565e-10
a O 0 5.806137237662767e-10
non O 0 5.54289014687015e-09
- O 0 1.9417551811784506e-05
Jewish O 0 2.963101906061638e-06
family O 0 6.592586743181528e-08
with O 0 2.532816401057403e-09
hereditary B-Disease 0 0.4190727770328522
non I-Disease 0 7.977290806593373e-05
- I-Disease 1 0.9999855756759644
polyposis I-Disease 1 0.9999854564666748
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 1.8326052213524235e-06

We O 0 7.62894444505946e-07
describe O 0 1.5182298085392176e-08
a O 0 1.5287422439058673e-09
French O 0 9.62852254815516e-07
Canadian O 0 2.437666125842952e-06
hereditary B-Disease 1 0.9796290993690491
non I-Disease 0 0.0018491406226530671
- I-Disease 1 0.9999980926513672
polyposis I-Disease 1 0.9999991655349731
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 2.1140956505405484e-06
HNPCC B-Disease 0 0.4706198573112488
) O 0 1.717592823524683e-08
kindred O 0 1.4515228485834086e-06
which O 0 2.5179425211518947e-09
carries O 0 5.790941060013211e-10
a O 0 1.2007471406061399e-10
novel O 0 4.1214306634174136e-08
truncating O 0 5.7738247960514855e-06
mutation O 0 1.2070374850736698e-06
in O 0 9.103082176942223e-10
hMLH1 O 0 9.094860615732614e-06
. O 0 1.2349196332195334e-08

Interestingly O 0 1.6930445099205826e-06
, O 0 1.0703340991291554e-10
the O 0 3.1230996521552923e-12
I1307K O 0 2.6628272919992924e-09
APC O 0 6.870803370695455e-10
polymorphism O 0 2.9000798917877546e-07
, O 0 3.4487471212152343e-10
associated O 0 3.9541664387243713e-10
with O 0 3.070603146748674e-11
an O 0 7.320333922367084e-11
increased O 0 3.379106203738047e-07
risk O 0 0.00010644764552125707
of O 0 0.00013687298633158207
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 1.6059138943091966e-06
is O 0 7.102446630824488e-08
also O 0 3.6529948488350783e-07
present O 0 7.036289328965495e-10
in O 0 2.5532062575273073e-10
this O 0 1.895921419858837e-09
family O 0 1.0319796928115466e-07
. O 0 1.352615086602782e-08

The O 0 5.253130375137971e-09
I1307K O 0 5.4400501880991214e-08
polymorphism O 0 3.031189407920465e-06
has O 0 3.169215645471013e-08
previously O 0 4.082286952922232e-09
only O 0 1.4829511230107784e-10
been O 0 9.63788604479987e-10
identified O 0 4.950624443722518e-08
in O 0 8.895173486678232e-11
individuals O 0 3.9951605391996825e-12
of O 0 3.988300575213932e-12
self O 0 1.388783311995212e-05
- O 0 0.0071915131993591785
reported O 0 1.871646304607566e-06
Ashkenazi O 0 8.202311619243119e-06
Jewish O 0 1.3784198671373815e-08
origins O 0 4.074230375294974e-08
. O 0 3.794152103608894e-09

In O 0 7.285000380718998e-10
addition O 0 1.356734863344755e-10
, O 0 1.1338777833325153e-10
in O 0 4.26231341887906e-11
this O 0 5.831175542425626e-10
family O 0 1.442005981289185e-08
, O 0 3.349054089607506e-10
there O 0 3.219451649716376e-10
appears O 0 1.3777233576206527e-08
to O 0 6.37860708696536e-10
be O 0 1.5421199872633906e-09
no O 0 2.97633639956274e-10
relationship O 0 3.1344532525068303e-10
between O 0 2.628255078851449e-11
the O 0 3.288009621515986e-12
I1307K O 0 7.557639514210734e-10
polymorphism O 0 8.667363715630927e-08
and O 0 2.670650145475406e-09
the O 0 4.458847874255767e-11
presence O 0 1.5186286672630445e-09
or O 0 1.572634467095213e-09
absence O 0 1.4244226909099211e-09
of O 0 5.763841487427257e-11
cancer B-Disease 0 4.141509998589754e-05
. O 0 6.466314705910747e-10
. O 0 4.3929064830194875e-09

Identification O 0 4.200690995048717e-08
of O 0 8.015847534348364e-12
a O 0 6.369048344279093e-11
novel O 0 3.139013715625083e-09
mutation O 0 1.1584921466578635e-08
of O 0 1.3544763184311637e-12
the O 0 1.9468500422892276e-10
CPO O 0 1.1493402780615725e-05
gene O 0 8.896255820900478e-08
in O 0 1.3803443110749214e-10
a O 0 4.237642237114869e-09
Japanese O 0 2.017110637098085e-05
hereditary B-Disease 0 0.10282863676548004
coproporphyria I-Disease 0 0.00038284060428850353
family O 0 9.882570566333015e-07
. O 0 1.1709502700796293e-08

Hereditary B-Disease 1 0.9984835982322693
coproporphyria I-Disease 0 0.20097075402736664
( O 0 3.411036431089087e-08
HCP B-Disease 0 0.001285298028960824
) O 0 4.94892260505253e-09
is O 0 2.25926672925425e-08
an O 0 1.7669384533292032e-07
autosomal B-Disease 1 0.9999961853027344
dominant I-Disease 1 0.9999982118606567
disease I-Disease 1 0.9999971389770508
characterized O 0 8.942201930040028e-06
by O 0 3.248580515702315e-09
a O 0 3.3867631827888545e-06
deficiency B-Disease 0 0.1391497403383255
of I-Disease 0 1.497965987362626e-11
coproporphyrinogen I-Disease 0 0.0010621692053973675
oxidase I-Disease 0 1.689429336693138e-05
( O 0 3.4263694659308896e-10
CPO O 0 1.2705676454061177e-05
) O 0 1.0633019464911797e-10
caused O 0 5.20747778232078e-10
by O 0 1.308403906052913e-12
a O 0 8.337186496731874e-11
mutation O 0 3.349351018755442e-08
in O 0 1.1960338275329718e-10
the O 0 1.7713226718729658e-10
CPO O 0 2.547976328060031e-05
gene O 0 3.6235093148206943e-07
. O 0 5.8451750106769396e-09

Only O 0 8.392224515318958e-08
11 O 0 1.3625940376016388e-09
mutations O 0 6.417734788044527e-09
of O 0 6.402365616831052e-13
the O 0 4.20032446324381e-11
gene O 0 2.743638560787076e-07
have O 0 2.0307984627265796e-08
been O 0 3.5898202188633377e-09
reported O 0 2.050019887178678e-08
in O 0 5.164137117930068e-09
HCP B-Disease 1 0.5051589012145996
patients O 0 1.5080584034876665e-06
. O 0 1.3091846495782988e-09

We O 0 2.583655941634788e-06
report O 0 3.2924937776179775e-10
another O 0 1.6788010218093952e-11
mutation O 0 3.972098649995814e-09
in O 0 9.416088568581227e-12
a O 0 7.331069085125819e-10
Japanese O 0 1.0246135389024857e-05
family O 0 1.0477192802227364e-07
. O 0 3.683862992431841e-09

Polymerase O 0 0.00013677201059181243
chain O 0 8.183154022844974e-06
reaction O 0 3.517972047006879e-08
- O 0 5.221586434345227e-07
single O 0 1.6408581160476388e-09
strand O 0 2.9498400522243173e-07
conformational O 0 2.4781193763701026e-10
polymorphism O 0 4.1465675337803987e-08
and O 0 3.337663131985913e-11
direct O 0 9.297321593160213e-12
sequence O 0 3.460248265696464e-08
analyses O 0 1.2364562707034565e-08
demonstrated O 0 3.9875647922515967e-11
a O 0 1.1658252488389031e-11
C O 0 8.280855468001391e-07
to O 0 3.736094766892961e-11
T O 0 5.3366111529840055e-08
substitution O 0 7.331061972759567e-12
in O 0 8.403528524089654e-13
exon O 0 1.0036718123274113e-09
1 O 0 4.5083100447262936e-11
of O 0 3.1899114426303665e-13
the O 0 3.3294863394095486e-11
CPO O 0 4.198368230845517e-07
gene O 0 1.682720185414155e-09
at O 0 1.1724174409089017e-10
nucleotide O 0 2.0512820331219928e-09
position O 0 1.3565318646158175e-08
85 O 0 1.2316305753046208e-09
, O 0 4.647218720954527e-10
which O 0 4.000374254076178e-09
lies O 0 2.2953929601499112e-07
in O 0 3.440828177936339e-11
the O 0 7.5676713159889e-12
putative O 0 1.668701843371423e-09
presequence O 0 9.201471584674437e-09
for O 0 1.7741363933510002e-13
targeting O 0 1.9485673075081422e-09
to O 0 3.8401268276366807e-10
mitochondria O 0 4.1694252672641596e-07
. O 0 2.9614675156608428e-09

This O 0 1.0131618877196047e-09
mutation O 0 6.730476620475656e-09
changes O 0 6.349810954819901e-11
the O 0 6.930164450115461e-13
codon O 0 1.3050105440726156e-10
for O 0 9.131322136141443e-14
glutamine O 0 1.1068279626158528e-10
to O 0 1.8100367125267747e-12
a O 0 4.458250175282119e-12
termination O 0 7.892981268575738e-10
codon O 0 1.1311658276724756e-08
at O 0 6.03156913303593e-10
amino O 0 2.8329540935345676e-09
acid O 0 3.5169238632448696e-09
position O 0 4.443705847734236e-09
29 O 0 5.789696277958001e-09
. O 0 5.884098763786483e-10

MaeI O 0 1.125632206822047e-05
restriction O 0 2.9608365537114878e-08
analysis O 0 2.2519430764589288e-09
showed O 0 3.2598395094396437e-09
two O 0 1.2361189545909146e-12
other O 0 1.4603122313813777e-12
carriers O 0 3.3384670028446806e-10
in O 0 1.9083352953419563e-10
the O 0 1.6271328728834078e-09
family O 0 1.4708824380704755e-07
. O 0 1.2095244805720995e-08

The O 0 1.6661543611462548e-07
C O 0 0.0030520292930305004
- O 0 0.045036956667900085
T O 0 0.2022123634815216
mutation O 0 2.0257905362086603e-06
is O 0 4.892532490252677e-10
located O 0 4.74959316321133e-09
within O 0 4.135164780039169e-11
a O 0 2.978845295431576e-11
recently O 0 2.4097970285907877e-09
proposed O 0 3.7021094523304043e-11
putative O 0 4.170406520120906e-10
alternative O 0 9.234247047573696e-12
translation O 0 3.565688855289295e-10
initiation O 0 1.489936125864677e-11
codon O 0 1.8616931996007224e-08
( O 0 1.8729986311916136e-11
TIC O 0 7.468527201126562e-07
- O 0 1.0132941952178953e-07
1 O 0 1.2679998717679553e-10
) O 0 3.2668928326429203e-12
, O 0 1.944406224571593e-12
supporting O 0 1.7542816158067076e-11
that O 0 3.065396547707877e-10
TIC O 0 3.2953607842500787e-06
- O 0 8.46346779326268e-08
1 O 0 2.8747015878849425e-10
is O 0 8.01238173031571e-11
the O 0 4.566046759441056e-12
real O 0 3.639165357949281e-10
TIC O 0 4.876373793649691e-08
rather O 0 8.932312897148853e-13
than O 0 9.983987378156534e-13
TIC O 0 3.0136274631331617e-07
- O 0 5.1300347081451037e-08
2 O 0 2.989593017588277e-10
. O 0 4.253225896477808e-11
. O 0 3.573095708198082e-10

Human B-Disease 0 8.840669920573418e-07
complement I-Disease 0 6.413124538084958e-07
factor I-Disease 0 2.3303327907342464e-05
H I-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999327659606934
associated O 0 0.00039267298416234553
with O 0 0.009487644769251347
hemolytic B-Disease 1 0.9999972581863403
uremic I-Disease 1 0.9999995231628418
syndrome I-Disease 1 0.999998927116394
. O 0 2.5406425265828148e-06

This O 0 9.157694602635047e-10
study O 0 3.5612145177221777e-11
reports O 0 6.060869861546081e-11
on O 0 6.129790564024518e-10
six O 0 2.5709354090075465e-10
cases O 0 9.101901454755534e-10
of O 0 7.89810528090129e-09
deficiency B-Disease 1 0.8180891275405884
in I-Disease 0 6.871890834148076e-10
the I-Disease 0 1.7722079359572263e-10
human I-Disease 0 2.564778944780244e-10
complement I-Disease 0 2.030792617402355e-10
regulatory I-Disease 0 2.396905451895748e-10
protein I-Disease 0 2.337634086302387e-09
Factor I-Disease 0 3.7525765606005734e-08
H I-Disease 1 0.9999996423721313
( O 0 1.5627842075982556e-10
FH O 0 4.476479080040008e-05
) O 0 9.346787233077691e-12
in O 0 2.361786764423779e-12
the O 0 4.589297691870442e-12
context O 0 2.0190436822442592e-10
of O 0 6.721617706872962e-11
an O 0 6.1961090978002176e-06
acute B-Disease 1 0.9999154806137085
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 8.789037337919581e-07

Five O 0 1.4889148802765817e-09
of O 0 2.455184764261348e-13
the O 0 2.8353174842676854e-12
cases O 0 9.858701528753233e-12
were O 0 7.683476771491726e-11
observed O 0 5.4399951210371e-09
in O 0 3.504233014872682e-10
children O 0 5.52983492330128e-10
presenting O 0 3.825850303229572e-09
with O 0 1.5902522136457264e-05
idiopathic O 1 0.9999994039535522
hemolytic B-Disease 1 0.9999998807907104
uremic I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999998807907104
( O 0 4.8555370995018166e-06
HUS B-Disease 1 0.9999562501907349
) O 0 1.311619371335837e-06
. O 0 1.652883980796105e-07

Two O 0 2.7204425379068198e-09
of O 0 1.567526273713038e-12
the O 0 1.9972193343598121e-10
children O 0 2.0477912698879663e-09
exhibited O 0 9.435144932012918e-08
a O 0 1.3575103707808012e-08
homozygous O 0 0.002833429491147399
deficiency O 1 0.7538599371910095
characterized O 0 9.144716983655599e-08
by O 0 3.0173999410187946e-10
the O 0 3.0125593131202777e-09
absence O 0 1.5582756196508285e-09
of O 0 3.860021568873051e-13
the O 0 1.2126872422912882e-11
150 O 0 4.225690544007454e-12
- O 0 1.4238169532276856e-09
kD O 0 2.5796209612849452e-09
form O 0 4.921450053041454e-11
of O 0 7.337912829447069e-13
Factor O 0 6.931952611921588e-08
H O 1 1.0
and O 0 4.449822910146395e-08
the O 0 3.226704320402618e-11
presence O 0 9.724224203644383e-11
, O 0 7.224810485116639e-13
upon O 0 3.759894549567114e-14
immunoblotting O 0 4.065906278327702e-09
, O 0 1.498307988095915e-12
of O 0 1.6460135460042748e-14
the O 0 3.209626141253974e-12
42 O 0 7.424161979630028e-11
- O 0 1.6437650129930148e-09
kD O 0 2.856176806176336e-08
Factor O 0 1.021432005643419e-08
H O 1 0.999997615814209
- O 0 4.743203874113533e-08
like O 0 4.79874473491293e-10
protein O 0 2.573398161231921e-10
1 O 0 1.8176626870314294e-11
( O 0 1.344599778740907e-12
FHL O 0 1.7849785649559635e-08
- O 0 2.3670592597113682e-08
1 O 0 5.0845740812155427e-11
) O 0 3.291724314999356e-12
and O 0 3.984645252641528e-11
other O 0 9.252000207626843e-12
FH O 0 0.00019179488299414515
- O 0 8.805634621467107e-08
related O 0 1.515018110964661e-09
protein O 0 3.6541720760396856e-08
( O 0 3.022467345847879e-11
FHR O 0 4.3445385244922363e-07
) O 0 1.456602026495002e-11
bands O 0 6.813499209279428e-10
. O 0 2.1728221444305973e-09

Southern O 0 7.036067017907044e-07
blot O 0 0.00014802126679569483
and O 0 1.3855935843132272e-10
PCR O 0 5.257179580553384e-09
analysis O 0 1.0086720521329529e-11
of O 0 2.439652924395453e-14
DNA O 0 2.507453302769136e-07
of O 0 1.474100138829093e-12
one O 0 1.0972442510137626e-08
patient O 0 4.044900663302542e-07
with O 0 2.372192220434499e-09
homozygous O 0 0.00017129936895798892
deficiency O 0 0.2228689044713974
ruled O 0 3.823923179879785e-06
out O 0 8.434074771912492e-08
the O 0 6.526655604854881e-11
presence O 0 1.3048712110830252e-10
of O 0 1.2618600825700654e-13
a O 0 9.086662845769755e-12
large O 0 2.3251896935638783e-11
deletion O 0 5.981178929914677e-08
of O 0 1.5951352651949469e-12
the O 0 1.9273788121054736e-10
FH O 0 9.190278797177598e-05
gene O 0 1.1303634472881186e-08
as O 0 5.995275803583056e-11
the O 0 2.3359203460415756e-11
underlying O 0 2.429282197624616e-08
defect O 0 6.925437219251762e-07
for O 0 2.063834346477389e-11
the O 0 1.0397463512390459e-07
deficiency O 0 0.025916216894984245
. O 0 5.040951656098969e-09

The O 0 1.0652674298228249e-09
other O 0 8.603145106034216e-12
four O 0 5.3800484900445866e-11
children O 0 2.1531739932689753e-11
presented O 0 4.716457085995884e-11
with O 0 1.2746111721639863e-08
heterozygous O 0 0.025240810588002205
deficiency O 1 0.8190590739250183
and O 0 7.3424075708317105e-09
exhibited O 0 1.6046907092004403e-07
a O 0 1.9071428880579333e-09
normal O 0 1.0976967956821682e-07
immunoblotting O 0 1.6871516663741204e-06
pattern O 0 4.230513752645493e-07
of O 0 9.10497914043129e-13
proteins O 0 1.6424990256780347e-09
of O 0 6.91276810099728e-12
the O 0 2.126538234392683e-08
FH O 1 0.9450182914733887
family O 0 2.688319682420115e-07
. O 0 4.212242110668285e-09

Factor B-Disease 0 0.022869788110256195
H I-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999011754989624
is O 0 1.2684655104067133e-08
the O 0 3.629448741548913e-09
only O 0 1.2473696187953465e-05
complement B-Disease 1 0.9999997615814209
deficiency I-Disease 1 0.9999998807907104
associated O 0 2.736225326316344e-07
with O 0 8.541537965811585e-08
HUS B-Disease 1 0.9999617338180542
. O 0 2.232840415672399e-06

These O 0 2.1254826787497905e-09
observations O 0 1.2023612105949155e-09
suggest O 0 2.9418964486715993e-10
a O 0 2.0524491394641187e-12
role O 0 1.864127775752511e-11
for O 0 3.7238706042386216e-12
FH O 0 0.0004860269546043128
and O 0 5.24996535133937e-09
/ O 0 5.149689968675375e-06
or O 0 6.198513702315722e-09
FH O 0 0.003106857417151332
receptors O 0 3.934630399271555e-09
in O 0 3.030398501580045e-11
the O 0 1.185613135445962e-10
pathogenesis O 0 2.38850520872802e-06
of O 0 1.4507274548325455e-10
idiopathic O 1 0.9996572732925415
HUS B-Disease 1 0.9999910593032837
. O 0 8.149192467499233e-07
. O 0 4.35807443466274e-08

Further O 0 6.890532144865347e-09
evidence O 0 1.910808455907187e-10
for O 0 5.390551286593714e-13
a O 0 8.138181101235986e-12
major O 0 1.242028563330777e-10
ancient O 0 3.789828895151004e-08
mutation O 0 0.0006972269038669765
underlying O 0 0.0040236893109977245
myotonic B-Disease 1 0.9999992847442627
dystrophy I-Disease 1 0.9999991655349731
from O 0 1.0828006269392176e-09
linkage O 0 0.00011325759260216728
disequilibrium O 0 6.866995681775734e-05
studies O 0 7.604462837207393e-09
in O 0 1.4559825567417306e-11
the O 0 6.698223226075939e-11
Japanese O 0 4.65759200096727e-07
population O 0 6.524916162931049e-10
. O 0 2.0391539568009875e-09

The O 0 3.228509012842551e-05
myotonic B-Disease 1 0.9999932050704956
dystrophy I-Disease 1 0.9999994039535522
( O 0 2.5307278974651126e-06
DM B-Disease 1 0.9999996423721313
) O 0 7.937161683457816e-08
mutation O 0 6.840917194494978e-06
is O 0 6.750790149112618e-09
an O 0 2.545950672505626e-10
unstable O 0 0.00024264704552479088
( O 0 4.335963532664522e-11
CTG O 0 2.95823525675587e-07
) O 0 2.760509529298183e-11
n O 0 1.1772719972213963e-06
repeat O 0 4.318832725402899e-05
, O 0 2.3185975361883493e-09
present O 0 9.952606794261243e-11
at O 0 4.351433935401161e-10
a O 0 2.3507805944900095e-12
copy O 0 1.293950191438853e-08
number O 0 2.474778541816658e-11
of O 0 9.044001983947447e-13
5 O 0 3.1181164317217736e-09
- O 0 2.2149658889247803e-06
37 O 0 7.612880104090891e-09
repeats O 0 3.513607396143925e-07
on O 0 7.734871632081308e-10
normal O 0 5.564063876306591e-09
chromosomes O 0 4.9566404314305146e-09
but O 0 1.7045488284739285e-11
amplified O 0 2.902347806532646e-10
to O 0 7.619696540395182e-12
50 O 0 4.403722178580871e-12
- O 0 6.685730302713466e-10
3000 O 0 1.3701563494894486e-10
copies O 0 5.972589645075743e-10
on O 0 2.385111201874679e-06
DM B-Disease 1 0.9999986886978149
chromosomes O 0 3.428607669775374e-05
. O 0 2.1656241244727426e-08

Previous O 0 1.2142842820139776e-07
findings O 0 1.90457019044743e-08
in O 0 2.3936619353293054e-10
Caucasian O 0 0.000185851298738271
populations O 0 1.8757835107408027e-07
of O 0 4.818754770208322e-11
a O 0 2.2456879378296435e-06
DM B-Disease 1 1.0
founder O 0 0.0021106719505041838
chromosome O 0 0.0030560684390366077
raise O 0 2.5265054492962236e-09
a O 0 8.440580179236434e-11
question O 0 6.576916788958442e-11
about O 0 1.1897121742626693e-12
the O 0 2.5634509705912967e-12
molecular O 0 1.9219723590424564e-09
events O 0 9.021751401494527e-11
involved O 0 5.5543777910394e-11
in O 0 2.4928854119865562e-11
the O 0 1.3183194119692487e-11
expansion O 0 2.2594820237031854e-08
mutation O 0 5.49841445263155e-07
. O 0 4.183832835735757e-09

To O 0 4.389229868451139e-09
investigate O 0 1.065342591921592e-09
whether O 0 6.266587249115219e-11
a O 0 4.844623660571479e-11
founder O 0 8.221381797568483e-09
chromosome O 0 7.915202331787441e-06
for O 0 3.44135310526017e-11
the O 0 1.3559525058326471e-08
DM B-Disease 1 0.9999998807907104
mutation O 0 8.369397255592048e-05
exists O 0 1.620876588503961e-08
in O 0 1.9475880977393167e-11
the O 0 7.978617766468687e-11
Japanese O 0 4.035299241422763e-07
population O 0 7.015875380655956e-11
, O 0 3.311853569165635e-11
we O 0 8.636627524261087e-10
genotyped O 0 4.524794761096018e-09
families O 0 6.112093795494766e-13
using O 0 1.9441319214219543e-12
polymorphic O 0 2.5585016327767107e-09
markers O 0 9.133173080044799e-06
near O 0 2.1860605556867085e-06
the O 0 8.874385115653638e-10
( O 0 1.4704336706583554e-11
CTG O 0 9.936043454672472e-08
) O 0 3.1571800729324195e-11
n O 0 1.246430656465236e-06
repeat O 0 4.874320438830182e-05
region O 0 9.796691529118107e-07
and O 0 3.825086380970788e-08
constructed O 0 2.316060636076145e-05
haplotypes O 0 2.1818284949404188e-05
. O 0 1.5053608137804986e-08

Six O 0 3.0280502549828725e-09
different O 0 2.945050106561986e-11
haplotypes O 0 3.9709640020646475e-08
were O 0 8.839685650130491e-10
found O 0 5.9827969245418444e-09
and O 0 3.490461608635087e-08
DM B-Disease 1 0.9999996423721313
alleles O 0 3.033665336715785e-07
were O 0 9.184988769561642e-09
always O 0 6.792145512690695e-09
haplotype O 0 3.6124612279309076e-07
A O 0 4.336450132313985e-08
. O 0 1.0639380043642177e-08

To O 0 2.673357712978941e-08
find O 0 4.5406048365670415e-10
an O 0 1.865790779254778e-13
origin O 0 1.9781327183915343e-12
of O 0 4.545988151888336e-13
the O 0 1.630294371723906e-10
( O 0 1.2724862830104655e-11
CTG O 0 2.225564088575993e-08
) O 0 8.463661195501349e-12
n O 0 6.352485115712625e-08
repeat O 0 1.5151047136896523e-06
mutation O 0 7.310388809855795e-07
and O 0 1.081956835236042e-08
to O 0 4.8898805143915425e-11
investigate O 0 3.421301852934988e-10
the O 0 9.48615838658462e-12
mechanism O 0 1.6289236626221282e-10
of O 0 2.6284918049090424e-14
the O 0 7.265774353698573e-12
expansion O 0 6.532213103760398e-10
mutation O 0 4.046256218970257e-09
in O 0 2.0489885829699794e-11
the O 0 4.402926287450093e-11
Japanese O 0 3.7664096907974454e-07
population O 0 1.4081270004184798e-11
we O 0 1.3048910563195903e-10
have O 0 1.1544708331673315e-12
studied O 0 5.891148679992853e-11
90 O 0 3.595195322003697e-11
Japanese O 0 3.025783144039451e-07
DM B-Disease 1 0.9999984502792358
families O 0 5.774958844462219e-10
comprising O 0 5.342344188558057e-12
190 O 0 1.5203668879415488e-10
affected O 0 1.2232631574349284e-09
and O 0 2.45018283440146e-10
130 O 0 1.3979079005466133e-10
unaffected O 0 1.1071589511857383e-07
members O 0 1.172705248880801e-11
. O 0 6.527107188070147e-10

The O 0 1.6675636871354982e-08
results O 0 3.149178473549341e-09
suggest O 0 1.4726411201593237e-09
that O 0 6.631129673140279e-11
a O 0 2.421314260203644e-10
few O 0 5.418556159320076e-10
common O 0 4.829375788162338e-10
ancestral O 0 1.3263565961096901e-06
mutations O 0 3.977760115958517e-06
in O 0 2.2333436489052616e-10
both O 0 1.8713686156246467e-09
Caucasian O 0 0.003273214213550091
and O 0 2.0551725299355894e-07
Japanese O 0 7.1302019932772964e-06
populations O 0 3.201366638450054e-08
have O 0 6.35996810771644e-11
originated O 0 1.909004204714293e-11
by O 0 9.390557586088158e-14
expansion O 0 4.228552837742816e-12
of O 0 8.056134427093797e-14
an O 0 3.3627356541693354e-12
ancestral O 0 1.7750792835613538e-07
n O 0 5.652405889122747e-06
= O 0 5.632650186271349e-07
5 O 0 7.117204048334713e-11
repeat O 0 4.695263911003167e-08
to O 0 3.323796515797284e-10
n O 0 2.450303099976736e-06
= O 0 1.064171920006629e-05
19 O 0 2.4439483770066772e-09
- O 0 5.520482559973061e-08
37 O 0 8.411318308532145e-10
copies O 0 2.0007395740151424e-09
. O 0 2.9176012716902733e-09

These O 0 3.5749228577408587e-10
data O 0 1.1840989300182514e-10
support O 0 2.1643643908358934e-12
multistep O 0 9.792070487790738e-10
models O 0 1.1708491953754674e-09
of O 0 9.256130584223143e-12
triplet O 0 0.01217920333147049
repeat O 0 6.2362546486838255e-06
expansion O 0 3.934518044701463e-09
that O 0 6.916706096760095e-10
have O 0 8.586984595604363e-11
been O 0 6.452755430680357e-12
proposed O 0 5.390739070409989e-12
for O 0 5.141799312713413e-12
both O 0 7.360189613336843e-08
DM B-Disease 1 1.0
and O 0 2.4472616132698022e-05
Friedreichs B-Disease 0 0.06971602886915207
ataxia I-Disease 1 0.9969382286071777
. O 0 9.242085319272064e-09
. O 0 5.674682057588143e-09

The O 0 3.890220368063524e-10
molecular O 0 5.872542896412369e-09
basis O 0 2.2084289952317704e-09
of O 0 2.077356811014397e-07
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 2.222398487461419e-09
the O 0 1.2659191750419296e-10
western O 0 3.641835917278513e-07
Cape O 0 3.2449381137666933e-07
, O 0 1.715937530955003e-10
South O 0 1.8287870773292525e-07
Africa O 0 4.826339328189988e-09
. O 0 1.0978774833692029e-10

Deficiency B-Disease 1 0.9996751546859741
of I-Disease 0 1.293512102984451e-10
the I-Disease 0 4.798433317354522e-10
sixth I-Disease 0 2.1033878283560625e-07
component I-Disease 0 8.405821816381831e-09
of I-Disease 0 1.090380737089891e-11
human I-Disease 0 1.5813855114288344e-08
complement I-Disease 0 2.170785151633936e-08
( O 0 9.88929146905626e-11
C6 O 0 3.141275010420941e-05
) O 0 5.915032352810101e-10
has O 0 4.979118628511969e-08
been O 0 1.182579012493079e-08
reported O 0 3.089453315396895e-08
in O 0 1.1155701362675075e-11
a O 0 1.5537272857191198e-11
number O 0 2.588045749929435e-11
of O 0 5.680778113539842e-13
families O 0 2.0204910661236752e-11
from O 0 2.1857491402758888e-13
the O 0 4.430310718978037e-12
western O 0 1.6518054479774946e-08
Cape O 0 8.399587692053956e-09
, O 0 1.2011502903419569e-10
South O 0 1.8353915720581426e-07
Africa O 0 2.773532514765975e-09
. O 0 9.626767438764006e-11

Meningococcal B-Disease 1 0.9995272159576416
disease I-Disease 1 0.999929666519165
is O 0 2.1684348538997256e-08
endemic O 0 2.584409912742558e-07
in O 0 4.26128299313433e-10
the O 0 2.0335766404144806e-09
Cape O 0 3.858644106458087e-07
and O 0 1.6373777333988926e-10
almost O 0 3.520806216017469e-11
all O 0 6.474984610982393e-12
pedigrees O 0 5.046024043053876e-08
of O 0 9.58971096975958e-11
total O 0 0.0003567081585060805
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 3.40441808077685e-09
C6Q0 O 0 0.0002891909098252654
) O 0 2.720965119884511e-10
have O 0 2.0628605490458085e-09
been O 0 3.6321774476988367e-09
ascertained O 0 3.3373950714121747e-07
because O 0 2.4113373520151526e-09
of O 0 2.0998175420672283e-10
recurrent O 1 0.9999088048934937
disease O 1 0.9998780488967896
. O 0 4.243646145596358e-08

We O 0 1.5161251667450415e-06
have O 0 1.5228684979717855e-10
sequenced O 0 2.5719077978436644e-09
the O 0 5.450393608663617e-12
expressed O 0 7.870569972666386e-13
exons O 0 7.823857117728039e-09
of O 0 3.910988720379205e-12
the O 0 1.9795916295084481e-10
C6 O 0 1.1800485708590713e-06
gene O 0 9.680874768491776e-09
from O 0 1.702682916535081e-12
selected O 0 5.0109513760610014e-11
cases O 0 7.723180983632005e-10
and O 0 2.5470898279422727e-08
have O 0 4.7633307076466735e-08
found O 0 6.957090459280835e-09
three O 0 4.658435859283827e-10
molecular O 0 1.262906334886793e-05
defects O 1 0.9277063012123108
leading O 0 3.5554651844904583e-07
to O 0 2.845541047236111e-08
total O 0 2.2881411609887436e-07
deficiency O 0 0.15494222939014435
879delG O 0 6.124226274550892e-06
, O 0 6.657598028425582e-09
which O 0 1.0019279628181721e-08
is O 0 3.357804034820333e-10
the O 0 1.5731287106302005e-10
common O 0 1.976394337077636e-08
defect O 0 5.754585345130181e-06
in O 0 2.6060381630443885e-10
the O 0 1.1764433871519486e-09
Cape O 0 3.6995464824940427e-07
and O 0 6.611091674102454e-10
hitherto O 0 7.724838013700719e-08
unreported O 0 2.329906712006391e-09
, O 0 1.7058768286837278e-10
and O 0 6.184905365635984e-10
1195delC O 0 2.684948015030386e-07
and O 0 2.354252570668791e-09
1936delG O 0 5.672612246598874e-07
, O 0 2.9125571399113426e-10
which O 0 7.21809945147811e-10
have O 0 3.8152386805379024e-10
been O 0 3.7583106071714667e-10
previously O 0 1.2592353826335057e-08
reported O 0 2.2115534292765915e-08
in O 0 3.2102906444286816e-10
African O 0 1.1437570890393545e-09
- O 0 1.5723645674370346e-06
Americans O 0 2.1153121920747253e-08
. O 0 9.316005744608447e-10

We O 0 5.065637196821626e-06
also O 0 3.2430932939142565e-10
show O 0 1.6477666453518225e-10
that O 0 7.471420183924327e-12
the O 0 8.90798806246762e-12
879delG O 0 2.529526227590395e-06
and O 0 7.708956673013745e-08
1195delC O 0 4.9109185056295246e-05
defects O 0 0.1556328684091568
are O 0 1.2466750722028852e-11
associated O 0 2.6203541558800225e-09
with O 0 4.822299892737192e-09
characteristic O 0 0.0011279715690761805
C6 O 1 0.9572111368179321
/ O 1 0.6845588684082031
C7 O 0 0.008741271682083607
region O 0 1.98472548618156e-06
DNA O 0 0.0012704990804195404
marker O 0 3.0259958293754607e-05
haplotypes O 0 9.332709851150867e-06
, O 0 6.690246134866129e-10
although O 0 6.487337056437781e-11
small O 0 3.193482284169491e-11
variations O 0 1.8614233709968175e-08
were O 0 3.0699149888846478e-09
observed O 0 1.8546620594861452e-07
. O 0 6.902765470329086e-09

The O 0 1.3159096923232028e-08
1936delG O 0 1.3085134469292825e-06
defect O 0 7.214730885607423e-06
was O 0 1.819169814787358e-09
observed O 0 1.3452611247188884e-09
only O 0 3.747422927524724e-10
once O 0 3.04589882205164e-08
in O 0 3.4991089886693416e-11
the O 0 1.8094586939909618e-10
Cape O 0 6.151370257612143e-08
, O 0 5.488955123755801e-11
but O 0 2.8290524436980213e-11
its O 0 9.745251480786088e-13
associated O 0 4.939320619179455e-10
haplotype O 0 2.3235188564285636e-06
could O 0 2.0942107425980794e-07
be O 0 2.9144409108283753e-10
deduced O 0 6.94969273240531e-08
. O 0 3.1269669076294804e-09

The O 0 1.203623201107007e-09
data O 0 1.2084906408915685e-09
from O 0 1.848304712406823e-12
the O 0 4.889131634266963e-12
haplotypes O 0 3.8484535025418154e-07
indicate O 0 2.809510313284136e-08
that O 0 3.2640687375184996e-10
these O 0 5.0961863201637314e-11
three O 0 4.237422357444842e-10
molecular O 0 1.6283218428725377e-05
defects O 1 0.8835632801055908
account O 0 5.327079222183784e-09
for O 0 1.5382569662492074e-09
the O 0 6.581606157851638e-07
defects O 1 0.9956333041191101
in O 0 2.7242694766727027e-09
all O 0 4.048431034853195e-10
the O 0 4.5323503283789535e-10
38 O 0 9.7544949895223e-09
unrelated O 0 7.998876228043628e-09
C6Q0 O 0 6.286629650276154e-05
individuals O 0 1.3082354644033956e-10
we O 0 2.8577393784701144e-09
have O 0 1.8799099429922528e-11
studied O 0 2.75164807606032e-10
from O 0 8.47383307186339e-13
the O 0 6.200091828834076e-11
Cape O 0 6.557172582688509e-08
. O 0 6.29277352448554e-10

We O 0 7.800668754498474e-06
have O 0 5.603734143377892e-10
also O 0 3.033891887715967e-11
observed O 0 6.692731091550996e-11
the O 0 9.09590545244976e-12
879delG O 0 5.740174060520076e-07
defect O 0 1.7715764215608942e-06
in O 0 2.7889890397148065e-10
two O 0 4.981560408623409e-08
Dutch O 1 0.9992115497589111
C6 B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999973773956299
deficient I-Disease 1 0.9999998807907104
kindreds O 0 0.1466110199689865
, O 0 4.278738696683604e-09
but O 0 2.1549172168899844e-10
the O 0 5.863792090776698e-12
879delG O 0 1.7155375076072232e-07
defect O 0 2.649151440436981e-07
in O 0 7.1467463023944244e-12
the O 0 6.0705301896391e-11
Cape O 0 3.6448167151093e-08
probably O 0 3.830026962248212e-09
did O 0 6.151895437511712e-09
not O 0 2.2047060357910375e-11
come O 0 1.8573872908461686e-12
from O 0 6.952005296304367e-14
The O 0 5.6780975754566754e-11
Netherlands O 0 1.6516029290869483e-06
. O 0 7.041588839795665e-11
. O 0 6.11506456582589e-10

Complement B-Disease 1 0.9986298084259033
C7 I-Disease 1 0.999998927116394
deficiency I-Disease 1 1.0
: O 0 1.3842431201283034e-07
seven O 0 5.167150041174295e-10
further O 0 1.0612984935320924e-09
molecular O 0 0.0007187430746853352
defects O 1 0.999945878982544
and O 0 1.1853163783825948e-07
their O 0 4.007728815480505e-09
associated O 0 2.0932023403474886e-07
marker O 0 0.0009127011289820075
haplotypes O 0 0.0007552112801931798
. O 0 7.124630485577654e-08

Seven O 0 4.317630253325433e-09
further O 0 5.1112357402072206e-11
molecular O 0 2.3993871778316134e-08
bases O 0 1.4651924175268505e-05
of O 0 3.5174227832612814e-06
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 1.238238134249059e-08
described O 0 1.4106016124060261e-06
. O 0 1.3277921873111609e-08

All O 0 1.6432258886922568e-09
these O 0 1.1927800760980212e-11
new O 0 5.1920037713593103e-11
molecular O 0 7.199818128356128e-07
defects O 0 0.01680171489715576
involve O 0 4.1133296768691707e-10
single O 0 8.47648919943822e-08
- O 0 1.5501295820286032e-06
nucleotide O 0 4.907566335532465e-07
events O 0 1.2473327926088018e-09
, O 0 1.4546531514059158e-11
deletions O 0 3.124303304957721e-08
and O 0 8.348300717386792e-09
substitutions O 0 2.580024416332094e-09
, O 0 2.5789296045908294e-11
some O 0 5.049217337640965e-13
of O 0 2.9400537993745646e-12
which O 0 1.6774400535268796e-08
alter O 0 2.9761120003968244e-06
splice O 0 2.79073301499011e-05
sites O 0 1.199016764985572e-06
, O 0 1.3532389653292398e-09
and O 0 6.145090547526877e-10
others O 0 1.8510902533019902e-10
codons O 0 6.395546137127894e-08
. O 0 1.9728567668408914e-09

They O 0 8.121125461002521e-08
are O 0 1.869011672858689e-12
distributed O 0 2.5693358898792873e-11
along O 0 3.696250194806794e-09
the O 0 2.249109093410695e-10
C7 O 0 1.9255071492807474e-06
gene O 0 1.6284955108858412e-06
, O 0 1.1833951596429415e-09
but O 0 4.096619224402964e-11
predominantly O 0 2.6832472875548685e-12
towards O 0 1.3299699015700828e-11
the O 0 1.5163117289551664e-11
3 O 0 1.892391354729739e-09
end O 0 6.588791023887097e-08
. O 0 4.0944514445584446e-09

All O 0 2.938791210382874e-09
were O 0 1.2384755720962204e-10
found O 0 5.741764702582586e-11
in O 0 2.6109062828405527e-12
compound O 0 1.5291746535694983e-08
heterozygous O 0 2.535307075390847e-08
individuals O 0 4.343529008687952e-11
. O 0 1.2738085031216428e-09

The O 0 3.81877043764689e-07
C6 O 0 0.001959857763722539
/ O 0 0.014920808374881744
C7 O 0 0.0015149113023653626
marker O 0 0.0007593481568619609
haplotypes O 0 0.0003731373290065676
associated O 0 2.1371074581111316e-06
with O 0 3.7601999736125435e-08
most O 0 2.03914026997154e-07
C7 B-Disease 1 0.9994390606880188
defects I-Disease 1 0.9999456405639648
are O 0 7.867162921115778e-09
tabulated O 0 4.0749564504949376e-05
. O 0 1.9327175415639886e-09
. O 0 3.058383990506286e-09

A O 0 1.3637392726195685e-07
genome O 0 5.224206347520521e-07
- O 0 4.5146689444663934e-06
wide O 0 1.0661074689721772e-08
search O 0 2.081190109137765e-09
for O 0 2.3748473673701476e-11
chromosomal O 0 0.008448380045592785
loci O 0 1.8929057432615082e-07
linked O 0 0.0006411434733308852
to O 0 6.565632588717563e-07
mental O 0 0.12155493348836899
health O 0 2.4025615630307584e-07
wellness O 0 8.236089570345939e-07
in O 0 3.702196327282081e-10
relatives O 0 8.876149593106675e-09
at O 0 7.395042800339979e-09
high O 0 3.479168952935652e-08
risk O 0 2.027180556751773e-07
for O 0 2.76762435191813e-09
bipolar B-Disease 1 0.9999920129776001
affective I-Disease 1 0.9940154552459717
disorder I-Disease 1 0.936165452003479
among O 0 1.8073709195931542e-11
the O 0 6.570245736359226e-11
Old O 0 1.36149119498441e-05
Order O 0 4.1615724200028126e-09
Amish O 0 0.00017602865409571677
. O 0 8.776154025724736e-09

Bipolar B-Disease 1 0.9999241828918457
affective I-Disease 1 0.9995235204696655
disorder I-Disease 1 0.9998458623886108
( O 0 5.560078989219619e-06
BPAD B-Disease 1 0.9999986886978149
; O 0 0.001499437727034092
manic B-Disease 1 0.999993085861206
- I-Disease 1 0.999998927116394
depressive I-Disease 1 0.9999998807907104
illness I-Disease 1 0.9999845027923584
) O 0 8.501658821380431e-10
is O 0 4.677986470413842e-11
characterized O 0 4.68289229615948e-09
by O 0 9.648563198405569e-12
episodes O 0 1.3973713919313013e-07
of O 0 2.68668115532833e-10
mania B-Disease 0 0.22238712012767792
and O 0 3.050655266179092e-07
/ O 0 0.0026039057411253452
or O 0 1.8354107567120082e-07
hypomania B-Disease 0 0.03583228215575218
interspersed O 0 0.00011950599582633004
with O 0 5.381634249346234e-09
periods O 0 1.0190738919391151e-07
of O 0 3.5578218149368013e-10
depression B-Disease 0 0.00010209908214164898
. O 0 3.024044570310025e-09

Compelling O 0 3.420959515665345e-08
evidence O 0 2.5271127412906935e-09
supports O 0 5.426168958599931e-10
a O 0 6.2033533691774334e-12
significant O 0 3.600168557368888e-12
genetic O 0 7.513764188615824e-08
component O 0 6.840848776334951e-09
in O 0 2.9757743491565236e-10
the O 0 6.082331305279354e-10
susceptibility O 0 2.154210233129561e-05
to O 0 4.562164690469217e-08
develop O 0 8.668619557283819e-06
BPAD B-Disease 1 0.9999932050704956
. O 0 2.8916153382851917e-07

To O 0 1.789819670250381e-08
date O 0 2.753871797267493e-08
, O 0 1.6673266933775466e-10
however O 0 2.5845742213093104e-10
, O 0 7.3236833264545e-12
linkage O 0 1.8950745470647234e-06
studies O 0 4.069607317802593e-09
have O 0 5.503403288642517e-10
attempted O 0 3.705598601300153e-07
only O 0 5.906430344815305e-10
to O 0 1.9056510536241689e-10
identify O 0 2.9966521708502114e-08
chromosomal O 0 0.0021545453928411007
loci O 0 8.562367526110393e-08
that O 0 2.0376356246742944e-07
cause O 0 3.4769672652146255e-07
or O 0 1.4477326892858855e-08
increase O 0 2.2425434842432423e-09
the O 0 1.5093972294266678e-08
risk O 0 8.225730141475651e-08
of O 0 1.1926299357811754e-11
developing O 0 2.836810836015502e-06
BPAD B-Disease 1 0.9999982118606567
. O 0 1.2397060800140025e-07

To O 0 2.035171364767052e-09
determine O 0 1.152392972714189e-10
whether O 0 2.8834094834007118e-11
there O 0 1.3322887237876557e-10
could O 0 6.4406662225735545e-09
be O 0 6.903390359358497e-11
protective O 0 8.893231928652767e-09
alleles O 0 5.803436065043854e-10
that O 0 6.3040812570136495e-09
prevent O 0 2.2242447528242337e-07
or O 0 9.486121399504555e-08
reduce O 0 2.1419925815280294e-06
the O 0 6.791655948745756e-08
risk O 0 1.258354842548215e-07
of O 0 1.0335063534150368e-11
developing O 0 1.9978670025011525e-06
BPAD B-Disease 1 0.9999998807907104
, O 0 1.013764960866581e-09
similar O 0 2.7607886463054676e-11
to O 0 1.2731909970753463e-10
what O 0 8.183419220042509e-11
is O 0 4.428614766571748e-11
observed O 0 1.7909628224899166e-09
in O 0 5.272400294131785e-10
other O 0 2.593689032437396e-07
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 1.5051568880153354e-08
we O 0 3.3833498491731007e-07
used O 0 8.88314752955921e-06
mental O 0 0.353596031665802
health O 0 1.1868042975038406e-06
wellness O 0 3.977350388595369e-06
( O 0 1.1632757951351991e-10
absence O 0 7.85798148772443e-10
of O 0 1.4141183016236347e-11
any O 0 8.44809619593434e-07
psychiatric B-Disease 1 0.9959828853607178
disorder I-Disease 0 0.005901013035327196
) O 0 1.3707097956672243e-11
as O 0 3.2170882624527053e-10
the O 0 3.3653970721303494e-09
phenotype O 0 3.61853490176145e-05
in O 0 3.21009174797382e-08
our O 0 1.599196330914765e-08
genome O 0 2.2788096032400063e-07
- O 0 3.6416454349819105e-06
wide O 0 6.42845705556283e-08
linkage O 0 4.25484286097344e-05
scan O 0 4.1036895709112287e-05
of O 0 2.9658155271949926e-12
several O 0 3.4729514403197825e-11
large O 0 5.10720354895966e-10
multigeneration O 0 7.384977379842894e-06
Old O 0 8.152245754899923e-06
Order O 0 3.63569646610884e-10
Amish O 0 7.890976689850504e-07
pedigrees O 0 3.673066828469018e-08
exhibiting O 0 5.251825085927919e-10
an O 0 4.906676627502993e-12
extremely O 0 6.270871044655735e-10
high O 0 5.822342163952499e-09
incidence O 0 0.0007677711546421051
of O 0 7.335607676850486e-08
BPAD B-Disease 1 0.9999995231628418
. O 0 2.4210037281591212e-06

We O 0 1.1621874364209361e-05
have O 0 8.800521977825326e-10
found O 0 2.1592031981820803e-11
strong O 0 6.780753801331751e-13
evidence O 0 6.394314331498174e-12
for O 0 1.9603432375656094e-13
a O 0 3.852097113510311e-11
locus O 0 3.999262787601765e-08
on O 0 1.5985199297574582e-07
chromosome O 0 0.00020849228894803673
4p O 0 3.642729643615894e-05
at O 0 3.819259575266187e-09
D4S2949 O 0 5.804811742393667e-09
( O 0 1.686637808584468e-12
maximum O 0 2.5626504390752203e-11
GENEHUNTER O 0 9.897491963783978e-07
- O 0 7.872676377473908e-08
PLUS O 0 2.506197471774385e-10
nonparametric O 0 1.4085939525898539e-08
linkage O 0 1.923855052154977e-06
score O 0 3.927637237666204e-07
= O 0 3.1016636370395645e-08
4 O 0 7.219665837387979e-11
. O 0 2.4758880709518927e-11
05 O 0 4.5623735900335305e-08
, O 0 4.906004769100747e-11
P O 0 1.845114275056403e-05
= O 0 9.87439605637519e-08
5 O 0 2.5187275876081827e-11
. O 0 2.1658096323318166e-12
22 O 0 6.4314001173293445e-12
x O 0 3.692615990757986e-08
10 O 0 1.1116412651501761e-10
( O 0 1.2218535211383497e-11
- O 0 5.553071673602972e-07
4 O 0 8.084628522198045e-10
) O 0 5.606144021230719e-12
; O 0 1.1666882737682016e-11
SIBPAL O 0 8.61994848833092e-08
Pempirical O 0 8.529697836934247e-09
value O 0 3.4201370034681045e-12
< O 0 1.3167669732361276e-10
3 O 0 5.1436459258535905e-11
x O 0 7.941035846670275e-07
10 O 0 3.222271338643168e-10
( O 0 1.828117691948794e-11
- O 0 1.4028488521944382e-06
5 O 0 8.637122128618557e-10
) O 0 4.982291055416477e-12
) O 0 2.8062860195354755e-12
and O 0 1.5970000322163003e-10
suggestive O 0 8.221981318001781e-08
evidence O 0 2.2379233188818404e-10
for O 0 7.067038469178721e-13
a O 0 3.4903500228944395e-11
locus O 0 1.10461506608317e-07
on O 0 2.97292473305788e-07
chromosome O 0 0.00879728514701128
4q O 0 0.0006783436983823776
at O 0 1.2581454100768497e-08
D4S397 O 0 3.3958769130038036e-09
( O 0 1.1647289036020858e-12
maximum O 0 1.1250318385225277e-11
GENEHUNTER O 0 1.0102862688654568e-06
- O 0 2.423664398065739e-07
PLUS O 0 5.626911159239967e-10
nonparametric O 0 1.7599013801827823e-08
linkage O 0 3.30415923599503e-06
score O 0 2.6822198151421617e-07
= O 0 1.1893741991286788e-08
3 O 0 1.535543914243931e-11
. O 0 3.4160688600765043e-12
29 O 0 3.9192063483461936e-10
, O 0 3.391458988644125e-11
P O 0 1.4835412002867088e-05
= O 0 3.7028152632956335e-07
2 O 0 1.7210179115156876e-10
. O 0 6.4810635157230845e-12
57 O 0 5.292995486350094e-10
x O 0 2.968788237467379e-07
10 O 0 4.498280359310769e-10
( O 0 2.8871186691370454e-11
- O 0 5.852206186318654e-07
3 O 0 1.6027438265453497e-09
) O 0 6.608954269265999e-12
; O 0 6.195974722872366e-12
SIBPAL O 0 1.4041544815768248e-08
Pempirical O 0 2.791300302007471e-09
value O 0 3.5864200064600338e-12
< O 0 1.8286591685345854e-10
1 O 0 5.1314757998355276e-11
x O 0 1.289035481022438e-06
10 O 0 1.6356367371628266e-09
( O 0 4.9186630463049497e-11
- O 0 9.883561688184272e-06
3 O 0 5.5000062282317685e-09
) O 0 1.6823655316078323e-11
) O 0 1.8635368855685064e-12
that O 0 1.5151380150513205e-11
are O 0 8.762776095017077e-12
linked O 0 5.374915417633019e-06
to O 0 2.2833236812402902e-07
mental O 0 0.0015353712951764464
health O 0 2.7740424002331565e-07
wellness O 0 7.90924059401732e-06
. O 0 2.214181726856168e-09

These O 0 1.943216254574054e-08
findings O 0 1.6106627143130936e-09
are O 0 6.194462044001314e-12
consistent O 0 7.371985244475354e-10
with O 0 7.327427727077396e-12
the O 0 2.3195110762652682e-11
hypothesis O 0 1.4196172237745941e-08
that O 0 7.440064189734308e-12
certain O 0 5.909827748701302e-12
alleles O 0 3.0851224352979045e-10
could O 0 9.051547777971791e-08
prevent O 0 1.8554469960463393e-08
or O 0 4.155615407341884e-09
modify O 0 1.5576839359709993e-05
the O 0 4.182269197627875e-09
clinical O 0 7.234203849293408e-07
manifestations O 0 3.903960532625206e-08
of O 0 6.73778144388848e-10
BPAD B-Disease 1 1.0
and O 0 5.222791514825076e-07
perhaps O 0 4.5898188028026254e-10
other O 0 5.0039885429731257e-11
related O 0 2.978634654482448e-07
affective B-Disease 1 0.9881375432014465
disorders I-Disease 1 0.9985125660896301
. O 0 2.3246565561407806e-08

Segregation O 0 0.00019584698020480573
distortion O 0 0.0011046527652069926
in O 0 2.0680754460045137e-06
myotonic B-Disease 1 0.9999866485595703
dystrophy I-Disease 1 0.9999940395355225
. O 0 1.5121167962206528e-06

Myotonic B-Disease 1 0.9999822378158569
dystrophy I-Disease 1 0.9999982118606567
( O 0 2.292245699209161e-05
DM B-Disease 1 0.9999996423721313
) O 0 4.161734068475198e-07
is O 0 2.0429274272260045e-08
an O 0 1.944039240697748e-08
autosomal B-Disease 1 0.9999908208847046
dominant I-Disease 1 0.9999982118606567
disease I-Disease 1 0.9999995231628418
which O 0 1.70119199083274e-06
, O 0 2.7999063068051555e-09
in O 0 2.0765024422164657e-10
the O 0 1.406506439094457e-10
typical O 0 5.0632426251695506e-08
pedigree O 0 1.124471282309969e-06
, O 0 7.699610046763006e-12
shows O 0 1.3805101506392248e-10
a O 0 7.637010815408907e-12
three O 0 2.897688859693215e-11
generation O 0 7.399031387578248e-10
anticipation O 0 1.63004568176639e-10
cascade O 0 6.35333265108784e-07
. O 0 7.425671189054128e-09

This O 0 1.4673259940423122e-08
results O 0 6.517707618058921e-08
in O 0 6.436727062464342e-08
infertility B-Disease 1 0.9998584985733032
and O 0 0.20367802679538727
congenital B-Disease 1 0.9999997615814209
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 8.95032670200635e-08
CDM B-Disease 0 2.5341345462948084e-05
) O 0 6.731740859189372e-11
with O 0 4.91700291593844e-11
the O 0 8.644665538959373e-11
disappearance O 0 2.388156019605958e-07
of O 0 4.0223385733284545e-10
DM B-Disease 1 1.0
in O 0 7.416940661642002e-08
that O 0 9.55803880486883e-09
pedigree O 0 1.8998229052158422e-06
. O 0 9.801676137399795e-10

The O 0 3.226496569919135e-10
concept O 0 4.770060388348263e-11
of O 0 6.232869580700962e-13
segregation O 0 3.053519321838394e-07
distortion O 0 7.704193194513209e-07
, O 0 5.190379723241101e-11
where O 0 5.802126834542065e-11
there O 0 2.397515996496735e-12
is O 0 5.068573056925263e-13
preferential O 0 3.4748728200417744e-11
transmission O 0 4.2117144971598464e-07
of O 0 1.2851513202152137e-13
the O 0 2.8055366189938535e-12
larger O 0 3.1606748468471224e-11
allele O 0 2.73191846922316e-09
at O 0 1.518785985865634e-08
the O 0 6.278521702540729e-09
DM B-Disease 1 0.9999997615814209
locus O 0 2.4306496925419196e-05
, O 0 3.707888751591781e-08
has O 0 1.6098832489319648e-08
been O 0 1.9903068082527398e-09
put O 0 1.2272066385321523e-07
forward O 0 1.1897547391725993e-09
to O 0 1.3706974444360753e-10
explain O 0 1.1180640413499532e-08
partially O 0 1.1799298960113447e-07
the O 0 1.604296036294972e-11
maintenance O 0 5.9537264007758495e-08
of O 0 1.6398656044191995e-10
DM B-Disease 1 0.9999998807907104
in O 0 9.397554379120265e-08
the O 0 1.8095147602537054e-09
population O 0 8.945659768500036e-10
. O 0 1.3528156372899502e-09

In O 0 1.1054424042811206e-09
a O 0 7.630288068050106e-11
survey O 0 4.31076774276562e-09
of O 0 9.109186495381838e-12
DM B-Disease 1 0.9999997615814209
in O 0 1.0931002947245361e-07
Northern O 0 1.539316690468695e-05
Ireland O 0 5.402513920671481e-07
, O 0 5.335534097872241e-11
59 O 0 9.651887067363418e-10
pedigrees O 0 1.578540498314851e-08
were O 0 1.4558862448943444e-10
ascertained O 0 3.1834468927627313e-07
. O 0 1.9059609446259174e-09

Sibships O 0 0.00016573980974499136
where O 0 3.988620633776918e-08
the O 0 1.0844840650503507e-11
status O 0 2.8249113118161695e-11
of O 0 8.265200047812005e-13
all O 0 6.76873002092293e-11
the O 0 1.882672837072441e-11
members O 0 3.582309416553381e-13
had O 0 1.8608793395102907e-09
been O 0 1.859447665286673e-11
identified O 0 1.8890043695929393e-10
were O 0 8.642814762482853e-12
examined O 0 2.379351826675702e-09
to O 0 3.727964117961058e-12
determine O 0 2.1381098280759403e-11
the O 0 1.5558913749394443e-12
transmission O 0 1.3232057654022356e-06
of O 0 3.3704538725948252e-12
the O 0 1.0312316334193383e-08
DM B-Disease 1 0.9999996423721313
expansion O 0 4.1444968701398466e-07
from O 0 3.3620720096827483e-10
affected O 0 1.650498582250748e-08
parents O 0 9.161625902365245e-10
to O 0 3.7371286620846433e-11
their O 0 9.597835720631664e-11
offspring O 0 4.764128203049722e-09
. O 0 4.121921692856745e-10

Where O 0 6.743456992808206e-08
the O 0 1.0516239268287819e-10
transmitting O 0 8.668832833791384e-07
parent O 0 1.4002928594436526e-07
was O 0 5.893000576406848e-08
male O 0 3.3354583539590976e-09
, O 0 3.3207468025375775e-11
58 O 0 1.1046273229453618e-08
. O 0 1.4277085069736017e-09

3 O 0 1.1242870634475821e-08
% O 0 2.3723073852566223e-11
of O 0 3.982574632490493e-13
the O 0 2.2843792135684993e-10
offspring O 0 9.333671613376282e-09
were O 0 5.733198915613968e-10
affected O 0 1.5087842086813907e-08
, O 0 1.1694721857580248e-09
and O 0 4.215304549859411e-09
in O 0 5.056566276806507e-11
the O 0 2.4649893237693732e-11
case O 0 2.641473706432862e-10
of O 0 1.2158613146243807e-13
a O 0 3.547603044662395e-10
female O 0 2.246083319334957e-09
transmitting O 0 8.189518325707468e-07
parent O 0 3.8720951778259405e-08
, O 0 1.457169662710811e-10
68 O 0 5.243142808808443e-08
. O 0 1.716514486105325e-09

7 O 0 1.2134091775806155e-07
% O 0 2.2021394430193908e-10
were O 0 7.394940215732504e-10
affected O 0 1.8709840787778376e-08
. O 0 3.645475477043192e-09

Studies O 0 7.31915861251764e-08
on O 0 3.352850774795968e-10
meiotic O 0 1.0146668500965461e-06
drive O 0 7.616188668180257e-06
in O 0 4.860000846207413e-09
DM B-Disease 1 0.9999996423721313
have O 0 1.4230253952973726e-07
shown O 0 2.9064137208045793e-10
increased O 0 2.1553599183210537e-11
transmission O 0 4.166483620338113e-07
of O 0 1.7560508169117695e-13
the O 0 1.4658347235671498e-12
larger O 0 4.162058284823411e-12
allele O 0 2.272341759201879e-10
at O 0 1.097480106793114e-09
the O 0 3.8115874345656664e-10
DM B-Disease 1 0.999998927116394
locus O 0 8.310301495839667e-07
in O 0 2.881334282278658e-09
non O 0 2.6293971444601993e-08
- O 0 0.014417004771530628
DM O 1 0.9999945163726807
heterozygotes O 0 1.03887168734218e-06
for O 0 2.2274133926192263e-10
CTGn O 0 2.7873471481143497e-05
. O 0 1.0763725910578614e-08

This O 0 3.966874828620348e-09
study O 0 7.285261283129785e-11
provides O 0 7.528798764977473e-12
further O 0 2.8340467993215324e-12
evidence O 0 3.2316808951105e-11
that O 0 5.845470635312822e-11
the O 0 1.0056341315234363e-09
DM B-Disease 1 0.9999996423721313
expansion O 0 8.04902185791434e-07
tends O 0 3.474387710866722e-08
to O 0 2.5707920167650222e-11
be O 0 3.646055679595861e-11
transmitted O 0 5.611568809626988e-08
preferentially O 0 2.7981995387449388e-08
. O 0 2.0946704371027636e-09

Diagnosis O 1 0.9793301224708557
of O 0 9.807238399162088e-08
hemochromatosis B-Disease 1 0.9999980926513672
. O 0 8.376707228308078e-06

If O 0 0.000434791058069095
untreated O 0 0.01357316318899393
, O 0 3.412709475014708e-07
hemochromatosis B-Disease 1 1.0
can O 1 0.7153564691543579
cause O 0 0.0005464514833875
serious O 0 0.000664062041323632
illness O 1 0.6044974327087402
and O 0 1.1725599335932202e-07
early B-Disease 0 4.940955022902926e-07
death I-Disease 0 2.866245722543681e-06
, O 0 3.5293368227939936e-08
but O 0 1.371694793306233e-06
the O 0 1.7749744074535556e-07
disease O 0 0.3402697443962097
is O 0 1.1495658869264958e-09
still O 0 1.246211045469181e-08
substantially O 0 2.2710750613441633e-07
under O 0 9.930529643042973e-08
- O 1 0.9870206713676453
diagnosed O 1 0.6955721974372864
. O 0 1.3225777806269434e-08

The O 0 2.8729366108315446e-10
cornerstone O 0 1.98910665716312e-10
of O 0 7.42820247586623e-14
screening O 0 3.4023863726417858e-09
and O 0 1.3360898325209813e-11
case O 0 2.67316481450397e-11
detection O 0 1.2815881689220987e-08
is O 0 3.043639125455133e-12
the O 0 4.864284973080113e-13
measurement O 0 2.6653323992320566e-09
of O 0 1.8461165755823128e-12
serum O 0 1.361082979656203e-08
transferrin O 0 6.392357754236855e-10
saturation O 0 8.920816862989511e-10
and O 0 1.2585480435589602e-09
the O 0 1.4488608923723945e-10
serum O 0 5.803530029879767e-07
ferritin O 0 1.5640642914149794e-06
level O 0 2.5842613382565105e-08
. O 0 3.105740775666277e-09

Once O 0 1.298755614698166e-05
the O 0 1.3784428043450703e-09
diagnosis O 0 7.52748383092694e-05
is O 0 3.428426986751276e-11
suspected O 0 8.231778565459535e-07
, O 0 2.103754392912549e-10
physicians O 0 2.595234305236005e-10
must O 0 7.973992993681733e-11
use O 0 6.838992705482383e-10
serum O 0 2.505225893401075e-06
ferritin O 0 5.123169830767438e-05
levels O 0 2.0219688394718105e-06
and O 0 1.2768470014634659e-06
hepatic O 1 0.5733811259269714
iron O 1 0.8283440470695496
stores O 0 0.0031146842520684004
on O 0 9.161683556158096e-05
liver O 0 0.0002136957336915657
biopsy O 0 0.000963380269240588
specimens O 0 6.3510765535568225e-09
to O 0 2.8089180981183404e-10
assess O 0 1.946228245230941e-08
patients O 0 4.832812483535065e-10
for O 0 2.0710130387967957e-13
the O 0 1.747419223208091e-11
presence O 0 2.1269670469337143e-09
of O 0 1.2470585675217194e-10
iron B-Disease 1 0.5794771909713745
overload I-Disease 0 0.0037940572947263718
. O 0 8.119588557065072e-09

Liver O 1 0.9805497527122498
biopsy O 1 0.9352332949638367
is O 0 3.752897104192243e-09
also O 0 4.113771101543762e-09
used O 0 1.5966239885756295e-08
to O 0 2.510263941157831e-10
establish O 0 2.855783165500725e-09
the O 0 4.036478096214324e-11
presence O 0 6.416584596991015e-09
or O 0 3.7506659111841145e-08
absence O 0 7.970548665525712e-09
of O 0 1.492772849776003e-10
cirrhosis B-Disease 0 0.09999902546405792
, O 0 5.767828437086564e-09
which O 0 1.0117453541624855e-07
can O 0 6.222823571988556e-07
affect O 0 2.269101514684735e-06
prognosis O 0 0.0015979977324604988
and O 0 5.224871202358372e-09
management O 0 1.3196427062212024e-07
. O 0 1.362557622286431e-09

A O 0 4.148092536127024e-09
DNA O 0 8.601083436587942e-07
- O 0 4.9315779904191004e-08
based O 0 2.9858149286354774e-10
test O 0 4.502556993912776e-09
for O 0 1.5510460754306066e-13
the O 0 6.724845506844712e-12
HFE O 0 2.5313604510301957e-06
gene O 0 2.4950534083245657e-08
is O 0 2.7034064223330212e-11
commercially O 0 1.326052045946824e-10
available O 0 1.5239930151178527e-10
, O 0 2.647082275597512e-10
but O 0 2.189922243545084e-09
its O 0 2.402630351616697e-11
place O 0 4.213529791741166e-08
in O 0 1.2616599431858333e-10
the O 0 4.626929117623746e-10
diagnosis O 0 5.835845149704255e-05
of O 0 6.627576959461479e-11
hemochromatosis B-Disease 1 1.0
is O 0 1.4814592077527777e-06
still O 0 3.934594872134767e-08
being O 0 1.6622343501637715e-09
evaluated O 0 1.3928207032165574e-08
. O 0 7.127138323959059e-10

Currently O 0 1.8522935363307624e-07
, O 0 5.360967780809744e-10
the O 0 6.3432952467079584e-12
most O 0 7.359330159162347e-13
useful O 0 7.843703117571543e-12
role O 0 1.142465202302878e-11
for O 0 9.544411701950528e-13
this O 0 2.7774841454553112e-11
test O 0 6.535768815041365e-09
is O 0 2.895521713022764e-12
in O 0 5.616748385839365e-13
the O 0 8.625058132982755e-13
detection O 0 6.880580372126133e-08
of O 0 1.2023514128767232e-10
hemochromatosis B-Disease 1 1.0
in O 0 6.065376965125324e-07
the O 0 8.703207932114765e-09
family O 0 8.552896169078394e-09
members O 0 2.0610825600484578e-13
of O 0 9.611547668875176e-13
patients O 0 1.1706661195987067e-09
with O 0 1.1120027424912915e-12
a O 0 2.0298632219528656e-10
proven O 0 5.213353748700911e-09
case O 0 2.1892196389039498e-10
of O 0 8.106361068516144e-12
the O 0 5.802888267680828e-07
disease O 1 0.5115112066268921
. O 0 1.3126734366153414e-08

It O 0 1.7081999814649862e-08
is O 0 9.78465364287473e-11
crucial O 0 2.0392629807020057e-09
to O 0 6.58566179367881e-08
diagnose O 1 0.9998170733451843
hemochromatosis B-Disease 1 1.0
before O 0 0.12139035016298294
hepatic B-Disease 1 0.9999477863311768
cirrhosis I-Disease 1 0.9998500347137451
develops O 0 0.019159018993377686
because O 0 2.2463839286501752e-06
phlebotomy O 1 0.8307974934577942
therapy O 0 0.39179378747940063
can O 0 0.00038942729588598013
avert O 1 0.5730249881744385
serious O 1 0.8843753337860107
chronic O 1 0.9999966621398926
disease O 1 0.9999986886978149
and O 0 6.832441431470215e-05
can O 0 9.445847535971552e-05
even O 0 2.5545591597619932e-06
lead O 0 0.00010573240433586761
to O 0 7.851364003386152e-09
normal O 0 1.7425132625703554e-07
life O 0 1.1135568911413429e-07
expectancy O 0 1.0084321729664225e-05
. O 0 1.6395684809822342e-10
. O 0 1.3194149106610098e-09

Prevalence O 0 0.0011131962528452277
of O 0 7.26239693382702e-11
the O 0 1.5056204893948433e-10
I1307K O 0 6.419096365561927e-08
APC B-Disease 0 5.1342707863000214e-09
gene O 0 7.68527286254539e-09
variant O 0 9.055412988345779e-07
in O 0 4.468180270222888e-10
Israeli O 0 3.866833253596269e-07
Jews O 0 2.8181013078665273e-09
of O 0 2.5490227333405113e-13
differing O 0 1.6914905240361655e-11
ethnic O 0 1.8708332660821725e-09
origin O 0 8.214657398752934e-09
and O 0 5.779151024398743e-07
risk O 0 4.6604182557530294e-07
for O 0 6.114989332672849e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.5404531268359278e-06

BACKGROUND O 0 0.0007218443206511438
& O 0 0.00026254530530422926
AIMS O 0 3.374970845015923e-07
Israeli O 0 3.1972297165339114e-07
Jews O 0 8.668256157307042e-08
of O 0 7.526132494994897e-11
European O 0 2.209176130918422e-07
birth O 0 6.004863450925768e-08
, O 0 2.466603588047178e-10
i O 0 3.070549610129092e-07
. O 0 5.565403606716535e-12
e O 0 1.2660858472735015e-10
. O 0 1.5659641985910078e-11
, O 0 1.1005731048729928e-11
Ashkenazim O 0 8.80032828831645e-08
, O 0 7.22229637206695e-11
have O 0 6.650310302447338e-10
the O 0 1.2549794092819866e-08
highest O 0 0.43970227241516113
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 1 0.9733707308769226
of O 0 8.088865688371527e-11
any O 0 4.404285292025634e-08
Israeli O 0 0.0013960120268166065
ethnic O 0 2.4030798613239313e-06
group O 0 4.6983645916043315e-06
. O 0 5.612679210287297e-09

The O 0 1.893486434312308e-08
I1307K O 0 1.1774883290627258e-07
APC B-Disease 0 1.904297697308266e-08
gene O 0 6.22350100343283e-08
variant O 0 1.9113036614726298e-05
was O 0 2.0317572761996416e-06
found O 0 9.916463206138815e-09
in O 0 3.465621123410756e-10
6 O 0 8.237804394184423e-08
. O 0 1.4479369703224165e-08

1 O 0 2.0438344350282023e-09
% O 0 1.0287428894861783e-11
of O 0 2.28784683255559e-13
American O 0 8.415522723126401e-10
Jews O 0 2.2798849030891688e-08
, O 0 2.951839606080142e-10
28 O 0 3.838947770784529e-10
% O 0 9.61024554206602e-13
of O 0 1.3864308139044379e-11
their O 0 0.00017304842185694724
familial O 1 0.9999988079071045
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 9.514236808172427e-06
, O 0 3.2983113129603225e-08
but O 0 1.221981733579014e-07
not O 0 7.255481992984869e-09
in O 0 1.238314867313406e-10
non O 0 8.872996781761344e-10
- O 0 7.435519819409819e-06
Jews O 0 6.27225233529316e-07
. O 0 1.5297521471779874e-08

We O 0 1.0655224258471208e-07
assessed O 0 1.2301842877704416e-09
the O 0 3.6787618090672325e-11
I1307K O 0 4.230448880093718e-08
prevalence O 0 3.937571364076575e-06
in O 0 6.89412693599678e-11
Israeli O 0 8.527261741164693e-08
Jews O 0 9.988287974493915e-10
of O 0 2.28097109342823e-13
differing O 0 1.473223973369464e-11
ethnic O 0 4.793420105286827e-10
origin O 0 3.088644895399284e-09
and O 0 1.9984604193723499e-07
risk O 0 4.437449092620227e-07
for O 0 1.1671861557260854e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 1.3116219861331047e-06

METHODS O 0 8.795764472324663e-08
DNA O 0 3.6835209016317094e-07
samples O 0 8.752712443715893e-10
from O 0 4.035904097900167e-13
500 O 0 5.845478615040811e-12
unrelated O 0 2.6860355606395103e-10
Jews O 0 2.83661059086171e-08
of O 0 7.339767682523757e-11
European O 0 6.682682283098984e-07
or O 0 7.441295579724283e-09
non O 0 4.488597937779559e-09
- O 0 2.1468602426466532e-05
European O 0 2.734708992591095e-08
origin O 0 2.1445803466413338e-10
, O 0 9.940805817398868e-11
with O 0 2.241775688693881e-11
or O 0 7.109772215407872e-10
without O 0 3.8488729564578605e-11
a O 0 1.568244666072527e-11
personal O 0 1.3352582373116206e-09
and O 0 2.098302900321869e-07
/ O 0 0.01256166584789753
or O 0 3.8509645605699916e-07
family O 0 9.688174884558975e-08
history O 0 2.6750446302514774e-09
of O 0 2.9967319858242858e-12
neoplasia B-Disease 0 1.2379082363622729e-05
, O 0 3.1323793558968305e-10
were O 0 1.2983369934715938e-10
examined O 0 2.568937951252792e-08
for O 0 2.3557132806939496e-12
the O 0 9.959228754186089e-12
I1307K O 0 1.0858822729886697e-09
variant O 0 1.060069099168004e-08
by O 0 5.028853201916039e-12
the O 0 6.5373791449663265e-12
allele O 0 3.3356981066212654e-10
- O 0 1.181163344909919e-08
specific O 0 3.197718131953131e-11
oligonucleotide O 0 5.576964667852735e-07
( O 0 4.605094361398443e-10
ASO O 0 7.118827852536924e-06
) O 0 1.4459450130288598e-11
method O 0 1.8423979009085656e-09
. O 0 2.074425076159514e-09

RESULTS O 0 1.9343967778695514e-06
In O 0 1.3913351026850762e-10
persons O 0 2.580179299382923e-11
at O 0 1.4077310428461942e-09
average O 0 4.88730051984021e-07
risk O 0 4.570522378344322e-06
for O 0 1.7598797057871707e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 2.4231553652498405e-08
I1307K O 0 5.724326115341682e-07
was O 0 1.2751490885420935e-07
found O 0 2.6079087778185794e-09
in O 0 2.475200044926851e-10
5 O 0 5.320833995625662e-09
. O 0 4.181567536676312e-09

0 O 0 1.5394553187775273e-08
% O 0 7.541431888691275e-12
of O 0 1.6451260926447775e-13
120 O 0 3.226447164994539e-10
European O 0 3.1942242628701933e-08
and O 0 1.0642160930274258e-08
1 O 0 6.242102834619345e-09
. O 0 4.508744932962827e-09

6 O 0 4.726009805722242e-08
% O 0 1.9950405910629243e-11
of O 0 5.564084349513054e-13
188 O 0 1.212179689957793e-09
non O 0 2.389151765314068e-09
- O 0 1.8841265045921318e-05
European O 0 1.860071030534982e-08
Jews O 0 1.1469646565842595e-08
( O 0 3.809673757015908e-11
P O 0 1.4193136848916765e-05
= O 0 2.4474675797137024e-07
0 O 0 4.4137163368596077e-10
. O 0 1.1278377537449202e-11
08 O 0 1.5788340079758711e-10
) O 0 1.5897358082717084e-11
. O 0 3.0671629125400557e-10

It O 0 8.628781955621889e-08
occurred O 0 5.2859789434478444e-08
in O 0 5.103248032489738e-11
15 O 0 4.542909104454651e-10
. O 0 5.121846280431441e-10

4 O 0 1.1443206382466542e-08
% O 0 1.0116373017066138e-11
of O 0 5.73679992399434e-13
52 O 0 2.9424272796063633e-08
Ashkenazi O 0 0.00017659923469182104
Israelis O 0 9.255394979845732e-05
with O 0 1.7500074989129644e-07
familial O 1 0.8679903149604797
cancer B-Disease 1 0.9320739507675171
( O 0 3.772511192323691e-09
P O 1 0.9119269251823425
= O 0 0.001641758601181209
0 O 0 1.1520452147806282e-07
. O 0 2.0528398980701468e-09
02 O 0 3.5690135291588376e-07
) O 0 4.4178913999326497e-11
and O 0 3.70477648559131e-09
was O 0 1.8690192860049137e-07
not O 0 2.9685591762529384e-09
detected O 0 5.421517812465027e-07
in O 0 2.67331934367121e-10
51 O 0 2.0761962105098064e-07
non O 0 2.7847595340801945e-09
- O 0 7.5305169957573526e-06
European O 0 1.2068121613140192e-08
Jews O 0 1.2278828620537752e-08
at O 0 1.777361902099983e-08
increased O 0 1.3458778092001467e-08
cancer B-Disease 0 5.352194420993328e-06
risk O 0 2.872928561714616e-08
. O 0 1.4043867180291159e-09

Colorectal B-Disease 1 0.996441662311554
neoplasia I-Disease 1 0.7134773135185242
occurred O 0 0.0006136735901236534
personally O 0 6.936343652341748e-06
or O 0 1.0645631931538446e-08
in O 0 6.934208207631798e-10
the O 0 7.543640712093236e-10
families O 0 5.4664089227385304e-11
of O 0 4.239687485634025e-13
13 O 0 4.841889042483949e-11
of O 0 5.144857521781343e-13
20 O 0 1.4920072122226458e-10
Ashkenazi O 0 2.550459612393752e-07
I1307K O 0 2.2919086628547802e-09
carriers O 0 1.1638728175666913e-10
, O 0 1.4517454079154835e-11
8 O 0 1.1684325729177658e-10
of O 0 2.1911725905932045e-12
whom O 0 8.804523758954019e-07
also O 0 3.898573140759254e-06
had O 0 8.568085831939243e-06
a O 0 9.154294211555225e-09
personal O 0 4.010124499131962e-08
or O 0 1.2312651165302668e-07
family O 0 3.067388121280601e-08
history O 0 4.233053907398698e-09
of O 0 7.140333463384607e-11
noncolonic O 0 0.000721214571967721
neoplasia B-Disease 0 0.0005283557111397386
. O 0 4.5325364794734924e-08

CONCLUSIONS O 0 1.5473925714104553e-06
The O 0 2.2867343574262122e-09
I1307K O 0 1.4097071243668324e-07
APC O 0 6.559073995049403e-08
variant O 0 5.741155291616451e-06
may O 0 1.3265619713820342e-08
represent O 0 9.371743832364832e-12
a O 0 1.3984333135930171e-10
susceptibility O 0 4.584731527756958e-07
gene O 0 3.2275884223054163e-06
for O 0 1.0102431247105415e-07
colorectal B-Disease 1 1.0
, I-Disease 0 1.5293546766770305e-06
or I-Disease 0 2.815444304360426e-07
other I-Disease 0 1.0597884880780839e-07
, I-Disease 0 4.727632585854735e-06
cancers I-Disease 1 0.7613357901573181
in O 0 8.890280511764104e-09
Ashkenazi O 0 0.03190840035676956
Jews O 0 3.633882079157047e-05
, O 0 1.4149655669370986e-07
and O 0 1.7802737772854016e-07
partially O 0 1.2890360267192591e-05
explains O 0 3.510043882215541e-07
the O 0 5.239106024013118e-11
higher O 0 1.029615503966852e-09
incidence O 0 0.4010172486305237
of O 0 0.0009514666744507849
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 7.106266934897576e-07
European O 0 2.7160738227394177e-06
Israelis O 0 2.82529836113099e-05
. O 0 1.3365710316293189e-08

Systematic O 0 2.9874473739255336e-07
analysis O 0 2.102479745857977e-09
of O 0 1.382216823636595e-11
coproporphyrinogen O 0 1.1400839866837487e-05
oxidase O 0 2.688891618163325e-05
gene O 0 0.0006908574141561985
defects O 1 0.9970345497131348
in O 0 2.5357858035590652e-08
hereditary B-Disease 1 0.922756552696228
coproporphyria I-Disease 0 0.06085033714771271
and O 0 2.370857430378237e-07
mutation O 0 1.9531173620634945e-06
update O 0 2.733882502070628e-05
. O 0 2.990371683608828e-08

Hereditary B-Disease 1 0.9966374635696411
coproporphyria I-Disease 0 0.006105334497988224
( O 0 9.0254088647157e-09
HC B-Disease 0 0.015820849686861038
) O 0 2.734662096770535e-08
is O 0 3.80585234438513e-08
an O 0 7.067533829285821e-07
acute O 1 0.9997902512550354
hepatic B-Disease 1 0.9999978542327881
porphyria I-Disease 1 0.9999994039535522
with O 0 0.03256923332810402
autosomal O 1 0.9999954700469971
dominant O 1 0.9791141152381897
inheritance O 1 0.5314674973487854
caused O 0 7.824709609849378e-05
by O 0 1.2858968334583665e-09
deficient B-Disease 0 2.9883252864237875e-05
activity I-Disease 0 2.7660622681224822e-09
of I-Disease 0 7.49405572320061e-12
coproporphyrinogen I-Disease 0 4.247513061272912e-05
III I-Disease 0 1.1474127859401051e-05
oxidase I-Disease 0 9.937195954989875e-07
( O 0 8.830412789873066e-11
CPO O 0 2.297763330716407e-06
) O 0 4.5007003679486957e-10
. O 0 1.6285455206599408e-09

Clinical O 0 0.00015526384231634438
manifestations O 0 2.227049662906211e-06
of O 0 5.425661586677677e-10
the O 0 2.303195515196421e-06
disease O 1 0.8321600556373596
are O 0 7.739220375668765e-11
characterized O 0 1.2573461845022393e-06
by O 0 1.4122525371362826e-08
acute O 0 0.002306105801835656
attacks O 0 0.08986883610486984
of O 0 1.5358206155724474e-06
neurological B-Disease 1 0.9999986886978149
dysfunction I-Disease 0 0.16128942370414734
often O 0 1.173707744328567e-07
precipitated O 0 3.4825017536377345e-08
by O 0 5.151736329200851e-11
drugs O 0 1.3129863418726018e-08
, O 0 1.3925349762189398e-10
fasting O 0 1.002256766469145e-08
, O 0 3.686974892058714e-10
cyclical O 0 5.52569372302969e-06
hormonal O 0 8.027549824873859e-07
changes O 0 3.934790271387101e-08
, O 0 2.461417736299154e-08
or O 0 2.8028578071825905e-06
infectious B-Disease 1 0.9951021671295166
diseases I-Disease 1 0.9283525943756104
. O 0 3.65684940106803e-08

Skin O 1 0.9999699592590332
photosensitivity O 1 0.9989548921585083
may O 0 6.915150879649445e-05
also O 0 2.985191471793769e-08
be O 0 7.859300432677685e-10
present O 0 8.238927318160449e-10
. O 0 5.389400037358882e-09

The O 0 8.330641176890197e-10
seven O 0 2.2558186221766086e-11
exons O 0 4.566175437759057e-09
, O 0 6.366239566762966e-12
the O 0 7.941958180511521e-13
exon O 0 2.6178426537626365e-08
/ O 0 5.302327190292999e-05
intron O 0 0.052709244191646576
boundaries O 0 0.0004790012608282268
and O 0 3.0436553277723988e-09
part O 0 2.791712694349968e-11
of O 0 6.431372361753729e-13
3 O 0 5.4803977328488074e-11
noncoding O 0 2.6571969513611293e-08
sequence O 0 1.305776375915002e-08
of O 0 1.7318730000451255e-12
the O 0 1.2161553708534e-10
CPO O 0 8.836278198032232e-07
gene O 0 1.124231285842825e-08
were O 0 1.2734045762297086e-10
systematically O 0 9.910415599279077e-08
analyzed O 0 1.8305855442601882e-10
by O 0 9.57911186353147e-14
an O 0 2.653547208895414e-14
exon O 0 3.802730130786358e-09
- O 0 1.487522496290694e-07
by O 0 3.647286986319109e-11
- O 0 3.45052058037254e-08
exon O 0 2.1838133079654654e-07
denaturing O 0 3.269921216997318e-05
gradient O 0 1.0052003744931426e-06
gel O 0 2.2991505829850212e-05
electrophoresis O 0 4.874081582784129e-07
( O 0 1.5680991227728924e-10
DGGE O 0 5.583089546234987e-07
) O 0 1.4158806072028796e-11
strategy O 0 1.5097210981362963e-10
followed O 0 3.841631873724438e-12
by O 0 6.007148852784847e-14
direct O 0 1.5645989278473271e-12
sequencing O 0 4.834022515609604e-09
in O 0 7.687860070770824e-11
seven O 0 6.084591164245978e-11
unrelated O 0 1.8076934393818078e-09
heterozygous O 0 6.695153587088498e-08
HC B-Disease 0 9.917542774928734e-05
patients O 0 1.0816864914886537e-06
from O 0 1.1131943283837487e-10
France O 0 2.3672142560826614e-05
, O 0 8.758528124985787e-09
Holland O 0 0.0003729934396687895
, O 0 1.1584936343567165e-09
and O 0 1.201146915263962e-08
Czech O 0 0.00026947297737933695
Republic O 0 1.6787352024039137e-06
. O 0 4.971033717993123e-08

Seven O 0 4.875434100881648e-08
novel O 0 1.6843328509708044e-08
mutations O 0 1.1067847935919417e-06
and O 0 4.2098147190472446e-10
two O 0 4.2674848030332946e-12
new O 0 6.941906077750915e-11
polymorphisms O 0 3.298462729617313e-07
were O 0 6.8439285350052614e-09
detected O 0 4.1583398342481814e-06
. O 0 6.534472074548603e-09

Among O 0 5.325504481845655e-09
these O 0 8.964426423396787e-11
mutations O 0 2.0126401878428624e-08
two O 0 3.8094992438342246e-11
are O 0 1.1480287206988571e-11
missense O 0 3.429947582844761e-06
( O 0 9.82990355780089e-11
G197W O 0 1.1299974289613601e-07
, O 0 9.513813348238642e-11
W427R O 0 6.946217823156076e-09
) O 0 8.979566222533375e-12
, O 0 1.0262931129934039e-11
two O 0 2.8316061301270068e-11
are O 0 2.9693490721793836e-11
nonsense O 0 3.5283017041365383e-06
( O 0 7.126953974895267e-12
Q306X O 0 2.114149522114417e-09
, O 0 2.183239006248172e-11
Q385X O 0 1.345568989563617e-09
) O 0 3.428503791633175e-12
, O 0 9.59541560791033e-12
two O 0 3.9454910692737766e-12
are O 0 1.6747832504507287e-12
small O 0 8.077888358215546e-11
deletions O 0 7.185673780440993e-07
( O 0 1.7550724762394054e-10
662de14bp O 0 1.7184644818257766e-08
; O 0 4.3790821663280965e-11
1168del3bp O 0 1.9895905367661726e-08
removing O 0 5.399110047932254e-10
a O 0 7.529836476560803e-11
glycine O 0 8.515348071114204e-08
at O 0 8.352267322209173e-09
position O 0 4.84061735139818e-10
390 O 0 3.957287969535983e-11
) O 0 4.1041586795742546e-11
, O 0 1.4917853063955988e-10
and O 0 1.0755553114805139e-09
one O 0 7.626911602276465e-11
is O 0 2.902798661164052e-12
a O 0 1.237973482406951e-12
splicing O 0 2.1390067672655277e-07
mutation O 0 9.801048861390882e-08
( O 0 7.562129741844892e-12
IVS1 O 0 8.721938229427906e-07
- O 0 4.868074938713107e-07
15c O 0 5.223197430126447e-09
- O 0 8.272743201587218e-08
- O 0 1.841254118062352e-07
> O 0 4.288510435657145e-09
g O 0 6.022884235790116e-07
) O 0 6.342279132431905e-12
which O 0 1.4514132083698339e-11
creates O 0 1.8441293631044076e-11
a O 0 6.165253637474555e-12
new O 0 3.498134421020538e-11
acceptor O 0 3.5151648258846535e-10
splice O 0 4.5983679228811525e-06
site O 0 1.917325334943598e-06
. O 0 7.147384462058426e-09

The O 0 3.868468656520463e-09
pathological O 0 5.76130041451961e-08
significance O 0 2.266580395593465e-10
of O 0 2.802910464491659e-12
the O 0 1.0252572124613835e-09
point O 0 1.9443031362698093e-07
mutations O 0 1.0157206276062425e-07
G197W O 0 1.1878530159492584e-08
, O 0 1.297534215488616e-11
W427R O 0 5.090576404853664e-09
, O 0 6.956525633317057e-11
and O 0 2.0395848898679958e-10
the O 0 1.5649192011690793e-11
in O 0 1.344844929862532e-10
- O 0 1.88689443803014e-06
frame O 0 4.922987864119932e-05
deletion O 0 2.0808067802136065e-07
390delGly O 0 1.2586831132921361e-08
were O 0 4.060028008234795e-11
assessed O 0 2.936793516705727e-11
by O 0 4.568834460066951e-12
their O 0 3.584637101039512e-11
respective O 0 2.0160691172055323e-10
expression O 0 4.356557614659806e-10
in O 0 4.6711367412966e-12
a O 0 3.842694825534343e-12
prokaryotic O 0 6.370916381254199e-12
system O 0 2.7023857110397564e-11
using O 0 9.922445677601477e-12
site O 0 4.498147632148175e-08
- O 0 2.7084848852609866e-07
directed O 0 9.822401381143209e-08
mutagenesis O 0 3.831226891293227e-08
. O 0 9.99896165865266e-10

These O 0 3.677770976651118e-08
mutations O 0 6.389632858372352e-07
resulted O 0 5.186901130826982e-09
in O 0 4.587996302318764e-11
the O 0 3.856870378626809e-10
absence O 0 2.2298374258156173e-09
or O 0 1.5031242917018517e-10
a O 0 1.710242364394432e-10
dramatic O 0 4.389089980350036e-08
decrease O 0 6.067109925567138e-09
of O 0 4.100387390737481e-11
CPO O 0 0.0006879586144350469
activity O 0 3.258654430737806e-07
. O 0 6.356130288764916e-09

The O 0 8.833500597660304e-10
two O 0 5.639866351714318e-11
polymorphisms O 0 4.60088465104036e-08
were O 0 2.3386498293476166e-10
localized O 0 4.5821522576261486e-08
in O 0 1.9914905835527463e-10
noncoding O 0 3.271042032793048e-06
part O 0 6.511886585514048e-10
of O 0 1.249831401567425e-12
the O 0 1.1259291242404768e-11
gene O 0 1.0253119464564975e-09
1 O 0 1.5035306333288645e-11
) O 0 9.267608382101944e-13
a O 0 4.7183649348747636e-11
C O 0 1.7264038660869119e-06
/ O 0 8.761336403040332e-07
G O 0 2.2486281068268e-06
polymorphism O 0 6.491133603958588e-07
in O 0 2.001300680731788e-09
the O 0 4.05461331176582e-10
promotor O 0 3.6738488233822864e-06
region O 0 1.0863220545331842e-08
, O 0 5.376383799965412e-12
142 O 0 2.678779247033969e-11
bp O 0 4.837820699599149e-10
upstream O 0 3.456615202401814e-11
from O 0 6.440686742617552e-14
the O 0 4.74585004812695e-14
transcriptional O 0 4.171764669824718e-11
initiation O 0 1.7634764091709054e-12
site O 0 2.5691524463411497e-09
( O 0 2.838564019252976e-12
- O 0 1.8152574554619605e-08
142C O 0 8.181834765252916e-09
/ O 0 5.901278541387001e-07
G O 0 4.5689134253734665e-07
) O 0 4.260018986873559e-12
, O 0 1.7606069380171618e-11
and O 0 1.160700494051703e-10
2 O 0 6.93886129110588e-11
) O 0 1.0575021761050074e-12
a O 0 4.684519699232892e-12
6 O 0 8.864128875352151e-11
bp O 0 8.876552270997706e-10
deletion O 0 7.725302619832064e-10
polymorphism O 0 3.449316565706795e-08
in O 0 1.6060112961735484e-10
the O 0 1.888974567043622e-11
3 O 0 1.5545105480629928e-10
noncoding O 0 1.787874026604186e-07
part O 0 3.640942825011706e-10
of O 0 1.910194225018813e-12
the O 0 6.46474540566544e-11
CPO O 0 2.9786021968902787e-06
gene O 0 9.61605994831416e-09
, O 0 1.4806215281604196e-11
574 O 0 1.176227448773659e-10
bp O 0 1.0885365941959435e-09
downstream O 0 2.5959967508981663e-10
of O 0 2.0801658735369183e-13
the O 0 5.598688526675666e-11
last O 0 4.291093869124296e-10
base O 0 2.1693344343098886e-10
of O 0 8.964977062575138e-14
the O 0 1.2762439542679527e-11
normal O 0 1.2391045967063974e-09
termination O 0 1.8112826793981185e-09
codon O 0 8.63202131995422e-09
( O 0 2.229210219195643e-11
+ O 0 4.503673878275549e-09
574 O 0 2.591670522633649e-08
delATTCTT O 0 2.1478743406078138e-07
) O 0 8.556024777561788e-10
. O 0 1.4960173100320162e-09

Five O 0 9.695273206489219e-08
intragenic O 0 3.69928216059634e-06
dimorphisms O 0 7.42559905120288e-06
are O 0 4.218366767005932e-10
now O 0 5.200929020787726e-09
well O 0 2.23618235040135e-10
characterized O 0 4.098946959629757e-08
and O 0 3.0454090360620967e-09
the O 0 8.096162629200876e-12
high O 0 9.84089615352346e-11
degree O 0 9.534735848082398e-12
of O 0 1.474001042750528e-13
allelic O 0 2.141374011443986e-08
heterogeneity O 0 2.9038651518931147e-06
in O 0 1.4383251922822637e-08
HC B-Disease 0 0.07663469761610031
is O 0 7.774844590358043e-08
demonstrated O 0 2.7457409679243483e-09
with O 0 2.5203231862613862e-11
seven O 0 2.099488291551488e-11
new O 0 7.027644959023416e-12
different O 0 3.529861515930155e-12
mutations O 0 6.718727796339863e-09
making O 0 1.0232869239457099e-11
a O 0 4.658309155081142e-11
total O 0 1.7801140769768686e-11
of O 0 4.4704097194869785e-12
nineteen O 0 4.924077501300417e-08
CPO O 0 0.0005548566114157438
gene B-Disease 0 0.0004195917281322181
defects I-Disease 1 0.7268404960632324
reported O 0 4.6100556261308157e-08
so O 0 1.0805725203510974e-09
far O 0 7.969176429867275e-10
. O 0 3.828702910269044e-10
. O 0 2.8003657170927454e-09

Coincidence O 0 2.083261136931469e-07
of O 0 2.8271322782824626e-11
two O 0 9.270322703924805e-11
novel O 0 2.1969269070609698e-08
arylsulfatase O 0 1.6081929743450019e-06
A O 0 2.4953996646814858e-09
alleles O 0 8.195313760950285e-09
and O 0 7.002620705520712e-09
mutation O 0 5.0988969491072567e-08
459 O 0 1.5274897791073272e-08
+ O 0 3.4612650523513366e-08
1G O 0 2.298137769685127e-05
> O 0 2.588020890925691e-07
A O 0 4.028677125234026e-08
within O 0 1.4921872626416643e-09
a O 0 1.5585468915446654e-08
family O 0 6.460070380853722e-07
with O 0 2.0456393485801527e-06
metachromatic B-Disease 1 0.9999995231628418
leukodystrophy I-Disease 1 0.9999954700469971
: O 0 4.04176275781154e-11
molecular O 0 1.490528117598089e-10
basis O 0 3.675954506066059e-12
of O 0 1.7193789794700542e-12
phenotypic O 0 2.0355611241029692e-07
heterogeneity O 0 7.788782386342064e-05
. O 0 1.4105867762737034e-07

In O 0 1.6743042507982864e-08
a O 0 3.273522120039729e-09
family O 0 6.707472799405423e-09
with O 0 4.115448537511668e-10
three O 0 9.716206506027447e-09
siblings O 0 8.988750721528049e-08
, O 0 1.3793015340990422e-11
one O 0 1.2451684648639993e-11
developed O 0 3.6346723408797743e-09
classical O 0 4.832236868423934e-07
late O 0 4.246759999659844e-05
infantile O 1 0.9999501705169678
metachromatic B-Disease 1 0.9999994039535522
leukodystrophy I-Disease 1 0.9999992847442627
( O 0 8.015233561309287e-07
MLD B-Disease 1 0.9999945163726807
) O 0 1.5837640532367914e-08
, O 0 1.0102905179110167e-09
fatal O 0 2.647681185408146e-06
at O 0 5.990609253103685e-08
age O 0 4.110101148313561e-09
5 O 0 3.1373481590435404e-10
years O 0 1.0642190600984591e-10
, O 0 3.1915334958165786e-11
with O 0 7.167339499680736e-10
deficient O 0 0.00013981727533973753
arylsulfatase O 0 2.894180624934961e-06
A O 0 4.000948905513724e-08
( O 0 1.552063477738841e-10
ARSA O 0 6.88820582581684e-05
) O 0 1.4359710469313836e-11
activity O 0 2.4539009713109294e-10
and O 0 9.410582035851434e-11
increased O 0 4.647005835689555e-10
galactosylsulfatide O 0 2.7947973649133928e-05
( O 0 1.6846671613279796e-08
GS O 1 0.9999979734420776
) O 0 2.4151620703349863e-09
excretion O 0 1.0471195466266181e-08
. O 0 2.5988813323607474e-09

The O 0 4.035196621288151e-09
two O 0 8.213724839167824e-11
other O 0 7.750092928526797e-11
siblings O 0 1.7281320197071182e-07
, O 0 6.920585216008135e-10
apparently O 0 1.5387367113817163e-07
healthy O 0 3.9857800393505727e-10
at O 0 2.8965685405779595e-10
12 O 0 7.715840986965983e-12
( O 0 2.479515074163552e-13
1 O 0 2.2871508506550065e-11
/ O 0 3.137944304398843e-07
2 O 0 2.943020716017486e-09
) O 0 1.8536126800139385e-10
and O 0 6.507160144053614e-09
15 O 0 1.2627866807779498e-10
years O 0 1.7712473848741084e-11
, O 0 1.8124767311999967e-11
respectively O 0 9.645407805791706e-10
, O 0 3.3346376770992947e-09
and O 0 3.0811502682581704e-08
their O 0 1.0878854261875404e-08
father O 0 1.1583449577301508e-06
, O 0 1.959906015258639e-09
apparently O 0 6.018921538952782e-08
healthy O 0 1.548703526532691e-11
as O 0 1.2949549202043165e-12
well O 0 2.423114486838074e-11
, O 0 1.2249009966047719e-11
presented O 0 5.530763624861379e-10
ARSA O 0 0.006281645968556404
and O 0 2.2383219402399845e-06
GS O 1 0.9999992847442627
values O 0 2.0621679919230473e-09
within O 0 1.81080411082446e-11
the O 0 9.285643434719937e-12
range O 0 1.8915398136698514e-09
of O 0 9.62840696061562e-10
MLD B-Disease 1 0.9999982118606567
patients O 0 1.6881795090739615e-05
. O 0 2.71910938209885e-09

Mutation O 0 2.1047130758233834e-06
screening O 0 1.0336935929444735e-07
and O 0 9.448818810708914e-11
sequence O 0 1.2490302125911512e-09
analysis O 0 5.680017567399887e-10
disclosed O 0 3.5804468723199534e-08
the O 0 1.582046646464441e-11
involvement O 0 7.663780166033973e-10
of O 0 3.100219950549765e-12
three O 0 6.1662003281171e-10
different O 0 2.665579978966548e-10
ARSA O 0 0.009296955540776253
mutations O 0 7.554906460427446e-07
being O 0 2.1063641109098086e-10
the O 0 9.495095681932852e-13
molecular O 0 1.3438884727268174e-10
basis O 0 1.0167498787350127e-11
of O 0 3.0763581786164007e-12
intrafamilial O 0 1.4545141311828047e-05
phenotypic O 0 5.238984499555954e-07
heterogeneity O 0 7.622529665241018e-05
. O 0 1.8811758195624861e-07

The O 0 1.3070251725366688e-07
late O 0 1.1994319493169314e-06
infantile O 1 0.7368811368942261
patient O 0 0.0033487107139080763
inherited O 0 0.0002572211960796267
from O 0 7.76468500607308e-10
his O 0 1.9069551626671455e-07
mother O 0 2.5691251721582375e-06
the O 0 3.340044907318429e-11
frequent O 0 5.3960755863613485e-09
0 O 0 1.2728595066846538e-08
- O 0 3.7608781440212624e-06
type O 0 5.998332653689431e-06
mutation O 0 1.0192469090952727e-07
459 O 0 1.6118827383948542e-09
+ O 0 1.6629383425836863e-09
1G O 0 4.553449457489478e-07
> O 0 2.743742300026497e-08
A O 0 3.624117539402505e-07
, O 0 4.2430614577426695e-09
and O 0 5.547078352208246e-09
from O 0 1.2647559388678786e-10
his O 0 4.7160508387378286e-08
father O 0 5.919168799550789e-08
a O 0 4.0737115070133e-11
novel O 0 8.408130192094632e-09
, O 0 4.138478795767675e-11
single O 0 7.378934685497995e-10
basepair O 0 2.354572536944488e-08
microdeletion O 0 1.2612947353218829e-09
of O 0 1.1516747841847086e-13
guanine O 0 1.2471138566283457e-09
at O 0 3.1541467354623265e-11
nucleotide O 0 1.9124857253416394e-10
7 O 0 1.6263244223546636e-11
in O 0 6.049925642924447e-13
exon O 0 1.4443980234091214e-08
1 O 0 1.8941466173316712e-09
( O 0 1.1453960002683061e-10
7delG O 0 3.4171614515798865e-07
) O 0 3.7777728167931457e-10
. O 0 2.422239075983157e-09

The O 0 3.5106388907024666e-08
two O 0 4.560743782633381e-09
clinically O 0 4.000283661298454e-05
unaffected O 0 4.2744613892864436e-05
siblings O 0 7.0984367539495e-07
carried O 0 4.751597870722435e-08
the O 0 1.5980299028495182e-10
maternal O 0 2.0847555504133197e-07
mutation O 0 2.1234779268297643e-08
459 O 0 8.382015082020189e-09
+ O 0 7.190429140990773e-09
1G O 0 9.670945928519359e-07
> O 0 1.24968181580698e-07
A O 0 2.2989003412021702e-07
and O 0 7.218767450467567e-08
, O 0 1.7872935076379548e-10
on O 0 8.79196548897454e-10
their O 0 4.4114836783570865e-11
paternal O 0 8.198518308688563e-09
allele O 0 1.2410245053828817e-10
, O 0 4.3289707755966855e-12
a O 0 1.3271970328299076e-12
novel O 0 3.442891249871849e-10
cytosine O 0 1.3413032462494812e-08
to O 0 1.4734543446470738e-11
thymidine O 0 3.2763345814146305e-08
transition O 0 3.663291003874747e-09
at O 0 1.968030183263636e-10
nucleotide O 0 1.2075690447588272e-09
2435 O 0 2.2320127968100678e-08
in O 0 1.930298152222343e-12
exon O 0 4.610308135255536e-09
8 O 0 2.1964354779413497e-09
, O 0 1.5469616906904626e-11
resulting O 0 5.779713513343054e-12
in O 0 6.879867769232773e-13
substitution O 0 5.866301194812351e-11
of O 0 1.7093275579693756e-12
alanine O 0 4.366253563148348e-07
464 O 0 4.327499247835931e-09
by O 0 3.881903964941813e-10
valine O 0 0.0010484872618690133
( O 0 1.1769882291012834e-10
A464V O 0 5.2968992747537413e-08
) O 0 3.2398042582038045e-10
. O 0 1.7516655903548894e-09

The O 0 1.4296085204534847e-08
fathers O 0 1.0594990662582404e-08
genotype O 0 9.091426278473591e-09
thus O 0 2.4451313196394153e-10
was O 0 2.075940974677337e-09
7delG O 0 6.521675004478311e-07
/ O 0 1.9000593965756707e-05
A464V O 0 1.9413364498177543e-06
. O 0 9.307449921891475e-09

Mutation O 0 2.104000304825604e-05
A464V O 0 4.1621945001679705e-07
was O 0 1.7400349605622978e-08
not O 0 1.0332939365254035e-10
found O 0 1.6384117673684528e-10
in O 0 1.6712676381702707e-11
18 O 0 1.1696349444534349e-09
unrelated O 0 1.3206137055021827e-06
MLD B-Disease 1 0.9999996423721313
patients O 0 9.201661305269226e-05
and O 0 2.369876739294341e-09
50 O 0 5.772624045441432e-10
controls O 0 0.00030571012757718563
. O 0 1.0853863585680301e-07

A464V O 0 1.5030509530333802e-05
, O 0 5.221772791941248e-09
although O 0 9.82805281601884e-10
clearly O 0 3.302533579940814e-09
modifying O 0 2.2162390678204247e-07
ARSA O 1 0.9540108442306519
and O 0 0.0001486248947912827
GS O 1 0.9999996423721313
levels O 0 4.398435521579813e-06
, O 0 8.50899184445808e-10
apparently O 0 3.794168534909659e-08
bears O 0 1.602072252637754e-08
little O 0 1.577750291525959e-10
significance O 0 1.5518709928219465e-10
for O 0 3.703541379823649e-12
clinical O 0 2.3285306127718286e-08
manifestation O 0 2.179122216006135e-09
of O 0 2.537757226583892e-10
MLD B-Disease 1 0.9999977350234985
, O 0 3.1577496173440522e-09
mimicking O 0 1.2933190873809508e-07
the O 0 1.8580303962068e-10
frequent O 0 2.3150620620526752e-07
ARSA O 0 0.00720613356679678
pseudodeficiency O 0 9.82190431386698e-06
allele O 0 1.4318167984583852e-07
. O 0 5.558463467281172e-09

Our O 0 3.028167441243568e-07
results O 0 3.5160585554194768e-09
demonstrate O 0 1.9993844080357093e-10
that O 0 1.329957324824882e-11
in O 0 2.6649164645842216e-12
certain O 0 8.415310115417185e-11
genetic O 0 0.00015612981223966926
conditions O 0 0.0008572922088205814
MLD B-Disease 1 0.9999970197677612
- O 0 0.004380123224109411
like O 0 8.117537618090864e-06
ARSA O 1 0.89225834608078
and O 0 9.650249012338463e-06
GS O 1 0.9999992847442627
values O 0 8.536992623930928e-08
need O 0 3.418353655693096e-10
not O 0 2.4810266688324312e-11
be O 0 9.790935423525937e-13
paralleled O 0 7.820560199434112e-09
by O 0 2.874253279827599e-09
clinical O 0 0.01517514605075121
disease O 1 0.9729999303817749
, O 0 2.3762442014074736e-10
a O 0 1.2229009471731445e-10
finding O 0 1.1760014073658454e-09
with O 0 1.3249100705436945e-09
serious O 0 8.795407957506995e-09
diagnostic O 0 2.827584239639691e-06
and O 0 1.2600258614270388e-08
prognostic O 0 0.00013165574637241662
implications O 0 2.736729243224545e-07
. O 0 1.553208228699532e-08

Moreover O 0 1.6915903415792855e-06
, O 0 2.2688737555398575e-09
further O 0 4.305738876553278e-09
ARSA O 0 0.0011126152239739895
alleles O 0 2.4612957005842873e-08
functionally O 0 9.668902123394219e-08
similar O 0 3.4617979594031567e-09
to O 0 6.986927703067636e-10
A464V O 0 7.145451377255085e-07
might O 0 1.6728908747154492e-07
exist O 0 7.034886806422946e-08
which O 0 1.4306805518060628e-08
, O 0 2.5747876053472396e-10
together O 0 2.2035803737274762e-10
with O 0 2.767343298959446e-10
0 O 0 2.820289353167027e-07
- O 0 0.00014455853670369834
type O 0 0.0002979297423735261
mutations O 0 0.00019631156465038657
, O 0 3.906068357650838e-08
may O 0 6.432296117964142e-08
cause O 0 4.810100318053401e-09
pathological O 0 8.808859092823695e-06
ARSA O 1 0.9814149737358093
and O 0 0.0015673396410420537
GS O 1 1.0
levels O 0 2.0606041289283894e-05
, O 0 6.962516119202178e-10
but O 0 8.499295489627912e-09
not O 0 4.2740406769326e-09
clinical O 0 7.250767453115259e-08
outbreak O 0 4.352765969883876e-08
of O 0 3.8429606719070364e-11
the O 0 2.47792445406958e-06
disease O 1 0.6455251574516296
. O 0 7.706229543380516e-10
. O 0 2.225911011066728e-09

Human O 0 0.016177132725715637
MLH1 O 1 0.9966873526573181
deficiency O 1 0.9964991807937622
predisposes O 0 0.0007446517702192068
to O 0 2.945471635484864e-07
hematological B-Disease 1 0.9893604516983032
malignancy I-Disease 1 0.9992615580558777
and O 0 7.960546099639032e-06
neurofibromatosis B-Disease 1 0.9986259937286377
type I-Disease 0 0.010622221045196056
1 I-Disease 0 9.524335951027751e-07
. O 0 8.979001364650685e-08

Heterozygous O 0 1.0113792086485773e-05
germ O 0 0.0024994928389787674
- O 0 0.0009630146087147295
line O 0 9.137183951679617e-05
mutations O 0 3.9834512222114427e-07
in O 0 1.2839299935729631e-11
the O 0 8.290644559760807e-11
DNA O 0 0.0004908491973765194
mismatch O 0 0.001722755841910839
repair O 0 0.0005136773688718677
genes O 0 2.2399106001103064e-06
lead O 0 7.5955313150188886e-06
to O 0 1.6305298800034507e-07
hereditary B-Disease 1 0.999954104423523
nonpolyposis I-Disease 1 0.9999960660934448
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 1.6797901480458677e-05

The O 0 9.898220014292747e-06
disease O 0 0.001401720568537712
susceptibility O 0 2.291500322826323e-06
of O 0 5.3564781082870994e-11
individuals O 0 4.085488392036041e-09
who O 0 1.1964751820414676e-06
constitutionally O 0 1.3286329703987576e-05
lack O 0 1.1549378342579075e-08
both O 0 2.6670154973373883e-09
wild O 0 5.1875940698664635e-06
- O 0 0.00042379219667054713
type O 0 1.5223686204990372e-05
alleles O 0 4.962969590849298e-09
is O 0 1.8626441500302349e-09
unknown O 0 1.7784808292731213e-08
. O 0 3.481324561960264e-09

We O 0 3.215130846001557e-06
have O 0 1.9614158908165535e-10
identified O 0 9.277756896075573e-10
three O 0 3.946900792306529e-11
offspring O 0 8.836971709946795e-10
in O 0 6.21927925825716e-11
a O 0 3.601941500619432e-07
hereditary B-Disease 1 0.9999933242797852
nonpolyposis I-Disease 1 0.9999991655349731
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.04267989844083786
who O 0 0.00017380512144882232
developed O 0 0.00021807814482599497
hematological B-Disease 1 0.8545874357223511
malignancy I-Disease 1 0.8921077847480774
at O 0 7.487298603336967e-08
a O 0 4.2536418831673473e-10
very O 0 7.812818725305704e-10
early O 0 9.68933466793942e-09
age O 0 1.25315677834692e-08
, O 0 2.688152200835958e-10
and O 0 3.3662062026706963e-09
at O 0 3.070465437460257e-09
least O 0 9.654933103009355e-12
two O 0 6.05122115610035e-12
of O 0 2.3135128795342963e-13
them O 0 1.381039588244093e-10
displayed O 0 1.4762098210496788e-09
signs O 0 1.43471867719569e-09
of O 0 3.6579793014079875e-12
neurofibromatosis B-Disease 1 0.7040423154830933
type I-Disease 0 4.482793519855477e-05
1 I-Disease 0 1.2381555336560268e-08
( O 0 8.163499320978929e-10
NF1 B-Disease 0 0.00015320874808821827
) O 0 1.2070808796948995e-09
. O 0 4.5342805066184155e-09

DNA O 0 3.0437502118729753e-07
sequence O 0 4.4282053579536296e-09
analysis O 0 5.148045878478058e-10
and O 0 2.5122359054163823e-11
allele O 0 1.6372622702043316e-10
- O 0 3.248154101243017e-08
specific O 0 3.739523968260272e-11
amplification O 0 7.729465778538724e-08
in O 0 7.375192123681984e-10
two O 0 1.4941666792722685e-09
siblings O 0 8.969757914201182e-08
revealed O 0 8.16565215444598e-09
a O 0 8.100800585886248e-11
homozygous O 0 1.3510093310742377e-07
MLH1 O 0 0.00017685808415990323
mutation O 0 2.3674253668559686e-07
( O 0 2.876191819434215e-11
C676T O 0 8.855928967932414e-08
- O 0 3.954751809942536e-05
- O 0 8.264606003649533e-05
> O 0 6.431425276787195e-07
Arg226Stop O 0 2.9662245651707053e-05
) O 0 3.051512653673427e-10
. O 0 3.3196720372608013e-10

Thus O 0 8.577077892368834e-08
, O 0 4.9334616253338126e-11
a O 0 2.2985913519790735e-11
homozygous O 0 3.381052593454115e-08
germ O 0 0.0052386559545993805
- O 0 0.11862556636333466
line O 0 0.005232540890574455
MLH1 O 0 0.0023515629582107067
mutation O 0 1.7532362107886e-05
and O 0 9.477097506760401e-08
consequent O 0 2.4289627617690712e-05
mismatch O 1 0.9997722506523132
repair O 1 0.9999921321868896
deficiency O 1 0.9999061822891235
results O 0 1.0944125250489378e-07
in O 0 3.3299071833248206e-10
a O 0 3.397711978436746e-08
mutator O 0 0.18308480083942413
phenotype O 0 0.00011146946781082079
characterized O 0 7.531699566243333e-07
by O 0 1.468692278905337e-08
leukemia B-Disease 1 0.998044490814209
and O 0 8.061267180892173e-06
/ O 1 0.9999786615371704
or O 1 0.9976740479469299
lymphoma B-Disease 1 1.0
associated O 0 0.0025062677450478077
with O 0 7.481658599317598e-07
neurofibromatosis B-Disease 1 0.99989914894104
type I-Disease 0 0.009416582994163036
1 I-Disease 0 1.1920307230184335e-07
. O 0 1.0278305317967806e-08
. O 0 1.2030912266425275e-08

Missense O 0 0.006831054575741291
mutations O 0 0.03891335427761078
in O 0 1.3164060952419732e-09
the O 0 5.47889268676105e-11
most O 0 3.225004248028074e-12
ancient O 0 4.7242272593894796e-11
residues O 0 1.6119480861220836e-08
of O 0 1.532856740843469e-12
the O 0 3.431824269206629e-10
PAX6 O 0 4.860117405769415e-05
paired O 0 2.223371069476343e-07
domain O 0 2.5760133581798073e-08
underlie O 0 8.003778617649004e-08
a O 0 1.4997564301566513e-10
spectrum O 0 1.692028739341822e-08
of O 0 1.37691080759339e-09
human O 0 0.0027880414854735136
congenital B-Disease 1 0.999997615814209
eye I-Disease 1 0.9999465942382812
malformations I-Disease 1 0.999548614025116
. O 0 1.1967354112130124e-06

Mutations O 0 6.43081366433762e-05
of O 0 3.896366909672544e-11
the O 0 1.2455729503368929e-10
human O 0 5.607350583858306e-09
PAX6 O 0 0.0003534170100465417
gene O 0 0.00045810607844032347
underlie O 1 0.9969024062156677
aniridia B-Disease 1 0.9999998807907104
( O 0 0.00028982714866288006
congenital B-Disease 1 0.9999942779541016
absence I-Disease 0 2.2622599260557763e-07
of I-Disease 0 3.156132646897625e-11
the I-Disease 0 1.2696685480761971e-08
iris I-Disease 0 0.037317149341106415
) O 0 9.593123628803824e-09
, O 0 7.590330586282334e-10
a O 0 6.014409414945021e-09
rare O 0 1.3813855730404612e-06
dominant O 0 0.17925798892974854
malformation B-Disease 1 0.9938283562660217
of I-Disease 0 2.8398178253397077e-10
the I-Disease 0 7.479077623884223e-08
eye I-Disease 1 0.7058637142181396
. O 0 1.3726000247515913e-07

The O 0 9.458092087299974e-10
spectrum O 0 1.5033599920499796e-09
of O 0 1.2934226606420296e-11
PAX6 O 0 0.00018614107102621347
mutations O 0 0.00014773671864531934
in O 0 1.0535667627209477e-07
aniridia B-Disease 1 0.9999997615814209
patients O 0 4.9067806685343385e-05
is O 0 3.816495730557534e-11
highly O 0 9.585029991932004e-11
biased O 0 9.226938004758267e-07
, O 0 2.7406432678844794e-10
with O 0 1.3035403312322558e-10
92 O 0 2.305202428942721e-08
% O 0 1.7347790955482556e-12
of O 0 5.008471393695701e-13
all O 0 9.718593707574996e-10
reported O 0 3.572200739654363e-07
mutations O 0 4.643768534151604e-06
leading O 0 9.397715672321283e-08
to O 0 1.2380934055755688e-09
premature O 0 1.5931582719730386e-09
truncation O 0 6.067401869813693e-08
of O 0 3.149577820771299e-11
the O 0 2.7949869085830414e-09
protein O 0 1.398552598175229e-07
( O 0 2.5624157309889206e-11
nonsense O 0 2.276392052635856e-07
, O 0 6.703456149545484e-13
splicing O 0 1.2302641128059122e-09
, O 0 7.798636736389142e-12
insertions O 0 3.091727540649458e-09
and O 0 4.95865237759574e-10
deletions O 0 6.260562912530077e-08
) O 0 5.198922403693018e-10
and O 0 1.2212403532885219e-08
just O 0 2.807608723287558e-08
2 O 0 4.623894045430177e-10
% O 0 1.6843231453664287e-12
leading O 0 4.0073732526790806e-11
to O 0 1.5283689027908998e-13
substitution O 0 1.285193631204995e-12
of O 0 2.3113826933159054e-13
one O 0 3.7495606619586397e-10
amino O 0 1.0371329350888914e-09
acid O 0 1.0931926197610409e-10
by O 0 9.078411850396706e-13
another O 0 2.2430343693535804e-10
( O 0 3.6574718947912643e-11
missense O 0 1.5596701814502012e-06
) O 0 1.522311721124936e-09
. O 0 3.252188518487742e-09

The O 0 1.8635823995083456e-09
extraordinary O 0 4.6076226167812706e-11
conservation O 0 2.3662790477052553e-11
of O 0 1.6655567983830943e-13
the O 0 3.3800978509190838e-12
PAX6 O 0 4.42260329691635e-07
protein O 0 1.3982614177621144e-08
at O 0 9.676992540619267e-10
the O 0 2.2915872324724695e-11
amino O 0 8.19275136620945e-09
acid O 0 1.9772992132516265e-08
level O 0 1.5050011237249805e-09
amongst O 0 6.309295447204377e-11
vertebrates O 0 1.810288985382158e-08
predicts O 0 1.0202597877650987e-06
that O 0 3.581223761983665e-09
pathological O 0 2.869582658604486e-06
missense O 0 0.00018534640548750758
mutations O 0 0.012956035323441029
should O 0 4.7208112619046005e-07
in O 0 2.1519352966237193e-10
fact O 0 8.573688425883574e-09
be O 0 4.79559014721076e-09
common O 0 2.1383361747950858e-09
even O 0 1.568357710368673e-08
though O 0 1.527649828858557e-08
they O 0 7.878951713280458e-09
are O 0 2.624653099025931e-11
hardly O 0 1.0392006366544138e-08
ever O 0 2.7706876792876756e-09
seen O 0 8.691065644939044e-09
in O 0 4.1812185713752115e-08
aniridia B-Disease 1 0.9999991655349731
patients O 0 1.5408559193019755e-05
. O 0 1.1559312396158816e-09

This O 0 1.2588295739135447e-08
indicates O 0 1.6266184843516385e-08
that O 0 7.844171145965362e-11
there O 0 1.1025270106601592e-11
is O 0 6.013571259878836e-13
a O 0 2.572522056487614e-12
heavy O 0 6.356166259990914e-09
ascertainment O 0 9.902857556198796e-08
bias O 0 1.011953600027482e-06
in O 0 1.0896390734149719e-10
the O 0 1.5462714442193715e-11
selection O 0 4.671885274476484e-12
of O 0 1.6187538505810228e-12
patients O 0 5.08363628970443e-10
for O 0 8.76825521911595e-13
PAX6 O 0 7.21835112926783e-06
mutation O 0 5.828412596997623e-08
analysis O 0 8.698710196597403e-09
and O 0 5.16279818896237e-09
that O 0 2.0520296573067753e-09
the O 0 3.4583991226355693e-09
missing O 0 9.169236250272661e-07
PAX6 O 0 0.00048051978228613734
missense O 0 0.0003567600215319544
mutations O 0 0.0020488977897912264
frequently O 0 6.083142125135055e-06
may O 0 1.4411541826575558e-07
underlie O 0 2.8269154427107424e-05
phenotypes O 0 9.634725756768603e-06
distinct O 0 3.217226662854955e-08
from O 0 2.953508326797305e-09
textbook O 1 0.7511140704154968
aniridia B-Disease 1 0.999995231628418
. O 0 2.5264162104576826e-06

Here O 0 7.321349926314724e-07
we O 0 1.108639846592041e-08
present O 0 1.4026800554400864e-11
four O 0 2.0188385685404597e-11
novel O 0 1.8777051025153924e-08
PAX6 O 0 2.0673616745625623e-05
missense O 0 5.159342981642112e-05
mutations O 0 0.00029302146867848933
, O 0 3.279784221987825e-09
two O 0 2.0997777128162198e-10
in O 0 4.0206973861423023e-10
association O 0 2.187362235783752e-10
with O 0 3.418953731237906e-10
atypical O 0 1.4138732694846112e-05
phenotypes O 0 1.2736927601508796e-05
ectopia B-Disease 0 6.3161707657855e-05
pupillae I-Disease 0 3.6352375900605693e-05
( O 0 3.2702629493286395e-10
displaced B-Disease 0 5.315643036851725e-08
pupils I-Disease 0 2.1238999181605323e-07
) O 0 4.9297440796181036e-08
and O 0 0.0005002462421543896
congenital B-Disease 1 0.999997615814209
nystagmus I-Disease 0 0.005879170261323452
( O 0 5.644076872535209e-10
searching B-Disease 0 4.9127073964427836e-08
gaze I-Disease 0 8.01206988398917e-05
) O 0 5.148576009972317e-10
, O 0 1.3673061571850553e-09
and O 0 9.914363552354644e-09
two O 0 2.1621684442862943e-09
in O 0 1.6557254456373016e-09
association O 0 3.8184691519838054e-11
with O 0 1.855189439570193e-11
more O 0 5.956795473549548e-11
recognizable O 0 3.810150519711897e-05
aniridia B-Disease 1 0.999996542930603
phenotypes O 0 0.0002817518834490329
. O 0 1.803396543209601e-08

Strikingly O 0 8.930628609959967e-06
, O 0 3.4493936595936248e-09
all O 0 2.665314323413437e-11
four O 0 9.680790891142266e-11
mutations O 0 3.793017810949095e-08
are O 0 5.852975656223114e-12
located O 0 1.8201113505256217e-08
within O 0 4.685686838534764e-10
the O 0 1.0590413962452416e-10
PAX6 O 0 7.174318852776196e-06
paired O 0 9.292393343685035e-08
domain O 0 2.8352698677736043e-07
and O 0 6.442005595630462e-09
affect O 0 1.9199106304768065e-08
amino O 0 2.712728885967408e-08
acids O 0 1.952038886088303e-08
which O 0 6.093699989051515e-10
are O 0 2.3145424379172885e-12
highly O 0 1.100117653224375e-11
conserved O 0 6.7493481914482345e-09
in O 0 6.60801580121273e-10
all O 0 7.865280648999828e-11
known O 0 3.1853824022931576e-09
paired O 0 4.265418596105519e-08
domain O 0 3.13468362378444e-08
proteins O 0 5.3616684425605854e-08
. O 0 5.036434824745584e-09

Our O 0 4.70303461952426e-07
results O 0 1.7307330013593969e-09
support O 0 2.0369973069422898e-12
the O 0 9.148608086373411e-12
hypothesis O 0 6.210465919309627e-09
that O 0 2.1310540138097522e-11
the O 0 5.790062873600732e-12
under O 0 1.1475011912898125e-11
- O 0 3.949480298359731e-09
representation O 0 2.0658913468807327e-10
of O 0 8.51300887422246e-12
missense O 0 0.000291163451038301
mutations O 0 2.9640414140885696e-05
is O 0 4.2506570485656425e-10
caused O 0 5.785895651477801e-10
by O 0 9.547874643689447e-12
ascertainment O 0 5.169077326172555e-07
bias O 0 2.6459942091605626e-05
and O 0 1.971966234748379e-08
suggest O 0 4.2784611409274476e-09
that O 0 3.832544004378491e-11
a O 0 1.7512996261515035e-11
substantial O 0 2.065320137134563e-10
burden O 0 2.259077191979486e-08
of O 0 1.500788555930388e-11
PAX6 B-Disease 1 0.9712688326835632
- I-Disease 1 0.994648277759552
related I-Disease 0 0.034650616347789764
disease I-Disease 1 0.9996654987335205
remains O 0 2.9917697474957095e-07
to O 0 7.511006816507404e-10
be O 0 2.639021223771465e-10
uncovered O 0 2.6028570232483617e-07
. O 0 6.527231533048905e-10
. O 0 1.0946891171315087e-09

The O 0 1.2868249577024926e-08
chromosomal O 0 0.00012164774670964107
order O 0 1.8035056781329217e-09
of O 0 1.3823196927387205e-11
genes O 0 1.3869826034351718e-06
controlling O 0 6.22108273091726e-05
the O 0 7.289855386005684e-09
major O 0 6.545661790369195e-09
histocompatibility O 0 1.7766441828825918e-07
complex O 0 4.42164100888931e-08
, O 0 7.623595504879788e-11
properdin O 0 9.116834576161637e-08
factor O 0 5.0445776444973944e-09
B O 0 0.0022316225804388523
, O 0 3.4229568512955666e-08
and O 0 4.095667463843711e-06
deficiency B-Disease 0 5.055178553448059e-05
of I-Disease 0 3.7098105078355037e-13
the I-Disease 0 2.465512516369728e-10
second I-Disease 0 8.031285858578485e-09
component I-Disease 0 5.93242066582178e-10
of I-Disease 0 9.696235134248887e-12
complement I-Disease 0 1.3465715653637744e-07
. O 0 4.805405851016076e-09

The O 0 5.761022769945612e-09
relationship O 0 5.504768307851293e-10
of O 0 4.041288516939273e-13
the O 0 2.262707816252929e-12
genes O 0 9.647722204464415e-11
coding O 0 3.400564807520823e-08
for O 0 2.4145737492764496e-12
HLA O 0 7.533481038990431e-07
to O 0 6.7982659432419545e-12
those O 0 3.8138361826284273e-13
coding O 0 2.306579105493256e-08
for O 0 1.2260550647652524e-12
properdin O 0 7.693386550045034e-08
Factor O 0 1.879850941577388e-09
B O 0 1.19298420031555e-06
allotypes O 0 9.603120361134643e-07
and O 0 6.138957076018414e-08
for O 0 1.6568755256685108e-09
deficiency B-Disease 0 2.1014458980062045e-05
of I-Disease 0 6.063048826020212e-13
the I-Disease 0 2.2943218158655299e-10
second I-Disease 0 5.993018969974173e-09
component I-Disease 0 6.201514302084377e-10
of I-Disease 0 4.975909441429227e-12
complement I-Disease 0 4.272314768627439e-08
( O 0 2.8428256970691734e-10
C2 O 0 1.2439685633580666e-05
) O 0 3.314324162340121e-11
was O 0 2.1533498539838547e-08
studied O 0 2.927056286239349e-08
in O 0 9.840071119038285e-11
families O 0 4.35738632675875e-11
of O 0 7.103299719257716e-12
patients O 0 8.011430452370405e-08
with O 0 8.481551105887775e-08
connective O 1 0.9999927282333374
tissue O 1 0.999988317489624
disorders O 1 0.9995418787002563
. O 0 6.33358752111235e-08

Patients O 0 5.4581933000008576e-06
were O 0 1.2942302785035054e-10
selected O 0 1.7354650702627872e-11
because O 0 3.998104972091632e-11
they O 0 1.661006228392825e-11
were O 0 2.9378673972735303e-12
heterozygous O 0 3.8410716274306367e-10
or O 0 8.823089481246882e-11
homozygous O 0 6.126196581135446e-07
for O 0 8.011359568627086e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
. O 0 4.796854824462571e-08

12 O 0 4.960918076335474e-08
families O 0 4.72673511442423e-10
with O 0 3.238159393403883e-11
15 O 0 1.97862531914339e-10
matings O 0 2.049407839876949e-06
informative O 0 0.0001438483304809779
for O 0 0.00045685519580729306
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
were O 0 1.122380144380486e-08
found O 0 4.8530004903568624e-08
. O 0 9.204209838742372e-09

Of O 0 1.923259551617207e-09
57 O 0 4.840530110072905e-08
informative O 0 9.332499928405014e-08
meioses O 0 7.3437090577499475e-06
, O 0 3.5615815852096944e-11
two O 0 2.996244745367971e-13
crossovers O 0 1.9247704818869948e-10
were O 0 1.4181408825031383e-10
noted O 0 2.049338476695084e-09
between O 0 1.2293686957320915e-08
the O 0 9.989505633711815e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999992847442627
gene O 0 1.4040625728739542e-07
and O 0 8.519043803723036e-10
the O 0 2.97822183581431e-10
HLA O 0 0.01412847638130188
- O 0 0.0007168616284616292
B O 0 2.3890132069936953e-05
gene O 0 2.1350768264483122e-08
, O 0 2.866562239314807e-12
with O 0 8.710559536032406e-14
a O 0 1.9299399047194993e-13
recombinant O 0 3.4841957877868035e-12
fraction O 0 4.704989869930287e-12
of O 0 9.390387772922892e-12
0 O 0 1.1142112299467044e-07
. O 0 1.839750130017137e-09

035 O 0 0.007939822971820831
. O 0 1.0600244877423393e-06

A O 0 5.7722225221823464e-08
lod O 0 0.0002651066752150655
score O 0 2.595955663764471e-07
of O 0 6.132623163630779e-13
13 O 0 5.369622455009271e-11
was O 0 6.720732997900214e-11
calculated O 0 6.207250685674737e-11
for O 0 2.27756377126076e-12
linkage O 0 0.232626810669899
between O 0 0.11209898442029953
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
and O 0 4.1861738964144024e-08
HLA O 0 0.0006340495892800391
- O 0 0.005353595595806837
B O 0 0.00036569545045495033
at O 0 8.038818222200206e-11
a O 0 2.696873757299101e-13
maximum O 0 2.445696911049927e-13
likelihood O 0 3.914762665511301e-13
value O 0 2.3484488550877536e-13
of O 0 2.230580459651032e-14
the O 0 1.7706645069441584e-13
recombinant O 0 2.237622196907263e-12
fraction O 0 4.231319721686999e-12
of O 0 3.0180647477701106e-12
0 O 0 1.580107067411518e-08
. O 0 5.545181536170674e-10

04 O 0 0.0016132232267409563
. O 0 3.7253525420055666e-07

18 O 0 3.7649152773155947e-07
families O 0 4.852366286556276e-10
with O 0 5.954659682005925e-11
21 O 0 3.734736131466576e-10
informative O 0 1.1606634542360439e-09
matings O 0 6.450848388794839e-08
for O 0 7.2336524790939105e-12
both O 0 4.244999837754726e-11
properdin O 0 8.25500933387957e-07
Factor O 0 1.7966182985773571e-09
B O 0 1.229366034749546e-06
allotype O 0 1.808943466130586e-07
and O 0 5.246761691779511e-09
HLA O 0 0.00011912418267456815
- O 0 0.0001229550689458847
B O 0 7.594609633088112e-05
were O 0 2.2536951471696653e-10
found O 0 1.2032719265420155e-09
. O 0 7.86466891611326e-10

Of O 0 1.8619976671629956e-09
72 O 0 3.69128201782587e-07
informative O 0 1.0799717387044439e-07
meioses O 0 2.9897648346377537e-05
, O 0 7.562455106580046e-10
three O 0 3.1267727990114125e-11
recombinants O 0 2.6400917363389453e-07
were O 0 7.93838050849871e-10
found O 0 3.596905273628437e-10
, O 0 7.634895320129953e-13
giving O 0 9.741084214210868e-14
a O 0 6.180918678353603e-14
recombinant O 0 1.6989457800667407e-12
fraction O 0 3.3407948716451807e-12
of O 0 4.320729971724058e-12
0 O 0 5.9073826719213685e-08
. O 0 1.8620261998947285e-09

042 O 0 0.0015447521582245827
. O 0 8.207093742385041e-07

A O 0 3.9162440401696585e-08
lod O 0 6.333837518468499e-05
score O 0 1.553087400907316e-07
of O 0 8.519924132519008e-13
16 O 0 2.6797656108024093e-11
between O 0 7.881754277017095e-11
HLA O 0 0.00010763492900878191
- O 0 2.8033524358761497e-05
B O 0 2.8999385904171504e-05
and O 0 3.3991995329607505e-10
Factor O 0 1.2192048759462892e-10
B O 0 8.750484425945615e-08
allotypes O 0 4.881786974664237e-09
was O 0 5.111404077773329e-10
calculated O 0 3.419290892092697e-11
at O 0 3.3770046221209826e-12
a O 0 1.3527612190145089e-13
maximum O 0 1.5446631061906413e-13
likelihood O 0 4.61180301846581e-13
value O 0 1.4265161046769087e-13
of O 0 2.2045933194226805e-14
the O 0 3.5945953245214435e-13
recombinant O 0 4.114345582978407e-12
fraction O 0 5.359939922455759e-12
of O 0 3.732496516722916e-12
0 O 0 7.841071436587299e-08
. O 0 3.09631276174116e-09

04 O 0 0.0006362003041431308
. O 0 1.0195230260023891e-07

A O 0 5.57165480419286e-10
crossover O 0 6.413938269389519e-10
was O 0 7.98133470425455e-09
shown O 0 1.3810369514644094e-10
to O 0 7.397331011627095e-12
have O 0 4.0956037172801274e-11
occurred O 0 5.789361767760681e-10
between O 0 1.493400672222811e-12
genes O 0 6.954960218852335e-11
for O 0 2.938403914718585e-13
Factor O 0 1.665146631690817e-10
B O 0 9.559662430547178e-07
and O 0 1.3185872393961517e-09
HLA O 0 9.355753718409687e-06
- O 0 9.18787918635644e-06
D O 0 5.762647106166696e-06
, O 0 1.770085467089899e-11
in O 0 2.795452020906697e-12
which O 0 8.381734889484349e-11
HLA O 0 8.868993290889193e-07
- O 0 4.039245879994269e-07
D O 0 3.400760135718883e-07
segregared O 0 9.742967321813012e-09
with O 0 2.0819224816337467e-11
HLA O 0 4.405320396472234e-06
- O 0 2.915245431722724e-07
A O 0 1.7535752405706262e-08
and O 0 1.0698720132040762e-08
B O 0 3.968741566495737e-06
. O 0 8.07307165562321e-10

These O 0 1.140764194218491e-08
studies O 0 5.587831308773161e-10
suggest O 0 1.1993508963747956e-10
that O 0 3.033114991807251e-12
the O 0 5.424949768920162e-13
genes O 0 1.492786276535707e-11
for O 0 2.311507105515198e-12
Factor O 0 1.86231517318447e-07
B O 1 0.9999706745147705
and O 1 0.999929666519165
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 6.293046639349598e-11
located O 0 1.5998674385286904e-08
outside O 0 3.376327217807784e-09
those O 0 2.410754105022783e-12
for O 0 1.4392113802802475e-12
HLA O 0 7.789145456627011e-06
, O 0 3.981560914301241e-11
that O 0 2.0083575427709555e-11
the O 0 2.7105509677050055e-12
order O 0 1.1827260525121286e-11
of O 0 1.6567299019210752e-13
genese O 0 4.2774601638484455e-07
is O 0 2.515368191513545e-10
HLA O 0 5.436066317088262e-07
- O 0 5.755995502454425e-08
A O 0 4.5023167416502474e-09
, O 0 1.3135863230484546e-10
- O 0 1.4719853425049223e-07
B O 0 8.127398700708e-07
, O 0 2.0230284461519865e-11
- O 0 1.1995099136186127e-08
D O 0 2.705561641391796e-08
, O 0 6.148190897364847e-12
Factor O 0 1.0142325174156142e-10
B O 0 4.757918759423774e-06
allotype O 0 6.657105404883623e-05
, O 0 0.0005002256948500872
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
, O 0 5.81077330349955e-12
that O 0 2.1489142930375404e-12
the O 0 1.358756098086833e-12
genes O 0 3.709888840575104e-09
coding O 0 0.037085071206092834
for O 0 0.00037956490996293724
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 2.2236884333892704e-08
Factor O 0 1.1114217990382258e-08
B O 0 1.6685915397829376e-05
allotypes O 0 9.169693271360302e-08
are O 0 4.96665512536576e-12
approximately O 0 1.232583306254309e-11
3 O 0 1.0692144947199722e-09
- O 0 1.4674233170808293e-06
- O 0 1.0012422535510268e-06
5 O 0 8.17416828668982e-11
centimorgans O 0 5.5895394979188495e-09
from O 0 1.8411471349247255e-13
the O 0 6.828841420288001e-13
HLA O 0 6.46003357474001e-08
- O 0 1.2536923499339991e-08
A O 0 2.7777464772782423e-09
and O 0 9.778184928421751e-10
HLA O 0 6.202428721735487e-06
- O 0 5.633387900161324e-06
B O 0 4.742706494198501e-07
loci O 0 2.7983979716816876e-11
, O 0 3.2847329023422134e-11
and O 0 4.974773024080115e-11
that O 0 1.0070597827871453e-10
the O 0 3.2949674239057813e-11
apparent O 0 6.941419661288251e-10
lack O 0 7.928914469435e-12
of O 0 1.0494282851568337e-13
recombinants O 0 1.1319442450030692e-07
between O 0 1.217754109356095e-11
the O 0 1.113947822872774e-11
Factor O 0 2.1801367378060377e-09
B O 0 4.828565215575509e-05
gene O 0 0.003870293265208602
and O 1 0.9996602535247803
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
gene O 0 4.898353836324532e-06
suggests O 0 4.4713566182963405e-08
that O 0 4.727041535979026e-10
these O 0 4.2098605851359494e-11
two O 0 1.5065462211083513e-09
genes O 0 1.2527501667136676e-06
lie O 0 0.01056644506752491
in O 0 1.3032451784411592e-09
close O 0 6.050944278968018e-08
proximity O 0 2.5518025381643383e-07
to O 0 1.8707442261955975e-09
one O 0 3.545201909815887e-10
another O 0 3.5455349767232747e-09
. O 0 1.8362419140771635e-08

Distribution O 0 3.358390188168414e-08
of O 0 2.8429435888766008e-11
emerin O 0 3.401518188184127e-05
and O 0 5.4376741331907397e-08
lamins O 0 8.266859367722645e-05
in O 0 2.556901579353621e-09
the O 0 8.648336269345691e-09
heart O 0 7.366983481915668e-06
and O 0 6.879786185187697e-10
implications O 0 3.884985111390904e-10
for O 0 7.731356527207467e-11
Emery B-Disease 1 0.9345373511314392
- I-Disease 1 0.9999165534973145
Dreifuss I-Disease 1 0.9999783039093018
muscular I-Disease 1 0.9921180605888367
dystrophy I-Disease 1 0.9877206683158875
. O 0 1.0129150851412305e-08

Emerin O 0 0.00023497668735217303
is O 0 1.091697066080144e-09
a O 0 1.1633290858403811e-10
nuclear O 0 1.6704326810668135e-07
membrane O 0 1.860731657643555e-07
protein O 0 9.157353275668356e-08
which O 0 2.8043640742936304e-09
is O 0 2.8323798861862315e-10
missing O 0 6.656696971418796e-09
or O 0 7.041028315946107e-10
defective O 0 5.351398158381926e-06
in O 0 1.3092308392970153e-07
Emery B-Disease 1 0.9996784925460815
- I-Disease 1 0.9999927282333374
Dreifuss I-Disease 1 0.9999957084655762
muscular I-Disease 1 0.9990173578262329
dystrophy I-Disease 1 0.9981697797775269
( O 0 5.5236952789528004e-08
EDMD B-Disease 1 0.9999915361404419
) O 0 2.5477119081074306e-08
. O 0 4.7320867224698304e-09

It O 0 7.372919412773626e-07
is O 0 2.892543704557937e-10
one O 0 1.654249653926243e-11
member O 0 7.666926447012778e-13
of O 0 1.1144885470222576e-13
a O 0 3.2915787873122326e-09
family O 0 4.435559475268747e-09
of O 0 5.222830848361504e-12
lamina O 0 2.16876323975157e-05
- O 0 0.00018440067651681602
associated O 0 1.472976833838402e-07
proteins O 0 1.7261383433719857e-08
which O 0 1.987036230000072e-10
includes O 0 7.634946147527799e-11
LAP1 O 0 4.283242560632061e-06
, O 0 1.443958702607162e-10
LAP2 O 0 7.550814871137845e-07
and O 0 4.359809846476992e-09
lamin O 0 5.756715836469084e-05
B O 0 6.0213082178961486e-05
receptor O 0 6.022732090826821e-09
( O 0 2.4524504649292567e-10
LBR O 0 8.865280688041821e-05
) O 0 1.3822261113460854e-09
. O 0 3.929717884432193e-09

A O 0 1.3229411344184427e-08
panel O 0 4.307726619856567e-09
of O 0 5.4513503086606185e-12
16 O 0 2.4083759986304187e-10
monoclonal O 0 2.903474616289259e-08
antibodies O 0 4.3448448394656225e-08
( O 0 2.3954418310045966e-11
mAbs O 0 2.8703215804171123e-08
) O 0 1.9906931658653093e-10
has O 0 3.33306715560866e-09
been O 0 2.134941556874992e-09
mapped O 0 2.0447403585421853e-05
to O 0 6.063612945084174e-10
six O 0 5.192644491475162e-12
specific O 0 7.117712452417435e-13
sites O 0 3.260466063803591e-10
throughout O 0 8.056884326368419e-11
the O 0 2.5845272103031114e-12
emerin O 0 2.374763496959531e-09
molecule O 0 3.313091814782787e-11
using O 0 2.5090709024344626e-11
phage O 0 1.3421114219980268e-09
- O 0 3.360126399343244e-08
displayed O 0 3.268205150952497e-10
peptide O 0 1.4344989085479654e-10
libraries O 0 7.318537442735362e-10
and O 0 1.3218508509993399e-09
has O 0 6.631588611583084e-10
been O 0 6.778006628183064e-11
used O 0 3.4976760376892457e-10
to O 0 3.512663077076539e-11
localize O 0 4.429331283972715e-07
emerin O 0 9.717377906781621e-06
in O 0 3.6719933760309686e-09
human O 0 8.33910647202174e-08
and O 0 4.710216501280229e-07
rabbit O 1 0.9853389263153076
heart O 0 0.017261404544115067
. O 0 4.552125076884295e-08

Several O 0 1.070641020284313e-09
mAbs O 0 6.789195339251819e-08
against O 0 5.133857228223349e-10
different O 0 1.555711115486247e-11
emerin O 0 9.064225992005959e-07
epitopes O 0 3.997275143774459e-06
did O 0 1.7945202444025199e-06
not O 0 4.489588978362491e-10
recognize O 0 6.012341735583959e-10
intercalated O 0 1.3490440764485356e-08
discs O 0 6.608163675991818e-05
in O 0 1.6135574298914435e-07
the O 0 9.356682539873873e-07
heart O 0 0.002831072546541691
, O 0 4.240666484633948e-09
though O 0 6.3385274806648795e-09
they O 0 7.242095256820846e-10
recognized O 0 8.885762264876362e-11
cardiomyocyte O 0 6.826227405554164e-08
nuclei O 0 2.0241845977153616e-09
strongly O 0 3.0860598521087468e-09
, O 0 1.2179335318052154e-10
both O 0 5.302089323144799e-10
at O 0 5.1542507151225436e-08
the O 0 1.898595503035949e-09
rim O 0 3.8950831367401406e-05
and O 0 2.963469292183163e-08
in O 0 6.635461069492976e-10
intranuclear O 0 5.850537490914576e-06
spots O 0 1.5835244937534299e-07
or O 0 1.5855826651645089e-09
channels O 0 3.025639045972639e-07
. O 0 1.1657690812683086e-08

A O 0 2.962707412734744e-07
polyclonal O 0 8.381365660170559e-06
rabbit O 0 0.00021969221415929496
antiserum O 0 1.934908505063504e-05
against O 0 1.2630678725145117e-07
emerin O 0 8.384782995563e-05
did O 0 1.0537733032833785e-06
recognize O 0 5.276144854349241e-09
both O 0 6.900260918207834e-10
nuclear O 0 2.5608721898606746e-06
membrane O 0 2.083945446429425e-06
and O 0 3.86290910370235e-09
intercalated O 0 1.618084333188108e-08
discs O 0 1.5055178437251016e-06
but O 0 2.166590995500428e-08
, O 0 2.002488886515552e-12
after O 0 6.887350932627267e-13
affinity O 0 1.8001212499785257e-12
purification O 0 2.171002544404388e-10
against O 0 1.746513628164692e-10
a O 0 2.205143533051679e-11
pure O 0 3.432223394383982e-10
- O 0 1.2311835462242016e-06
emerin O 0 3.695505483847228e-07
band O 0 1.279295974709882e-10
on O 0 1.3900663606292163e-11
a O 0 1.372012486261509e-11
western O 0 1.0332559696735188e-07
blot O 0 0.35078221559524536
, O 0 3.7562339905150566e-09
it O 0 3.7595602186968335e-09
stained O 0 1.0010799996962305e-05
only O 0 3.099147327656482e-10
the O 0 2.053201879348432e-11
nuclear O 0 1.450959388193951e-07
membrane O 0 5.106381308905839e-07
. O 0 4.988365276403783e-09

These O 0 1.945419114690594e-08
results O 0 2.0925061683385593e-09
would O 0 5.158424798423766e-10
not O 0 6.863896950815018e-11
be O 0 1.31011260867675e-11
expected O 0 3.093966055578434e-11
if O 0 9.644911536099698e-10
immunostaining O 0 2.0932513962179655e-06
at O 0 2.5634547817787734e-09
intercalated O 0 1.0345329037875217e-09
discs O 0 1.9672493181133177e-06
were O 0 4.013606158537186e-08
due O 0 1.2653162961839826e-09
to O 0 8.005125728960394e-11
a O 0 7.346939029373445e-11
product O 0 3.2500864222129167e-09
of O 0 2.7236626582577417e-12
the O 0 4.111133655726462e-10
emerin O 0 2.42871851696691e-06
gene O 0 3.3419858027627924e-06
and O 0 2.998908428253344e-07
, O 0 1.4470776799058171e-09
therefore O 0 9.814228318916207e-10
, O 0 9.932159261705209e-12
cast O 0 1.3138919119359826e-10
some O 0 2.0326002166115575e-12
doubt O 0 4.3707711061546917e-11
upon O 0 3.6764710199810313e-13
the O 0 5.39172612806782e-12
hypothesis O 0 8.927020900273419e-08
that O 0 2.3047498132200417e-08
cardiac B-Disease 0 0.020271310582756996
defects I-Disease 1 0.968548595905304
in O 0 6.125717391114449e-07
EDMD B-Disease 1 1.0
are O 0 3.3817175904005126e-07
caused O 0 3.6140119163974305e-07
by O 0 1.1595609195058643e-10
absence O 0 6.745869973734386e-10
of O 0 3.816130137584972e-12
emerin O 0 1.4116504644334782e-05
from O 0 1.0791404575494212e-10
intercalated O 0 1.576465109565106e-07
discs O 0 1.8887032638303936e-05
. O 0 6.665580087883427e-08

Although O 0 4.787066032463372e-08
emerin O 0 4.2733599912025966e-06
was O 0 9.063118255880909e-09
abundant O 0 5.356243226728452e-11
in O 0 2.4678025248303648e-11
the O 0 3.731423503516851e-11
membranes O 0 8.473674597553327e-07
of O 0 3.0781191397849517e-12
cardiomyocyte O 0 1.73466207797901e-06
nuclei O 0 1.8632384524153167e-08
, O 0 1.1002594391129605e-09
it O 0 1.251207848440572e-08
was O 0 1.7054465217825054e-07
absent O 0 6.447533618114676e-10
from O 0 7.681578355171748e-13
many O 0 2.5589174876272658e-12
non O 0 8.6223361783766e-11
- O 0 3.6086228192289127e-06
myocyte O 0 3.542634431141778e-06
cells O 0 3.578761038625089e-07
in O 0 9.904355113832253e-11
the O 0 1.5545529308269579e-09
heart O 0 1.1021209502359852e-05
. O 0 4.071788684001376e-09

This O 0 2.7613483721822263e-10
distribution O 0 2.350921957106067e-10
of O 0 3.1435505240540174e-12
emerin O 0 2.6418954348628176e-06
was O 0 1.5575929879219075e-08
similar O 0 2.01958953033321e-11
to O 0 6.725952433894733e-11
that O 0 4.729907090994523e-11
of O 0 1.292696852339681e-12
lamin O 0 1.8037830159300938e-05
A O 0 1.9426535402544687e-07
, O 0 2.7750853698327305e-11
a O 0 1.8580862543027266e-11
candidate O 0 4.783289042631367e-11
gene O 0 1.0403827133131927e-08
for O 0 1.7708723376586022e-11
an O 0 6.654471973455145e-10
autosomal O 0 0.0017921158578246832
form O 0 2.3360357204182947e-07
of O 0 9.268302392229089e-08
EDMD B-Disease 1 0.9999998807907104
. O 0 2.389582959949621e-06

In O 0 6.95695723251788e-09
contrast O 0 3.316321084412266e-08
, O 0 1.6822645498848487e-09
lamin O 0 0.0007293257513083518
B1 O 1 0.6505649089813232
was O 0 9.041711734880664e-08
absent O 0 4.153323518440999e-10
from O 0 1.7946497152948604e-12
cardiomyocyte O 0 1.7477026403867058e-07
nuclei O 0 6.070188796059028e-09
, O 0 4.609591180981809e-11
showing O 0 7.835804893829845e-09
that O 0 3.7969680732885536e-09
lamin O 0 0.010197005234658718
B1 O 1 0.5013979077339172
is O 0 7.832632875626189e-10
not O 0 5.4087755108067626e-11
essential O 0 9.082828347946326e-13
for O 0 6.12977753950382e-14
localization O 0 8.736517620455686e-10
of O 0 5.520489664359585e-13
emerin O 0 3.969271801906871e-06
to O 0 2.876154869824177e-10
the O 0 9.020151292560286e-11
nuclear O 0 5.251259835858946e-07
lamina O 0 1.5538444131379947e-06
. O 0 6.610249680960578e-09

Lamin O 1 0.9797629714012146
B1 O 1 0.9995952248573303
is O 0 7.618489235028392e-07
also O 0 2.114604882308413e-07
almost O 0 2.6625034621474697e-08
completely O 0 3.380059570190497e-05
absent O 0 6.171877942051651e-08
from O 0 1.1833448110287748e-10
skeletal O 0 0.003918199799954891
muscle O 0 1.18867899345787e-06
nuclei O 0 1.4308352547232062e-07
. O 0 5.508121514452569e-09

In O 0 1.0854898135903568e-07
EDMD B-Disease 1 0.9999542236328125
, O 0 8.049281380317908e-11
the O 0 4.562901163678024e-13
additional O 0 1.109966285550712e-12
absence O 0 6.153649811935225e-11
of O 0 6.98268396229218e-12
lamin O 0 0.37553635239601135
B1 O 1 0.998802900314331
from O 0 1.4381989821288244e-08
heart O 0 0.0010193033376708627
and O 0 7.283242666744627e-07
skeletal O 1 0.8399781584739685
muscle O 0 1.4014745829626918e-05
nuclei O 0 7.416035145979549e-07
which O 0 2.3552468064735876e-07
already O 0 2.1601688615646708e-07
lack O 0 2.2394628373945125e-08
emerin O 0 0.00021001521963626146
may O 0 6.622595094540884e-08
offer O 0 1.4166856923680804e-11
an O 0 6.346534625958911e-13
alternative O 0 4.2761481855446704e-11
explanation O 0 2.565938572729465e-10
of O 0 3.1667678462160564e-12
why O 0 1.0984800979940701e-07
these O 0 4.2202336070218394e-10
tissues O 0 5.013855641777809e-08
are O 0 1.6982500475326567e-11
particularly O 0 6.2368393782819e-10
affected O 0 4.802867437092573e-09
. O 0 1.8220372433042087e-10
. O 0 1.7954057129898615e-09

Genetic O 0 3.5450273117021425e-06
mapping O 0 2.0312484139139997e-07
of O 0 4.4045218861032964e-11
the O 0 3.90988263987424e-09
copper B-Disease 0 2.6748535674414597e-05
toxicosis I-Disease 0 0.00031266588484868407
locus O 0 1.7312430600213702e-07
in O 0 1.3576313406815643e-09
Bedlington O 0 0.000236181280342862
terriers O 0 4.903562512481585e-05
to O 0 1.5742731562795598e-09
dog O 0 6.332068551273551e-06
chromosome O 0 6.13290467299521e-05
10 O 0 1.234452762233218e-09
, O 0 1.7304714605703708e-10
in O 0 6.264089941199202e-11
a O 0 4.498247996309601e-09
region O 0 3.212021795206965e-07
syntenic O 0 0.00014333405124489218
to O 0 5.338074426930461e-09
human O 0 2.7090576892874196e-08
chromosome O 0 8.171139779733494e-05
region O 0 2.866044326310657e-07
2p13 O 0 1.1458208746262244e-06
- O 0 6.963232863199664e-06
p16 O 0 3.031478854609304e-07
. O 0 3.9444438826308215e-09

Abnormal O 1 0.9985861778259277
hepatic B-Disease 1 0.9989981055259705
copper I-Disease 0 0.031220020726323128
accumulation I-Disease 0 1.8330023522139527e-05
is O 0 1.3186954861410527e-09
recognized O 0 1.1582175218904922e-09
as O 0 6.884597070211385e-08
an O 0 7.911094144219533e-05
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 3.5426776179292574e-08
man O 0 2.4972161554615013e-05
, O 0 5.348650411463041e-10
mouse O 0 1.884087032522075e-05
, O 0 4.5151735683646166e-09
rat O 0 0.00044718559365719557
and O 0 2.4908120010991297e-08
dog O 0 1.2941303793922998e-05
. O 0 6.0448055450024185e-09

The O 0 1.5721886015285236e-08
major O 0 4.123795527277707e-09
cause O 0 8.117145000596793e-08
of O 0 1.1142059497259993e-09
hepatic B-Disease 1 0.9989008903503418
copper I-Disease 0 0.3942945599555969
accumulation I-Disease 0 0.00015761952090542763
in O 0 8.99013983257646e-08
man O 0 7.522660598624498e-05
is O 0 6.215724601688066e-10
a O 0 7.575968186124271e-10
dysfunctional O 0 6.13900920143351e-06
ATP7B O 0 7.630511390743777e-06
gene O 0 3.305196514702402e-06
, O 0 7.93447973990169e-09
causing O 0 2.5500369247311028e-06
Wilson B-Disease 0 0.1800338327884674
disease I-Disease 1 0.891948401927948
( O 0 1.7336404534162853e-09
WD B-Disease 1 0.9999425411224365
) O 0 9.471513351400063e-08
. O 0 1.7645801264620786e-08

Mutations O 0 0.0014757383614778519
in O 0 1.0300810204810773e-09
the O 0 1.9395263173294097e-10
ATP7B O 0 2.8738422770402394e-05
genes O 0 6.533739451697329e-07
have O 0 3.010820393001268e-08
also O 0 7.190620987529428e-09
been O 0 1.6699756022475754e-09
demonstrated O 0 4.2286943391367515e-10
in O 0 1.1719590575776095e-10
mouse O 0 6.176158058224246e-05
and O 0 2.8669737162090314e-07
rat O 0 0.00040878966683521867
. O 0 6.61794574696728e-09

The O 0 6.764956150817625e-09
ATP7B O 0 4.485409135668306e-06
gene O 0 6.380425929819467e-07
has O 0 2.2543982680645058e-08
been O 0 1.116840064874225e-09
excluded O 0 1.5370573702711e-09
in O 0 9.323319893894677e-12
the O 0 5.7281761799143904e-12
much O 0 1.419642875477578e-10
rarer O 0 1.2899885177830583e-06
human O 0 1.2617506399692502e-05
copper B-Disease 1 0.692799985408783
overload I-Disease 1 0.9994531273841858
disease O 1 0.9954164028167725
non B-Disease 0 5.996074037284416e-08
- I-Disease 0 0.05227654427289963
Indian I-Disease 0 0.029894033446907997
childhood I-Disease 0 0.1101759746670723
cirrhosis I-Disease 0 0.0015864273300394416
, O 0 3.6022997085272124e-11
indicating O 0 2.9701789916458665e-09
genetic O 0 8.67809660576313e-07
heterogeneity O 0 1.783873995009344e-05
. O 0 4.578972223612254e-08

By O 0 6.992527112892333e-10
investigating O 0 3.2746463318744645e-09
the O 0 1.6698353810795652e-09
common O 0 9.704760941531276e-07
autosomal O 1 0.9730931520462036
recessive O 1 0.9964954257011414
copper B-Disease 0 0.4440537691116333
toxicosis I-Disease 0 0.3552531898021698
( O 0 1.3206084004124818e-09
CT B-Disease 0 0.013178055174648762
) O 0 4.662524810683522e-10
in O 0 2.5617769017216574e-10
Bedlington O 0 0.0018224585801362991
terriers O 0 0.0032076125498861074
, O 0 8.77193606640958e-09
we O 0 5.8354840959395915e-09
have O 0 1.2732533777315425e-11
identified O 0 8.287323605138397e-11
a O 0 2.2058492185617062e-12
new O 0 3.4157187495109653e-11
locus O 0 4.98787056102401e-09
involved O 0 5.588942197931601e-09
in O 0 2.5738975182321155e-06
progressive O 1 0.9997326731681824
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 2.9975788606861897e-07

We O 0 7.967133086594913e-08
examined O 0 3.3248634956350998e-09
whether O 0 3.452806443537959e-11
the O 0 4.12800141291747e-11
WD B-Disease 1 0.9832058548927307
gene O 0 4.526723387243692e-06
ATP7B O 0 7.6575881394092e-05
was O 0 1.1507427899459799e-07
also O 0 1.5844299483536162e-10
causative O 0 3.2072198230537197e-09
for O 0 5.947593762975489e-13
CT B-Disease 0 2.6672982130548917e-05
by O 0 3.974381154042694e-12
investigating O 0 1.4415205140672072e-10
the O 0 4.4595471759834027e-10
chromosomal O 0 0.1389262080192566
co O 0 0.00015217530017253011
- O 0 1.9393528418731876e-06
localization O 0 3.093563805123267e-07
of O 0 4.194213552854986e-12
ATP7B O 0 1.0392370313638821e-05
and O 0 1.699965307411233e-10
C04107 O 0 2.821219091675431e-10
, O 0 6.566641219500624e-14
using O 0 6.939489673001009e-13
fluorescence O 0 3.007997670390061e-11
in O 0 5.739265399734572e-12
situ O 0 2.653721020706712e-09
hybridization O 0 6.643590677590794e-10
( O 0 1.6678157119254244e-11
FISH O 0 5.5214830041450114e-08
) O 0 3.91829457768722e-10
. O 0 2.0522683552570697e-09

C04107 O 0 1.0812700566020794e-05
is O 0 5.784019929677697e-10
an O 0 5.485561657692095e-12
anonymous O 0 1.3017166511364309e-10
microsatellite O 0 8.119968697428703e-06
marker O 0 2.0035617126268335e-05
closely O 0 6.056995260905751e-08
linked O 0 9.412081567461428e-07
to O 0 3.7075120751239865e-09
CT B-Disease 0 0.4698786437511444
. O 0 2.932286413681595e-08

However O 0 1.5451524859599886e-06
, O 0 2.564080725520057e-09
BAC O 0 1.541493588774756e-06
clones O 0 2.4133453280228423e-07
containing O 0 1.8244514787824073e-09
ATP7B O 0 0.00010484106314834207
and O 0 4.045793033924383e-09
C04107 O 0 2.6807665420847115e-08
mapped O 0 1.0130879672942683e-05
to O 0 4.875364001399873e-10
the O 0 1.6684592596405423e-10
canine O 0 0.00015360134420916438
chromosome O 0 0.0016222362173721194
regions O 0 4.421523556175089e-07
CFA22q11 O 0 0.0018832701025530696
and O 0 8.777296045536787e-08
CFA10q26 O 0 5.9336452977731824e-05
, O 0 1.2879236566121222e-10
respectively O 0 7.936605539438091e-11
, O 0 4.2999540560140215e-12
demonstrating O 0 5.7440104755945853e-11
that O 0 9.453690053007335e-10
WD B-Disease 1 0.9998511075973511
cannot O 0 1.6298160971928155e-06
be O 0 2.0455484528447698e-11
homologous O 0 4.838355827097018e-10
to O 0 4.472298920088491e-10
CT B-Disease 0 0.03188740089535713
. O 0 2.7539243774299393e-08

The O 0 2.4785094865364954e-08
copper O 0 5.47336469480797e-07
transport O 0 2.98195352854691e-08
genes O 0 2.4393205677597507e-08
CTR1 O 0 2.1579917302005924e-05
and O 0 1.1353158413385245e-08
CTR2 O 0 2.1990936147631146e-05
were O 0 3.7125291729722676e-09
also O 0 1.845112840292984e-09
excluded O 0 2.1671147099056043e-09
as O 0 5.1657969568630335e-11
candidate O 0 4.435436393168679e-11
genes O 0 2.0160960401138794e-10
for O 0 3.641161590989261e-12
CT B-Disease 0 0.15487827360630035
since O 0 2.0540124978651875e-07
they O 0 2.608271820747632e-09
both O 0 1.5522559626557353e-10
mapped O 0 0.0004285915056243539
to O 0 2.0130663358486345e-08
canine O 0 0.009638257324695587
chromosome O 0 0.045072901993989944
region O 0 9.203383342537563e-06
CFA11q22 O 0 0.0009880972793325782
. O 0 3.8279257097428854e-08

2 O 0 2.25179462631786e-07
- O 0 5.028483792557381e-05
22 O 0 3.7909202887931315e-08
. O 0 3.6400764624744397e-09

5 O 0 1.0044288956123637e-06
. O 0 4.698399180824708e-08

A O 0 5.951395820602556e-09
transcribed O 0 1.397198161612323e-07
sequence O 0 1.0555499585507278e-07
identified O 0 2.709104052200928e-08
from O 0 2.1533291642839014e-12
the O 0 3.874061488273739e-11
C04107 O 0 7.856070993739195e-08
- O 0 1.9811315610240854e-07
containing O 0 6.431775112503146e-10
BAC O 0 7.083396667439956e-06
was O 0 2.7596556151365803e-08
found O 0 7.899543519318541e-11
to O 0 3.245478755534159e-12
be O 0 1.7883452965022917e-12
homologous O 0 2.637439745767356e-11
to O 0 9.279747109625092e-12
a O 0 1.7512227779015177e-11
gene O 0 9.238475229267351e-08
expressed O 0 3.8289274528757744e-11
from O 0 6.965922630386423e-12
human O 0 2.4936821496623907e-09
chromosome O 0 1.4679420928587206e-05
2p13 O 0 1.377203773245128e-07
- O 0 1.757105906108336e-06
p16 O 0 7.76514941236428e-09
, O 0 1.5254733587433122e-10
a O 0 1.0838022146408832e-10
region O 0 8.393934436412565e-09
devoid O 0 1.7034131882809334e-09
of O 0 1.4054182080266986e-13
any O 0 4.988757670854049e-12
positional O 0 1.1692501544757761e-07
candidate O 0 1.0911604952923426e-08
genes O 0 2.1687806395220832e-07
. O 0 1.188467102508639e-08

Molecular O 0 7.412160130115808e-08
analysis O 0 1.3152666733518004e-09
of O 0 9.452072371324283e-13
the O 0 1.2152040658464092e-11
APC B-Disease 0 6.101064542463064e-09
gene O 0 1.3860998571146865e-08
in O 0 5.670586222805696e-11
205 O 0 2.7993390938618745e-10
families O 0 6.503393656931422e-11
: O 0 4.755106031151257e-12
extended O 0 1.1400631549918216e-09
genotype O 0 4.6480916893187896e-08
- O 0 3.7956995129206916e-06
phenotype O 0 4.5440012286235287e-07
correlations O 0 1.5102150641155276e-08
in O 0 4.0898891912055646e-11
FAP B-Disease 0 3.90286425400177e-09
and O 0 1.561753226742013e-10
evidence O 0 2.0210627615924182e-10
for O 0 5.088226389705908e-13
the O 0 2.438901728143983e-12
role O 0 1.766813778614207e-11
of O 0 2.9179572169982237e-13
APC B-Disease 0 1.995035958657354e-08
amino O 0 2.5040103324158736e-09
acid O 0 4.671598219374573e-09
changes O 0 1.5976080902646572e-08
in O 0 0.0017799276392906904
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 0.7529882192611694
. O 0 5.497376776020246e-08

BACKGROUND O 0 1.2838709153584205e-05
/ O 0 0.0002203143812948838
AIMS O 0 1.8047664696041466e-07
The O 0 1.9293355801863754e-10
development O 0 5.271216352298325e-09
of O 0 5.908841558266431e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 2.2066277693966185e-08
a O 0 4.713156948055186e-11
variable O 0 3.5949454524342173e-09
range O 0 9.524244504177659e-09
of O 0 1.6710292871646715e-10
extracolonic O 0 0.1519193947315216
manifestations O 0 0.015583815053105354
in O 0 0.0006779723335057497
familial B-Disease 1 0.9999998807907104
adenomatous I-Disease 1 0.9999830722808838
polyposis I-Disease 1 0.9999994039535522
( O 0 2.0881181228560308e-07
FAP B-Disease 0 1.7187845742228092e-06
) O 0 1.3892144101745885e-09
is O 0 5.842107353437598e-10
the O 0 1.0826803342744995e-10
result O 0 1.4821458504954421e-09
of O 0 1.618630468373794e-12
the O 0 3.009928750685731e-09
dominant O 0 4.658399484469555e-05
inheritance O 0 1.81838076969143e-05
of O 0 1.0497491302885464e-06
adenomatous B-Disease 1 0.9999996423721313
polyposis I-Disease 1 0.999990701675415
coli I-Disease 1 0.9999992847442627
( O 0 1.2185411790710532e-08
APC B-Disease 0 2.2681616940189997e-07
) O 0 1.7120471706988383e-10
gene O 0 5.590010800915479e-07
mutations O 0 2.1756966816610657e-05
. O 0 2.0132697287067458e-08

In O 0 3.4444891383600407e-09
this O 0 1.2998428722266198e-11
study O 0 1.7462897447528825e-11
, O 0 3.9707042450050356e-13
direct O 0 6.237284994048409e-12
mutation O 0 1.5005582332250356e-09
analysis O 0 7.209662034046715e-11
of O 0 2.429656139908004e-13
the O 0 3.301308532099867e-11
APC B-Disease 0 1.1615166606304683e-08
gene O 0 1.028731162477925e-07
was O 0 4.7593438523563236e-08
performed O 0 5.689703375111321e-09
to O 0 1.9066461950933977e-11
determine O 0 2.531926612814317e-10
genotype O 0 9.626777597304681e-09
- O 0 1.046726083586691e-06
phenotype O 0 1.3407104404450365e-07
correlations O 0 3.139253301753797e-09
for O 0 3.421782995838285e-11
nine O 0 9.96804327968448e-09
extracolonic O 0 1.0692154319258407e-05
manifestations O 0 7.366178920165112e-07
and O 0 2.7549316161668003e-09
to O 0 3.534727718856878e-11
investigate O 0 6.870659041702254e-10
the O 0 4.463272113008898e-11
incidence O 0 8.179572432709392e-06
of O 0 1.796685022981137e-11
APC B-Disease 0 3.489767777864472e-06
mutations O 0 6.560251677001361e-06
in O 0 5.580910400482253e-09
non O 0 9.184761893266113e-07
- O 1 0.9997525811195374
FAP O 1 0.9995224475860596
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 8.109320788207697e-07

METHODS O 0 4.4391927644937823e-07
The O 0 3.0451982602208716e-10
APC B-Disease 0 5.53015455651007e-09
gene O 0 1.696184170896231e-08
was O 0 1.8314594285584462e-09
analysed O 0 4.870914338539478e-09
in O 0 6.039598508811306e-12
190 O 0 5.66041796767891e-11
unrelated O 0 9.537255429847846e-10
FAP B-Disease 0 7.191021467178871e-08
and O 0 8.800862261182374e-09
15 O 0 2.0419796964432635e-09
non O 0 2.3517409886153473e-07
- O 1 0.9997233748435974
FAP O 1 0.9994826316833496
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
patients O 0 7.501692778077995e-08
using O 0 2.5913318713044475e-10
denaturing O 0 4.0784867451293394e-05
gradient O 0 8.343532499566209e-06
gel O 0 0.00011813370656454936
electrophoresis O 0 6.743026119693241e-07
, O 0 5.5498449585966725e-11
the O 0 1.2846765751889366e-12
protein O 0 3.432583661755473e-10
truncation O 0 1.1263989563303767e-06
test O 0 1.2834350854973309e-05
, O 0 1.9604200207634648e-11
and O 0 2.0957954122158284e-11
direct O 0 4.0837958015238485e-10
sequencing O 0 2.3693278308201116e-06
. O 0 2.0161786906669477e-08

RESULTS O 0 6.339597348414827e-06
Chain O 0 1.8568190398582374e-06
terminating O 0 2.6565990296489872e-08
signals O 0 2.20946638762598e-08
were O 0 2.436797708060823e-10
only O 0 3.285948943498873e-11
identified O 0 5.433340888316707e-08
in O 0 8.973121135014139e-10
patients O 0 2.25734431147373e-09
belonging O 0 6.205276292803319e-10
to O 0 1.863344145647261e-09
the O 0 3.007540327892855e-10
FAP B-Disease 0 7.93168268842237e-08
group O 0 1.2647709546342867e-09
( O 0 4.268143997954166e-12
105 O 0 2.7509829969574184e-09
patients O 0 1.267749638600435e-08
) O 0 1.5421192101072734e-10
. O 0 2.6175768219616202e-09

Amino O 0 9.331392902822699e-07
acid O 0 1.971815777324082e-08
changes O 0 6.426780635448992e-11
were O 0 1.57733427014195e-11
identified O 0 4.310932499862474e-09
in O 0 1.5702689148966442e-10
four O 0 6.645951344808054e-09
patients O 0 2.1249974224701873e-08
, O 0 5.52399237463419e-11
three O 0 3.705896353678462e-11
of O 0 3.333703972596691e-12
whom O 0 6.434308374991815e-08
belonged O 0 1.543073267384898e-06
to O 0 7.234419174828588e-10
the O 0 2.7890995069057567e-11
non O 0 2.2702191515566739e-10
- O 0 2.714856748298189e-07
FAP O 0 3.2428246754534484e-08
group O 0 8.399687345672646e-08
of O 0 1.1479623935883865e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 7.251139322761446e-05
. O 0 5.360408561472241e-09

Genotype O 0 0.0005948307225480676
- O 0 0.0007076942129060626
phenotype O 0 1.5048953173391055e-05
correlations O 0 6.300489303612267e-07
identified O 0 6.854787102383852e-07
significant O 0 8.69469163333747e-10
differences O 0 1.6798787783045555e-06
in O 0 9.612429074934425e-09
the O 0 7.697224524427781e-10
nature O 0 8.917385052598092e-09
of O 0 2.285187447256809e-12
certain O 0 1.5598933256200098e-09
extracolonic O 0 5.723162030335516e-05
manifestations O 0 1.5436972944371519e-06
in O 0 1.3692244005270027e-09
FAP B-Disease 0 2.247816865974528e-07
patients O 0 4.552617838271544e-09
belonging O 0 2.0680004930717644e-10
to O 0 3.538048187756715e-10
three O 0 2.8814536867649565e-10
mutation O 0 2.1488227730515064e-07
subgroups O 0 1.0305668638466159e-06
. O 0 3.458572450654174e-08

CONCLUSIONS O 0 2.311231355633936e-06
Extended O 0 1.3548090294079884e-07
genotype O 0 1.9022321566808387e-06
- O 0 4.2259376641595736e-05
phenotype O 0 3.4563083772809478e-06
correlations O 0 1.11336942154594e-06
made O 0 2.0025348490548822e-08
in O 0 2.578960378585293e-10
this O 0 1.0811243567054873e-10
study O 0 1.0488621082771488e-09
may O 0 4.929130437147933e-09
have O 0 1.278349509581389e-10
the O 0 2.576243905705322e-12
potential O 0 1.2214573970326104e-11
to O 0 1.5623334223557883e-11
determine O 0 6.153860754309903e-11
the O 0 3.979249113376937e-13
most O 0 2.622338652648326e-13
appropriate O 0 2.506285760525695e-12
surveillance O 0 5.553299615712604e-07
and O 0 3.4360636558261604e-09
prophylactic O 0 1.1368085779395187e-06
treatment O 0 3.202838527727181e-08
regimens O 0 2.5756239363516897e-09
for O 0 1.9715635374284446e-12
those O 0 2.461278958421076e-10
patients O 0 2.268043086672833e-09
with O 0 4.350877713665824e-10
mutations O 0 0.00020561492419801652
associated O 0 1.2199898264952935e-06
with O 0 1.7545160346799094e-07
life O 0 3.7076933949720114e-05
threatening O 0 0.0038816421292722225
conditions O 0 3.88449989259243e-05
. O 0 5.923807666619041e-09

This O 0 3.1133444711173297e-09
study O 0 1.6269828539972053e-10
also O 0 3.0867277484025735e-11
provided O 0 5.28413337391731e-12
evidence O 0 2.2581776726315894e-11
for O 0 2.4464445226579645e-12
the O 0 6.981195482813618e-11
pathological O 0 1.0175662055189605e-06
nature O 0 3.786380542436518e-09
of O 0 1.662821573142348e-12
amino O 0 1.726543352731369e-08
acid O 0 1.7780256156285645e-09
changes O 0 7.137677254798191e-11
in O 0 4.52498004344104e-11
APC O 0 2.205752558381846e-08
associated O 0 1.1092441409843445e-09
with O 0 4.417301940895513e-11
both O 0 1.3294336742575297e-09
FAP B-Disease 0 2.982357614200737e-07
and O 0 4.529312747081349e-08
non O 0 3.2955009032775706e-07
- O 1 0.9998371601104736
FAP O 1 0.9995731711387634
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.00011497754167066887
. O 0 7.127301526743679e-10
. O 0 2.721413094874947e-09

Inherited B-Disease 1 0.999859094619751
colorectal I-Disease 1 0.9999997615814209
polyposis I-Disease 1 0.9999788999557495
and O 1 0.9782694578170776
cancer B-Disease 1 0.9720327854156494
risk O 0 4.887426712230081e-07
of O 0 2.1112812019496996e-12
the O 0 5.66518387756787e-10
APC O 0 4.5293992911865644e-07
I1307K O 0 1.1041159098112985e-07
polymorphism O 0 2.49126469498151e-06
. O 0 1.075174260734002e-08

Germ O 0 0.17006772756576538
- O 0 0.00890122726559639
line O 0 0.00010877609747694805
and O 0 5.085391552306362e-10
somatic O 0 2.2918300590646368e-09
truncating O 0 4.924096401737188e-07
mutations O 0 7.404480015793524e-07
of O 0 2.42220761677292e-12
the O 0 5.271844766285838e-11
APC B-Disease 0 1.4424350602837421e-08
gene O 0 4.2609624273381996e-08
are O 0 3.9328932471827116e-11
thought O 0 3.2497283086740936e-08
to O 0 2.413536703826935e-09
initiate O 0 1.2602978131326381e-05
colorectal B-Disease 1 0.9999998807907104
tumor I-Disease 1 0.984355092048645
formation O 0 6.85939130562474e-06
in O 0 0.0076781632378697395
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999992847442627
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 0.0007632762426510453
sporadic O 1 0.9853589534759521
colorectal O 1 0.9999998807907104
carcinogenesis O 1 0.9991793036460876
, O 0 8.039087902034225e-07
respectively O 0 6.280380375756067e-07
. O 0 1.9997907330093767e-08

Recently O 0 4.863842605118407e-06
, O 0 3.255923031186825e-10
an O 0 4.37682572476672e-12
isoleucine O 0 0.0004044394881930202
- O 0 3.477249720162945e-06
- O 0 1.7370244904668652e-06
> O 0 2.614074068318928e-09
lysine O 0 2.141504573671682e-08
polymorphism O 0 1.4235543410734408e-08
at O 0 3.0449545662669664e-10
codon O 0 1.0045438258998729e-08
1307 O 0 9.103642284458147e-09
( O 0 3.409728445771809e-12
I1307K O 0 4.931055563872633e-10
) O 0 9.307999249835719e-13
of O 0 3.6079324342583666e-14
the O 0 2.8524922007777676e-11
APC B-Disease 0 8.665424822140722e-09
gene O 0 1.415505295199182e-07
has O 0 9.420109137181498e-09
been O 0 2.922010688966026e-10
identified O 0 1.5861755242596587e-09
in O 0 2.4430976339195887e-11
6 O 0 1.1500461694069486e-09
% O 0 1.3691264268145265e-11
- O 0 6.420283966690477e-07
7 O 0 9.737486372785042e-09
% O 0 2.7000246656527782e-12
of O 0 6.945250039143425e-13
the O 0 5.249281564978503e-10
Ashkenazi O 0 1.572682049300056e-05
Jewish O 0 1.514209913011655e-08
population O 0 2.921213826390101e-10
. O 0 4.55151305533974e-10

To O 0 3.7644682926440964e-09
assess O 0 9.646186960310388e-09
the O 0 6.345113323646956e-11
risk O 0 2.890971906310824e-10
of O 0 5.361621655550555e-14
this O 0 9.834830866362054e-12
common O 0 3.349552579745563e-10
APC B-Disease 0 2.9754483321653424e-08
allelic O 0 7.430944748421098e-08
variant O 0 0.023366596549749374
in O 0 0.0003337754460517317
colorectal O 1 1.0
carcinogenesis O 1 0.9991053938865662
, O 0 1.2186201274744235e-06
we O 0 6.8199409497538e-07
have O 0 7.74969699524064e-10
analyzed O 0 3.126740200087852e-09
a O 0 6.928581840204284e-12
large O 0 4.2971199515351444e-11
cohort O 0 8.798776707230616e-10
of O 0 1.7660883606246403e-12
unselected O 0 3.0371038519660942e-06
Ashkenazi O 0 1.5901385268080048e-05
Jewish O 0 3.440774420937487e-08
subjects O 0 4.464044778274001e-08
with O 0 2.8110043182039135e-09
adenomatous B-Disease 0 0.0005102686118334532
polyps I-Disease 0 0.3181961476802826
and O 0 8.27158999072708e-07
. O 0 4.806287847713975e-07
or O 1 0.9496175646781921
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 1.2824782125164802e-08
for O 0 7.79396772815355e-12
the O 0 1.2288610407029665e-10
APC O 0 1.467572872115852e-07
I1307K O 0 2.7728885854116925e-08
polymorphism O 0 8.131406730171875e-07
. O 0 1.069182431479021e-08

The O 0 1.103193358886756e-08
APC O 0 3.039259866000066e-08
I1307K O 0 1.1648488396076573e-08
allele O 0 1.4123137104249395e-09
was O 0 8.265574891197502e-10
identified O 0 3.4038966090221834e-10
in O 0 1.8301996203284876e-12
48 O 0 2.826346656714662e-10
( O 0 6.328885982995192e-13
10 O 0 4.5337635555531275e-12
. O 0 2.8732075312704053e-12
1 O 0 1.3320821008744321e-11
% O 0 1.6634053075920141e-12
) O 0 9.839610680059674e-13
of O 0 8.359565210197539e-13
476 O 0 1.6296516491820512e-07
patients O 0 7.527032863663408e-08
. O 0 1.09920217372661e-09

Compared O 0 7.1088135378261086e-09
with O 0 4.39848374736429e-12
the O 0 2.593905559095111e-12
frequency O 0 1.3430672574088476e-08
in O 0 2.4455792946298516e-10
two O 0 3.94852692209291e-11
separate O 0 6.223744297706446e-10
population O 0 9.396035338671282e-11
control O 0 2.629714117574622e-07
groups O 0 7.145659758345246e-11
, O 0 1.9209481227910885e-11
the O 0 1.5065735117780754e-11
APC O 0 8.81423378729096e-09
I1307K O 0 1.4842080897636833e-09
allele O 0 5.053907292662529e-10
is O 0 1.3035006407591254e-10
associated O 0 4.3526870996402067e-10
with O 0 2.2097159171896585e-11
an O 0 7.31724576763515e-12
estimated O 0 1.120875614546435e-09
relative O 0 3.126610437220734e-08
risk O 0 8.615852031823579e-09
of O 0 2.93254895193662e-12
1 O 0 4.910908657507207e-08
. O 0 2.513294283801315e-08

5 O 0 8.778300752965151e-08
- O 0 3.0944543141231406e-06
1 O 0 1.6195631502569086e-08
. O 0 5.9219100734253516e-09

7 O 0 7.509522674808977e-07
for O 0 1.2921916869856886e-08
colorectal B-Disease 1 0.9999977350234985
neoplasia I-Disease 1 0.9504855275154114
( O 0 2.9352747787925182e-08
both O 0 4.1809477124843397e-07
P O 1 0.9995884299278259
= O 1 0.5593512058258057
. O 0 1.1568706526077221e-07
01 O 0 3.042933940378134e-06
) O 0 2.4569077328173705e-10
. O 0 1.4391366986998833e-09

Furthermore O 0 2.853147691439517e-07
, O 0 6.005405200903979e-11
compared O 0 5.460197918805143e-11
with O 0 5.486401263854468e-11
noncarriers O 0 2.004389352805447e-05
, O 0 3.983560425968591e-10
APC O 0 2.3466682819162088e-08
I1307K O 0 1.0495410762700885e-08
carriers O 0 1.507983737880636e-09
had O 0 3.0989832922045935e-09
increased O 0 5.992232317980628e-12
numbers O 0 1.5309824241693804e-10
of O 0 3.736529835540736e-11
adenomas B-Disease 1 0.9467742443084717
and O 1 0.8670883178710938
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9999817609786987
per O 0 2.1888713064299736e-08
patient O 0 7.932065636850893e-05
( O 0 1.827994999814564e-08
P O 1 0.9998346567153931
= O 1 0.867645800113678
. O 0 2.6838267785933567e-07
03 O 0 2.712268724280875e-06
) O 0 4.314563636920177e-11
, O 0 4.646445034284241e-11
as O 0 5.2868077971002236e-11
well O 0 6.798282076170281e-11
as O 0 2.8681388861140356e-11
a O 0 3.113633795237547e-10
younger O 0 6.539446761877343e-09
age O 0 1.3626348660533694e-10
at O 0 4.815691401205413e-09
diagnosis O 0 2.4490125724696554e-05
. O 0 1.539974370246e-09

We O 0 9.199638384416176e-07
conclude O 0 5.371676881082976e-09
that O 0 1.3025133055455385e-11
the O 0 1.3589745648245888e-11
APC O 0 1.1975508584782801e-08
I1307K O 0 1.7049027078996914e-08
variant O 0 3.1987044621928362e-06
leads O 0 6.769785159121966e-07
to O 0 1.6485564025003896e-09
increased O 0 1.2452539976948174e-07
adenoma B-Disease 1 0.9999992847442627
formation O 0 1.2740080137518817e-06
and O 0 1.7988995182349754e-08
directly O 0 1.0053113896901777e-10
contributes O 0 2.205657739784428e-10
to O 0 6.33982727427096e-11
3 O 0 6.188206891355463e-11
% O 0 3.4371138747657515e-12
- O 0 5.2193758648400035e-08
4 O 0 3.244089163967345e-10
% O 0 1.2367745716446166e-12
of O 0 4.983581364421952e-13
all O 0 2.313927938146776e-09
Ashkenazi O 0 0.3588002920150757
Jewish O 1 0.9784653186798096
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
. O 0 4.684127361542778e-07

The O 0 3.533491055307536e-09
estimated O 0 4.331832670345648e-10
relative O 0 2.412666733064839e-09
risk O 0 2.6539943576153746e-09
for O 0 1.6435996444061352e-12
carriers O 0 9.94058879655313e-09
may O 0 9.106399523339803e-10
justify O 0 1.4475194376473155e-09
specific O 0 5.6018367028398686e-12
clinical O 0 9.656194732698964e-10
screening O 0 2.860562897666341e-10
for O 0 3.43957121898969e-13
the O 0 3.1115054109631668e-12
360 O 0 5.608256636868703e-10
, O 0 7.676339598694515e-12
000 O 0 2.5672578212593278e-12
Americans O 0 2.9146952212899535e-11
expected O 0 1.0255222018806798e-11
to O 0 1.6809767119929653e-11
harbor O 0 2.9527871259205085e-09
this O 0 3.5254861096428725e-13
allele O 0 1.372222474538276e-10
, O 0 4.8590971524209436e-11
and O 0 2.0399466837961455e-10
genetic O 0 1.342724544883822e-07
testing O 0 2.4466082493290742e-08
in O 0 3.469964940383541e-11
the O 0 9.162826747344255e-11
setting O 0 1.1990776371817446e-08
of O 0 4.505439424318247e-11
long O 0 1.699173708402668e-07
- O 0 1.394105083818431e-06
term O 0 6.6728285119666e-09
- O 0 1.365691559840343e-07
outcome O 0 3.1068117523069816e-10
studies O 0 3.53797199870165e-11
may O 0 6.311012910181768e-12
impact O 0 8.69093599170645e-12
significantly O 0 7.170791036514856e-07
on O 1 0.9070017337799072
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 0.0016872197156772017
in O 0 6.058479828929819e-10
this O 0 2.1559079521615843e-10
population O 0 1.591005438505988e-09
. O 0 2.6944468878298267e-09

Localization O 0 7.402732535410905e-06
of O 0 2.4197027714834007e-10
human O 0 4.73048302751522e-08
BRCA1 O 0 0.00014082454435992986
and O 0 1.803500140340475e-07
its O 0 2.1942121453122354e-09
loss O 0 1.1446500138845295e-06
in O 0 1.6191238350060644e-09
high O 0 5.087492382926939e-08
- O 0 3.231672599213198e-05
grade O 0 2.5960398488678038e-05
, O 0 4.752891413772886e-09
non B-Disease 0 1.305084680325308e-07
- I-Disease 1 0.9978220462799072
inherited I-Disease 1 0.9998341798782349
breast I-Disease 1 0.9998284578323364
carcinomas I-Disease 1 0.9999996423721313
. O 0 9.316630894318223e-06

Although O 0 4.573918133132793e-08
the O 0 1.0482550591439654e-11
link O 0 7.381066779998946e-08
between O 0 5.920912649060028e-10
the O 0 4.615349880054964e-09
BRCA1 O 0 0.04842730984091759
tumour B-Disease 1 0.9999992847442627
- O 0 4.6023424147279e-06
suppressor O 0 9.282450264436193e-06
gene O 0 0.00020110001787543297
and O 0 0.0004970540176145732
hereditary B-Disease 1 0.9999982118606567
breast I-Disease 1 0.9999998807907104
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 3.209351859823073e-07
established O 0 2.0976260728389207e-08
, O 0 1.2972553586898528e-10
the O 0 4.2949074852138835e-11
role O 0 5.398268498879588e-09
, O 0 3.381539215308038e-10
if O 0 3.9208064572804346e-10
any O 0 7.970643242649622e-12
, O 0 1.856052984916534e-11
of O 0 2.60471353687175e-12
BRCA1 O 0 2.38826141867321e-05
in O 0 3.878200161011591e-08
non B-Disease 0 2.37767585531401e-06
- I-Disease 1 0.9973441958427429
familial I-Disease 1 0.9988462924957275
cancers I-Disease 1 0.9998226761817932
is O 0 6.31616448032446e-09
unclear O 0 3.0246976479020304e-08
. O 0 4.004703235693796e-09

BRCA1 O 0 0.0058366977609694
mutations O 0 0.0003803882864303887
are O 0 1.852221376275054e-09
rare O 0 2.522029163287698e-08
in O 0 1.581150144147614e-08
sporadic B-Disease 1 0.8771580457687378
cancers I-Disease 1 0.9999977350234985
, O 0 2.0526849198176933e-07
but O 0 1.431267833140737e-07
loss O 0 1.0309605613656458e-07
of O 0 8.10375239135297e-11
BRCA1 O 0 0.00021471914078574628
resulting O 0 2.5632409972331516e-08
from O 0 3.481747945510705e-10
reduced O 0 9.216825702651477e-08
expression O 0 2.0920408871916152e-07
or O 0 1.1890249673740527e-08
incorrect O 0 2.4028988718782784e-06
subcellular O 0 7.560157973784953e-05
localization O 0 5.527390385395847e-06
is O 0 1.4325494956946017e-10
postulated O 0 1.2554870032488452e-08
to O 0 2.3736757004400033e-10
be O 0 4.674927112091609e-11
important O 0 1.4344435361746122e-11
in O 0 2.644467977930276e-10
non B-Disease 0 2.0850140458605892e-07
- I-Disease 1 0.9774904251098633
familial I-Disease 1 0.999983549118042
breast I-Disease 1 0.9999996423721313
and I-Disease 1 0.9999991655349731
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 2.2735268885298865e-06

Epigenetic O 0 0.0010647705057635903
loss O 0 8.769178384682164e-05
, O 0 7.686591807498644e-09
however O 0 4.5134944670621735e-09
, O 0 1.6685292036910937e-10
has O 0 3.12806425206702e-09
not O 0 2.651533992370503e-10
received O 0 1.052881198025657e-12
general O 0 8.624964457915052e-12
acceptance O 0 5.197098307263559e-10
due O 0 3.5475627990777525e-10
to O 0 1.1168347496814945e-11
controversy O 0 2.288359605973067e-11
regarding O 0 1.3288441527703476e-11
the O 0 1.0023011066950804e-11
subcellular O 0 4.526929160419968e-07
localization O 0 6.511930195074456e-08
of O 0 7.734583806762174e-12
BRCA1 O 0 6.642330845352262e-06
proteins O 0 1.0815838180633364e-07
, O 0 2.6046315104721884e-10
reports O 0 5.962004778758967e-10
of O 0 3.949813132814173e-12
which O 0 5.8959351179055375e-08
have O 0 1.1043134406918398e-08
ranged O 0 4.8632835536466246e-09
from O 0 2.332668997198639e-12
exclusively O 0 2.9727675876500825e-10
nuclear O 0 4.952881909048301e-07
, O 0 2.258710796523844e-12
to O 0 6.69137163213096e-13
conditionally O 0 2.424835887637755e-10
nuclear O 0 5.6937988546224005e-08
, O 0 2.8660266434415993e-12
to O 0 3.072042403448605e-12
the O 0 7.964751080891119e-11
ER O 0 0.0004606732982210815
/ O 0 6.114084044384072e-06
golgi O 0 5.672515726473648e-06
, O 0 4.098057310164549e-11
to O 0 8.142093770036052e-12
cytoplasmic O 0 2.1220122548015752e-08
invaginations O 0 1.0433798536269023e-07
into O 0 1.2434080154388738e-10
the O 0 8.95658200383842e-11
nucleus O 0 2.985890423801152e-09
. O 0 4.4132111853834033e-10

In O 0 3.8194780671574335e-09
an O 0 5.463802674188223e-11
attempt O 0 7.47839266068695e-08
to O 0 2.8142216335069747e-10
resolve O 0 2.2980413127982047e-09
this O 0 1.0926625056140171e-11
issue O 0 3.534473547173178e-10
, O 0 1.3181045144250447e-09
we O 0 3.316460350788475e-08
have O 0 8.50749859448996e-10
comprehensively O 0 2.0664865587605163e-06
characterized O 0 4.548876830767767e-09
19 O 0 9.646879961522359e-10
anti O 0 4.878662096530206e-08
- O 0 0.0007078514317981899
BRCA1 O 0 0.00021581847977358848
antibodies O 0 7.467772320524091e-07
. O 0 3.708650941902647e-09

These O 0 4.577441981012953e-09
reagents O 0 1.7854349110280054e-08
detect O 0 3.505413204152319e-08
a O 0 9.838714912224766e-12
220 O 0 8.888711294785523e-11
- O 0 5.2458837274116377e-08
kD O 0 1.0357125290738622e-07
protein O 0 1.0391565385958756e-09
localized O 0 2.952466049421787e-09
in O 0 8.874527848701241e-12
discrete O 0 1.1320852699725492e-08
nuclear O 0 2.1306084818206728e-05
foci O 0 3.6783993095923506e-07
in O 0 2.0089407914980484e-10
all O 0 3.854118066359824e-11
epithelial O 0 3.0008794738023425e-07
cell O 0 0.0005403050454333425
lines O 0 0.0004094909818377346
, O 0 4.480187609789965e-10
including O 0 1.0137638992158138e-11
those O 0 1.2184092276767977e-11
derived O 0 2.860186254505237e-10
from O 0 1.0330624355958662e-08
breast B-Disease 0 0.012156453914940357
malignancies I-Disease 0 0.006662978790700436
. O 0 1.475192306088502e-07

Immunohistochemical O 0 0.00047190210898406804
staining O 0 7.241078856168315e-05
of O 0 1.4630103795099103e-09
human O 0 1.8870528037950862e-06
breast O 0 0.012343631125986576
specimens O 0 4.4861434389531496e-07
also O 0 8.489514158327438e-08
revealed O 0 2.6220061499770964e-06
BRCA1 O 0 1.600259383849334e-05
nuclear O 0 1.1864616681123152e-05
foci O 0 7.661472409381531e-06
in O 0 7.401353485647633e-08
benign O 1 0.9049695730209351
breast O 1 0.9646872878074646
, O 0 1.7411923636245774e-06
invasive B-Disease 1 0.9405028223991394
lobular I-Disease 1 0.9999856948852539
cancers I-Disease 1 0.9999984502792358
and O 0 2.5196810383931734e-05
low B-Disease 0 0.0022189966402947903
- I-Disease 1 0.9916211366653442
grade I-Disease 0 0.27958807349205017
ductal I-Disease 1 0.9994785189628601
carcinomas I-Disease 1 0.9999998807907104
. O 0 4.6429304347839206e-05

Conversely O 0 7.934700079204049e-06
, O 0 3.5655340901996624e-09
BRCA1 O 0 5.578996820077009e-07
expression O 0 4.4661231157760994e-08
was O 0 1.3132499532275688e-07
reduced O 0 1.0514664694483145e-08
or O 0 1.633523716293439e-08
undetectable O 0 5.522416813619202e-06
in O 0 1.5289863819489824e-10
the O 0 8.5289247886422e-11
majority O 0 2.4175161872364015e-10
of O 0 3.6979933004666066e-12
high O 0 9.531590450251315e-08
- O 0 0.00039877984090708196
grade O 0 9.568232599121984e-06
, O 0 1.3898485029528729e-08
ductal B-Disease 0 0.22506354749202728
carcinomas I-Disease 1 1.0
, O 0 2.7377785727367154e-07
suggesting O 0 3.548960236798848e-08
that O 0 7.631936749241675e-10
absence O 0 1.0163647007344068e-10
of O 0 2.2058995255425096e-12
BRCA1 O 0 6.706332351313904e-05
may O 0 6.897727899968231e-08
contribute O 0 2.7035458941004897e-11
to O 0 8.234053022748711e-11
the O 0 5.742487388382678e-11
pathogenesis O 0 6.390132512024138e-07
of O 0 3.542263054059913e-13
a O 0 4.6754978361152055e-11
significant O 0 1.5116567719797303e-11
percentage O 0 3.964968353642462e-09
of O 0 1.6219449394672125e-10
sporadic B-Disease 1 0.9899700284004211
breast I-Disease 1 0.99998939037323
cancers I-Disease 1 0.9999661445617676
. O 0 1.6077168041306322e-08
. O 0 2.4943114240727482e-08

